

CURRICULUM VITAE

Dati Anagrafici:

Nome: Daniele

Cognome: Armenia

Titoli di studio e professionali:

- **Professore associato di seconda fascia** per il settore scientifico disciplinare **Microbiologia e Microbiologia Clinica (SSD MED/07 SC 06/A3)**
- **Dottorato di Ricerca in “Microbiologia Medica e Immunologia”** presso l’Università degli Studi di Roma “Tor Vergata”, Dipartimento di Medicina Sperimentale e Scienze Biochimiche - Cattedra di Virologia conseguito il 5 luglio 2010. Tesi sperimentale dal titolo: *"Impact of Integrase Polymorphisms and Minor Quasispecies in HIV-1 Infected Individuals Naive or Treated with Strand-transfer Integrase Inhibitors: a Refined Analysis by Cloning and 454-Pyrosequencing Techniques"*. Relatori: Proff. Carlo Federico Perno e Francesca Ceccherini-Silberstein
- **Laurea in Biotecnologie Farmaceutiche (Vecchio ordinamento quinquennale)** conseguita il 20 Dicembre 2005 con votazione 110/110 presso l’Università degli Studi di Bologna. Tesi sperimentale dal titolo *"Distribuzione e valenza clinica delle varianti genotipiche della glicoproteina gN di HCMV in pazienti immunocompromessi e immunocompetenti"*, relatore: Prof.ssa Paola Dal Monte.
- **Diploma di maturità scientifica** conseguito con votazione 80/100 nel Luglio 1999 presso il Liceo Scientifico Statale “Stanislao Cannizzaro” di Vittoria (RG).

Posizione attuale:

Professore associato di seconda fascia presso l’Università degli Studi “Saint Camillus International University of Health Sciences”, Roma. Settore scientifico disciplinare MED/07.

Presidente del corso di laurea triennale in “Tecniche di Laboratorio Biomedico” presso l’Università degli Studi “Saint Camillus International University of Health Sciences”, Roma.

Esperienze lavorative:

(01/12/2018-30/09/2021): Ricercatore a tempo determinato di tipo A presso l’Università degli Studi “Saint Camillus International University of Health Sciences”, Roma. Settore scientifico disciplinare MED/07.

(01/07/2018-01/12/2018) Borsista presso la Cattedra di Virologia, Facoltà di Medicina e Chirurgia dell’Università degli Studi di Roma “Tor Vergata”, Via Montpellier, 1 00133, Roma. Settore scientifico disciplinare MED/07.

(15/04/2016- 15/04/18) Assegnista di ricerca di III fascia presso la Cattedra di Virologia dell’Università degli Studi di Roma “Tor Vergata” nell’ambito del progetto FIRB RBAP11YS7K: Studio multidisciplinare finalizzato all’identificazione e caratterizzazione di marker innovativi in grado di definire il ruolo di virus epatotropi nello sviluppo del carcinoma epatocellulare: un modello di incontro tra ricerca di base ed applicativa di cui è responsabile il Prof. Carlo Federico Perno. Ruolo: Gestione e supervisione di dati di next generation sequencing e gestione e analisi di database clinico-virologici.

(15/04/15- 14/04/16) Assegnista di ricerca di III fascia presso la cattedra di virologia dell’Università degli Studi di Roma “Tor Vergata” per nell’ambito del progetto MIUR- PRIN2012- 2012L783TW_00 “Studio dei determinanti della resistenza secondaria e primaria di HIV-1 ai farmaci antiretrovirali” di cui è responsabile la Prof.ssa Francesca Ceccherini-Silberstein. Ruolo: Gestione e supervisione di dati di next generation sequencing e gestione e analisi di database clinico-virologici.

(05/03/12-04/03/15) Assegnista di ricerca di I fascia presso la Cattedra di Virologia dell’Università degli Studi di Roma “Tor Vergata” per nell’ambito del progetto FIRB RBAP11YS7K: “Studio multidisciplinare

finalizzato all'identificazione e caratterizzazione di marker innovativi in grado di definire il ruolo di virus epatotropi nello sviluppo del carcinoma epatocellulare: un modello di incontro tra ricerca di base ed applicativa" di cui è responsabile il Prof. Carlo Federico Perno. Ruolo: Gestione e supervisione di dati di next generation sequencing e gestione e analisi di database clinico-virologici.

(31/07/11-04/03/12) Contratto di consulenza per il progetto "Characterization of patients failing to DRV and impact on the subsequent regimen multi center retrospective analysis" presso l'Università degli Studi di Roma "Tor Vergata", presso il Laboratorio di Virologia del Dipartimento di Medicina Sperimentale e Scienze Biochimiche (Prof. Carlo Federico Perno) finanziato dalla Fondazione Italiana per gli studi e le ricerche Antivirali (AVIRALIA).

(01/04/2010- 30/07/2011) Borsa di studio dall'Università degli Studi di Roma "Tor Vergata" per il progetto "Collaborative HIV and anti-HIV drug resistance network (CHAIN)".

(07/11/2010-03/12/2010) Laboratorio di Virologia presso l'ospedale "Pitié-Salpêtrière" di Parigi per la produzione di mutanti di HIV-1 per mutagenesi sito specifica e ricombinanti HIV-1

(06/07/2007- 30/09/2007) Laboratori di virologia della società "Virco BVBA" – Mechelen (Belgio) per la produzione e la valutazione fenotipica di cloni virali derivanti da pazienti HIV-1 infetti

(01/11/2006-31/10/2009) Borsa di studio ministeriale per dottorato di ricerca in Microbiologia Medica e Immunologia presso la Cattedra di Virologia dell'Università degli Studi di Roma "Tor Vergata"

Attività didattica:

- (AA.AA 2020-2021) Relatore tesi di Laurea di Ricardo Jerry Paul, Corso di Laurea Triennale in Tecniche di Laboratorio Biomedico, titolo tesi: "Evaluation of HIV-DNA levels and resistance for the management of treatment optimization in HIV-1 infected virologically suppressed individuals".
- (AA.AA 2019-oggi) Docente per il corso integrato in lingua inglese "Microbiology" per l'insegnamento di "Virology" del corso di laurea in Medicina e Chirurgia (LM-41) presso l'Università degli Studi "Saint Camillus International University of Health Sciences", Roma. 2 CFU SSD MED/07
- (AA.AA 2019-oggi) Docente del corso integrato in lingua italiana di "Patologia generale e fisiopatologia" per l'insegnamento di "Microbiologia e microbiologia clinica" del corso di laurea in Ostetricia (abilitante alla professione sanitaria di Ostetrica/o, L/SNT1) presso l'Università degli Studi "Saint Camillus International University of Health Sciences", Roma. 2 CFU SSD MED/07
- (AA.AA 2019-oggi) Docente e coordinatore del corso integrato in lingua inglese "General Pathology and Physiopathology" per il modulo "Microbiology and Clinical Microbiology" del Corso di Laurea Triennale in Infermieristica (abilitante alla professione sanitaria di Infermiere, L/SNT1) presso l'Università degli Studi "Saint Camillus International University of Health Sciences", Roma. 1 CFU SSD MED/07
- (AA.AA 2018-oggi) Docente e coordinatore del corso integrato in lingua inglese "General pathology and microbiology" per il modulo "Microbiology and Clinical Microbiology" del Corso di Laurea Triennale in Fisioterapia (abilitante alla professione sanitaria di Fisioterapista, L/SNT2) presso l'Università degli Studi "Saint Camillus International University of Health Sciences", Roma. 2 CFU SSD MED/07
- (AA.AA 2018- oggi) Docente per il corso integrato in lingua italiana di "Biochimica, fisiologia e microbiologia" per l'insegnamento di "Microbiologia" del corso di laurea in Tecniche di laboratorio biomedico (abilitante alla professione sanitaria di Tecnico di laboratorio biomedico, L/SNT3) presso l'Università degli Studi "Saint Camillus International University of Health Sciences", Roma. 2 CFU SSD MED/07
- (AA.AA 2018- oggi) Docente e coordinatore del corso integrato in lingua italiana di "Microbiologia Clinica" per l'insegnamento di "Microbiologia, batteriologia e virologia" del corso di laurea in Tecnici di laboratorio biomedico presso l'Università degli Studi "Saint Camillus International University of Health Sciences", Roma. 4 CFU SSD MED/07

- (AA.AA 2018-oggi) Docente per il corso integrato in lingua inglese “Biological and biochemical foundations of living systems” per l’insegnamento di “Microbiology” del corso di laurea in Tecniche di radiologia medica, per immagini e radioterapia (abilitante alla professione sanitaria di Tecnico di radiologia medica, L/SNT3) presso l’Università degli Studi “Saint Camillus International University of Health Sciences”, Roma. 1 CFU SSD MED/07
- (AA.AA 2018-2019) Docente a contratto per il corso di “Microbiologia Ambientale” del Corso di Laurea in “Biologia evolutiva, ecologia e antropologia applicata” dell’Università degli Studi di Roma “Tor Vergata”. 6 CFU SSD MED/07
- (AA.AA. 2016- oggi) Docente a contratto per il corso integrato di “Microbiologia” per l’insegnamento di “Virologia” del Corso di Laurea in Medicina, Facoltà di Medicina e Chirurgia dell’Università degli Studi “Nostra Signora del Buon Consiglio”, Tirana, Albania. 2 CFU.
- (AA.AA. 2017- oggi) Cultore della materia e membro della commissione d’esame per il corso integrato di Microbiologia del Corso di Laurea in Medicina, Facoltà di Medicina e Chirurgia dell’Università degli Studi di Roma “Tor Vergata”.
- (AA.AA 2016-2017) Correlatore tesi di Laurea di Giuseppe Oliveto, Corso di Laurea Magistrale in Biotecnologie Mediche, titolo tesi: “Valutazione dell’impatto della resistenza ai farmaci antiretrovirali nel DNA provirale in pazienti HIV-1 infetti virologicamente soppressi”.
- (AA.AA 2015-2016) Correlatore tesi di specializzazione di Monica Fiorentini, scuola di Specializzazione in Microbiologia e Virologia, titolo tesi: “Monitoraggio e rilevanza clinica della resistenza in pazienti infetti da HIV-1 attraverso l’uso del pirosequenziamento ultrasensibile 454”.
- (AA.AA. 2012- 2017) Lezioni integrative per il corso di Microbiologia Clinica e Virologia (6 CFU) per il Corso di Laurea Magistrale in biologia della salute e della nutrizione curriculum bio-sanitario presso la Facoltà di Scienze Dipartimento di Medicina Clinica, Sanità pubblica, Scienze della Vita e dell’Ambiente (MESVA) dell’Università di L’Aquila.
- (AA.AA. 2011-2017) Lezioni integrative e componente delle commissioni d’esame di profitto per il Corso di Virologia Speciale (1 CFU), per il Corso Integrato di Microbiologia e Microbiologia Clinica per la Laurea Triennale in Tecniche Diagnostiche di Laboratorio Biomedico, Facoltà di Medicina e Chirurgia dell’Università degli Studi di Roma “Tor Vergata”.
- (AA.AA. 2011-2015) Lezioni integrative per il corso Virologia Speciale per la Scuola di Specializzazione in Microbiologia e Virologia, Facoltà di Medicina e Chirurgia dell’Università degli Studi di Roma “Tor Vergata”.
- (AA.AA. 2011-2013) Lezioni integrative e componente delle commissioni d’esame di profitto per il corso di Virologia Molecolare (4 CFU) per la Laurea Specialistica in Biotecnologie Mediche, Facoltà di Medicina e Chirurgia dell’Università degli Studi di Roma “Tor Vergata”.
- (AA.AA. 2009-2011) Lezioni integrative e componente delle commissioni d’esame di profitto per il corso di Virologia (4 CFU) per il Corso di Laurea in Scienze Biologiche presso la Facoltà di Scienze MM.FF.NN dell’Università di L’Aquila.

Attività Scientifica

L’attività di ricerca effettuata a oggi è inerente ai seguenti progetti:

- Produzione di mutanti di HIV-1 per mutagenesi sito specifica e ricombinanti HIV-1 contenenti regioni paziente specifiche.
- Studi di suscettibilità fenotipica sotto pressione farmacologica e studi di fitness virale di ceppi di HIV-1 mutati e/o ricombinati.
- Analisi delle mutazioni di HIV in relazione a parametri viro-immunologici, terapia antiretrovirale e progressione della malattia al fine di: i) caratterizzare parametri viro-immunologici predittivi di progressione della malattia, ii) definire i marker indicatori di progressione della malattia.
- Caratterizzazione delle aree del genoma e delle proteine di HIV che, per le loro peculiari caratteristiche, possono costituire nuovi target per farmaci antivirali.
- Caratterizzazione delle mutazioni nuove e note associate alla resistenza a farmaci anti-HIV attualmente in uso nella pratica clinica e in fase di sperimentazione. La caratterizzazione di tali mutazioni e del loro ruolo nella farmaco-resistenza è di notevole rilevanza clinica in quanto consente di migliorare la previsione della risposta ai farmaci antiretrovirali. Inoltre contribuisce ad una migliore valutazione dell'efficacia dei farmaci di nuova generazione.
- Studio e caratterizzazione genetica di HIV, HBV e HCV con le metodiche di sequenziamento classiche (sequenziamento di Sanger) e di nuova generazione (*Next-generation sequencing*): studio della comparsa e scomparsa di mutazioni associate alla resistenza ai farmaci antivirali e/o di varianti genetiche relazionate al responso alla terapia antivirale o alla virulenza.
- Raccolta e analisi di dati multicentrici per studi di coorte a livello nazionale e internazionale per la valutazione di fattori prognostici di fallimento alla terapia antiretrovirale.

Durante questi anni il Prof. Armenia ha lavorato all'estero per collaborazioni con compagnie farmaceutico-diagnostiche (Virco BVBA, Beerse, Belgium) e centri clinici europei (Pitié-Salpêtrière Hospital).

Premi

- Premio per la migliore presentazione orale “Ricardo Camacho award” al “European HIV & Hepatitis workshop, 26-28 Maggio 2021, virtual meeting
- ICAR – CROI Awards 2019 for the Italian Scientific Research: CROI affiliated event for Italian young investigators; CROI Seattle, USA, 4-7 March, 2019 (primo autore).
- Premio per la migliore presentazione orale al 2nd European HIV Clinical Forum: Integrase inhibitors, 22 Ottobre 2016, Glasgow (presenting author)
- Premio per il miglior poster al XIV European HIV & Hepatitis workshop, 25-27 Maggio 2016, Roma (co-autore)
- Premio “Joep Lange” come miglior lavoro presentato al Workshop “10th INTEREST”, 3 - 6 May 2016, Yaoundé, Cameroon (coautore).
- ICAR – CROI Awards 2015 for the Italian Scientific Research: CROI affiliated event for Italian young investigators; CROI Seattle, USA, 3-5 February 23-26, 2015 (primo autore).
- Premio per la migliore presentazione orale al 6th Italian Conference on AIDS and Retroviruses, Rome, Italy, 25-27 May, 2014 (co-autore).
- Premio per la migliore presentazione orale al congresso 3rd Italian Conference on AIDS and Retroviruses, Florence, Italy, 27-29 March, 2011 (co-autore).
- Premio per la migliore presentazione orale al 1st Italian Conference on AIDS and Retroviruses, Milan 24-26 May 2009 (co-autore).

Ruolo in Progetti Scientifici finanziati

- 2018-2019: Attività di raccolta, gestione e analisi dati dello studio virologico multicentrico internazionale dal titolo “Non-interventional and epidemiological study of genotypic tests performed in HIV-1-infected treatment-naïve patients in routine clinical care in France and Italy to study prevalence of Doravirine associated resistance mutations”
- 2017-2018: Co-ricercatore del progetto Gilead nell'ambito del Fellowship Program 2017 dal titolo “Valutazione dell'impatto della quantità di HIV-DNA e resistenza archiviata sull'outcome virologico

di pazienti che cambiano terapia nel contesto di ottimizzazione della terapia antiretrovirale in real life”

- 2016-2018: Attività di raccolta, gestione e analisi dati dello studio virologico multicentrico sulla “Sorveglianza, resistenza ed efficacia in pazienti che falliscono gli inibitori dell’integrasi in Italia”
- 2015-2018: Attività di raccolta, gestione e analisi dati dello studio virologico multicentrico “INIMAGE – Integrase Inhibitors Management by Genotype”
- 2014-2017: Collaboratore di Unità Operativa del Progetto di Ricerca Triennale PRIN finanziato dal Ministero dell’Università e della Ricerca, dal Titolo “Studio dei determinanti della resistenza secondaria e primaria di HIV-1 ai farmaci antiretrovirali per il controllo
- 2013-2016: Collaboratore di un’Unità Operativa del Progetto di Ricerca PRIN “Tecnologie OMICS e Systems Biology per la definizione di nuove strategie finalizzate al controllo delle infezioni virali”, protocollo n° 2010PHT9NF_001
- 2012-2017: Collaboratore del Progetto triennale FIRB dal titolo “Studio multidisciplinare finalizzato all’identificazione e caratterizzazione di marker innovativi in grado di definire il ruolo di virus epatotropi nello sviluppo del carcinoma epatocellulare”. Studio HIRMA Protocollo RBAP11YS7K_001.
- 2009-2014: Collaboratore all’interno della Unità Operativa dell’Università degli Studi di Roma “Tor Vergata” nel Progetto di Ricerca Europeo CHAIN, the “Collaborative HIV and Anti-HIV Drug Resistance Network”, Integrated Project no. 223131 finanziato da European Commission Framework 7 Program

Collaborazioni scientifiche con ospedali, aziende, fondazioni di ricerca, coorti

- Esperienza attiva per lo studio, il collazionamento e l’analisi di dati relativi allo studio di dati virologici con i seguenti enti/strutture di ricerca nazionali e internazionali
- Cattedra di Virologia, Dipartimento di medicina Sperimentale, Università di Roma “Tor Vergata”
- Unità HIV-AIDS, Istituto di Malattie Infettive “Lazzaro Spallanzani”, Roma
- Laboratorio di Virologia, Istituto di Malattie Infettive Lazzaro Spallanzani, Roma
- Unità di Malattie Infettive, Policlinico dell’Università di Roma "Tor Vergata"
- Policlinico Universitario di Modena, Modena
- Istituto di Malattie Infettive dell’Ospedale IFO San Gallicano, Roma
- Ospedale “Santa Maria Goretti” di Latina”, Latina
- Dipartimento di Oncologia e Emato-oncologia, Università di Milano, Milano
- Laboratorio di Virologia dell’Ospedale “Pitié Salpêtrière”, Parigi
- INSERM, Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique(IPLESP)e´quipe Epidémiologie clinique des maladies virales chroniques, Parigi
- Chantal Biya International Reference Centre for research on HIV/AIDS Prevention and Management, Yaounde, Cameroon
- Divisione di Malattie Infettive, Università di Torino, Torino
- Virco BVBA Mechelen, Belgium
- Ospedale “Luigi Sacco”, Milano
- Azienda Ospedaliera “SS Annunziata”, Firenze
- Ospedale San Martino, Genova
- Clinica malattie infettive, Università di Bari, Bari
- Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
- CHAIN, the “Collaborative HIV and Anti-HIV Drug Resistance Network”
- Cohort of antiretroviral-naive patients (ICONA) Study group. ICONA si affianca oggi ad altre prestigiose coorti europee ed americane, con le quali collabora in progetti di ricerca internazionali e rappresenta l’unica esperienza di studio multicentrico su larga scala italiano basato sull’utilizzo di una rete informatica alimentata ed a disposizione sia della ricerca di base che della pratica clinica. (http://www.fondazioneicona.org/_new2/index.php)
- Coorte ARCA (Antiviral Response Cohort Analysis). ARCA è una banca dati multicentrica a cui afferiscono circa 100 laboratori di virologia e cliniche di malattie infettive, operativa sul territorio nazionale dal 2002. Contiene i dati clinici e virologici di oltre 30.000 pazienti con infezione da HIV ed è orientata alla tematica delle farmacoresistenze agli antivirali. (ARCA, www.hivarca.net)

- Fondazione AVIRALIA. La FONDAZIONE ITALIANA PER GLI STUDI E LE RICERCHE ANTIVIRALI (o, più brevemente, FONDAZIONE AVIRALIA) è un ente non lucrativo di utilità sociale (Onlus) costituitosi nel Febbraio del 2010 dalla precedente Associazione Italiana per gli Studi e le Ricerche Antivirali, con il fine di promuovere e sviluppare la ricerca medico-scientifica (in Italia e a livello internazionale) nel campo delle patologie umane di origine virale (<http://www.aviraliafoundation.org/fondazione-chi-siamo.php>).

Partecipazioni a congressi

Ha partecipato a >100 congressi scientifici nazionali e internazionali presentandovi comunicazioni orali e poster (vedi pubblicazioni). Ha tenuto diverse letture a invito a Congressi Nazionali e Internazionali (vedi sotto). Ha fatto parte della segreteria scientifica del workshop nazionale “Terapia a lungo termine e nuovi paradigmi in HIV: virologia e clinica”, Firenze, 6-7 novembre 2018.

Corsi in qualità di relatore

- 07 Giugno 2022: Partecipazione in qualità di relatore al Convegno Internazionale “European HIV Clinical Forum 2022” nella sessione “Antiretroviral Therapy 2022 - State of ART Plenary Lectures” con la lettura dal titolo “Resistance Considerations in Choice of Regimen”.

- 22 Luglio 2020: Partecipazione in qualità di relatore al Convegno Nazionale IMPACT: “HIV, Epatiti e altri virus: clinica, diagnostica e nuovi standard di gestione” nella sessione “L’infezione da HIV multi-farmaco resistente: attualità” con la lettura dal titolo “I dati italiani di multiresistenza”

- 23 Maggio 2018: Partecipazione in qualità di relatore della mini lettura introduttiva alla sessione “Antiretroviral therapy: focus on integrase inhibitor” del 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018. Titolo relazione: The new frontier in HIV drug resistance: the integrase inhibitors

- 13 Dicembre 2016: Partecipazione in qualità di relatore al corso didattico di perfezionamento “Progetto BYKE” organizzato dalla società italiana di malattie infettive (SIMIT). Titolo relazione: HIV e resistenze.

- 25 Novembre 2016: Partecipazione in qualità di relatore al workshop internazionale “Comprehensive Management of Aging in HIV-Infected Subjects” tenutosi a Barcellona (Spagna) il 24-25 Novembre 2016. Titolo relazione: Management of HIV resistance in HIV aging patients. Switching to the most suitable regimen

- 25 Maggio 2014: Partecipazione in qualità di relatore al corso pre-Congressuale “Virologia e diagnostica di laboratorio avanzata” tenutosi durante il 6° congresso nazionale “Italian Conference on AIDS and Retroviruses”, Roma 25-27 Maggio 2014. Titolo relazione: Genotipizzazione virale a basso numero di copie. Fattibilità e rilevanza clinica.

- 15 Ottobre 2012: Partecipazione in qualità di relatore al workshop nazionale “Next generation sequencing: la tecnologia 454 tra presente e futuro”, organizzato da Roche Diagnostic S.p.A. presso Ospedale universitario San Raffaele, Milano. Titolo relazione: Next-generation sequencing nella pratica clinica: impatto delle quasispecie minoritarie di HIV-1 sul tropismo e sulla resistenza alla terapia antiretrovirale

- 9 Luglio 2012: Partecipazione in qualità di relatore al workshop nazionale “Next generation sequencing: la tecnologia 454 tra presente e futuro”, organizzato da Roche Diagnostic S.p.A. presso il polo didattico universitario- Ospedale Luigi Sacco, Milano. Titolo relazione: Next-generation sequencing nella pratica clinica: impatto delle quasispecie minoritarie di HIV-1 sul tropismo e sulla resistenza alla terapia antiretrovirale

- 4 Maggio 2012: Partecipazione in qualità di relatore al workshop internazionale "AREVIR-GenaFor-Meeting", tenutosi a Bonn, Germania il 4-5 Maggio 2012. Titolo relazione: NGS in clinical Italian practice: impact of minor quasispecies on antiretroviral drug resistance and viral tropism

Attività editoriale

- Dal 2016 revisore di articoli scientifici dalle seguenti riviste "peer reviewed": Journal of Antimicrobial Chemotherapy, Journal of Medical Virology, Antiviral therapy, PLOS ONE, BMC infectious disease, Diagnostic Microbiology & Infectious Disease, Sexually Transmitted Infections, Scientific Report.

- Dal 2015 sector editor per la rivista internazionale impattata Infectious Diseases & Tropical Medicine

- Dal 2013 a oggi: autore di capitoli ed editoriali scientifici inerenti le nuove frontiere della ricerca in HIV per la rivista ReAd Files, Il Punto in infettivologia, Le Infezioni in Medicina, Quaderni di Farmacologia Antinfettiva.

- Dal 2016 revisore di articoli scientifici dalle seguenti riviste "peer reviewed": Journal of Antimicrobial Chemotherapy, Journal of Medical Virology, Antiviral therapy, PLOS ONE, BMC infectious disease, Diagnostic Microbiology & Infectious Disease, Sexually Transmitted Infections, Scientific Report.
- Dal 2015 sector editor per la rivista internazionale impattata Infectious Diseases & Tropical Medicine
- Dal 2013 a oggi: autore di capitoli ed editoriali scientifici inerenti le nuove frontiere della ricerca in HIV per la rivista ReAd Files, Il Punto in infettivologia, Le Infezioni in Medicina, Quaderni di Farmacologia Antinfettiva.

Tecniche di laboratorio possedute

Oltre alle basilari procedure di laboratorio, il sottoscritto ha acquisito negli anni una padronanza di varie metodiche in diversi settori utili per la microbiologia.

In biologia cellulare:

Propagazione e mantenimento di linee cellulari (COS-7, HeLa, U2OS, Jurkat, MT-4, 293T, C8166)

Isolamento cellule linfo-monocitarie da sangue periferico o buffy-coat (Ficoll, CD14 MicrobeadsMiltenyi Kit)

Transfezione di linee cellulari (con il metodo del calcio fosfato, della lipofectamina)

Infezione di linee cellulari e con il Citomegalovirus umano (HCMV) e HIV-1

In biologia/microbiologia molecolare:

Estrazione di RNA e DNA

Analisi e sequenziamento dell'RNA e del DNA (RT-PCR, PCR Touchdown e Nested, elettroforesi su gel agarosio, sequenziamento DNA con metodica Sanger)

Mutagenesi sito specifica (disegno primer, trasformazione batterica al calore o elettroporazione, preparazione di DNA plasmidico da batteri [midipreparazione e minipreparazione])

In bioinformatica/biostatistica:

Allineamento e analisi sequenze genomiche da sequenziamento sanger e next generation sequencing di HIV-1, HCV, HBV (Integrative Genomics Viewer (IGV), Emboss package, Bioedit, Mega 5.0, ClustalX, SeqScape v.2.5 AppliedBiosystems, Amplicon Variant Analyzer Roche, Gs-Denovo Roche, GS-Mapper Roche, Exonerate package, Shorah package, Geneious 8.0, Pseq, Hydra)

-Valutazione dell'impatto della proteine cellulari Apobec 3G-F nell'editing del HIV-DNA in pazienti virologicamente soppressi attraverso i seguenti tool bioinformatici: Hypermut ver 2.0, Stanford HIVdb algorithm ver. 9.0

- Coordinamento pipeline estrazione bioinformatica dati di sequenziamento da piattaforma MiSeq Illumina

- Conoscenze di base della piattaforma Linux (Ubuntu 11, Fedora)

- Gestione e analisi di dati clinici, genotipici e fenotipici per lo studio della farmaco resistenza ad antivirali e dell'evoluzione virale attraverso l'utilizzo di Database (MS Excel, MS Access, SQL Express, R 11.0), tools statistici (SPSS26, MS Excel, R 11.0) e tools disponibili in web (Geno2Pheno, Comet HIV-1 v0.1, REGA HIV-1 SubtypingTool - Version 2.0, HIVseq e HIValg da Standford Universisty HIV Drug Database web site)

- Padronanza ed esperienza nella gestione e analisi di dati clinici multicentrici attraverso l'utilizzo di test statistici di base e inferenziali (regressione logistica, analisi di sopravvivenza, test parametrici e non-parametrici) attraverso l'utilizzo dei programmi di statistica SPSS 26 e R 11.0.

- Applicativi (Pacchetto MS Office 2019)

Attività scientifica personale e indici bibliometrici

Autore di 45 articoli in extenso su riviste internazionali citate su PubMed con IF e autore in >100 lavori presentati a congressi.

Totale Citazioni (fonte: Scopus, 31 Agosto 2022): 673;

Indice H (fonte: Scopus, 31 Agosto 2022): 13.

Le pubblicazioni riguardano i seguenti argomenti: impatto dei trattamenti antiretrovirali sull'infezione da HIV; meccanismi di resistenza ai farmaci anti HIV, HBV e HCV; fitness ed evoluzione virale di HIV e virus epatitici; analisi genotipica, fenotipica, strutturale e funzionale di proteine virali. L'impact IF è riferito all'anno di pubblicazione

Pubblicazioni

Papers in international journals (*indica il primo nome in condivisione)

1. Santoro MM, **Armenia D***, Teyssou E, Santos JR, Charpentier C, Lambert-Niclot S, Antinori A, Katlama C, Descamps D, Perno CF, Calvez V, Paredes R, Ceccherini-Silberstein F, Marcelin AG; LAMRES Study Group. Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V - The LAMRES Study. *J Glob Antimicrob Resist.* 2022 Aug 7:S2213-7165(22)00189-8. doi: 10.1016/j.jgar.2022.07.022. Epub ahead of print. PMID: 35948240. IF: 4.349.
2. **Armenia D**, Forbici F, Bertoli A, Berno G, Malagnino V, Gagliardini R, Borghi V, Gennari W, Cicalini S, Buonomini A, Teti E, Lanini S, Latini A, Sarmati L, Mussini C, Andreoni M, Antinori A, Perno CF, Ceccherini-Silberstein F, Santoro MM. Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice. *J Glob Antimicrob Resist.* 2022 Jul 3:S2213-7165(22)00161-8. doi: 10.1016/j.jgar.2022.06.027. Epub ahead of print. PMID: 35793776. IF: 4.349
3. Teto G, Nka AD, Fokam J, Bouba Y, Takou D, Fabeni L, Carioti L, **Armenia D**, Semengue ENJ, Dambaya B, Sosso SM, Colizzi V, Perno CF, Ceccherini-Silberstein F, Santoro MM, Ndjolo A. Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients. *Sci Rep.* 2022 Jan 26;12(1):1374. doi: 10.1038/s41598-022-05375-9. PMID: 35082353; PMCID: PMC8791941. IF: 4.996
4. **Armenia D**, Santoro MM, Bellocchi MC, Carioti L, Galli L, Galli A, Scutari R, Salsi E, Mussini C, Sterrantino G, Calza L, Rossetti B, Zazzi M, Castagna A; PRESTIGIO Registry Study Group. Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV. *Int J Antimicrob Agents.* 2022 Jan;59(1):106492. doi: 10.1016/j.ijantimicag.2021.106492. Epub 2021 Dec 3. PMID: 34871747. IF: 15.441
5. Bouba Y, **Armenia D***, Forbici F, Bertoli A, Borghi V, Gagliardini R, Vergori A, Cicalini S, Mazzotta V, Malagnino V, Lichtner M, Latini A, Mussini C, Andreoni M, Antinori A, Perno CF, Ceccherini-Silberstein F, Santoro MM. Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. *J Antimicrob Chemother.* 2021 Nov 12;76(12):3272-3279. doi: 10.1093/jac/dkab322. PMID: 34529797. IF: 5.758
6. Fokam J, Ngoufack Jagni Semengue E, **Armenia D**, Takou D, Dambaya B, Teto G, Chenwi CA, Nka AD, Beloumou GA, Ndjeyep SCD, Tchouaket MCT, Fainguem N, Sosso SM, Colizzi V, Perno CF, Ndjolo A, Ceccherini-Silberstein F, Santoro MM. High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries. *Diagn Microbiol Infect Dis.* 2022 Feb;102(2):115574. doi: 10.1016/j.diagmicrobio.2021.115574. Epub 2021 Oct 22. PMID: 34864527. IF: 2.983

7. **Armenia D**, Bouba Y, Gagliardini R, Fabeni L, Borghi V, Berno G, Vergori A, Cicalini S, Mussini C, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM. Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice. *HIV Med.* 2021 Jul;22(6):519-525. doi: 10.1111/hiv.13062. Epub 2021 Jan 21. PMID: 33480094. IF: 3.094
8. Semengue ENJ, **Armenia D**, Inzaule S, Santoro MM, Dambaya B, Takou D, Teto G, Nka AD, Yagai B, Fabeni L, Chenwi C, Angong Beloumou G, Djupsa Ndjeyep SC, Colizzi V, Perno CF, Ceccherini-Silberstein F, Fokam J. Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings. *J Antimicrob Chemother.* 2021 Apr 13;76(5):1277-1285. doi: 10.1093/jac/dkab004. PMID: 33501504. IF:5.578
9. Lombardi F, Giacomelli A, **Armenia D**, Lai A, Dusina A, Bezenchek A, Timelli L, Saladini F, Vichi F, Corsi P, Colao G, Bruzzone B, Gagliardini R, Callegaro A, Castagna A, Santoro MM; ARCA Study Group. Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database. *Int J Antimicrob Agents.* 2021 Feb;57(2):106252. doi: 10.1016/j.ijantimicag.2020.106252. Epub 2020 Nov 28. PMID: 33259914. IF: 15.441
10. Malagnino V, Cerva C, Teti E, Campogiani L, Compagno M, Foroghi Biland L, Saderi L, Armenia D, Salpini R, Svicher V, Sotgiu G, Iannetta M, Andreoni M, Sarmati L. Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers. *Sci Rep.* 2021 Feb 17;11(1):3965. doi: 10.1038/s41598-021-83616-z. PMID: 33597631; PMCID: PMC7889897. IF: 4.996
11. **Armenia D**, Bouba Y, Gagliardini R, Gori C, Bertoli A, Borghi V, Gennari W, Micheli V, Callegaro AP, Gazzola L, Bruzzone B, Giannetti A, Mazzotta V, Vergori A, Mastrocrosa I, Colafigli M, Lichtner M, Di Biagio A, Maggiolo F, Rizzardini G, D'Arminio Monforte A, Andreoni M, Mussini C, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM, for the Italian INI-Surveillance Group. Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. *J Clin Virol* 2020;130. <https://doi.org/10.1016/j.jcv.2020.104534>. IF: 2.950
12. **Armenia D**, Di Carlo D, Flandre P, Bouba Y, Borghi V, Forbici F, Bertoli A, Gori C, Fabeni L, Gennari W, Pinnetti C, Mondì A, Cicalini S, Gagliardini R, Vergori A, Bellagamba R, Malagnino V, Montella F, Colafigli M, Latini A, Marocco R, Lichtner M, Andreoni M, Mussini C, Ceccherini-Silberstein F, Antinori A, Perno CF, Santoro MM. HIV MDR is still a relevant issue despite its dramatic drop over the years. *J Antimicrob Chemother* 2020:1301–10. <https://doi.org/10.1093/jac/dkz554>. IF: 4.940
13. Soulie C, Santoro MM, Storto A, Abdi B, Charpentier C, **Armenia D**, Jary A, Forbici F, Bertoli A, Gennari W, Andreoni M, Mussini C, Antinori A, Perno CF, Calvez V, Ceccherini-Silberstein F, Descamps D, Marcelin AG. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. *J Antimicrob Chemother* 2020;75:1026–30. <https://doi.org/10.1093/jac/dkz553>. IF:4.940

14. Malagnino V, Cerva C, Maffongelli G, Teti E, Foroghi Biland L, Cesta N, De Masi M, Stingone C, Armenia D, Svicher V, Salpini R, Andreoni M, Sarmati L. HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy. *Sci Rep* 2019;9:1–9. <https://doi.org/10.1038/s41598-019-46976-1>. IF:4.120
15. Sorbo MC, Carioti L, Bellocchi MC, Antonucci F, Sforza D, Lenci I, Ciancio Manuelli M, Armenia D, De Leonardis F, Milana M, Manzia TM, Angelico M, Tisone G, Cento V, Perno CF, Ceccherini-Silberstein F. HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma. *Liver Int* 2019;39:1986–98. <https://doi.org/10.1111/liv.14168>. IF:5.200
16. **Armenia D**, Di Carlo D, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, D'Arminio Monforte A, Perno CF, Santoro MM . Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. *Antivir Ther* 2019;24:321–31. <https://doi.org/10.3851/IMP3309>. IF:2.010
17. Alteri C, Scutari R, Bertoli A, **Armenia D**, Gori C, Fabbri G, Mastroianni CM, Cerva C, Cristaudo A, Vicenti I, Bruzzone B, Zazzi M, Andreoni M, Antinori A, Svicher V, Ceccherini-Silberstein F, Perno CF, Santoro MM. Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. *Virus Genes*. 2019 Jun;55(3):290-297. doi: 10.1007/s11262-019-01649-z. Epub 2019 Feb 22. PMID: 30796743. IF: 2.046
18. F. Marino-Merlo, B. Macchi, **D. Armenia**, M.C. Bellocchi, F. Ceccherini-Silberstein, A. Mastino, S. Grelli, Focus on recently developed assays for detection of resistance/sensitivity to reverse transcriptase inhibitors., *Appl. Microbiol. Biotechnol.* (2018). doi:10.1007/s00253-018-9390-x IF: 3.340.
19. **Armenia D.**, Zaccarelli M., Borghi V., Gennari W., Di Carlo D., Giannetti A., Forbici F., Bertoli A., Gori C., Fabeni L., Pinnetti C., Marocco R., Latini A., Ceccherini-Silberstein F., Mastroianni C.M., Mussini C., Antinori A., Perno C.F., Santoro M.M. 2018. Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. *Journal of Clinical Virology* <https://doi.org/10.1016/j.jcv.2018.04.001>. IF: 3.051
20. Fokam, J., Bellocchi, M. C., **Armenia, D.**, Nanfack, A. J., Carioti, L., Continenza, F., Takou, D., Temgoua, E. S., Tangimpundu, C., Torimiro, J. N., Koki, P. N., Fokunang, C. N., Cappelli, G., Ndjolo, A., Colizzi, V., Ceccherini-Silberstein, F., Perno, C.-F. and Santoro, M. M. 2018. 'Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children', *Medicine*, 97(13), p. e0176. doi: 10.1097/MD.0000000000010176. IF: 1.804
21. Santoro MM, Di Carlo D, **Armenia D**, Zaccarelli M, Pinnetti C, Colafigli M, Prati F, Boschi A, Antoni AMD, Lagi F, Sighinolfi L, Gervasoni C, Andreoni M, Antinori A, Mussini C, Perno CF, Borghi V,

- Sterrantino G. 2017. Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. *Antivir Ther.* doi: 10.3851/IMP3197. IF:2.594
22. Salpini, R., Surdo, M., Warner, N., Cortese, M.F., Colledge, D., Soppe, S., Bellocchi, M.C., **Armenia, D.**, Carioti, L., Continenza, F., Carlo, D. Di, Saccomandi, P., Mirabelli, C., Pollicita, M., Longo, R., Romano, S., Cappiello, G., Spanò, A., Trimoulet, P., Fleury, H., Vecchiet, J., Iapadre, N., Barlattani, A., Bertoli, A., Mari, T., Pasquazzi, C., Missale, G., Sarrecchia, C., Orecchini, E., Michienzi, A., Andreoni, M., Francioso, S., Angelico, M., Verheyen, J., Ceccherini-Silberstein, F., Locarnini, S., Perno, C.F., Svicher, V., 2017. Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro; *Oncotarget*. doi:10.18632/oncotarget.14944. IF: 5.168
23. Jaffré, J., **Armenia, D.**, Bellocchi, M.C., Wirden, M., Carioti, L., Lambert, S., Valantin, M.-A., Nguyen, T., Simon, A., Katlama, C., Andreoni, M., Perno, C.F., Calvez, V., Ceccherini-Silberstein, F., Marcelin, A.-G., Todesco, E., 2017. Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation. *J. Antimicrob. Chemother.* 86, 2696–705. doi:10.1093/jac/dkw571. IF: 4.590
24. **Armenia, D.***, Di Carlo, D., Maffongelli, G., Borghi, V., Alteri, C., Forbici, F., Bertoli, A., Gori, C., Giuliani, M., Nicastrì, E., Zaccarelli, M., Pinnetti, C., Cicalini, S., D’Offizi, G., Ceccherini-Silberstein, F., Mussini, C., Antinori, A., Andreoni, M., Perno, C., Santoro, M., 2016. Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens. *HIV Med.* 26–28. doi:10.1111/hiv.12388. IF: 3.257
25. Zaccarelli, M., Santoro, M.M., **Armenia, D.**, Borghi, V., Gennari, W., Gori, C., Forbici, F., Bertoli, A., Fabeni, L., Giannetti, A., Cicalini, S., Bellagamba, R., Andreoni, M., Mastroianni, C.M., Mussini, C., Ceccherini-Silberstein, F., Perno, C.F., Antinori, A., 2016. Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. *J. Clin. Virol.* 82, 94–100. doi:10.1016/j.jcv.2016.07.007. IF: 3.051
26. **Armenia, D.***, Di Carlo, D., Calcagno, A., Vendemiati, G., Forbici, F., Bertoli, A., Berno, G., Carta, S., Continenza, F., Fedele, V., Bellagamba, R., Cicalini, S., Ammassari, A., Libertone, R., Zaccarelli, M., Ghisetti, V., Andreoni, M., Ceccherini-Silberstein, F., Bonora, S., Di Perri, G., Antinori, A., Perno, C.F., Santoro, M.M., 2016. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. *J. Antimicrob. Chemother.* dkw512. doi:10.1093/jac/dkw512. IF:4.590
27. Aragri, M., Alteri, C., Battisti, A., Di Carlo, D., Minichini, C., Sagnelli, C., Bellocchi, M.C., Pisaturo, M.A., Starace, M., **Armenia, D.**, Carioti, L., Pollicita, M., Salpini, R., Sagnelli, E., Perno, C.F., Coppola, N., Svicher, V., 2016. Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations

Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B. *J. Infect. Dis.* 213, 1897–1905. doi:10.1093/infdis/jiw049. IF:6.273

28. Salpini, R., Colagrossi, L., Bellocchi, M.C., Surdo, M., Becker, C., Alteri, C., Aragri, M., Ricciardi, A., **Armenia, D.**, Pollicita, M., Di Santo, F., Carioti, L., Louzoun, Y., Mastroianni, C.M., Lichtner, M., Paoloni, M., Esposito, M., D'Amore, C., Marrone, A., Marignani, M., Sarrecchia, C., Sarmati, L., Andreoni, M., Angelico, M., Verheyen, J., Perno, C.F., Svicher, V., 2015. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. *Hepatology* 61, 823–833. doi:10.1002/hep.27604. IF: 11.711
29. Cento, V., Tontodonati, M., Di Maio, V.C., Bellocchi, M.C., Valenti, F., Manunta, A., Fortuna, S., **Armenia, D.**, Carioti, L., Antonucci, F.P., Bertoli, A., Trave, F., Cacciatore, P., Angelico, M., Navarra, P., Neumann, A.U., Vecchiet, J., Parruti, G., Babudieri, S., Perno, C.F., Ceccherini-Silberstein, F., 2015. Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. *Dig. Liver Dis.* 47, 233–241. doi:10.1016/j.dld.2014.12.004. IF:4.502
30. **Armenia, D.***, Fabeni, L., Alteri, C., Di Pinto, D., Di Carlo, D., Bertoli, A., Gori, C., Carta, S., Fedele, V., Forbici, F., D'Arrigo, R., Svicher, V., Berno, G., Pizzi, D., Nicastri, E., Sarmati, L., Pinnetti, C., Ammassari, A., D'Offizi, G., Latini, A., Andreoni, M., Antinori, A., Ceccherini-Silberstein, F., Perno, C.F., Santoro, M.M., 2015. HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. *J. Antimicrob. Chemother.* 70, 1865–73. doi:10.1093/jac/dkv029. IF: 5.313
31. Pollicita, M., Alteri, C., Bellocchi, M.C., Armenia, D., Carioti, L., Salpini, R., Colagrossi, L., Battisti, A., Aragri, M., Fabeni, L., Mariani, R., Dalessandro, M., Ranelli, A., Paoloni, M., Parruti, G., Perno, C.F., Svicher, V., 2015. A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy. *Clin. Microbiol. Infect.* 21, 1124.e1-4. doi:10.1016/j.cmi.2015.07.022. IF: 4.575
32. Alteri, C., Surdo, M., Bellocchi, M.C., Saccomandi, P., Continenza, F., **Armenia, D.**, Parrotta, L., Carioti, L., Costa, G., Fourati, S., Di Santo, F., Scutari, R., Barbaliscia, S., Fedele, V., Carta, S., Balestra, E., Alcaro, S., Marcelin, A.G., Calvez, V., Ceccherini-Silberstein, F., Artese, A., Perno, C.F., Svicher, V., 2015. Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage. *Antimicrob. Agents Chemother.* 59, 4870–81. doi:10.1128/AAC.00137-15. IF:4.415
33. **Armenia, D.**, Soulie, C., Di Carlo, D., Fabeni, L., Gori, C., Forbici, F., Svicher, V., Bertoli, A., Sarmati, L., Giuliani, M., Latini, A., Boumis, E., Zaccarelli, M., Bellagamba, R., Andreoni, M., Marcelin, A.G., Calvez, V., Antinori, A., Ceccherini-Silberstein, F., Perno, C.F., Santoro, M.M., 2014. A very low

geno2pheno false positive rate is associated with poor viro-immunological response in drug-naive patients starting a first-line HAART. *PLoS One* 9. doi:10.1371/journal.pone.0105853. IF: 3.234

34. Santoro, M.M., Fabeni, L., **Armenia, D.**, Alteri, C., Di Pinto, D., Forbici, F., Bertoli, A., Di Carlo, D., Gori, C., Carta, S., Fedele, V., D'Arrigo, R., Berno, G., Ammassari, A., Pinnetti, C., Nicastrì, E., Latini, A., Tommasi, C., Boumis, E., Petrosillo, N., D'Offizi, G., Andreoni, M., Ceccherini-Silberstein, F., Antinori, A., Perno, C.F., 2014. Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. *Clin. Infect. Dis.* 58, 1156–64. doi:10.1093/cid/ciu020. IF:8.886
35. Svicher, V., Cento, V., Rozera, G., Abbate, I., Santoro, M.M., **Armenia, D.**, Fabeni, L., Bruselles, A., Latini, A., Palamara, G., Micheli, V., Rizzardini, G., Gori, C., Forbici, F., Ippolito, G., Andreoni, M., Antinori, A., Ceccherini-Silberstein, F., Capobianchi, M.R., Perno, C.F., 2013. The Genotypic False Positive Rate Determined by V3 Population Sequencing Can Predict the Burden of HIV-1 CXCR4-using Species Detected by Pyrosequencing. *PLoS One* 8. doi:10.1371/journal.pone.0053603. IF: 3.534
36. Santoro, M.M., **Armenia, D.***, Alteri, C., Flandre, P., Calcagno, A., Santoro, M., Gori, C., Fabeni, L., Bellagamba, R., Borghi, V., Forbici, F., Latini, A., Palamara, G., Libertone, R., Tozzi, V., Boumis, E., Tommasi, C., Pinnetti, C., Ammassari, A., Nicastrì, E., Buonomini, A., Svicher, V., Andreoni, M., Narciso, P., Mussini, C., Antinori, A., Ceccherini-Silberstein, F., Perri, G. Di, Perno, C.F., 2013. Impact of pre-therapy viral load on virological response to modern first-line HAART. *Antivir. Ther.* 18, 867–876. doi:10.3851/IMP2531. IF:3.143
37. Fourati, S., Visseaux, B., **Armenia, D.**, Morand-Joubert, L., Artese, A., Charpentier, C., Eede, P. Van Den, Costa, G., Alcaro, S., Wirlden, M., Perno, C.F., Silberstein, F.C., Descamps, D., Calvez, V., Marcelin, A.G., 2013. Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors. *J. Antimicrob. Chemother.* 68, 2199–2204. doi:10.1093/jac/dkt200. IF: 5.439
38. Geretti, A.M., **Armenia, D.**, Ceccherini-Silberstein, F., 2012. Emerging patterns and implications of HIV-1 integrase inhibitor resistance. *Curr. Opin. Infect. Dis.* 1. doi:10.1097/QCO.0b013e32835a1de7. IF: 4.870
39. **Armenia, D.**, Vandenbroucke, I., Fabeni, L., Van Marck, H., Cento, V., D'Arrigo, R., Van Wesenbeeck, L., Scopelliti, F., Micheli, V., Bruzzone, B., Lo Caputo, S., Aerssens, J., Rizzardini, G., Tozzi, V., Narciso, P., Antinori, A., Stuyver, L., Perno, C.F., Ceccherini-Silberstein, F., 2012. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: A refined analysis by ultra-deep 454 pyrosequencing. *J. Infect. Dis.* 205, 557–567. doi:10.1093/infdis/jir821. IF: 5.821
40. Santoro, M.M., **Armenia, D.***, Fabeni, L., Santoro, M., Gori, C., Forbici, F., Svicher, V., Bertoli, A., Dori, L., Surdo, M., Balestra, E., Palamara, G., Girardi, E., Angarano, G., Andreoni, M., Narciso, P., Antinori, A., Ceccherini-Silberstein, F., Perno, C.F., 2012. The lowest X4 Geno2Pheno false-positive

rate is associated with greater CD4 depletion in HIV-1 infected patients. *Clin. Microbiol. Infect.* 18. doi:10.1111/j.1469-0691.2012.03905.x. IF: 4.578

41. Malet, I., Fourati, S., Charpentier, C., Morand-Joubert, L., **Armenia, D.**, Wirden, M., Sayon, S., Vanhoutte, M., Ceccherini-Silberstein, F., Brun-Vézinet, F., Perno, C.F., Descamps, D., Capt, A., Calvez, V., Marcelin, A.G., 2011. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. *J. Antimicrob. Chemother.* 66, 2827–2830. doi:10.1093/jac/dkr389. IF: 5.068
42. Malet, I., Wirden, M., Fourati, S., **Armenia, D.**, Masquelier, B., Fabeni, L., Sayon, S., Katlama, C., Perno, C.F., Calvez, V., Marcelin, A.G., Ceccherini-Silberstein, F., 2011. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naïve and -treated patients. *J. Antimicrob. Chemother.* 66, 1481–1483. doi:10.1093/jac/dkr152. IF: 5.068
43. Ceccherini-Silberstein, F., Van Baelen, K., Armenia, D., Trignetti, M., Rondelez, E., Fabeni, L., Scopelliti, F., Pollicita, M., Van Wesenbeeck, L., Van Eygen, V., Dori, L., Sarmati, L., Aquaro, S., Palamara, G., Andreoni, M., Stuyver, L.J., Perno, C.F., 2010. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naïve patients have little or no effect on susceptibility to integrase inhibitors. *Antimicrob. Agents Chemother.* 54, 3938–3948. doi:10.1128/AAC.01720-09. IF: 4.672

Papers in study Group

44. Di Maio, V.C., Cento, V., Di Paolo, D., Aragri, M., De Leonardis, F., Tontodonati, M., Micheli, V., Bellocchi, M.C., Antonucci, F.P., Bertoli, A., Lenci, I., Milana, M., Gianserra, L., Melis, M., Di Biagio, A., Sarrecchia, C., Sarmati, L., Landonio, S., Francioso, S., Lambiase, L., Nicolini, L.A., Marengo, S., Nosotti, L., Giannelli, V., Siciliano, M., Romagnoli, D., Pellicelli, A., Vecchiet, J., Magni, C.F., Babudieri, S., Mura, M.S., Taliani, G., Mastroianni, C., Vespasiani-Gentilucci, U., Romano, M., Morisco, F., Gasbarrini, A., Vullo, V., Bruno, S., Baiguera, C., Pasquazzi, C., Tisone, G., Picciotto, A., Andreoni, M., Parruti, G., Rizzardini, G., Angelico, M., Perno, C.F., Ceccherini-Silberstein, F., Mariani, R., Paoloni, M., Iapadre, N., Grimaldi, A., Menzaghi, B., Quirino, T., Vecchiet, J., Bruzzone, B., De Maria, A., Di Biagio, A., Marengo, S., Picciotto, A., Viscoli, C., Casinelli, K., Delle Monache, M., Lichtner, M., Mastroianni, C., Aghemo, A., Bruno, S., Cerrone, M., Colombo, M., D'Arminio Monforte, A., Danieli, E., Donato, F., Gubertini, G., Landonio, S., Magni, C.F., Mancon, A., Micheli, V., Monaco, S., Niero, F., Puoti, M., Rizzardini, G., Russo, M.L., Alfieri, R., Gnocchi, M., Orro, A., Milanese, L., Baldelli, E., Bertolotti, M., Borghi, V., Mussini, C., Romagnoli, D., Brancaccio, G., Caporaso, N., Gaeta, G.B., Lembo, V., Morisco, F., Calvaruso, V., Craxì, A., Di Marco, V., Mazzola, A., Petta, S., D'Amico, E., Cacciatore, P., Consorte, A., Pace Palitti, V., Parruti, G., Pieri, A., Polilli, E., Tontodonati, M., Andreoni, M., Angelico, M., Antenucci, F., Antonucci, F.P., Aragri, M., **Armenia, D.**, Baiocchi, L., Bellocchi, M., Bertoli, A., Biliotti, E., Biolato, M., Carioti, L., Ceccherini-Silberstein, F., Cento, V.,

Cerasari, G., Cerva, C., Ciotti, M., D'Ambrosio, C., D'Ettore, G., De Leonardis, F., De Sanctis, A., Di Maio, V.C., Di Paolo, D., Francioso, S., Furlan, C., Gallo, P., Gasbarrini, A., Giannelli, V., Gianserra, L., Grieco, A., Grieco, S., Lambiase, L., Lattanzi, B., Lenci, I., Malagnino, V., Manuelli, M., Merli, M., Miglioresi, L., Milana, M., Nosotti, L., Palazzo, D., Pasquazzi, C., Pellicelli, A., Perno, C.F., Romano, M., Santopaolo, F., Santoro, M.M., Sarmati, L., Sarrecchia, C., Sforza, D., Siciliano, M., Sorbo, M.C., Spaziante, M., Svicher, V., Taliani, G., Teti, E., Tisone, G., Vullo, V., Mangia, A., Babudieri, S., Maida, I., Melis, M., Mura, M.S., Falconi, L., Di Giammartino, D., Tarquini, P., 2016. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. *J Antimicrob Chemother.* 2016 Mar;71(3):739-50. doi: 10.1093/jac/dkv403. Epub 2015 Dec 17. IF:4.590

45. Fabeni L, Berno G, Fokam J, Bertoli A, Alteri C, Gori C, Forbici F, Takou D, Vergori A, Zaccarelli M, Maffongelli G, Borghi V, Latini A, Pennica A, Mastroianni CM, Montella F, Mussini C, Andreoni M, Antinori A, Perno CF, Santoro MM; Resistance Study Group: Alteri C, Andreoni M, **Armenia D**, Bellocchi MC, Bertoli A, Biddittu A, Bruni M, Buonomini AR, Carioti L, Ceccherini-Silberstein F, Cerva C, Cesta N, Di Carlo D, Dori L, Foroghi L, Gentilotti E, Giannella S, Guenci T, Maffongelli G, Malagnino V, Ricciardi A, Romani M, Salpini R, Santoro MM, Sarmati L, Scutari R, Serafini V, Sordillo P, Stazi F, Stingone C, Svicher V, Teti E, Viscione M, Abbate I, Acinapura R, Alba L, Antinori A, Ammassari A, Baldini F, Bellagamba R, Boumis E, Berno G, Capobianchi MR, Carta S, Cicalini S, Continenza F, De Carli G, D'Arrigo R, D'Offizi G, Fabeni L, Fedele V, Galati V, Giannetti A, Girardi E, Gori C, Grisetti S, Libertone R, Liuzzi G, Lorenzini P, Maddaluno R, Mariano A, Navarra A, Nicastri E, Nurra G, Orchi N, Palummieri A, Perno CF, Pinnetti C, Pittalis S, Pizzi D, Puro V, Sampaolesi A, Sciarrone MR, Scognamiglio P, Sias C, Visco-Comandini U, Zaccarelli M, Colafigli M, Cristaudo A, Giuliani M, Latini A, Pacifici A, Pennica A, Di Sora F, Iebba F, Montella F, Lichtner M, Marocco R, Mastroianni CM, Bernardi S, Anzalone E, Bonaventura ME, Marchili M, Pitorri A, Falconi Di Francesco L, Di Giammartino D, Caterini A, Armignacco O, Mariani R, Paoloni M, Parruti G, Pieri A, Sozio F, Cellini A, Grimaldi A, Marian M, Picchi G, Borghi V, Mussini C, Gennari W, Fokam J, Nanfack AJ, Ndjolo A, Takou D, Torimiro JN. Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. *J Clin Microbiol.* 2017 Sep;55(9):2827-2837. doi: 10.1128/JCM.00656-17. Epub 2017 Jul 12. IF:3.051

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome Stefano Bonora

ESPERIENZA LAVORATIVA

Il 5 marzo 2001 ha assunto il ruolo di **Ricercatore** presso la **Clinica delle Malattie Infettive dell'Università di Torino**, dopo essere risultato vincitore della procedura di valutazione comparativa 116_R indetta dalla facoltà di Medicina e Chirurgia di Torino (G.U. n.29 del 11/04/2000)

Nel marzo 2005 è stato nominato **Professore Associato di Malattie Infettive** presso l'Università di Torino.

Ha conseguito **l'Abilitazione Scientifica Nazionale** per l'accesso alla prima fascia dei professori universitari nel 2014

ISTRUZIONE E FORMAZIONE

Stefano Bonora è nato a Verona l'8/7/1967.

-Nel 1986 ha conseguito la maturità classica con la votazione finale di 60/60.

-Si è laureato in Medicina e Chirurgia con 110/110 e lode presso l'Università di Verona il 5/11/1992, discutendo una tesi dal titolo "Epidemiologia batterica ed infezioni nosocomiali in un reparto di terapia intensiva neurochirurgica".

-Iscrizione all'Albo Professionale dei Medici e Chirurghi della provincia di Verona nel 16/03/1993.

.-Ha frequentato la Scuola di Specializzazione in Malattie Infettive dell'Università di Verona, dove si è diplomato il 23/10/1997 con 50/50 e lode discutendo una tesi dal titolo: "Aspetti clinico-epidemiologici e

analisi microbiologica di isolati di Mycobacterium Avium-complex in corso di infezione da HIV".

- Nel periodo 24 marzo-30 maggio 1997 ha frequentato il corso di Mycobactériologie Médicale (Micotteriologia Medica) presso l'Istituto Pasteur di Parigi, risultando primo negli esami di fine corso.

- Ha fruito dal 1/8/1998 al 31/1/1999 di una borsa di studio concessa riguardante un progetto di ricerca dal titolo: "Epidemiologia molecolare della tubercolosi" (responsabile scientifico Prof. Ercole Concia).

-Nel periodo compreso tra il 1/2/1999 ed il 31/12/1999 il dott. Bonora ha usufruito di una borsa di studio concessa dall'ANLAIDS-Sezione Veneto per il progetto di ricerca "Monitoraggio degli effetti collaterali dei farmaci inibitori della proteasi in corso di infezione da HIV" (responsabile scientifico Prof. Ercole Concia).

-Dal 2/3/98 al 10/7/98 e dal 28/2/2000 al 10/3/2000 ha effettuato due stages di perfezionamento concernenti "Il typing molecolare dei bacilli della tubercolosi" presso il Centro Nazionale di Riferimento

per Micobatteri dell'Istituto Pasteur di Parigi

-Nel 2000-2001 è risultato vincitore di una borsa di studio finalizzata alla lotta all'AIDS dell'Istituto Superiore di Sanità (D.D. 8/05/2000) per un progetto dal titolo "L'impatto dell'infezione da HIV sulla dinamica diffusiva della malattia tubercolare nell'area veronese".

- Nel marzo 2004 ha partecipato al corso HIV Management: Three-day Preceptorship for Italian Specialists tenutosi presso il Johns Hopkins Hospital di Baltimora (USA), responsabile prof John G. Bartlett.

-Membro dal 2010 dell'HIV/AIDS Italian Expert Panel che redige annualmente le Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1

-Membro del Comitato Scientifico della Fondazione ICONA - Italian Cohort of Antiretroviral Naive Patients dal 2009.

-Referee di riviste internazionali tra le quali AIDS, Clinical Infectious Diseases, Antiviral Therapy, HIV Medicine, Journal of Chemotherapy.

-Membro del Scientific Committee dell'International Workshop on Clinical Pharmacology of HIV Therapy dal 2012.

-Presso la Clinica di Malattie Infettive dell'Università di Torino è Responsabile del Centro di Sperimentazione Clinica della Terapia Antiretrovirale e dell'Ambulatorio di Prevenzione, Diagnosi e Cura dell'infezione da HIV/AIDS, nonché Referente Clinico del Laboratorio di Farmacologia Clinica e Farmacogenetica e del Laboratorio di Epidemiologia Molecolare della Tubercolosi.

Progetti finanziati e premi di ricerca

-Partecipante al progetto di ricerca "Produzione di citochine da parte di granulociti polimorfonucleati umani nella Sindrome da Immunodeficienza Acquisita e meccanismi di regolazione" coordinato dal Prof. Cassatella nell'ambito dell'VIII Progetto di Ricerca sull'AIDS 1995 dell'Istituto Superiore di Sanità.- Nel 2002 ha ottenuto un finanziamento come collaboratore in un progetto dal titolo "Valutazione di procedure innovative per l'isolamento e la caratterizzazione di mycobacterium bovis e per l'evidenziazione della reattività immunitaria del bovino". Progetto di ricerca corrente 2001

- Nell'aprile 2004 ha ottenuto un finanziamento dalla regione Piemonte per: "Studio epidemiologico-molecolare della diffusione dei ceppi di *M. tuberculosis* appartenenti alla famiglia Beijing nell'area urbana di Torino" nel quadro dei progetti di Ricerca Scientifica Applicata anno 2003

- Progetto di ricerca dal titolo "Analisi ed evoluzione di processi integrati operativi e gestionali per lo studio delle infezioni tubercolari negli animali e nell'uomo con particolare riferimento a Mycobacterium bovis". Ricerca corrente anno 2009 tra l'Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d'Aosta e l'Università degli Studi di Torino - Dipartimento di Discipline Medico-Chirurgiche - Sezione di Malattie Infettive. finanziamento di € 8.725,00 (avvio ricerca 01/11/2011 fino al 30/06/2013).

- Programma Nazionale di Ricerca sull'AIDS 2009-2010 dal titolo: "REYAGEN STUDY: PHARMACOGENETICS-BASED TAILORING OF UNBOOSTED ATAZANAVIR DOSING WHEN ADMINISTERED WITH TENOFOVIR IN HIV-POSITIVE PATIENTS" con l'Istituto Superiore di Sanità, durata della ricerca di 24 mesi a decorrere dal 01/12/2010 ed è finanziata per un importo pari a Euro 48.000,00.

"Progetti di ricerca finanziati dall'Università degli Studi di Torino (ex 60%):

- Anno 2002 (anno di presentazione 2001) - "Applicazione clinica del Therapeutic Drug Monitoring (TDM) dell'efavirenz somministrato in associazione alla terapia antitubercolare contenente rifampicina" finanziamento ottenuto € 4.660,00

- Anno 2003 - "Valutazione di una nuova metodica di genotipizzazione degli isolati di Mycobacterium tuberculosis nell'ambito di un progetto di epidemiologia tubercolare" finanziamento ottenuto € 4.756,00

- Anno 2004 - "Studio epidemiologico-molecolare della tubercolosi causata da ceppi appartenenti alla famiglia dei Beijing dell'area torinese" finanziamento ottenuto € 5.044,00

- Anno 2005 - "Valutazione farmacocinetica e farmacodinamica dell'utilizzo di enfuvirtide come componente di terapie antiretrovirali di salvataggio nei pazienti HIV-positivi" finanziamento ottenuto € 5.563,00

- Anno 2006 - "Valutazione del Quoziente Inibitorio genotipico (gIQ) come fattore predittivo dell'efficacia di tipranavir nei regimi antiretrovirali di salvataggio." finanziamento ottenuto € 5.501,00

- Anno 2007 - "Studio del passaggio transplacentare dei farmaci antiretrovirali" finanziamento ottenuto € 7.013,00

Anno 2008 - "Valutazione del Quoziente Inibitorio genotipico di darunavir come fattore predittivo di efficacia nella terapia di salvataggio nei pazienti HIV positivi" finanziamento ottenuto € 6.414,95

- Anno 2012 - "Studio randomizzato e controllato di switch a TDF/FTC/EFV somministrati tre volte la settimana in pazienti HIV-positivi con stabile soppressione virologica" finanziamento ottenuto € 3.824,40

Principali aree dell'attività di ricerca

- Produzione di citochine da parte dei granulociti neutrofili e ruolo patogenetico nelle malattie infettive
- Malaria: epidemiologia, patogenesi e terapia delle forme gravi.
- Tubercolosi: sviluppo di metodiche di fingerprinting degli isolati di *M.tuberculosis* ed epidemiologia
- Clinica, diagnostica e terapia delle infezioni opportunistiche in corso di Infezione da HIV/AIDS;
- Farmacologia clinica e farmacogenetica degli antiretrovirali;
- Farmacodinamica degli antiretrovirali con particolare riguardo ai determinati di efficacia virologica ed ai profili di tossicità;
- Epatite C: trattamento dell'infezione acuta, farmacologia clinica e farmacogenetica dei composti anti-HCV.

Attività didattica

-Negli anni 2000, 2001, 2002, 2003 e 2005 è stato invitato in qualità di docente presso l'Istituto Pasteur di Parigi nell'ambito del corso "Molecular tools and epidemiology of tuberculosis" su incarico conferito della

Prof.ssa Veronique Vincent.

-Titolare dell'insegnamento di Malattie Infettive nell'ambito del corso integrato "Malattie gastroenteriche ed infettive" del canale B della Facoltà di Medicina e Chirurgia dell'Università di Torino dall'anno accademico 2009/2010 .

-Affidatario dei seguenti insegnamenti nella Scuola di Specializzazione di Malattie Infettive dell'Università

di Torino (direttore Prof. Di Perri):

Vecchio Ordinamento (V.O.):

- dall'A.A. 2001/2002 all'A.A. 2002-2003: al I anno titolare del corso "Biologia molecolare".

-dall'A.A. 2001/2002 all'A.A. 2008/2009: al II anno titolare del corso "Malattie Infettive dell'apparato respiratorio.)"

- dall'A.A. 2003/2004 all'A.A. 2007/2008: al I anno titolare del corso "Applicazioni Biomolecolari delle Malattie Infettive."

Nuovo Ordinamento (N.O.):

- dal 2008/09: Tutor

- dall'A.A. 2010/2011: al III anno titolare del corso "Malattie Infettive (VI)- Malattie Infettive dell'apparato respiratorio I"

- dall'A.A. 2011/2012: al IV anno titolare del corso "Malattie Infettive XIII- Clinica e Terapia dell'infezione da HIV"

-Affidatario dell'insegnamento di Malattie Infettive, al IV anno N.O., dall'A.A. 2011-2012 nella Scuola di Specializzazione in Pediatria dell'Università di Torino

-Affidatario dell'insegnamento di Malattie Tropicali, al IV anno V.O., dall'A.A. 2005-2006 fino all'A.A. 2010/2011 nella Scuola di Specializzazione di Chirurgia Generale III dell'Università di Torino

-Nell'anno accademico 2001-2002 è stato affidatario per i canali canale A e B dell'insegnamento di Malattie Infettive nell'ambito del corso integrato "Tecniche infermieristiche applicate alla medicina clinica

specialistica" del Corso di Diploma Universitario di Infermiere dell'Università di Torino. Dal 2003-2004 è affidatario per il canale A e canale B dell'insegnamento di Malattie Infettive nell'ambito del corso integrato

"Problemi di salute IV" del Corso di Laurea in Infermieristica della Facoltà di Medicina e Chirurgia dell'Università di Torino

⊞Risulta affidatario dell'insegnamento di Malattie Infettive, al IV anno N.O., dall'A.A. 2011-2012 nella Scuola di Specializzazione in Pediatria dell'Università di Torino

CAPACITÀ E COMPETENZE PERSONALI

Acquisite nel corso della vita e ufficiali.

PRIMA LINGUA

italiano

ALTRE LINGUE

Inglese, francese

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

buona

buona

buona

CAPACITÀ E COMPETENZE RELAZIONALI

Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.

ottime

CAPACITÀ E COMPETENZE ORGANIZZATIVE

Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.

ottime

CAPACITÀ E COMPETENZE TECNICHE

Con computer, attrezzature specifiche, macchinari, ecc.

buone

CAPACITÀ E COMPETENZE ARTISTICHE

Musica, scrittura, disegno ecc.

scadenti

ALTRE CAPACITÀ E COMPETENZE

Competenze non precedentemente indicate.

nessuna

PATENTE O PATENTI

B

ULTERIORI INFORMAZIONI

Il Prof Bonora è autore di circa 350 pubblicazioni scientifiche recensite

ALLEGATI

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base al D. Lgs. 196 del 30 giugno 2003,

Torino, 28 MARZO 2022

Bonora (FIRMA)

Dr. Andrea Calcagno

Current position Since October 2020 Associate Professor of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.

Education Infectious Diseases Specialist since December 2007; graduated with honours at the University of Torino with a dissertation on the pharmacogenetics of nevirapine entitled "Effects of Cytochrome P450 2B6 Single Nucleotide Polymorphisms on the pharmacokinetic profile of nevirapine in a heterogenous cohort of HIV-infected patients".

Diploma in Tropical Medicine & Hygiene (DTM&H) at the Mahidol University, Bangkok, Thailand during 2006.

Graduated with honours in Medicine and Surgery at the University of Torino, Torino, Italy with a dissertation on antibiotic resistance in Intensive Care Units.

Admitted to the college of Physicians of Torino on the 19th December 2003: Licence number 20030.

Working Experience October 2012 - September 2020 Temporary Assistant Professor in Infectious Diseases ("RTD-B" since October 2017), Department of Medical Sciences, University of Turin.

Temporary Research Fellow at the University of Torino, Department of Infectious Diseases (March 2008- March 2012): shifts as Infectious Diseases Consultant and work as Clinical Researcher. Receiving a grant from the University of Torino for a research project entitled "Pharmacokinetics and Pharmacogenetics of raltegravir".

Six months (October 2006 – April 2007) and then one month (February 2009) in a rural hospital in Burundi as responsible of Paediatric and Malnourished children ward (50 beds) and HIV clinic.

Since October 2003 working in the HIV Clinic of the "Ospedale Amedeo di Savoia" in Torino mainly researching pharmacokinetics and pharmacodynamics of antiretroviral drugs. Participated in the conduction of phase II and phase III Clinical Trials.

During August 2003 one month attendance in the Internal Medicine ward of the University Hospital in Khartoum (Sudan).

2001/2 medical course attended at the University of Cordoba, Cordoba, Spain.

Spoken Languages Good knowledge of English and Spanish, basic knowledge of French. Italian as mother tongue.

Teaching Experience From the academic year 2013/2014 responsible of the Infectious Diseases course at the Nursing School and from the academic year 2017/2018 co-responsible of the Infectious Disease course at the School of Medicine and Surgery, University of Torino. Since 2007 participates in the preparation and conduction of lectures during the Infectious Diseases Course at the University of Torino (both to Medical Students and Nursing school students). Since 2012 teaching in the post-graduate school in Infectious Diseases at the University of Torino.

Since the academic year 2021/2022 teaching in the PhD Programme in Experimental Medicine and Therapy, University of Torino.

Ordinary Professor Qualification National Scientific Qualification (art.16 of the law 30 December 2010, n.240) for Ordinary Professor obtained on October 31st 2018 (and valid until October 30th, 2024).

Appointments 2015-2019 Member of the Governing Council of the Italian Society of Infectious Diseases and Tropical Medicine (SIMIT).

Editorial Board Since 2018, Academic Editor of "PlosOne".

Since 2017, Coordinator of the Study group on Mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine (SIMIT).

Since 2017 in the Scientific Committee of "IRENE" (Italian Registry of Pulmonary non tubercular Mycobacteria).

Since 2015 member of the GEPPPO (GEriatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group and from 2017 in the Scientific Committee of the cohort.

Since 2015, Vice Editor of "Infectious Diseases and Tropical Medicine".

Since 2015, in the Scientific Committee of the ICONA foundation (Italian Cohort Naïve Antiretrovirals).

Since 2013, Associate Editor of "BMC Infectious Diseases" Journal.

Conference Organization Since 2018, Member of the Organizing Committee of the International "Antivirals PK Workshop".

Member of the Scientific Committee of the Italian Conference on AIDS and Retroviruses in the years 2013, 2016, 2017, 2018, 2019, 2020 and 2021.

Guidelines Since 2012 member of the HIV/AIDS expert Panel writing the Italian Guidelines on the use of antiretroviral drugs and on the management of HIV-positive patients.

International Collaborations Since 2014, Collaboration with the Infectious Disease Institute, Makerere University, Kampala, Uganda. Capacity building for the creation of a Laboratory of Pharmacogenetics in Uganda and conduction of phase IV studies. He won two Erasmus+ projects (in collaboration with the Department of Social Sciences) for the years 2020-2022 and 2021-2023 for promoting the exchange between the University of Torino and the Makerere University.

- Awards**
- Winner of the "ICAR CROI Award 2012" for young Italian researchers for the project entitled "Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting" (Calcagno A et al. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 Marzo 2012, P603).
 - Winner of the "ICAR CROI Award 2013" for young Italian researchers for the project entitled "Cerebrospinal Fluid Viral and Neurodegenerative Markers in HIV-positive Very Late-presenters." Calcagno A et al. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 Marzo 2013, Atlanta, GE, USA. P438).
 - Winner of the "ICAR CROI Award 2014" for young Italian researchers for the project entitled "ABCC4 3348 T>C SNP Affects Tenofovir Urinary Output in HIV-Positive Patients". (Calcagno A, et al. 21st Conference on Retroviruses and Opportunistic Infections, March 3-6 2014, Boston, MA, USA. P 503).
 - Winner of the "ICAR CROI Award 2015" for young Italian researchers for the project entitled "Neurocognitive Screening Tests Are Associated with Cardiovascular Risk and VACS scores" (Calcagno A, et al. 22nd Conference on Retroviruses and Opportunistic Infections, february 23-26, 2015, Seattle, WA, USA. P487).
 - Winner of the "ICAR CROI Award 2016" for young Italian researchers for the project entitled "Predicting Drug Discontinuation in TDF-Tolerant Patients: A Prospective PK/PG Study" (Calcagno A, et al. 23rd Conference on Retroviruses and Opportunistic Infections. Boston, MA, US. February 22-25, 2016. P426).
 - Winner of the special jury "ICAR CROI Award 2017" for young Italian researchers for the project entitled "Discordant HIV RNA in Olfactory Mucosa of HIV-positive Patients" (Calcagno A, et al. 24th Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017, Seattle, WA, USA. P379).

- Fund Raising**
- "Ricerca Finalizzata 2013": 225.246 € for the network projects NET-2013-02355333-4 "Plasma, intracellular and tissue concentrations reached by a multi-target antiretroviral treatment during the treatment of patients with primary HIV infection: a pharmacokinetic/pharmacodynamic study".
 - BMS grant support 2014: 20000 € for the project "Intracellular penetration of antiretrovirals into astrocytes: an *in vitro* study".
 - Gilead Fellowship 2014: 15000 € for the project "Antiretroviral toxicity on astrocytes: an *in vitro* and *in vivo* study".

- Gilead Fellowship 2012: 25000 € for the project “Determinants of proximal tubular dysfunction in HIV-positive patients: a cross-sectional analysis in patients above 50 years of age”

Orcid ID 0000-0003-2534-8815

Publications

1. Airoldi C, Calcagno A, Di Perri G, Valinotto R, Gallo L, Locana E, Trunfio M, Patrucco F, Vineis P, Faggiano F. Seroprevalence of SARS-CoV-2 Among Workers in Northern Italy. **Ann Work Expo Health**. **2021**. Impact factor 1.81
2. Trunfio M, Scabini S, Mornese Pinna S, Ruge W, Alcantarini C, Pirriatore V, Di Perri G, Bonora S, Castelnuovo B, Calcagno A. The Manifesto of Pharmacoenosis: Merging HIV Pharmacology into Pathocoenosis and Syndemics in Developing Countries. **Microorganisms**. **2021** Jul 31;9(8):1648. Impact factor 4.128.
3. Cusato J, Mula J, Palermi A, Manca A, Antonucci M, Avataneo V, De Vivo ED, Ianniello A, Calcagno A, Di Perri G, De Nicolò A, D'Avolio A. Seasonal Variation of Antiretroviral Drug Exposure during the Year: The Experience of 10 Years of Therapeutic Drug Monitoring. **Biomedicines**. **2021** Sep 12;9(9):1202.
4. Parietti M, Trunfio M, Delmonte S, Conti L, Trentalange A, Bonora S, Calcagno A, Ribero S. Efflorescence of acquired epidermodysplasia verruciformis due to immune reconstitution inflammatory syndrome-like mechanisms following anti-HPV vaccination in a HIV-positive patient. **Int J STD AIDS**. **2021** Oct 11:9564624211048343.
5. Avallone G, Trunfio M, Mastorino L, Agostini A, Merli M, Rubatto M, Caracciolo D, Calcagno A, Senetta R, Fierro MT, Quaglino P, Ribero S. Case Report: Atypical Cutaneous Presentation of Human T-cell Lymphotropic Virus Type 1-Related Adult T-cell Lymphoma. **Am J Trop Med Hyg**. **2021** Oct 11:tpmd210630.
6. Focà E, Calcagno A, Calza S, Renzetti S, Chiesa A, Siano M, De Socio G, Piconi S, Orofino G, Madeddu G, Cattelan AM, Nozza S, Ferrara M, Milic J, Celesia BM, Castelli F, Guaraldi G. Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPPO cohort. **PLoS One**. **2021** Oct 13;16(10):e0258533.
7. Cusato J, Tempestilli M, Calcagno A, Vergori A, Piselli P, Antonucci M, Avataneo V, Palermi A, Notari S, Antinori A, Di Perri G, Agrati C, D'Avolio A. Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz. **Nutrients**. **2021** Oct 12;13(10):3571.
8. Clerico M, Dogliotti I, Calcagno A, Grimaldi D, Leone S, Ragaini S, Boffini M, Caracciolo D, Ferrero S, Barbero C, Zanutto E, Stroffolini G, Cavallo R, Rinaldi M, Bruno B, Cavallo F. COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment. **Hemasphere** **2021**.
9. Chan TY, De Zan V, Gregg A, Alagaratnam J, Gerevini S, Antinori A, Monforte AD, Saracino A, Trunfio M, Everitt A, Rackstraw S, Marta M, Calcagno A,

- Cinque P, Winston A. Cerebrospinal fluid HIV RNA escape symptomatology. **AIDS 2021.**
10. De Nicolò A, Manca A, Ianniello A, Palermiti A, Calcagno A, Ferrara M, Antonucci M, Cusato J, Avataneo V, De Vivo E, Bonora S, De Rosa FG, Di Perri G, D'Avolio A. Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma. **Pharmaceuticals (Basel) 2021.**
 11. De Nicolò A, Avataneo V, Cusato J, Palermiti A, Mula J, De Vivo E, Antonucci M, Bonora S, Calcagno A, Di Perri G, De Rosa FG, D'Avolio A. Analytical Validation and Clinical Application of Rapid Serological Tests for SARS-CoV-2 Suitable for Large-Scale Screening. **Diagnostics (Basel) 2021.**
 12. Caligaris G, Trunfio M, Ghisetti V, Cusato J, Nigra M, Atzori C, Imperiale D, Bonora S, Di Perri G, Calcagno A. Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers. **Diagnostics (Basel) 2021.**
 13. Calcagno A, Trunfio M, D'Avolio A, Di Perri G, Bonora S. The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV. *Expert Opin Drug Metab Toxicol* 2021.
 14. Calcagno A, de Nicolò A, Pizzi C, Trunfio M, Tettoni C, Ferrara M, Alcantarini C, Trentini L, D'Avolio A, Di Perri G, Bonora S. Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. *Br J Clin Pharmacol* 2021.
 15. Trunfio M, Calcagno A, Bonora S, Di Perri G. Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases. *Lancet Infect Dis* 2021.
 16. Trunfio M, Longo BM, Alladio F, Venuti F, Cerutti F, Ghisetti V, Bonora S, Di Perri G, Calcagno A. On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases. *Front Microbiol* 2021.
 17. Ancona G, Merlini E, Tincati C, Barassi A, Calcagno A, Augello M, Bono V, Bai F, Cannizzo ES, d'Arminio Monforte A, Marchetti G. Long-Term Suppressive cART Is Not Sufficient to Restore Intestinal Permeability and Gut Microbiota Compositional Changes. *Front Immunol* 2021.
 18. Trunfio M, Venuti F, Alladio F, Longo BM, Burdino E, Cerutti F, Ghisetti V, Bertucci R, Picco C, Bonora S, Di Perri G, Calcagno A. Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. *Viruses* 2021.
 19. Guaraldi G, Calza S, Milic J, Calcagno A, Focà E, Rota M, Renzetti S, Celotti A, Siano M, Celesia BM, Piconi S, de Socio GV, Cattelan AM, Orofino G, Riva A, Nozza S, di Perri G. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV. *AIDS* 2021.
 20. Lin SP, Calcagno A, Letendre SL, Ma Q. Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants. *Curr Top Behav Neurosci* 2021.

21. Trentalange A, Borgogno E, Motta I, Antonucci M, Pirriatore V, Costa C, Rossi G, Barco A, De Nicolò A, Piccioni P, D'Avolio A, Bonora S, Perri GD, Calcagno A. Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses? *Int J Antimicrob Agents* 2021.
22. The TB/COVID-19 Global Study Group. TB and COVID-19 co-infection: rationale and aims of a global study. *Int J Tuberc Lung Dis* 2021.
23. Trunfio M, Salvador E, Gaviraghi A, Audagnotto S, Marinaro L, Motta I, Casciaro R, Ghisetti V, Fava C, Bonora S, Di Perri G, Calcagno A; e-COVID Study Group. Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity. *Antivir Ther* 2021.
24. De Nicolò A, Ianniello A, Ferrara M, Avataneo V, Cusato J, Antonucci M, De Vivo E, Waitt C, Calcagno A, Trentalange A, Muccioli G, Bonora S, Di Perri G, D'Avolio A. Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. *Pharmaceuticals (Basel)* 2020.
25. Calcagno A, Dal Conte I, Cattaneo D, Testi R, Mistrangelo M, Gervasoni C, de Nicolò A, Bonora S, D'Avolio A, Di Perri G. Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders. *Antimicrob Agents Chemother* 2020.
26. Maggiolo F, Bandera A, Bonora S, Borderi M, Calcagno A, Cattelan A, Cingolani A, Gianotti N, Lichtner M, Lo Caputo S, Madeddu G, Maggi P, Marchetti GC, Maserati R, Nozza S, Rusconi S, Zazzi M, Di Biagio A. Enhancing care for people living with HIV: current and future monitoring approaches. *Expert Rev Anti Infect Ther* 2020.
27. Trunfio M, Salvador E, Cabodi D, Marinaro L, Alcantarini C, Gaviraghi A, Trentalange A, Lipani F, Sciascia S, Roccatello D, Bonora S, Di Perri G, Calcagno A; e-COVID Study group. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. *Thromb Res* 2020.
28. Calcagno A, Ghisetti V, Emanuele T, Trunfio M, Faraoni S, Boglione L, Burdino E, Audagnotto S, Lipani F, Nigra M, D'Avolio A, Bonora S, Di Perri G. Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy. *Emerg Infect Dis* 2020.
29. Calcagno A, Ghisetti V, Burdino E, Trunfio M, Alice T, Boglione L, Bonora S, Di Perri G. Coinfection with other respiratory pathogens in COVID-19 patients. *Clin Microbiol Infect* 2020.
30. De Benedetto I, Trunfio M, Guastamacchia G, Bonora S, Calcagno A. A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs. *J Neurovirol* 2020.
31. Calcagno A, Moltò J, Borghetti A, Gervasoni C, Milesi M, Valle M, Avataneo V, Alcantarini C, Pla-Junca F, Trunfio M, D'Avolio A, Di Giambenedetto S, Cattaneo D, Di Perri G, Bonora S. Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. *Clin Pharmacokinet* 2020.
32. Trunfio M, Ruggie W, Mighetto L, Vai D, Atzori C, Nigra M, Domini S, Borgogno E, Guastamacchia G, Bonora S, Di Perri G, Calcagno A. Dual

antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. *AIDS*. 2020.

33. Taramasso L, Fabbiani M, Nozza S, De Benedetto I, Bruzzesi E, Mastrangelo A, Pinnetti C, Calcagno A, Ferrara M, Bozzi G, Focà E, Quiros-Roldan E, Ripamonti D, Campus M, Celesia BM, Torti C, Cosco L, Di Biagio A, Rusconi S, Marchetti G, Mussini C, Gulminetti R, Cingolani A, d'Ettorre G, Madeddu G, Franco A, Orofino G, Squillace N, Muscatello A, Gori A, Antinori A, Tambussi G, Bandera A; INACTION study group. Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (IN ACTION) cohort. *HIV Med* 2020.
34. Dravid AN, Gawali R, Betha TP, Sharma AK, Medisetty M, Natrajan K, Kulkarni MM, Saraf CK, Mahajan US, Kore SD, Rathod NM, Mahajan US, Letendre SL, Wadia RS, Calcagno A. Two treatment strategies for management of Neurosymptomatic cerebrospinal fluid HIV escape in Pune, India. *Medicine (Baltimore)* 2020.
35. Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, Bonora S, Calcagno A, Cecchi I, Cinnirella G, Converso M, Cozzi M, Crosasso P, De Iaco F, Di Perri G, Eandi M, Fenoglio R, Giusti M, Imperiale D, Imperiale G, Livigni S, Manno E, Massara C, Milone V, Natale G, Navarra M, Oddone V, Osella S, Piccioni P, Radin M, Roccatello D, Rossi D. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. *Clin Exp Rheumatol* 2020.
36. Muscatello A, Nozza S, Fabbiani M, De Benedetto I, Ripa M, Dell'acqua R, Antinori A, Pinnetti C, Calcagno A, Ferrara M, Focà E, Quiros-Roldan E, Ripamonti D, Campus M, Maurizio Celesia B, Torti C, Cosco L, Di Biagio A, Rusconi S, Marchetti G, Mussini C, Gulminetti R, Cingolani A, D'ettorre G, Madeddu G, Franco A, Orofino G, Squillace N, Gori A, Tambussi G, Bandera A; Inaction Study Group. Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV InfectiON (IN ACTION) Retrospective Study. *Pathog Immun* 2020.
37. Mornese Pinna S, Trunfio M, Imperiale D, Calcagno A. JC virus DNA in cerebrospinal fluid: insight into clinical significance. *Diagn Microbiol Infect Dis* 2020.
38. Lupia T, Milia MG, Atzori C, Gianella S, Audagnotto S, Imperiale D, Mighetto L, Pirriatore V, Gregori G, Lipani F, Ghisetti V, Bonora S, Di Perri G, Calcagno A. Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation. *AIDS* 2020.
39. Joseph SB, Trunfio M, Kincer LP, Calcagno A, Price RW. What can characterization of cerebrospinal fluid escape populations teach us about viral reservoirs in the central nervous system? *AIDS* 2019.
40. Lwanga I, Nabaggala MS, Kiragga A, Calcagno A, Guaraldi G, Lamorde M, Castelnuovo B. Implementing routine physical function screening among elderly HIV-positive patients in Uganda. *AIDS Care* 2019.
41. Goletti D, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, De Carli G, Fondaco L, Franzetti F, Giannetti A, Gori A, Lapadula G, Lichtner M,

- Mastroianni CM, Mazzotta V, Orchi N, Pavone P, Piacentini D, Pirriatore V, Pontali E, Sarmati L, Spolti A, Tacconelli E, Galli M, Antinori A, Calcagno A, Girardi E. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. *Int J Infect Dis*. 2020.
42. Lupia T, Scabini S, Stroffolini G, Calcagno A. I have got you under my skin. *Infection* 2020.
 43. Montrucchio C, De Nicolò A, D'Ettorre G, D'Ascenzo F, Lazzaro A, Tettoni M, D'Avolio A, Bonora S, Celani L, Di Perri G, Calcagno A. Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic Supplementation. *Int J Antimicrob Agents*. 2020.
 44. Costa C, Scabini S, Kaimal A, Kasozi W, Cusato J, Kafufu B, Borderi M, Mwaka E, Di Perri G, Lamorde M, Calcagno A, Castelnuovo B. Calcaneal quantitative ultrasound and urine retinol binding protein in HIV-positive antiretroviral-treated patients in Uganda: a pilot study. *J Infect Dis* 2020.
 45. Calcagno A, Cusato J, Ferrara M, De Nicolò A, Lazzaro A, Manca A, D'Avolio A, Di Perri G, Bonora S. Antiretroviral concentrations in the presence and absence of valproic acid. *J Antimicrob Chemother* 2020.
 46. Cusato J, Calcagno A, Marinaro L, Avataneo V, D'Avolio A, Di Perri G, Bonora S. Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. *Pharmacogenomics J* 2019.
 47. Focà E, Magro P, Guaraldi G, Riva A, Cattelan AM, De Socio GV, Costa C, Piconi S, Celesia BM, Nozza S, Orofino G, Castagna A, Di Perri G, Castelli F, Calcagno A; GEPPPO (GERiatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group. Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPPPO" Cohort. *PLoS One* 2019.
 48. Trunfio M, Manini C, Trentalange A, Boghi A, Audagnotto S, Imperiale D, Taraglio S, Bonora S, Di Perri G, Calcagno A. The "milky way" galaxy of HIV-related central nervous system immune reaction syndromes. *J Neurovirol* 2019.
 49. Di Stefano A, Alcantarini C, Atzori C, Lipani F, Imperiale D, Burdino E, Audagnotto S, Mighetto L, Milia MG, Di Perri G, Calcagno A. Cerebrospinal fluid biomarkers in patients with central nervous system infections: a retrospective study. *CNS Spectr* 2019.
 50. Armenia D, Di Carlo D, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, Santoro MM; ICONA Foundation Study Group. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. *Antivir Ther* 2019.
 51. Cusato J, Calcagno A, De Nicolò A, Mogyorosi K, D'Avolio A, Di Perri G, Bonora S. Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. *Diagn Microbiol Infect Dis* 2019.

52. Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P. Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines? *Antimicrob Agents Chemother* 2019.
53. Ssebambulidde K, Segawa I, Laker E, Lamorde M, Castelnuovo B, Nakasujja N, Calcagno A. Symptomatic cerebrospinal fluid HIV-1 escape in two patients on second-line antiretroviral therapy in Uganda. *Oxf Med Case Reports*. 2019. *Not Impacted*.
54. Calcagno A, Cusato J, Sekaggya-Wiltshire C, von Braun A, Motta I, Turyasingura G, Castelnuovo B, Fehr J, Di Perri G, Lamorde M. The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Co-infected Patients in Uganda in the SOUTH Study. *Clin Pharmacol Ther* 2019.
55. Pinzone MR, Ceccarelli M, Venanzi Rullo E, Maresca M, Bruno R, Condorelli F, Di Rosa M, Madeddu G, Focà E, Calcagno A, Celesia BM, Cacopardo B, Nunnari G, Pellicanò GF. Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV+ subjects on cART: A potential marker of kidney disease. *Biomed Rep*. 2019. *Not Impacted*.
56. Peyracchia M, Verardi R, Rubin SR, Abu-Assi E, Montrucchio C, Perl L, Grossomarra W, Calcagno A, Omedè P, Montefusco A, Bonora S, Moretti C, D'Amico M, Mauro R, D'Ascenzo F. In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis. *J Cardiovasc Med (Hagerstown)* 2019.
57. Mondì A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A; Ico Foundation Study Group. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Ico cohort. *J Int AIDS Soc* 2019.
58. Lupia T, Costa C, Forni N, Calcagno A. A "Tinea" immune reconstitution inflammatory syndrome in a HIV-positive patient starting combination antiretroviral treatment. *G Ital Dermatol Venereol* 2019.
59. Bertero L, Joseph SB, Trunfio M, Alice T, CATERA S, Imperiale D, Cassoni P, Kincer LP, Pirriatore V, Ghisetti V, Amasio E, Zanusso G, Bonora S, Di Perri G, Calcagno A. HIV-1 detection in the olfactory mucosa of HIV-1 infected participants. *AIDS* 2019.
60. Borghetti A, Calcagno A, Lombardi F, Cusato J, Belmonti S, D'Avolio A, Ciccarelli N, La Monica S, Colafigli M, Delle Donne V, De Marco R, Tamburrini E, Visconti E, Di Perri G, De Luca A, Bonora S, Di Giambenedetto S. SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. *J Antimicrob Chemother* 2018.
61. Trunfio M, Pinnetti C, Focà E, Bai F, Maffongelli G, Celani L, Cinque P, Celotti A, Andreoni M, Monforte AD, D'Ettorre G, Antinori A, Calcagno A. Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions? *AIDS* 2018.
62. Di Perri G, Calcagno A, Trentalange A, Bonora S. The clinical pharmacology of integrase inhibitors. *Expert Rev Clin Pharmacol* 2018.
63. Calcagno A, Fiumanò M, Zugna D, Cusato J, Montrucchio C, Marinaro L, Trentini L, Ferrara M, D'Avolio A, Pizzi C, Di Perri G, Bonora S. Tenofovir

disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization? *Pharmacogenomics J* 2019.

64. von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, Fehr J, Calcagno A, Lamorde M, Sekaggya-Wiltshire C. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. *J Antimicrob Chemother* 2019.
65. Trentalange A, Prochet A, Imperiale D, Cusato J, Tettoni M, Nunnari G, Barco A, Bonora S, Di Perri G, Calcagno A. Cerebral white matter Hyperintensities in HIV-positive patients. *Brain Imaging Behav* 2018.
66. Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, Calcagno A, Nardini S, Assael BM, Tortoli E, Besozzi G, Ferrarese M, Matteelli A, Girardi E, De Lorenzo S, Seia M, Gramegna A, Del Prato B, Terranova L, Oriano M, Sverzellati N, Mirsaeidi M, Chalmers JD, Haworth CS, Loebinger MR, Aksamit T, Winthrop K, Ringshausen FC, Previdi G, Blasi F; IRENE Network. The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. *Multidiscip Respir Med* 2018. *Not Impacted*.
67. Merlini E, Iannuzzi F, Calcagno A, Bai F, Trunfio M, d'Arminio Monforte A, Bonora S, Marchetti G. Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). *J Neurovirol* 2018.
68. Scabini S, Trunfio M, Pirriatore V, Imperiale D, Audagnotto S, Bertucci R, Ghisetti V, Cinnirella G, Cistaro A, Perna M, Calcagno A, Di Perri G. Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy. *Infez Med* 2018. *Not Impacted*.
69. Allegra S, Cardellino CS, Fatiguso G, Cusato J, De Nicolò A, Avataneo V, Bonora S, D'Avolio A, Di Perri G, Calcagno A. Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. *J Clin Pharmacol* 2018.
70. Focà E, Cavaglià G, Rusconi S, Cascavilla A, Cenderello G, Re A, Casari S, van den Bogaart L, Zinzani PL, Caracciolo D, Di Perri G, Bonito A, Lucchini A, Cassola G, Viale P, Calcagno A. Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. *HIV Med* 2018.
71. Peyracchia M, De Lio G, Montrucchio C, Omedè P, d'Ettore G, Calcagno A, Vullo V, Cerrato E, Pennacchi M, Sardella G, Manga P, GrossoMarra W, Vullo F, Fedele F, Biondi-Zoccai G, Moretti C, Vachiat A, Bonora S, Rinaldi M, Mancone M, D'Ascenzo F. Evaluation of coronary features of HIV patients presenting with ACS: The CUORE, a multicenter study. *Atherosclerosis* 2018.
72. Trunfio M, Vai D, Montrucchio C, Alcantarini C, Livelli A, Tettoni MC, Orofino G, Audagnotto S, Imperiale D, Bonora S, Di Perri G, Calcagno A. Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. *HIV Med* 2018.
73. Focà E, Calcagno A, Bonito A, Cusato J, Domenighini E, D'Avolio A, Quiros Roldan E, Trentini L, Castelnuovo F, Di Perri G, Castelli F, Bonora S. Pharmacokinetic Changes during Pregnancy According to Genetic Variants:

- a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. *Antimicrob Agents Chemother* 2018.
74. Guaraldi G, Malagoli A, Calcagno A, Mussi C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Riva A, Focà E, Nozza S, Di Perri G. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years. *BMC Geriatr* 2018.
 75. Calcagno A, Pinnetti C, De Nicolò A, Scarvaglieri E, Gisslen M, Tempestilli M, D'Avolio A, Fedele V, Di Perri G, Antinori A, Bonora S. Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration. *Br J Clin Pharmacol*. 2018 Feb 14. doi: 10.1111/bcp.13552. [Epub ahead of print] Impact factor 2016: 3.493.
 76. Bigliano P, Calcagno A, Lucchini A, Audagnotto S, Montrucchio C, Marinaro L, Alcantarini C, Ghisetti V, Di Perri G, Bonora S. The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment. *Antivir Ther* 2018.
 77. Calcagno A, Barco A, Trunfio M, Bonora S. CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose. *Curr HIV/AIDS Rep* 2018.
 78. Palazzo A, Trunfio M, Pirriatore V, Milesi M, De Nicolò A, Alcantarini C, D'Avolio A, Bonora S, Di Perri G, Calcagno A. Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. *J Antimicrob Chemother* 2017.
 79. Trunfio M, Joseph SB, Ghisetti V, Romito A, Martini C, Cusato J, Audagnotto S, Pesci Kincer L, Ferrara M, Sala A, Imperiale D, Di Perri G, Calcagno A. Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. *J Neurovirol*. 2017.
 80. Motta I, Calcagno A, Bonora S. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? *Expert Opin Drug Metab Toxicol* 2018.
 81. Cusato J, Allegra S, Nicolò A, Calcagno A, D'Avolio A. Precision medicine for HIV: where are we? *Pharmacogenomics*. 2018.
 82. Motta I, Trunfio M, Calcagno A, Pirriatore V, Scabini S, Palazzo A, Audagnotto S, Fatiguso G, Liberini V, Bellò M, D'Avolio A, Di Perri G, Bonora S. Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during *Mycobacterium genavense* and Leishmania abdominal infections. *J Antimicrob Chemother* 2017.
 83. Focà E, Calcagno A, Bonito A, Simiele M, Domenighini E, D'Avolio A, Quiros Roldan E, Trentini L, Casari S, Di Perri G, Castelli F, Bonora S. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. *J Antimicrob Chemother* 2017.
 84. Calcagno A, Piconi S, Focà E, Nozza S, Carli F, Montrucchio C, Cattelan AM, Orofino G, Celesia BM, Morena V, De Socio GV, Guaraldi G; GEPPO (GERiatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group. Role of Normalized T-Cell Subsets in Predicting Comorbidities

- in a Large Cohort of Geriatric HIV-infected Patient. *J Acquir Immune Defic Syndr* 2017.
85. Mornese Pinna S, Scarvaglieri E, Milia MG, Imperiale D, Ghisetti V, Audagnotto S, Prochet A, Lipani F, Bonora S, Di Perri G, Calcagno A. Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? *J Neurovirol* 2017.
 86. Nozza S, Malagoli A, Maia L, Calcagno A, Focà E, De Socio G, Piconi S, Orofino G, Cattelan AM, Celesia BM, Gervasi E, Guaraldi G; GEPPPO Study Group. Antiretroviral therapy in geriatric HIV patients: the GEPPPO cohort study. *J Antimicrob Chemother* 2017.
 87. Allegra S, Fatiguso G, Calcagno A, Baietto L, Motta I, Favata F, Cusato J, Bonora S, Di Perri G, D'Avolio A. Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. *Pharmacogenomics* 2017.
 88. Calcagno A, Lucchini A, Caracciolo D, Balbiano R, Bracchi M, Sordella F, Gregori G, Lipani F, Audagnotto S, Chiriotto M, Cavaglià G, Ghisetti V, Di Perri G, Bonora S. High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders. *Curr HIV Res* 2017.
 89. Calcagno A, Pagani N, Ariaudo A, Arduino G, Carcieri C, D'Avolio A, Marinaro L, Tettoni MC, Trentini L, Di Perri G, Bonora S. Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure. *J Antimicrob Chemother* 2017.
 90. Biagini R, Montrucchio C, Calcagno A, Trentini L, Tettoni MC, Alcantarini C, Barco A, Trentalange A, Milesi M, Ferrara M, Bertucci R, Di Perri G, Bonora S. Geriatrics in HIV infection: multimorbidity, polipharmacy and primary prevention in patients above 65 years). *Journal of HIV and Ageing*. 2017. *Not Impacted*
 91. Motta I, Alice T, Romito A, Ferrara M, Ecclesia S, Imperiale D, Ghisetti V, Di Perri G, Bonora S, Calcagno A. Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia. *Antivir Ther* 2017.
 92. Motta I, Calcagno A, Baietto L, Bigliano P, Costa C, Baruffi K, Fatiguso G, D'Avolio A, Di Perri G, Bonora S. Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs. *Br J Clin Pharmacol* 2017.
 93. Montrucchio C, Biagini R, Alcantarini C, Calcagno A, Barco A, Ferrara M, Milesi M, Costa C, Trentalange A, Trunfio M, Tettoni MC, Grosso Marra W, D'Ascenzo F, Ballocca F, Lonni E, Gili S, Vai D, Imperiale D, Gaita F, Bonora S, Di Perri G. Cardiovascular risk and neurocognitive deficits in HIV-positive individuals. *Infectious Diseases & Tropical Medicine* 2017. *Not Impacted*.
 94. Calcagno A, Di Perri G, Bonora S. Treating HIV Infection in the Central Nervous System. *Drugs* 2017.
 95. Armenia D, Di Carlo D, Calcagno A, Vendemiati G, Forbici F, Bertoli A, Berno G, Carta S, Continenza F, Fedele V, Bellagamba R, Cicalini S, Ammassari A, Libertone R, Zaccarelli M, Ghisetti V, Andreoni M, Ceccherini-Silberstein F, Bonora S, Di Perri G, Antinori A, Perno CF, Santoro MM. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. *J Antimicrob Chemother* 2016.

96. Marinaro L, Calcagno A, Ripamonti D, Cenderello G, Pirriatore V, Trentini L, Salassa B, Bramato C, Orofino G, D'Avolio A, Rizzi M, Di Perri G, Rusconi S, Bonora S. Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. *J Clin Virol* 2016.
97. Guaraldi G, Menozzi M, Zona S, Calcagno A, Silva AR, Santoro A, Malagoli A, Dolci G, Mussi C, Mussini C, Cesari M, Khoo SH. Impact of polypharmacy on antiretroviral prescription in people living with HIV. *J Antimicrob Chemother* 2016.
98. Calcagno A, Romito A, Atzori C, Ghisetti V, Cardellino C, Audagnotto S, Scarvaglieri E, Lipani F, Imperiale D, Di Perri G, Bonora S. Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis. *J Neuroimmune Pharmacol* 2016.
99. Sanfilippo C, Nunnari G, Calcagno A, Malaguarnera L, Blennow K, Zetterberg H, Di Rosa M. The chitinases expression is related to Simian Immunodeficiency Virus Encephalitis (SIVE) and in HIV encephalitis (HIVE). *Virus Res* 2016.
100. Calcagno A, Cusato J, D'Avolio A, Bonora S. Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. *Clin Pharmacokinet* 2016.
101. Gili S, Mancone M, Ballocca F, Grosso Marra W, Calcagno A, D'Ettore G, Cannillo M, D'Ascenzo F, Orofino G, Marruncheddu L, Lonni E, Cinque A, Vullo F, Ceccarelli G, Vilardi I, Sardella G, Vullo V, Moretti C, Fedele F, Bonora S, Gaita F. Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study. *J Cardiovasc Med (Hagerstown)* 2016.
102. Ruggiero T, Burdino E, Calcagno A, Bonora S, Boglione L, Di Perri G, Ghisetti V. HCV NS3 naturally occurring variants in HIV/HCV coinfecting DAA-naïve patients: consideration for HCV genotyping resistance testing. *Infection* 2016.
103. Focà E, Nunnari G, Calcagno A. The good, the bad and the ugly: Determinants of antiretroviral-associated toxicities. *Future Virology* 2016.
104. Patti F, Calcagno A, Simiele M, Bonasso M, Di Perri G, D'Avolio A, Bonora S. Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms. *Am J Health Syst Pharm* 2016.
105. Calcagno A, Di Perri G, Bonora S. What do we know about tailoring treatment with tenofovir? *Pharmacogenomics* 2016.
106. Calcagno A, Simiele M, Motta I, Mornese Pinna S, Bertucci R, D'Avolio A, Di Perri G, Bonora S. Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients. *AIDS Res Hum Retroviruses* 2016.
107. Ballocca F, Gili S, D'Ascenzo F, Marra WG, Cannillo M, Calcagno A, Bonora S, Flammer A, Coppola J, Moretti C, Gaita F. HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era. *Prog Cardiovasc Dis* 2016.
108. Trentalange A, Calcagno A, Ghisetti V, Atzori C, Busolli P, Bonora S, Imperiale D. Clearance of cerebrospinal fluid JCV DNA with mirtazapine in a patient with

- progressive multifocal leukoencephalopathy and sarcoidosis. *Antivir Ther* 2016.
109. Gili S, Grosso Marra W, D'Ascenzo F, Lonni E, Calcagno A, Cannillo M, Ballocca F, Cerrato E, Pianelli M, Barbero U, Mancone M, DiNicolantonio JJ, Lavie CJ, Omedè P, Montefusco A, Bonora S, Gasparini M, Biondi-Zoccai G, Moretti C, Gaita F. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. *Eur Heart J* 2016.
 110. Lucchini A, Lipani F, Costa C, Scavaglieri M, Balbiano R, Carosella S, Calcagno A, Audagnotto S, Barbui AM, Brossa S, Ghisetti V, Dal Conte I, Caramello P, Di Perri G. Louseborne Relapsing Fever among East African Refugees, Italy, 2015. *Emerg Infect Dis.* 2016.
 111. Cusato J, Tomasello C, Simiele M, Calcagno A, Bonora S, Marinaro L, Leggieri A, Allegra S, Di Perri G, D'Avolio A. Efavirenz pharmacogenetics in a cohort of Italian patients. *Int J Antimicrob Agents* 2015.
 112. Motta I, Calcagno A, Baietto L, D'Avolio A, De Rosa FG, Bonora S. A probable drug-to-drug interaction between voriconazole and haloperidol in a slow CYP2C9 metabolizer. *Infez Med* 2015. *Not impacted.*
 113. Bonora S, Calcagno A, Trentalange A, Perri GD. Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults. *Expert Opin Pharmacother* 2015.
 114. Fatiguso G, Allegra S, Calcagno A, Baietto L, Motta I, Favata F, Cusato J, Bonora S, Perri GD, D'Avolio A. Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. *Int J Pharm.* 2015.
 115. Calcagno A, Rostagno R, Arnaudo I, Zanusso G, Bonora S, Lucchini A, Maiello A, Dal Conte I, Meoli I, Ferrari S, Monaco S, Rizzuto N, Di Perri G. CSF 14-3-3 protein and its ζ isoform are prognostic markers in HIV positive patients with CNS disease. *Infectious Diseases & Tropical Medicine* 2015. *Not Impacted.*
 116. Calcagno A, Cusato J, Marinaro L, Simiele M, Lucchiari M, Alcantarini C, Tettoni MC, Trentini L, Mengozzi G, D'Avolio A, Di Perri G, Bonora S. Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment. *AIDS* 2016.
 117. Livelli A, Orofino GC, Calcagno A, Farenga M, Penoncelli D, Guastavigna M, Carosella S, Caramello P, Pia L. Evaluation of a Cognitive Rehabilitation Protocol in HIV Patients with Associated Neurocognitive Disorders: Efficacy and Stability Over Time. *Front Behav Neurosci* 2015.
 118. Andreoni M, Marcotullio S, Puro V, De Carli G, Tambussi G, Nozza S, Gori A, Rusconi S, Santoro MM, Clementi M, Perno CF, d'Arminio Monforte A, Maggiolo F, Castagna A, De Luca A, Galli M, Giacomelli A, Borderi M, Guaraldi G, Calcagno A, Di Perri G, Bonora S, Mussini C, Di Biagio A, Puoti M, Bruno R, Zuccaro V, Antinori A, Cinque P, Croce D, Restelli U, Rizzardini G, Lazzarin A. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaimProject. *New Microbiol* 2015.
 119. Calcagno A, Cusato J, Marinaro L, Trentini L, Alcantarini C, Mussa M, Simiele M, D'Avolio A, Di Perri G, Bonora S. Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. *Pharmacogenomics J* 2015.

120. Calcagno A, Montrucchio C, Capetti A, Guaraldi G, Cenderello G, Calza L, Lanzafame M, Marinaro L, Tettoni MC, Trentini L, D'Avolio A, Di Perri G, Bonora S. Raltegravir plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-positive Patients: Safety, Efficacy and Pharmacokinetics. *Curr HIV Res* 2015.
121. Calcagno A, Trentalange A, Simiele M, Marinaro L, Patti F, Tettoni MC, Trentini L, Di Perri G, D'Avolio A, Bonora S. Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole. *Ther Drug Monit* 2015.
122. Calcagno A, Atzori C, Romito A, Vai D, Audagnotto S, Stella ML, Montrucchio C, Imperiale D, Di Perri G, Bonora S. Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients. *J Neurovirol* 2015.
123. Siccardi M, Olagunju A, Simiele M, D'Avolio A, Calcagno A, Di Perri G, Bonora S, Owen A. Class-specific relative genetic contribution for key antiretroviral drugs. *J Antimicrob Chemother* 2015.
124. Bonora S, Rusconi S, Calcagno A, Bracchi M, Viganò O, Cusato J, Lanzafame M, Trentalange A, Marinaro L, Siccardi M, D'Avolio A, Galli M, Di Perri G. Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). *J Antimicrob Chemother* 2015.
125. Calcagno A, Motta I, Ghisetti V, Lo Re S, Alice T, Marinaro L, Milia MG, Tettoni MC, Trentini L, Orofino G, Salassa B, Di Perri G, Bonora S. HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients. *AIDS Res Hum Retroviruses* 2015.
126. Calcagno A, D'Avolio A, Bonora S. Pharmacokinetic and pharmacodynamic evaluation of Raltegravir and Experience from Clinical Trials in HIV-positive Patients. *Expert Opinion On Drug Metabolism and Toxicology* 2015.
127. Baietto L, Calcagno A, Motta I, Baruffi K, Poretti V, Di Perri G, Bonora S, D'Avolio A. A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. *J Antimicrob Chemother* 2015.
128. Simiele M, Carcieri C, De Nicolò A, Ariaudo A, Sciandra M, Calcagno A, Bonora S, Di Perri G, D'Avolio A. A LC-MS method to quantify tenofovir urinary concentrations in treated patients. *J Pharm Biomed Anal* 2015.
129. Calcagno A, Nozza S, Muss C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Ripamonti D, Riva A, Di Perri G. Ageing with HIV: a multidisciplinary review. *Infection* 2015.
130. Cerrato E, Calcagno A, D'Ascenzo F, Biondi-Zoccai G, Mancone M, Grosso Marra W, Demarie D, Omedè P, Abbate A, Bonora S, Di Nicolantonio JJ, Estrada V, Escaned J, Moretti C, Gaita F. Cardiovascular disease in HIV patients: from bench to bedside and backwards. *Open Heart* 2015. *Not Impacted*.
131. D'Ascenzo F, Cerrato E, Calcagno A, Grossomarra W, Ballocca F, Omedè P, Montefusco A, Veglia S, Barbero U, Gili S, Cannillo M, Pianelli M, Mistretta E, Raviola A, Salera D, Garabello D, Mancone M, Estrada V, Escaned J, De Marie D, Abbate A, Bonora S, Zoccai GB, Moretti C, Gaita F. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis. *Atherosclerosis* 2015.
132. Ghisetti V, Calcagno A, Burdino E, Orofino G, Bonora S. Acute HIV infection: Improved algorithms for HIV testing. *J Clin Virol* 2015.

133. Calcagno A, Motta I, Milia M, Rostagno R, Simiele M, Libanore V, Fontana S, D'Avolio A, Ghisetti V, Di Perri G, Bonora S. Dried Plasma/Blood Spots for Monitoring Antiretroviral Treatment Efficacy and Pharmacokinetics: a Cross-sectional Study in Rural Burundi. *Br J Clin Pharmacol* 2015.
134. Calcagno A, Simiele M, Alberione MC, Bracchi M, Marinaro L, Ecclesia S, Di Perri G, D'Avolio A and Bonora S. Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. *Clin Infect Dis* 2015.
135. Baietto L, D'Avolio A, Cusato J, Pace S, Calcagno A, Motta I, Corcione S, Di Perri G, De Rosa FG. Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. *J Antimicrob Chemother* 2014.
136. Calcagno A, Di Perri G, Bonora S. Pharmacokinetics and Pharmacodynamics of Antiretrovirals in the Central Nervous System. *Clinical Pharmacokinetics* 2014.
137. Trentalange A, Calcagno A, Raviolo S, Prochet A, Audagnotto S, Ghisetti V, Di Perri G and Bonora S. Cytomegalovirus Central Nervous System Compartmentalization in a Patient Presenting with AIDS. *Antiviral therapy* 2014.
138. Bonora S, Calcagno A, Viganò O, Bigliano P, Marinaro L, Colella E, Orofino G, Trentini L, Tettoni MC, D'Avolio A, Mercadante S, Galli M, Di Perri G and Rusconi S. Efficacy, Tolerability and Virological Consequences of Long-term Use of Unboosted Atazanavir plus 2 NRTIs in HIV-infected Patients. *Current HIV Research* 2014.
139. Calcagno A, Baietto L, Pagani N, Simiele M, Audagnotto S, D'Avolio A, De Rosa FG, Di Perri G and Bonora S. Voriconazole and Atazanavir: a CYP 2C19-dependant Manageable Drug to Drug Interaction. *Pharmacogenomics* 2014.
140. Cannillo M, D'Ascenzo F, Grosso Marra W, Cerrato E, Calcagno A, Omedè P, Bonora S, Mancone M, Vizza D, Di Nicolantonio JJ, Pianelli M, Barbero U, Gili S, Annone U, Raviola A, Salera D, Mistretta E, Vilardi I, Colaci C, Abbate A, Zoccai GB, Moretti C, Gaita F. Heart failure in patients with human immunodeficiency virus: a review of the literature. *J Cardiovasc Med (Hagerstown)* 2014.
141. Lanzafame M, Bonora S, Lattuada E, Calcagno A, Di Perri G, Concia E. Disappearance of renal stones in a HIV-1-infected patient after reduction of atazanavir dose. *AIDS Res Hum Retroviruses* 2014.
142. D'Avolio A, Carcieri C, Cusato J, Simiele M, Calcagno A, Allegra S, Sciandra M, Trentini L, Di Perri G, Bonora S. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. *J Antimicrob Chemother* 2014.
143. D'Ascenzo F, Quadri G, Cerrato E, Calcagno A, Omedè P, Grosso Marra W, Abbate A, Bonora S, Biondi Zoccai G, Moretti C, Gaita F. A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era. *J Cardiovasc Med (Hagerstown)* 2014.
144. Calcagno A, Alberione MC, Romito A, Imperiale D, Ghisetti V, Audagnotto S, Lipani F, Raviolo S, Di Perri G, Bonora S. Prevalence and predictors of blood-brain barrier damage in the HAART era. *J Neurovirol.* 2014.
145. D'Ascenzo F, Cerrato E, Appleton D, Moretti C, Calcagno A, Abouzaki N, Vetrovec G, Lhermusier T, Carrie D, Das Neves B, Escaned J, Cassese S, Kastrati A, Chinaglia A, Belli R, Capodanno D, Tamburino C, Santilli F, Parodi G, Vachiat

- A, Manga P, Vignali L, Mancone M, Sardella G, Fedele F, DiNicolantonio JJ, Omedè P, Bonora S, Gaita F, Abbate A, Biondi Zoccai G. Prognostic Indicators for Recurrent Thrombotic Events in HIV-infected Patients With Acute Coronary Syndromes: Use of Registry Data From 12 sites in Europe, South Africa and the United States. *Thrombosis Research* 2014.
146. Calcagno A, Marinaro L, Nozza S, Aldieri C, Carbone A, Ghisetti V, Trentalange A, D'Avolio A, Castagna A, Di Perri G and Bonora S. Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. *Antiviral Res* 2014.
147. Calcagno A, Lamorde M, D'Avolio A and Bonora S. Personalizing HIV Therapeutics in Resource-Limited Rural Communities: Lessons Learned From the Use of New Tools in Africa. *Current Pharmacogenomics and Personalized Medicine* 2014. *Not Impacted*
148. De Nicolò A, Simiele M, Calcagno A, Abdi AM, Bonora S, Di Perri G and D'Avolio A. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitors regimens. *Antimicrob Agents Chemother* 2014.
149. Calcagno A, Nozza S, Simiele M, Milia MG, Chiappetta S, D'Avolio A, Ghisetti V, Lazzarin A, Di Perri G, Bonora S. Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. *J Antimicrob Chemother* 2014.
150. De Nicolò A, Simiele M, Calcagno A, Mohamed Abdi A, Bonora S, Di Perri G, D'Avolio A. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitors regimens. *Antimicrob Agents Chemother* 2014.
151. Corcione S, Cardellino CS, Calcagno A, Fossati L, Costa C, Cavallo R, Di Perri G, De Rosa FG. Health-care Associated KPC-BSI: The Time Has Come. *Clin Infect Dis* 2014.
152. Salizzoni S, D'Ascenzo F, Moretti C, Bonora S, Calcagno A, Omedè P, Montrucchio C, Cerrato E, Colaci C, Sheiban I, Marra S, Rinaldi M, Gaita F. Transcatheter aortic valve implantation in a 54-year-old patient with aggressive HIV. *World J Clin Cases* 2014. *Not Impacted*
153. Marchetti G, Cozzi-Lepri A, Tincati C, Calcagno A, Ceccherini-Silberstein F, De Luca A, Antinori A, Castagna A, Puoti M, Monforte Ad; Iona Foundation Study Group. Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Iona Foundation study. *BMC Infect Dis* 2014.
154. Nozza S, Bigoloni A, Calcagno A, Galli L, Pignataro AR, D'Avolio A, Carbone A, Ripa M, Bonora S, Lazzarin A, Castagna A. Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. *J Antimicrob Chemother* 2014.
155. De Francia S, D'Avolio A, Ariaud A, Pirro E, Piccione F, Simiele M, Fava C, Calcagno A, Di Perri G, Saglio G. Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia. *Ther Drug Monit* 2014.
156. Calcagno A, D'Avolio A, Di Perri G and Bonora S. Comment on "Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral therapy is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid". *J Acquir Immune Defic Syndr* 2013.

157. Calcagno A, Cusato J, Simiele M, et al. High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. *J Antimicrob Chemother* 2014.
158. Ruggiero T, De Rosa F, Cerutti F, Pagani N, Alice T, Stella ML, Milia MG, Calcagno A, Burdino E, Gregori G, Urbino R, Di Perri G, Ranieri MV, Ghisetti V. A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection. *Influenza Other Respi Viruses* 2013.
159. Calcagno A, Baietto L, Pagani N, et al. Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment. *Scand J Infect Dis* 2013.
160. D'Avolio A, Cusato J, Calcagno A and Di Perri G. Estimating Ribavirin plasma exposure: genetics or therapeutic drug monitoring? *J Hepatol* 2013.
161. Calcagno A, Trentini L, Marinaro L, Montrucchio C, D'Avolio A, Ghisetti V, Di Perri G, Bonora S. Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy. *J Antimicrob Chemother* 2013.
162. Calcagno A, Nozza S, de Requena DG, Galli A, D'Avolio A, Simiele M, Chiappetta S, Di Perri G, Lazzarin A, Bonora S. Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. *J Antimicrob Chemother* 2013.
163. Calcagno A, Boglione L, De Rosa FG, Di Perri G, Bonora S. Elimination Half-Life May Explain the Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1. *Clin Infect Dis* 2013.
164. Calcagno A, Gonzalez de Requena D, Simiele M, D'Avolio A, Tettoni M, Salassa B, Orofino G, Bramato C, Libanore V, Motta I, Bigliano P, Orsucci E, Di Perri G, Bonora S. Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. *Antimicrob Agents Chemother* 2013.
165. Santoro MM, Armenia D, Alteri C, Flandre P, Calcagno A, Santoro M, Gori C, Fabeni L, Bellagamba R, Borghi V, Forbici F, Latini A, Palamara G, Libertone R, Tozzi V, Boumis E, Tommasi C, Pinnetti C, Ammassari A, Nicastrì E, Buonomini A, Svicher V, Andreoni M, Narciso P, Mussini C, Antinori A, Ceccherini-Silberstein F, Di Perri G, Perno CF. Impact of pre-therapy viral load on virological response to modern first-line HAART. *Antivir Ther* 2013.
166. Cerrato E, D'Ascenzo F, Biondi-Zoccai G, Calcagno A, Frea S, Grosso Marra W, Castagno D, Omedè P, Quadri G, Sciuto F, Presutti D, Frati G, Bonora S, Moretti C, Gaita F. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. *Eur Heart J* 2013.
167. Calcagno A, Tettoni MC, Simiele M, Trentini L, Montrucchio C, D'Avolio A, Di Perri G, Bonora S. Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. *J Antimicrob Chemother* 2013.
168. Rekić D, Röshammar D, Bergstrand M, Tarning J, Calcagno A, D'Avolio A, Ormaasen V, Vigan M, Barrail-Tran A, Ashton M, Gisslén M, Abelö A. External

- Validation of the Bilirubin-Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients. AAPS J 2013.
169. D'Avolio A, Simiele M, Calcagno A, Siccardi M, Larovere G, Agati S, Baietto L, Cusato J, Tettoni M, Sciandra M, Trentini L, Di Perri G, Bonora S. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. *J Antimicrob Chemother* 2012.
 170. D'Avolio A, Ciancio A, Siccardi M, Smedile A, Simiele M, Cusato J, Baietto L, Marucco DA, Cariti G, Calcagno A, Gonzalez de Requena D, Sciandra M, Troshina G, Caviglia GP, Bonora S, Rizzetto M, Di Perri G. Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. *Ther Drug Monit* 2012.
 171. Calcagno A, Rostagno R, Di Perri G. Anti-CD20 antibody therapy for B-cell lymphomas. *N Engl J Med* 2012.
 172. Bibas M, Lorenzini P, Cozzi-Lepri A, Calcagno A, di Giambenedetto S, Costantini A, Castagna A, Manfrin V, Monforte AD, Antinori A; for the ICONA Cohort Study Group. Polyclonal serum free light chains elevation in HIV-infected patients. *AIDS* 2012.
 173. Calcagno A, Yilmaz A, Cusato J, Simiele M, Bertucci R, Siccardi M, Marinaro L, D'Avolio A, Di Perri G, Bonora S. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. *AIDS*. 2012.
 174. D'Avolio A, De Nicolò A, Simiele M, Turini S, Agnesod D, Boglione L, Cusato J, Baietto L, Cariti G, Calcagno A, Sciandra M, Di Perri G, Bonora S. Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. *J Pharm Biomed Anal*. 2012.
 175. Calcagno A, D'Avolio A, Simiele M, Cusato J, Rostagno R, Libanore V, Baietto L, Siccardi M, Bonora S and Di Perri G. Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive Patients Using Dried Sample Spots Devices. *British Journal of Clinical Pharmacology* 2012.
 176. D'Avolio A, Ciancio A, Siccardi M, Smedile A, Baietto L, Simiele M, Aguilar Marucco D, Cariti G, Calcagno A, Gonzalez de Requena D, Sciandra M, Cusato J, Troshina M, Bonora S, Rizzetto M and Di Perri G. ITPA polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associated anaemia in patients under standard anti-HCV treatment. *Therapeutic Drug Monitoring* 2012.
 177. Bonora S, Calcagno A, Cometto C, Fontana S, Aguilar D, D'Avolio A, Gonzalez de Requena D, Maiello A, Dal Conte I, Lucchini A and Di Perri G. Short Term Additional Enfuvirtide Therapy is Associated with a Greater Immunological Recovery in HIV Very Late Presenters: a Controlled Pilot Study. *Infection* 2012.
 178. Siccardi M, D'Avolio A, Rodriguez-Novoa S, Simiele M, Baietto L, Calcagno A, Moss D, Back D, Owen A, Bonora S and Di Perri G. Intra and inter patient pharmacokinetic variability of raltegravir in the clinical setting. *Therapeutic Drug Monitoring* 2012.
 179. D'Avolio, Ciancio A, Siccardi M, Baietto L, Simiele M, Cariti G, Calcagno A, Smedile A, Cusato J, Bonora S, Rizzetto M and Di Perri G. Ribavirin Pharmacokinetics and IL28 plus CYP27B1 SNPs as predictors of response to Peg-IFN/RBV treatment in HCV ¼ infected patients. *Hepatology* 2011.

180. Calcagno A, Bonora S, Simiele M, Rostagno R, Tettoni MC, Bonasso M, Romito A, Imperiale D, D'Avolio A and Di Perri G. Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. *AIDS* 2011.
181. Calcagno A, Nozza S, Bonora S, Castagna A, Gonzalez de Requena D, D'Avolio A, Lazzarin A and Di Perri G. Pharmacokinetics of the Raltegravir/Maraviroc/Etravirine Combination. *J Antimicrob Chemother* 2011.
182. Bonora S, Gonzalez de Requena D, D'Avolio A, Calcagno A, Tettoni MC, Siccardi M, Baietto L, Simiele M, Trentini L, Di Perri G. Pharmacokinetics of switching unboosted Atazanavir co-administered with Tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. *Antiviral Therapy* 2011.
183. Gonzalez de Requena D, Bonora S, Viganò O, Calcagno A, Cometto C, D'Avolio A, Baietto L, Ghisetti V, Magnani S, Ferramosca S, Vitiello P, Galli M, Rusconi S, Di Perri G. Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. *J Antimicrob Chemother* 2011.
184. Calcagno A, Baietto L, De Rosa FG, Tettoni MC, Libanore V, Bertucci R, D'Avolio A, Di Perri G. Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. *J Antimicrob Chemother* 2011.
185. Lanzafame M, Bonora S, Lattuada E, Calcagno A, Vento S. A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients. *Braz J Infect Dis* 2011.
186. Siccardi M, D'Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, Moss D, Kwan W, Castagna A, Lazzarin A, Calcagno A, Bonora S, Back D, Di Perri G, Owen A. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521C>T polymorphism. *Pharmacogenet Genomics* 2010.
187. Calcagno A, Rostagno R, Audagnotto S, D'Avolio A, Bonora S, Ghisetti V, Di Perri G. Is peritoneal fluid a sanctuary site for HIV? *J Antimicrob Chemother* 2010.
188. Calcagno A, Bonora S, D'Avolio A, Siccardi M, Simiele M, Chiesa M, Gonzalez de Requena D, Di Perri G. Raltegravir penetration in seminal plasma of healthy volunteers. *Antimicrob Agents Chemother* 2010.
189. Calcagno A, Bonora S, Bertucci R, Lucchini A, D'Avolio A, Di Perri G. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. *AIDS* 2010.
190. Lanzafame M, Hill A, Lattuada E, Calcagno A, Bonora S. Raltegravir: is a 400 mg once-daily dose enough? *J Antimicrob Chemother* 2010.
191. Calcagno A, Bonora S, Tettoni MC, D'Avolio A, Lanzafame M, Penco G, Di Perri G. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. *J Acquir Immune Defic Syndr* 2009.
192. Bonora S, Calcagno A, Di Perri G. HIV infection: treatment of naïve patients. *Infez Med* 2009. *Not Impacted*.
193. Bonora S, Nicastrì E, Calcagno A, Gonzalez de Requena D, D'Ettorre G, Sarmati L, Palmisano L, Vullo V, Di Perri G, Andreoni M. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. *J Med Virol* 2009.

194. Bonora S, Mondo A, Trentini L, Calcagno A, Lucchini A, Di Perri G. Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. *Journal of Infection* 2008.
195. González de Requena D, Bonora S, Castagna A, Hasson H, Marucco Aguilar D, D'Avolio A, Sciandra M, Trentini L, Calcagno A, Lazzarin A, Di Perri G. Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. *J Antimicrob Chemother* 2008.
196. González de Requena DG, Bonora S, Calcagno A, D'Avolio A, Siccardi M, Fontana S, Milia MG, Sciandra M, Garazzino S, Di Garbo A, Baietto L, Trentini L, Di Perri G. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. *Antimicrob Agents Chemother* 2008.
197. Bonora S, Calcagno A, Fontana S, D'Avolio A, Siccardi M, Gobbi F, Di Perri G. Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. *Clin Infect Dis* 2007.
198. Aguilar Marucco D, Veronese L, de Requena DG, Bonora S, Calcagno A, Cavecchia I, Sinicco A, De Rosa FG, Cariti G, Di Perri G. Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. *J Antimicrob Chemother* 2007.
199. González de Requena D, Calcagno A, Bonora S, Ladetto L, D'Avolio A, Sciandra M, Siccardi M, Bargiacchi O, Sinicco A, Di Perri G. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. *AIDS* 2006.
200. Garazzino S, Tettoni M, Calcagno A, D'Avolio A, Bonora S, Di Perri G. Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases. *J Antimicrob Chemother* 2006.
201. Bonora S, Calcagno A, Gonzalez de Requena D, Bargiacchi O, Di Perri G. Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors. *Infez Med* 2006. *Not Impacted*.

<p>Published articles: 201 (188 with Impact Factor) Citations: 2239; Average Citations: 11.1 H-index (Scopus): 25 H-index (Google Scholar): 31 i10-index (Google Scholar): 99</p>

Lectures at National and International Conferences

- Calcagno A. "COVID-19 from a recovered healthcare worker's perspective" – COVID-19 – A IAS Virtual Conference – July 10-11 2020.
- Calcagno A and Cavassini M. "HIV-associated neurocognitive disorders and neurological complications – An update" – 17th European AIDS Conference – November 6-9 2019, Basel, Switzerland.
- Calcagno A. "Antiretrovirals distribution in sanctuaries" – 11th Italian Conference on AIDS and Antiviral Research – June 5-7, 2019, Milan, Italy.

- Calcagno A. “Last Advances in HIV Pharmacogenomics” - 19th International Workshop on Clinical Pharmacology of Antiviral Therapy, 22 - 24 May 2018, Baltimore, Maryland, USA
- Calcagno A, et al. “Age, Inflammation, Blood Brain Barrier Permeability and Single Nucleotide Polymorphisms in Transporters May Influence Cerebrospinal Fluid Antiretrovirals’ Concentrations” - 19th International Workshop on Clinical Pharmacology of Antiviral Therapy, 22 - 24 May 2018, Baltimore, Maryland, USA
- Calcagno A, et al. “SLC22A2 Genetic Variants and Dolutegravir Trough Concentrations Correlate with Specific Psychiatric Symptoms in HIV-positive Patients on Dolutegravir” - 19th International Workshop on Clinical Pharmacology of Antiviral Therapy, 22 - 24 May 2018, Baltimore, Maryland, USA
- Calcagno A. “La gestione dell’HIV nella popolazione che invecchia” - XVI Congresso Nazionale SIMIT – Salerno 15-18 Ottobre 2017
- Calcagno A. “Asymptomatic CSF Escape” - Seventh International Meeting on HIV Infection of the Central Nervous System – Pollenzo – 12-14th October, 2017
- Calcagno A. “Pharmacokinetic correlates of effective HAART”- 8th Italian Conference on AIDS and Retroviruses, 2016, 6-8 June, Milano, Italy.
- Calcagno A. “Therapeutics of the CNS With HIV Infection”. Conference on Retroviruses and Opportunistic Infections. Boston, MA, US. February 22-25, 2016.
- Calcagno A. “Toxicities in HIV”. 15th European AIDS Conference. October 20th-24th 2015. Barcelona, Spain.
- Calcagno A, et al. “The relevance of CSF PK in managing CNS ART effectiveness”. Sixth International meeting on HIV infection of the Central Nervous System. October 8th-10th 2015, Matera, Italy
- Calcagno A, et al. “Antiretroviral Drug Concentrations in the Central Nervous System: Scarce, Enough or Too Much?”. 7th Italian Conference on AIDS and Retroviruses, 2015, 17-19 May, Riccione, Italy.
- Calcagno A, et al. “Blood Brain Barrier Impairment is Associated with Cerebrospinal Fluid Markers of Neuronal Damage in HIV-positive Patients”7th Italian Conference on AIDS and Retroviruses, 2015, 17-19 May, Riccione, Italy.
- Calcagno A, et al. “Concordance Among Cardiovascular Risk Scores in HIV-positive Patients: Framingham, D:A:D and Progetto Cuore”. 6th Italian Conference on AIDS and Retroviruses, 2014, 25-27 May, Roma, Italy.
- Calcagno A, et al. “Level of HIV Viremia Below 50 copies/ml Predicts Virologic Rebound in HAART-treated Patients”. 14th Conference of the European AIDS Clinical Society, Bruxelles, Belgium. 16-19 October, 2013.
- Calcagno A, et al. “High Incidence of Cytomegalovirus Reactivation in HIV-positive Patients Treated for Haematological Malignancies”. 5th Italian Conference on AIDS and Retroviruses, 2013, 12-14 May, Torino, Italy.
- Calcagno A, et al. “Cerebrospinal Fluid Concentrations Above Drugs IC95s are Associated With CSF Viral Loads Below 50 copies/ml”. 14th International Workshop on Clinical Pharmacology of HIV Treatment, Amsterdam, Netherlands, 22-24 April 2013.

- Calcagno A, et al. "Measurement of CSF tau, phosphorylated tau and β -amyloid (1-42) in HIV-positive patients at different stages of infection." 4th Italian Conference on AIDS and Retroviruses, 2012, Naples, Italy.
- Calcagno A "TB, poly-pharmacy and Drug Interactions". EACS Pre-Educational Course, 13th European AIDS Conference, October 12-15, 2011 - Belgrade, Serbia
- Calcagno A, et al. "Monitoring of Virological and Pharmacological Cerebrospinal Fluid Parameters in HAART-treated HIV-positive Patients in the Clinical Setting". ICAR 2011, Florence, Italy.
- Calcagno A, et al. "A Filter-based Cross-sectional Analysis of a HIV Positive HAART-treated Cohort in Rural Burundi: Pharmacokinetics, Pharmacogenetics and Viral Load". HIV10, 10th International Congress on Drug Therapy in HIV Infection, Glasgow, Glasgow, Regno Unito, November 2010.
- Calcagno A, et al. "Raltegravir in the CSF: is Cmax more appropriate than Ctough?". 3rd Meeting on HIV Infection and the Central Nervous System, Stresa, Italy, October 2009.
- Calcagno A, et al. "La Rinascita degli Inibitori Non Nucleosidici". Convegno Nazionale SIMIT, Società Italiana di Malattie Infettive, Modena, Italia, Novembre 2009.
- Calcagno A, et al. "Greater immunological recovery associated with additional enfuvirtide in the treatment of naïve HIV-infected patients at very advanced disease stages: results of a randomized, controlled, pilot study". 1st Italian Conference on AIDS and Retroviruses, 2009, Milano, Italy.
- Calcagno A, et al. "Effect of Darunavir (DRV) genotypic inhibitory quotient (glQ) on the virological response to DRV-containing salvage regimens at 24 weeks". IWCPHT, 9th International Workshop on Clinical Pharmacology of HIV Treatment, New Orleans, USA, 2008.

Books

Co-Wrote the chapter "Aging with HIV and Oxidative stress", in the book "HIV/AIDS, Oxidative Stress and Dietary Antioxidants" Elsevier. Editors: Victor Preedy Ronald Watson. ISBN: 9780128098530.

Wrote the chapter "Antiretroviral Drug Penetration into the CNS Compartment" in the printed and online "Encyclopedia of AIDS" Springer. Editors: Thomas J. Hope, Mario Stevenson, Douglas Richman. ISBN: 978-1-4614-9610-6 (Online)

Partecipated in the writing of the chapter "Natural History of HIV Infection and Evoluton of Antiretroviral Therapy" in the book "Cardiovascular Disease in AIDS", Springer-verlag Italia S.r.l., 2008, Barbaro G, Boccara F and Skolnik PR.

Partecipated in the writing of the chapter "Donovanosis" in the book "Infezioni Genitali: Aspetti patogenetici, clinici e diagnostici", Latino MA, Magliano E, AMCLI, Milano, 2009.

Torino, Italy; October 25th 2021

CALCAGNO ANDREA

*Autorizzo il trattamento dei miei dati personali ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n°196-
"Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 – "Regolamento
europeo sulla protezione dei dati personali*

Torino, Italy; October 25th 2021

CALCAGNO ANDREA



INFORMAZIONI PERSONALI

Nome LEONARDO CALZA

ESPERIENZA LAVORATIVA

- Date (da – a) Dal Gennaio 2005 al Settembre 2014
 - Nome e indirizzo del datore di lavoro Università di Bologna, via Zamboni 33, 40138 Bologna
 - Tipo di azienda o settore Ricercatore Universitario, SSD MED/17 Malattie Infettive
 - Tipo di impiego
- Date (da – a) dal Settembre 2014, a tutt'oggi
 - Nome e indirizzo del datore di lavoro Università di Bologna, via Zamboni 33, 40138 Bologna
 - Tipo di azienda o settore Professore Associato, SSD MED/17 Malattie Infettive
 - Tipo di impiego
- Date (da – a) Dal Settembre 2005, a tutt'oggi
 - Nome e indirizzo del datore di lavoro U.O. Malattie Infettive, Azienda Ospedaliero-Universitaria, Policlinico di S.Orsola, Via G. Massarenti, 11 – 40138 Bologna
 - Tipo di azienda o settore Dirigente medico
 - Tipo di impiego
- Principali mansioni e responsabilità Dal Giugno 2017, Responsabile della Struttura Semplice Interaziendale-Programma Interaziendale "Percorso gestionale multidisciplinare del paziente affetto da infezione da HIV, coinfezione con virus epatitici e MTS".

ISTRUZIONE E FORMAZIONE

- Date (da – a) 30/10/1997
 - Nome e tipo di istituto di istruzione o formazione Università di Bologna
 - Qualifica conseguita LAUREA IN MEDICINA E CHIRURGIA
- Date (da – a) 06/11/2002
 - Nome e tipo di istituto di istruzione o formazione Università di Bologna
 - Qualifica conseguita DIPLOMA DI SPECIALIZZAZIONE IN MALATTIE INFETTIVE

CAPACITÀ E COMPETENZE PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

PRIMA LINGUA

ITALIANO

ALTRE LINGUE

INGLESE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

OTTIMA

BUONA

BUONA

FRANCESE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

OTTIMA

BUONA

BUONA

ULTERIORI INFORMAZIONI

Autore e coautore di oltre 250 pubblicazioni a stampa su riviste nazionali ed internazionali; autore di oltre 50 comunicazioni orali presentate a congressi scientifici nazionali ed internazionali.

Impact factor >150 (Research gate)

H index 27 (Scopus)

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Il sottoscritto inoltre **autorizza il trattamento dei propri dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali"**.

Codice fiscale **CLZLRD72E29A944Q**

Bologna, 09/03/22

CURRICULUM VITAE

PERSONAL DATA

ELISABETTA CARINI

**Working address: San Raffaele Hospital Scientific Institute
- Infectious Diseases Department - Via Stamira d'Ancona, 20 20127 Milan
(Italy)**

CURRICULUM STUDIORUM

1994 Commercial Diploma "Ragioniere e perito commerciale"
at Istituto Tecnico Commerciale Statale "R. Mattioli" in
Milan - Italy (vote 48/60).

PROFESSIONAL EXPERIENCES AND TRAINING

1994 Stage at "Banca Popolare di Milano" DUOMO Agency for
3 weeks.

From 1995 to 1999 Accountant and secretary part time at "Gavazzi F.lli
S.n.c.". Experience in administrative accountability and invoices, customers
contacts, estimates and orders materials.

1999 (since July) Data Manager at the Division of Infectious Diseases
Department (focus on HIV/AIDS infection) - Prof. Adriano Lazzarin
Director of Unit - San Raffaele Scientific Institute-.

2000 Study Coordinator for sponsored international clinical trials (phase II
- III - IV and EAP Program): attendance to Investigator's Meeting,
contacts with Ethics Committee for the submission of documentation
regarding HIV and HCV trials, contacts with sponsors and monitors CRA,
fill in data on CRFs and electronic CRFs, drug accountability, contacts
with patients for dispensing drugs and appointments, evaluation of
compliance, administration of quality of life questionnaire (QOL, MOS-
HIV, FAHI).

2002 Roche Certificate of attending: Course in Trial Research
(methodology and GCP regulation).

2003 Certificate of Attending; Course in Clinical Trial organized by Fondazione Centro San Raffaele del Monte Tabor.

2004 Study Coordinator for Italian Multicenter Trial title "Mas Que Nada" coordinated and promoting by Fondazione Centro San Raffaele del Monte Tabor.

2006 Certificate of Completion in Human Participants Protection Education for Research Teams (online course), sponsored by the National Institutes of Health (NIH).

Oct 2006 Certificate of attending; Course in Clinical Trials, Regulations (GCP and International Guidelines) and Reports coordinated by "Istituto di Ricerca Internazionale" in Milan.

13 July 2009 Certificate of Completion for NIH web-based training course "Protecting Human Research Participants" Certification Number: 255888

15 July 2009 Certificate of attending at the Meeting "Compassionate use of drugs and Expanded Access Program" organized by Doctor Gianna Zoppi - Fondazione Centro San Raffaele del Monte Tabor.

December 2009-2010

During this period Mrs Carini performed n.14 open-visits in different Italian sites taking part in MONO Study (an Italian Phase III no profit study that received an economic grant from Agenzia Italiana del Farmaco - AIFA Regulatory Site). Title of study was "Studio randomizzato di confronto tra l'introduzione immediata o differita di un nuovo regime antiretrovirale nel paziente con infezione da HIV non responder: ruolo della monoterapia con Lamivudina". As study coordinator she supported and trained the Italian sites participating to these studies in submitting and follow the procedures required by their Ethics Committees to receive the local approval.

10 Feb 2010 Participation attendance at "Drug vigilance in clinical trials - Advanced course".

22 Feb 2010 Participation attendance at SSFA Course "Draw an Informed Consent: which are the most frequent errors and how prepare a correct information for patients".

29 Oct 2010 GCP Investigator Training Course and Best Practices (version January 2010) organized during a Teleconference from Johnson and Johnson (Certificate of Attendance).

15-18-19 November 2010 Certificate of Attendance: X Course in Clinical Trial (GCP, Rules and Methodology) organized by Fondazione Centro San Raffaele del Monte Tabor.

2011 During this period Mrs Carini worked as study coordinator for the Italian sites taking part in to MODAt Study (an Italian phase III no profit study

that received a grant from BMS). Title of the study was "Efficacy of atazanavir / ritonavir monotherapy as maintenance in patients with viral suppression. Randomized, open label non inferiority trial". As coordinator she supported and trained the Italian sites participating to these studies in submitting the study to their Ethics Committees in order to receive the local approval. She coordinated the open visits with the monitor of the study as a backup and she will be able to record the study on web site Clinical Trial.gov

Aug 2011 Mrs Carini supported doctors to obtain the regulatory approval for n.3 compassionate uses of drug assisted them with the preparation of all the documents requested by Ethics Committee.

Feb 2012 Mrs Carini supported doctors to obtain the regulatory approval for n.1 compassionate use of drug assisted them with the preparation of all the documents requested by Ethics Committee.

17 Apr 2012 Certificate of Attendance in Deepening Lesson by Ufficio Ricerche Cliniche HSR "The Informed Consent: general aspects, most frequent errors and suggestions for the correct preparation".

19 Apr 2012 Certificate of Attendance in course "Traceability in Clinical Studies; from the design of the study to the submission". Organized by Italian ePharma day 2012.

22 May 2012 Certificate of Attendance in course "Good Pharmacovigilance practise ". Organized by Ufficio Ricerche Cliniche San Raffaele Hospital.

19 June 2012 Certificate of Attendance in course "Compassionate use of drugs ". Organized by Ufficio Ricerche Cliniche San Raffaele Hospital.

18 Sep 2012 Certificate of Attendance in course "Budget in clinical trials ". Organized by Ufficio Ricerche Cliniche San Raffaele Hospital.

22-25 April 2013 Mrs Carini supported Ospedale San Raffaele Infectious Diseases Department Clinical Trial Unit for Food and Drug (FDA) Inspection focused on GSK study Viking-3 ING112574 (a phase III study). The results of the inspection performed by Ethan P.Stegman in San Raffaele Hospital was NO ACTION INDICATED.

28 May 2013 Certificate of Attendance in course "Informed Consent Form in clinical trials". Organized by Ufficio Ricerche Cliniche San Raffaele Hospital.

27 May 2014 Certificate of Attendance in course "Good Clinical Practise". Organized by Ufficio Ricerche Cliniche San Raffaele Hospital and Dr Maria Primula Leone GlaxoSmithKline.

03 Nov 2014 Certificate of Attendance in course "GCP in clinical trials". Organized by Ufficio Ricerche Cliniche San Raffaele Hospital and Dr Maria Primula Leone GlaxoSmithKline.

21 Nov 2014 Speaker at hospital course in clinical trials "The management of randomized clinical trials; experience with FDA inspection".

15 Apr 2015 Certificate of Attendance course "Privacy regulation in Health Organization". Organized by Legal Office in IRCCS San Raffaele Hospital Milan.

17 Jun 2015 Certificate of Attendance in course "The New Italian Osservatorio Ministeriale AIFA". Organized by Ufficio Ricerche Cliniche San Raffaele Hospital.

17 Nov 2017 Certificate of Attendance in course "Topics in Clinical Trials management". Organized by San Raffaele Hospital.

26 Jan 2018 Certificate of Attendance in lesson "Good Clinical Practice and new addendum E06 ". Organized by Ufficio Ricerche Cliniche San Raffaele Hospital. Speaker Dr Maria Primula Leone (GlaxoSmithKline).

19 Apr 2018 Certificate of Attendance in course "No- profit studies; guidelines to contracts and insurance policy"

25 Nov 2019 Certificate of completion ICH GCP Obligations of Investigators Conducting Clinical Trials (GCP02 Ver 4.1)

Mar/May 2020 Conducting trials as study coordinator focused on drug Remdesivir (anti Covid-19)

17 Nov 2020 Speaker for the course "The compassionate use of drugs; how to submit a request to the Local EC; topic on compassionate use of anti Covid-19 drugs".

21 Jan 2021 Certificate of Attendance in lesson "Good Clinical Practice and new addendum E06". Organized by Ufficio Ricerche Cliniche San Raffaele Hospital. Speaker Dr Maria Primula Leone (GlaxoSmithKline).

25 Feb 2021 Certificate of Attendance in lesson "The New European Regulation". Organized by Ufficio Ricerche Cliniche San Raffaele Hospital.

SPOKEN LANGUAGES

Italian mother tongue and English spoken and written.

PUBLICATIONS

1. [Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA \(APACHE study\).](#)

- Castagna A, Muccini C, Galli L, Bigoloni A, Poli A, Spagnuolo V, Nozza S, Racca S, Galli A, Cinque P, Carini E, Lazzarin A. *J Antimicrob Chemother.* 2019 Jul 1;74(7):2039-2046. doi: 10.1093/jac/dkz138. PMID: 31225610
2. [Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study \(E-184V study\).](#) Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, Boeri E, Galli A, Cernuschi M, Hasson H, Clementi M, Lazzarin A. *AIDS.* 2006 Apr 4;20(6):795-803. doi: 10.1097/01.aids.0000218542.08845.b2. PMID: 16549962 Clinical Trial.
 3. [Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.](#) Galizzi N, Galli L, Poli A, Gianotti N, Carini E, Bigoloni A, Tambussi G, Nozza S, Lazzarin A, Castagna A, Mancusi D, Termini R. *PLoS One.* 2018 Feb 16;13(2):e0191300. doi: 10.1371/journal.pone.0191300. eCollection 2018. PMID: 29451870
 4. [Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.](#) Castagna A, Spagnuolo V, Galli L, Vinci C, Nozza S, Carini E, D'Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, Lazzarin A; MODAt Study Group. *AIDS.* 2014 Sep 24;28(15):2269-79. doi: 10.1097/QAD.0000000000000407. PMID: 25058680 Clinical Trial.
 5. [Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients.](#) Spagnuolo V, Galli L, Poli A, Salpietro S, Gianotti N, Piatti P, Cossarini F, Vinci C, Carini E, Lazzarin A, Castagna A. *BMC Infect Dis.* 2017 Jan 7;17(1):43. doi: 10.1186/s12879-016-2099-5. PMID: 28061820
 6. [An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study.](#) Galli L, Poli A, Muccini C, Galizzi N, Danise A, Spagnuolo V, Gianotti N, Carini E, Lazzarin A, Castagna A. *Infect Dis (Lond).* 2018 Mar;50(3):220-222. doi: 10.1080/23744235.2017.1374552. Epub 2017 Sep 11. PMID: 28891371
 7. [Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression.](#)

Carbone A, Galli L, Bigoloni A, Bossolasco S, Guffanti M, Maillard M, Carini E, Salpietro S, Spagnuolo V, Gianotti N, Lazzarin A, Castagna A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19811. doi: 10.7448/IAS.17.4.19811. eCollection 2014.

PMID: 25397555

8. [Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.](#)
Bigoloni A, Gianotti N, Spagnuolo V, Galli L, Nozza S, Cossarini F, Salpietro S, Carini E, Piatti P, Vinci C, Lazzarin A, Castagna A.
AIDS. 2012 Sep 10;26(14):1837-40. doi: 10.1097/QAD.0b013e32835705dd. PMID: 22739393

9. [Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients.](#)
Seminari E, Gentilini G, Galli L, Hasson H, Danise A, Carini E, Dorigatti F, Soldarini A, Lazzarin A, Castagna A.
J Antimicrob Chemother. 2005 Oct;56(4):790-2. doi: 10.1093/jac/dki314. Epub 2005 Sep 5. PMID: 16143711

10. [Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.](#)
Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M.
New Microbiol. 2004 Apr;27(2 Suppl 1):51-61.
PMID: 15646065

11. [Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.](#)
Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M.
Antimicrob Agents Chemother. 2004 Sep;48(9):3253-9. doi: 10.1128/AAC.48.9.3253-3259.2004.
PMID: 15328081

12. [Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients.](#)
Hasson H, Biswas P, Galli L, Burastero SE, Danise A, Bigoloni A, Carini E, Locatelli M, Vecchi A, Lazzarin A, Castagna A.
New Microbiol. 2006 Oct;29(4):223-30. PMID: 17201088

I hereby authorize the processing of my personal data above pursuant to Italian law 196/2003 on confidentiality.

Date, 10 Sep 2021



**SPERIMENTAZIONI CLINICHE:
INCONTRI DI APPROFONDIMENTO – 11° anno**

*a cura del COMITATO ETICO IRCCS - OSPEDALE SAN RAFFAELE
e della sua SEGRETERIA TECNICO SCIENTIFICA*

Si attesta che

ELISABETTA CARINI

ha partecipato da remoto alla lezione

***La stesura di un protocollo di ricerca:
fondamenti e criticità
22 aprile 2021***

Dott.ssa Elisabetta Riva
Presidente CE IRCCS OSPEDALE SAN RAFFAELE



CURRICULUM VITAE

EUROPEAN FORM



PERSONAL INFORMATION

First name / Surname Castagna Antonella

Address

Phone

Fax

E-mail

Nationality

Place and Date of birth

PROFESSIONAL EXPERIENCE

November 2016 – to date

Director of specialization school in Infectious and Tropical Diseases, Vita-Salute San Raffaele University, School of Medicine, Milan, Italy

Director of PML Center of Studies, Vita-Salute San Raffaele University, Milan, Italy.

Director of Studies and research project for Physician-Scientist (PhS), Experimental and Clinical Medicine on HIV cures. Vita-Salute San Raffaele University, Milan, Italy.

April 2015 – to date

Associate Professor in Infectious Diseases, Vita-Salute San Raffaele University, Milan, Italy.

April 2013 – to date

Italian National Scientific Qualification (ASN) of Italian Ministry for Education, University and Research (MIUR) for Full Professor role in Infectious Diseases, sector 06/D4

Italian National Scientific Qualification (ASN) of Italian Ministry for Education, University and Research (MIUR) for Professor role in Infectious Diseases, sector 06/D4

2002 – to date

Head of Unit for “Management of HIV Infection and antiretroviral treatment” at the Department of Infectious Diseases, San Raffaele Hospital, Milan, Italy (Dir. Prof. Adriano Lazzarin).

1992 - 2001	<p>Medical Doctor at the Department of Infectious Diseases, San Raffaele Hospital, Milano, Italy (Dir. Prof Adriano Lazzarin)</p> <p>Consultant in Infectious Diseases at Neurological Institute “C. Besta”, Milan.</p> <p>Consultant in Infectious Diseases at National Cancer Institute, Milan.</p>
1988 - 1992	<p>Medical Doctor at Infectious Diseases University Clinic, Ospedale “L. Sacco”, Università degli Studi di Milano (Dir. Prof. Mauro Moroni)</p> <p>Senior registrar at Infectious Diseases University Clinic, Ospedale “L. Sacco”, Università degli Studi di Milano (Dir. Prof. Mauro Moroni)</p> <p>Associate Researcher at the Department of Neurology, Karolinska Institute (Dir. Prof. Hans Link), Huddinge, Sweden</p> <p>Associate Researcher at the National Bacteriological Laboratory (Dir. Prof Britta Wharen) Stoccolma, Sweden</p> <p>Fellow at the Neuroimmunology Lab, Department of Neurology, University of Chicago, Illinois, USA (Dir. Prof Robert Roos)</p>

EDUCATIONAL AND TRAINING

1989	Degree of Specialization in Infectious Diseases, post-graduated school of medicine, Università degli studi di Milano, Italy
1985	Degree in Medicine and Surgery, Università degli studi di Milano, Italy

LANGUAGES

Italian mother tongue.
 English: C2 level in understanding, speaking and writing
 French: B2 level in understanding, speaking and writing

COMPUTER SKILLS

Basic knowledge of the Microsoft Office programs (for Windows and Apple)

DRIVING LICENSE

Category B, Italy

ADDITIONAL INFORMATION

1999 – to date	Chief of the CSLHIV Cohort Study (the Infectious Diseases database on HIV-infected patients at the San Raffaele Hospital, Milan), collecting clinical and laboratory data from all people who living with HIV followed at the Department of Infectious Diseases.
2019 – to date	Principal Investigators and Italian National Coordinator of STIPnet (European HIV & STI Prevention Study)

2017 – to date	Principal Investigator and Coordinator of National PRESTIGIO Registry (Italian Register of Patients with HIV Infection and resistance to Inverse Transcriptase Inhibitors, Integrase, Viral protease) (www.registroprestigio.com)
2016 – to date	Member of the Steering Committee of RESPOND (International Cohort Consortium of Infectious Diseases) Member of the Scientific Committee of Fondazione “The Bridge”
2012 – to date	Member of the Scientific Committee of ICONA (Italian Cohort of Antiretroviral Naive Patients) Member of the EUROSIDA Study group
2019 - date	Chair of Panel on Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.
2005 – to date	Member of Panel on Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. <i>Ad hoc reviewer for:</i> Lancet Infectious Diseases Lancet HIV AIDS Journal of Antimicrobial Chemotherapy JAIDS Journal of Acquired Immune Deficiency Syndromes PlosOne BMC Infectious Diseases Scientific Report HIV Medicine

SUMMARY OF SCIENTIFIC PRODUCTION

Author or coauthor of 394 peer-reviewed scientific publications

ORIGINAL ARTICLES	394
TOTAL N. CITATIONS	9493
AVERAGE N. CITATIONS/PAPER	24
H-INDEX (ISI Web of Knowledge)	47
ORCID N.	0000-0002-8338-9714

MOST RELEVANT PUBLICATIONS

Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P, Latiff G, DeJesus E, Gummel M, Gartland M, Pierce A, Ackerman P, Llamoso C, Lataillade M; BRIGHT Trial Team. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. *N Engl J Med.* 2020 Mar 26;382(13):1232-1243. doi: 10.1056/NEJMoa1902493. PubMed PMID: 32212519.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastrì E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *N Engl J Med.* 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10. PMID: 32275812

Greenberg L, Ryom L, Wandeler G, Grabmeier-Pfistershammer K, Ållinger A, Neesgaard B, Stephan C, Calmy A, Rauch A, Castagna A, Spagnuolo V, Johnson M, Stingone C, Mussini C, De Wit S, Necsoi C, Campins AA, Pradier C, Stecher M, Wasmuth JC, Monforte AD, Law M, Pühr R, Chkhartishvili N, Tsertsvadze T, Garges H, Thorpe D, Lundgren JD, Peters L, Bansi-Matharu L, Mocroft A; RESPOND Study Group. Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. *J Acquir Immune Defic Syndr.* 2020 Mar 1;83(3):240-250. doi:10.1097/QAI.0000000000002250. PubMed PMID: 31923088.

Castagna A, Muccini C, Galli L, Bigoloni A, Poli A, Spagnuolo V, Nozza S, Racca S, Galli A, Cinque P, Carini E, Lazzarin A. Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study). *J Antimicrob Chemother.* 2019 Jul 1;74(7):2039-2046. doi: 10.1093/jac/dkz138. PubMed PMID: 31225610.

Gianotti N, Castagna A. Switching antiretrovirals in older patients. *Lancet HIV.* 2019 Oct;6(10):e640-e641. doi: 10.1016/S2352-3018(19)30229-2. PubMed PMID:31578950.

Castagna A, Galli L. Stepping up HIV-1 low-level viraemia surveillance in South Africa. *Lancet Infect Dis.* 2018 Feb;18(2):130-131. doi:10.1016/S1473-3099(17)30680-1. Epub 2017 Nov 17. PubMed PMID: 29158100.

leDEA and COHERE Cohort Collaborations. Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clin Infect Dis. 2018 Mar 5;66(6):893-903. doi: 10.1093/cid/cix915. PubMed PMID: 29373672; PubMed Central PMCID: PMC5848308.

The undersigned is aware that, pursuant to art. art. 76 of Presidential Decree 445/2000, false declarations, falsehood in the deeds and use of false deeds are punished pursuant to the penal code and special laws.

Furthermore, the undersigned authorizes the processing of personal data in accordance with the provisions of EU Regulation 679/2016.

Milan, July 20, 2020

22 Feb 2021

Professor Antonella Castagna



ABBREVIATED CURRICULUM VITAE

Last Name:	CATTELAN
First Name:	ANNA MARIA
Current Position:	HEAD OF INFECTIOUS DISEASE DEPARTMENT
Date from (dd-mmm-yyyy):	01 Jul 2014
Department/Institution /Address:	AZIENDA OSPEDALE-UNIVERSITA' PADOVA VIA NICOLO' GIUSTINIANI, 2-35128 PADOVA

Previous Appointments / Positions Held

Position held:	FELLOW
Name of Department /Institution:	DEPARTMENT OF INTERNAL MEDICINE
Date from / to (dd-mmm-yyyy):	FROM 15 JUL 1988 TO 15 JUL 1990
Position held	FELLOW
Name of Department /Institution:	DEPARTMENT OF INFECTIOUS DISEASES
Date from / to (dd-mmm-yyyy):	FROM 16 JUL 1990 TO 14 OCT 1992
Position held	HOSPITAL ASSISTANT
Name of Department /Institution:	DEPARTMENT OF INFECTIOUS DISEASES
Date from / to (dd-mmm-yyyy):	FROM 15 OCT 1992 TO 14 FEB 2007
Position held	HEAD OF INFECTIOUS DISEASES DIVISION
Name of Department /Institution:	DEPARTMENT OF INTERNAL MEDICINE, AZIENDA ULSS 18- ROVIGO
Date from / to (dd-mmm-yyyy):	FROM 15 FEB 2007 TO 30 JUN 2014

Education: Please Indicate Most Current Education

Qualification 1:	MEDICAL DEGREE
Name of Institution:	UNIVERSITY OF PADOVA, ITALY
Date Obtained (dd-mmm-yyyy):	20 JUL 1988
Qualification 2:	RESPIRATORY TRACT DISEASE SPECIALITY
Name of Institution:	UNIVERSITY OF PADOVA, ITALY

□

Date Obtained (dd-mmm-yyyy):	16 DEC 1992
Qualification 3:	INFECTIOUS DISEASES SPECIALITY
Name of Institution:	UNIVERSITY OF VERONA, ITALY
Date Obtained (dd-mmm-yyyy):	25 OCT 1998
Qualification 3:	ASSOCIATE PROFESSOR OF INFECTIOUS DISEASES
Name of Institution:	
Date Obtained (dd-mmm-yyyy):	06 APR 2019

Valid and Current Medical Licence or Medical Board Certification

Medical Licence	Number: TV/3171
Number or Equivalent:	Expiry date (if applicable): _____
	Copy of Medical Licence attached <input type="checkbox"/> Yes <input type="checkbox"/> No (if required by local regulations)

Expertise

Dr. ANNAMARIA CATTELAN has treated thousands of patients admitted at the Infectious Diseases Division of Padova with various infectious pathologies. In particolare, she has gained considerable experience in treating patients with HIV and immunocompromised patients.

Projects

Dr. ANNAMARIA CATTELAN has participated in many multicenter trials conducted in GPC since 1992, mainly in the field of HIV infection, fungal infection and Health-Care-Associated Infections

Publications

Dr. ANNAMARIA CATTELAN has published more than 200 papers on peer-reviewed international journals

Membership of Professional Societies or Organisations

SIMIT (Italian society of Infectious and Tropical Diseases)

SIMM (Italian Society of Medical Managers)

EACS (European AIDS Clinical Society)

By signing this form, I confirm that the information completed on this Abbreviated CV is accurate and reflects my current employment and qualifications.

Signature: Annamaria Cattelan Date: September, 8 2021

CURRICULUM VITAE										
INFORMAZIONI PERSONALI										
Cognome e Nome	CENDERELLO GIOVANNI									
Data di nascita										
Qualifica	Dirigente medico									
Amministrazione	Ente Ospedaliero Ospedali Galliera									
Unità operativa	S.C. Malattie infettive									
Incarico attuale	Incarico professionale									
Numero telefonico dell'ufficio										
E-mail istituzionale										
TITOLI DI STUDIO E PROFESSIONALI ED ESPERIENZE LAVORATIVE										
Titolo di studio	laurea in medicina e chirurgia									
Altri titoli di studio e professionali	Specializzazione in Malattie Infettive									
Esperienze professionali (incarichi ricoperti)	<p>Dal 23 Settembre 2002 al 22 Settembre 2004 Dirigente Medico a tempo determinato presso UO Malattie Infettive ASL-1 Imperiese</p> <p>Dal 23 Settembre 2004 al 30 Settembre 2009 Dirigente Medico a Tempo determinato presso UO Malattie Infettive ASL-1 Imperiese</p> <p>Dal 1 Giugno 2008 al 30 Settembre 2009 Responsabile ambulatorio HIV e patologie correlate ASL-1 Imperiese</p> <p>Dal 1 Ottobre 2009 Dirigente Medico a tempo indeterminato presso UO Malattie Infettive EO Ospedali Galliera.</p> <p>Tutor di Progetto di collaborazione transfrontaliera INTERREG 109 tra Malattie Infettive ASL-1 Imperiese e Malattie Infettive Università di Nizza.</p>									
Capacità linguistiche	<table border="1"> <thead> <tr> <th>Lingua</th> <th>Livello parlato</th> <th>Livello scritto</th> </tr> </thead> <tbody> <tr> <td>Inglese</td> <td>Eccellente</td> <td>Fluente</td> </tr> <tr> <td>Spagnolo</td> <td>Scolastico</td> <td>Scolastico</td> </tr> </tbody> </table>	Lingua	Livello parlato	Livello scritto	Inglese	Eccellente	Fluente	Spagnolo	Scolastico	Scolastico
Lingua	Livello parlato	Livello scritto								
Inglese	Eccellente	Fluente								
Spagnolo	Scolastico	Scolastico								
Capacità nell'uso delle tecnologie	Utilizzo di Sistema Operativo Windows e MACOS. Buona conoscenza pacchetto Office e Filemaker per creazione database.									

ESPERIENZA
PROFESSIONALE**Dal 15/02/2021 Dirigente medico in Malattie Infettive**

Azienda Ospedaliera Universitaria Policlinico di Modena

Attività clinica e di ricerca nell'ambito delle malattie infettive, dell'infezione da HIV, infezioni nel paziente trapiantato di organo solido. Antimicrobial stewardship in reparti di degenza.

03/2020-02/2021 Dirigente medico in Malattie Infettive

Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione IRCCS, Palermo

Attività clinica e di ricerca nell'ambito della trapiantologia, infezioni nel paziente immunodepresso e antimicrobial stewardship in reparti di degenza e terapia intensiva. Membro della task force per prevenzione, diagnosi e trattamento delle *sternal wound infections*.

02/2015–02/2020 Medico in formazione specialistica in Malattie Infettive

Azienda Ospedaliera Universitaria (AOU) Policlinico P. Giaccone, Palermo

Attività clinico-assistenziale nel reparto di degenza ordinaria, in Day Hospital e ambulatorio. Diagnosi, trattamento e follow-up di pazienti con: infezioni da germi comuni, multi-resistenti e associati all'assistenza, infezioni virali, infezione da HIV, patologie opportunistiche nel paziente immunodepresso, tubercolosi.

Partecipazione al programma di Antimicrobial Stewardship con attività di consulenza in reparti di medicina, chirurgia e terapia intensiva del Policlinico.

Gestione di patologie internistiche.

Esperienza in rachicentesi, toracentesi eco-guidate e paracentesi eco-guidate.

Attività di raccolta dati per coorti regionali e nazionali, ricerca scientifica. Organizzazione e partecipazione a seminari accademici

08/2019–12/2019 Observership con attività clinica e di ricerca scientifica

Servizio di malattie virali croniche – Dipartimento di Malattie Infettive del Centro Ospedaliero Universitario McGill, Montreal (Canada)

Attività clinico-assistenziale ambulatoriale.

Attività di ricerca scientifica sull'infezione da HIV e co-infezione HBV/HCV.

01/2019–08/2019 Medico in formazione specialistica in Malattie Infettive

Ospedale Universitario Saint-Pierre, Bruxelles (Belgio)

Attività clinico-assistenziale nei reparti di degenza ordinaria e in ambulatorio. Esperienza specifica:

- Antimicrobial Stewardship: attività di consulenza in terapia intensiva e altri reparti di degenza

- Diagnosi e trattamento di tubercolosi (multi-sensibile, *multi drug resistant* e *extensively drug resistant*) in pazienti con e senza infezione da HIV.
- Gestione di pazienti con infezione da HIV e patologie opportunistiche

- Malattie sessualmente trasmissibili e gestione delle profilassi pre- e post-esposizione (*S-Clinic*)
- Prevenzione di infezioni in pazienti immunodepressi (progetto Immunostart), malattie tropicali e vaccinazioni (*Travel and Vaccine Clinic*)

Collaborazione ad attività di ricerca scientifica

12/2014–01/2015 Medico tirocinante

Ambulatorio di medicina generale per cittadini stranieri non in regola con le norme di soggiorno, presidio sanitario Poliambulatorio Quartiere 5, Firenze

07/2014–09/2014 Medico di Continuità Assistenziale (sostituto)

Azienda Sanitaria Locale (ASL) 10, Firenze

01/2013–10/2013 Tirocinante in Malattie infettive

Unità Operativa Malattie Infettive, Azienda Ospedaliera Universitaria Careggi, Firenze

Attività clinico-assistenziale nel reparto di degenza di malattie infettive, nell'ambulatorio di malattie infettive in gravidanza e nell'ambulatorio di infezione da HCV e HBV.

04/2012–07/2012 Tirocinante in Malattie infettive

Unità Operativa Malattie Infettive, Ospedale Saint Antoine, Parigi (Francia)

Attività clinico-assistenziale nel reparto di degenza di malattie infettive. Conduzione di e partecipazione a seminari accademici.

ISTRUZIONE

02/2015–02/2020 Laurea Specialistica in Malattie Infettive, *summa cum laude*

Università degli Studi di Palermo, Palermo

Argomento di Tesi: "Non-alcoholic fatty liver disease in tre grandi coorti di pazienti con infezione da HIV: impatto della NAFLD, della lean NAFLD e della fibrosi epatica sul rischio cardiovascolare"

08/2019–12/2019 Attività di ricerca scientifica e formazione clinica in Malattie Infettive

Servizio di malattie virali croniche – Dipartimento di Malattie Infettive del Centro Ospedaliero Universitario McGill, Montreal (Canada)

Partecipazione a seminari e Journal Club settimanali in malattie infettive ed epatologia (patologie infettive in pazienti con trapianto di fegato)

01/2019–08/2019 Attività di formazione clinica in Malattie Infettive

Ospedale Universitario Saint-Pierre, Bruxelles (Belgio)

Partecipazione a seminari settimanali in medicina interna e malattie infettive. Partecipazione a incontri settimanali su attività di ricerca scientifica. Partecipazione a incontri e seminari su metodiche di isolamento respiratorio e/o da contatto.

09/2008–10/2013 Laurea in Medicina e Chirurgia, *summa cum laude*

Scuola di Scienze della Salute Umana, Università degli Studi di Firenze, Firenze

Argomento di Tesi: "Epidemiologia dell'infezione da *Clostridium difficile* presso l'Azienda Ospedaliera Universitaria Careggi nel periodo 2012-2013: analisi dei dati di un anno di studio osservazionale".

09/2011–07/2012 Programma di scambio universitario dell'Unione Europea " Erasmus"

Université Pierre et Marie Curie Paris VI, Parigi (Francia)

Tirocinio trimestrale presso: Unità Operativa di Malattie Infettive dell'Ospedale Saint Antoine; Pronto Soccorso dell'Ospedale Tenon; Chirurgia vascolare dell'Ospedale Pitié-Salpêtrière.

2002–2007 Esame di Stato, *cum laude*

Liceo Scientifico G. Battaglini, Taranto

CORSI DI FORMAZIONE E
ABILITAZIONE

07/2020 Corso BLSD (*Basic Life Support and Defibrillation*)

Istituto Mediterraneo per Trapianti e Terapie Specialistiche Avanzate – IRCCS ISMETT di Palermo

09/2019–12/2019 Corso di "Principi di Epidemiologia Clinica"

(EXMD 642-001) – Università McGill, Montreal (Canada)

09/2019 Certificato di Ricerca Clinica

ICH – *Good Clinical Practice* (GCP)

Istituto di Ricerca del Centro Universitario Ospedaliero McGill, Montreal (Canada)

Procedure operative standardizzate (RI-MUHC SOPs)

01/2018–12/2019 Operatore esperto in Elastografia Epatica (FibroScan) con software per *controlled attenuation parameter* (CAP)

Azienda Ospedaliero Universitaria Policlinico di Palermo

Esecuzione di oltre 500 misurazioni

04/2018 Corso BLSD (*Basic Life Support and Defibrillation*) e ACLS (*Advanced Cardiovascular Support*)

Istituto Mediterraneo per Trapianti e Terapie Specialistiche Avanzate – IRCCS ISMETT di Palermo

10/2016 Corso di eco-color-doppler per medici infettivologi

Clinica di Malattie Infettive, Università degli Studi di Bari

02/2014 – 03/2014 Abilitazione all'esercizio della Professione di Medico e iscrizione all'Albo Professionale dei Medici Chirurghi di Firenze (n°13676)

COMPETENZE PERSONALI e
AFFILIAZIONI

Lingua madre italiano

Altre lingue

	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
inglese	C1	C1	B2	B2	B2
francese	C1	C1	C1	C1	C1

Livelli: A1 e A2: Utente base - B1 e B2: Utente autonomo - C1 e C2: Utente avanzato [Quadro Comune Europeo di Riferimento delle Lingue](#)

Competenze professionali Eccellenti capacità di adattamento grazie a molteplici esperienze in diversi contesti lavorativi.
Fast learning.

Ottime capacità di organizzazione del lavoro e team working.
 Capacità di condivisione e comunicazione delle conoscenze, delle esperienze e delle acquisizioni scientifiche attraverso incontri strutturati e non.
 Esperienza di lavoro con popolazioni migranti.
 Eccellente capacità di ascolto.
 Empatia e attenzione al paziente. Entusiasmo e iniziativa.

Competenza digitale

AUTOVALUTAZIONE				
Elaborazione delle informazioni	Comunicazione	Creazione di Contenuti	Sicurezza	Risoluzione di problemi
Utente avanzato	Utente avanzato	Utente autonomo		

Competenze digitali - Scheda per l'autovalutazione

Ottima conoscenza del pacchetto MS Office (Word, Excel, PowerPoint); navigazione Internet.

Ricerca scientifica attraverso biblioteche digitali.

Buona conoscenza di software per l'analisi statistica (STATA16)

Affiliazioni

Società Italiana Trapianti d'Organo (SITO)
 Società Italiana Malattie Infettive e Tropicali (SIMIT)
 European AIDS Clinical Society (EACS), YING (the EACS Young Investigator)
 European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

COMPETENZE PERSONALI e AFFILIAZIONI

Lingua madre italiano

Altre lingue	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
inglese	C1	C1	B2	B2	B2
francese	C1	C1	C1	C1	C1

Livelli: A1 e A2: Utente base - B1 e B2: Utente autonomo - C1 e C2: Utente avanzato Quadro Comune Europeo di Riferimento delle Lingue

Competenze professionali Eccellenti capacità di adattamento grazie a molteplici esperienze in diversi contesti lavorativi.
 Fast learning.

Ottime capacità di organizzazione del lavoro e team working.
 Capacità di condivisione e comunicazione delle conoscenze, delle esperienze e delle acquisizioni scientifiche attraverso incontri strutturati e non.
 Esperienza di lavoro con popolazioni migranti.
 Eccellente capacità di ascolto.
 Empatia e attenzione al paziente. Entusiasmo e iniziativa.

Competenza digitale

AUTOVALUTAZIONE				
Elaborazione delle informazioni	Comunicazione	Creazione di Contenuti	Sicurezza	Risoluzione di problemi
Utente avanzato	Utente avanzato	Utente autonomo		

Competenze digitali - Scheda per l'autovalutazione

Ottima conoscenza del pacchetto MS Office (Word, Excel, PowerPoint); navigazione Internet.

Ricerca scientifica attraverso biblioteche digitali.

Buona conoscenza di software per l'analisi statistica (STATA16)

Affiliazioni

Società Italiana Trapianti d'Organo (SITO)

Società Italiana Malattie Infettive e Tropicali (SIMIT)

European AIDS Clinical Society (EACS), YING (the EACS Young Investigator)

European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

PUBBLICAZIONI

Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.

Sebastiani G, Milic J, Gioe C, Al Hinai AS, **Cervo A**, Lebouche B, Deschenes M, Cascio A, Mazzola G, Guaraldi G.

Lancet HIV. 2022 Mar; 9 Suppl 1:S4. doi: 10.1016/S2352-3018(22)00069-8. PMID: 35304846.

Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV.

Cervo A, Sebastiani G, Milic J, Krahn T, Mazzola S, Petta S, Cascio A, Guaraldi G, Mazzola G.

HIV Med. 2022 Feb 24. doi: 10.1111/hiv.13274. Epub ahead of print. PMID: 35199429.

Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis.

Mularoni A, Mezzatesta ML, Pilato M, Medaglia AA, **Cervo A**, Bongiorno D, Aprile A, Luca A, Stefani S, Grossi P.

Int J Infect Dis. 2021 Jul;108:510-512. doi: 10.1016/j.ijid.2021.05.085. Epub 2021 Jun 4. PMID: 34091004.

NASH in HIV

Cervo A, Shengir M, Patel K, Sebastiani G

Curr HIV/AIDS Rep 2020 Sept 28. <https://doi.org/10.1007/s11904-020-00531-0>

Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus

Cervo A, Milic J, Mazzola G, Schepis F, Petta S, Krahn T, Lebouche B, Deschenes M, Cascio A, Guaraldi G, Sebastiani G.

Clin Infect Dis. 2020 Dec 17;71(10):e694-e701. doi: 10.1093/cid/ciaa430. PMID: 32280969.

Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients.

Sebastiani G, Cocciolillo S, Mazzola G, Malagoli A, Falutz J, **Cervo A**, Petta S, Pembroke T, Ghali P, Besutti G, Franconi I, Milic J, Cascio A, Guaraldi G.

HIV Med. 2019 Oct 23. doi: 10.1111/hiv.12799.

Prediction of oesophageal varices by liver stiffness and platelets in persons with HIV infection and compensated advanced chronic liver disease.

Merchante N, Saroli Palumbo C, Mazzola G, Pineda JA, Téllez F, Rivero-Juárez A, Ríos-Villegas MJ, Maurice JB, Westbrook RH, Judge R, Guaraldi G, Schepis F, Perazzo H, Rockstroh J, Boesecke C, Klein MB, **Cervo A**, Ghali P, Wong P, Petta S, De Ledingham V, Macías J, Sebastiani G.

Clin Infect Dis. 2019 Dec 9. pii: ciz1181. doi: 10.1093/cid/ciz1181.

Direct-acting antivirals and visceral leishmaniasis: a case report.

Colomba C, Saporito L, Di Carlo P, Tolomeo M, **Cervo A**, Firenze A, Trizzino M, Cascio A. BMC Infect Dis. 2019 Apr 18;19(1):328. doi: 10.1186/s12879-019-3947-x.

Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients.

Mazzola G, Adamoli L, Calvaruso V, Macaluso FS, Colletti P, Mazzola S, **Cervo A**, Trizzino M, Di Lorenzo F, Iaria C, Prestileo T, Orlando A, Di Marco V, Cascio A.

Infection. 2019 Jun;47(3):409-415. doi: 10.1007/s15010-018-1258-6. Epub 2018 Dec 5.

Leishmaniasis and biological therapies for rheumatologic diseases: a concise review.

Iaria C, Scarlata F, Caputo V, Rea T, Serra N, **Cervo A**, Mililli D, De Luca A, Romanin B, Colomba C.

Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 October; 177(10):548-55.

Madura foot: an imported case of a non-common diagnosis.

Fasciana T, Colomba C, **Cervo A**, Di Carlo P, Scarlata F, Mascarella C, Giammanco A, Cascio A.

Infez Med. 2018 Jun 1;26(2):167-170

Modena, 4/4/2022

In fede
Adriana Cervo

EUROPEAN
CURRICULUM VITAE
FORMAT



PERSONAL INFORMATION

Name **CLEMENTE, Tommaso**

WORK EXPERIENCE

- Dates (from – to) April, 2021 - July, 2021
- Name and address of employer Novegro Massive Vaccination Center - Gruppo San Donato (20054, Segrate, Italy)
 - Type of business or sector COVID-19 Mass Vaccination Center
 - Occupation or position held **Vaccinating Doctor**
- Main activities and responsibilities SARS-CoV-2 Vaccination Campaign

EDUCATION AND TRAINING

- Dates (from – to) January, 2021 - present (expected postgraduate degree date: January, 2025)
- Name and type of organization providing education and training Vita-Salute San Raffaele University (20132, Milan, Italy)
 - Principal subjects/occupational skills covered Infectious Diseases, IRCCS San Raffaele Scientific Institute (20127, Milan, Italy)
Infectious and Tropical Diseases
 - Inpatient activity at the ward of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy (January, 2021 - present)
 - Outpatient activity at HIV Clinic, IRCCS San Raffaele Scientific Institute, Milan, Italy (January, 2021 - present)
 - Outpatient activity at STI Clinic, IRCCS San Raffaele Scientific Institute, Milan, Italy (May, 2022 - present)
 - Consultation activities in other departments of IRCCS San Raffaele Scientific Institute, Milan, Italy (August, 2023 - present)
 - Activity at Emergency Department, IRCCS San Raffaele Scientific Institute, Milan, Italy (September, 2022 - November, 2022)
 - Inpatient and outpatient activity at Wound Care Center, Istituti Clinici Zucchi, Monza, Italy (March, 2022 - April, 2022)
 - Outpatient activity at Phthysiology Unit, Villa Marelli Institute, Niguarda Hospital, Milan, Italy (June 2021)
 - Research activity about clinical and immunological characteristics and treatment management in people living with HIV (January, 2021 - present)
 - Research activity on behalf of the PRESTIGIO Study Group (Italian Registry of HIV-1 Infected Patients With Drug-RESistant Virus to Reverse Transcriptase Inhibitors, InteGrasE and Viral

- Title of qualification awarded
- Level in national classification

- Dates (from – to)

- Name and type of organization providing education and training
- Principal subjects/occupational skills covered

- Title of qualification awarded
- Level in national classification

- Dates (from – to)

- Name and type of organization providing education and training
- Principal subjects/occupational skills covered

- Title of qualification awarded
- Level in national classification

RESEARCH ACTIVITY

- Publications

Protease; NCT04098315) (January, 2021 - present)

- Research activity on behalf of the SCohoLART study (Cohort Study of HIV-positive People, Treated With Long Acting Antiretroviral Therapy; NCT05663580) (January, 2023 - present)
- Research activity about other infections (SARS-CoV-2, Monkeypox, STIs, HHV8) (January, 2021 - present)
- Member of EACS - European AIDS Clinical Society
- Member of YING - EACS Young Investigators
- Member of SIMIT - Società Italiana di Malattie Infettive e Tropicali

Infectious Diseases Residency Program (ongoing)

Infectious Diseases Residency Program

June, 2023 - present (expected fellowship completion date: June, 2024)

EACS - European AIDS Clinical Society (1000, Brussels, Belgium)

HIV and AIDS

- Collaboration with Prof. Annemarie Wensing (mentor) and the ESAR - European Society of Translational Antiviral Research for research projects on virological failure and low-level viremia
- Visit to Infectious Diseases, University Medical Center, Utrecht, Netherlands and Translational Virology, University Medical Center, Utrecht, Netherlands (October, 2023 - December, 2023)

EACS Medical Exchange Programme - Career Development Fellowship (ongoing)

Not applicable

October, 2014 - June, 2020

Vita-Salute San Raffaele University (20132, Milan, Italy)

Medicine and Surgery

- Medical and research traineeship at Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy (September, 2018 - June, 2020)
- Research activity on behalf of the PRESTIGIO Study Group (Italian Registry of HIV-1 Infected Patients With Drug-RESistant Virus to Reverse Transcriptase Inhibitors, InteGrasE and Viral Protease; NCT04098315) (September, 2018 - June, 2020)
- Research activity on behalf of Neurovirology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy (September, 2019 - June, 2020)
- Medical and Surgical traineeships (September, 2017 - June, 2019)
- Research traineeship at Gene Therapy for Neurodegenerative Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy (September, 2016)
- Research traineeship at Chromatin Dynamics, IRCCS San Raffaele Scientific Institute, Milan, Italy (September, 2015)

Medical Degree, Qualification for Medical Profession

(vote: 110/110 cum laude and special mention; date: 30th June, 2020)

Medical Degree

1. **Clemente T**, Galli L, Lolatto R, Gagliardini R, Lagi F, Ferrara M, Cattelan AM, Focà E, Di Biagio A, Cervo A, Calza L, Maggiolo F, Marchetti G, Cenderello G, Rusconi S, Zazzi M, Santoro MM, Spagnuolo V, Castagna A; PRESTIGIO Study Group. **Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors.** *BMJ Open.* 2024 Feb 10;14(2):e080606. doi: 10.1136/bmjopen-2023-080606
2. Papaioannu Borjesson R, Galli L, Lolatto R, Menzaghi B, Feasi M, Gulminetti R, Fornabaio C, Cattelan AM, Bonora S, Lagi F, Zazzi M, Castagna A, Spagnuolo V; **PRESTIGIO Study Group. Lower aids-related hospitalizations in women living with HIV multidrug resistance.** *AIDS.* 2024 Mar 1;38(3):435-438. doi: 10.1097/QAD.0000000000003781
3. **Clemente T**, Lolatto R, Papaioannu Borjesson R, Fabbiani M, Manzillo E, Fronti E, Di Giambenedetto S, Gagliardini R, Rusconi S, Santoro MM, Castagna A, Spagnuolo V;

- PRESTIGIO Study Group. **Sexually transmitted infections in people with multidrug-resistant HIV.** *AIDS.* 2023 Dec 1;37(15):2425-2430. doi: 10.1097/QAD.0000000000003690
4. Papaioannu Borjesson R, Galli L, Muccini C, Poli A, **Clemente T**, Bottanelli M, Gianotti N, Nozza S, Castagna A, Spagnuolo V. **COVID-19 pandemic and increasing incidence and prevalence of metabolic syndrome in PLWH.** *Front Med (Lausanne).* 2023 Sep 18;10:1220631. doi: 10.3389/fmed.2023.1220631
 5. **Clemente T**, Galli L, Poli A, Papaioannu Borjesson R, Bresciani L, Muccini C, Canetti D, Candela C, Bossolasco S, Hasson H, Castagna A, Spagnuolo V. **Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting.** *Int J Antimicrob Agents.* 2023 Aug;62(2):106897. doi: 10.1016/j.ijantimicag.2023.106897
 6. Raccagni AR*, **Clemente T***, Ranzenigo M, Cicinelli MV, Castagna A, Nozza S. **Persistent ocular mpox infection in an immunocompetent individual.** *Lancet Infect Dis.* 2023 Jun;23(6):652-653. doi: 10.1016/S1473-3099(23)00266-9
 7. **Clemente T**, Caccia R, Galli L, Galli A, Poli A, Carla Marchetti G, Bandera A, Zazzi M, Mercedes Santoro M, Cinque P, Castagna A, Spagnuolo V; PRESTIGIO Study Group. **Inflammation burden score in multidrug resistant HIV-1 infection.** *Journal of Infection.* 2023 May;86(5):453-461. doi: 10.1016/j.jinf.2023.03.011
 8. Candela C, Raccagni AR, Bruzzesi E, Bertoni C, Rizzo A, Gagliardi G, Canetti D, Gianotti N, Mileto D, Gismondo MR, Castagna A, Nozza S; **Centro San Luigi (CSL) Working Group.** **Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics.** *Viruses.* 2023 Mar 2;15(3):667. doi: 10.3390/v15030667
 9. Saladini F, Giammarino F, Maggiolo F, Ferrara M, Cenderello G, Celesia BM, Martellotta F, Spagnuolo V, Corbelli GM, Gianotti N, Santoro MM, Rusconi S, Zazzi M, Castagna A; **PRESTIGIO Study Group.** **Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.** *Int J Antimicrob Agents.* 2023 Jan 25;61(3):106737. doi: 10.1016/j.ijantimicag.2023.106737
 10. Raccagni AR, Mileto D, Galli L, Bruzzesi E, Canetti D, Rizzo A, Bertoni C, **Clemente T**, Alberton F, Castagna A, Nozza S. **HIV viral load monitoring during monkeypox virus infection among PLWH.** *AIDS.* 2023 Apr 1;37(5):779-783. doi: 10.1097/QAD.0000000000003479
 11. **Clemente T**, Spagnuolo V, Bottanelli M, Ripa M, Del Forno B, Busnardo E, Di Lucca G, Castagna A, Danise A. **Disseminated Mycobacterium chimaera infection favoring the development of Kaposi's sarcoma: a case report.** *Ann Clin Microbiol Antimicrob.* 2022 Dec 9;21(1):57. doi: 10.1186/s12941-022-00547-x
 12. Spagnuolo V, Voarino M, Tonelli M, Galli L, Poli A, Bruzzesi E, Racca S, Clementi N, Oltolini C, Tresoldi M, Rovere Querini P, Dagna L, Zangrillo A, Ciceri F, Clementi M, Castagna A; **COVID-BioB Study Group.** **Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study.** *Drug Des Devel Ther.* 2022 Oct 19;16:3645-3654. doi: 10.2147/DDDT.S369473
 13. **Clemente T**, Canetti D, Dagna L, Uberti Foppa C, Castagna A, Spagnuolo V, Nozza S, Campochiaro C. **Monkeypox in a patient with undifferentiated connective tissue disease.** *Rheumatology (Oxford).* 2022 Oct 4;keac568. doi: 10.1093/rheumatology/keac568
 14. Ripa M, Galli L, D'Angelo A, Apruzzi L, Palumbo D, Campochiaro C, Tassan Din C, Danise A, Da Prat V, Vitali G, Brugiiera L, Poli A, Monardo R, Monti G, Baccellieri D, De Cobelli F, Clementi M, Iannaccone S, Dagna L, Rovere-Querini P, Ciceri F, Tresoldi M, Zangrillo A, Scarpellini P, Castagna A; **COVID-BioB Study Group.** **High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19.** *Open Forum Infect Dis.* 2022 Sep 2;9(9):ofac454. doi: 10.1093/ofid/ofac454
 15. Casula L, Poli A, **Clemente T**, Artuso G, Capparé P, Gherlone EF. **Prevalence of peri-implantitis in a sample of HIV-positive patients.** *Clin Exp Dent Res.* 2021 Dec;7(6):1002-1013. doi: 10.1002/cre2.469
1. **Clemente T**, Diotallevi S, Lolatto R, Gagliardini R, Giacomelli A, Fison M, Ferrara M, Cervo A, Calza L, Maggiolo F, Rusconi S, Santoro MM, Castagna A, Spagnuolo V; PRESTIGIO Study Group. **Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: a**

• Manuscripts submitted to peer-reviewed journals (pending approval)

retrospective cohort analysis of data from the PRESTIGIO Registry. 2nd revision under review on Int J Antimicrob Agents

2. **Clemente T**, Canetti D, Messina E, Carini E, Della Torre L, Papaioannu Borjesson R, Castagna A, Spagnuolo V. **Long-term outcome in a person with pandrug-resistant HIV: the added value of a multidisciplinary approach.** 1st revision under review on JAC Antimicrob Resist
3. **Clemente T**, Pontillo D, Malagnino V, Calza L, Di Biagio A, Cenderello G, Lolatto R, Manzillo E, Moioli MC, De Socio GV, Castagna A, Spagnuolo V; PRESTIGIO Study Group. **Cancer in people with multidrug-resistant HIV.** Under review on AIDS
4. Mazzitelli M, Pontillo D, **Clemente T**, Di Biagio A, Cenderello G, Rusconi S, Menzaghi B, Fornabaio C, Garlassi E, Zazzi M, Castagna A, Cattelan AM; PRESTIGIO Study Group. **Polypharmacy, anticholinergic burden, and drug-drug interaction assessment in people with 4-class resistant HIV: data from the PRESTIGIO Registry.** Under review on J Antimicrob Chemother
5. Armenia D, Spagnuolo V, Bellocchi MC, Galli L, Duca L, Marcheggiani G, **Clemente T**, Carioti L, Lolatto R, Calza L, Celesia BM, Cascio A, Francisci D, Saracino A, Torti C, Zazzi M, Castagna A, Santoro MM; PRESTIGIO Registry Group. **Use of next generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment experienced people with multidrug resistant HIV under virological control: Data from the PRESTIGIO Registry.** Under review on J Antimicrob Chemother
6. Muccini C, Gianotti N, Diotallevi S, Lolatto R, Spagnuolo V, Canetti D, Bagaglio S, Gordo Perez V, **Clemente T**, Bottanelli M, Candela C, Nozza S, Castagna A. **One-year of long-acting cabotegravir and rilpivirine in people with HIV and a long exposure to antiretroviral therapy: data from the SCohoLART study.** Under review on Open Forum Infect Dis

• Abstracts presented at international and national conferences

1. Morsica G, Lolatto R, Diotallevi S, Svicher V, Bertoni C, Siribelli A, Hasson H, Bagaglio S, **Clemente T (presenting author)**, Forniti A, Salpini R, D'Anna S, Uberti-Foppa C, Castagna A, Gianotti N. **Hepatitis B reactivation in PLWH with anti-core antibody after switch to an anti-HBV sparing regimen.** Poster presented at CROI 2024: Conference on Retroviruses and Opportunistic Infections (3rd-6th March, 2024, Denver, US)
2. **Clemente T (presenting author)**, Diotallevi S, Lolatto R, Gagliardini R, Giacomelli A, Malena M, Ferrara M, Cervo A, Calza L, Maggiolo F, Rusconi S, Santoro MM, Castagna A, Spagnuolo V. **Risk of virological failure after drug burden reduction in non-viremic people with 4-class drug-resistant HIV: data from the PRESTIGIO Registry.** Rapid abstract presentation presented at EACS 2023: 19th European AIDS Conference (18th-21st October, 2023, Warsaw, Poland)
3. **Clemente T (presenting author)**, Canetti D, Messina E, Carini E, Della Torre L, Papaioannu Borjesson R, Castagna A, Spagnuolo V. **How to choose the optimized background therapy with fostemsavir in viremic people with multidrug-resistant HIV? A clinical case.** ePoster presented at for EACS 2023: 19th European AIDS Conference (18th-21st October, 2023, Warsaw, Poland)
4. Papaioannu Borjesson R, **Clemente T**, Diotallevi S, Lolatto R, Forniti A, Bottanelli M, Galli L, Alberton F, Muccini C, Hasson H, Castagna A, Spagnuolo V. **Outcomes after virological failure to first-line second-generation INSTI-based therapy in a real-life setting.** Moderated ePoster presented at EACS 2023: 19th European AIDS Conference (18th-21st October, 2023, Warsaw, Poland)
5. Mazzitelli M, Pontillo D, **Clemente T**, Di Biagio A, Cenderello G, Rusconi S, Menzaghi B, Fornabaio C, Garlassi E, Zazzi M, Castagna A, Cattelan AM. **Polypharmacy, anticholinergic burden, and drug-drug interaction assessment in people living with HIV harboring a 4-class resistance: data from the PRESTIGIO Registry.** ePoster presented at EACS 2023: 19th European AIDS Conference (18th-21st October, 2023, Warsaw, Poland)
6. Alberton F, Galli L, Trentacapilli B, **Clemente T**, Candela C, Lolatto R, Forniti A, Nozza S, Castagna A, Gianotti N. **Well-being in people living with HIV (PLWH) starting long-acting therapy.** ePoster presented at EACS 2023: 19th European AIDS Conference (18th-21st October, 2023, Warsaw, Poland)
7. Armenia D, Spagnuolo V, Bellocchi MC, Galli L, Duca L, Marcheggiani G, **Clemente T**, Carioti L, Lolatto R, Calza L, Celesia BM, Cascio A, Francisci D, Saracino A, Torti C, Zazzi M, Castagna A, Santoro MM, PRESTIGIO Registry. **Do minority resistant**

- variants in HIV-DNA predict virological rebound in highly treatment experienced PLWH under virological control? Data from the PRESTIGIO Registry.** ePoster presented at EACS 2023: 19th European AIDS Conference (18th-21st October, 2023, Warsaw, Poland)
8. Armenia D, Spagnuolo V, Bellocchi MC, Galli L, Duca L, Marcheggiani G, **Clemente T**, Carioti L, Lolatto R, Calza L, Celesia BM, Cascio A, Francisci D, Saracino A, Torti C, Zazzi M, Castagna A, Santoro MM, PRESTIGIO Registry. **HIV-1 DNA resistance assessment through NGS in highly treatment-experienced individuals under virological control enrolled in the PRESTIGIO Registry.** Oral communication presented at 7th National Congress of the Italian Society for Virology. One Virology One Health (25th-27th June, 2023, Brescia, Italy)
 9. **Clemente T (presenting author)**, Pontillo D, Minisci D, Di Biagio A, Galli A, Attala L, Cenderello G, Malagnino V, Lo Caputo S, Tavio M, Giacomelli A, Castagna A, Spagnuolo V, on behalf of the PRESTIGIO Study Group. **Malignancies and MACEs in the PRESTIGIO Registry.** Oral communication presented at 15th ICAR Congress - Italian Conference on AIDS e Antiviral Research (14th-16th June, 2023, Bari, Italy)
 10. **Clemente T (presenting author)**, Lolatto R, Papaioannu Borjesson R, Fabbiani M, Manzillo E, Fronti E, Di Giambenedetto S, Gagliardini R, Rusconi S, Santoro MM, Castagna A, Spagnuolo V, on behalf of the PRESTIGIO Study Group. **Sexually Transmitted Infections In Men With Multidrug-Resistant Human Immunodeficiency Virus: Data From The PRESTIGIO Registry.** Oral communication presented at 15th ICAR Congress - Italian Conference on AIDS e Antiviral Research (14th-16th June, 2023, Bari, Italy)
 11. Armenia D, Spagnuolo V, Bellocchi MC, Galli L, Duca L, Marcheggiani G, **Clemente T**, Carioti L, Lolatto R, Calza L, Celesia BM, Cascio A, Francisci D, Saracino A, Torti C, Zazzi M, Castagna A, Santoro MM, PRESTIGIO Registry. **Does NGS on HIV-1 DNA improve resistance assessment in highly treatment-experienced and multi-resistant individuals under virological control? An experience from the PRESTIGIO Registry.** Oral communication presented at 15th ICAR Congress - Italian Conference on AIDS e Antiviral Research (14th-16th June, 2023, Bari, Italy)
 12. Candela C, Gordo V, Galli L, **Clemente T**, Trentacapilli B, Lucente MF, Monardo R, Alberton F, Lolatto R, Lavall M, Lettieri A, Melzi R, Striglia P, Zandonà D, Bagaglio S, Carini E, Castagna A, Gianotti N. **3-month outcome of long-acting cabotegravir and rilpivirine: preliminary results from the SCoholART Study.** Oral communication presented at 15th ICAR Congress - Italian Conference on AIDS e Antiviral Research (14th-16th June, 2023, Bari, Italy)
 13. Armenia D, Spagnuolo V, Bellocchi MC, Galli L, Duca L, Marcheggiani G, **Clemente T**, Carioti L, Lolatto R, Calza L, Celesia BM, Cascio A, Francisci D, Saracino A, Torti C, Zazzi M, Castagna A, Santoro MM, PRESTIGIO Registry. **Evaluation of HIV-1 DNA resistance burden through NGS in highly treatment-experienced and multi-resistant individuals under virological control enrolled in the PRESTIGIO Registry.** Oral communication presented at European Meeting on HIV & Hepatitis 2023 (7th-9th June, 2023, Rome, Italy)
 14. Candela C, Bruzzesi E, Raccagni AR, Bertoni C, Alberton F, **Clemente T**, Trentacapilli B, Strano M, Canetti D, Gianotti N, Castagna A, Nozza S. **Epidemia di monkeypox virus: analisi descrittiva della casistica dell'IRCCS San Raffaele, Milano.** Oral communication presented at XXI SIMIT National Congress (20th-23rd November, 2022, Rome, Italy)
 15. **Clemente T (presenting author)**, Rovatti PE, Punta M, Muccini C, Galli L, Toffalori C, Papaioannu Borjesson R, Bottanelli M, Tresoldi C, Ciceri F, Castagna A, Vago L, Spagnuolo V, on the behalf of COVID-BioB Study Group. **The role of antigen load on viral clearance and severity in SARS-CoV-2 infection.** Oral poster presented at 14th ICAR Congress - Italian Conference on AIDS e Antiviral Research (14th-16th June, 2022, Bergamo, Italy)
 16. Papaioannu Borjesson R, Galli L, Muccini C, Poli A, **Clemente T**, Bottanelli M, Gianotti N, Nozza S, Castagna A, Spagnuolo V. **Impact of COVID-19 Pandemic on Incidence and Prevalence of Metabolic Syndrome in PLWH.** Oral communication presented at 14th ICAR Congress - Italian Conference on AIDS e Antiviral Research (14th-16th June, 2022, Bergamo, Italy)
 17. **Clemente T (presenting author)**, Bottanelli M, Sferrazza B, Dell'Acqua R, Guffanti M, Chiurlo M, Spagnuolo V, Uberti-Foppa C, Castagna A, Canetti D. **Complicanze autoimmuni di COVID-19 in HIV: un case report.** Poster presented at XX SIMIT

- National Congress (28th November-1st December, 2021, Milan, Italy)
18. **Clemente T (presenting author)**, Bottanelli M, Messina E, Guffanti M, Ripa M, Scarpellini P, Badalucco Ciotta F, Spagnuolo V, Di Lucca G, Uberti-Foppa C, Castagna A, Danise A. **Infezione disseminata da Mycobacterium chimaera in paziente con sarcoma di Kaposi: un case report**. Poster presented at XX SIMIT National Congress (28th November-1st December, 2021, Milan, Italy)
 19. Bottanelli M, **Clemente T**, Monardo R, Papaioannu Borjesson R, Guffanti M, Finazzi R, Uberti-Foppa C, Castagna A, Danise A, Messina E. **Sinusite invasiva da Aspergillus post COVID-19 in infezione da HIV: un case report**. Poster presented at XX SIMIT National Congress (28th November-1st December, 2021, Milan, Italy)
 20. Raccagni AR, Bruzzesi E, Bottanelli M, **Clemente T**, Papaioannu R, Castagna A, Nozza S. **Proctite ricorrente da Neisseria Meningitidis: un'infezione sessualmente trasmissibile emergente**. Poster presented at XX SIMIT National Congress (28th November-1st December, 2021, Milan, Italy)
 21. Spagnuolo V, Bresciani L, Poli A, Galli L, **Clemente T**, Papaioannu R, Ponta G, Mori G, Canetti D, Muccini C, Castagna A. **Efficacy of rescue regimens after a dual therapy failure in a real-life setting**. Poster presented at EACS 2021: 18th European AIDS Conference (27th-30th October, 2021, London, UK)
 22. Gianotti N, Poli A, Galli L, Bossolasco S, Morsica G, Gaiera G, **Clemente T**, Papaioannu R, Bottanelli M, Lazzarin A, Castagna A. **Did lockdown due to SARS-Cov-2 pandemic jeopardize the efficacy of antiretroviral therapy?** Poster presented at EACS 2021: 18th European AIDS Conference (27th-30th October, 2021, London, UK)
 23. Gianotti N, Poli A, Galli L, Bossolasco S, Morsica G, Gaiera G, **Clemente T**, Papaioannu R, Bottanelli M, Lazzarin A, Castagna A. **Did lockdown due to SARS-Cov-2 pandemic jeopardize the efficacy of antiretroviral therapy?** Poster presented at 13th ICAR Congress - Italian Conference on AIDS e Antiviral Research (21st-23rd October, 2021, Riccione, Italy)
 24. **Clemente T (presenting author)**. **HIV in Italy: epidemiology and challenges**. Poster presented at EACS HIV Summer School 2021 (22nd e 24th September, 2021)
 25. **Clemente T (presenting author)**, Caccia R, Spagnuolo V, Galli L, Poli A, Galli A, Marchetti G, Andreoni M, Bandera A, Puoti M, Zazzi M, Santoro MM, Cinque P, Castagna A, on the behalf of the PRESTIGIO Study Group. **Inflammatory burden in people living with four-class drug resistant HIV: data from the PRESTIGIO Registry**. Oral communication presented at 12th ICAR Congress - Italian Conference on AIDS e Antiviral Research (12th-16th October, 2020, Riccione, Italy)
 26. Spagnuolo V, **Clemente T**, Caccia R, Galli L, Poli A, Sterrantino G, Gagliardini R, Rossetti B, Rusconi S, Santoro MM, Zazzi M, Cinque P, Castagna A, on behalf of the PRESTIGIO Study Group. **Inflammation, immune activation and microbial translocation in persons living with four-class drug resistant HIV: data from the PRESTIGIO Registry**. Poster presented at AIDS 2020: 23rd International AIDS Conference (6th-10th July, 2020, San Francisco, US)

• Abstracts scheduled for upcoming international and national conferences

1. Papaioannu-Borjesson R, Diotallevi S, Lolatto R, Cenderello G, Comi L, Cascio A, Saracino A, **Clemente T**, Mazzitelli M, Lo Caputo S, Armenia D, Santoro MM, Castagna A, Spagnuolo V, on behalf of the PRESTIGIO Study Group. **Persistence of CXCR4-tropic virus and incidence of clinical events in persons living with four-class drug resistant HIV: data from the PRESTIGIO registry**. Scheduled for AIDS 2024, the 25th International AIDS Conference (22nd-26th July, 2024, Munich, Germany)
2. Muccini C, Gianotti N, Diotallevi S, Lolatto R, Spagnuolo V, Canetti D, **Clemente T**, Bottanelli M, Candela C, Nozza S, Castagna A. **One-year outcomes of long-acting cabotegravir and rilpivirine in people living with HIV and a long exposure to antiretroviral therapy: data from the SCohLART Study**. Scheduled for AIDS 2024, the 25th International AIDS Conference (22nd-26th July, 2024, Munich, Germany)
3. Muccini C, Gianotti N, Diotallevi S, Lolatto R, Spagnuolo V, Canetti D, **Clemente T**, Bottanelli M, Candela C, Nozza S, Castagna A. **Effects of long-acting therapy on renal and metabolic profiles in people living with HIV: results from the SCohLART Study**. Scheduled for AIDS 2024, the 25th International AIDS Conference (22nd-26th July, 2024, Munich, Germany)

• Lectures presented at/scheduled for

1. **PRESTIGIO Registry meetiNG on HIV multidrug resistance** (scheduled for 22nd-23rd

upcoming international and national conferences

CONFERENCES, COURSES AND EVENTS

- April, 2024, Milan, Italy)
2. **The suspense around low-level viremia: Do we need to worry? Turkish AIDS and STI Society and Euroguidelines in Central and Eastern Europe Network Group Joint Webinar** (25th March, 2024, Webinar)
3. **EACS Live! Journal Club by YING: New HIV drugs** (27th September, 2023, Webinar)

1. **NEW CHALLENGES IN HIV TREATMENT** (04th and 08th April, 2024, Milan, Italy)
2. **CROI 2024: Conference on Retroviruses and Opportunistic Infections** (3rd-6th March, 2024, Denver, US)
3. **IDEA in HIV: Infectious Diseases Expert Advocacy** (8th-9th February, 2024, Milan, Italy)
4. **19th Residential Course on Clinical Pharmacology of Antiretrovirals** (17th-19th January, 2024, Turin, Italy)
5. **HIV infection: no one left behind** (01st December, 2023, Milan, Italy)
6. **NCHIV23: The 16th Netherlands Conference on HIV Pathogenesis, Epidemiology, Prevention and Treatment** (28th November, 2023, Amsterdam, Netherlands)
7. **ViiV Roundtable 'HIV Dynamics: Virology, Resistance, and Clinical Implications'** (24th October, 2023, Amsterdam, Netherlands)
8. **EACS 2023: 19th European AIDS Conference** (18th-21st October, 2023, Warsaw, Poland)
9. **EACS Live! Journal Club by YING: New HIV drugs** (27th September, 2023)
10. **15th ICAR Congress - Italian Conference on AIDS e Antiviral Research** (14th-16th June, 2023, Bari, Italy)
11. **9^o AMIT INTERNATIONAL CONGRESS: Topics of Infectious and Tropical Diseases** (16th-17th March, 2023, Milan, Italy)
12. **Fostemsavir: a BRIGHT Future Ahead** (21st December, 2022, Milan, Italy)
13. **HIV infection: evolving needs in an evolving world** (2nd December, 2022, Milan, Italy)
14. **14th ICAR Congress- Italian Conference on AIDS and Antiviral Research** (14th-16th June, 2022, Bergamo, Italy)
15. **1st PRESTIGIO Registry meetING on HIV Multidrug Resistance** (02nd-03rd May, 2022, Milan, Italy)
16. **Corso di ecocolordoppler carotideo per medici infettivologi** (04th-07th April, 2022, Milan, Italy)
17. **IDEA IN HIV: Infectious Disease Expert Advocacy** (1st September-19th December, 2021)
18. **HIV: a long road behind, a longer road ahead** (2nd December, 2021, Milan, Italy)
19. **XX SIMIT National Congress** (28th November-1st December, 2021, Milan, Italy)
20. **Malaria, XX SIMIT National Congress** (28th November, 2021, Milan, Italy)
21. **Management of Multi Drug Resistant Gram negative bacteria: challenges and options** (12th November, 2021, Milan, Italy)
22. **EACS HIV Summer School 2021** (22nd e 24th September, 2021)
23. **HIV in era COVID-19 - drive the change** (23rd September, 2021, Milan, Italy)
24. **ECCMID 2021 - 31st European Congress of Clinical Microbiology & Infectious Diseases** (9th-12th July, 2021)
25. **Cura dell'infezione da HIV: nuove esigenze nei pazienti e nuove soluzioni terapeutiche. I regimi ARV a due farmaci** (2nd December, 2020)
26. **Diagnosi e trattamento della psoriasi e infezioni cutanee** (20th November, 2020)
27. **12th ICAR Congress - Italian Conference on AIDS and Antiviral Research** (12th-16th October, 2020, Riccione, Italy)
28. **New challenges in sexually transmitted infections: sexual health, prevention and more** (12th October, 2020, Riccione, Italy)
29. **Infezione da HIV: dalla prevenzione alla cura** (2nd December, 2019, Milan, Italy)
30. **Eliminazione di HCV tra ambizione e realtà: ruolo di un network che snellisce e potenzia la corsia tra ospedale e territorio** (21st November, 2019, Milan, Italy)
31. **11th ICAR Congress - Italian Conference on AIDS and Antiviral Research** (5th-7th June, 2019, Milan, Italy)
32. **Il ruolo dei modelli matematici nella previsione del rischio di insorgenza di comorbidità nefrologiche nel paziente sieropositivo** (29th November, 2018, Milan, Italy)
33. **7th International Congress Aortic and Peripheral Surgery "How to do it"** (15th-17th

December, 2016, Milan, Italy)

PERSONAL SKILLS AND COMPETENCES

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

- Reading skills
- Writing skills
- Verbal skills

ENGLISH

ADVANCED

ADVANCED

ADVANCED

- Reading skills
- Writing skills
- Verbal skills

FRENCH

INTERMEDIATE

INTERMEDIATE

INTERMEDIATE

TECHNICAL SKILLS
AND COMPETENCES

MS EXCEL, WORD, POWER POINT

EXCELLENT

SPSS

GOOD

CAROTID DOPPLER ULTRASONOGRAPHY

BASIC

ADDITIONAL INFORMATION

Contacts for References:

- Prof. Antonella Castagna, Chief of Infectious Diseases, IRCCS San Raffaele Scientific Institute; Director of Infectious and Tropical Diseases Residency Program, Vita-Salute San Raffaele University; Full Professor of Infectious Diseases, Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy

- Dr. Vincenzo Spagnuolo, Infectious Diseases Specialist, Infectious Diseases, IRCCS San Raffaele Scientific Institute; Adjunct Professor, Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy

- Prof. Maria Santoro, Associate Professor, Laboratory of Virology, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy

- Prof. Annemarie Wensing, Director of Medical Microbiology Residency Program, University Medical Center Utrecht, Utrecht, Netherlands; Clinical Virologist, University Medical Center Utrecht, Utrecht, Netherlands; Honorary Professor, The Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa

According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV

Milan, 11^h April, 2024

CURRICULUM VITAE	
INFORMAZIONI PERSONALI	
Nome	Laura Comi
E-mail	
Nazionalità	
Data e luogo di nascita	
Indirizzo lavoro	

ESPERIENZA LAVORATIVA	
• Date (da – a)	Da settembre 2017 ad oggi
• Nome e indirizzo del datore di lavoro	ASST Papa Giovanni XXXIII P.za OMS 24127 (BG)
• Tipo di azienda o settore	AZIENDA SOCIO SANITARIA TERRITORIALE
• Tipo di impiego	Dirigente Medico a rapporto esclusivo a tempo determinato/indeterminato (dal 01/01/2019)

ESPERIENZA LAVORATIVA	
• Date (da – a)	Novembre 2015 – Settembre 2017
• Nome e indirizzo del datore di lavoro	ASST Papa Giovanni XXXIII P.za OMS 24127 (BG)
• Tipo di azienda o settore	AZIENDA SOCIO SANITARIA TERRITORIALE
• Tipo di impiego	Medico specialista con incarico di collaborazione libero professionale c/o UOC Malattie Infettive

ESPERIENZA LAVORATIVA	
• Date (da – a)	Luglio 2009 – Luglio 2015
• Nome e indirizzo del datore di lavoro	AO San Paolo - Via di Rudini 8- Milano
• Tipo di azienda o settore	UO Malattie Infettive e Tropicali
• Tipo di impiego	Medico Specializzando in Malattie Infettive

ISTRUZIONE E FORMAZIONE	
• Date (da – a)	Luglio 2009 – Luglio 2015
• Nome e tipo di istituto di istruzione o formazione	Scuola di Specializzazione in Malattie Infettive – Università degli Studi di Milano
• Qualifica conseguita Livello nella classificazione nazionale (se pertinente)	Specializzazione in Malattie Infettive (votazione 70/70 e lode) con tesi dal titolo "Systemic immune phenotype and T-cell response in HIV/HPV coinfecting males"

ISTRUZIONE E FORMAZIONE	
• Date (da – a)	10/02/2009
• Nome e tipo di istituto di istruzione o formazione	Università degli Studi di Milano
• Qualifica conseguita	Abilitazione all'esercizio della professione di medico chirurgo Iscrizione all'ordine dei Medici e degli Odontoiatri di Bergamo n° 006631

ISTRUZIONE E FORMAZIONE	
• Date (da – a)	Settembre 2002 – Ottobre 2008
• Nome e tipo di istituto di istruzione o formazione	Università degli Studi di Milano
• Qualifica conseguita	Laurea Magistrale in Medicina e Chirurgia (votazione 108/110)

ISTRUZIONE E FORMAZIONE	
• Date (da – a)	Settembre 2006 – Marzo 2007
• Nome e tipo di istituto di istruzione o formazione	FMUP – Faculdade de Medicina Universidade do Porto - Portugal
	Partecipazione al progetto Erasmus

ISTRUZIONE E FORMAZIONE	
• Date (da – a)	Settembre 1997 – Giugno 2002
• Nome e tipo di istituto di istruzione o formazione	Liceo Classico “Paolo Sarpi” - Bergamo
• Qualifica conseguita	Diploma di Maturità Classica (votazione 90/100)

CORSI DI FORMAZIONE PROFESSIONALE	
Data	Novembre 2019
	Corso Basic Life Support Defibrillation - BLS – ASST Papa Giovanni XXIII
Data	Settembre 2019
	Corso SIMIT regione Lombardia: “In tema di PreP” – Milano, checkpoint
Data	Maggio 2018
	Corso Antimicrobial Stewardship – Seriate
Data	Dicembre 2017
	Corso base di ecografia clinica in emergenza e urgenza – ASST Papa Giovanni XXIII
Data	Ottobre 2016
	ARCA Mentor School - Siena
Data	Maggio 2016
	Corso SIMIT regione Lombardia: Profilassi internazionale e Medicina delle migrazioni - Brescia

PUBBLICAZIONI SCIENTIFICHE	
	Maggiolo, F., Valenti, D., Teocchi, R., Comi, L. , Filippo, E. D., & Rizzi, M. Adherence to and Forgiveness of 3TC/DTG in a Real-World Cohort. <i>Journal of the International Association of Providers of AIDS Care (JIAPAC)</i> , 2022 21, 23259582221101815.
	Maggiolo F, Gianotti N, Comi L , Di Filippo E, Fumagalli L, Nozza S, Galli L, Valenti D, Rizzi M, Castagna A. Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial. <i>Antivir Ther.</i> 2021 May;26(3-5):51-57. doi: 10.1177/13596535211042226.
	Passera, M., Bonito, V., Comi, L. , Calvi, E., Manara, O., Farina, C., & Cogliati, M. First Autochthonous Case of Cryptococcal Meningitis in an Immunocompetent Host Due to <i>Cryptococcus gattii</i> VGlIn Northern Italy. <i>SN Comprehensive Clinical Medicine</i> , 2020 2(2), 237-241.
	F Maggiolo, N Gianotti, L Comi , E Di Filippo, L Fumagalli, S Nozza, L Galli, D Valenti, M Rizzi, A Castagna, Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2), <i>Journal of Antimicrobial Chemotherapy</i> , Volume 75, Issue 5, May 2020, Pages 1332–1337, https://doi.org/10.1093/jac/dkaa018
	Taramasso L, Di Biagio A, Riccardi N, Briano F, Di Filippo E, Comi L , Mora S, Giacomini

	M, Gori A, Maggiolo F. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia. <i>PLoS One.</i> 2019; 14(10): e0223181. Published online 2019 Oct 11. doi: 10.1371/journal.pone.0223181
	Raben D, Sullivan AK, Mocroft A, Kutsyna G, Hadžiosmanović V, Vassilenko A, Chkhartsvili N, Mitsura V, Pedersen C, Anderson J, Begovac J, Bak Dragsted U, Bertisch B, Grzeszczuk A, Minton J, Necsoi VC, Kitchen M, Ajana F, Sokhan A, Comi L , Farazmand P, Pesut D, De Wit S, Gatell JM, Gazzard B, d'Arminio Monforte A, Rockstroh JK, Yazdanpanah Y, Champenois K, Jakobsen ML, Lundgren JD; HIDES Study Group. Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study – 2012 – 2015. <i>PloS One</i> 2019 Aug 13;14(8):e0220108. doi: 10.1371/journal.pone.0220108. eCollection 2019.
	Gambato, M., Spinetti, A., Pasulo, L., D'ambrosio, R., Puoti, M., Schiavini, M., ... & Faggioli, S. (2019). Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients. <i>Digestive and Liver Disease, 51</i> , e55-e56.
	Comi L , Di Filippo E, Maggiolo F. Dolutegravir plus lamivudine as simplification dual therapy in virologically suppressed HIV-1 infected subjects. <i>J Immunological Sci.</i> (2018); 2(1): 60-64
	Castagna A, Ferrara M, Galli L, Comi L , Sterrantino G, Cenderello G, Zaccarelli M, Focà E, Roncadori A, Lazzarin A; PRESTIGIO Study Group. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus. <i>J Antimicrob Chemother</i> 2018; 73: 177–182 doi:10.1093/jac/dkx371
	Maggiolo F, Di Filippo E, Comi L , Callegaro A. Post treatment controllers after treatment interruption in chronically HIV infected patients. <i>AIDS</i> 2018 Mar 13;32(5):623-628. doi:0.1097/QAD.0000000000001743
	Zoboli F, Ripamonti D, Benatti SV, Comi L , Rizzi M. Autoimmune hepatitis and HIV infection: two case reports and review of the literature. <i>AIDS</i> 2017 Sep 24;31(15):2172-2175.
	Maggiolo F, Di Filippo E, Comi L , Callegaro A, Colombo GL, Di Matteo S, Valsecchi D, Rizzi M. Reduced adherence to antiretroviral therapy is associated with residual low-level viremia. <i>Pragmat Obs Res.</i> 2017 May 26;8:91-97.

PRIMA LINGUA	ITALIANO
--------------	----------

ALTRE LINGUE		INGLESE	PORTOGHESE	SPAGNOLO
• Capacità di lettura*		B2	B1	C1
• Capacità di scrittura*		B1	A2	C1
• Capacità di espressione orale*		B1	A2	C1

*sufficiente/discreta/buona/ottima

in alternativa:

A1/2 Livello base - B1/2 Livello intermedio - C1/2 Livello avanzato (Quadro Comune Europeo di Riferimento delle Lingue)

CAPACITÀ E COMPETENZE RELAZIONALI <i>Indicare ambiti e ruoli richiesti ove la comunicazione è importante ed essenziale per lavorare in squadra (settori cultura, sportivi...)</i>	<p>Ottime capacità comunicative acquisite durante l'attività clinica. Particolare interesse/attenzione nell'attività di counselling ai pazienti.</p> <p>Ottime capacità di instaurare relazione con i colleghi per favorire il lavoro in equipe.</p>
---	--

CAPACITÀ E COMPETENZE ORGANIZZATIVE <i>Coordinamento risorse umane, progettualità, attività di volontariato....</i>	<p>Buone capacità organizzative e di coordinazione, messe in pratica in particolare nella attività di tutoraggio sia nei confronti di studenti di medicina che di specializzandi frequentanti l'area di degenza.</p>
---	--

CAPACITÀ E COMPETENZE TECNICHE <i>Con computer, attrezzature specifiche, macchinari, ecc.</i>	<p>Ottima conoscenza del pacchetto Office e dei software aziendali.</p> <p>Formata all'utilizzo del FibroScan.</p>
---	--

PATENTE O PATENTI	B
--------------------------	---

“Il sottoscritto è a conoscenza che, ai sensi dell’art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l’uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali.

Il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dal Regolamento UE n. 679/2016 – GDPR General Data Protection Regulation, D.Lgs 196/2003 modificato da D.Lgs 101/2018.”

CITTA' Bergamo

DATA 15/01/2023

NOME E COGNOME (FIRMA)

Informazioni personali**Compagno Mirko**

Università degli studi di Roma Tor Vergata

Dipartimento di Medicina dei Sistemi, Via Montpellier 1,

00133 Roma (Italia)

Istruzione e formazione

2023-in corso

Corso di Dottorato in Malattie Infettive (MIMIT)

Università degli studi di Roma Tor Vergata, Roma, Italia

2016–2020

Specializzazione in Malattie Infettive e Tropicali

Università degli studi di Roma Tor Vergata, Roma, Italia

50/50 e lode

Progetto di tesi: *“Valutazione del danno epatico in corso di infezione da SARS-CoV-2 in una coorte di pazienti presso la UOC di Malattie Infettive del Policlinico Tor Vergata”*

Attività formative: Day Hospital e Ambulatorio HIV, Ambulatorio di HCV, Ambulatorio profilassi HBV nei pazienti immunocompromessi, Ambulatorio HBV cronica, Infezioni Sessualmente Trasmissibili (STDs), Anoscopia ad alta risoluzione (HRA), Ambulatorio PrEP, Ambulatorio Pep, Ambulatorio tubercolosi e LTBI, Reparto di Malattie Infettive, Pronto Soccorso Covid-19,

2008–2016

Laurea Magistrale a ciclo unico in Medicina e Chirurgia

Università degli Studi di Palermo, Palermo (Italia)

110/110 con lode

07/2013–09/2013

Clerkship - Research Exchange

Korle-Bu Teaching Hospital, Internal Medicine and Infectious diseases department, Accra (Ghana)

2003–2008

Diploma di Liceo Classico

Liceo Classico G.Garibaldi, Palermo, Italia

Esperienze professionali

Dicembre 2020 – in corso **Dirigente Medico UOC Malattie Infettive e Tropicali**

Policlinico Tor Vergata, Roma, Italia

- Marzo 2020 – Dicembre 2020 **Collaborazione Coordinata e Continuativa (Co.Co.Co.) per emergenza COVID**
Dipartimento di Malattie Infettive e Tropicali, Policlinico Tor Vergata, Roma, Italia
- 2019–2020 **Corrispondente Forum di Malattie Infettive - Corriere della sera**
- 20/02/2019 **Educatore alla salute**
Mamiani, Liceo Statale, Rome (Italia)
Progetto MST/HIV 2019
- 12/11/2018–18/11/2018 **Medico presso Presidio di Malattie Infettive**
Giornata Mondiale dei Poveri, Presidio Sanitario - Città del Vaticano (Città del Vaticano)
Cepheid Genexpert rapid molecular test for HIV, HCV, Mycobacterium tuberculosis at Vatican Point of Care for Homeless People
- 13/11/2017–19/11/2017 **Medico presso Presidio di Malattie Infettive**
Giornata Mondiale dei Poveri, Presidio Sanitario, Città del Vaticano (Città del Vaticano)
HCV seroprevalence and risk factors in a cohort of people who use drugs screened with rapid tests in Rome and Real world adherence to Direct-Acting Antivirals: the hidden epidemic and the challenging treatment of a key population toward eradication

Competenze

- Competenze comunicative**
- Counseling Infezioni Sessualmente trasmissibili e HIV
 - Gestione clinica del paziente PWID
- Competenze professionali**
- Esecuzione Anoscopia ad Alta Risoluzione (HRA) e gestione screening carcinoma anale HPV relato
 - Esecuzione biopsie della mucosa ano-rettale
 - Rachicentesi diagnostica
 - PAP test cervice uterina e ano
 - Ecografia tronchi sovra aortici
 - Misurazione fibrosi epatica mediante Fibroscan

Pubblicazioni

1. Antibiotics – Apr 2023

Resistance to Ceftazidime/Avibactam in Klebsiella pneumoniae KPC-Producing Isolates: A Real-Life Observational Study.
Laura Campogiani, Pietro Vitale, Alessandra Lodi, Alessandra Imeneo, Carla Fontana, Cartesio D'Agostini, Mirko Compagno, Luigi Coppola, Ilaria Spalliera, Vincenzo Malagnino, Elisabetta Teti, Marco Iannetta, Massimo Andreoni and Loredana Sarmati

2. Microorganism – Jan 2023

Remdesivir Influence on SARS-CoV-2 RNA Viral Load Kinetics in Nasopharyngeal Swab Specimens of COVID-19 Hospitalized Patients: A Real-Life Experience
Campogiani L, Iannetta M, Di Lorenzo A, Zordan M, Pace PG, Coppola L, **Compagno M**, Malagnino V, Teti E, Andreoni M, Sarmati L.

3. Viruses – Jan 2023

Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort.
Malagnino V, Salpini R, Teti E, **Compagno M**, Ferrari L, Mulas T, Svicher V, Zordan M, Basso M, Battagin G, Panese S, Rossi MC, Scaggiante R, Zago D, Iannetta M, Parisi SG, Andreoni M, Sarmati L.

4. Metabolites – Dec 2022

Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study

Jessica Cusato, Alberto Borghetti, Elisabetta Teti, Maurizio Milesi, Maria Cristina Tettoni, Stefano Bonora, Mattia Trunfio, Antonio D'Avolio, **Mirko Compagno**, Simona Di Giambenedetto, Giovanni Di Perri and Andrea Calcagno

5. OFID – Open Forum Infectious Diseases – Aug 2022

Hepatitis B–Related Hepatic Flare During Immune Reconstitution Syndrome After Antiretroviral Treatment Initiation in an HBV Surface Antigen–Positive Patient With HIV: Viroimmunological and Histological Characterization.

Iannetta M, Crea AMA, Di Lorenzo A, Campogiani L, Teti E, Malagnino V, **Compagno M**, Coppola L, Piermatteo L, Palmieri G, Cimino C, Salpini R, Zingaropoli MA, Ciardi MR, Mastroianni CM, Parisi SG, Svicher V, Andreoni M, Sarmati L.

6. IJERPH - International Journal of Environmental Research and Public Health – Aug 2022

Latent Tuberculosis Infection in Haematopoietic Stem Cell Transplant Recipients: A Retrospective Italian Cohort Study in Tor Vergata University Hospital, Rome.

Mirko Compagno, Assunta Navarra, Laura Campogiani, Luigi Coppola, Benedetta Rossi, Marco Iannetta, Vincenzo Malagnino, Saverio G. Parisi, Benedetta Mariotti, Raffaella Cerretti, William Arcese, Delia Goletti, Massimo Andreoni and Loredana Sarmati

7. Le infezioni in medicina - Jun 2022

Impact of SARS-CoV-2 infection on tuberculosis outcome and follow-up in Italy during the first COVID-19 pandemic wave: a nationwide online survey

Collaborator from Stop TB Italia research group

8. Microbiology Spectrum - Sep 2022

Longitudinal Evaluation of the QuantiFERON-TB Gold Plus Assay in Hospitalized COVID-19 Patients with a First Indeterminate Result: Resolution of Inflammation and Restoration of T-Lymphocyte Counts and Interferon-Gamma Production.

Alessio G, Imeneo A, Di Lorenzo A, Rossi B, Sorace C, **Compagno M**, Coppola L, Campogiani L, Crea AMA, Malagnino V, Buccisano F, Andreoni M, Sarmati L, Iannetta M.

9. Vaccines - Aug 2022

Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine

Ferrari L.; **Compagno M.**; Campogiani L.; Teti E.; Mulas T; Checchi D.; Alessio G.; Caldara F; Coppola L.; De Simone, G.; et al.

10. Scientific Reports – Apr 2022

Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020

Collaborator from SCIRE-SARS-CoV-2 Italian Research Enterprise-Collaborative Group

11. LIFE - Feb 2022

In Patients with Severe COVID-19, the Profound Decrease in the Peripheral Blood T-Cell Subsets Is Correlated with an Increase of QuantiFERON-TB Gold Plus Indeterminate Rates and Reflecting a Reduced Interferon-Gamma Production.

Alessandra Imeneo, Grazia Alessio, Andrea Di Lorenzo, Laura Campogiani, Alessandra Lodi, Filippo Barreca, Marta Zordan, Virginia Barchi, Barbara Massa, Simona Tedde, Angela Crea, Pietro Vitale, Iliaria Spalliera, **Mirko Compagno**, Luigi Coppola, Luca Dori, Vincenzo Malagnino, Elisabetta Teti, Massimo Andreoni, Loredana Sarmati and Marco Iannetta

12. ERJ - European Respiratory Journal - Nov 2021

Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study

Collaborator from the Global Tuberculosis Network

13. Clinical Infectious Diseases - Feb 2021

Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study.

Mario Tumbarello, Francesca Raffaelli, Maddalena Giannella, Elisabetta Mantengoli, Alessandra Mularoni, Mario Venditti, Francesco Giuseppe De Rosa, Loredana Sarmati, Matteo Bassetti, Gaetano Brindicci, Marianna Rossi, Roberto Luzzati, Paolo Antonio Grossi, Alberto Corona, Alessandro Capone, Marco Falcone, Cristina Mussini, Enrico Maria Treçarichi, Antonio Cascio, Elena Guffanti, Alessandro Russo, Gennaro De Pascale, Carlo Tascini, Ivan Gentile, Angela Raffaella Losito, Linda Bussini, Giampaolo Conti, Giancarlo Ceccarelli, Silvia Corcione, **Mirko Compagno**, Daniele Roberto Giacobbe, Annalisa Saracino, Massimo Fantoni, Spinello Antinori, Maddalena Peghin, Paolo Bonfanti, Alessandra Oliva, Andrea De Gasperi, Giusy Tiseo, Cristina Rovelli, Marianna Meschiari, Nour Shbaklo, Teresa Spanu, Roberto Cauda and Pierluigi Viale

14. Microorganism - Feb 2021

HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) treatment: Analysis of a Multicenter Italian Cohort.

Vincenzo Malagnino, Elisabetta Teti, **Mirko Compagno**, Luigi Coppola, Romina Salpini, Valentina Svicher, Monica Basso, Giuliana Battagin, Sandro Panese, Maria Cristina Rossi, Renzo Scaggiante, Daniela Zago, Marco Iannetta, Saverio Giuseppe Parisi, Massimo Andreoni and Loredana Sarmati

15. Multiple Sclerosis and Related Disorders - June 2020

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with

16. IJERPH - International Journal of Environ. Res. Public Health - 2020

Tuberculosis-Related Hospitalizations in a Low-Incidence Country: A Retrospective Analysis in Two Italian Infectious Diseases Wards.

Laura Campogiani, **Mirko Compagno**, Luigi Coppola, Vincenzo Malagnino, Gaetano Maffongelli, Lavinia Maria Saraca, Daniela Francisci, Franco Baldelli, Carla Fontana, Sandro Grelli, Massimo Andreoni, Giovanni Sotgiu, Laura Saderi and Loredana Sarmati

17. European Journal Gastroenterol Hepatol. - Mar 2020

Inflammatory bowel disease versus Chlamydia trachomatis infection: a case report and revision of the literature.

Benedetto Neri, Christof Stingone, Samanta Romeo, Giorgia Sena, Cristina Gesuale, **Mirko Compagno**, Elena De Cristofaro, Francesca Baciocchi, Giovanna Del Vecchio Blanco, Giampiero Palmieri, Loredana Sarmati and Livia Biancone

18. International Journal of Infectious Diseases - Dec 2019

Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases

Delia Goletti a, Assunta Navarra, Elisa Petruccioli, Claudia Cimaglia, **Mirko Compagno**, Gilda Cuzzia, Gabriella De Carli, Laura Fondaco, Fabio Franzetti, Alberto Giannetti, Andrea Gori, Giuseppe Lapadula, Miriam Lichtner, Claudio M. Mastroianni, Valentina Mazzotta, Nicoletta Orchi, Paolo Pavone, Daniela Piacentini, Veronica Pirriatore, Emanuele Pontali, Loredana Sarmati, Anna Spolti, Evelina Tacconelli, Massimo Galli, Andrea Antinori, Andrea Calcagno, Enrico Girardi

19. Journal of Hepatology, Vol. 68 - April 2018

Real World adherence to Direct-Acting Antivirals in a cohort of drug users in Rome, Italy

CONFERENZE

15/04/2023-18/04/2023

33° European Congress of Clinical Microbiology and Infectious Diseases – Copenhagen

ePoster Flash Session: "HIV reservoir evaluation in GALT and PBMCs of virologically suppressed

patients"

29/07/2022 – 02/08/2022

IAS 2022 International AIDS Society – Montreal, Canada

30/11/2021

XX Congresso Nazionale SIMIT – Milan, Italy

Presentazione orale dal titolo: "Valutazione del reservoir di HIV a livello del GALT in una coorte di pazienti virosoppressi".

15/01/2020-17/01/2020

15th Residential Course on Clinical Pharmacology of Antiretrovirals – Turin, Italy

13/12/2019

Infettivologo e neurologo nella SM: cinquanta sfumature di grigio – Rome, Italy

Relatore della sessione dal titolo: *Infezione tubercolare e DMTs*

24/11/2019 - 27/11/2019

XVIII Congresso Nazionale Simit – Palermo, Italy

05/06/2019 - 07/06/2019

11th ICAR-Italian Conference on AIDS and Antiviral Research - Milano, Italy

Influence of Sexually Transmitted Infection on seminal HIV levels among patients on ART: preliminary data of a case-control study.

13/09/2019

Un nuovo approccio in HIV: 2-drug regimen contenente Dolutegravir – Milano, Italy

12/09/2019

Attualità e nuove prospettive in HIV & Hepatitis – Rome, Italy

25/06/2019

Convegno Nazionale: La gestione dell'infezione da HCV nel consumatore di sostanze: where is the gap? - Venezia Mestre, Italy

- 14/06/2019 **Congresso Regionale Simit Lazio – Rome, Italy**
- 15/05/2019 – 16/05/2019 **Engage -Evolving nosocomial gram positive infection standards of care through long acting antibiotic treatment - Rome, Italy**
Presentazione orale
Dalbavancina nel trattamento di infezioni cutanee e ossee da germi Gram-positivi: l'esperienza real life del Policlinico Tor Vergata, Rome
- 20/03/2019 **AHEAD, Achieving Health through Anti-infective Drugs – Rome, Italy**
- 25/02/2019 – 26/02/2019 **Outpatients Clinical Diagnostics: High Resolution Anoscopy and Clinical Manometry – Perugia, Italy**
- 22/02/2019 **Infezioni gravi nel paziente complesso, esperienza a confronto – Rome, Italy**
- 02/10/2018 - 07/10/2018 **IDWeek2018 – San Francisco, USA**
Poster Presentation
Migration Flows and Increase of Extrapulmonary Tuberculosis in a Low Prevalence Setting: a Retrospective Analysis in Two Italian Centers
-

08 settembre 2023

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



Nome
Indirizzo
Telefono
Fax
E-mail
Nazionalità
Data di nascita

ESPERIENZA LAVORATIVA

- Date (*Dal 16/03/2000 ad oggi*)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità
- Date (*dal 17.08.98 al 15/03/2000*)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità
- Date (*dal dicembre 2000 ad oggi*)

INFORMAZIONI PERSONALI

Giuseppe Vittorio L. De Socio

Dirigente Medico presso la Clinica di Malattie Infettive

Azienda Ospedaliero-Universitaria di Perugia, Ospedale "Santa Maria della

Misericordia", Clinica di Malattie Infettive, Piazzale Menghini, 1 – 06129 Perugia,

Clinica delle Malattie Infettive La clinica di Malattie Infettive, ha carattere di assistenza internistica semi-intensiva. Il numero di posti letto di degenza in reparto di isolamento è di 16. La clinica svolge un servizio ambulatoriale di Day Hospital per la gestione delle patologie infettive e ambulatoriali acute e croniche. La clinica è centro di riferimento regionale di alto livello per l'AIDS e le malattie infettive.

Dirigente Medico

Svolge attività di monitoraggio degli effetti avversi dei farmaci antiretrovirali all'interno di un programma nazionale "Scolta" del gruppo nazionale CISA.

E' titolare di un incarico professionale per la gestione e il controllo del rischio clinico per le malattie infettive. Ha collaborato in qualità di esperto alla stesura delle linee guida inter-aziendali per la gestione delle piaghe da decubito. Attività di Antimicrobial Stewardship presso l'azienda ospedaliera di Perugia da novembre 2017.

Da Aprile 2018 Attività di consulenza come infettivologo presso il presidio Ospedaliero di Gubbio-Guado Tadino. (3 ore la settimana)

Il 22/12/2009 ha ottenuto il giudizio di idoneità per l'incarico di direttore di malattie infettive della SDO di Ancona.

Dirigente medico presso la divisione di Malattie Infettive dell'Ospedale di Fermo

Azienda Sanitaria di Fermo

Divisione di Malattie Infettive

Dirigente Medico

Gestione clinica delle patologie infettive

Attività di consulenza specialistica extra-ospedaliera. Svolge, attività di consulenza specialistica infettivologica presso la Casa d'accoglienza D.Dante Savini per malati AIDS (secondo quanto previsto dall'art. 58

punto 2 lettera a) e b) del CCNL 8 giugno 2000). L'attività prevede 4 ore di consulenza alla settimana regolarmente svolte fino ad oggi. La convenzione è stata rinnovata annualmente per una specifica competenza professionale acquisita e riconosciuta. L'attività di consulenza è regolata con delibera del Direttore Generale dell'Azienda Ospedaliera di Perugia n°1194/2000.

<ul style="list-style-type: none"> • Nome e indirizzo del datore di lavoro • Date (Anno Accademico 1997/98) • Tipo di azienda o settore • Tipo di impiego • Principali mansioni e responsabilità 	<p>COMARS (soggetto che ha richiesto l'attività di consulenza con l'Azienda Ospedaliera di Perugia)</p> <p>Titolare di un contratto con la Facoltà di Medicina e Chirurgia dell'Università di Perugia per prestazione di lavoro autonomo, coordinata e continuativa per collaborazione all'attività didattica teorico-pratica</p> <p>Università degli studi di Perugia</p>
<p>ISTRUZIONE E FORMAZIONE</p> <ul style="list-style-type: none"> • Date 1997 1994 1989 1982 	<ul style="list-style-type: none"> • Specializzazione in Malattie Infettive con voti 50/50 e lode conseguita il 29.10.97 • Dottorato di ricerca in Infettivologia conseguito presso l'Università "La Sapienza" di Roma il 20/12/94. • Laurea in Medicina e Chirurgia conseguita presso l'Università di Perugia il 13/7/1989 con voti 110/110 e lode • Maturità scientifica conseguita nel 1982 con voti 60/60.
<ul style="list-style-type: none"> • Nome e tipo di istituto di istruzione o formazione • Principali materie / abilità professionali oggetto dello studio 	<p><i>Training in biologia molecolare presso il laboratorio diretto dal prof M.M. Anceschi (Perugia '89-91), Training clinico e in laboratorio virologico presso l'Istituto di Malattie Infettive dell'Università di Perugia (89-98), diretto dal prof. Sergio Pauluzzi (ex Presidente della società italiana di Malattie Infettive). In particolare durante gli anni di dottorato ha acquisito una solida formazione metodica di PCR per la quantificazione di HIV e HCV. Ha organizzato e avviato in prima persona un laboratorio di biologia molecolare virologica. Ha frequentato a novembre 1997 il laboratorio di Virologia di Pavia diretto dal prof. Gerna per approfondire le conoscenze riguardanti le metodiche di quantificazione virale e lo studio delle resistenze virali ai farmaci.</i></p> <p><i>Dal 2000 in poi si è occupato principalmente delle co-morbidità associate all'infezione da HIV, soprattutto le patologie cardiovascolari.</i></p>
<ul style="list-style-type: none"> • Qualifica conseguita • Livello nella classificazione nazionale (se pertinente) • Date (da - a) • Nome e tipo di istituto di istruzione o formazione 	<p>03/08/2017 Abilitazione Scientifica Nazionale all'insegnamento di seconda fascia in MED/17. Setto e concorsuale 06/D4 Malattie cutanee, malattie infettive e malattie dell'apparato digerente.</p>

Produzione Scientifica

Attività di ricerca clinica applicata.

Collaboratore e membro del comitato scientifico del gruppo di studio nazionale CISA dal 2004 (coordinato dalla Clinica di Malattie Infettive del "Sacco" di Milan).

Ha coordinato con lo stesso gruppo nazionale CISA progetti di ricerca multicentrici che riguardano gli effetti avversi dei farmaci antiretrovirali e la tossicità metabolica (studi: SimOne, Hermes, Scolta, HIVHY, STOPSHIV).

Ha una attività di ricerca clinica applicata, collaborando con i colleghi della Medicina Interna, con i Microbiologi e con altri colleghi dell'Azienda Ospedaliera di Perugia come documentato dalle varie pubblicazioni internazionali.

Negli ultimi anni la sua attività scientifica ha focalizzato importanti aspetti della patologia cardiovascolare dei pazienti HIV positivi.

E' coautore di numerose pubblicazioni tutte attinenti la specializzazione in Malattie Infettive su riviste scientifiche indicizzate:

Il profilo scientifico e le pubblicazioni aggiornate sono

disponibili ai seguenti indirizzi internet:

[http://www.researchgate.net/profile/Giuseppe De Socio](http://www.researchgate.net/profile/Giuseppe_De_Socio)

e all'indirizzo:

<http://www.ncbi.nlm.nih.gov/pubmed/19111111>

L'indice H delle citazioni dei lavori scientifici da google scholar è=18.

Ha collaborato alla traduzione dell' 13° e della 14° edizione del volume Isselbacher Harrisso "Principi di Medicina Interna" e alla stesura del volume di Malattie Infettive del trattato di Medicina Interna fondato da Paolo Larizza (Piccin Editore 2007).

Attività di Associate Editor per la rivista:

PLOS ONE

Attività come Reviewer per le seguenti riviste scientifiche internazionali:

Journal of Acquired Immune Deficiency Syndromes, Journal of Antimicrobial Chemotherapy, Clinical Microbiology and Infection, Journal of Infection, HIV Medicine, Annals of Pharmacotherapy, Plos one Current HIV Research, BMC infectious diseases, Journal of the International AIDS Society, International Journal of STD & AIDS, Journal of Drug Assessment, European Journal of Internal Medicine, European Journal of Clinical Nutrition, Metabolism, BMJ Case Reports, Journal of AIDS and HIV Research, Journal of Medicine and Medical Sciences, Indian Journal of Dental Research, Collegium Antropologicum. Germs.ro, Future Virology, Yonsei Medical Journal

Riconoscimento da parte della rivista JAIDS: "top 10 reviewers of 2009."

- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Livello nella classificazione nazionale (se pertinente)

Ha partecipato in qualità di relatore e/o auditore a numerosi convegni nazionali e internazionali e a seminari scientifici con accredito ECM

CAPACITÀ E COMPETENZE

PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

PRIMA LINGUA

Italiano

ALTRE LINGUE

Inglese

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

ottima
buona
sufficiente

CAPACITÀ E COMPETENZE

RELAZIONALI

Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.

Ha svolto quotidianamente attività clinica e di ricerca che implicano collaborazione con varie figure.

CAPACITÀ E COMPETENZE ORGANIZZATIVE

Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.

CAPACITÀ E COMPETENZE TECNICHE

Con computer, attrezzature specifiche, macchinari, ecc.

ALTRE CAPACITÀ E COMPETENZE

Competenze non precedentemente indicate.

PATENTE O PATENTI

Patente di Guida B

ULTERIORI INFORMAZIONI

Ai sensi del D.Lgs 30 giugno 2003 n. 196, autorizzo la pubblicazione del curriculum e l'utilizzo dei dati contenuti per i fini stessi dell'accreditamento ECM. Consapevole che le dichiarazioni false comportano l'applicazione delle sanzioni penali previste dall'art. 76 del D.P.R. 445/2000, dichiaro che le informazioni riportate nel seguente curriculum vitae, redatto in formato europeo, corrispondono a verità.

Data 04/04/2018

University of California, San Francisco

CURRICULUM VITAE

Name: Steven Grant Deeks, MD
Position: Professor In Residence, Step 7
Medicine
School of Medicine

Address:

EDUCATION

1990 - 1993	University of California, San Francisco	Residency	Internal Medicine
1986 - 1990	University of California, San Francisco	M.D	Medicine
1981 - 1986	University of California, Berkeley	B.S.	Biology

LICENSES, CERTIFICATION

2017	Board Certification, American Board of Internal Medicine, 152133
1991	California License, GO73895
1991	DEA, BD3191309

PRINCIPAL POSITIONS HELD

07/1993 - 0/61995	University of California, San Francisco	Clinical Instructor	Department of Medicine
07/1995 - 06/2001	University of California, San Francisco	Assistant Clinical Professor of Medicine	Department of Medicine
07/2001 - 06/2003	University of California, San Francisco	Associate Clinical Professor of Medicine	Department of Medicine
07/2003 - 06/2007	University of California, San Francisco	Associate Professor Medicine in Residence	Department of Medicine
06/2007 - present	University of California, San Francisco	Professor Medicine in Residence	Department of Medicine

OTHER POSITIONS HELD CONCURRENTLY

07/1993 - present	San Francisco General Hospital, San Francisco, CA	Medical staff	Department of Medicine
-------------------	---	---------------	------------------------

HONORS AND AWARDS

2022	UCSF Lifetime Mentoring Award	University of California, San Francisco
2021	Web of Science World's Most Cited Scientists	Web of Science, Thomas Reuters
2021	Raymond Schinazi Distinguished Lectureship	Emory University, Atlanta GA
2020	Association of American Physicians (AAP)	Association of American Physicians (AAP)
2020	Web of Science World's Most Cited Scientists	Web of Science, Thomas Reuters
2019	Web of Science World's Most Cited Scientists	Web of Science, Thomas Reuters
2018	Web of Science World's Most Cited Scientists	Web of Science, Thomas Reuters
2017	Web of Science World's Most Cited Scientists	Web of Science, Thomas Reuters
2017	Tim Gill Visiting Professor	University of Colorado, Denver
2016	Web of Science World's Most Cited Scientists	Web of Science, Thomas Reuters
2015	Web of Science World's Most Cited Scientists	Web of Science, Thomas Reuters
2013	Third Annual Faculty Research Lecture – Translational Science	University of California, San Francisco
2011	Thomas M. Kelley Award	Project Inform
2011	15th Jonathan Lax Lecture	Wistar Institute, University of Pennsylvania
2010	Research in Action Award	Treatment Action Group (TAG)
2008	Sarlo Award for Excellence in Teaching	University of California, San Francisco
2008	American Society for Clinical Investigation (ASCI)	American Society for Clinical Investigation (ASCI)
2005	Emerging Leader in HIV Research	HIV Medical Association
2001	Alpha Omega Alpha	University of California, San Francisco

1995	Class of 1995 Teaching Award Nominee	University of California, San Francisco
1987	Dean's Research Fellowship	University of California, San Francisco
1986	Department Citation, Department of Biology	University of California, Berkeley
1985	Phi Beta Kappa, University of California	University of California, Berkeley
1984	President's Undergraduate Research Fellowship	University of California, Berkeley

KEYWORDS/AREAS OF INTEREST

HIV, antiretroviral therapy, inflammation, immunotherapy, cure, remission, SARS-CoV2, COVID-19

CLINICAL ACTIVITIES

CLINICAL ACTIVITIES SUMMARY

I have been a member of the San Francisco General Hospital medical staff since 1993. I have attended on the medical service in the past. I maintain a primary care clinic for people with HIV and currently manage a panel of approximately 100 individuals. I also attend in the urgent care clinic and manage several clinical trials.

CLINICAL SERVICES

1993 - present	Outpatient HIV clinic (San Francisco General Hospital)	1-3 times/week
1993 - present	Outpatient urgent care clinic (San Francisco General)	3-12 times/year
1993 - 2005	Inpatient medical service (San Francisco General Hospital)	1 month/year

PROFESSIONAL ACTIVITIES

MEMBERSHIPS

2023 - present	Infectious Disease Society of America (IDSA)
2020 - present	Association of American Physicians (AAP)
2008 - present	American Society of Clinical Investigation (ASCI)
2005 - 2009	HIV Medical Association (HIVMA)
2003 - 2005	American Academy of HIV Medicine
1996 - present	International AIDS Society (IAS)
1994 - present	International AIDS Society USA

SERVICE TO PROFESSIONAL PUBLICATIONS

2020 - 2020	Editor, Connection between Cancer and HIV Immunology, Frontiers in Immunology
-------------	---

- 2018 - present Editor, Current Opinion HIV & AIDS
- 2017 - 2018 Guest Editor, PLOS Medicine Advances in HIV Prevention, Treatment and Cure
- 2017 - present Member, Editorial Board, Journal of Viral Eradication
- 2014 - present Member, Advisory Board, eBioMedicine
- 2009 - present Member, Scientific Advisory Board, Science Translational Medicine
- 2005 - present Member, Editorial Board, Journal of Acquired Immune Deficiency Syndromes (JAIDS)
- 1996 - present Ad hoc reviewer and/or editorial board member for multiple journals, including AIDS (Editorial Board), AIDS Research and Human Retroviruses, Annals of Internal Medicine, Antiviral Research (Editorial Board), AIDS Reviews (Editorial Board), Archives of Internal Medicine, Atherosclerosis, Blood, BMJ, Circulation, Clinical Infectious Diseases, Clinical and Experimental Immunology, Current Opinion in HIV and AIDS (Editorial Board), HIV Medicine, Human Retrovirology (Editorial Board), Journal of the Acquired Immune Deficiency Syndromes (JAIDS) (Editorial Board), Journal of the American Medical Association (JAMA), Journal of Antimicrobial Chemotherapy, Journal of Clinical Investigation (JCI), Journal of Clinical Immunology, Journal of Clinical Microbiology, Journal of Clinical Virology, Journal of Experimental Medicine, Journal of Infectious Diseases (Editorial Board), Journal of International AIDS Society, Journal of Immunology, Journal of Leukocyte Biology, Journal of Medical Virology, Journal of Virology, Immunity, Lancet, The Medical Letter, Nature, Nature Medicine, New England Journal of Medicine, PloS Biology, Plos Medicine (Academic Editor on Six Submissions) , PloS Pathogens, PloS ONE, Retrovirology, Science, Science Translational Medicine (Advisory Board), Trends in Immunology, Trends in Microbiology, Virology

INVITED PRESENTATIONS - INTERNATIONAL

- | | | |
|------|---|-----------------|
| 2023 | "Immunotherapy for an HIV Cure", 3rd Human & Translational Immunology Conference, 3rd Human & Translational Immunology Conference, Rhodes, Greece | Invited speaker |
| 2023 | "Post-interventional Control: Are we making progress?":8th Annual HIV Cure Symposium, Ghent Belgium | Invited speaker |
| 2023 | "Infectious Associated Chronic Illnesses: Translation from the Laboratory to the Clinic", National Academy of Science, Engineering and Medicine (NASEM), Washington, DC | Invited speaker |
| 2023 | "Combinatorial therapy with a therapeutic conserved element DNA/MVA vaccine strategy, a TLR9 agonist and broadly neutralizing antibodies: A proof-of-concept study aimed at inducing an HIV remission", Keystone Symposia, Keystone, Colorado | Invited speaker |
| 2023 | "Effects of Sex on HIV and COVID-19"; International Workshop on HIV & Women 2023 | Invited speaker |

2022	"Do we really need a cure for HIV when we already have ART?" HIV DART 2022, Los Cabos, Mexico	Invited speaker
2022	Inaugural Session of RECOVER Webinar Series: The Epidemiology of the Post-Acute Sequelae of SARS-CoV-2 (PASC)	Invited speaker
2022	"Post-acute Sequelae of SARS-CoV-2 Infection (PASC), Long COVID", 29th Conference on Retroviruses and Opportunistic Infections (CROI)	Invited speaker
2022	"HIV Cure", Medicine 2042, Tel Aviv, Israel	Invited speaker
2022	"Mangement of Long COVID", 14th Italian Conference on Antiviral Research, Bergamo Italy	Invited speaker
2021	"Update in HIV Cure Strategies", Mexican Medical Association of HIV/AIDS (AMMVIH) XXII International Symposium	Invited speaker
2021	"HIV Cure: Are we Making any Progress?", 23rd Annual Conference of European Society for Clinical Virology	Plenary speaker
2021	"HIV Cure: Target Product Profile", 11th International AIDS Society Conference on HIV Science	Invited speaker
2021	"Kinetics and predictors of post-treatment control: Implications for an HIV cure strategy", Keystone Symposia: HIV Vaccines / HIV Pathogenesis and Cure	Invited speaker
2021	"Progress and Prospects for an HIV Cure", IPFA/PEI 27th International Virtual Workshop on Surveillance and Screening of Blood-borne Pathogens	Invited speaker
2021	"Impact of viral infections on long-term health: A tale of two pandemics", HIV & Aging in the era of ART and COVID19 / an Inter-CFAR Virtual Meeting	Plenary speaker
2021	"The Nature of the Reservoir during Long-term ART: Implications for curative strategies", Rockefeller University, New York, New York	Invited speaker
2020	"Progress towards developing an effective cure of HIV infection", HIV Drug Therapy/Glasgow 2020	Invited speaker
2020	"Immunotherapy and HIV Control", UCI/UCLA New Horizons in AIDS Reserch	Invited speaker
2019	"HIV Cure Immunotherapy", HIV Prevention Workshop, Drakensberg, Kwazulu-Natal, South Africa	Invited speaker
2019	"Global HIV Research Agenda", Eight International Meeting on HIV Infection in the Central Nervous System, Rome Italy	Invited speaker

2019	"HIV Cure Immunotherapy", Cent Gardes Conference on HIV Vaccines, d'Annecy, Veyrier-Du-Lac, France	Invited speaker
2019	"HIV Cure: Who, What, Where, How and Why"; 11th Italian Conference on AIDS and Antiviral Research (ICAR); Milan, Italy	Plenary speaker
2019	"Achieving an HIV Remission: Viable Pathways and Recent Advances", Africa Health Research Institute, 1st Max Planck Workshop on HIV Reservoirs and Evolution, St. Lucia, South Africa	Keynote speaker
2018	"HIV Control and the Cure Agenda: Getting There May not be the Same as Staying There"; 8th CIENI-Oaxaca Meeting; Centro de Investigación en Enfermedades Infecciosas (CIENI), Oaxaca, Mexico	Invited speaker
2018	"HIV Cure and Cancer Immunotherapy: Cross-disciplinary Research at its Best", HIV Drug Therapy, Glasgow HIV Meeting; Glasgow, Scotland	Invited speaker
2018	"Harnessing the Immune System to Eliminate and/or Control HIV"; Grand Challenges Meeting, Bill and Melinda Gates Foundation; Berlin, Germany	Invited speaker
2018	"Therapeutic Vaccines for Cure", 22nd International AIDS Conference, Amsterdam, the Netherlands	Invited speaker
2018	"Harnessing the Immune System to Eliminate and/or Control HIV", 27th Canadian Association for HIV Research Annual Meeting, Vancouver, BC	Plenary speaker
2018	"Harnessing the Immune System to Eliminate and/or Control HIV", XIII Advanced Course on HIV Pathogenesis, Sao Paulo, Brazil	Invited speaker
2017	"HIV Cure & Vaccine, Where are We?"; 19th International Conference on AIDS and STIs in Africa (ICASA), Abidjan, Cote d'Ivoire	Plenary speaker
2017	"Harnessing the Immune System to Eliminate and/or Control HIV"; Center for Research in Infectious Diseases (CIENI) Research Meeting, Oaxaca, Mexico	Invited speaker
2017	"In search of a cure for HIV infection"; XX Brazilian Congress of Infectious Diseases, Rio de Janeiro, Brazil	Invited speaker
2017	"2017 HIV Cure Global Research Academy", Wits Rural Facility, South Africa	Conference co-chair
2017	"Advances in HIV Cure Research and Impact of early Therapy on HIV Diagnosis and Donor", IPFA/PEI 24th International Workshop, Zagreb, Croatia	Invited speaker

2017	Toward's and HIV Cure: A Clinician's Perspective; HIV & Hepatitis in the Americas Congress; Rio de Janeiro, Brazil	Invited speaker
2016	HIV persistence: implications for long-term complications in treated HIV disease and for achieving a cure; 10th Netherlands Conference on HIV Pathogenesis, Epidemiology, Prevention & Treatment; Amsterdam, The Netherlands	Plenary speaker
2016	"HIV Cure: Applying the Oncology Model", International Anal Neoplasia Conference, San Francisco, CA	
2016	"Immunology of HIV Persistence: Implications for the Development of a Cure", HIV Glasgow 2016, Glasgow, Scotland	
2016	"HIV Cure: Promises and Challenges with the Nonhuman Primate Model", 34th Annual Symposium on Nonhuman Primate Models for AIDS, New Orleans, LA	
2016	"HIV, Inflammation and Health", HIV 2016: HIV and Non-Communicable Diseases — Opportunities and Challenges, United Nations AIDS (UNAIDS) and New York Academy of Sciences, New York, New York	
2016	"Inflammation, HIV and the role of antiretroviral therapy" 2016 New Zealand HIV Update, Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM), Auckland, New Zealand	
2015	"Eliminating HIV: Bringing together Prevention, Treatment and Cure", Nature Webinar	
2015	"Towards an HIV Cure: Shift from eradication (cure) to durable control (remission)", 2015 Cent Gardes Meeting on HIV Vaccines, Fondation Mérieux, Annecy, France.	
2015	"Conference Summary", HIV-1 and How to Kill a Killer: Attempts at Total or Functional Cure of HIV-1, Banbury Conference, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (Conference Co-Chair)	
2015	"Immunology of HIV Persistence Systemically and in CNS: Implications for an HIV Cure", NeuroHIV 2015: Sixth International Meeting on HIV Infection of the Central Nervous System, Matera, Italy	
2015	"Immunotherapeutics and the Pursuit of an HIV Cure", Agence nationale de recherches sur le sida et les hépatites virales (ANRS), Institute Pasteur, Paris, France	

- 2015 "Immunology of HIV Persistence: Implications for the Development of a Cure" Bridging the Science: Chikungunya, Dengue, Ebola, HIV, Norovirus and Emerging Infections, Fort Lauderdale, Florida
- 2015 "HIV Cure: Are we making progress or just a lot of noise?" 4th Annual Norman Bethune Symposium, University of British Columbia, Vancouver, Canada
- 2015 "HIV Curative Interventions: An Overview", Danish HIV Cure Meeting, Copenhagen, Denmark
- 2014 "Towards an HIV Cure", Southern Africa HIV Clinicians Second Biennial Conference, Cape Town, South Africa (Plenary)
- 2014 "Should ART be Offered to Everyone?" Italian Conference on AIDS and Retroviruses, Rome, Italy
- 2014 "HIV Inflammation and Immune Dysfunction during ART: Implications for Cure", International Congress on HIV Drug Therapy, Glasgow, UK
- 2014 "Towards an HIV Cure", Oxford University, Oxford, UK
- 2013 "Towards an HIV Cure: Some Progress, Many Questions", Nobel Forum, Stockholm, Sweden
- 2013 he "End of AIDS": HIV as a Chronic Inflammatory Disease; Ontario HIV Treatment Network; Toronto, Ontario, Canada
- 2013 "The End of AIDS: Treated HIV as a Chronic Disease", 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Kuala Lumpur, Malaysia (Keynote Speaker)
- 2013 "Progress Towards a Cure for HIV Infection", Institute Pasteur: 30 years of HIV science: Imagine the Future Symposium; Paris, France
- 2013 "Progress Towards an HIV Cure", 7th International Workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource-limited Settings (INTEREST), Dakar, Senegal
- 2013 "HIV Infection, Imflammation and Aging", Keystone Symposium: Immune Activation in HIV Infection: Basic Mechanisms and Clinical Implications; Breckenridge, CO
- 2012 "Prospects for an HIV Cure", China Association for Science and Technology High Level Forum on HIV Cure Research; Beijing, China

- 2012 "Prospects for an HIV Cure: An Update on Ongoing Work in the Clinic"; HIV DART 2012: Frontiers in Drug Development for Antiretroviral Therapies; San Diego, CA
- 2012 "Prospects for an HIV Cure"; Australasian HIV/AIDS Conference 2012 ; Melbourne, Australia
- 2012 "Therapeutic Approaches to HIV Cure: Role of Host Immunity in HIV Cure Strategies"; AIDS Vaccine 2012; Boston, MA
- 2012 "Why is inflammation elevated in treated HIV infection and why does it matter?"; XIX International AIDS Conference; Washington, DC
- 2012 "HIV Infection, Inflammation, Immunosenescence and Aging" Aging and Immunity (Mérieux Foundation/WHO); Sienna, Italy
- 2012 "HIV and Aging" 22nd Annual Swiss Academic Foundation for Education in Infectious Diseases (SAFE-ID); Saanen/Gstaad, Switzerland
- 2011 "The Host Response as a Barrier to an HIV Cure" Fifth International Workshop on HIV Persistence, St. Maarten, West Indies
- 2011 "Prospects for HIV Eradication", 5th Netherlands Conference on HIV Pathogenesis, Prevention and Treatment; The Royal Tropical Institute, Amsterdam, The Netherlands
- 2011 "Case Records of the Massachusetts General Hospital Clinicopathological Conference (CPC)" 5th Annual Workshop on Advanced Clinical Care (AWACC) – AIDS, Durban, South Africa
- 2011 "The Pathogenesis of HIV-associated Inflammation during Long-term Antiretroviral Therapy" 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; Rome, Italy
- 2011 "The Host Response as a Barrier to an HIV Cure" New Concepts in HIV Immunopathogenesis, Treatment and Vaccines; Rome, Italy
- 2010 "Impact of CMV on HIV-Associated Inflammation" HIV DART 2010 (Frontiers in Drug Development for Antiretroviral Therapies); Los Cabos, Mexico
- 2010 "Impact of HIV-Associated Inflammation on Aging" II Congreso Nacional (GeSIDA); Madrid, Spain (Opening Plenary)

- 2010 "HIV and Inflammation: The Pathogenesis of Treated HIV disease and its Implications for When to Start Antiretroviral Therapy" DAGNA (German Association of Physicians in HIV/AIDS Care) National Meeting, Cologne, Germany (Opening Plenary)
- 2010 "The Clinical Implications of HIV Persistence During Therapy" Towards a Cure: HIV Reservoirs and Strategies to Control Them, International AIDS Conference Workshop, Vienna, Austria (Opening Plenary)
- 2009 "Pathogenesis of Non-AIDS Morbidity and Mortality: Are Patients on HAART Aging too Quickly, and if so, Why?" 21st Annual Conference of the Australasian Society for HIV Medicine; Brisbane, Australia
- 2009 "Clinical Implications of Integrase Inhibitor Resistance VIII" Brazilian Symposium of Basic Research on HIV/AIDS – SIMPAIDS 2009; Rio de Janeiro, Brazil
- 2009 "HAART, Aging and non-AIDS Morbidity" 9th Congresso Colombiano de Enfermedades Infecciosas (plenary presentation)
- 2009 "Clinical Implications of Integrase Inhibitor Resistance" 7th European HIV Drug Resistance Workshop, Stockholm, Sweden
- 2009 "HIV Elite Controllers"; 16th Conference on Retroviruses and Opportunistic Infections (invited symposium speaker), Montreal, Canada
- 2008 "The Pathogenesis of Non-AIDS Morbidities in HIV Disease and Implications for Management" 9th International Congress on Drug Therapy in HIV Infection; Glasgow, Scotland
- 2008 Natural History of Drug-Resistant HIV: Implications for First HAART Failure in Absence of Viral Load Monitoring. ART failure Definitions in the Context of Public Health Approach; World Health Organization (WHO), Switzerland
- 2008 "Antiretroviral Therapy: 2nd Decade: Evolving Concepts Regarding Treatment Failure" University of British Columbia, Vancouver, BC
- 2007 "HIV "Elite" Controllers: the Relationship Between Persistent HIV and Immune Responses"; Third International Workshop on HIV Persistence during Therapy, St. Maarten

- 2007 "Immunologic failure: What is it, how Common is it, Why does it Happen, and What to do about it?"; 9th Annual Alberta Infectious Disease Conference, Banff, Canada
- 2007 "Pathogenesis of Drug-Resistant HIV: Implications for first HAART Failure in Absence of Viral Load Monitoring"; 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia
- 2006 "Management of Multi-drug Resistant HIV"; British HIV Association Conference; London, UK. Plenary Speaker
- 2005 "Switching therapy: strategic approaches"; Third International AIDS Society Conference; Rio de Janeiro, Brazil
- 2005 "Immune Activation and Viral Fitness"; 2005 Keystone Symposia on HIV Pathogenesis, Banff, Canada
- 2004 "Factors Associated with Durable Suppression of Drug-Resistant HIV"; Frontiers in Drug Development for Antiretroviral Therapies (DART), Montego Bay, Jamaica
- 2003 "Pathogenesis of Drug-resistant HIV: Implications for Treatment Management"; 9th European AIDS Meeting, Warsaw, Poland
- 2003 "Immunologic Control of Drug-Resistant HIV"; British HIV Association Conference; London, UK. Plenary Speaker
- 2003 "Pathogenesis of Drug-Resistant HIV: Implications for Treatment Management"; Brazilian Infectious Diseases Congress, Goiania, Brazil
- 2002 "Pathogenesis of Drug-Resistant Viremia"; Third Colloque Centre Lemanique de Recherche sur le SIDA (CCLRS), Lausanne, Switzerland
- 2000 "Structured Treatment Interruptions"; Ninth Annual Canadian Conference on HIV/AIDS Research, Montreal Canada

INVITED PRESENTATIONS - NATIONAL

- 2023 "Combination Immunotherapy and Post-interventional Control", Seminar, Ragon Institute of MGH, MIT and Harvard Invited speaker
- 2023 "Combination Immunotherapy and Post-interventional Control of HIV", University of Pennsylvania, Philadelphia, PA Invited speaker

Prepared: November 19, 2023

2023	"Combination Immunotherapy and Post-interventional Control of HIV", U.S. Military HIV Research Program (MHRP), Walter Reed Army Institute of Research, Silver Spring, MD	Invited speaker
2023	"Combination Immunotherapy and Post-interventional Control of HIV", Seminar A NYC-Wide Research Symposium: Pathways to an HIV Cure, Rockefeller, University, NY NY	Invited speaker
2022	"The pathogenesis of Long COVID and its implication for treatment", National Center for Health Research, Washington, DC	Invited speaker
2022	"Post-acute complications of of SARS-CoV-2 Infection: Long COVID", 71st Annual Yosemite Postgraduate Institute, Yosemite, CA	Invited speaker
2022	"Biology of Post-acute Sequelae of SARS-CoV-2 Infection Emerging therapeutic agenda", Veteran's Administration Saint Louis Health Care System	Invited speaker
2021	"Impact of viral infections on long-term health: A tale of two pandemics", Miami/Emory Center for AIDS Research HIV and Aging in the Era of ART and COVID Meeting, Miami, FL	Keynote speaker
2021	"Towards an HIV Remission: When and How", Ray Schinazi Distinguished Lectureship, Emory, Atlanta GA	Invited speaker
2019	"HIV Cure Research in an Aging Population: Unique Opportunities and Challenges"; 10th International Workshop on HIV & Aging, New York, NY	Invited speaker
2019	"The Global HIV Cure Agenda: Why it is Needed and How it Might be Achieved", Kaiser Permanente National HIV, Hepatitis, and STD Symposium, Las Vegas, NV	Invited speaker
2019	HIV and Cancer Curative Approaches: Cross-disciplinary Research"; American College of Clinical Pharmacology Annual Meeting, Chicago IL	Invited speaker
2019	"HIV Cure: Shock and Kill, Block and Lock, Reduce and Control"; 5th Annual Breakthroughs in Medicine Conference , Rancho Palos Verdes, CA.	Invited speaker
2019	"HIV Cure"; National Psoriasis Foundation Symposium: The Future of Psoriatic Disease: Prevention, Precision Medicine, and Cure; Seattle, WA	Invited speaker
2019	"Impact of Aging on HIV Biology" NIH/OAR Aging and HIV-Related Neurodegeneration Workshop, Bethesda, MD	Invited speaker

2019	"Immunotherapy and an HIV Cure: mTOR Inhibition"; Stanford ITI Human Immune Monitoring Technology and Bioinformatics Conference, Palo Alto CA	Invited speaker
2018	"Moving Toward a Cure: Where are We Now?"; UCSF CME: The Medical Management of HIV/AIDS and Hepatitis; San Francisco, CA	Invited speaker
2018	"State of the Art Lecture: Harnessing the immune system to eliminate and/or control HIV", HIV DART and Emerging Viruses, Miami	Invited speaker
2018	"Immunotherapy and an HIV Remission"; University of North Carolina, Chapel Hill, NC	Invited speaker
2017	DARE: Progress and Future Directions; 8th HIV Persistence during Therapy Workshop; Miami, FL	Invited speaker
2017	"An HIV Cure: Why is it Needed and How Might it be Achieved?", Tim Gill Visting Professorship, University of Colorado, Denver CO	Visiting Professor
2017	Individualized Treatment in the Management of HIV/AIDS: Advanced Strategies for Improved Patient Outcomes; National Association of Managed Care Physicians, Las Vegas, NV	Invited speaker
2017	"HIV Cure: A clinician's perspective"; 15th Annual HIV CME Symposium: Tough Decisions Made Easier; University of California, Los Angeles, Los Angeles, CA	Invited speaker
2017	"Harnessing the Immune System to Eliminate and/or Control HIV: A viable and testable roadmap"; UCLA Immunology, Inflammation, Infectious Disease and Transplantation (I3T) Seminar Series; University of California, Los Angeles, Los Angeles, CA	Invited speaker
2017	"The State of Cure Research", 17th Ryan White HIV/AIDS Program (RWHAP) Clinical Care Conference, San Antonio, TX	Invited speaker
2017	"HIV Cure Research Questions and a Few Answers; IAS USA Improving the Management of HIV Disease, Chicago, IL	Invited speaker
2017	HIV Cure Research: Understanding of the T cell Reservoir – What Bar Needs to be Reached to Determine the Potential Relevance of Macrophages to HIV Persistence and Latency, Ragon Institute, Boston, MA	Invited speaker
2016	"The Role of Immunotherapy in Curing HIV Infection", Oregon Health Sciences University/Vaccine and Gene Therapy Institute; Beaverton, OR	

- 2016 "HIV Cure and Research", Northeast Caribbean AIDS Education and Training Center (AETC), Cherry Hill, New Jersey
- 2016 "Harnessing the Immune System to Eliminate and/or Control HIV", New York State 2016 HIV Cure Symposium: Connecting Research to Clinical Practice, New York, New York
- 2016 "Immunology of HIV Persistence: Implications for the Development of a Cure", Bay Area Symposium on Viruses, Berkeley, CA
- 2016 "HIV and Altered Aging", New York Academy of Sciences, New York, New York.
- 2015 "HIV Cure Research", Kaiser Permanente 9th National HIV/AIDS, Hepatitis & STI Conference, San Diego, CA
- 2015 "Immune Therapy: Implications for an HIV Cure", Drexler School of Medicine, Philadelphia, PA
- 2015 "Towards an HIV Remission: Lessons from Oncology", University of Pennsylvania Institute for Immunology & Center for AIDS Research Joint Symposium: "HIV & Immunology: Strategies for Prevention and Cure", Philadelphia, PA
- 2015 "Immunotherapeutics: Clinical Implications for Therapy and Prevention", New York Course, New York, NY
- 2015 "Short-term Disulfiram to Reverse Latent HIV Infection: a Dose Escalation Study", Keystone Symposia, Boston, MA
- 2015 "HIV Cure: An Overview:", 73rd Annual American Academy of Dermatology Meeting, San Francisco, CA
- 2015 "Disulfiram and the need for less toxic latency reactivating agents", 2015 Palm Springs Symposium on HIV/AIDS, "HIV Disease: From Cause to Cure", University of California Irvine/University of California, Los Angeles, Palm Springs, CA
- 2014 "Immunology of HIV Persistence: How HIV Vaccine Efforts can Contribute to a Cure", The Collaboration for AIDS Vaccine Discovery (CAVD), Bill and Melinda Gates Foundation, Seattle, WA
- 2014 "HIV Cure: Implications of Recent Advances and Setbacks" Conference on Cell & Gene Therapy for HIV Cure, Seattle, WA

- 2014 "HIV and Aging in MSM", UNAIDS-New York Academy of Science symposium: HIV 2014: Science, Community and Policy for Key Vulnerable Populations, New York, NY
- 2014 "HIV Disease, Aging and the Microbiome", National Institutes of Health, Bethesda, MD
- 2014 "Immunology of HIV Persistence: Implications for an HIV Cure", Ragon Institute, Harvard, Boston, MA
- 2014 "Graft-versus-host Disease and the Berlin Patient"; National Institutes of Health, Bethesda, MD
- 2014 "Co-Morbidity in HIV Disease: Research Priorities"; Office of AIDS Research Advisory Council (OARAC), National Institutes of Health, Rockville, MD
- 2013 "Towards and HIV Cure", Office of AIDS Research Advisory Council (OARAC), National Institutes of Health, Rockville, MD
- 2013 "Aging and Inflammation: Does HIV Alter the Landscape?", IDWeek; San Francisco, CA
- 2013 "Towards an HIV Cure: A brief primer for non-expert" Nevada AIDS Education and Training Center (HRSA/DHHS), Nevada
- 2013 "The "End of AIDS": HIV as a Chronic Inflammatory Disease", Lancet and Cell Translational Medicine Symposium, San Francisco, CA
- 2013 "Towards an HIV Cure", IDWeek; San Francisco, CA
- 2013 "HIV Infection, Inflammation and Aging", National Cancer Institute (NCI), Bethesda, CA
- 2013 "Role of Inflammation in HIV Persistence"; Emory CFAR Science Symposium, Atlanta, GA
- 2012 "Targeting HIV Reservoirs"; National Institute of Allergy and Infectious Diseases (NIAID) AIDS Research Advisory Committee (ARAC); Bethesda, MD
- 2011 "HIV Disease and Accelerated Aging"; 49th Annual Meeting of the Infectious Diseases Society of America (IDSA); Boston, Massachusetts
- 2011 "Residual Disease during Effective Antiretroviral Therapy: Implications for Non-human Primate Research"; 29th Annual Symposium on Nonhuman Primate Models for AIDS; Seattle, Washington

- 2011 "Top Research Papers in HIV Pathogenesis", 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA
- 2011 "The Host Response as a Barrier to an HIV Cure"; Jonathan Lax 15th Memorial Lecture, Wistar Institute, Philadelphia, Pennsylvania
- 2011 "The Clinical Implications of HIV Persistence during Therapy"; University of Pennsylvania HIV Grand Rounds, Philadelphia, PA
- 2011 "Management of HIV Disease: Trends and Future Directions"; American Society of Clinical Oncology, Chicago, IL
- 2011 "The Clinical Implications of HIV Persistence during Therapy"; Rush University Center for AIDS Research Symposium, Chicago, IL
- 2011 "The Clinical Implications of HIV Persistence during Therapy"; 8th Annual HIV Symposium: The Road to a Cure for HIV/AIDS, University of Miami, Miami, FL
- 2011 "The Immunologic Basis of Cardiovascular Disease and Endothelial Dysfunction in HIV-infected Adults"; Harvard University Center for AIDS Research Symposium: Metabolic and Cardiovascular Complications in HIV-infected Patients: Pathogenesis and Treatment in 2011; Boston, MA
- 2011 "Rationale for Using Immune-based Therapeutics to Cure HIV Infection"; Office of AIDS Research, NIH, Bethesda, MD
- 2010 "The Cause and Implications of HIV-associated Inflammation"; 1st International Workshop on HIV & Aging, Baltimore, MD
- 2010 "AIDS as the Acquired Inflammatory Disease Syndrome"; Immune Activation in HIV Pathogenesis: Models and Targets (Co-sponsored by the Division of AIDS, NIAID and the NIH Office of AIDS Research); Bethesda, MD
- 2010 "HIV-Association Inflammation as a Cause of Accelerated Aging"; Keystone Symposium: HIV Biology and Pathogenesis, Santa Fe, NM
- 2009 "Novel Therapeutic Strategies for the Management of HIV Disease"; 47th Infectious Diseases Society of America (IDSA), Philadelphia, PA

- 2009 "Virus Control, Inflammation and HIV Disease Progression"; 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA
- 2009 "Role of premature immunosenescence in causing age-related morbidity long-term antiretroviral treated HIV disease"; University of California, Davis "Emerging Challenge in Microbiology and Immunology"; Davis, CA
- 2009 "HIV Elite Controllers"; 16th Conference on Retroviruses and Opportunistic Infections (invited symposium speaker), Montreal, CA
- 2008 "Are Patients on HAART Aging too Quickly, and if so Why?"; 12th Annual National Conference of the National Institutes of Health Centers for AIDS Research (CFAR), Cleveland, OH
- 2008 "HIV "Elite" Controllers: Are there Unique Clinical and Biologic Phenotypes"; NIAID Grand Rounds, Bethesda, MD
- 2008 "HIV "Elite" Controllers: Are there Unique Clinical and Biologic Phenotypes within the Controllers Amenable to Whole Genomic Analysis?"; Harvard University Center for AIDS Research (CFAR), Boston MA
- 2007 "CCR5 Inhibitors in First Line Therapy"; 3rd International Workshop on Targeting HIV Entry, Washington, DC
- 2007 "Adherence/Fitness Interactions: Why do some Drugs Rapidly Select for Resistance while others Do Not?"; 2nd International Conference on HIV Treatment Adherence, Jersey City, NJ
- 2007 "UCSF "Elite" Controller Cohort"; UCI/UCLA 9th Annual HIV Research Symposia on HIV/AIDS, Palm Springs, CA
- 2006 "Immune Activation in Elite Controllers: Isolating the Good from the Bad Inflammatory responses"; NIH Immune Activation Workshop, Washington DC
- 2006 "Impact of Treatment on Envelope Fitness and Virulence"; 13th International HIV Dynamics and Evolution, Woods Hole, MA
- 2006 "Impact of Treatment on Envelope Fitness and Virulence"; University of Pennsylvania Center for AIDS Research, Philadelphia, PA

- 2005 "Viral Fitness"; 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, LA
- 2005 "Pathogenesis of Drug-Resistant HIV: Implications for Novel Treatment Strategies"; Mathematical Biosciences Institute, Ohio State University, Columbus, OH
- 2004 "A US Clinical Perspective on the Implications of Antiretroviral Resistance for Resource-Constrained Settings"; Institute of Medicine Workshop on Antiretroviral Drug Use in Resource Constrained Settings, Washington DC
- 2003 "Immunologic Determinants of Treatment Outcome in Patients with Multi-Drug Resistant HIV"; Fourth NCI HIV Drug Resistance Program Symposium, Washington, DC
- 2003 "When to Switch"; CPCRA National Meeting, Reston, VA
- 2003 "Determinants of Treatment Outcome in Patients with Multi-Drug Resistant HIV: Role of Partial Treatment Interruptions"; Palm Springs Symposium on HIV/AIDS: HIV Pathogenic Mechanisms and Therapeutics, Palm Springs, CA
- 2003 "When to Switch Antiretroviral Therapy"; Tenth Conference on Retroviruses and Opportunistic Infections, Boston MA
- 2001 "Structured Treatment Interruptions in Patients with Drug-Resistant Viremia"; 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL
- 2001 "Clinical Management of Virologic Failure"; 39th Annual Meeting of Infectious Diseases Society of America (IDSA), San Francisco, CA
- 2000 "Preservation of CD4 T Cells during Prolonged Virologic Failure"; 2000 International Meeting of the Institute of Human Virology. Baltimore, MD
- 2000 "Mechanisms and Predictors of Virologic Failure"; 3rd International Conference on Salvage Therapy, Chicago, IL
- 1999 "Issues in Salvage Therapy"; 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA

GOVERNMENT AND OTHER PROFESSIONAL SERVICE

- 2023 - 2023 International AIDS Society Research for a Cure Academy, Wits Rural Facility, South Africa Organizer and co-chair

Prepared: November 19, 2023

2023 - 2023	Board of Scientific Counselors, NIAID, NIH	Member (ad hoc)
2022 - 2023	Viral Infections and Inflammation Workshop 2022, Washington DC	Organizer and co-chair
2022 - 2023	2023 HIV Cure & Immunotherapy Forum, International AIDS Society	Organizing committee
2022 - present	RECOVER PASC Intervention Prioritization Panel, Biologics Subcommittee	Co-chair
2021 - present	RECOVER: Researching COVID to Enhance Recovery, Adult Cohorts	Steering committee member
2021 - present	International Workshop on Long-term Complications of HIV and SARS-CoV-2	Organizing meeting
2022 - 2022	Expert testimony on "Long COVID", State of California Senate Health Committee; Special Committee on Pandemic Emergency Response	Expert testimony
2021 - 2023	HIV Prevention: Vaccines, Immunoprophylaxis and Drugs; Keystone Symposium, Keystone, CO	Co-chair
2021 - 2022	"Sunnylands 3: Ensuring Accessibility of Gene Therapy-Based Cures for HIV and Sickle Cell Disease", Sunnylands Estate, Rancho Mirage, CA	Steering committee member
2021 - 2021	Member, University of Cape Town Doctoral Degrees Committee for Sherazaan Dineo Ismail	Doctoral degree committee member
2021 - 2021	"Long COVID", US House of Representatives Subcommittee on Health, April 28, 2021	Expert testimony
2021 - 2021	National Academies of Sciences, Engineering, and Medicine: Planning Committee for Long Covid and Disability Workshop	Planning committee member
2020 - 2020	Social Security Administration National Disability Forum, "COVID-19 and SSA Programs: Long-Term Health Effects", November 18, 2020	Expert testimony
2019 - 2021	ACTG Transformative Scientific Group, HIV Cure	Scientific meeting member
2019 - present	Voting Member, Scientific Governance Committee, HIV Vaccine Trials Network	Committee member
2019 - 2019	NIH HIV-Associated Co-morbidities Workshop	Meeting co-chair
2019 - 2019	2019 HIV & HBV Cure Forum, International AIDS Society, Mexico City, Mexico	Meeting co-chair

Prepared: November 19, 2023

2018 - present	A Phase 1/2a Open Label Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults (IAVI T003)	Safety monitor committee member
2019 - present	City of Hope, California Institute for Regenerative Medicine (CIRM)	Clinical advisor
2018 - 2019	Scientific Committee, Ragon Institute of MGH, MIT and Harvard Forum on Analytic Treatment Interruptions	Meeting organizer
2017 - present	International AIDS Society Towards an HIV Cure Advisory Board	Committee member
2015 - 2021	HIV Reservoir Assay Validation and Evaluation Network (RAVEN); Bill and Melinda Gates Foundation	Steering committee member
2015 - 2015	Keystone Symposia: Mechanisms of HIV Persistence: Implications for a Cure, Boston MA	Meeting organizer and co-chair
2015 - 2015	"HIV-1 and How to Kill a Killer: Attempts at Total or Functional Cure of HIV-1", Banbury Center of Cold Spring Harbor Laboratory.	Meeting co-chair
2014 - 2015	NIH Office of AIDS Research (OAR) Research Toward a Cure Planning Group	Committee co- chair
2014 - 2021	Steering Committee, amfAR Institute for an HIV Cure	Steering committee member
2013 - 2013	Summit on Public-Private Partnerships for Research Toward a Cure for HIV, The Annenberg Retreat at Sunnylands, Rancho Mirage, CA	Meeting organizer and co-chair
2013 - 2013	Scientific Evaluation Committee of the Amsterdam Cohort Studies	Scientific committee member
2013 - 2018	European Commission "COMorBidity in Relation to Aids" (COBRA) Program	Scientific advisory board member
2013 - 2013	Scientific Organizing Committee of AIDS Vaccine 2013	Organizing committee member
2012 - 2021	Member, Scientific Committee, International Congress on Drug Therapy in HIV Infection (HIV Glasgow Conference)	Program committee member
2011 - 2015	NIH Office of AIDS Research Advisory Council (OARAC)	Advisory council member
2011 - 2015	HIV Reservoirs and Viral Eradication Transformative Science Group (Cure TSG), ACTG (NIH)	Scientific committee member
2011 - 2011	XIX International AIDS Conference	Scientific committee member

Prepared: November 19, 2023

2011 - 2011	NIH Scientific Review Panel, AIDS Fellowship Program	Review panel member
2011 - present	"Towards an HIV Cure" International Working Group, International AIDS Society (IAS)	Meeting organizer and co-chair
2011 - 2011	Working Group on HIV and Aging, Office of AIDS Research, National Institute of Health (NIH)	Working group member
2010 - 2019	Member, Executive Committee, INSIGHT Scientific Steering Committee	Scientific committee member
2010 - 2012	Member, Scientific Monitoring Committee (SMC), Protocol 08-0053, NIH	Scientific monitoring committee member
2008 - 2008	WHO Expert Consultation on ART Failure Definitions in the Context of Public Health Approach	Consultant
2008 - 2008	ACE Study Section, NIAID, NIH (ad hoc member three times)	Committee member
2007 - 2007	NIAID Special Emphasis Panel, Novel HIV Therapies: Integrated Preclinical/Clinical Program (IPCP)	Committee member
2007 - 2011	Member, ACTG TRADD Immunology Focus Group	Scientific committee member
2007 - 2007	INSIGHT/NIAID Meeting, "SMART Specimen Think Tank"	Co-chair
2007 - 2014	Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents	Committee member
2006 - 2010	Steering Committee, North American Consortium for the NIH International Epidemiologic Databases to Evaluate AIDS (IEDEA) Program	Steering committee member
2006 - 2006	Food and Drug Administration; R5 Inhibitors Advisory Committee	Invited expert
2003 - 2005	NIAID Scientific Review Panels	Committee member
2003 - 2008	National HIV/AIDS Clinicians' Consultation Center, HRSA	Consultant
2001 - 2001	Fitness Working Group, ACTG HIV Disease RAC	Committee co-chair
2001 - 2001	Food and Drug Administration; Antiviral Drugs Advisory Committee	Invited expert
2001 - 2001	NIAID Scientific Review Panel, Special Emphasis Panel	Committee member
2000 - 2001	When to Switch Focus Group, ACTG HIV Disease RAC	Committee co-chair

2000 - 2001	HIV Disease Research Agenda Committee (RAC); AIDS Clinical Trials Group (ACTG)	Committee member
2000 - 2000	Immunology Research Agenda Committee; AIDS Clinical Trials Group (ACTG)	Committee member

UNIVERSITY AND PUBLIC SERVICE

SERVICE ACTIVITIES SUMMARY

I have made a number of public service contributions at the University, national and international levels.

At the University level, I am member of the UCSF Chancellor's Conflict of Interest Advisory Committee and the Department of Medicine Clinical and Outcomes Research (COR) Search Committee.

At the national level, I was recently a member of the Office of AIDS Research Advisory Council (ORAC) and was the extramural co-chair for the OAR Research Toward a Cure Planning Group I was also a member of the Department on Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents for many years, and retired from the committee a few years ago when my term ended. I am an active member of the Scientific Committee for the INSIGHT, an NIAID-sponsored clinical trials network and was recently a member of the scientific subcommittee on HIV cure within the ACTG, another NIAD-sponsored network.

At the international level, I have been the co-chair of the "Towards an HIV Cure" initiative within the Internal AIDS Society (IAS). This initiative sponsors an annual international meeting (which I co-chair) and several active working groups. I am also a member of the Scientific Advisory Board for the European Commission sponsored "CO-morBidity in Relation to Aids" (COBRA) program. I recent co-chaired a Keystone meeting on HIV cure and have served on the organizing committee for several other international scientific meetings. I periodically provide consultation and advice to UNAIDS and WHO. I have provided peer review to a number of governmental and other funding, including programs sponsored by South Africa, Denmark, Canada and a variety of foundations and trusts.

Finally, I have been an active member of the Scientific Advisory Board for Science and Translational Medicine since its inception. I am also on the advisory board for a number of major journals, include eBioMedicine, JAIDS, and AIDS.

UCSF CAMPUSWIDE

2023 - 2023	Zuckerberg San Francisco General Cytopathology Search Committee	Committee member
2021 - present	AIDS Research Institute (ARI) Leadership Committee	Committee member
2021 - present	Conflict of Interest (COI) Program Evaluation	Committee member
2021 - present	Living Therapeutics Committee on Clinical Delivery	Committee member

2021 - present	Clinical and Outcomes Research (COR) Search Committee, Department of Medicine	Committee member
2021 - present	Gladstone-UCSF Institute of Genomic Immunology	Member
2012 - present	UCSF Chancellor's Conflict of Interest Advisory Committee	Committee member
2008 - 2008	RAP Clinical HIV/AIDS, Infectious Diseases, Global Health Review Committee (UCSF CTSI)	Committee member
2006 - 2015	Clinical and Outcomes Research (COR) Search Committee, Department of Medicine	Committee member
2005 - 2010	Committee on Human Research (CHR), UCSF	Committee member
2007 - 2018	CTSI Clinical Research Center Advisory Committee (GAC)	Committee member
2001 - present	USCF Center for AIDS Research (CFAR)	Committee member
1998 - 2000	Dean's AIDS Advisory Committee to the UCSF AIDS Clinical Research Center	Committee member
1996 - 1998	Committee on Human Research (CHR), UCSF	Committee member

COMMUNITY AND PUBLIC SERVICE

2020 - present	Caring Cross, Gaithersberg, MD	Scientific advisory board member
2019 - 2019	HIV/AIDS Biomedical and Clinical Research, Canadian Institutes of Health Research (CIHR)	Review committee member
2020 - present	Cell and Gene Therapy Institute	Committee member
2018 - 2018	HIV Cure Research with the Community Workshop, 22nd International AIDS Conference, Amsterdam, the Netherlands	Co-chair
2017 - present	International AIDS Society HIV Research-for-Cure Academy, Wits Rural Facility, Bushback Ridge, Limpopo Province, South Africa	Organizer and co-chair
2018 - 2018	International AIDS Society HIV Cure Advocacy Meeting, Kampala, Uganda	Co-chair
2013 - 2013	UNAIDS Consultation on Defining the End of AIDS, Crozet, France	Expert consultant
2012 - 2017	Scientific Advisory Board, "CO-morBidity in Relation to Aids" (COBRA), European Commission	Scientific advisory board member

2013 - 2013	Canadian Institute of Health Research	Review committee member
2013 - 2013	AIDS Vaccine 2013	Organizing committee member
2009 - 2009	Scientific Impulse Mandate-Ulysses F.R.S.-FNRS, Belgium	Review committee member
2009 - 2009	IFARA CROI Update [community-based organization]	Committee member
2008 - 2008	amfAR Review Committee, amfAR - The Foundation for AIDS Research	Review committee member
2008 - 2008	Project Inform HAART Conference, Washington, DC	Organizing committee member
2008 - 2008	Workshop on HIV Persistence and Eradication, Washington, DC	Organizing committee member
2008 - 2008	Project Inform/Forum for Collaborative Research HAART Conference, Washington, DC "HIV Infection, Inflammation and Accelerated "Aging": Treatment Considerations"	Organizing committee member
2008 - 2008	CDC meeting on HIV transmission/superinfection	Expert consultant
2007 - 2007	UCSF Community Consortium Executive Advisory Board	Committee chair
2007 - 2007	The American Conference for the Treatment of HIV	Organizing committee member

CONTRIBUTIONS TO DIVERSITY

CONTRIBUTIONS TO DIVERSITY Contributions to Diversity, Equity & Inclusion Guidance

I have spent my entire career working in a public health hospital, providing care to a diverse population of people with HIV, most of who face major socioeconomic challenges. The focus of my research has largely been on developing novel strategies aimed at serving this population. This includes a deep investment in identifying a safe, globally scalable HIV cure. I believe that such a cure will prove to be the most effective way to overcome many of the disparities in how HIV care is delivered, both nationally and globally. Towards this end, I have led several international panels aimed at guiding the development of a curative strategy that will have a global impact.

I received the Lifetime Achievement in Mentoring Award from UCSF in 2022. In the letter written on my behalf, it was noted that I had mentored “40 scientists over the last 20 years”, the majority of whom were women in science. Of those who I most closely mentored, and who contributed letters on my behalf, 16 of 25 were women. I have also sought to devote resources

whenever possible to those who are underrepresented in medicine. I have, for several years, been co-leading a mentoring program for early-stage African investigators, the highlight of which has been an annual three-day workshop held in South Africa. Through this program, I have provided mentorship to several early-stage African investigators, many of whom are now starting their own research program.

TEACHING AND MENTORING

TEACHING SUMMARY

Over the past several years, my teaching responsibilities have continually evolved away from a hospital and clinic setting to the research setting. I am now the formal primary mentor for several research fellows and junior faculty members. These mentees range from clinical research fellowships (most in infectious diseases) to late Assistant Clinical Professors. In addition to the direct day-to-day mentoring and supervision of mentees in my own group, I devote a substantial amount of my time to the less traditional co-mentoring of laboratory-based investigators, many of whom are based at other institutions. I devote over 25% of my effort to these teaching activities. My effort was supported by a K24 for ten years. In addition to mentoring, I lecture frequently to community groups, and give presentations at UCSF and elsewhere.

MENTORING SUMMARY

Most of my mentoring is provided in the context of an ongoing, prospective, pathogenesis-oriented cohort of HIV-infected adults (SCOPE). This cohort functions as an entry point for research fellows and junior investigators interested in human subjects-related HIV/AIDS research. All research fellows and junior investigators under my supervision are encouraged to have two “primary” mentors: myself and either a laboratory-based investigator or an epidemiologist. I provide overall guidance and focused training on the clinical aspects of translational research.

PREDOCTORAL STUDENTS SUPERVISED OR MENTORED

Dates	Name	Program or School	Mentor Type	Role	Current Position
2001 - 2001	Richard Loftus	Medical Student	Research/Scholarly Mentor	Antiretroviral treatment outcomes (primary mentor)	Private Practice
2001 - 2004	Jason Barbour	PhD Student	Research/Scholarly Mentor	Clinical implications of viral fitness (co-mentor)	Faculty, University of Hawaii
2004 - 2005	David Neager	Medical Student	Research/Scholarly Mentor	Role of CMV-specific cellular immunity in HIV disease outcomes (primary mentor)	Faculty, UCSF
2005 - 2010	Maya Peterson	MD/PhD Student	Research/Scholarly Mentor	Novel biostatistical approaches to analysis of cohort data	Faculty, UC Berkeley

Dates	Name	Program or School	Mentor Type	Role	Current Position
2008 - 2010	Rebecca Botelho	PhD Student (Thesis Committee)	Research/Scholarly Mentor	Role of dendritic cells in HIV pathogenesis	Venture capital consultant
2008 - 2011	Lillian Seu	PhD Student (Thesis Committee)	Research/Scholarly Mentor	Genetic predictors of HIV control	Post-doctoral fellow, Zambia
2016 - 2017	Judith Schouten	PhD Student (Thesis Committee)	Research/Scholarly Mentor	Cardiovascular Health and HIV	Amsterdam Medical Center, The Netherlands

POSTDOCTORAL FELLOWS AND RESIDENTS MENTORED

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2002 - 2009	Peter Hunt, MD	ID fellow	Research/Scholarly Mentor, Project Mentor, Career Mentor, Co-Mentor/Clinical Mentor	Inflammation during ART (primary mentor)	Faculty, UCSF
2002 - 2004	Annika Karlsson, PhD	Post-doctoral fellow	Research/Scholarly Mentor	Immunologic responses to drug-resistant variants (co-mentor)	Staff Researcher, Swedish Institute for Infectious Disease Control
2003 - 2010	Brinda Emu, MD	ID fellow	Research/Scholarly Mentor, Project Mentor, Career Mentor, Co-Mentor/Clinical Mentor	Immune correlates of HIV control (primary mentor)	Faculty, Yale School of Medicine
2003 - 2010	Dennis Hartigan-O'Connor, MD, PHD	Post-doctoral fellow	Research/Scholarly Mentor	Role of T regulatory cells in HIV disease (co-mentor)	Faculty, UC Davis

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2005 - 2008	Hiroyu Hatano, MD	ID fellow	Research/Scholarly Mentor, Project Mentor, Career Mentor, Co-Mentor/Clinical Mentor	Establishment of drug-resistant latency (primary mentor)	Private Practice
2006 - 2011	Paul Baum, MD	ID fellow	Research/Scholarly Mentor	Impact of HIV on TCR repertoire (co-mentor)	Scientist, Roche Molecular
2007 - 2010	Andy Choi, MD	Renal fellow	Research/Scholarly Mentor	Impact of HIV on kidney function (co-mentor)	Faculty, UCSF
2007 - 2008	Colleen Kelly, MD	Medical resident	Research/Scholarly Mentor, Career Mentor	CD4+ T cell gains during ART (primary mentor)	Faculty, Emory University
2007 - 2011	Elvin Geng, MD	ID fellow	Research/Scholarly Mentor, Project Mentor, Career Mentor, Co-Mentor/Clinical Mentor	Determinants of outcome during ART (co-mentor)	Faculty, Washington University
2008 - 2012	Vivek Jain, MD	ID fellow	Research/Scholarly Mentor, Project Mentor, Career Mentor, Co-Mentor/Clinical Mentor	Determinants of HIV transmission (primary mentor)	Faculty, UCSF
2010 - 2012	Devi SenGupta, MD	ID fellow	Research/Scholarly Mentor	Impact of HERV expression on HIV disease (co-mentor)	Research Scientist, Gilead
2010 - 2014	Leslie Cockerham, MD	ID fellow	Research/Scholarly Mentor, Project Mentor, Career Mentor, Co-Mentor/Clinical Mentor	Impact of inflammation on HIV persistence (primary mentor)	Faculty, Medical College of Wisconsin

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2011 - 2014	Meredith Greene, MD	Geriatrics fellow	Research/Scholarly Mentor	HIV and aging (primary mentor)	Faculty, UCSF
2013 - 2014	Sergio Serrano-Villar, MD	Post-doctoral research fellow	Research/Scholarly Mentor	HIV inflammation (primary mentor)	Faculty, Madrid, Spain
2013 - 2019	Sulggi Lee, MD, PhD	ID fellow	Research/Scholarly Mentor, Project Mentor, Career Mentor, Co-Mentor/Clinical Mentor	Pharmacogenomics of HIV cure therapeutics (primary mentor)	Faculty, UCSF
2014 - 2019	Charline Bacchus-Souffan	Post-doctoral research fellow	Research/Scholarly Mentor, Career Mentor	HIV immunology	Adjunct faculty, UCSF
2014 - 2014	Felicia Chow, MD	Neurology fellow	Research/Scholarly Mentor	HIV-associated inflammation (co-mentor)	Faculty, UCSF
2015 - 2021	Rachel Rutishauser, MD, PhD	ID fellow	Research/Scholarly Mentor, Project Mentor, Career Mentor, Co-Mentor/Clinical Mentor	HIV-specific CD8+ T cell immunity (co-mentor)	Faculty, UCSF
2017 - 2019	Annie Antar, MD	ID fellow	Research/Scholarly Mentor, Career Mentor	HIV persistence (co-mentor)	Faculty, Johns Hopkins University
2018 - present	Michael Peluso, MD	ID fellow	Research/Scholarly Mentor, Project Mentor, Career Mentor, Co-Mentor/Clinical Mentor	HIV cure (primary mentor)	ID Fellow, UCSF

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2019 - present	Amelia Deitchman, PharmD, PhD	Assistant Professor	Research/Scholarly Mentor, Project Mentor, Career Mentor	HIV Cure (primary mentor)	Faculty, UCSF
2021 - present	Matt Durstenfeld, MD	Cardiology fellow	Research/Scholarly Mentor, Project Mentor, Career Mentor	SARS-CoV-2 and the heart (co-mentor)	Cardiology Fellow, UCSF
2021 - present	Rose Magala Nabatazi, PhD	Research Fellow	Research/Scholarly Mentor	Non-subtype B reservoir measurements	Fellow, Makerere University, Uganda

FACULTY MENTORING

Dates	Name	Position while Mentored	Mentor Type	Mentoring Role	Current Position
2004 - 2007	George Beatty, MD	Assistant Professor	Research/Scholarly Mentor	Viral fitness	Department of Health, State of California
2004 - 2010	Priscilla Hsue, MD	Assistant Professor	Research/Scholarly Mentor, Career Mentor	Cardiovascular complications associated with HIV	Faculty, UCSF
2005 - 2006	Jeff Critchfield, MD	Assistant Professor		Role of immunomodulatory drugs in HIV infection	Faculty, UCSF
2003 - 2015	Christina Ramirez, PhD	Assistant Professor	Research/Scholarly Mentor	Modeling HIV pathogenesis	Faculty, UCLA
2009 - 2009	Sheri Weiser, MD	Assistant Professor	Career Mentor	Food insecurity and HIV disease	Faculty, UCSF
2011 - 2017	Satish Pillai, PhD	Assistant Professor	Research/Scholarly Mentor	HIV pathogenesis	Faculty UCSF
2011 - 2018	Ma Somsouk, MD	Assistant Professor	Research/Scholarly Mentor	HIV-associated inflammation	Faculty, UCSF
2012 - 2016	Steven Yukl, MD	Assistant Professor	Research/Scholarly Mentor	HIV reservoirs	Faculty, UCSF

Dates	Name	Position while Mentored	Mentor Type	Mentoring Role	Current Position
2014 - 2017	Adam Spivak, MD	ID Fellow, Johns Hopkins Univeristy	Research/Scholarly Mentor	HIV cure	Faculty, University of Utah
2015 - 2017	Eileen Scully, MD, PhD	Assistant Professor, Harvard	Research/Scholarly Mentor	HIV reservoirs	Faculty, Johns Hopkins University
2015 - 2018	Timothy Henrich, MD	Assistant Professor, UCSF	Research/Scholarly Mentor	HIV reservoirs	Faculty, UCSF
2017 - 2022	Kara Chew, MD	Assistant Professor, UCLA	Research/Scholarly Mentor	HIV cure	Faculty, UCLA
2019 - present	Karine Dubé	Assistant Professor, UNC	Research/Scholarly Mentor, Career Mentor	Medical ethics	Faculty, UNC
2019 - 2022	Lillian Cohn, PhD	Faculty, Chan Zuckerberg Biohub	Research/Scholarly Mentor, Career Mentor	HIV persistence	Faculty, University of Washington, Seattle

RESEARCH AND CREATIVE ACTIVITIES

RESEARCH AND CREATIVE ACTIVITIES SUMMARY

Over the past 20 years I have led a growing group of clinic- and laboratory-based investigators interested in performing translational and clinical research. Most of our work has focused on the immunopathogenesis of HIV infection. This work has been supported by the evolving clinical research infrastructure that I co-direct. At center of this infrastructure is a biologically-oriented cohort of HIV-infected adults of over 2000 adults (the SCOPE cohort). Doznes of individual investigators (many of them just starting their career) are supported each year. Over 35,000 biologic specimens have been distributed since the cohort's inception. We have also structured SCOPE so that it is able to support the regulatory, data management, recruitment and operational needs of investigators interested in performing intensive, single-center investigator-initiated clinical trials. Approximately 20 clinical trials have been supported. These studies have led to many of our most important contributions.

My own research agenda has continually evolved in response to changing unmet clinical needs of our patient population. Our initial work focused on patients who harbored multi-drug resistant HIV. We observed that (1) certain drug-resistance mutations reduce viral fitness in vivo, (2) some drug classes had residual treatment benefit even in presence of drug-

resistance, and (3) reduced immune activation during partial viral suppression independently predicted subsequent clinical benefit.

We subsequently expanded our interest to include individuals who were able to control HIV replication in absence of therapy ("elite" controllers), and observed that these individuals have higher than normal levels of both immune activation and atherosclerosis and that strong T cells in blood and mucosa tissues are strong correlates of control. We pioneered work on the study of inflammation, virus control, comorbidities (particularly heart disease), aging, transplantation, and coinfections (CMV, EBV, viral hepatitis).

More recently, we have focused on the pathogenesis of long-term antiretroviral treatment-mediated viral suppression. We have found that inflammation is elevated during otherwise effective therapy, that immune activation likely contributes to suboptimal CD4+ T cell gains during therapy, that CMV, microbial translocation, thymic dysfunction and perhaps residual HIV replication contribute to excess immune activation during therapy, and that elevated immune activation correlates with or predicts disease progression. We have also documented the degree to which cardiovascular disease and other conditions persist despite long-term treatment-mediated suppression of HIV replication.

We are now very actively involved in HIV cure research. I am one of the principal investigators for a large UM-funded Martin Delaney Collaboratory (DARE). Our consortium includes dozens of investigators from US and abroad. The overall objectives of DARE are to develop an cure or remission for HIV disease. I also recent directed the amfAR Institute for an HIV Cure.

Once the SARS-CoV-2 pandemic spread to San Francisco, we leveraged the SCOPE infrastructure to rapidly begin enrolling adults who have a recent history of COVID-19 into a new cohort (Long-term Impact of Infection with a Novel Coronavirus, or LIINC, NCT04362150). LIINC was designed specifically to study the long-term clinical consequences of COVID. We have identified nearly 100 cases individuals with persistent symptoms (PASC) and initiated several studies addressing the pathogenesis of this syndrome. We have distributed over thousands of samples and are supporting dozens of collaborations. We are now participating in RECOVER initiative, a national research program aimed at defining the epidemiology and biology of PASC.

Our research environment has proven to be a fertile environment for junior investigators. This includes those mentees for which I have primary responsibility and a large and evolving network of laboratory-based investigators at UCSF and elsewhere.

In addition to my clinical and translational investigation, I maintain a primary care clinic for people living with HIV (PWH).

RESEARCH AWARDS - CURRENT

1. UM1AI164560	Principal Investigator	20% % effort	Deeks (PI)
NIAID, NIH		08/16/2021	06/30/2026
Delaney AIDS Research Enterprise to Cure HIV		\$ 4,686,209.00	\$ 23,431,797 total
		direct/yr 1	

The major goals of this project are to: (1) to characterize the mechanisms for HIV persistence during antiretroviral therapy (ART), (2) to identify the mechanisms of HIV/SIV control post-ART, (3) to develop a combinatorial therapy for controlling SIV post-ART and (4) to identify potential therapies to accelerate the death of HIV-infected cells.

Principal Investigator

2.	OT2HL161847 NIH	UCSF Contact PI	20% % effort 10/01/2021	Deeks (PI) 05/01/2025
	Researching COVID to Enhance Recovery (RECOVER) Initiative		\$ 5088365 direct/yr 1	\$ 25,441,826 total
	RECOVER, a research initiative from the National Institutes of Health (NIH), seeks to understand, prevent, and treat post-acute sequelae of SARS-CoV-2 infection (PASC, Long COVID).			
	Contact PI			

3.	CLIN2-12090 California Institute of Regenerative Medicine (CIRM)	Principal Investigator	2.5% % effort 01/01/2020	Deeks (PI) 12/31/2025
	Anti-HIV duoCAR-T cell therapy for HIV infection		\$ 2,000,000 direct/yr 1	\$ 8,970,732 total

The main goals of this proposal are to (1) conduct a phase I/IIa clinical trial that evaluates the safety and efficacy of LVgp120duoCAR-T cells in HIV-infected subjects in the absence of antiretroviral therapy; (2) co-current with the clinical trial, prepare the vector and cell manufacturing process for market approval, so that an approved product is broadly affordable; and (3) develop a regulatory pathway plan for affordable decentralized place-of-care market approval at clinical centers.

Principle Investigator

4.	U01AI131296 NIAID	Principal investigator	20% % effort 04/01/2017	Deeks (PI) 03/31/2024
	Therapeutic vaccination and PD-1 blockade in treated HIV disease		\$ 1,289,102 direct/yr 1	\$ 6,950,921 total
	The goals of this program are to define the safety and immunogenicity of novel DNA vaccine in HIV-infected adults on antiretroviral therapy and to determine if DP-1 inhibition during vaccination improves immunogenicity			

Principal investigator

5.	U01AI131295 NIAID	Subaward PI	10% % effort 10/15/2020	Sekaly (PI) 7/15/2024
	Resetting immune homeostasis: a non-invasive approach towards HIV eradication		\$ 77306 direct/yr 1	\$ 386,532 total
	The goal of this study is to define the safety and potential anti-HIV efficacy of infusing autologous T cells that have undergone ex vivo zinc finger nuclease-mediated disruption of the CCR5 gene.			
	Site principal investigator			

6.	P01AI169606	Subaward PI	7.5% % effort	Yuki (PI)
----	-------------	-------------	---------------	-----------

NIH/NIAID		05/15/2022	04/15/2027
The heterogeneous HIV-expressing reservoir: dynamics, persistence mechanisms, tissue distribution, and contribution to rebound		\$ 1736331 direct/yr 1	\$ 8,681,658 total
<p>The goals of this project are to understand how the diverse reservoirs of HIV- infected cells that do or do not produce different forms of HIV RNA and/or protein differ in many respects, including their cell numbers, survival, clearance by immune responses, contribution to inflammation, production of human RNA and proteins, differences across tissues, contribution to virologic relapse after stopping anti-HIV medicines, and susceptibility to new therapies aimed at HIV cure.</p> <p>Co-investigator</p>			
7. R01DK120387	UCSF PI	5% % effort	Yuki (PI)
NIH/NIDDK		06/15/2019	04/15/2024
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodes		\$ 114000 direct/yr 1	\$ 570,000 total
<p>The goal of this project is to determine the degree to which different mechanisms reversibly block virus production in individual patient cells with intact or defective proviruses by using a novel approach that combines both single genome whole provirus sequencing and single genome HIV transcription profiling.</p> <p>Co-investigator</p>			
8. R01 AI147777	Subaward PI	2.5% % effort	Roan (PI)
NIAID/NIH		08/21/2019	08/21/2024
Phenotypic and mechanistic analysis of the in vivo HIV latent reservoir by single-cell technologies		\$ 40000 direct/yr 1	\$ 200,000 total
<p>The goals of these projects are: 1) To use PP-SLIDE on CyTOF-phenotyped cells to compare the latently-infected cells present in the blood and tissues of clinically-matched men and women. 2) To characterize the extent to which markers identified in Aim 1, as well as markers identified from an unbiased approach implementing PP-SLIDE on cells analyzed by single-cell RNAseq, enrich for reservoir cells harboring HIV with genetically-intact replication-competent HIV 3) To characterize the mechanisms that allow the latently-infected cells to persist, focusing on the role of antigen- and homeostasis-driven clonal expansion of CD4+ T cells</p> <p>Co-investigator</p>			
9. R01 DK120387	Subaward PI	2.5% % effort	Yukl (PI)
NIH/NIH		06/01/2019	04/30/2024
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodes		\$ 27,939 direct/yr 1	\$ 139695 total

The goal of this projects is to determine the degree to which different mechanisms reversibly block virus production in individual patient cells with intact or defective proviruses by using a novel approach that combines both single genome whole provirus sequencing and single genome HIV transcription profiling.

Co-investigator

10. INV-002707	Subaward PI	10% % effort	Cohn (PI)
Bill and Melinda Gates Foundation		12/02/2019	10/31/2024
Treatment interruption to characterize the HIV-1 latent reservoir and identify biomarkers of viral rebound		\$ 136319 direct/yr 1	\$ 681,597 total
<p>The objective of this study is the use a highly monitored treatment interruption protocol to define the source of the rebounding virus and to identify a potential biomarker for the reservoir. Additional studies aimed at defining the host factors associated with virus control will be performed.</p>			
Co-investigator			
11. INV-002703	Subaward PI	9% % effort	Yu (PI)
Bill and Melinda Gates Foundation		11/20/2109	10/31/2025
Evolutionary Dynamics of Viral Reservoir Cells		\$ 250,000 direct/yr 1	\$ 3,000,000 total
<p>The objective of this study is characterize the nature of the HIV reservoir in a diverse population of people living with HIV. The study will assess the impact of age, sex, race, HIV subtype and region on the size and distribution of the reservoir.</p>			
Co-investigator			
12. R24AI067039	Co-Investigator	2% % effort	Saag (PI)
NIH/NIAID; University of Alabama Subaward		09/01/2011	08/31/2026
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences (CNICS)		\$ 319,099 direct/yr 1	\$ 1,916,060 total
<p>The principle goals of this project are to build and support the CNICS infrastructure, to address the challenging research agenda of the evolving HIV epidemic, to prepare for the expansion of CNICS by developing standard operating procedures and software tools to facilitate data quality control and transmission, and to serve as a resource for the development of similar research networks</p>			
13. P30AI027763	Co-investigator	2% % effort	Gandhi (PI)
NIH/NIAID		09/15/2007	08/31/2026
UCSF-GIVI Center for AIDS Research		\$ 300,000 direct/yr 1	\$ 1,500,000 total
<p>The primary goal of the CFAR Clinical Core is to provide basic science and clinical investigators access to specimens and data from clinically well-characterized subjects and to provide expertise in the design and conduct of translational research.</p>			
Co-director of Clinical Core			
14. R01 AI152932	Co-investigator	2.5% % effort	Henrich (PI)
NIAID/NIH		09/01/2020	08/31/2025

In Vivo PET Imaging of HIV Infection \$ 735805.2 direct/yr \$ 3,679,026.00 total
1

The major goals of this project are to: (1a) quantify 89Zr-VRC01 PET activity in HIV-infected participants (ART suppressed, HIV controller, viremic) and matched uninfected controls, (1b) compare 89Zr-VRC01 uptake before and after initiation of ART, and (1c) determine the correlation between PET signal and tissue measures of HIV burden, (2) determine if the ultra-sensitive EXPLORER platform will increase the ability of 89Zr-VRC01 PET imaging to detect persistent HIV in ART-suppressed individuals, and, (3) determine the anatomical foci of HIV recrudescence during ATI using the 89Zr-VRC01 PET, PET-MR, and EXPLORER platforms.

Co-investigator

15. R01 AI158013	Co-investigator	2.5% % effort	Gandhi (PI)
NIAID/NIH		07/01/2020	06/20/2024
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic		\$ 622050 direct/yr 1	\$ 3,110,248.00 total

This proposal will answer vital questions concerning the interplay COVID-19 and HIV in a large safety-net clinic for publicly-insured patients with HIV in San Francisco. Aim 1 will examine whether SARS-CoV-2 infection risk, prevalence and clinical outcomes vary by HIV status and/or antiretroviral regimen (i.e. tenofovir). Aim 2 will explore whether HIV infection will impair humoral or T-cell responses to COVID-19. Aim 3 data will evaluate the impact of disruption of healthcare and social support systems on PWH, including viral suppression; retention in care; hospitalizations, co-morbidity outcomes, and death, and socio-behavioral outcomes during and after social distancing.

Co-investigator

16. R01 DK123746	Co-investigator	2.5% % effort	Ott (PI)
NIAID/NIH		01/10/2020	12/31/2024
Modeling intestinal dysfunction in HIV infection with organoid technology		\$ 177,297 direct/yr 1	\$ 886485 total

The goals of these project are 1) to define how HIV infection influences intestinal stem cell function in T cell and 2) to determine the effects of chronic HIV infection on intestinal stem cell function.

Co-investigator

17. R01 AI159454	Co-investigator	1% % effort	Demirci (PI)
NIAID/NIH		03/31/2021	03/31/2026
Ultrasensitive HIV viral load quantitation using designer DNA nanostructure capture probes and photonic resonator interference scattering microscopy		\$ 465,866 direct/yr 1	\$ 2329330 total

The goals of this proposal include development of a point-of-care version of the PRISM instrument, and statistically robust characterization of detection limits, repeatability, and robustness. Our study will conclude with validation of the system using clinical specimens and direct comparison against gold-standard laboratory

Co-investigator

RESEARCH AWARDS - PAST

1.	R01 AI052745	Principal Investigator	20 % effort	Deeks (PI)
	NIH/NIAID		2002-09-01	2007-02-28
	Immunologic Control of Drug-Resistant HIV-1		\$ 224,389	\$ 1,537,914 total
			direct/yr 1	

The primary goal of this project is to elucidate the mechanisms by which some individuals with HIV infection are able to maintain partial control of drug-resistant viremia while others experience rapid virologic rebound

2.	OT2HL161847	Principal Investigator	20 % effort	Deeks (PI)
	NIH		06/09/2021	07/08/2021
	Prevalence, Determinants and Prediction of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) in a Population-Based Sample in Northern California: A Clinical Recovery Cohort		\$ 23,479	\$ 23,479 total
			direct/yr 1	

The investigators will participate in Phase 1 activities in collaboration with the PASC Consortium Clinical Science Core to support achievement of the Phase 1 scientific goals of the consortium (creation of a master protocol for each cohort type). To support creation of the master protocol, the investigators will attend meetings and working groups scheduled by the Clinical Science Core, complete informational surveys as requested by the Clinical Science Core, and lend their scientific expertise in verbal and written communications to the Clinical Science Core leadership and other PASC Consortium Phase 1 investigators.

Principal Investigator

3.	R21 AI055273	Principal Investigator	20 % effort	Deeks (PI)
	NIH/NIAID		2004-11-01	2006-04-30
	Treatment Intensification for Drug-Resistant HIV		\$ 150,000	\$ 300,000 total
			direct/yr 1	

This goal of this program was to define the impact of drug resistance mutations on viral fitness and pathogenicity.

PI

4.	ID04-SF-012 Deeks	Principal Investigator	5 % effort	Deeks (PI)
	University-wide AIDS Research Program (UARP)		2004-11-01	2006-10-31
	Enfuvirtide intensification for multi-drug resistant HIV		\$ 99,961	\$ 99,961 total
			direct/yr 1	

The goal of this project is to determine if intermittent enfuvirtide can lead to a durable immunologic benefit for patients with multi-drug resistant HIV

5.	U01 AI069911	Co-Investigator	5 % effort	Yiannoutsos (PI)
	NIH/NIAID		2006-07-01	2011-04-30
	East Africa Consortium of International Epidemiologic Databases to Evaluate AIDS		\$ 5000 direct/yr 1	\$ 166,123 total

The major goal of this project is to develop a large cohort in East Africa to evaluate the response to antiretroviral therapy among HIV-infected individuals. Data from East Africa are subsequently shared with the larger international network in 6 other regions worldwide

Co-investigator

6.	P01 AT002024 NIH/NCAM MBSR, Stress Arousal and Immune Response in Early HIV	Co-Investigator	2004-09-30	Folkman (PI) 2009-06-30 \$ 914,433 total
<p>The major goal of this project is to study the efficacy and mechanisms of action of a mind-body meditation-based intervention, Mindfulness Based Stress Reduction (MBSR), to slow disease progression and improve quality of life in people with early stage HIV disease who are not on antiretroviral therapy</p>				
7.	R01 MH054907 NIH/NIMH HIV ARV Adherence, Resistance and Survival	Co-Investigator	2005-02-01	Bangsberg (PI) 2010-03-31 \$ 1,205,557 total
<p>To study the behavioral and biologic determinants of HIV antiretroviral drug resistance and disease progression in two prospective observational cohorts on HIV antiretroviral therapy</p>				
8.	R01 AI040880 NIH/NIAID (University of Pennsylvania Subcontract) HIV Entry Inhibitors: A New Therapeutic Option	Principle Investigator of UCSF Subcontract	2006-07-01 \$ 25,000 direct/yr 1	Doms (PI) 2011-06-30 \$ 124,676 total
<p>The goal of this project is determine how HIV acquires resistance to entry inhibitors and to use these insights as a means of investigating envelope function.</p>				
9.	R01 CA119903 NIH/NCI Antiretroviral Therapy of AIDS-Related Kaposi Sarcoma in Africa	Co-Investigator	2005-09-30	Martin (PI) 2009-07-31 \$ 433,263 total
<p>The goal of this randomized clinical study is to determine if a protease inhibitor-based regimen is more effective for the treatment of Kaposi's sarcoma than a non-nucleoside reverse transcriptase inhibitor-based regimen in HIV infected individuals</p>				
10.	M12-SF-010-0704-1TO1 Institute of Clinical Research, Inc; under University of Minnesota Subaward Agreement M661-6284-7909; under NIH Prime Award U01 AI068641 International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)	Principal Investigator of UCSF Subcontract	2006-12-01 \$ 306,867 direct/yr 1	Deeks (PI) 2011-05-31 \$ 747,141 total

The primary objective is to develop strategies for the optimization of treatment – antiretroviral therapies, immunomodulatory therapies and interventions to prevent and treat complications of HIV and ART – in order to prolong disease-free survival in a demographically, socio-economically and geographically diverse population of individuals infected with HIV.

11. amfAR #106710-40-RGRL	Principal Investigator		Deeks (PI)
American Foundation for AIDS Research (amfAR)		2006-07-01	2007-06-30
HIV controllers: a potential model for HIV eradication		\$ 100,000 direct/yr 1	\$ 100,000 total
This study will use a unique cohort of individuals who are able to maintain undetectable HIV RNA levels in the absence of therapy as potential model for HIV eradication.			
12. R01 DA017476	Co-Investigator		Lum (PI)
NIH/NIDA		2005-07-01	2007-06-30
Methamphetamine Use and HIV Disease Pathogenesis		\$ 321,052 direct/yr 1	\$ 1,609,270 total
The major goals are to describe potential for drug-resistant HIV transmission in methamphetamine users and to examine whether methamphetamine use is associated with disease progression			
13. R21 AI078870	Co-Investigator		Montaner (PI)
NIH/NIAID		2009-05-22	2011-04-30
Innate Effector Function and HIV-1 Control		\$ 42,000 direct/yr 1	\$ 74,000 total
The objective of this grant is to determine the role of NK cell activity in maintaining long-term host-mediated control of HIV infection.			
14. K24 AI069994	Principle Investigator		Deeks (PI)
NIH/NIAID		2007-05-01	2012-04-30
Preventing the Establishment of HIV-1 Resistance in the Latent Reservoir		\$ 157,170 direct/yr 1	\$ 834,437 total
The goal of this career development award is to further investigate the pathogenesis of drug-resistant HIV and to mentor junior investigators interested in translational research.			
15. R01 AI087145	Principle Investigator		Deeks (PI)
NIH/NIAID.		2009-09-26	2012-08-31
The impact of early antiretroviral therapy on HIV persistence and inflammation		\$ 505,487 direct/yr 1	\$ 1,013,102 total

The overall objective of this study is to measure the degree of HIV persistence in long-term treated patients, as well as the validation of an assay for measuring viral persistence and defining the relationship between viral persistence and inflammation.

16. P01 AI071713	Project Director of Project 2		Hecht (PI)
NIH		2007-09-01	2012-08-31
The Biology of HIV Transmission		\$ 250,367 direct/yr 1	\$ 1,196,395 total
The overall goal of this program project is to investigate the biology of HIV transmission in a cohort of transmitting and non-transmitting pairs			
17. amfAR 108072-50-RGRL	Co-Principle Investigator		McCune (PI)
American Foundation for AIDS Research (amfAR)		2010-05-01	2012-05-31
Inflammation and HIV Persistence		\$ 83,333 direct/yr 1	\$ 187,500 total
The overall goal of this project is to identify the host mechanisms which contribute to HIV persistence during long-term effective antiretroviral therapy.			
18. R01 HL091526	Co-Investigator		Hsue (PI)
NIH/NHLBI		2007-09-16	2012-07-31
Epidemiology and Pathogenesis of Pulmonary Hypertension in HIV Patients			\$ 440,422 total
The goals of the study are to determine the association between HAART therapy and viral suppression in HIV-infected patients and to investigate the role of the HIV-1 Nef protein and HHV-8 in the development of pulmonary hypertension.			
19. R01 AI057020	Co-Investigator		Shacklett (PI)
NIH/NIAID (University of California, Davis Subcontract)		2008-02-01	2013-01-31
HIV-Specific T-Cell Responses in Rectal Mucosa		\$ 44,765 direct/yr 1	\$ 217,885 total
The primary objective of this study is to determine the role of mucosal HIV-specific T cells in controlling HIV replication.			
20. EraMune 02 Project	Principal Investigator		Deeks (PI)
Northwestern University Subcontract		2012-05-05	2013-04-30
Multicenter, randomized, non-comparative, controlled study of therapeutic intensification plus immunomodulation in HIV-infected patients with long-term viral suppression			\$ 94,048 total

The hypothesis of this clinical trial is that viral eradication in selected HIV-infected patients is possible with intensive antiretroviral therapy (ART) plus immunomodulation.

21. U01 HL098964	Co-Investigator		Huang (PI)
NIH/NHLBI		2009-09-25	2014-07-31
Lung Microbiome in Cohorts of HIV-Infected Persons (Lung MicroCHIP) Study		\$ 526,310 direct/yr 1	\$ 2,612,287 total
Goals: (1) To compare the lung microbiome in subjects with and without HIV infection, (2) To determine whether the degree of HIV-mediated immunosuppression is related to the lung microbiome of HIV-infected subjects without acute illness/pneumonia, (3) To determine the effect of initiation of antiretroviral therapy and opportunistic pneumonia prophylaxis on the lung microbiome of HIV-infected subjects over time			
22. amfAR #108269-51-RGRL	Principal Investigator		Deeks (PI)
American Foundation for AIDS Research (amfAR)		2011-10-01	2012-09-30
HIV Persistence after successful CCR5 depleted stem cell transplantation		\$ 39,509 direct/yr 1	\$ 39,509 total
The overall goal of this project is to define the nature of HIV persistence in a patient who has apparently been "cured" of this disease.			
23. R01 DA030216	Co-Investigator		Verdin (PI)
NIH/NIDA		2010-07-01	2015-06-30
Epigenetic regulation of HIV latency			
The major goals of this project are: 1) to understand the mechanism of HIV promoter silencing via DNA methylation, 2) to identify small molecules and cellular factors that reactivate latent HIV in synergy with methylation inhibitors, 3) to study HIV DNA methylation in primary lymphocytes.			
24. R21 AI102959	Subcontract PI		Pillai (PI)
NIH/NIAID; Blood Research Systems Institute Subcontract		2013-08-15	2015-06-30
Characterization of the HIV-1 Latent Reservoir in CCR5-Delta 32 Heterozygotes		\$ 37,102 direct/yr 1	\$ 75,095 total
The overall goal of this project is to do determine the association between immune function, inflammation and CCR5 expression on the characteristics of HIV persistence during effective antiretroviral therapy			
25. R01 HL095130	Co-Investigator		Hsue (PI)
NIH-NHLBI		2008-09-30	2014-06-30
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection		\$ 650,000 direct/yr 1	\$ 3,480,698 total

To determine the influence of traditional and novel markers of inflammation on endothelial function and IMT progression and to determine if intensification with raltegravir in subjects on long-term antiretroviral therapy with clinically undetectable HIV RNA levels will improve endothelial function

26. R01 HL117713	Co-Investigator		Hsue (PI)
NIH/NHLBI		2012-09-26	2016-06-30
Effect of low dose methotrexate on endothelial function and inflammation in HIV		\$ 583,966 direct/yr 1	\$ 2,086,676 total
<p>The goals of this project are to: 1) Demonstrate that treatment with LDMTX improves endothelial function, as assessed by flow-mediated vasodilation (FMD) of the brachial artery, in virally suppressed HIV-infected individuals; 2) Assess whether treatment with LDMTX reduces hsCRP and interleukin-6 (IL-6), inflammatory markers of increased CVD risk, in virally suppressed HIV-infected individuals; and 3) Assess whether treatment with LDMTX decreases levels of immune activation and senescence in virally suppressed HIV-infected individuals.</p>			
27. P01 AI076174	Principle Investigator of UCSF subcontract		Lederman (PI)
NIH/NIAID; Case Western Reserve University Subcontract		2008-08-01	2014-07-31
Core B: Specimen Repository Core		\$ 40,971 direct/yr 1	\$ 216,452 total
<p>The overall objective of the program project is to determine the cause of chronic immune activation in HIV infected persons. The UCSF SCOPE cohort will provide access to well characterized peripheral blood and gut mucosa derived biologic specimens to project investigators via the specimen core.</p>			
28. OPP1062806	Co-Investigator		Pilcher (PI)
Bill and Melinda Gates Foundation		2012-09-01	2015-07-31
HIV Incidence Testing using Multiple Biological Specimens		\$ 942,654 direct/yr 1	\$ 3,022,473 total
<p>This project will facilitate both discovery and development of new and better approaches to HIV incidence measurement. Our overall goals are to provide a key new resource for HIV incidence biomarker discovery, and to provide a new resource for evaluating dried blood spot and whole blood assays by the CEPHIA program.</p>			
29. R34 AI106479	Co-Investigator		Stock (PI)
NIH/NIAID		2013-05-15	2014-04-30
Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients		\$ 161,911 direct/yr 1	\$ 161,911 total

The R34 planning grant will be used to prepare for a future prospective, multi-center, double-blind phase II study of kidney transplantation in HIV+ individuals assessing the safety and efficacy of a maraviroc-based antiretroviral regimen given post-transplant. Subjects will be consented and enrolled until 120 eligible subjects are randomized.

30. 108687-54-RGRL	Co-Investigator		Chomont (PI)
American Foundation for AIDS Research (amfAR); Vaccine and Gene Therapy Institute Subcontract		2013-06-01	2014-05-31
Identifying and targeting HIV persistence in T cell subsets during ART		\$ 58,333 direct/yr 1	\$ 58,333 total
The overall goal of this project is to do determine the impact of long-term antiretroviral therapy on the size and distribution of the latent HIV reservoir.			
31. R21 AI102959	Subcontract PI		Pillai (PI)
NIH/NIAID; Blood Research Systems Institute Subcontract		2013-08-15	2015-06-30
Characterization of the HIV-1 Latent Reservoir in CCR5-Delta 32 Heterozygotes		\$ 37,102 direct/yr 1	\$ 75,095 total
The overall goal of this project is to do determine the association between immune function, inflammation and CCR5 expression on the characteristics of HIV persistence during effective antiretroviral therapy			
32. 108545-53-RGRL	Subcontract PI		
American Foundation for AIDS Research (amfAR); Blood Systems Research Institute Subcontract		2013-07-01	2014-06-30
Effects of CCR5-Delta 32 Heterozygosity on the HIV-1 Reservoir		\$ 54,820 direct/yr 1	\$ 54,820 total
33. R56 AI102959	Subcontract PI		Bradley (PI)
NIH/NIAID; Mayo Clinic Subcontract		07/02/2013	06/30/2014
Enhancing control of HIV by inhibiting TRAILshort		\$ 6,566 direct/yr 1	\$ 6,566 total
The overall goal of this project is to do determine the effect of T cell apoptosis on the size of the HIV reservoir during effective antiretroviral therapy.			
34. K24AI069994	Principal Investigator	25 % effort	Deeks (PI)
NIH/NIAID		06/21/2012	5/31/2017
Impact of HIV-associated inflammation on disease		\$ 127,024 direct/yr 1	\$ 543,512 total

The goal of this career development award is to investigate the role of inflammation in treated HIV-disease and to mentor junior investigators interested in translational research.

35. U19AI096109	Principal Investigator		Deeks, McCune, Sekaly (PI)
NIH/NIAID		07/08/2011	06/30/2017
DARE: Delaney AIDS Research Enterprise to find a cure		\$ 3,618,073 direct/yr 1	\$ 24,685,997 total
The goals of this proposed collaboration are to determine the host mechanisms that contribute to HIV persistence and to define novel methods aimed at reversing this process.			
36. UM1AI120197	Subaward PI	1 % effort	Neaton (PI)
NIH/NIAID; University of Minnesota Subaward		08/19/2015	07/31/2018
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT): START		\$ 120,697 direct/yr 1	\$ 362,091 total
The International Network for Strategic Initiatives in Global HIV Trials is a worldwide collaborative clinical trials network that conducts research in the area of optimization of HIV management and co-morbidities.			
37. OPP1115400	Subaward PI	10 % effort	Busch (PI)
Bill and Melinda Gates Foundation; Blood Systems Research Institute Subaward		11/01/2014	10/31/2018
Validation of Existing and Ultra-Sensitive Assays for Quantifying HIV Persistence		\$ 214,724 direct/yr 1	\$ 768,494 total
This project aims to deliver one or more high-throughput assay(s) with well-characterized performance characteristics that are optimized for all major HIV subtypes and which will provide robust estimates of the size of the replication-competent HIV-1 reservoir.			
38. R01AG045032	Subaward PI	2 % effort	Baker (PI)
NIH; Minneapolis Medical Research Foundation Subaward		04/01/2014	03/31/2017
Treatment to reduce inflammation and improve immune recovery among older HIV pts		\$ 88,812 direct/yr 1	\$ 137,212 total
The goals of this study are to determine whether adding an angiotensin receptor blocker (losartan) to standard ART will reduce inflammation and improve tissue fibrosis in treated, HIV-infected subjects			
39. R01AI118694	Subaward PI	3 % effort	Betts (PI)
NIH/NIDDK; University of Pennsylvania Subaward		06/15/2015	05/31/2020
Viral control mechanisms of HIV-specific T cells in HIV-infected lymph node		\$ 43,783 direct/yr 1	\$ 182,539 total

The main objective of this study is to determine the role of HIV-specific CD8+ T cells in controlling HIV in lymphoid tissues.

40. U19AI117950	Subaward PI	3 % effort	Riley (PI)
NIH; University of Pennsylvania Subaward		04/01/2015	03/31/2020
Engineering T cells to provide Durable Control of HIV-1 Replication		\$ 25,091 direct/yr 1	\$ 74,843 total
The goal of this U19 is to develop a novel T cell therapy to control HIV in the absence of antiretroviral therapy			
41. 109226-58-RGRL	Site PI	5 % effort	Lewin (PI)
University of Melbourne/ amfAR-The Foundation for AIDS Research Subaward		07/01/2016	06/30/2021
Combination immune checkpoint blocker inhibition to eliminate HIV latency			
The goal of this project is to determine the impact of immune checkpoint blockade on HIV expression and T cell function in non-human primates and in HIV-infected adults who have cancer that is being treated with PD-1 and/or CTLA-4 inhibitors			
42. R01AI116368	Co-Investigator	4 % effort	McCune (PI)
NIH/NIAID		02/04/2015	01/31/2020
Timing of ART and Homeostasis of the Persistent HIV Reservoir in the Adult		\$ 542,675 direct/yr 1	\$ 2,620,925 total
The major goals of this project are to: evaluate how the time of initiation and the duration of effective ART affect the distribution and composition of the persistent HIV reservoir; 2) evaluate the turnover and differentiation capacity of CD4+ T cells harboring persistent HIV in vivo; and 3) investigate the role of the yc cytokines, IL-7 and IL-15, on the establishment and maintenance of the persistent HIV reservoir.			
43. 109380-59-RGRL	Principal Investigator	2 % effort	Deeks (PI)
amfAR-The Foundation for AIDS Research		02/01/2016	01/31/2017
Analytic Treatment Interruption to Study Viral Reservoirs and as Test for Cure in HIV-Infected Adults on Antiretroviral Therapy		\$ 64,803 direct/yr 1	\$ 64,803 total
The goal of this study is to determine if antiretroviral therapy administered during "hyperacute" HIV infection can prevent the establishment of a permanent reservoir of replication-competent HIV.			
44. R01AI110271	Co-Investigator	2 % effort	Hunt (PI)
NIH/NIAID		06/01/2014	05/31/2019
Determinants of Functional Immune Defects in Treated HIV Infection and Aging		\$ 499,952 direct/yr 1	\$ 2,469,620 total

The major goals are: (1) To determine whether ART-suppressed HIV-infected individuals have impaired vaccine responsiveness and whether these defects can be attenuated by early ART initiation; (2) to characterize the T cell phenotypes associated with poor vaccine responsiveness in treated HIV infection and aging; and (3) to characterize the relationship between innate immune activation and vaccine responsiveness in treated HIV infection and aging

45. R01HL125034	Co-Investigator	2 % effort	Hsue (PI)
NIH/NHLBI		04/01/2015	08/31/2018
Effect of IL-1B inhibition on inflammation and cardiovascular risk in HIV		\$ 51,766 direct/yr 1	\$ 1,725,714 total

The major goals of this project are to perform a randomized placebo controlled study: 1) determine the safety, tolerability, and pharmacokinetics of IL-1B inhibition using canakinumab in effectively treated and suppressed HIV-infected adults; 2) determine whether IL-1B inhibition decreases systemic inflammatory markers, decreases circulating levels of monocyte activation, and improves vascular inflammation and endothelial dysfunction among treated and suppressed HIV-infected individuals; and 3) determine whether IL-1B inhibition reduces T cell activation and decreases the size of the HIV reservoir in blood.

Co-investigator

46. 109301-59-RGRL	Principal Investigator	20 % effort	Deeks (PI)
amfAR		01/01/2016	12/31/2022
amfAR Institute for HIV Cure Research		\$ 4011954 direct/yr 1	\$ 20,059,771.00 total

The major goals of this project are to determine where HIV resides during antiretroviral therapy, to develop assays to quantify the latent reservoir in tissues and to develop novel immune-based therapeutics that reverse latency and clear infected cells.

I was initially a member of the institute's board of directors. I became the principal investigator in 2019. I am currently conducting a clinical trial assessing a complex curative intervention for HIV.

47. R33 HL141047	Co-investigator	5 % effort	Hsue (PI)
NHLBI/NIH		02/01/2019	01/31/2023
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection		\$ 579,238 direct/yr 1	\$ 2896190 total

The goals of this study are to: 1) determine whether PCSK9 inhibition can improve arterial inflammation as assessed by FDG-PET/CT in treated and suppressed HIV-infected individuals. 2) assess the effect of PCSK9 inhibition on endothelial function as assessed by FMD in treated and suppressed HIV; 3) perform a pilot evaluation of the impact of PCSK9 inhibition on non-calcified plaque in HIV as measured by serial coronary CT angiography.

Co-investigator

48. R56 AI114442	Subaward PI	5 % effort	Youngblood (PI)
NIAID/NIH		06/01/2020	05/31/2022

Epigenetic reprogramming of HIV-specific CD8 T cell stemness to enable sustained viral control \$ 89,318 direct/yr 1 \$ 446590 total

The goals of this project are: 1) To determine if gene expression program preservation in exhausted HIV-specific CD8 T cells is coupled to maintenance of DNA methylation at transcriptional regulatory regions. 2) To identify DNA methylation programs acquired during differentiation of functional HIV-specific CD8 T cells. 3) To determine if modulation of DNA methylation reprogramming of HIV-specific CD8 T cells by chain signaling and PD-1 signal blockade rescues HIV specific CD8 function and killing

Co-investigator

49. UM1AI126611	Principal Investigator	20 % effort	Deeks (PI)
NIH/NIAID		07/14/2016	06/30/2022
Delaney AIDS Research Enterprise to Cure HIV		\$ 4,555,724 direct/yr 1	\$ 22,763,080 total

The major goals of this project are to: (1) to characterize and then therapeutically overcome the barriers to CD8+ T cell-mediated clearance and/or control of SIV/HIV during and after ART, (2) determine the location and burden of HIV in lymphoid tissues during ART, (3) determine the impact of immune checkpoint blockers on HIV/SIV-specific immunity and reservoir during ART, and (4) determine the safety and immunogenicity of a human CMV/HIV vector.

50. AI141003-03S1	Co-investigator	10 % effort	Henrich (PI)
NIAID/NIH		05/15/2020	04/30/2022
Longitudinal Immunological Impact of SARS-CoV-2 Infection (LIINC)		\$ 740398 direct/yr 1	\$ 1,480,795 total

The major goals of this project are to: (1) expand the LIINC cohort to collect large volumes of PBMC, plasma, serum and saliva at frequent intervals from early disease convalescence (21 days following initial symptoms) to 24 months after recovery, (2-a) determine the impact of SARS-CoV-2 infection on viral-specific CD4 and CD8 T cell responses up to 24 months following onset of symptoms, and identify other clinical factors that influence development and maintenance of adaptive T cell immunity.

Co-investigator

51. U01 AI118594	Co-investigator	10 % effort	Stock (PI)
NIAID/NIH		08/19/2015	07/31/2022
Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients		\$ 1,447,887 direct/yr 1	\$ 7239435 total

The primary goal of this study is determine if maraviroc (a CCR5 inhibitor) can prevent kidney transplant failure in HIV-infected adults on antiretroviral therapy. A secondary goal is to determine the impact of maraviroc on T cell function and the size of the HIV reservoir.

Co-investigator

PEER REVIEWED PUBLICATIONS

- 1988 Deeks S, Richards J, Nandi S. Maintenance of normal rat mammary epithelial cells by insulin and insulin-like growth factor 1. *Exp Cell Res.* 1988 Feb; 174(2):448-60. PMID: 3276539
- 1995 Deeks S, Volberding P. An approach to antiretroviral treatment of HIV disease. Combined antiretroviral therapy: the emerging role. *Hosp Pract* (1995). 1995 Aug; 30 Suppl 1:23-31. PMID: 7635914
- 1996 Eron JJ, Ashby MA, Giordano MF, Chernow M, Reiter WM, Deeks SG, Lavelle JP, Conant MA, Yangco BG, Pate PG, Torres RA, Mitsuyasu RT, Twaddell T. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. *Lancet.* 1996 Dec 7; 348(9041):1547-51. PMID: 8950881
- 1997 Deeks SG, Volberding PA. HIV-1 protease inhibitors. *AIDS Clin Rev.* 1997-1998; 145-85. PMID: 9305448
- 1997 Deeks S, Kertesz D, Ryan A, Johnson W, Ashton F. Surveillance of invasive meningococcal disease in Canada, 1995-1996. *Can Commun Dis Rep.* 1997 Aug 15; 23(16):121-5. PMID: 9439039
- 1997 Gordon M, Deeks S, De Marzo C, Goodgame J, Guralnik M, Lang W, Mimura T, Pearce D, Kaneko Y. Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity. *J Med.* 1997; 28(1-2):108-28. PMID: 9249617
- 1997 Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. *JAMA.* 1997 Jan 8; 277(2):145-53. PMID: 8990341
- 1997 Deeks SG. New principles of HIV-related medical care. *Focus.* 1997 Apr; 12(5):5-7. PMID: 11364329
- 1997 Deeks SG, Abrams DI. Genotypic-resistance assays and antiretroviral therapy. *Lancet.* 1997 May 24; 349(9064):1489-90. PMID: 9167453
- 1997 Deeks SG, Coleman RL, White R, Pachi C, Schambelan M, Chernoff DN, Feinberg MB. Variance of plasma human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days. *J Infect Dis.* 1997 Aug; 176(2):514-7. PMID: 9237721

- 1997 Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, Toole J, Jaffe HS, Mulato AS, Lamy PD, Li W, Cherrington JM, Hellmann N, Kahn J. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. *J Infect Dis.* 1997 Dec; 176(6):1517-23. PMID: 9395363
- 1998 Deeks SG. Practical issues regarding the use of antiretroviral therapy for HIV infection. *West J Med.* 1998 Feb; 168(2):133-9. PMID: 9499754.
- 1998 Deeks S, Ellis A, Ciebin B, Khakhria R, Naus M, Hockin J. Salmonella Oranienburg, Ontario. *Can Commun Dis Rep.* 1998 Nov 15; 24(22):177-8; discussion 178-9. PMID: 9844252
- 1998 Deeks S. Clinical implications of virological PMID: 11365047
- 1998 Follansbee S, Deeks S, Bartnoff H. Fifth Conference on Retroviruses & Opportunistic Infections. Interview by Ron Baker. *Newsline People AIDS Coalit N Y.* 1998 Mar; 7-14. PMID: 11367453
- 1998 Deeks SG. Antiretroviral agents: the next generation. *AIDS Clin Care.* 1998 May; 10(5):33-6, 39-40. PMID: 11365427
- 1998 Volberding PA, Deeks SG. Antiretroviral therapy for HIV infection: promises and problems. *JAMA.* 1998 May 6; 279(17):1343-4. PMID: 9582033
- 1998 Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. *AIDS.* 1998 Jul 9; 12(10):F97-102. PMID: 9677159
- 1998 Deeks SG, Sax PE. Should we argue with success? *AIDS Clin Care.* 1998 Sep; 10(9):68, 72. PMID: 11365809
- 1998 Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, Hellmann NS, Safrin S, Kahn JO. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. *Antimicrob Agents Chemother.* 1998 Sep; 42(9):2380-4. PMID: 9736567.
- 1999 Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E, Schmidt D, Hoh R, Neese R, Macallan D, Deeks S, McCune JM. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. *Nat Med.* 1999 Jan; 5(1):83-9. PMID: 9883844

- 1999 Deeks SG. Failure of HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy. *Adv Exp Med Biol.* 1999; 458:175-82. PMID: 10549390
- 1999 Deeks SG, Grant RM. Sustained CD4 responses after virological failure of protease inhibitor-containing therapy. *Antivir Ther.* 1999; 4 Suppl 3:7-11. PMID: 16021865
- 1999 Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, Aweeka F, Deeks S, Price RW. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. *AIDS.* 1999 Jun 18; 13(9):1051-61.
- 1999 Deeks S, De Serres G, Boulianne N, Duval B, Rochette L, Déry P, Halperin S. Failure of physicians to consider the diagnosis of pertussis in children. *Clin Infect Dis.* 1999 Apr; 28(4):840-6. PMID: 10825048
- 1999 Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. *AIDS.* 1999 Apr 16; 13(6):F35-43. PMID: 10397555
- 1999 Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding PA. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. *J Infect Dis.* 1999 Jun; 179(6):1375-81. PMID: 10228057
- 1999 Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, Aweeka F, Deeks S, Price RW. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. *AIDS.* 1999 Jun 18; 13(9):1051-61. PMID: 10397535
- 1999 Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, Hardy D, Beall G, Cooper R, Murphy R, Basgoz N, Ng E, Deeks S, Winslow D, Toole JJ, Coakley D. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. *JAMA.* 1999 Dec 22-29; 282(24):2305-12. PMID: 10612317
- 2000 McCune JM, Hanley MB, Cesar D, Halvorsen R, Hoh R, Schmidt D, Wieder E, Deeks S, Siler S, Neese R, Hellerstein M. Factors influencing T-cell turnover in HIV-1-seropositive patients. *J Clin Invest.* 2000 Mar; 105(5):R1-8.

- 2000 McCune JM, Hanley MB, Cesar D, Halvorsen R, Hoh R, Schmidt D, Wieder E, Deeks S, Siler S, Neese R, Hellerstein M. Factors influencing T-cell turnover in HIV-1-seropositive patients. *J Clin Invest*. 2000 Mar; 105(5):R1-8. PMID: 10712441.
- 2000 Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. *J Infect Dis*. 2000 Mar; 181(3):946-53. PMID: 10720517
- 2000 Huang SS, Barbour JD, Deeks SG, Huang JS, Grant RM, Ng VL, McCune JM. Reversal of human immunodeficiency virus type 1-associated hematosuppression by effective antiretroviral therapy. *Clin Infect Dis*. 2000 Mar; 30(3):504-10. PMID: 10722435
- 2000 Deeks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. *Clin Infect Dis*. 2000 Jun; 30 Suppl 2:S177-84. PMID: 10860903
- 2000 Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S, Lin AA, Pennathur-Das R, Hege KM. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. *Blood*. 2000 Aug 1; 96(3):785-93. PMID: 10910888
- 2000 Parkin NT, Deeks SG, Wrin MT, Yap J, Grant RM, Lee KH, Heeren D, Hellmanna NS, Petropoulos CJ. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. *AIDS*. 2000 Dec 22; 14(18):2877-87. PMID: 11153669
- 2001 Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA, Herndier BG, Andersson J, McCune JM. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. *Nat Med*. 2001 Jan; 7(1):73-9. PMID: 11135619
- 2001 Deeks SG, Martin JN. Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient. *AIDS*. 2001 Jan 5; 15(1):117-9. PMID: 11192853
- 2001 Liegler TJ, Hayden MS, Lee KH, Hoh R, Deeks SG, Granta RM. Protease inhibitor-resistant HIV-1 from patients with preserved CD4 cell counts is cytopathic in activated CD4 T lymphocytes. *AIDS*. 2001 Jan 26; 15(2):179-84. PMID: 11216925

- 2001 Penn ML, Myers M, Eckstein DA, Liegler TJ, Hayden M, Mammano F, Clavel F, Deeks SG, Grant RM, Goldsmith MA. Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. *AIDS Res Hum Retroviruses*. 2001 Apr 10; 17(6):517-23.
- 2001 Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. *Curr Opin Infect Dis*. 2001 Feb; 14(1):23-8. PMID: 11979111
- 2001 Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. *N Engl J Med*. 2001 Feb 15; 344(7):472-80. PMID: 11172188
- 2001 Price RW, Paxinos EE, Grant RM, Drews B, Nilsson A, Hoh R, Hellmann NS, Petropoulos CJ, Deeks SG. Cerebrospinal fluid response to structured treatment interruption after virological failure. *AIDS*. 2001 Jul 6; 15(10):1251-9.
- 2001 Deeks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. *J Acquir Immune Defic Syndr*. 2001 Mar 1; 26 Suppl 1:S25-33. PMID: 11264999
- 2001 Penn ML, Myers M, Eckstein DA, Liegler TJ, Hayden M, Mammano F, Clavel F, Deeks SG, Grant RM, Goldsmith MA. Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. *AIDS Res Hum Retroviruses*. 2001 Apr 10; 17(6):517-23. PMID: 11350665
- 2001 Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, Kearney BP, Coleman RL, Lamy PD, Kahn JO, McGowan I, Lietman PS. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. *Antimicrob Agents Chemother*. 2001 Oct; 45(10):2733-9.
- 2001 Stoddart CA, Liegler TJ, Mammano F, Linnquist-Stepps VD, Hayden MS, Deeks SG, Grant RM, Clavel F, McCune JM. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. *Nat Med*. 2001 Jun; 7(6):712-8. PMID: 11385509
- 2001 Deeks SG, Barditch-Crovo P, Collier A, Smith A, Miller M, McGowan I, Coakley DF. Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate. *J Acquir Immune Defic Syndr*. 2001 Dec 1; 28(4):336-9.

- 2001 Sabin CA, Olmscheid B, Moyle G, Carr A, Boyle B, Cohen C, Cooper D, Deeks S, Gulick T, Saag M. Selected topics from the 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001. Chicago, Illinois. HIV Clin Trials. 2001 Jul-Aug; 2(4):366-86. PMID: 11590541
- 2001 Price RW, Paxinos EE, Grant RM, Drews B, Nilsson A, Hoh R, Hellmann NS, Petropoulos CJ, Deeks SG. Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS. 2001 Jul 6; 15(10):1251-9. PMID: 11426069
- 2001 Deeks SG. Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure. JAMA. 2001 Jul 11; 286(2):224-6. PMID: 11448286
- 2001 Teixeira L, Valdez H, McCune JM, Koup RA, Badley AD, Hellerstein MK, Napolitano LA, Douek DC, Mbisa G, Deeks S, Harris JM, Barbour JD, Gross BH, Francis IR, Halvorsen R, Asaad R, Lederman MM. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS. 2001 Sep 28; 15(14):1749-56. PMID: 11579235
- 2001 Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, Kearney BP, Coleman RL, Lamy PD, Kahn JO, McGowan I, Lietman PS. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2001 Oct; 45(10):2733-9. PMID: 11557462.
- 2001 Deeks SG, Barditch-Crovo P, Collier A, Smith A, Miller M, McGowan I, Coakley DF. Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr. 2001 Dec 1; 28(4):336-9. PMID: 11707669
- 2002 Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, Cesar D, Abe K, Hanley MB, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis. 2002 Feb 1; 185(3):315-23.
- 2002 Deeks SG, Hirschel B. Supervised interruptions of antiretroviral therapy. AIDS. 2002; 16 Suppl 4:S157-69. PMID: 12699013
- 2002 Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002 Jan 25; 16(2):201-7.

- 2002 Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, Cesar D, Abe K, Hanley MB, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. *J Infect Dis.* 2002 Feb 1; 185(3):315-23. PMID: 11807713
- 2002 Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. *AIDS.* 2002 Jan 25; 16(2):201-7. PMID: 11807304
- 2002 Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ, Sun E. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. *J Infect Dis.* 2002 Mar 1; 185(5):599-607. PMID: 11865416
- 2002 Castelli JC, Deeks SG, Shiboski S, Levy JA. Relationship of CD8(+) T cell noncytotoxic anti-HIV response to CD4(+) T cell number in untreated asymptomatic HIV-infected individuals. *Blood.* 2002 Jun 1; 99(11):4225-7. PMID: 12010831
- 2002 Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. *Mol Ther.* 2002 Jun; 5(6):788-97. PMID: 12027564
- 2002 Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, Deeks SG, Bates M, Hellmann NS, Petropoulos CJ. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. *AIDS.* 2002 Oct 18; 16(15):F41-7.
- 2002 Tebas P, Henry K, Mondy K, Deeks S, Valdez H, Cohen C, Powderly WG. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. *J Infect Dis.* 2002 Sep 15; 186(6):851-4. PMID: 12198623
- 2002 Bangsberg DR, Deeks SG. Is average adherence to HIV antiretroviral therapy enough? *J Gen Intern Med.* 2002 Oct; 17(10):812-3. PMID: 12390559.

- 2002 Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, Deeks SG, Bates M, Hellmann NS, Petropoulos CJ. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. *AIDS*. 2002 Oct 18; 16(15):F41-7. PMID: 12370521
- 2002 Barbour JD, Wrin T, Grant RM, Martin JN, Segal MR, Petropoulos CJ, Deeks SG. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. *J Virol*. 2002 Nov; 76(21):11104-12. PMID: 12368352.
- 2003 Anton PA, Mitsuyasu RT, Deeks SG, Scadden DT, Wagner B, Huang C, Macken C, Richman DD, Christopherson C, Borellini F, Lazar R, Hege KM. Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. *AIDS*. 2003 Jan 3; 17(1):53-63. PMID: 12478069
- 2003 Deeks SG, Grant RM, Wrin T, Paxinos EE, Liegler T, Hoh R, Martin JN, Petropoulos CJ. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. *AIDS*. 2003 Feb 14; 17(3):361-70. PMID: 12556690
- 2003 Jacobson MA, Liu L, Khayam-Bashi H, Deeks SG, Hecht FM, Kahn J. Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy. *AIDS*. 2003 Apr 11; 17(6):917-9. PMID: 12660541
- 2003 Hunt PW, Martin JN, Sinclair E, Brecht B, Hagos E, Lampiris H, Deeks SG. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. *J Infect Dis*. 2003 May 15; 187(10):1534-43. PMID: 12721933
- 2003 Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant RM, Martin JN, Nixon DF. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. *J Virol*. 2003 Jun; 77(12):6743-52. PMID: 12767994.
- 2003 Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Brecht BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. *Ann Intern Med*. 2003 Aug 19; 139(4):258-66. PMID: 12965981

- 2003 Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, Kitahata MM, Krone M, Neilands TB, Brand RJ, Lederman MM, Martin JN. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. *AIDS*. 2003 Sep 5; 17(13):1907-15. PMID: 12960823
- 2003 Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, Conroy KN, Clark R, Guzman D, Zolopa A, Moss A. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. *AIDS*. 2003 Sep 5; 17(13):1925-32. PMID: 12960825
- 2003 Jiang H, Deeks SG, Kuritzkes DR, Lallemand M, Katzenstein D, Albrecht M, DeGruttola V. Assessing resistance costs of antiretroviral therapies via measures of future drug options. *J Infect Dis*. 2003 Oct 1; 188(7):1001-8. PMID: 14513420
- 2003 Karlsson AC, Martin JN, Younger SR, Bredt BM, Epling L, Ronquillo R, Varma A, Deeks SG, McCune JM, Nixon DF, Sinclair E. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. *J Immunol Methods*. 2003 Dec; 283(1-2):141-53. PMID: 14659906
- 2003 Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. *Lancet*. 2003 Dec 13; 362(9400):2002-11. PMID: 14683662
- 2004 Price RW, Deeks SG. Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system. *J Neurovirol*. 2004; 10 Suppl 1:44-51. PMID: 14982739
- 2004 Deeks SG, Martin JN, Sinclair E, Harris J, Neilands TB, Maecker HT, Hagos E, Wrin T, Petropoulos CJ, Bredt B, McCune JM. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. *J Infect Dis*. 2004 Jan 15; 189(2):312-21. PMID: 14722897
- 2004 Deeks SG, Walker BD. The immune response to AIDS virus infection: good, bad, or both? *J Clin Invest*. 2004 Mar; 113(6):808-10. PMID: 15067312.
- 2004 Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, Waters DD. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. *Circulation*. 2004 Apr 6; 109(13):1603-8. PMID: 15023877

- 2004 Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. *J Antimicrob Chemother.* 2004 May; 53(5):696-9. PMID: 15044425
- 2004 Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narváez AB, Hunt P, Martin JN, Kahn JO, Levy J, McGrath MS, Hecht FM. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. *Blood.* 2004 Aug 15; 104(4):942-7. PMID: 15117761
- 2004 Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, Hunt PW, Hagos E, Nixon DF, Deeks SG. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. *AIDS.* 2004 Apr 30; 18(7):981-9. PMID: 15096800
- 2004 Bangsberg DR, Porco TC, Kagay C, Charlebois ED, Deeks SG, Guzman D, Clark R, Moss A. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. *J Infect Dis.* 2004 Jul 1; 190(1):162-5. PMID: 15195256
- 2004 Elrefaei M, McElroy MD, Preas CP, Hoh R, Deeks S, Martin J, Cao H. Central memory CD4+ T cell responses in chronic HIV infection are not restored by antiretroviral therapy. *J Immunol.* 2004 Aug 1; 173(3):2184-9. PMID: 15265956
- 2004 Aandahl EM, Quigley MF, Moretto WJ, Moll M, Gonzalez VD, Sönnnerborg A, Lindbäck S, Hecht FM, Deeks SG, Rosenberg MG, Nixon DF, Sandberg JK. Expansion of CD7(low) and CD7(negative) CD8 T-cell effector subsets in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment. *Blood.* 2004 Dec 1; 104(12):3672-8. PMID: 15308569
- 2004 Critchfield JM, Deeks SG. Treating the latent reservoir of HIV. *AIDS Read.* 2004 Sep; 14(9):485-6. PMID: 15457601
- 2004 Friend J, Parkin N, Liegler T, Martin JN, Deeks SG. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. *AIDS.* 2004 Sep 24; 18(14):1965-6. PMID: 15353986
- 2005 McEvers K, Elrefaei M, Norris P, Deeks S, Martin J, Lu Y, Cao H. Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways. *Vaccine.* 2005 Jul 14; 23(32):4128-35. PMID: 15964481

- 2005 Nixon DF, Deeks SG, Shacklett BL, Karlsson AC. Multidrug-resistant, dual-tropic HIV-1 and rapid progression. *Lancet*. 2005 Jun 4-10; 365(9475):1924-5. PMID: 15936414
- 2005 Cohan D, Feakins C, Wara D, Petru A, McNicholl I, Schillinger D, Lu J, Kuritzkes D, Deeks SG. Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. *AIDS*. 2005 Jun 10; 19(9):989-90. PMID: 15905684
- 2005 Gisslén M, Rosengren L, Hagberg L, Deeks SG, Price RW. Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. *AIDS Res Ther*. 2005 Aug 18; 2:6. PMID: 16109178.
- 2005 Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. *J Infect Dis*. 2005 Nov 1; 192(9):1537-44. PMID: 16206068
- 2005 Lo JC, Kazemi MR, Hsue PY, Martin JN, Deeks SG, Schambelan M, Mulligan K. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. *Clin Infect Dis*. 2005 Nov 1; 41(9):1335-40. PMID: 16206112
- 2005 Legrand FA, Abadi J, Jordan KA, Davenport MP, Deeks SG, Fennelly GJ, Wiznia AA, Nixon DF, Rosenberg MG. Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. *AIDS*. 2005 Oct 14; 19(15):1575-85. PMID: 16184026
- 2005 Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, Martin JN, Nixon DF, McCune JM, Deeks SG. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. *J Virol*. 2005 Nov; 79(22):14169-78. PMID: 16254352.
- 2005 Spudich SS, Nilsson AC, Lollo ND, Liegler TJ, Petropoulos CJ, Deeks SG, Paxinos EE, Price RW. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. *BMC Infect Dis*. 2005; 5:98. PMID: 16266436.
- 2005 Chin-Hong PV, Deeks SG, Liegler T, Hagos E, Krone MR, Grant RM, Martin JN. High-risk sexual behavior in adults with genotypically proven antiretroviral-resistant HIV infection. *J Acquir Immune Defic Syndr*. 2005 Dec 1; 40(4):463-71. PMID: 16280703

- 2006 Beatty G, Hunt P, Smith A, Hoh R, Huang W, Martin J, Deeks SG. A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide. *Antivir Ther.* 2006; 11(3):315-9. PMID: 16759047
- 2006 Wilson-Clark SD, Squires S, Deeks S. Bacterial meningitis among cochlear implant recipients--Canada, 2002. *MMWR Suppl.* 2006 Apr 28; 55(1):20-4. PMID: 16645578
- 2006 Jordan KA, Furlan SN, Gonzalez VD, Karlsson AC, Quigley MF, Deeks SG, Rosenberg MG, Nixon DF, Sandberg JK. CD8 T cell effector maturation in HIV-1-infected children. *Virology.* 2006 Mar 30; 347(1):117-26. PMID: 16406047
- 2006 Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, Parkin N, Deeks SG. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. *AIDS.* 2006 Jan 9; 20(2):223-31. PMID: 16511415
- 2006 Deeks SG. Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients. *Lancet.* 2006 Mar 4; 367(9512):711-3. PMID: 16517257
- 2006 Hunt PW, Deeks SG, Bangsberg DR, Moss A, Sinclair E, Liegler T, Bates M, Tsao G, Lampiris H, Hoh R, Martin JN. The independent effect of drug resistance on T cell activation in HIV infection. *AIDS.* 2006 Mar 21; 20(5):691-9. PMID: 16514299
- 2006 Deeks SG, Schweighardt B, Wrin T, Galovich J, Hoh R, Sinclair E, Hunt P, McCune JM, Martin JN, Petropoulos CJ, Hecht FM. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. *J Virol.* 2006 Jun; 80(12):6155-64. PMID: 16731954.
- 2006 Deeks SG. The risk of treatment versus the risk of HIV replication. *Lancet.* 2006 Jun 17; 367(9527):1955-6. PMID: 16782465
- 2006 Deeks SG. Antiretroviral treatment of HIV infected adults. *BMJ.* 2006 Jun 24; 332(7556):1489. PMID: 16793811.
- 2006 Nomura LE, Emu B, Hoh R, Haaland P, Deeks SG, Martin JN, McCune JM, Nixon DF, Maecker HT. IL-2 production correlates with effector cell differentiation in HIV-specific CD8+ T cells. *AIDS Res Ther.* 2006; 3:18. PMID: 16859558.

- 2006 Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, Leigler T, Martin JN, Deeks SG. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. *J Infect Dis.* 2006 Oct 1; 194(7):926-30. PMID: 16960780
- 2006 Marcial M, Lu J, Deeks SG, Ziermann R, Kuritzkes DR. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations. *J Clin Microbiol.* 2006 Sep; 44(9):3384-7. PMID: 16954280.
- 2006 Lu J, Deeks SG, Hoh R, Beatty G, Kuritzkes BA, Martin JN, Kuritzkes DR. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. *J Acquir Immune Defic Syndr.* 2006 Sep; 43(1):60-4. PMID: 16885776
- 2006 Rodríguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M, Boswell SL, Mathews WC, Bangsberg DR, Martin J, Whalen CC, Sieg S, Yadavalli S, Deeks SG, Lederman MM. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. *JAMA.* 2006 Sep 27; 296(12):1498-506. PMID: 17003398
- 2006 Hatano H, Hunt P, Weidler J, Coakley E, Hoh R, Liegler T, Martin JN, Deeks SG. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. *Clin Infect Dis.* 2006 Nov 15; 43(10):1329-36. PMID: 17051502
- 2006 Ahuja SK, Aiuti F, Berkhout B, Biberfeld P, Burton DR, Colizzi V, Deeks SG, Desrosiers RC, Dierich MP, Doms RW, Emerman M, Gallo RC, Girard M, Greene WC, Hoxie JA, Hunter E, Klein G, Korber B, Kuritzkes DR, Lederman MM, Malim MH, Marx PA, McCune JM, McMichael A, Miller C, Miller V, Montagnier L, Montefiori DC, Moore JP, Nixon DF, Overbaugh J, Pauza CD, Richman DD, Saag MS, Sattentau Q, Schooley RT, Shattock R, Shaw GM, Stevenson M, Trkola A, Wainberg MA, Weiss RA, Wolinsky S, Zack JA. A plea for justice for jailed medical workers. *Science.* 2006 Nov 10; 314(5801):924-5. PMID: 17062652
- 2006 Hunt PW, Deeks SG. Immune-based therapy for HIV infection: are acute and chronic HIV infection different diseases? *J Infect Dis.* 2006 Dec 15; 194(12):1632-4. PMID: 17109333

- 2006 Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. *J Infect Dis.* 2006 Dec 15; 194(12):1686-96. PMID: 17109340
- 2006 Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. *Nat Med.* 2006 Dec; 12(12):1365-71. PMID: 17115046
- 2006 Hsue PY, Hunt PW, Sinclair E, Brecht B, Franklin A, Killian M, Hoh R, Martin JN, McCune JM, Waters DD, Deeks SG. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. *AIDS.* 2006 Nov 28; 20(18):2275-83. PMID: 17117013
- 2006 Kitchen CM, Lu J, Suchard MA, Hoh R, Martin JN, Kuritzkes DR, Deeks SG. Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease. *AIDS Res Hum Retroviruses.* 2006 Dec; 22(12):1260-6. PMID: 17209769
- 2007 Deeks SG, Lu J, Hoh R, Neilands TB, Beatty G, Huang W, Liegler T, Hunt P, Martin JN, Kuritzkes DR. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. *J Infect Dis.* 2007 Feb 1; 195(3):387-91. PMID: 17205477
- 2007 Riddler SA, Jiang H, Tenorio A, Huang H, Kuritzkes DR, Acosta EP, Landay A, Bastow B, Haas DW, Tashima KT, Jain MK, Deeks SG, Bartlett JA. A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. *Antivir Ther.* 2007; 12(4):531-41. PMID: 17668562
- 2007 Deeks SG, Martin JN. Partial treatment interruptions. *Curr Opin HIV AIDS.* 2007 Jan; 2(1):46-55. PMID: 19372865
- 2007 Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, Calzavara L, Deeks SG, Eron JJ, Gebo KA, Gill MJ, Haas DW, Hogg RS, Horberg MA, Jacobson LP, Justice AC, Kirk GD, Klein MB, Martin JN, McKaig RG, Rodriguez B, Rourke SB, Sterling TR, Freeman AM, Moore RD. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). *Int J Epidemiol.* 2007 Apr; 36(2):294-301. PMID: 17213214.

- 2007 Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. *Am J Respir Crit Care Med.* 2007 Apr 1; 175(7):737-42. PMID: 17218620.
- 2007 Ray N, Harrison JE, Blackburn LA, Martin JN, Deeks SG, Doms RW. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. *J Virol.* 2007 Apr; 81(7):3240-50. PMID: 17251281.
- 2007 Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. *Curr HIV/AIDS Rep.* 2007 May; 4(2):65-72. PMID: 17547827
- 2007 Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, Colombo S, Brown EE, Shupert WL, Phair J, Goedert JJ, Buchbinder S, Kirk GD, Telenti A, Connors M, O'Brien SJ, Walker BD, Parham P, Deeks SG, McVicar DW, Carrington M. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. *Nat Genet.* 2007 Jun; 39(6):733-40. PMID: 17496894.
- 2007 Hatano H, Deeks SG. Drug resistant HIV. *BMJ.* 2007 Jun 2; 334(7604):1124-5. PMID: 17540912.
- 2007 Lederman MM, Miller V, Weller I, Deeks SG. A new approach for 'deep salvage' trials in advanced HIV infection. *AIDS.* 2007 Jul 31; 21(12):1503-6. PMID: 17630543
- 2007 Karlsson AC, Chapman JM, Heiken BD, Hoh R, Kallas EG, Martin JN, Hecht FM, Deeks SG, Nixon DF. Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol. *J Virol.* 2007 Oct; 81(20):11543-8. PMID: 17670829.
- 2007 Owen RE, Sinclair E, Emu B, Heitman JW, Hirschhorn DF, Epling CL, Tan QX, Custer B, Harris JM, Jacobson MA, McCune JM, Martin JN, Hecht FM, Deeks SG, Norris PJ. Loss of T cell responses following long-term cryopreservation. *J Immunol Methods.* 2007 Sep 30; 326(1-2):93-115. PMID: 17707394.
- 2007 Deeks SG. Protease inhibitors as immunomodulatory drugs for HIV infection. *Clin Pharmacol Ther.* 2007 Sep; 82(3):248-50. PMID: 17700590

- 2007 Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. *Immunity*. 2007 Sep; 27(3):406-16. PMID: 17892849
- 2007 Petersen ML, Deeks SG, Martin JN, van der Laan MJ. History-adjusted marginal structural models for estimating time-varying effect modification. *Am J Epidemiol*. 2007 Nov 1; 166(9):985-93. PMID: 17875580.
- 2007 Dolan MJ, Kulkarni H, Camargo JF, He W, Smith A, Anaya JM, Miura T, Hecht FM, Mamtani M, Pereyra F, Marconi V, Mangano A, Sen L, Bologna R, Clark RA, Anderson SA, Delmar J, O'Connell RJ, Lloyd A, Martin J, Ahuja SS, Agan BK, Walker BD, Deeks SG, Ahuja SK. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. *Nat Immunol*. 2007 Dec; 8(12):1324-36. PMID: 17952079
- 2007 Petersen ML, Deeks SG, van der Laan MJ. Individualized treatment rules: generating candidate clinical trials. *Stat Med*. 2007 Nov 10; 26(25):4578-601. PMID: 17450501.
- 2007 Barker E, Martinson J, Brooks C, Landay A, Deeks S. Dysfunctional natural killer cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on antiretroviral therapy. *AIDS*. 2007 Nov 12; 21(17):2363-5. PMID: 18090295
- 2008 Price RW, Parham R, Kroll JL, Wring SA, Baker B, Sailstad J, Hoh R, Liegler T, Spudich S, Kuritzkes DR, Deeks SG. Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. *Antivir Ther*. 2008; 13(3):369-74. PMID: 18572749.
- 2008 Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. *J Infect Dis*. 2008 Jan 1; 197(1):126-33. PMID: 18171295.
- 2008 Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, McCune JM, Deeks SG. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. *J Virol*. 2008 Jun; 82(11):5398-407. PMID: 18353945.

- 2008 Ahuja SK, Kulkarni H, Catano G, Agan BK, Camargo JF, He W, O'Connell RJ, Marconi VC, Delmar J, Eron J, Clark RA, Frost S, Martin J, Ahuja SS, Deeks SG, Little S, Richman D, Hecht FM, Dolan MJ. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. *Nat Med.* 2008 Apr; 14(4):413-20. PMID: 18376407.
- 2008 Sinclair E, Ronquillo R, Lollo N, Deeks SG, Hunt P, Yiannoutsos CT, Spudich S, Price RW. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. *J Acquir Immune Defic Syndr.* 2008 Apr 15; 47(5):544-52. PMID: 18362693.
- 2008 Hsue PY, Deeks SG, Farah HH, Palav S, Ahmed SY, Schnell A, Ellman AB, Huang L, Dollard SC, Martin JN. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. *AIDS.* 2008 Apr 23; 22(7):825-33. PMID: 18427200.
- 2008 Schwenecker M, Favre D, Martin JN, Deeks SG, McCune JM. HIV-induced changes in T cell signaling pathways. *J Immunol.* 2008 May 15; 180(10):6490-500. PMID: 18453567.
- 2008 Deeks SG. Transmitted minority drug-resistant HIV variants: a new epidemic? *PLoS Med.* 2008 Jul 29; 5(7):e164. PMID: 18666826.
- 2008 Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, Bangsberg DR. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. *PLoS One.* 2008; 3(7):e2783. PMID: 18665246.
- 2008 Probasco JC, Spudich SS, Critchfield J, Lee E, Lollo N, Deeks SG, Price RW. Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study. *Neurology.* 2008 Aug 12; 71(7):521-4. PMID: 18695163.
- 2008 Marconi V, Bonhoeffer S, Paredes R, Lu J, Hoh R, Martin JN, Deeks SG, Kuritzkes DR. Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide. *J Acquir Immune Defic Syndr.* 2008 Aug 15; 48(5):572-6. PMID: 18645515.
- 2008 Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. *AIDS.* 2008 Oct 18; 22(16):2097-106. PMID: 18832873.

- 2009 Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, Hoh R, Stramer SL, Linnen JM, McCune JM, Martin JN, Busch MP, Deeks SG. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. *J Virol.* 2009 Jan; 83(1):329-35. PMID: 18945778.
- 2009 Kitchen CM, Kroll J, Kuritzkes DR, Bloomquist E, Deeks SG, Suchard MA. Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment. *Comput Stat Data Anal.* 2009 Jan 15; 53(3):766-775. PMID: 20442796. PMCID: PMC2862497
- 2009 Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, Parkin NT, Petropoulos CJ, Deeks SG, Kuritzkes DR. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. *J Virol.* 2009 Feb; 83(4):2038-43. PMID: 19019971.
- 2009 Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, Garcia JC, Pollard RB, Yee HF, Martin JN, Deeks SG, Shacklett BL. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. *Blood.* 2009 Apr 23; 113(17):3978-89. PMID: 19109229.
- 2009 Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. *J Biol Chem.* 2009 Mar 13; 284(11):6782-9. PMID: 19136668.
- 2009 Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. *BMJ.* 2009; 338:a3172. PMID: 19171560
- 2009 Geng EH, Deeks SG. CD4+ T cell recovery with antiretroviral therapy: more than the sum of the parts. *Clin Infect Dis.* 2009 Feb 1; 48(3):362-4. PMID: 19123869
- 2009 Tenorio AR, Jiang H, Zheng Y, Bastow B, Kuritzkes DR, Bartlett JA, Deeks SG, Landay AL, Riddler SA. Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. *AIDS Res Hum Retroviruses.* 2009 Feb; 25(2):135-9. PMID: 19239354.
- 2009 Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, Crane HM, Willig J, Mugavero M, Saag M, Martin JN, Deeks SG. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. *Clin Infect Dis.* 2009 Mar 15; 48(6):787-94. PMID: 19193107.

- 2009 Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD. Effect of early versus deferred antiretroviral therapy for HIV on survival. *N Engl J Med*. 2009 Apr 30; 360(18):1815-26. PMID: 19339714.
- 2009 Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, Landay A, Martin J, Sinclair E, Asher AI, Deeks SG, Douek DC, Brenchley JM. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. *J Infect Dis*. 2009 Apr 15; 199(8):1177-85. PMID: 19265479.
- 2009 Jacobson MA, Ditmer DP, Sinclair E, Martin JN, Deeks SG, Hunt P, Mocarski ES, Shiboski C. Human herpesvirus replication and abnormal CD8+ T cell activation and low CD4+ T cell counts in antiretroviral-suppressed HIV-infected patients. *PLoS One*. 2009; 4(4):e5277. PMID: 19381272.
- 2009 Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, Martin JN, Deeks SG. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. *AIDS*. 2009 Jun 1; 23(9):1059-67. PMID: 19390417.
- 2009 Murphy RL, Autran B, Katlama C, Brucker G, Debre P, Calvez V, Clotet B, Clumeck N, Costagliola D, Deeks SG, Dorrell L, Gatell J, Haase A, Klein M, Lazzarin A, McMichael AJ, Papagno L, Schacker TW, Wain-Hobson S, Walker BD, Youle M. A step ahead on the HIV collaboratory. *Science*. 2009 Jun 5; 324(5932):1264-5. PMID: 19498149
- 2009 Garrison KE, Champiat S, York VA, Agrawal AT, Kallas EG, Martin JN, Hecht FM, Deeks SG, Nixon DF. Transcriptional errors in human immunodeficiency virus type 1 generate targets for T-cell responses. *Clin Vaccine Immunol*. 2009 Sep; 16(9):1369-71. PMID: 19571107.
- 2009 Huang W, Toma J, Stawiski E, Fransen S, Wrin T, Parkin N, Whitcomb JM, Coakley E, Hecht FM, Deeks SG, Gandhi RT, Eshleman SH, Petropoulos CJ. Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals. *AIDS Res Hum Retroviruses*. 2009 Aug; 25(8):795-802. PMID: 19678765.

- 2009 Jha AR, Pillai SK, York VA, Sharp ER, Storm EC, Wachter DJ, Martin JN, Deeks SG, Rosenberg MG, Nixon DF, Garrison KE. Cross-sectional dating of novel haplotypes of HERV-K 113 and HERV-K 115 indicate these proviruses originated in Africa before Homo sapiens. *Mol Biol Evol.* 2009 Nov; 26(11):2617-26. PMID: 19666991.
- 2009 Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. *Top HIV Med.* 2009 Sep-Oct; 17(4):118-23. PMID: 19890183
- 2009 Gress RE, Deeks SG. Reduced thymus activity and infection prematurely age the immune system. *J Clin Invest.* 2009 Oct; 119(10):2884-7. PMID: 19770512.
- 2009 Snyder-Cappione JE, Loo CP, Carvalho KI, Kuylentierna C, Deeks SG, Hecht FM, Rosenberg MG, Sandberg JK, Kallas EG, Nixon DF. Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression. *AIDS.* 2009 Sep 24; 23(15):1965-70. PMID: 19590406
- 2009 Hsue PY, Hunt PW, Wu Y, Schnell A, Ho JE, Hatano H, Xie Y, Martin JN, Ganz P, Deeks SG. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. *AIDS.* 2009 Sep 24; 23(15):2021-7. PMID: 19542863.
- 2009 Rosenblum M, Deeks SG, van der Laan M, Bangsberg DR. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. *PLoS One.* 2009; 4(9):e7196. PMID: 19787058.
- 2009 Choi AI, Shlipak MG, Hunt PW, Martin JN, Deeks SG. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. *AIDS.* 2009 Oct 23; 23(16):2143-9. PMID: 19684507.
- 2009 Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. *Clin Infect Dis.* 2009 Nov 15; 49(10):1582-90. PMID: 19845473.

- 2009 Thomas R, Apps R, Qi Y, Gao X, Male V, O'hUigin C, O'Connor G, Ge D, Fellay J, Martin JN, Margolick J, Goedert JJ, Buchbinder S, Kirk GD, Martin MP, Telenti A, Deeks SG, Walker BD, Goldstein D, McVicar DW, Moffett A, Carrington M. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. *Nat Genet.* 2009 Dec; 41(12):1290-4. PMID: 19935663.
- 2010 Hsue PY, Hunt PW, Ho JE, Farah HH, Schnell A, Hoh R, Martin JN, Deeks SG, Bolger AF. Impact of HIV infection on diastolic function and left ventricular mass. *Circ Heart Fail.* 2010 Jan; 3(1):132-9.
- 2010 Hsue PY, Hunt PW, Ho JE, Farah HH, Schnell A, Hoh R, Martin JN, Deeks SG, Bolger AF. Impact of HIV infection on diastolic function and left ventricular mass. *Circ Heart Fail.* 2010 Jan; 3(1):132-9. PMID: 19933410.
- 2010 Bangsberg DR, Deeks SG. Spending more to save more: interventions to promote adherence. *Ann Intern Med.* 2010 Jan 5; 152(1):54-6; W-13. PMID: 20048272.
- 2010 Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. *Circulation.* 2010 Feb 9; 121(5):651-8. PMID: 20100969.
- 2010 Naeger DM, Martin JN, Sinclair E, Hunt PW, Bangsberg DR, Hecht F, Hsue P, McCune JM, Deeks SG. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. *PLoS One.* 2010; 5(1):e8886. PMID: 20126452.
- 2010 Loke P, Favre D, Hunt PW, Leung JM, Kanwar B, Martin JN, Deeks SG, McCune JM. Correlating cellular and molecular signatures of mucosal immunity that distinguish HIV controllers from noncontrollers. *Blood.* 2010 Apr 15; 115(15):e20-32. PMID: 20160163.
- 2010 Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, Yiannoutsos CT, Glidden DV, Deeks SG, Martin JN. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. *J Acquir Immune Defic Syndr.* 2010 Mar; 53(3):405-11. PMID: 19745753.
- 2010 Probasco JC, Deeks SG, Lee E, Hoh R, Hunt PW, Liegler T, Price RW, Spudich SS. Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation. *AIDS.* 2010 Apr 24; 24(7):1001-5. PMID: 20299968

- 2010 Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, Grant R, Barbour J, Deeks SG. HIV RNA level in early infection is predicted by viral load in the transmission source. *AIDS*. 2010 Apr 24; 24(7):941-5. PMID: 20168202.
- 2010 Jain V, Deeks SG. When to start antiretroviral therapy. *Curr HIV/AIDS Rep*. 2010 May; 7(2):60-8. PMID: 20425559.
- 2010 Kosmrlj A, Read EL, Qi Y, Allen TM, Altfeld M, Deeks SG, Pereyra F, Carrington M, Walker BD, Chakraborty AK. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. *Nature*. 2010 May 20; 465(7296):350-4. PMID: 20445539.
- 2010 Owen RE, Heitman JW, Hirschhorn DF, Lanteri MC, Biswas HH, Martin JN, Krone MR, Deeks SG, Norris PJ. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. *AIDS*. 2010 May 15; 24(8):1095-105. PMID: 20400885.
- 2010 Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, Barbour JD, Lowe MM, Jayawardene A, Aweeka F, Huang Y, Douek DC, Brenchley JM, Martin JN, Hecht FM, Deeks SG, McCune JM. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. *Sci Transl Med*. 2010 May 19; 2(32):32ra36. PMID: 20484731.
- 2010 Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Justice AC, Gebo KA, Eron JJ, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Calzavara LM, Deeks SG, Martin JN, Rachlis AR, Napravnik S, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Kushel M, Goedert JJ, McKaig RG, Van Rumpae SE, Zhang J, Moore RD. Late presentation for human immunodeficiency virus care in the United States and Canada. *Clin Infect Dis*. 2010 Jun 1; 50(11):1512-20. PMID: 20415573.
- 2010 Geng EH, Glidden DV, Emenyonu N, Musinguzi N, Bwana MB, Neilands TB, Muyindike W, Yiannoutsos CT, Deeks SG, Bangsberg DR, Martin JN. Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa. *Trop Med Int Health*. 2010 Jun; 15 Suppl 1:63-9. PMID: 20586962.
- 2010 Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. *Lancet*. 2010 Jul 3; 376(9734):49-62. PMID: 20609987
- 2010 Saag M, Deeks SG. How do HIV elite controllers do what they do? *Clin Infect Dis*. 2010 Jul 15; 51(2):239-41. PMID: 20550453

- 2010 Ferre AL, Lemongello D, Hunt PW, Morris MM, Garcia JC, Pollard RB, Yee HF, Martin JN, Deeks SG, Shacklett BL. Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers. *J Virol.* 2010 Oct; 84(19):10354-65. PMID: 20668079.
- 2010 Ho JE, Deeks SG, Hecht FM, Xie Y, Schnell A, Martin JN, Ganz P, Hsue PY. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. *AIDS.* 2010 Jul 31; 24(12):1897-905. PMID: 20543654.
- 2010 Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, Hoh R, Martin JN, Lalezari J, Bangsberg D, Petropoulos C, Deeks SG. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. *J Acquir Immune Defic Syndr.* 2010 Aug; 54(4):389-93. PMID: 20300008.
- 2010 Deeks SG, McCune JM. Can HIV be cured with stem cell therapy? *Nat Biotechnol.* 2010 Aug; 28(8):807-10. PMID: 20697404
- 2010 Tilton JC, Wilen CB, Didigu CA, Sinha R, Harrison JE, Agrawal-Gamse C, Henning EA, Bushman FD, Martin JN, Deeks SG, Doms RW. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. *J Virol.* 2010 Oct; 84(20):10863-76. PMID: 20702642.
- 2010 Cummins NW, Jiang W, McGinty J, Bren GD, Bosch RJ, Landay A, Deeks SG, Martin JN, Douek D, Lederman MM, Brenchley J, Badley AD. Intracellular Casp8p41 content is inversely associated with CD4 T cell count. *J Infect Dis.* 2010 Aug 15; 202(3):386-91. PMID: 20565257.
- 2010 Ferre AL, Hunt PW, McConnell DH, Morris MM, Garcia JC, Pollard RB, Yee HF, Martin JN, Deeks SG, Shacklett BL. HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. *J Virol.* 2010 Nov; 84(21):11020-9. PMID: 20719952.
- 2010 Althoff KN, Justice AC, Gange SJ, Deeks SG, Saag MS, Silverberg MJ, Gill MJ, Lau B, Napravnik S, Tedaldi E, Klein MB, Gebo KA. Virologic and immunologic response to HAART, by age and regimen class. *AIDS.* 2010 Oct 23; 24(16):2469-79. PMID: 20829678.
- 2010 Hatano H, Delwart EL, Norris PJ, Lee TH, Neilands TB, Kelley CF, Hunt PW, Hoh R, Linnen JM, Martin JN, Busch MP, Deeks SG. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. *AIDS.* 2010 Oct 23; 24(16):2535-9. PMID: 20651585.

- 2010 Lundgren JD, Baxter J, Deeks SG, Lane HC. Biomarkers in HIV disease. *Curr Opin HIV AIDS*. 2010 Nov; 5(6):459-62. PMID: 20978387
- 2010 The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. *Science*. 2010 Dec 10; 330(6010):1551-7. PMID: 21051598.
- 2010 Vaidya NK, Rong L, Marconi VC, Kuritzkes DR, Deeks SG, Perelson AS. Treatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral load. *PLoS Comput Biol*. 2010; 6(11):e1001012. PMID: 21124866.
- 2010 Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. *AIDS*. 2010 Nov 27; 24(18):2835-40. PMID: 21045636.
- 2010 Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, Montaner JS. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. *J Acquir Immune Defic Syndr*. 2010 Dec; 55(4):460-5. PMID: 20838225.
- 2010 Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L, Pilcher CD, Grant RM, Deeks SG, Hecht FM. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. *PLoS One*. 2010; 5(12):e15510. PMID: 21170322.
- 2010 Althoff KN, Gebo KA, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Eron JJ, Napravnik S, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Deeks SG, Martin JN, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Goedert JJ, McKaig RG, Thorne J, Rachlis A, Moore RD, Justice AC. CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? *AIDS Res Ther*. 2010; 7:45. PMID: 21159161.
- 2011 Deeks SG. HIV infection, inflammation, immunosenescence, and aging. *Annu Rev Med*. 2011; 62:141-55. PMID: 21090961.
- 2011 Favre D, Stoddart CA, Emu B, Hoh R, Martin JN, Hecht FM, Deeks SG, McCune JM. HIV disease progression correlates with the generation of dysfunctional naive CD8(low) T cells. *Blood*. 2011 Feb 17; 117(7):2189-99. PMID: 21200021.

- 2011 Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, Xue X, Hunt P, Karim R, Kern DM, Hodis HN, Deeks SG. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. *J Infect Dis.* 2011 Feb 15; 203(4):452-63. PMID: 21220772.
- 2011 Hunt PW, Hatano H, Sinclair E, Lee TH, Busch MP, Martin JN, McCune JM, Deeks SG. HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers. *Clin Infect Dis.* 2011 Mar 1; 52(5):681-7. PMID: 21245154.
- 2011 Corrah TW, Goonetilleke N, Kopycinski J, Deeks SG, Cohen MS, Borrow P, McMichael A, Brackenridge S. Reappraisal of the relationship between the HIV-1-protective single-nucleotide polymorphism 35 kilobases upstream of the HLA-C gene and surface HLA-C expression. *J Virol.* 2011 Apr; 85(7):3367-74. PMID: 21248048.
- 2011 Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC. Plasma levels of soluble CD14 independently predict mortality in HIV infection. *J Infect Dis.* 2011 Mar 15; 203(6):780-90. PMID: 21252259.
- 2011 Choi AI, Lo JC, Mulligan K, Schnell A, Kalapus SC, Li Y, Hunt PW, Martin JN, Deeks SG, Hsue PY. Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons. *Clin Infect Dis.* 2011 Apr 1; 52(7):941-4. PMID: 21273298.
- 2011 Hunt PW, Landay AL, Sinclair E, Martinson JA, Hatano H, Emu B, Norris PJ, Busch MP, Martin JN, Brooks C, McCune JM, Deeks SG. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. *PLoS One.* 2011; 6(1):e15924. PMID: 21305005.
- 2011 Hersperger AR, Martin JN, Shin LY, Sheth PM, Kovacs CM, Cosma GL, Makedonas G, Pereyra F, Walker BD, Kaul R, Deeks SG, Betts MR. Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. *Blood.* 2011 Apr 7; 117(14):3799-808. PMID: 21289310.
- 2011 Duprez DA, Neuhaus J, Tracy R, Kuller LH, Deeks SG, Orkin C, Stoehr A, Woolley IJ, Neaton JD. N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. *AIDS.* 2011 Mar 13; 25(5):651-7. PMID: 21245726.

- 2011 Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, Xue X, Parrinello CM, Hunt P, Deeks SG, Hodis HN. T cell activation predicts carotid artery stiffness among HIV-infected women. *Atherosclerosis*. 2011 Jul; 217(1):207-13. PMID: 21492857.
- 2011 Sauce D, Larsen M, Fastenackels S, Pauchard M, Ait-Mohand H, Schneider L, Guihot A, Boufassa F, Zaunders J, Iguertsira M, Bailey M, Gorochov G, Duvivier C, Carcelain G, Kelleher AD, Simon A, Meyer L, Costagliola D, Deeks SG, Lambotte O, Autran B, Hunt PW, Katlama C, Appay V. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. *Blood*. 2011 May 12; 117(19):5142-51. PMID: 21436070.
- 2011 Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. *J Infect Dis*. 2011 Apr 1; 203(7):960-8. PMID: 21402547.
- 2011 Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM. Differential persistence of transmitted HIV-1 drug resistance mutation classes. *J Infect Dis*. 2011 Apr 15; 203(8):1174-81. PMID: 21451005.
- 2011 Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, Martin MP, Hunt P, Deeks SG, Telenti A, Pereyra F, Goldstein D, Wolinsky S, Walker B, Young HA, Carrington M. Differential microRNA regulation of HLA-C expression and its association with HIV control. *Nature*. 2011 Apr 28; 472(7344):495-8. PMID: 21499264.
- 2011 Yukl SA, Li P, Fujimoto K, Lampiris H, Lu CM, Hare CB, Deeks SG, Liegler T, Pandori M, Havlir DV, Wong JK. Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter. *J Virol Methods*. 2011 Aug; 175(2):261-5. PMID: 21536073.
- 2011 SenGupta D, Tandon R, Vieira RG, Ndhlovu LC, Lown-Hecht R, Ormsby CE, Loh L, Jones RB, Garrison KE, Martin JN, York VA, Spotts G, Reyes-Terán G, Ostrowski MA, Hecht FM, Deeks SG, Nixon DF. Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection. *J Virol*. 2011 Jul; 85(14):6977-85. PMID: 21525339.

- 2011 Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. *J Infect Dis.* 2011 May 15; 203(10):1474-83. PMID: 21502083.
- 2011 Jha AR, Nixon DF, Rosenberg MG, Martin JN, Deeks SG, Hudson RR, Garrison KE, Pillai SK. Human endogenous retrovirus K106 (HERV-K106) was infectious after the emergence of anatomically modern humans. *PLoS One.* 2011; 6(5):e20234. PMID: 21633511.
- 2011 Bacchetti P, Deeks SG, McCune JM. Breaking free of sample size dogma to perform innovative translational research. *Sci Transl Med.* 2011 Jun 15; 3(87):87ps24. PMID: 21677197.
- 2011 Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. *AIDS.* 2011 Jun 19; 25(10):1289-98. PMID: 21516027.
- 2011 Kitchen CM, Yeghiazarian L, Hoh R, McCune JM, Sinclair E, Martin JN, Deeks SG. Immune activation, CD4+ T cell counts, and viremia exhibit oscillatory patterns over time in patients with highly resistant HIV infection. *PLoS One.* 2011; 6(6):e21190. PMID: 21701594.
- 2011 Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, Kleiner DE, Deeks SG, Liang TJ, Heller T, Douek DC. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. *Gastroenterology.* 2011 Oct; 141(4):1220-30, 1230.e1-3. PMID: 21726511.
- 2011 Perelson AS, Deeks SG. Drug effectiveness explained: the mathematics of antiviral agents for HIV. *Sci Transl Med.* 2011 Jul 13; 3(91):91ps30. PMID: 21753120.
- 2011 Geng EH, Glidden DV, Bwana MB, Musinguzi N, Emenyonu N, Muyindike W, Christopoulos KA, Neilands TB, Yiannoutsos CT, Deeks SG, Bangsberg DR, Martin JN. Retention in care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: estimation via a sampling-based approach. *PLoS One.* 2011; 6(7):e21797. PMID: 21818265.
- 2011 Dias PT, Hahn JA, Delwart E, Edlin B, Martin J, Lum P, Evans J, Kral A, Deeks S, Busch MP, Page K. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. *BMC Infect Dis.* 2011; 11:208. PMID: 21810243.

- 2011 Abraham AG, Lau B, Deeks S, Moore RD, Zhang J, Eron J, Harrigan R, Gill MJ, Kitahata M, Klein M, Napravnik S, Rachlis A, Rodriguez B, Rourke S, Benson C, Bosch R, Collier A, Gebo K, Goedert J, Hogg R, Horberg M, Jacobson L, Justice A, Kirk G, Martin J, McKaig R, Silverberg M, Sterling T, Thorne J, Willig J, Gange SJ. Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. *Am J Epidemiol*. 2011 Sep 15; 174(6):727-35. PMID: 21813792.
- 2011 Deeks SG. HIV: How to escape treatment. *Nature*. 2011 Sep 1; 477(7362):36-7. PMID: 21886150
- 2011 Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, Pollard RB, Somsouk M, Deeks SG, Shacklett BL. Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. *J Virol*. 2011 Nov; 85(21):11422-34. PMID: 21880771.
- 2011 Mugavero MJ, Napravnik S, Cole SR, Eron JJ, Lau B, Crane HM, Kitahata MM, Willig JH, Moore RD, Deeks SG, Saag MS. Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. *Clin Infect Dis*. 2011 Nov; 53(9):927-35. PMID: 21890751.
- 2011 Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, John Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD. Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. *J Infect Dis*. 2011 Sep 15; 204(6):893-901. PMID: 21849286.
- 2012 Rajasuriar R, Booth DR, Gouillou M, Spelman T, James I, Solomon A, Chua K, Stewart G, Deeks S, Bangsberg DR, Muzoora C, Cameron PU, Hunt P, Martin J, Lewin SR. The role of SNPs in the a-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART. *Genes Immun*. 2012 Jan; 13(1):83-93. PMID: 21938017
- 2011 Appay V, Fastenackels S, Katlama C, Ait-Mohand H, Schneider L, Guihot A, Keller M, Grubeck-Loebenstein B, Simon A, Lambotte O, Hunt PW, Deeks SG, Costagliola D, Autran B, Sauce D. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. *AIDS*. 2011 Sep 24; 25(15):1813-22. PMID: 21412126

- 2012 Plaeger SF, Collins BS, Musib R, Deeks SG, Read S, Embry A. Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary. *AIDS Res Hum Retroviruses*. 2012 May; 28(5):469-77. PMID: 21854232.
- 2011 Geng EH, Kahn JS, Chang OC, Hare CB, Christopoulos KA, Jones D, Petersen ML, Deeks SG, Havlir DV, Gandhi M. The effect of AIDS Clinical Trials Group Protocol 5164 on the time from *Pneumocystis jirovecii* pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation. *Clin Infect Dis*. 2011 Nov; 53(10):1008-14. PMID: 21960715.
- 2012 Sips M, Sciaranghella G, Diefenbach T, Dugast AS, Berger CT, Liu Q, Kwon D, Ghebremichael M, Estes JD, Carrington M, Martin JN, Deeks SG, Hunt PW, Alter G. Altered distribution of mucosal NK cells during HIV infection. *Mucosal Immunol*. 2012 Jan; 5(1):30-40. PMID: 21993602.
- 2012 Seu L, Burt TD, Witte JS, Martin JN, Deeks SG, McCune JM. Variations in the heme oxygenase-1 microsatellite polymorphism are associated with plasma CD14 and viral load in HIV-infected African-Americans. *Genes Immun*. 2012 Apr; 13(3):258-67. PMID: 22048453.
- 2011 Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emenyonu N, Kembabazi A, Neilands TB, Bangsberg DR, Deeks SG, Martin JN. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. *AIDS*. 2011 Nov 13; 25(17):2123-31. PMID: 21881481.
- 2012 Eriksson EM, Milush JM, Ho EL, Batista MD, Holditch SJ, Keh CE, Norris PJ, Keating SM, Deeks SG, Hunt PW, Martin JN, Rosenberg MG, Hecht FM, Nixon DF. Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. *Blood*. 2012 Jan 19; 119(3):745-55. PMID: 22134167.
- 2012 Hsue PY, Ordovas K, Lee T, Reddy G, Gotway M, Schnell A, Ho JE, Selby V, Madden E, Martin JN, Deeks SG, Ganz P, Waters DD. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. *Am J Cardiol*. 2012 Mar 1; 109(5):742-7. PMID: 22169125.
- 2012 Deepe RN, Kistner-Griffin E, Martin JN, Deeks SG, Pandey JP. Epistatic interactions between Fc (GM) and Fc γ R genes and the host control of human immunodeficiency virus replication. *Hum Immunol*. 2012 Mar; 73(3):263-6. PMID: 22213007.

- 2012 Papasavvas E, Hsue P, Reynolds G, Pistilli M, Hancock A, Martin JN, Deeks SG, Montaner LJ. Increased CD34+/KDR+ cells are not associated with carotid artery intima-media thickness progression in chronic HIV-positive subjects. *Antivir Ther.* 2012; 17(3):557-63. PMID: 22300770.
- 2012 Gandhi RT, Deeks SG. Plasma HIV-1 RNA levels during antiretroviral therapy: how low is low enough? *Clin Infect Dis.* 2012 Mar 1; 54(5):733-5. PMID: 22238162.
- 2012 Kiem HP, Jerome KR, Deeks SG, McCune JM. Hematopoietic-stem-cell-based gene therapy for HIV disease. *Cell Stem Cell.* 2012 Feb 3; 10(2):137-47. PMID: 22305563.
- 2012 Justice AC, Freiberg MS, Tracy R, Kuller L, Tate JP, Goetz MB, Fiellin DA, Vanasse GJ, Butt AA, Rodriguez-Barradas MC, Gibert C, Oursler KA, Deeks SG, Bryant K. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? *Clin Infect Dis.* 2012 Apr; 54(7):984-94. PMID: 22337823.
- 2012 Tassiopoulos K, Landay A, Collier AC, Connick E, Deeks SG, Hunt P, Lewis DE, Wilson C, Bosch R. CD28-Negative CD4+ and CD8+ T Cells in Antiretroviral Therapy-Naive HIV-Infected Adults Enrolled in Adult Clinical Trials Group Studies. *J Infect Dis.* 2012 Jun; 205(11):1730-8.
- 2012 Chen H, Hayashi G, Lai OY, Dilthey A, Kuebler PJ, Wong TV, Martin MP, Fernandez Vina MA, McVean G, Wabl M, Leslie KS, Maurer T, Martin JN, Deeks SG, Carrington M, Bowcock AM, Nixon DF, Liao W. Psoriasis patients are enriched for genetic variants that protect against HIV-1 disease. *PLoS Genet.* 2012 Feb; 8(2):e1002514. PMID: 22577363.
- 2012 Hsue PY, Scherzer R, Grunfeld C, Nordstrom SM, Schnell A, Kohl LP, Nitta E, Martin JN, Deeks SG, Weiss EJ. HIV Infection Is Associated With Decreased Thrombin Generation. *Clin Infect Dis.* 2012 Apr; 54(8):1196-203.
- 2012 Baum PD, Young JJ, Schmidt D, Zhang Q, Hoh R, Busch M, Martin J, Deeks S, McCune JM. Blood T-cell receptor diversity decreases during the course of HIV infection, but the potential for a diverse repertoire persists. *Blood.* 2012 Apr 12; 119(15):3469-77. PMID: 22371879.
- 2012 Tassiopoulos K, Landay A, Collier AC, Connick E, Deeks SG, Hunt P, Lewis DE, Wilson C, Bosch R. CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies. *J Infect Dis.* 2012 Jun; 205(11):1730-8. PMID: 22448010.

- 2012 Hsue PY, Scherzer R, Grunfeld C, Nordstrom SM, Schnell A, Kohl LP, Nitta E, Martin JN, Deeks SG, Weiss EJ. HIV infection is associated with decreased thrombin generation. *Clin Infect Dis*. 2012 Apr; 54(8):1196-203. PMID: 22438347.
- 2012 Parrinello CM, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, Xue X, Hunt PW, Deeks SG, Hodis HN, Kaplan RC. Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. *J Infect Dis*. 2012 Jun 15; 205(12):1788-96. PMID: 22492856.
- 2012 Sacre K, Hunt PW, Hsue PY, Maidji E, Martin JN, Deeks SG, Autran B, McCune JM. A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. *AIDS*. 2012 Apr 24; 26(7):805-14. PMID: 22313962.
- 2012 Hsue PY, Scherzer R, Hunt PW, Schnell A, Bolger AF, Kalapus SC, Maka K, Martin JN, Ganz P, Deeks SG. Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. *J Am Heart Assoc*. 2012 Apr; 1(2). PMID: 23130122.
- 2012 Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, Shlipak MG. Association of tenofovir exposure with kidney disease risk in HIV infection. *AIDS*. 2012 Apr 24; 26(7):867-75. PMID: 22313955.
- 2012 Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, Goetz M, Tracy R, Oursler KK, Rimland D, Crothers K, Rodriguez-Barradas M, Crystal S, Gordon A, Kraemer K, Brown S, Gerschenson M, Leaf DA, Deeks SG, Rinaldo C, Kuller LH, Justice A, Freiberg M. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. *Clin Infect Dis*. 2012 Jul; 55(1):126-36. PMID: 22534147.
- 2012 Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, June CH. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. *Sci Transl Med*. 2012 May 2; 4(132):132ra53. PMID: 22553251.
- 2012 Ho JE, Scherzer R, Hecht FM, Maka K, Selby V, Martin JN, Ganz P, Deeks SG, Hsue PY. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. *AIDS*. 2012 Jun 1; 26(9):1115-20. PMID: 22382147.

- 2012 Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. *J Infect Dis.* 2012 Jun; 205 Suppl 3:S375-82. PMID: 22577211.
- 2012 Deeks SG, Verdin E, McCune JM. Immunosenescence and HIV. *Curr Opin Immunol.* 2012 Aug; 24(4):501-6. PMID: 22658763
- 2012 McLaren PJ, Ripke S, Pelak K, Weintrob AC, Patsopoulos NA, Jia X, Erlich RL, Lennon NJ, Kadie CM, Heckerman D, Gupta N, Haas DW, Deeks SG, Pereyra F, Walker BD, de Bakker PI. Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. *Hum Mol Genet.* 2012 Oct 1; 21(19):4334-47. PMID: 22718199.
- 2012 Champiat S, Raposo RA, Maness NJ, Lehman JL, Purtell SE, Hasenkrug AM, Miller JC, Dean H, Koff WC, Hong MA, Martin JN, Deeks SG, Spotts GE, Pilcher CD, Hecht FM, Kallas EG, Garrison KE, Nixon DF. Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection. *PLoS One.* 2012; 7(6):e39311. PMID: 22768072.
- 2012 High KP, Brennan-Ing M, Clifford DB, Cohen MH, Currier J, Deeks SG, Deren S, Effros RB, Gebo K, Goronzy JJ, Justice AC, Landay A, Levin J, Miotti PG, Munk RJ, Nass H, Rinaldo CR, Shlipak MG, Tracy R, Valcour V, Vance DE, Walston JD, Volberding P. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. *J Acquir Immune Defic Syndr.* 2012 Jul 1; 60 Suppl 1:S1-18. PMID: 22688010.
- 2012 Deeks SG, Barré-Sinoussi F. Public health: Towards a cure for HIV. *Nature.* 2012 Jul 19; 487(7407):293-4. PMID: 22810677
- 2012 Towards an HIV cure: a global scientific strategy. *Nat Rev Immunol.* 2012 Aug; 12(8):607-14. PMID: 22814509.
- 2012 Deeks SG. HIV: Shock and kill. *Nature.* 2012 Jul 26; 487(7408):439-40. PMID: 22836995
- 2012 Lim H, Kane L, Schwartz JB, Hesdorffer CS, Deeks SG, Greig N, Ferrucci L, Goetzl EJ. Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients. *Clin Exp Immunol.* 2012 Aug; 169(2):182-9. PMID: 22774993.

- 2012 Ormsby CE, Sengupta D, Tandon R, Deeks SG, Martin JN, Jones RB, Ostrowski MA, Garrison KE, Vázquez-Pérez JA, Reyes-Terán G, Nixon DF. Human endogenous retrovirus expression is inversely associated with chronic immune activation in HIV-1 infection. *PLoS One*. 2012; 7(8):e41021. PMID: 22879884.
- 2012 Li JZ, Gallien S, Do TD, Martin JN, Deeks S, Kuritzkes DR, Hatano H. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. *Antimicrob Agents Chemother*. 2012 Nov; 56(11):5998-6000. PMID: 22890763.
- 2012 Deeks SG. HIV infection, lymphoid fibrosis, and disease. *Blood*. 2012 Aug 30; 120(9):1753-4. PMID: 22936732
- 2012 Geng EH, Hare CB, Kahn JO, Jain V, Van Nunnery T, Christopoulos KA, Deeks SG, Gandhi M, Havlir DV. The effect of a PMID: 22955429.
- 2012 Tomescu C, Duh FM, Hoh R, Viviani A, Harvill K, Martin MP, Carrington M, Deeks SG, Montaner LJ. Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers. *AIDS*. 2012 Sep 24; 26(15):1869-78. PMID: 22874514.
- 2012 Selby VN, Scherzer R, Barnett CF, MacGregor JS, Morelli J, Donovan C, Deeks SG, Martin JN, Hsue PY. Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. *AIDS*. 2012 Sep 24; 26(15):1967-9. PMID: 22781217.
- 2012 Lee GQ, Swenson LC, Poon AF, Martin JN, Hatano H, Deeks SG, Harrigan PR. Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 PMID: 23049972.
- 2012 Deeks SG, Gandhi RT, Chae CU, Lewandrowski KB. Case records of the Massachusetts General Hospital. Case 30-2012. A 54-year-old woman with HIV infection, dyspnea, and chest pain. *N Engl J Med*. 2012 Sep 27; 367(13):1246-54. PMID: 23013077
- 2013 Dunham RM, Gordon SN, Vaccari M, Piatak M, Huang Y, Deeks SG, Lifson J, Franchini G, McCune JM. Preclinical evaluation of HIV eradication strategies in the simian immunodeficiency virus-infected rhesus macaque: a pilot study testing inhibition of indoleamine 2,3-dioxygenase. *AIDS Res Hum Retroviruses*. 2013 Feb; 29(2):207-14. PMID: 22924680.

- 2013 Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, Pollard RB, Somsouk M, Deeks SG, Shacklett BL. Short communication: HIV+ viremic slow progressors maintain low regulatory T cell numbers in rectal mucosa but exhibit high T cell activation. *AIDS Res Hum Retroviruses*. 2013 Jan; 29(1):172-7. PMID: 22998457.
- 2013 Seu L, Ortiz GM, Epling L, Sinclair E, Swainson LA, Bajpai UD, Huang Y, Deeks SG, Hunt PW, Martin JN, McCune JM. Higher CD27(+)CD8(+) T Cells Percentages during Suppressive Antiretroviral Therapy Predict Greater Subsequent CD4(+) T Cell Recovery in Treated HIV Infection. *PLoS One*. 2013; 8(12):e84091. PMID: 24391889
- 2013 Leeansyah E, Ganesh A, Quigley MF, Sönnnerborg A, Andersson J, Hunt PW, Somsouk M, Deeks SG, Martin JN, Moll M, Shacklett BL, Sandberg JK. Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. *Blood*. 2013 Feb 14; 121(7):1124-35. PMID: 23243281.
- 2013 Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, Hoh R, Martin JN, McCune JM, Hecht F, Busch MP, Deeks SG. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. *J Infect Dis*. 2013 Jul; 208(1):50-6. PMID: 23089590.
- 2013 Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, Kitahata MM, Horberg MA, Brooks JT, Buchacz K, Rourke SB, Rachlis A, Napravnik S, Eron J, Willig JH, Moore R, Kirk GD, Bosch R, Rodriguez B, Hogg RS, Thorne J, Goedert JJ, Klein M, Gill J, Deeks S, Sterling TR, Anastos K, Gange SJ. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. *J Acquir Immune Defic Syndr*. 2013 Feb 1; 62(2):149-63. PMID: 23187941.
- 2013 Lok JJ, Hunt PW, Collier AC, Benson CA, Witt MD, Luque AE, Deeks SG, Bosch RJ. The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy. *AIDS*. 2013 Aug 24; 27(13):2101-10. PMID: 24326304
- 2013 Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, Bosch RJ, Lai J, Chioma S, Emad F, Abdel-Mohsen M, Hoh R, Hecht F, Hunt P, Somsouk M, Wong J, Johnston R, Siliciano RF, Richman DD, O'Doherty U, Palmer S, Deeks SG, Siliciano JD. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. *PLoS Pathog*. 2013 Feb; 9(2):e1003174. PMID: 23459007.

- 2012 Hatano H, Scherzer R, Wu Y, Harvill K, Maka K, Hoh R, Sinclair E, Palmer S, Martin JN, Busch MP, Deeks SG, Hsue PY. A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection. *J Acquir Immune Defic Syndr*. 2012 Nov 1; 61(3):317-25. PMID: 22918156.
- 2012 Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fujiwara T. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. *J Acquir Immune Defic Syndr*. 2012 Nov 1; 61(3):297-301. PMID: 22878423.
- 2012 Laming AS, Lee TH, Martin JN, Hunt PW, Deeks SG, Busch M. Lack of evidence for mtDNA as a biomarker of innate immune activation in HIV infection. *PLoS One*. 2012; 7(11):e50486. PMID: 23209754.
- 2013 Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, Busch MP, Deeks SG, Carrington M, O'Doherty U, Kostman J, Montaner LJ. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. *J Infect Dis*. 2013 Jan 15; 207(2):213-22. PMID: 23105144.
- 2013 Champiat S, Garrison KE, Raposo RA, Burwitz BJ, Reed J, Tandon R, York VA, Newman LP, Nimityongskul FA, Wilson NA, Almeida RR, Martin JN, Deeks SG, Rosenberg MG, Wiznia AA, Spotts GE, Pilcher CD, Hecht FM, Ostrowski MA, Sacha JB, Nixon DF. T cells target APOBEC3 proteins in human immunodeficiency virus type 1-infected humans and simian immunodeficiency virus-infected Indian rhesus macaques. *J Virol*. 2013 Jun; 87(11):6073-80. PMID: 23536679.
- 2013 Hatano H, Somsouk M, Sinclair E, Harvill K, Gilman L, Cohen M, Hoh R, Hunt PW, Martin JN, Wong JK, Deeks SG, Yukl SA. Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers. *AIDS*. 2013 Sep 10; 27(14):2255-60. PMID: 24157906
- 2013 Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, Paredes R, Bakowska E, Engsig FN, Phillips A. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. *AIDS*. 2013 Mar 27; 27(6):973-9. PMID: 23698063
- 2012 Eriksson EM, Keh CE, Deeks SG, Martin JN, Hecht FM, Nixon DF. Differential expression of CD96 surface molecule represents CD8⁺ T cells with dissimilar effector function during HIV-1 infection. *PLoS One*. 2012; 7(12):e51696. PMID: 23272144.

- 2013 Yukl SA, Shergill AK, Ho T, Killian M, Girling V, Epling L, Li P, Wong LK, Crouch P, Deeks SG, Havlir DV, McQuaid K, Sinclair E, Wong JK. The Distribution of HIV DNA and RNA in Cell Subsets Differs in Gut and Blood of HIV-Positive Patients on ART: Implications for Viral Persistence. *J Infect Dis.* 2013 Oct; 208(8):1212-20. PMID: 23852128
- 2013 Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R, Yuki Y, Del Prete GQ, Goulder P, Brumme ZL, Brumme CJ, John M, Mallal S, Nelson G, Bosch R, Heckerman D, Stein JL, Soderberg KA, Moody MA, Denny TN, Zeng X, Fang J, Moffett A, Lifson JD, Goedert JJ, Buchbinder S, Kirk GD, Fellay J, McLaren P, Deeks SG, Pereyra F, Walker B, Michael NL, Weintrob A, Wolinsky S, Liao W, Carrington M. Influence of HLA-C expression level on HIV control. *Science.* 2013 Apr 5; 340(6128):87-91. PMID: 23559252.
- 2013 Deeks S, Drosten C, Picker L, Subbarao K, Suzich J. Roadblocks to translational challenges on viral pathogenesis. *Nat Med.* 2013 Jan; 19(1):30-4. PMID: 23296014
- 2013 Hunt PW, Shulman NS, Hayes TL, Dahl V, Somsouk M, Funderburg NT, McLaughlin B, Landay AL, Adeyemi O, Gilman LE, Clagett B, Rodriguez B, Martin JN, Schacker TW, Shacklett BL, Palmer S, Lederman MM, Deeks SG. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. *Blood.* 2013 Jun 6; 121(23):4635-46. PMID: 23589670.
- 2013 Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, Pollard RB, Somsouk M, Deeks SG, Shacklett BL. Short Communication: HIV(+) Viremic Slow Progressors Maintain Low Regulatory T Cell Numbers in Rectal Mucosa but Exhibit High T Cell Activation. *AIDS Res Hum Retroviruses.* 2013 Jan; 29(1):172-7. PMID: 22998457
- 2013 Parikh RV, Scherzer R, Grunfeld C, Nitta EM, Leone A, Martin JN, Deeks SG, Ganz P, Hsue PY. Elevated levels of asymmetric dimethylarginine are associated with lower CD4+ count and higher viral load in HIV-infected individuals. *Atherosclerosis.* 2013 Jul; 229(1):246-52. PMID: 23711612.
- 2013 Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, Epling L, Lee TH, Busch MP, McCune JM, Pilcher CD, Hecht FM, Deeks SG. Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size. *J Infect Dis.* 2013 Aug 15. PMID: 23852127

- 2013 Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, Eisele E, Haase A, Ho YC, Hütter G, Justement JS, Keating S, Lee TH, Li P, Murray D, Palmer S, Pilcher C, Pillai S, Price RW, Rothenberger M, Schacker T, Siliciano J, Siliciano R, Sinclair E, Strain M, Wong J, Richman D, Deeks SG. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. *PLoS Pathog.* 2013; 9(5):e1003347. PMID: 23671416.
- 2013 Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, Miller M, Vella S, Schmitz JE, Ahlers J, Richman DD, Sekaly RP. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. *Lancet.* 2013 Jun 15; 381(9883):2109-17. PMID: 23541541.
- 2013 Ranasinghe S, Cutler S, Davis I, Lu R, Soghoian DZ, Qi Y, Sidney J, Kranias G, Flanders MD, Lindqvist M, Kuhl B, Alter G, Deeks SG, Walker BD, Gao X, Sette A, Carrington M, Streeck H. Association of HLA-DRB1-restricted CD4⁺ T cell responses with HIV immune control. *Nat Med.* 2013 Jul; 19(7):930-3. PMID: 23793098.
- 2013 Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. *Lancet.* 2013 Nov 2; 382(9903):1525-33. PMID: 24152939
- 2013 Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, Hernandez RD, Lederman MM, Huang Y, Somsouk M, Deeks SG, Hunt PW, Lynch SV, McCune JM. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. *Sci Transl Med.* 2013 Jul 10; 5(193):193ra91. PMID: 23843452.
- 2013 Leeansyah E, Ganesh A, Quigley MF, Sönnernborg A, Andersson J, Hunt PW, Somsouk M, Deeks SG, Martin JN, Moll M, Shacklett BL, Sandberg JK. Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. *Blood.* 2013 Feb 14; 121(7):1124-35. PMID: 23243281
- 2013 Yukl SA, Shergill AK, Ho T, Killian M, Girling V, Epling L, Li P, Wong LK, Crouch P, Deeks SG, Havlir DV, McQuaid K, Sinclair E, Wong JK. The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. *J Infect Dis.* 2013 Oct 15; 208(8):1212-20. PMID: 23852128.

- 2013 Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, Kitahata MM, Horberg MA, Brooks JT, Buchacz K, Rourke SB, Rachlis A, Napravnik S, Eron J, Willig JH, Moore R, Kirk GD, Bosch R, Rodriguez B, Hogg RS, Thorne J, Goedert JJ, Klein M, Gill J, Deeks S, Sterling TR, Anastos K, Gange SJ. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. *J Acquir Immune Defic Syndr*. 2013 Feb 1; 62(2):149-63. PMID: 23187941
- 2013 Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, Epling L, Lee TH, Busch MP, McCune JM, Pilcher CD, Hecht FM, Deeks SG. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. *J Infect Dis*. 2013 Oct 15; 208(8):1202-11. PMID: 23852127.
- 2013 Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, Bosch RJ, Lai J, Chioma S, Emad F, Abdel-Mohsen M, Hoh R, Hecht F, Hunt P, Somsouk M, Wong J, Johnston R, Siliciano RF, Richman DD, O'Doherty U, Palmer S, Deeks SG, Siliciano JD. Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies. *PLoS Pathog*. 2013 Feb; 9(2):e1003174. PMID: 23459007
- 2013 Unemori P, Leslie KS, Hunt PW, Sinclair E, Epling L, Mitsuyasu R, Effros RB, Dock J, Dollard SG, Deeks SG, Martin JN, Maurer TA. Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection. *AIDS*. 2013 Jul 17; 27(11):1735-42. PMID: 23435301.
- 2013 Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, Paredes R, Bakowska E, Engsig FN, Phillips A. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. *AIDS*. 2013 Mar 27; 27(6):973-9. PMID: 23698063
- 2013 McLaren PJ, Coulonges C, Ripke S, van den Berg L, Buchbinder S, Carrington M, Cossarizza A, Dalmau J, Deeks SG, Delaneau O, De Luca A, Goedert JJ, Haas D, Herbeck JT, Kathiresan S, Kirk GD, Lambotte O, Luo M, Mallal S, van Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, O'Brien SJ, Pereyra F, Plummer FA, Poli G, Qi Y, Rucart P, Sandhu MS, Shea PR, Schuitemaker H, Theodorou I, Vannberg F, Veldink J, Walker BD, Weintrob A, Winkler CA, Wolinsky S, Telenti A, Goldstein DB, de Bakker PI, Zagury JF, Fellay J. Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. *PLoS Pathog*. 2013; 9(7):e1003515. PMID: 23935489.

- 2013 Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. *Immunol Rev.* 2013 Jul; 254(1):326-42. PMID: 23772629.
- 2013 Patterson S, Moran P, Epel E, Sinclair E, Kemeny ME, Deeks SG, Bacchetti P, Acree M, Epling L, Kirschbaum C, Hecht FM. Cortisol patterns are associated with T cell activation in HIV. *PLoS One.* 2013; 8(7):e63429. PMID: 23922644.
- 2013 Champiat S, Garrison KE, Raposo RA, Burwitz BJ, Reed J, Tandon R, York VA, Newman LP, Nimityongskul FA, Wilson NA, Almeida RR, Martin JN, Deeks SG, Rosenberg MG, Wiznia AA, Spotts GE, Pilcher CD, Hecht FM, Ostrowski MA, Sacha JB, Nixon DF. T Cells Target APOBEC3 Proteins in Human Immunodeficiency Virus Type 1-Infected Humans and Simian Immunodeficiency Virus-Infected Indian Rhesus Macaques. *J Virol.* 2013 Jun; 87(11):6073-80. PMID: 23536679
- 2013 Li L, Deng X, Linsuwanon P, Bangsberg D, Bwana MB, Hunt P, Martin JN, Deeks SG, Delwart E. AIDS alters the commensal plasma virome. *J Virol.* 2013 Oct; 87(19):10912-5. PMID: 23903845.
- 2013 Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R, Yuki Y, Del Prete GQ, Goulder P, Brumme ZL, Brumme CJ, John M, Mallal S, Nelson G, Bosch R, Heckerman D, Stein JL, Soderberg KA, Moody MA, Denny TN, Zeng X, Fang J, Moffett A, Lifson JD, Goedert JJ, Buchbinder S, Kirk GD, Fellay J, McLaren P, Deeks SG, Pereyra F, Walker B, Michael NL, Weintrob A, Wolinsky S, Liao W, Carrington M. Influence of HLA-C Expression Level on HIV Control. *Science.* 2013 Apr 5; 340(6128):87-91. PMID: 23559252
- 2013 Graf EH, Pace MJ, Peterson BA, Lynch LJ, Chukwulebe SB, Mexas AM, Shaheen F, Martin JN, Deeks SG, Connors M, Migueles SA, O'Doherty U. Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected]. *PLoS One.* 2013; 8(8):e71879. PMID: 23951263.
- 2013 Hunt PW, Shulman NS, Hayes TL, Dahl V, Somsouk M, Funderburg NT, McLaughlin B, Landay AL, Adeyemi O, Gilman LE, Clagett B, Rodriguez B, Martin JN, Schacker TW, Shacklett BL, Palmer S, Lederman MM, Deeks SG. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. *Blood.* 2013 Jun 6; 121(23):4635-46. PMID: 23589670

- 2013 Parikh RV, Scherzer R, Grunfeld C, Nitta EM, Leone A, Martin JN, Deeks SG, Ganz P, Hsue PY. Elevated levels of asymmetric dimethylarginine are associated with lower CD4+ count and higher viral load in HIV-infected individuals. *Atherosclerosis*. 2013 Jul; 229(1):246-52. PMID: 23711612
- 2013 Yuki SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, Eisele E, Haase A, Ho YC, Hütter G, Justement JS, Keating S, Lee TH, Li P, Murray D, Palmer S, Pilcher C, Pillai S, Price RW, Rothenberger M, Schacker T, Siliciano J, Siliciano R, Sinclair E, Strain M, Wong J, Richman D, Deeks SG. Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient. *PLoS Pathog*. 2013 May; 9(5):e1003347. PMID: 23671416
- 2013 Ranasinghe S, Cutler S, Davis I, Lu R, Soghoian DZ, Qi Y, Sidney J, Kranias G, Flanders MD, Lindqvist M, Kuhl B, Alter G, Deeks SG, Walker BD, Gao X, Sette A, Carrington M, Streeck H. Association of HLA-DRB1-restricted CD4(+) T cell responses with HIV immune control. *Nat Med*. 2013 Jul; 19(7):930-3. PMID: 23793098
- 2013 Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, Burkholder GA, Reid EG, Rodriguez B, Deeks SG, Mayer KH, Moore RD, Kitahata MM, Eron JJ, Richards KL. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. *J Natl Cancer Inst*. 2013 Aug 21; 105(16):1221-9. PMID: 23892362.
- 2013 Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, Hernandez RD, Lederman MM, Huang Y, Somsouk M, Deeks SG, Hunt PW, Lynch SV, McCune JM. Dysbiosis of the Gut Microbiota Is Associated with HIV Disease Progression and Tryptophan Catabolism. *Sci Transl Med*. 2013 Jul 10; 5(193):193ra91. PMID: 23843452
- 2013 Unemori P, Leslie KS, Hunt PW, Sinclair E, Epling L, Mitsuyasu R, Effros RB, Dock J, Dollard SG, Deeks SG, Martin JN, Maurer TA. Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection. *AIDS*. 2013 Jul 17; 27(11):1735-42. PMID: 23435301

- 2013 McLaren PJ, Coulonges C, Ripke S, van den Berg L, Buchbinder S, Carrington M, Cossarizza A, Dalmau J, Deeks SG, Delaneau O, De Luca A, Goedert JJ, Haas D, Herbeck JT, Kathiresan S, Kirk GD, Lambotte O, Luo M, Mallal S, van Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, O'Brien SJ, Pereyra F, Plummer FA, Poli G, Qi Y, Rucart P, Sandhu MS, Shea PR, Schuitemaker H, Theodorou I, Vannberg F, Veldink J, Walker BD, Weintrob A, Winkler CA, Wolinsky S, Telenti A, Goldstein DB, de Bakker PI, Zagury JF, Fellay J. Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls. *PLoS Pathog.* 2013 Jul; 9(7):e1003515. PMID: 23935489
- 2013 Patterson S, Moran P, Epel E, Sinclair E, Kemeny ME, Deeks SG, Bacchetti P, Acree M, Epling L, Kirschbaum C, Hecht FM. Cortisol Patterns Are Associated with T Cell Activation in HIV. *PLoS One.* 2013; 8(7):e63429. PMID: 23922644
- 2013 Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, Hoh R, Martin JN, McCune JM, Neaton JD, Tracy RP, Hsue PY, Richman DD, Deeks SG. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. *J Infect Dis.* 2013 Nov 1; 208(9):1436-42. PMID: 23975885.
- 2013 Li L, Deng X, Linsuwanon P, Bangsberg D, Bwana MB, Hunt P, Martin JN, Deeks SG, Delwart E. AIDS alters the commensal plasma virome. *J Virol.* 2013 Oct; 87(19):10912-5. PMID: 23903845
- 2013 Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, Burkholder GA, Reid EG, Rodriguez B, Deeks SG, Mayer KH, Moore RD, Kitahata MM, Richards KL, Eron JJ. Association of early HIV viremia with mortality after HIV-associated lymphoma. *AIDS.* 2013 Sep 24; 27(15):2365-73. PMID: 23736149.
- 2013 Graf EH, Pace MJ, Peterson BA, Lynch LJ, Chukwulebe SB, Mexas AM, Shaheen F, Martin JN, Deeks SG, Connors M, Migueles SA, O'Doherty U. Gag-Positive Reservoir Cells Are Susceptible to HIV-Specific Cytotoxic T Lymphocyte Mediated Clearance. *PLoS One.* 2013; 8(8):e71879. PMID: 23951263
- 2013 Hunt PW, Lederman MM, Deeks SG. Response: Maraviroc intensification and microbial translocation. *Blood.* 2013 Sep 26; 122(13):2283-4. PMID: 24072849

- 2013 Deeks SG, Tracy R, Douek DC. Systemic Effects of Inflammation on Health during Chronic HIV Infection. *Immunity*. 2013 Oct 17; 39(4):633-45. PMID: 24138880
- 2013 Abdel-Mohsen M, Raposo RA, Deng X, Li M, Liegler T, Sinclair E, Salama MS, Ghanem Hel-D, Hoh R, Wong JK, David M, Nixon DF, Deeks SG, Pillai SK. Expression profile of host restriction factors in HIV-1 elite controllers. *Retrovirology*. 2013; 10:106. PMID: 24131498.
- 2013 Hatano H, Yukl SA, Ferre AL, Graf EH, Somsouk M, Sinclair E, Abdel-Mohsen M, Liegler T, Harvill K, Hoh R, Palmer S, Bacchetti P, Hunt PW, Martin JN, McCune JM, Tracy RP, Busch MP, O'Doherty U, Shacklett BL, Wong JK, Deeks SG. Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers. *PLoS Pathog*. 2013 Oct; 9(10):e1003691. PMID: 24130489
- 2013 Picker LJ, Deeks SG. HIV: Antibodies advance the search for a cure. *Nature*. 2013 Nov 14; 503(7475):207-8. PMID: 24172894
- 2014 Abdel-Mohsen M, Deng X, Liegler T, Guatelli JC, Salama MS, Ghanem Hel-D, Rauch A, Ledergerber B, Deeks SG, Günthard HF, Wong JK, Pillai SK. Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity In Vivo. *J Virol*. 2014 Jan; 88(1):763-7. PMID: 24155399
- 2014 Burbelo PD, Bayat A, Rhodes CS, Hoh R, Martin JN, Fromentin R, Chomont N, Hütter G, Kovacs JA, Deeks SG. HIV antibody characterization as a method to quantify reservoir size during curative interventions. *J Infect Dis*. 2014 May 15; 209(10):1613-7. PMID: 24286982.
- 2013 Asher AK, Santos GM, Evans J, Dokubo EK, Lee TH, Martin JN, Deeks SG, Tobler LH, Busch M, Hunt PW, Page K. Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers. *AIDS*. 2013 Nov 13; 27(17):2691-6. PMID: 23939233
- 2013 Kulkarni S, Qi Y, O'huigin C, Pereyra F, Ramsuran V, McLaren P, Fellay J, Nelson G, Chen H, Liao W, Bass S, Apps R, Gao X, Yuki Y, Lied A, Ganesan A, Hunt PW, Deeks SG, Wolinsky S, Walker BD, Carrington M. Genetic interplay between HLA-C and MIR148A in HIV control and Crohn disease. *Proc Natl Acad Sci U S A*. 2013 Nov 18. PMID: 24248364

- 2013 Josefsson L, von Stockenstrom S, Faria NR, Sinclair E, Bacchetti P, Killian M, Epling L, Tan A, Ho T, Lemey P, Shao W, Hunt PW, Somsouk M, Wylie W, Douek DC, Loeb L, Custer J, Hoh R, Poole L, Deeks SG, Hecht F, Palmer S. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. *Proc Natl Acad Sci U S A*. 2013 Dec 17; 110(51):E4987-96. PMID: 24277811
- 2014 Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, Emad F, Buckheit R, McCance-Katz EF, Lai J, Kennedy M, Chander G, Siliciano RF, Siliciano JD, Deeks SG. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. *Clin Infect Dis*. 2014 Mar; 58(6):883-90. PMID: 24336828.
- 2013 Milush JM, López-Vergès S, York VA, Deeks SG, Martin JN, Hecht FM, Lanier LL, Nixon DF. CD56negCD16⁺ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. *Retrovirology*. 2013; 10:158. PMID: 24351015.
- 2014 Hatano H, Bacchetti P, Hsue PY, Deeks SG. Reply to Karch et al. *J Infect Dis*. 2014 Jul 1; 210(1):159-60. PMID: 24421253.
- 2014 Boufassa F, Lechenadec J, Meyer L, Costagliola D, Hunt PW, Pereyra F, Deeks S, Pancino G, Taulera O, Lichtenfeld M, Delobel P, Saez-Cirion A, Lambotte O. Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration. *PLoS One*. 2014; 9(1):e85516. PMID: 24465584.
- 2014 Emu B, Moretto WJ, Hoh R, Krone M, Martin JN, Nixon DF, Deeks SG, McCune JM. Composition and function of T cell subpopulations are slow to change despite effective antiretroviral treatment of HIV disease. *PLoS One*. 2014; 9(1):e85613. PMID: 24465619.
- 2014 Michaud HA, de Mulder M, SenGupta D, Deeks SG, Martin JN, Pilcher CD, Hecht FM, Sacha JB, Nixon DF. Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection. *Retrovirology*. 2014; 11:10. PMID: 24472118.
- 2014 Yuki SA, Sinclair E, Somsouk M, Hunt PW, Epling L, Killian M, Girling V, Li P, Havlir DV, Deeks SG, Wong JK, Hatano H. A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4⁺ T cells, including myeloid cells. *AIDS*. 2014 Jan 28; 28(3):439-42. PMID: 24322272.

- 2014 Heredia A, Davis C, Amin MN, Le NM, Wainberg MA, Oliveira M, Deeks SG, Wang LX, Redfield RR. Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1. *AIDS*. 2014 Jan 28; 28(3):317-23. PMID: 24326355.
- 2014 Dunham RM, Vujkovic-Cvijin I, Yuki SA, Broadhurst MJ, Loke P, Albright RG, Wong JK, Lederman MM, Somsouk M, Hunt PW, Martin JN, Deeks SG, McCune JM. Discordance between peripheral and colonic markers of inflammation during suppressive ART. *J Acquir Immune Defic Syndr*. 2014 Feb 1; 65(2):133-41. PMID: 24121758.
- 2014 Payne RP, Branch S, Kløverpris H, Matthews PC, Koofhethile CK, Strong T, Adland E, Leitman E, Frater J, Ndung'u T, Hunter E, Haubrich R, Mothe B, Edwards A, Riddell L, Chen F, Harrigan PR, Brumme ZL, Mallal S, John M, Jooste JP, Shapiro R, Deeks SG, Walker BD, Brander C, Landis C, Carlson JM, Prado JG, Goulder PJ. Differential escape patterns within the dominant HLA-B*57:03-restricted HIV Gag epitope reflect distinct clade-specific functional constraints. *J Virol*. 2014 May; 88(9):4668-78. PMID: 24501417.
- 2014 Parikh RV, Scherzer R, Nitta EM, Leone A, Hur S, Mistry V, Macgregor JS, Martin JN, Deeks SG, Ganz P, Hsue PY. Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection. *AIDS*. 2014 Feb 20; 28(4):511-9. PMID: 24469026.
- 2014 Lee SA, Sinclair E, Hatano H, Hsue PY, Epling L, Hecht FM, Bangsberg DR, Martin JN, McCune JM, Deeks SG, Hunt PW. Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging. *PLoS One*. 2014; 9(2):e89444. PMID: 24586783.
- 2014 Byakwaga H, Boum Y, Huang Y, Muzoora C, Kembabazi A, Weiser SD, Bennett J, Cao H, Haberer JE, Deeks SG, Bangsberg DR, McCune JM, Martin JN, Hunt PW. The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. *J Infect Dis*. 2014 Aug 1; 210(3):383-91. PMID: 24585899.
- 2014 Lee SA, Sinclair E, Jain V, Huang Y, Epling L, Van Natta M, Meinert CL, Martin JN, McCune JM, Deeks SG, Lederman MM, Hecht FM, Hunt PW. Low proportions of CD28- CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. *J Infect Dis*. 2014 Aug 1; 210(3):374-82. PMID: 24585893.

- 2014 Bashirova AA, Martin-Gayo E, Jones DC, Qi Y, Apps R, Gao X, Burke PS, Taylor CJ, Rogich J, Wolinsky S, Bream JH, Duggal P, Hussain S, Martinson J, Weintrob A, Kirk GD, Fellay J, Buchbinder SP, Goedert JJ, Deeks SG, Pereyra F, Trowsdale J, Lichtenfeld M, Telenti A, Walker BD, Allen RL, Carrington M, Yu XG. LILRB2 interaction with HLA class I correlates with control of HIV-1 infection. *PLoS Genet.* 2014 Mar; 10(3):e1004196. PMID: 24603468.
- 2014 Stock PG, Barin B, Hatano H, Rogers RL, Roland ME, Lee TH, Busch M, Deeks SG. Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients. *Am J Transplant.* 2014 May; 14(5):1136-41. PMID: 24698537.
- 2014 Siewe B, Wallace J, Rygielski S, Stapleton JT, Martin J, Deeks SG, Landay A. Regulatory B cells inhibit cytotoxic T lymphocyte (CTL) activity and elimination of infected CD4 T cells after in vitro reactivation of HIV latent reservoirs. *PLoS One.* 2014; 9(4):e92934. PMID: 24739950.
- 2014 Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, Robinson J, Huang Y, Epling L, Martin JN, Deeks SG, Meinert CL, Van Natta ML, Jabs DA, Lederman MM. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. *J Infect Dis.* 2014 Oct 15; 210(8):1228-38. PMID: 24755434.
- 2014 Gopal S, Patel MR, Achenbach CJ, Yanik EL, Cole SR, Napravnik S, Burkholder GA, Mathews WC, Rodriguez B, Deeks SG, Mayer KH, Moore RD, Kitahata MM, Richards KL, Eron JJ. Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort. *Clin Infect Dis.* 2014 Jul 15; 59(2):279-86. PMID: 24755860.
- 2014 Symons J, Vandekerckhove L, Hütter G, Wensing AM, van Ham PM, Deeks SG, Nijhuis M. Dependence on the CCR5 coreceptor for viral replication explains the lack of rebound of CXCR4-predicted HIV variants in the Berlin patient. *Clin Infect Dis.* 2014 Aug 15; 59(4):596-600. PMID: 24759824
- 2014 Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, Plants J, Seth A, Wilson CC, Deeks SG, Lederman MM, Landay AL. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. *J Infect Dis.* 2014 Oct 15; 210(8):1248-59. PMID: 24795473.

- 2014 Asher AK, Santos GM, Evans J, Dokubo EK, Lee TH, Martin JN, Deeks SG, Tobler LH, Busch M, Hunt PW, Page K. A closer look at hepatitis C clearance in HIV controllers: a response. *AIDS*. 2014 May 15; 28(8):1241-2. PMID: 25028914.
- 2014 Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, Ferre AL, Hayes TL, Somsouk M, Hsue PY, Van Natta ML, Meinert CL, Lederman MM, Hatano H, Jain V, Huang Y, Hecht FM, Martin JN, McCune JM, Moreno S, Deeks SG. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. *PLoS Pathog*. 2014 May; 10(5):e1004078. PMID: 24831517.
- 2014 Sandler NG, Zhang X, Bosch RJ, Funderburg NT, Choi AI, Robinson JK, Fine DM, Coombs RW, Jacobson JM, Landay AL, Douek DC, Tressler R, Read SW, Wilson CC, Deeks SG, Lederman MM, Gandhi RT. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. *J Infect Dis*. 2014 Nov 15; 210(10):1549-54. PMID: 24864123.
- 2014 Tandon R, Chew GM, Byron MM, Borrow P, Niki T, Hirashima M, Barbour JD, Norris PJ, Lanteri MC, Martin JN, Deeks SG, Ndhlovu LC. Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers. *AIDS Res Hum Retroviruses*. 2014 Jul; 30(7):654-64. PMID: 24786365.
- 2014 Scherzer R, Gandhi M, Estrella MM, Tien PC, Deeks SG, Grunfeld C, Peralta CA, Shlipak MG. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans. *AIDS*. 2014 Jun 1; 28(9):1289-95. PMID: 24922479.
- 2014 Wang C, Abdel-Mohsen M, Strain MC, Lada SM, Yukl S, Cockerham LR, Pilcher CD, Hecht FM, Sinclair E, Liegler T, Richman DD, Deeks SG, Pillai SK. Decreased HIV Type 1 Transcription in CCR5- Δ 32 Heterozygotes During Suppressive Antiretroviral Therapy. *J Infect Dis*. 2014 Dec 1; 210(11):1838-43. PMID: 24935955.
- 2014 Li P, Fujimoto K, Bourguignon L, Yukl S, Deeks S, Wong JK. Exogenous and endogenous hyaluronic acid reduces HIV infection of CD4(+) T cells. *Immunol Cell Biol*. 2014 Oct; 92(9):770-80. PMID: 24957217.
- 2014 Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. *Science*. 2014 Jul 11; 345(6193):169-74. PMID: 25013067.

- 2014 Michaud HA, SenGupta D, de Mulder M, Deeks SG, Martin JN, Kobie JJ, Sacha JB, Nixon DF. Cutting edge: An antibody recognizing ancestral endogenous virus glycoproteins mediates antibody-dependent cellular cytotoxicity on HIV-1-infected cells. *J Immunol.* 2014 Aug 15; 193(4):1544-8. PMID: 25024383.
- 2014 Lewin SR, Deeks SG, Barré-Sinoussi F. Towards a cure for HIV--are we making progress? *Lancet.* 2014 Jul 19; 384(9939):209-11. PMID: 25042220
- 2014 Deeks SG, Hunt PW. Antiretroviral therapy: stubborn limitations persist. *Lancet.* 2014 Jul 19; 384(9939):214-6. PMID: 25042221
- 2014 Cockerham LR, Jain V, Sinclair E, Glidden DV, Hartogenesis W, Hatano H, Hunt PW, Martin JN, Pilcher CD, Sekaly R, McCune JM, Hecht FM, Deeks SG. Programmed death-1 expression on CD4⁺ and CD8⁺ T cells in treated and untreated HIV disease. *AIDS.* 2014 Jul 31; 28(12):1749-58. PMID: 24871455.
- 2014 Borges ÁH, Weitz JI, Collins G, Baker JV, Lévy Y, Davey RT, Phillips AN, Neaton JD, Lundgren JD, Deeks SG. Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. *AIDS.* 2014 Jul 31; 28(12):1791-6. PMID: 25003720.
- 2014 Seu L, Ortiz GM, Burt TD, Deeks SG, Martin JN, McCune JM. Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4⁺ T cell recovery after the initiation of antiretroviral therapy for HIV disease. *AIDS Res Ther.* 2014; 11:27. PMID: 25180041.
- 2014 Klatt NR, Bosinger SE, Peck M, Richert-Spuhler LE, Heigele A, Gile JP, Patel N, Taaffe J, Julg B, Camerini D, Torti C, Martin JN, Deeks SG, Sinclair E, Hecht FM, Lederman MM, Paiardini M, Kirchhoff F, Brenchley JM, Hunt PW, Silvestri G. Limited HIV infection of central memory and stem cell memory CD4⁺ T cells is associated with lack of progression in viremic individuals. *PLoS Pathog.* 2014 Aug; 10(8):e1004345. PMID: 25167059.
- 2014 Petersen ML, Tran L, Geng EH, Reynolds SJ, Kambugu A, Wood R, Bangsberg DR, Yiannoutsos CT, Deeks SG, Martin JN. Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa. *AIDS.* 2014 Sep 10; 28(14):2097-107. PMID: 24977440.
- 2014 Ribeiro SP, Milush JM, Cunha-Neto E, Kallas EG, Kalil J, Somsouk M, Hunt PW, Deeks SG, Nixon DF, SenGupta D. The CD8⁺ Memory Stem T Cell (TSCM) Subset Is Associated with Improved Prognosis in Chronic HIV-1 Infection. *J Virol.* 2014 Dec 1; 88(23):13836-44. PMID: 25253339.

- 2014 Cockerham LR, Deeks SG. Biomarker reveals HIV's hidden reservoir. *Elife*. 2014; 3:e04742. PMID: 25321627.
- 2014 Cockerham LR, Siliciano JD, Sinclair E, O'Doherty U, Palmer S, Yukl SA, Strain MC, Chomont N, Hecht FM, Siliciano RF, Richman DD, Deeks SG. CD4+ and CD8+ T Cell Activation Are Associated with HIV DNA in Resting CD4+ T Cells. *PLoS One*. 2014; 9(10):e110731. PMID: 25340755.
- 2014 Deeks SG, Siliciano R. HIV Prevention and Treatment Fields Join Forces. *EBioMedicine*. 2014 Nov; 1(1):4-5. PMID: 26137503.
- 2015 Sanchez JL, Hunt PW, Reilly CS, Hatano H, Beilman GJ, Khoruts A, Jasurda JS, Somsouk M, Thorkelson A, Russ S, Anderson J, Deeks SG, Schacker TW. Lymphoid fibrosis occurs in long-term nonprogressors and persists with antiretroviral therapy but may be reversible with curative interventions. *J Infect Dis*. 2015 Apr 1; 211(7):1068-75. PMID: 25344521.
- 2015 Freedberg KA, Possas C, Deeks S, Ross AL, Rosettie KL, Di Mascio M, Collins C, Walensky RP, Yazdanpanah Y. The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis. *J Virus Erad*. 2015; 1(4):245-249. PMID: 26878073. PMCID: PMC4748959
- 2015 Law MG, Achhra A, Deeks SG, Gazzard B, Migueles SA, Novak RM, Ristola M. Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. *HIV Med*. 2015 Apr; 16 Suppl 1:37-45. PMID: 25711322.
- 2015 Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, Gill MJ, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, Del Amo J, Moreno S, Rodríguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Pérez-Hoyos S, Jarrin I, Guest JL, Monforte AD, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hernán MA. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. *Int J Epidemiol*. 2015 Dec 31. PMID: 26721599
- 2015 Serrano-Villar S, Deeks SG. CD4/CD8 ratio: an emerging biomarker for HIV. *Lancet HIV*. 2015 Mar; 2(3):e76-7. PMID: 26424546

- 2015 Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. *Nat Rev Dis Primers*. 2015; 1:15035. PMID: 27188527
- 2014 Deeks S. Towards an HIV cure. *J Int AIDS Soc*. 2014; 17(4 Suppl 3):19479. PMID: 25393988.
- 2014 Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sékaly RP, Lewin SR. Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy. *PLoS Pathog*. 2014 Oct; 10(10):e1004473. PMID: 25393648.
- 2015 Hollingsworth TD, Pilcher CD, Hecht FM, Deeks SG, Fraser C. High Transmissibility During Early HIV Infection Among Men Who Have Sex With Men-San Francisco, California. *J Infect Dis*. 2015 Jun 1; 211(11):1757-60. PMID: 25542958.
- 2015 Achenbach CJ, Assoumou L, Deeks SG, Wilkin TJ, Berzins B, Casazza JP, Lambert-Niclot S, Koup RA, Costagliola D, Calvez V, Katlama C, Autran B, Murphy RL. Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial. *Lancet HIV*. 2015 Mar; 2(3):e82-91. PMID: 26424549
- 2014 Somsouk M, Dunham RM, Cohen M, Albright R, Abdel-Mohsen M, Liegler T, Lifson J, Piatak M, Gorelick R, Huang Y, Wu Y, Hsue PY, Martin JN, Deeks SG, McCune JM, Hunt PW. The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial. *PLoS One*. 2014; 9(12):e116306. PMID: 25545673.
- 2015 Somsouk M, Estes JD, Deleage C, Dunham RM, Albright R, Inadomi JM, Martin JN, Deeks SG, McCune JM, Hunt PW. Gut epithelial barrier and systemic inflammation during chronic HIV infection. *AIDS*. 2015 Jan 2; 29(1):43-51. PMID: 25387317.
- 2015 von Stockenstrom S, Odevall L, Lee E, Sinclair E, Bacchetti P, Killian M, Epling L, Shao W, Hoh R, Ho T, Faria NR, Lemey P, Albert J, Hunt P, Loeb L, Pilcher C, Poole L, Hatano H, Somsouk M, Douek D, Boritz E, Deeks SG, Hecht FM, Palmer S. Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy. *J Infect Dis*. 2015 Aug 15; 212(4):596-607. PMID: 25712966.

- 2015 Deng K, Perteau M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H, Margolick JB, Gurer C, Murphy AJ, Valenzuela DM, Yancopoulos GD, Deeks SG, Strowig T, Kumar P, Siliciano JD, Salzberg SL, Flavell RA, Shan L, Siliciano RF. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. *Nature*. 2015 Jan 15; 517(7534):381-5. PMID: 25561180.
- 2015 Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin AG, Strain MC, Richman DD, O'Doherty U, Palmer S, Hecht FM, Hoh R, Barnard RJ, Miller MD, Hazuda DJ, Deeks SG, Sékaly RP, Chomont N. A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. *EBioMedicine*. 2015 Aug; 2(8):872-81. PMID: 26425694.
- 2015 Badejo OA, Chang CC, So-Armah KA, Tracy RP, Baker JV, Rimland D, Butt AA, Gordon AJ, Rinaldo CR, Kraemer K, Samet JH, Tindle HA, Goetz MB, Rodriguez-Barradas MC, Bedimo R, Gibert CL, Leaf DA, Kuller LH, Deeks SG, Justice AC, Freiberg MS. CD8 (+) T-Cells Count in Acute Myocardial Infarction in HIV Disease in a Predominantly Male Cohort. *Biomed Res Int*. 2015; 2015:246870. PMID: 25688354.
- 2015 Secemsky EA, Scherzer R, Nitta E, Wu AH, Lange DC, Deeks SG, Martin JN, Snider J, Ganz P, Hsue PY. Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals. *JACC Heart Fail*. 2015 Aug; 3(8):591-9. PMID: 26164679.
- 2015 Clayton KL, Douglas-Vail MB, Rahman AK, Medcalf KE, Xie IY, Chew GM, Tandon R, Lanteri MC, Norris PJ, Deeks SG, Ndhlovu LC, Ostrowski MA. Soluble T Cell Immunoglobulin Mucin Domain 3 Is Shed from CD8+ T Cells by the Sheddase ADAM10, Is Increased in Plasma during Untreated HIV Infection, and Correlates with HIV Disease Progression. *J Virol*. 2015 Apr 1; 89(7):3723-36. PMID: 25609823.
- 2015 Gornalusse GG, Mummidi S, Gaitan AA, Jimenez F, Ramsuran V, Picton A, Rogers K, Manoharan MS, Avadhanam N, Murthy KK, Martinez H, Molano Murillo A, Chykarenko ZA, Hutt R, Daskalakis D, Shostakovich-Koretskaya L, Abdool Karim S, Martin JN, Deeks SG, Hecht F, Sinclair E, Clark RA, Okulicz J, Valentine FT, Martinson N, Tiemessen CT, Ndung'u T, Hunt PW, He W, Ahuja SK. Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor. *Proc Natl Acad Sci U S A*. 2015 Aug 25; 112(34):E4762-71. PMID: 26307764.

- 2015 Geng EH, Neilands TB, Thiébaut R, Bwana MB, Nash D, Moore RD, Wood R, Zannou DM, Althoff KN, Lim PL, Nachega JB, Easterbrook PJ, Kambugu A, Little F, Nakigozi G, Nakanjako D, Kiggundu V, Ki Li PC, Bangsberg DR, Fox MP, Prozesky H, Hunt PW, Davies MA, Reynolds SJ, Egger M, Yiannoutsos CT, Vittinghoff EV, Deeks SG, Martin JN. CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. *Int J Epidemiol*. 2015 Feb; 44(1):251-63. PMID: 25859596.
- 2015 Chow FC, Boscardin WJ, Mills C, Ko N, Carroll C, Price RW, Deeks S, Sorond FA, Hsue PY. Cerebral vasoreactivity is impaired in treated, virally suppressed HIV-infected individuals. *AIDS*. 2015 Sep 13. PMID: 26372478.
- 2015 Abdel-Mohsen M, Wang C, Strain MC, Lada SM, Deng X, Cockerham LR, Pilcher CD, Hecht FM, Liegler T, Richman DD, Deeks SG, Pillai SK. Select host restriction factors are associated with HIV persistence during antiretroviral therapy. *AIDS*. 2015 Feb 20; 29(4):411-20. PMID: 25602681.
- 2015 Li L, Deng X, Da Costa AC, Bruhn R, Deeks SG, Delwart E. Virome analysis of antiretroviral-treated HIV patients shows no correlation between T-cell activation and anelloviruses levels. *J Clin Virol*. 2015 Nov; 72:106-13. PMID: 26479202.
- 2015 Brew BJ, Robertson K, Wright EJ, Churchill M, Crowe SM, Cysique LA, Deeks S, Garcia JV, Gelman B, Gray LR, Johnson T, Joseph J, Margolis DM, Mankowski JL, Spencer B. HIV eradication symposium: will the brain be left behind? *J Neurovirol*. 2015 Jun; 21(3):322-34. PMID: 25750070.
- 2015 Elliott JH, McMahon JH, Chang CC, Lee SA, Hartogensis W, Bumpus N, Savic R, Roney J, Hoh R, Solomon A, Piatak M, Gorelick RJ, Lifson J, Bacchetti P, Deeks SG, Lewin SR. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. *Lancet HIV*. 2015 Dec; 2(12):e520-9. PMID: 26614966
- 2015 Tjiam MC, Taylor JP, Morshidi MA, Sariputra L, Burrows S, Martin JN, Deeks SG, Tan DB, Lee S, Fernandez S, French MA. Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification. *J Immunol*. 2015 Jun 1; 194(11):5320-8. PMID: 25911748.
- 2015 Burbelo PD, Klimavicz JS, Deeks SG, Kovacs JA, Ragheb JA. Lack of Evidence for Molecular Mimicry in HIV-Infected Subjects. *PLoS One*. 2015; 10(11):e0127662. PMID: 26599070.

- 2015 Henrich TJ, Hanhauser E, Hu Z, Stellbrink HJ, Noah C, Martin JN, Deeks SG, Kuritzkes DR, Pereyra F. Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ 32. *AIDS*. 2015 May 15; 29(8):867-76. PMID: 25730507.
- 2015 Greene M, Covinsky KE, Valcour V, Miao Y, Madamba J, Lampiris H, Cenzer IS, Martin J, Deeks SG. Geriatric Syndromes in Older HIV-Infected Adults. *J Acquir Immune Defic Syndr*. 2015 Jun 1; 69(2):161-7. PMID: 26009828.
- 2015 Lange DC, Glidden D, Secemsky EA, Ordovas K, Deeks SG, Martin JN, Bolger AF, Hsue PY. Mitral Annular and Coronary Artery Calcification Are Associated with Mortality in HIV-Infected Individuals. *PLoS One*. 2015; 10(7):e0130592. PMID: 26132465.
- 2016 Churchill MJ, Deeks SG, Margolis DM, Siliciano RF, Swanstrom R. HIV reservoirs: what, where and how to target them. *Nat Rev Microbiol*. 2016 Jan; 14(1):55-60. PMID: 26616417
- 2016 Ribeiro SP, Milush JM, Cunha-Neto E, Kallas EG, Kalil J, Passero LFD, Hunt PW, Deeks SG, Nixon DF, SenGupta D. p16INK4a Expression and Immunologic Aging in Chronic HIV Infection. *PLoS One*. 2016; 11(11):e0166759. PMID: 27861555. PMCID: PMC5115792
- 2016 So-Armah KA, Tate JP, Chang CH, Butt AA, Gerschenson M, Gibert CL, Leaf D, Rimland D, Rodriguez-Barradas MC, Budoff MJ, Samet JH, Kuller LH, Deeks SG, Crothers K, Tracy RP, Crane HM, Sajadi MM, Tindle HA, Justice AC, Freiberg MS. Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People? *J Acquir Immune Defic Syndr*. 2016 Jun 1; 72(2):206-213. PMID: 27824677
- 2016 Lee SA, Deeks SG. The Benefits of Early Antiretroviral Therapy for HIV Infection: How Early is Early Enough? *EBioMedicine*. 2016 Sep; 11:7-8. PMID: 27515690. PMCID: PMC5049928
- 2016 Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, Lai J, Strain MC, Lada SM, Hoh R, Ho YC, Richman DD, Deeks SG, Siliciano JD, Siliciano RF. Defective proviruses rapidly accumulate during acute HIV-1 infection. *Nat Med*. 2016 Sep; 22(9):1043-9. PMID: 27500724
- 2016 Delagrèverie HM, Delaugerre C, Lewin SR, Deeks SG, Li JZ. Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. *Open Forum Infect Dis*. 2016 Oct; 3(4):ofw189. PMID: 27757411. PMCID: PMC5066458

- 2016 Boritz EA, Darko S, Swaszek L, Wolf G, Wells D, Wu X, Henry AR, Laboune F, Hu J, Ambrozak D, Hughes MS, Hoh R, Casazza JP, Vostal A, Bunis D, Nganou-Makamdop K, Lee JS, Migueles SA, Koup RA, Connors M, Moir S, Schacker T, Maldarelli F, Hughes SH, Deeks SG, Douek DC. Multiple Origins of Virus Persistence during Natural Control of HIV Infection. *Cell*. 2016 Aug 11; 166(4):1004-15. PMID: 27453467.
- 2016 Nedellec R, Herbeck JT, Hunt PW, Deeks SG, Mullins JI, Anton ED, Reeves JD, Mosier DE. High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia. *AIDS Res Hum Retroviruses*. 2016 Oct 12. PMID: 27604829. PMCID: PMC5333564
- 2016 Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Chun TW, Mann S, Kashuba AD, Siewe B, Albanese A, Troia-Cancio P, Sinclair E, Somasunderam A, Yotter T, Deeks SG, Landay A, Pollard RB, Miller CJ, Moreno S, Asmuth DM. Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. *PLoS Pathog*. 2016 Mar; 12(3):e1005540. PMID: 27015639.
- 2016 Nititham J, Gupta R, Zeng X, Hartogensis W, Nixon DF, Deeks SG, Hecht FM, Liao W. Psoriasis risk SNPs and their association with HIV-1 control. *Hum Immunol*. 2016 Oct 31. PMID: 27810495. PMCID: PMC5253078
- 2016 Wacleche VS, Goulet JP, Gosselin A, Monteiro P, Soudeyns H, Fromentin R, Jenabian MA, Vartanian S, Deeks SG, Chomont N, Routy JP, Ancuta P. New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy. *Retrovirology*. 2016; 13(1):59. PMID: 27553844.
- 2016 Kiniry BE, Ganesh A, Critchfield JW, Hunt PW, Hecht FM, Somsouk M, Deeks SG, Shacklett BL. Predominance of weakly cytotoxic, Tbet(Low)Eomes(Neg) CD8(+) T-cells in human gastrointestinal mucosa: implications for HIV infection. *Mucosal Immunol*. 2016 Nov 09. PMID: 27827375
- 2016 Cockerham LR, Hatano H, Deeks SG. Post-Treatment Controllers: Role in HIV PMID: 26781112
- 2016 Kohanski RA, Deeks SG, Gravekamp C, Halter JB, High K, Hurria A, Fuldner R, Green P, Huebner R, Macchiarini F, Sierra F. Reverse geroscience: how does exposure to early diseases accelerate the age-related decline in health? *Ann N Y Acad Sci*. 2016 Dec; 1386(1):30-44. PMID: 27907230

- 2016 Phillips AN, Cambiano V, Revill P, Nakagawa F, Lundgren JD, Bansi-Matharu L, Mabugu T, Sculpher M, Garnett G, Staprans S, Becker S, Murungu J, Lewin SR, Deeks SG, Hallett TB. Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa. *J Infect Dis.* 2016 Jul 1; 214(1):73-9. PMID: 27034345.
- 2016 Tawakol A, Ishai A, Li D, Takx RA, Hur S, Kaiser Y, Pampaloni M, Rupert A, Hsu D, Sereti I, Fromentin R, Chomont N, Ganz P, Deeks SG, Hsue PY. Association of Arterial and Lymph Node Inflammation With Distinct Inflammatory Pathways in Human Immunodeficiency Virus Infection. *JAMA Cardiol.* 2016 Dec 07. PMID: 27926762. PMCID: PMC5310978
- 2016 Chew GM, Fujita T, Webb GM, Burwitz BJ, Wu HL, Reed JS, Hammond KB, Clayton KL, Ishii N, Abdel-Mohsen M, Liegler T, Mitchell BI, Hecht FM, Ostrowski M, Shikuma CM, Hansen SG, Maurer M, Korman AJ, Deeks SG, Sacha JB, Ndhlovu LC. TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. *PLoS Pathog.* 2016 Jan; 12(1):e1005349. PMID: 26741490.
- 2016 Deeks SG, Odorizzi PM, Sekaly RP. The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure? *J Clin Invest.* 2016 Dec 12. PMID: 27941242. PMCID: PMC5199692
- 2016 Cobos Jiménez V, Wit FW, Joerink M, Maurer I, Harskamp AM, Schouten J, Prins M, van Leeuwen EM, Booiman T, Deeks SG, Reiss P, Kootstra NA. T-Cell Activation Independently Associates With Immune Senescence in HIV-Infected Recipients of Long-term Antiretroviral Treatment. *J Infect Dis.* 2016 Jul 15; 214(2):216-25. PMID: 27073222
- 2016 Sinha A, Ma Y, Scherzer R, Hur S, Li D, Ganz P, Deeks SG, Hsue PY. Role of T-Cell Dysfunction, Inflammation, and Coagulation in Microvascular Disease in HIV. *J Am Heart Assoc.* 2016 Dec 20; 5(12). PMID: 27998918. PMCID: PMC5210441
- 2016 Ramirez CM, Sinclair E, Epling L, Lee SA, Jain V, Hsue PY, Hatano H, Conn D, Hecht FM, Martin JN, Mccune JM, Deeks SG, Hunt PW. Immunologic profiles distinguish aviremic HIV-infected adults. *AIDS.* 2016 Feb 5. PMID: 26854811
- 2016 Ganesh A, Lemongello D, Lee E, Peterson J, McLaughlin BE, Ferre AL, Gillespie GM, Fuchs D, Deeks SG, Hunt PW, Price RW, Spudich SS, Shacklett BL. Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers. *AIDS Res Hum Retroviruses.* 2016 May 2. PMID: 27019338.

- 2016 Parikh RV, Ma Y, Scherzer R, Heringer AS, Macgregor JS, Martin JN, Deeks SG, Ganz P, Hsue PY. Endothelin-1 Predicts Hemodynamically Assessed Pulmonary Arterial Hypertension in HIV Infection. *PLoS One*. 2016; 11(1):e0146355. PMID: 26752193.
- 2016 Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F. International AIDS Society global scientific strategy: towards an HIV cure 2016. *Nat Med*. 2016 Aug; 22(8):839-50. PMID: 27400264
- 2016 Kohli P, Ganz P, Ma Y, Scherzer R, Hur S, Weigel B, Grunfeld C, Deeks S, Wasserman S, Scott R, Hsue PY. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent PMID: 27130349.
- 2016 Fromentin R, Bakeman W, Lawani MB, Khoury G, Hartogensis W, DaFonseca S, Killian M, Epling L, Hoh R, Sinclair E, Hecht FM, Bacchetti P, Deeks SG, Lewin SR, Sékaly RP, Chomont N. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. *PLoS Pathog*. 2016 Jul; 12(7):e1005761. PMID: 27415008.
- 2016 Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Wook-Chun T, Mann S, Kashuba AD, Siewe B, Albanese A, Troia-Cancio P, Sinclair E, Somasunderam A, Yotter T, Deeks SG, Landay A, Pollard RB, Miller CJ, Moreno S, Asmuth DM. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. *PLoS Pathog*. 2016 Jan; 12(1):e1005381. PMID: 26795282.
- 2016 Lee SA, Bacchetti P, Chomont N, Fromentin R, Lewin SR, O'Doherty U, Palmer S, Richman DD, Siliciano JD, Yukl SA, Deeks SG, Burbelo PD. Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy. *PLoS One*. 2016; 11(8):e0160192. PMID: 27483366.
- 2016 Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, Cohen CJ, Phillips A, Lundgren JD, Neaton JD. Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy. *PLoS One*. 2016; 11(5):e0155100. PMID: 27171281.

- 2016 Gach JS, Gorlani A, Dotsey EY, Becerra JC, Anderson CT, Berzins B, Felgner PL, Forthal DN, Deeks SG, Wilkin TJ, Casazza JP, Koup RA, Katlama C, Autran B, Murphy RL, Achenbach CJ. HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. *PLoS One*. 2016; 11(8):e0160341. PMID: 27500639
- 2016 Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, Mugavero MJ, Hernandez-Diaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, Mathews WC, Del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice AC, Tate JP, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hernán MA. When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study. *J Acquir Immune Defic Syndr*. 2016 Jun 1; 72(2):214-21. PMID: 26895294.
- 2016 Hsu DC, Ma YF, Hur S, Li D, Rupert A, Scherzer R, Kalapus SC, Deeks S, Sereti I, Hsue PY. Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy. *AIDS*. 2016 Aug 24; 30(13):2065-74. PMID: 27177313
- 2016 So-Armah KA, Tate JP, Chang CC, Butt AA, Gerschenson M, Gibert CL, Leaf D, Rimland D, Rodriguez-Barradas MC, Budoff MJ, Samet JH, Kuller LH, Deeks SG, Crothers K, Tracy RP, Crane HM, Sajadi MM, Tindle HA, Justice AC, Freiberg MS. Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People? *J Acquir Immune Defic Syndr*. 2016 Jun 1; 72(2):206-13. PMID: 26885807.
- 2016 Abdel-Mohsen M, Chavez L, Tandon R, Chew GM, Deng X, Danesh A, Keating S, Lanteri M, Samuels ML, Hoh R, Sacha JB, Norris PJ, Niki T, Shikuma CM, Hirashima M, Deeks SG, Ndhlovu LC, Pillai SK. Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation. *PLoS Pathog*. 2016 Jun; 12(6):e1005677. PMID: 27253379.
- 2016 Khoury G, Anderson JL, Fromentin R, Hartogenesis W, Smith MZ, Bacchetti P, Hecht FM, Chomont N, Cameron PU, Deeks SG, Lewin SR. Persistence of integrated HIV DNA in CXCR3⁺CCR6⁺memory CD4⁺ T cells in HIV-infected individuals on antiretroviral therapy. *AIDS*. 2016 Jun 19; 30(10):1511-20. PMID: 26807971.

- 2016 Martinez-Picado J, Deeks SG. Persistent HIV-1 replication during antiretroviral therapy. *Curr Opin HIV AIDS*. 2016 Jul; 11(4):417-23. PMID: 27078619
- 2017 Jacobs ES, Keating SM, Abdel-Mohsen M, Gibb SL, Heitman JW, Inglis HC, Martin JN, Zhang J, Kaidarova Z, Deng X, Wu S, Anastos K, Crystal H, Villacres MC, Young M, Greenblatt RM, Landay AL, Gange SJ, Deeks SG, Golub ET, Pillai SK, Norris PJ. Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication in vitro and Modulate HIV Restriction Factor Expression. *J Virol*. 2017 Jan 04. PMID: 28053103. PMCID: PMC5331794
- 2017 Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Wook-Chun T, Mann S, Kashuba AD, Siewe B, Albanese A, Troia-Cancio P, Sinclair E, Somasunderam A, Yotter T, Deeks SG, Landay A, Pollard RB, Miller CJ, Moreno S, Asmuth DM. Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. *PLoS Pathog*. 2017 May; 13(5):e1006368. PMID: 28467485. PMCID: PMC5415081
- 2017 Knox JJ, Buggert M, Kardava L, Seaton KE, Eller MA, Canaday DH, Robb ML, Ostrowski MA, Deeks SG, Slifka MK, Tomaras GD, Moir S, Moody MA, Betts MR. T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response. *JCI Insight*. 2017 Apr 20; 2(8). PMID: 28422752. PMCID: PMC5396521
- 2017 Estes JD, Kityo C, Ssali F, Swainson L, Makamdop KN, Del Prete GQ, Deeks SG, Luciw PA, Chipman JG, Beilman GJ, Hoskuldsson T, Khoruts A, Anderson J, Deleage C, Jasurda J, Schmidt TE, Hafertepe M, Callisto SP, Pearson H, Reimann T, Schuster J, Schoepfoerster J, Southern P, Perkey K, Shang L, Wietgreffe SW, Fletcher CV, Lifson JD, Douek DC, McCune JM, Haase AT, Schacker TW. Defining total-body AIDS-virus burden with implications for curative strategies. *Nat Med*. 2017 Nov; 23(11):1271-1276. PMID: 28967921. PMCID: PMC5831193
- 2017 Khoury G, Fromentin R, Solomon A, Hartogensis W, Killian M, Hoh R, Somsouk M, Hunt PW, Girling V, Sinclair E, Bacchetti P, Anderson JL, Hecht FM, Deeks SG, Cameron PU, Chomont N, Lewin SR. Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy. *J Infect Dis*. 2017 03 15; 215(6):911-919. PMID: 28453847. PMCID: PMC5407052
- 2017 Deeks SG, Lewin SR, Bekker LG. The end of HIV: Still a very long way to go, but progress continues. *PLoS Med*. 2017 Nov; 14(11):e1002466. PMID: 29190733. PMCID: PMC5708775

- 2017 Schlusser KE, Pilcher C, Kallas EG, Santos BR, Deeks SG, Facente S, Keating SM, Busch MP, Murphy G, Welte A, Quinn T, Eshleman SH, Laeyendecker O. Comparison of cross-sectional HIV incidence assay results from dried blood spots and plasma. *PLoS One*. 2017; 12(2):e0172283. PMID: 28231277. PMCID: PMC5322916
- 2017 Angelidou K, Hunt PW, Landay AL, Wilson CC, Rodriguez B, Deeks SG, Bosch RJ, Lederman MM. Changes in inflammation but not in T cell activation precede non-AIDS-defining events in a case-control study of patients on long-term antiretroviral therapy. *J Infect Dis*. 2017 Dec 22. PMID: 29309629
- 2017 Hiener B, Horsburgh BA, Eden JS, Barton K, Schlub TE, Lee E, von Stockenstrom S, Odevall L, Milush JM, Liegler T, Sinclair E, Hoh R, Boritz EA, Douek D, Fromentin R, Chomont N, Deeks SG, Hecht FM, Palmer S. Identification of Genetically Intact HIV-1 Proviruses in Specific CD4+ T Cells from Effectively Treated Participants. *Cell Rep*. 2017 Oct 17; 21(3):813-822. PMID: 29045846
- 2017 Tauriainen J, Scharf L, Frederiksen J, Naji A, Ljunggren HG, Sönnnerborg A, Lund O, Reyes-Terán G, Hecht FM, Deeks SG, Betts MR, Buggert M, Karlsson AC. Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. *Sci Rep*. 2017 Jan 13; 7:40354. PMID: 28084312. PMCID: PMC5233961
- 2017 Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeier CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. *PLoS Med*. 2017 Nov; 14(11):e1002417. PMID: 29112956. PMCID: PMC5675377
- 2017 Henrich TJ, Deeks SG, Pillai SK. Measuring the Size of the Latent Human Immunodeficiency Virus Reservoir: The Present and Future of Evaluating Eradication Strategies. *J Infect Dis*. 2017 Mar 15; 215(suppl_3):S134-S141. PMID: 28520968. PMCID: PMC5410981
- 2017 Kiniry BE, Li S, Ganesh A, Hunt PW, Somsouk M, Skinner PJ, Deeks SG, Shacklett BL. Detection of HIV-1-specific gastrointestinal tissue resident CD8+ T-cells in chronic infection. *Mucosal Immunol*. 2017 Nov 15. PMID: 29139476

- 2017 Vujkovic-Cvijin I, Deeks SG. Mucosal Microbes Mitigate Maladies. *Immunity*. 2017 Jan 17; 46(1):1-3. PMID: 28099858
- 2017 Caniglia EC, Cain LE, Sabin CA, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RD, Reiss P, van Sighem A, Mathews WC, Del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Justice AC, Tate JP, Gill J, Pacheco A, Veloso VG, Bucher HC, Egger M, Furrer H, Porter K, Touloumi G, Crane H, Miro JM, Sterne JA, Costagliola D, Saag M, Hernán MA. Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. *Lancet HIV*. 2017 Jun; 4(6):e251-e259. PMID: 28411091. PMCID: PMC5492888
- 2017 Charlins P, Schmitt K, Remling-Mulder L, Hogan LE, Hanhauser E, Hobbs KS, Hecht F, Deeks SG, Henrich TJ, Akkina R. A humanized mouse-based HIV-1 viral outgrowth assay with higher sensitivity than in vitro qVOA in detecting latently infected cells from individuals on ART with undetectable viral loads. *Virology*. 2017 Jul; 507:135-139. PMID: 28432928
- 2017 Ribeiro SP, Milush JM, Cunha-Neto E, Kallas EG, Kalil J, Passero LFD, Hunt PW, Deeks SG, Nixon DF, SenGupta D. Correction: p16INK4a Expression and Immunologic Aging in Chronic HIV Infection. *PLoS One*. 2017; 12(4):e0176509. PMID: 28426830. PMCID: PMC5398691
- 2017 Rutishauser RL, Hartogensis W, Deguit CD, Krone M, Hoh R, Hecht FM, Pilcher CD, Bacchetti P, Deeks SG, Hunt PW, McCune JM. Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression. *AIDS Res Hum Retroviruses*. 2017 Jul; 33(7):658-667. PMID: 28335609. PMCID: PMC5512309
- 2017 Yucha RW, Hobbs KS, Hanhauser E, Hogan LE, Nieves W, Ozen MO, Inci F, York V, Gibson EA, Thanh C, Shafiee H, El Assal R, Kiselinova M, Robles YP, Bae H, Leadabrand KS, Wang S, Deeks SG, Kuritzkes DR, Demirci U, Henrich TJ. High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay. *EBioMedicine*. 2017 Jun; 20:217-229. PMID: 28529033. PMCID: PMC5478213
- 2017 Boehm D, Jeng M, Camus G, Gramatica A, Schwarzer R, Johnson JR, Hull PA, Montano M, Sakane N, Pagans S, Godin R, Deeks SG, Krogan NJ, Greene WC, Ott M. SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency. *Cell Host Microbe*. 2017 May 10; 21(5):569-579.e6. PMID: 28494238. PMCID: PMC5490666

- 2017 Pillai SK, Deeks SG. Signature of the Sleeper Cell: A Biomarker of HIV Latency Revealed. *Trends Immunol.* 2017 Jul; 38(7):457-458. PMID: 28511815
- 2017 Tjiam MC, Morshidi MA, Sariputra L, Martin JN, Deeks SG, Tan D, Lee S, Fernandez S, French MA. The association of HIV-1 Gag-specific IgG antibodies with natural control of HIV-1 infection in individuals not carrying HLA-B*57: 01 is only observed in viremic controllers. *J Acquir Immune Defic Syndr.* 2017 Jun 09. PMID: 28604502. PMCID: PMC5634911
- 2017 Burbelo PD, Gunti S, Keller JM, Morse CG, Deeks SG, Lionakis MS, Kapoor A, Li Q, Cohen JI, Notkins AL, Alevizos I. Ultrarapid Measurement of Diagnostic Antibodies by Magnetic Capture of Immune Complexes. *Sci Rep.* 2017 Jun 19; 7(1):3818. PMID: 28630417. PMCID: PMC5476601
- 2017 Buranapraditkun S, Pissani F, Teigler JE, Schultz BT, Alter G, Marovich M, Robb ML, Eller MA, Martin J, Deeks S, Michael NL, Streeck H. Preservation of Peripheral T Follicular Helper Cell Function in HIV Controllers. *J Virol.* 2017 Jul 15; 91(14). PMID: 28468877. PMCID: PMC5487582
- 2017 Phan BAP, Weigel B, Ma Y, Scherzer R, Li D, Hur S, Kalapus SC, Deeks S, Hsue P. Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis. *Circ Cardiovasc Imaging.* 2017 Jul; 10(7). PMID: 28674084. PMCID: PMC5516666
- 2017 Keating SM, Pilcher CD, Jain V, Lebedeva M, Hampton D, Abdel-Mohsen M, Deng X, Murphy G, Welte A, Facente SN, Hecht F, Deeks SG, Pillai SK, Busch MP. HIV Antibody Level as a Marker of HIV Persistence and Low-Level Viral Replication. *J Infect Dis.* 2017 Jul 01; 216(1):72-81. PMID: 28498985
- 2017 Cockerham LR, Yukl SA, Harvill K, Somsouk M, Joshi SK, Sinclair E, Liegler T, Hoh R, Lyons S, Hunt PW, Rupert A, Sereti I, Morcock DR, Rhodes A, Emson C, Hellerstein MK, Estes JD, Lewin S, Deeks SG, Hatano H. A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals. *Pathog Immun.* 2017; 2(3):310-334. PMID: 28936485. PMCID: PMC5604865
- 2017 Booiman T, Wit FW, Girigorie AF, Maurer I, De Francesco D, Sabin CA, Harskamp AM, Prins M, Franceschi C, Deeks SG, Winston A, Reiss P, Kootstra NA. Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls. *PLoS One.* 2017; 12(8):e0183357. PMID: 28806406. PMCID: PMC5555623

- 2017 de Mulder M, SenGupta D, Deeks SG, Martin JN, Pilcher CD, Hecht FM, Sacha JB, Nixon DF, Michaud HA. Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers. *Retrovirology*. 2017 Aug 22; 14(1):41. PMID: 28830571. PMCID: PMC5568399
- 2017 Leitman EM, Willberg CB, Tsai MH, Chen H, Buus S, Chen F, Riddell L, Haas D, Fellay J, Goedert JJ, Piechocka-Trocha A, Walker BD, Martin J, Deeks S, Wolinsky SM, Martinson J, Martin M, Qi Y, Sáez-Cirión A, Yang OO, Matthews PC, Carrington M, Goulder PJR. HLA-B*14:02-RESTRICTED ENV-SPECIFIC CD8+ T-CELL ACTIVITY HAS HIGHLY POTENT ANTIVIRAL EFFICACY ASSOCIATED WITH IMMUNE CONTROL OF HIV INFECTION. *J Virol*. 2017 Sep 06. PMID: 28878089. PMCID: PMC5660483
- 2017 Trapecar M, Khan S, Roan N, Chen TH, Telwatte S, Deswal M, Pao M, Somsouk M, Deeks SG, Hunt PW, Yukl S, Sanjabi S. An Optimized and Validated Method for Isolation and Characterization of Lymphocytes from HIV+ Human Gut Biopsies. *AIDS Res Hum Retroviruses*. 2017 Sep 07. PMID: 28882052. PMCID: PMC5684666
- 2017 Teigler JE, Zelinskyy G, Eller MA, Bolton DL, Marovich M, Gordon AD, Alrubayyi A, Alter G, Robb ML, Martin JN, Deeks SG, Michael NL, Dittmer U, Streeck H. Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection. *J Virol*. 2017 Sep 13. PMID: 28904197. PMCID: PMC5686724
- 2018 Hogan LE, Vasquez J, Hobbs KS, Hanhauser E, Aguilar-Rodriguez B, Hussien R, Thanh C, Gibson EA, Carvidi AB, Smith LCB, Khan S, Trapecar M, Sanjabi S, Somsouk M, Stoddart CA, Kuritzkes DR, Deeks SG, Henrich TJ. Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. *PLoS Pathog*. 2018 Feb; 14(2):e1006856. PMID: 29470552. PMCID: PMC5823470
- 2018 Scully EP, Rutishauser RL, Simoneau CR, Delagrèverie H, Euler Z, Thanh C, Li JZ, Hartig H, Bakkour S, Busch M, Alter G, Marty FM, Wang CC, Deeks SG, Lorch J, Henrich TJ. Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. *Ann Oncol*. 2018 Oct 01; 29(10):2141-2142. PMID: 30032204. PMCID: PMC6225895
- 2018 Scully EP, Gandhi M, Johnston R, Hoh R, Lockhart A, Dobrowolski C, Pagliuzza A, Milush JM, Baker CA, Girling V, Ellefson A, Gorelick R, Lifson J, Altfeld M, Alter G, Cedars M, Solomon A, Lewin SR, Karn J, Chomont N, Bacchetti P, Deeks SG. Sex-Based Differences in HIV-1 Reservoir Activity and Residual Immune Activation. *J Infect Dis*. 2018 Oct 29. PMID: 30371873

- 2018 Lee SA, Elliott JH, McMahon J, Hartogenesis W, Bumpus NN, Lifson JD, Gorelick RJ, Bacchetti P, Deeks SG, Lewin SR, Savic RM. Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase 2b Trial. *Clin Pharmacol Ther.* 2018 Aug 23. PMID: 30137649
- 2018 Goulder P, Deeks SG. HIV control: Is getting there the same as staying there? *PLoS Pathog.* 2018 Nov; 14(11):e1007222. PMID: 30383857. PMCID: PMC6211749
- 2018 Brown R, Deeks SG, Eyal N. Maximising the global health impact of future HIV cure-related interventions through advance planning. *J Virus Erad.* 2018 Jul 01; 4(3):182-185. PMID: 30050682. PMCID: PMC6038126
- 2018 Telwatte S, Lee S, Somsouk M, Hatano H, Baker C, Kaiser P, Kim P, Chen TH, Milush J, Hunt PW, Deeks SG, Wong JK, Yukl SA. Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency. *PLoS Pathog.* 2018 Nov; 14(11):e1007357. PMID: 30440043. PMCID: PMC6237391
- 2018 Narla V, Bhakta N, Freedman JE, Tanriverdi K, Maka K, Deeks SG, Ganz P, Hsue P. Unique Circulating MicroRNA profiles in HIV Infection. *J Acquir Immune Defic Syndr.* 2018 Sep 04. PMID: 30204717
- 2018 Hsue PY, Li D, Ma Y, Ishai A, Manion M, Nahrendorf M, Ganz P, Ridker PM, Deeks SG, Tawakol A. IL-1 β Inhibition Reduces Atherosclerotic Inflammation in HIV Infection. *J Am Coll Cardiol.* 2018 Dec 04; 72(22):2809-2811. PMID: 30497570
- 2018 Kiniry BE, Hunt PW, Hecht FM, Somsouk M, Deeks SG, Shacklett BL. Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 Infection. *J Immunol.* 2018 Mar 01; 200(5):1876-1888. PMID: 29352005. PMCID: PMC5821568
- 2018 Wang CC, Thanh C, Gibson EA, Ball-Burack M, Hogan LE, Descours B, Jones N, Carvidi AB, Munter S, Bakkour S, Busch MP, Milush JM, Deeks SG, Henrich TJ. Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. *Blood Adv.* 2018 Dec 11; 2(23):3479-3482. PMID: 30530753. PMCID: PMC6290106

- 2018 Hsue PY, Ribaldo HJ, Deeks SG, Bell T, Ridker PM, Fichtenbaum C, Daar ES, Havlir D, Yeh E, Tawakol A, Lederman M, Currier JS, Stein JH. Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. *Clin Infect Dis*. 2018 Sep 14. PMID: 30219823
- 2018 Chang CC, Naranbhai V, Stern J, Roche M, Dantanarayana A, Ke R, Tennakoon S, Solomon A, Hoh R, Hartogensis W, Hecht FM, Sikaris K, Price DJ, Elliott JH, Deeks SG, Churchill M, Cameron PU, Hengartner N, Perelson AS, Lewin SR. Variation in cell associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator BMAL-1. *AIDS*. 2018 Jul 12. PMID: 30005017
- 2018 Carrico AW, Hunt PW, Neilands TB, Dilworth SE, Martin JN, Deeks SG, Riley ED. Stimulant Use and Viral Suppression In the Era of Universal Antiretroviral Therapy. *J Acquir Immune Defic Syndr*. 2018 Sep 21. PMID: 30272634
- 2018 Ramsuran V, Naranbhai V, Horowitz A, Qi Y, Martin MP, Yuki Y, Gao X, Walker-Sperling V, Del Prete GQ, Schneider DK, Lifson JD, Fellay J, Deeks SG, Martin JN, Goedert JJ, Wolinsky SM, Michael NL, Kirk GD, Buchbinder S, Haas D, Ndung'u T, Goulder P, Parham P, Walker BD, Carlson JM, Carrington M. Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. *Science*. 2018 01 05; 359(6371):86-90. PMID: 29302013. PMCID: PMC5933048
- 2018 Eyal N, Holtzman LG, Deeks SG. Ethical issues in HIV remission trials. *Curr Opin HIV AIDS*. 2018 Jul 14. PMID: 30015634
- 2018 Buggert M, Nguyen S, McLane LM, Steblyanko M, Anikeeva N, Paquin-Proulx D, Del Rio Estrada PM, Ablanedo-Terrazas Y, Noyan K, Reuter MA, Demers K, Sandberg JK, Eller MA, Streeck H, Jansson M, Nowak P, Sönnnerborg A, Canaday DH, Naji A, Wherry EJ, Robb ML, Deeks SG, Reyes-Teran G, Sykulev Y, Karlsson AC, Betts MR. Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease. *PLoS Pathog*. 2018 Apr; 14(4):e1006973. PMID: 29652923. PMCID: PMC5919077
- 2018 Das B, Dobrowolski C, Luttge B, Valadkhan S, Chomont N, Johnston R, Bacchetti P, Hoh R, Gandhi M, Deeks SG, Scully E, Karn J. Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. *Proc Natl Acad Sci U S A*. 2018 Jul 30. PMID: 30061382. PMCID: PMC6099847

- 2018 Ferdin J, Goricar K, Dolan V, Plemenitaš A, Martin JN, Peterlin BM, Deeks SG, Lenassi M. Viral protein Nef is detected in plasma of half of HIV-infected adults with undetectable plasma HIV RNA. *PLoS One*. 2018; 13(1):e0191613. PMID: 29364927. PMCID: PMC5783402
- 2018 Namazi G, Fajnzylber JM, Aga E, Bosch R, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith D, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks S, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ. The Control of HIV after Antiretroviral Medication Pause (CHAMP) study: post-treatment controllers identified from 14 clinical studies. *J Infect Dis*. 2018 Aug 06. PMID: 30085241
- 2018 Battivelli E, Dahabieh MS, Abdel-Mohsen M, Svensson JP, Tojal Da Silva I, Cohn LB, Gramatica A, Deeks S, Greene WC, Pillai SK, Verdin E. Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T Cells. *Elife*. 2018 May 01; 7. PMID: 29714165. PMCID: PMC5973828
- 2018 Adland E, Hill M, Lavandier N, Csala A, Edwards A, Chen F, Radkowski M, Kowalska JD, Paraskevis D, Hatzakis A, Valenzuela-Ponce H, Pfafferott K, Williams I, Pellegrino P, Borrow P, Mori M, Rockstroh J, Prado JG, Mothe B, Dalmau J, Martinez-Picado J, Tudor-Williams G, Frater J, Stryhn A, Buus S, Teran GR, Mallal S, John M, Buchbinder S, Kirk G, Martin J, Michael N, Fellay J, Deeks S, Walker B, Avila-Rios S, Cole D, Brander C, Carrington M, Goulder P. Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. *J Virol*. 2018 02 15; 92(4). PMID: 29167337. PMCID: PMC5790925
- 2018 Hecht FM, Moskowitz JT, Moran P, Epel ES, Bacchetti P, Acree M, Kemeny ME, Mendes WB, Duncan LG, Weng H, Levy JA, Deeks SG, Folkman S. A Randomized, Controlled Trial of Mindfulness-Based Stress Reduction in HIV Infection. *Brain Behav Immun*. 2018 May 26. PMID: 29842903
- 2018 Chitre AS, Kattah MG, Rosli YY, Pao M, Deswal M, Deeks SG, Hunt PW, Abdel-Mohsen M, Montaner LJ, Kim CC, Ma A, Somsouk M, McCune JM. A20 upregulation during treated HIV disease is associated with intestinal epithelial cell recovery and function. *PLoS Pathog*. 2018 Mar; 14(3):e1006806. PMID: 29505600. PMCID: PMC5854440

- 2018 Buggert M, Nguyen S, Salgado-Montes de Oca G, Bengsch B, Darko S, Ransier A, Roberts ER, Del Alcazar D, Brody IB, Vella LA, Beura L, Wijeyesinghe S, Herati RS, Del Rio Estrada PM, Ablanado-Terrazas Y, Kuri-Cervantes L, Sada Japp A, Manne S, Vartanian S, Huffman A, Sandberg JK, Gostick E, Nadolski G, Silvestri G, Canaday DH, Price DA, Petrovas C, Su LF, Vahedi G, Dori Y, Frank I, Itkin MG, Wherry EJ, Deeks SG, Naji A, Reyes-Terán G, Masopust D, Douek DC, Betts MR. Identification and characterization of HIV-specific resident memory CD8+ T cells in human lymphoid tissue. *Sci Immunol*. 2018 Jun 01; 3(24). PMID: 29858286
- 2018 Burbelo PD, Price RW, Hagberg L, Hatano H, Spudich S, Deeks SG, Gisslén M. Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir? *J Infect Dis*. 2018 Mar 13; 217(7):1024-1032. PMID: 29401308
- 2018 Lidofsky A, Holmes JA, Feeney ER, Kruger AJ, Salloum S, Zheng H, Seguin IS, Altinbas A, Masia R, Corey KE, Gustafson JL, Schaefer EA, Hunt PW, Deeks S, Somsouk M, Chew KW, Chung RT, Alatrakchi N. Macrophage Activation Marker Soluble CD163 is a Dynamic Marker of Liver Fibrogenesis in HIV/HCV Coinfection. *J Infect Dis*. 2018 Jun 04. PMID: 29868909
- 2018 Martin MP, Naranbhai V, Shea PR, Qi Y, Ramsuran V, Vince N, Gao X, Thomas R, Brumme ZL, Carlson JM, Wolinsky SM, Goedert JJ, Walker BD, Segal FP, Deeks SG, Haas DW, Migueles SA, Connors M, Michael N, Fellay J, Gostick E, Llewellyn-Lacey S, Price DA, Lafont BA, Pymm P, Saunders PM, Widjaja J, Wong SC, Vivian JP, Rossjohn J, Brooks AG, Carrington M. Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. *J Clin Invest*. 2018 Apr 03. PMID: 29461980
- 2019 Li Z, Wu J, Chavez L, Hoh R, Deeks SG, Pillai SK, Zhou Q. Reiterative Enrichment and Authentication of CRISPRi Targets (REACT) identifies the proteasome as a key contributor to HIV-1 latency. *PLoS Pathog*. 2019 01; 15(1):e1007498. PMID: 30645648. PMCID: PMC6333332
- 2019 Bacchetti P, Bosch RJ, Scully EP, Deng X, Busch MP, Deeks SG, Lewin SR. Statistical analysis of single-copy assays when some observations are zero. *J Virus Erad*. 2019 Sep 18; 5(3):167-173. PMID: 31700666
- 2019 Bacchetti P, Bosch RJ, Scully EP, Deng X, Busch MP, Deeks SG, Lewin SR. Statistical analysis of single-copy assays when some observations are zero. *J Virus Erad*. 2019 Sep 18; 5(3):167-173. PMID: 31700665

- 2019 Xu Y, Trumble IM, Warren JA, Clutton G, Abad-Fernandez M, Kirchnerr J, Adimora AA, Deeks SG, Margolis DM, Kuruc JD, Gay CL, Archin NM, Mollan KR, Hudgens M, Goonetilleke N. HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral Therapy. *Mol Ther Methods Clin Dev.* 2019 Dec 13; 15:9-17. PMID: 31534983. PMCID: PMC6745511
- 2019 Lee E, Bacchetti P, Milush J, Shao W, Boritz E, Douek D, Fromentin R, Liegler T, Hoh R, Deeks SG, Hecht FM, Chomont N, Palmer S. Memory CD4 + T-Cells Expressing HLA-DR Contribute to HIV Persistence During Prolonged Antiretroviral Therapy. *Front Microbiol.* 2019; 10:2214. PMID: 31611857. PMCID: PMC6775493
- 2019 Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, Fray EJ, Beg SA, Antar AAR, Jenike KM, Bertagnolli LN, Capoferri AA, Kufera JT, Timmons A, Nobles C, Gregg J, Wada N, Ho YC, Zhang H, Margolick JB, Blankson JN, Deeks SG, Bushman FD, Siliciano JD, Laird GM, Siliciano RF. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. *Nature.* 2019 02; 566(7742):120-125. PMID: 30700913. PMCID: PMC6447073
- 2019 Deguit CDT, Hough M, Hoh R, Krone M, Pilcher CD, Martin JN, Deeks SG, McCune JM, Hunt PW, Rutishauser RL. Some Aspects of CD8+ T Cell Exhaustion are Associated with Altered T Cell Mitochondrial Features and ROS content in HIV Infection. *J Acquir Immune Defic Syndr.* 2019 Oct 03. PMID: 31592837
- 2019 Pohlmeier CW, Gonzalez VD, Irrinki A, Ramirez RN, Li L, Mulato A, Murry JP, Arvey A, Hoh R, Deeks SG, Kukulj G, Cihlar T, Pflanz S, Nolan GP, Min-Oo G. Identification of NK cell subpopulations that differentiate HIV-infected subject cohorts with diverse level of virus control. *J Virol.* 2019 Jan 30. PMID: 30700608. PMCID: PMC6430550
- 2019 Hsu DC, Ma YF, Narwan A, Rahalkar S, Rupert A, Scherzer R, Mills C, Deeks S, Sereti I, Hsue PY. Plasma tissue factor and immune activation are associated with carotid intima-media thickness progression in treated HIV infection. *AIDS.* 2019 Oct 10. PMID: 31634197

- 2019 Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søggaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. *Lancet HIV*. 2019 Apr; 6(4):e259-e268. PMID: 30885693. PMCID: PMC6688772
- 2019 Wonderlich ER, Subramanian K, Cox B, Wiegand A, Lackman-Smith C, Bale MJ, Stone M, Hoh R, Kearney MF, Maldarelli F, Deeks SG, Busch MP, Ptak RG, Kulpa DA. Effector memory differentiation increases detection of replication-competent HIV-1 in resting CD4+ T cells from virally suppressed individuals. *PLoS Pathog*. 2019 Oct; 15(10):e1008074. PMID: 31609991. PMCID: PMC6812841
- 2019 Fromentin R, DaFonseca S, Costiniuk CT, El-Far M, Procopio FA, Hecht FM, Hoh R, Deeks SG, Hazuda DJ, Lewin SR, Routy JP, Sékaly RP, Chomont N. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals. *Nat Commun*. 2019 02 18; 10(1):814. PMID: 30778080. PMCID: PMC6379401
- 2019 Herzig E, Kim KC, Packard TA, Vardi N, Schwarzer R, Gramatica A, Deeks SG, Williams SR, Landgraf K, Killeen N, Martin DW, Weinberger LS, Greene WC. Attacking Latent HIV with convertible CAR-T Cells, a Highly Adaptable Killing Platform. *Cell*. 2019 Oct 31; 179(4):880-894.e10. PMID: 31668804. PMCID: PMC6922308
- 2019 Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage Iii GR, Bonnet F, Le Marec F, Moore RD, Reiss P, van Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA. Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. *Stat Med*. 2019 Jun 15; 38(13):2428-2446. PMID: 30883859. PMCID: PMC6499640

- 2019 Kulkarni S, Lied A, Kulkarni V, Rucevic M, Martin MP, Walker-Sperling V, Anderson SK, Ewy R, Singh S, Nguyen H, McLaren PJ, Viard M, Naranbhai V, Zou C, Lin Z, Gatanaga H, Oka S, Takiguchi M, Thio CL, Margolick J, Kirk GD, Goedert JJ, Hoots WK, Deeks SG, Haas DW, Michael N, Walker B, Le Gall S, Chowdhury FZ, Yu XG, Carrington M. Author Correction: CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome. *Nat Immunol.* 2019 Nov; 20(11):1555. PMID: 31548709
- 2019 Gonzalo-Gil E, Rapuano PB, Ikediobi U, Leibowitz R, Mehta S, Coskun AK, Porterfield JZ, Lampkin TD, Marconi VC, Rimland D, Walker BD, Deeks S, Sutton RE. Transcriptional down-regulation of *ccr5* in a subset of HIV+ controllers and their family members. *Elife.* 2019 Apr 09; 8. PMID: 30964004. PMCID: PMC6456299
- 2019 Prator CA, Thanh C, Kumar S, Pan T, Peluso MJ, Bosch R, Jones N, Milush JM, Bakkour S, Stone M, Busch MP, Deeks SG, Hunt PW, Henrich TJ. Circulating CD30+ CD4+ T Cells Increase Prior to HIV Rebound Following Analytical Antiretroviral Treatment Interruption. *J Infect Dis.* 2019 Nov 02. PMID: 31677350
- 2019 Peluso MJ, Deeks SG, McCune JM. HIV PMID: 30982768. PMCID: PMC6491910
- 2019 Kulpa DA, Talla A, Brehm JH, Ribeiro SP, Yuan S, Bebin-Blackwell AG, Miller M, Barnard R, Deeks SG, Hazuda D, Chomont N, Sékaly RP. Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4+ T Cells. *J Virol.* 2019 Dec 15; 93(24). PMID: 31578289. PMCID: PMC6880164
- 2019 Rosenbloom DIS, Bacchetti P, Stone M, Deng X, Bosch RJ, Richman DD, Siliciano JD, Mellors JW, Deeks SG, Ptak RG, Hoh R, Keating SM, Dimapasoc M, Massanella M, Lai J, Sobolewski MD, Kulpa DA, Busch MP. Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size. *PLoS Comput Biol.* 2019 04; 15(4):e1006849. PMID: 30978183. PMCID: PMC6481870
- 2019 Patro SC, Brandt LD, Bale MJ, Halvas EK, Joseph KW, Shao W, Wu X, Guo S, Murrell B, Wiegand A, Spindler J, Raley C, Hautman C, Sobolewski M, Fennessey CM, Hu WS, Luke B, Hasson JM, Niyongabo A, Capoferri AA, Keele BF, Milush J, Hoh R, Deeks SG, Maldarelli F, Hughes SH, Coffin JM, Rausch JW, Mellors JW, Kearney MF. Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors. *Proc Natl Acad Sci U S A.* 2019 Nov 27. PMID: 31776247. PMCID: PMC6925994

- 2019 Vásquez JJ, Aguilar-Rodriguez BL, Rodriguez L, Hogan LE, Somsouk M, McCune JM, Deeks SG, Laszik ZG, Hunt PW, Henrich TJ. CD32-RNA Co-localizes with HIV-RNA in CD3+ Cells Found within Gut Tissues from Viremic and ART-Suppressed Individuals. *Pathog Immun.* 2019; 4(1):147-160. PMID: 31139759. PMCID: PMC6508427
- 2019 Anderson JL, Khoury G, Fromentin R, Solomon A, Chomont N, Sinclair E, Milush JM, Hartogensis W, Bacchetti P, Roche M, Tumpach C, Gartner M, Pitman MC, Epling CL, Hoh R, Hecht FM, Somsouk M, Cameron PU, Deeks SG, Lewin SR. Human Immunodeficiency Virus (HIV)-Infected CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral Therapy. *J Infect Dis.* 2019 Dec 04. PMID: 31796951
- 2019 Sinha A, Ma Y, Scherzer R, Rahalkar S, Neilan BD, Crane H, Drozd D, Martin J, Deeks SG, Hunt P, Hsue PY. Carnitine Is Associated With Atherosclerotic Risk and Myocardial Infarction in HIV -Infected Adults. *J Am Heart Assoc.* 2019 May 07; 8(9):e011037. PMID: 31030595. PMCID: PMC6512101
- 2019 Ndung'u T, McCune JM, Deeks SG. Why and where an HIV cure is needed and how it might be achieved. *Nature.* 2019 12; 576(7787):397-405. PMID: 31853080
- 2019 Hutchinson JM, Mesa KA, Alexander DL, Yu B, O'Rourke SM, Limoli KL, Wrin T, Deeks SG, Berman PW. Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies. *Front Immunol.* 2019; 10:1021. PMID: 31156622. PMCID: PMC6530427
- 2019 Nguyen S, Deleage C, Darko S, Ransier A, Truong DP, Agarwal D, Japp AS, Wu VH, Kuri-Cervantes L, Abdel-Mohsen M, Del Rio Estrada PM, Ablanedo-Terrazas Y, Gostick E, Hoxie JA, Zhang NR, Naji A, Reyes-Terán G, Estes JD, Price DA, Douek DC, Deeks SG, Buggert M, Betts MR. Elite control of HIV is associated with distinct functional and transcriptional signatures in lymphoid tissue CD8+ T cells. *Sci Transl Med.* 2019 Dec 18; 11(523). PMID: 31852798
- 2019 Paim AC, Cummins NW, Natesampillai S, Garcia-Rivera E, Kogan N, Neogi U, Sönnnerborg A, Sperk M, Bren GD, Deeks S, Polley E, Badley AD. HIV elite control is associated with reduced TRAILshort expression. *AIDS.* 2019 May 29. PMID: 31149947
- 2019 Roche M, Tumpach C, Symons J, Gartner M, Anderson JL, Khoury G, Cashin K, Cameron PU, Churchill MJ, Deeks SG, Gorry PR, Lewin SR. CXCR4-using HIV strains predominate in naïve and central memory CD4+ T cells in people living with HIV on antiretroviral therapy: implications for how latency is established and maintained. *J Virol.* 2019 Dec 18. PMID: 31852784

- 2019 Kulkarni S, Lied A, Kulkarni V, Rucevic M, Martin MP, Walker-Sperling V, Anderson SK, Ewy R, Singh S, Nguyen H, McLaren PJ, Viard M, Naranbhai V, Zou C, Lin Z, Gatanaga H, Oka S, Takiguchi M, Thio CL, Margolick J, Kirk GD, Goedert JJ, Hoots WK, Deeks SG, Haas DW, Michael N, Walker B, Le Gall S, Chowdhury FZ, Yu XG, Carrington M. CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome. *Nat Immunol*. 2019 07; 20(7):824-834. PMID: 31209403. PMCID: PMC6584055
- 2019 Eyal N, Deeks SG. Risk to Nonparticipants in HIV Remission Studies With Treatment Interruption: A Symposium. *J Infect Dis*. 2019 Jul 02; 220(Supplement_1):S1-S4. PMID: 31264687. PMCID: PMC6603969
- 2019 Margolis DM, Deeks SG. How Unavoidable Are Analytical Treatment Interruptions in HIV Cure-Related Studies? *J Infect Dis*. 2019 Jul 02; 220(Supplement_1):S24-S26. PMID: 31264691. PMCID: PMC6636248
- 2019 McManus WR, Bale MJ, Spindler J, Wiegand A, Musick A, Patro SC, Sobolewski MD, Musick VK, Anderson EM, Cyktor JC, Halvas EK, Shao W, Wells D, Wu X, Keele BF, Milush JM, Hoh R, Mellors JW, Hughes SH, Deeks SG, Coffin JM, Kearney MF. HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy. *J Clin Invest*. 2019 Jul 30; 130. PMID: 31361603
- 2019 Deguit CDT, Hough M, Hoh R, Krone M, Pilcher CD, Martin JN, Deeks SG, McCune JM, Hunt PW, Rutishauser RL. Some Aspects of CD8+ T-Cell Exhaustion Are Associated With Altered T-Cell Mitochondrial Features and ROS Content in HIV Infection. *J Acquir Immune Defic Syndr*. 2019 Oct 01; 82(2):211-219. PMID: 31513075. PMCID: PMC6746248
- 2020 Horsburgh BA, Lee E, Hiener B, Eden JS, Schlub TE, von Stockenstrom S, Odeval L, Milush JM, Liegler T, Sinclair E, Hoh R, Boritz EA, Douek DC, Fromentin R, Chomont N, Deeks SG, Hecht FM, Palmer S. High levels of genetically-intact HIV in HLA-DR+ memory T-cells indicates their value for reservoir studies. *AIDS*. 2020 Jan 06. PMID: 31913161
- 2020 Schnittman SR, Deitchman AN, Beck-Engeser G, Ahn H, York VA, Hartig H, Hecht FM, Martin JN, Deeks SG, Aweeka FT, Hunt PW. Some But Not All Biomarkers of Immune Activation Remain Abnormal Despite Very Early Treatment of HIV. *J Infect Dis*. 2020 Sep 11. PMID: 32915986
- 2020 Gabuzda D, Jamieson BD, Collman RG, Lederman MM, Burdo TH, Deeks SG, Dittmer DP, Fox HS, Funderburg NT, Pahwa SG, Pandrea I, Wilson CC, Hunt PW. Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop. *Pathog Immun*. 2020; 5(1):143-174. PMID: 32856008. PMCID: PMC7449259

- 2020 Neidleman J, Luo X, Frouard J, Xie G, Hsiao F, Ma T, Morcilla V, Lee A, Telwatte S, Thomas R, Tamaki W, Wheeler B, Hoh R, Somsouk M, Vohra P, Milush J, James KS, Archin NM, Hunt PW, Deeks SG, Yukl SA, Palmer S, Greene WC, Roan NR. Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir. *Elife*. 2020 09 29; 9. PMID: 32990219. PMCID: PMC7524554
- 2020 Paiardini M, Dhodapkar K, Harper J, Deeks SG, Ahmed R. Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches. *Front Immunol*. 2020; 11:519. PMID: 32296432. PMCID: PMC7138010
- 2020 McLaughlin MM, Ma Y, Scherzer R, Rahalkar S, Martin JN, Mills C, Milush J, Deeks SG, Hsue PY. Association of Viral Persistence and Atherosclerosis in Adults With Treated HIV Infection. *JAMA Netw Open*. 2020 10 01; 3(10):e2018099. PMID: 33119103. PMCID: PMC7596582
- 2020 Simonetti FR, White JA, Tumiotto C, Ritter KD, Cai M, Gandhi RT, Deeks SG, Howell BJ, Montaner LJ, Blankson JN, Martin A, Laird GM, Siliciano RF, Mellors JW, Siliciano JD. Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. *Proc Natl Acad Sci U S A*. 2020 Jul 20. PMID: 32690683. PMCID: PMC7414172
- 2020 Das J, Devadhasan A, Linde C, Broge T, Sassic J, Mangano M, O'Keefe S, Suscovich T, Streeck H, Irrinki A, Pohlmeier C, Min-Oo G, Lin S, Weiner JA, Cihlar T, Ackerman ME, Julg B, Deeks S, Lauffenburger DA, Alter G. Mining for humoral correlates of HIV control and latent reservoir size. *PLoS Pathog*. 2020 10; 16(10):e1008868. PMID: 33048992. PMCID: PMC7553335
- 2020 Peluso MJ, Thanh C, Prator CA, Hogan LE, Arechiga VM, Stephenson S, Norris PJ, Di Germanio C, Fuchs D, Zetterberg H, Deeks SG, Gisslén M, Price RW, Henrich TJ. Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. *J Virus Erad*. 2020 Feb 20; 6(1):19-26. PMID: 32175087. PMCID: PMC7043898
- 2020 Bashirova AA, Viard M, Naranbhai V, Grifoni A, Garcia-Beltran W, Akdag M, Yuki Y, Gao X, O'hUigin C, Raghavan M, Wolinsky S, Bream JH, Duggal P, Martinson J, Michael NL, Kirk GD, Buchbinder SP, Haas D, Goedert JJ, Deeks SG, Fellay J, Walker B, Goulder P, Cresswell P, Elliott T, Sette A, Carlson J, Carrington M. HLA tapasin independence: broader peptide repertoire and HIV control. *Proc Natl Acad Sci U S A*. 2020 11 10; 117(45):28232-28238. PMID: 33097667. PMCID: PMC7668082

- 2020 Henrich TJ, Schreiner C, Cameron C, Hogan LE, Richardson B, Rutishauser RL, Deitchman AN, Chu S, Rogers R, Thanh C, Gibson EA, Zarinsefat A, Bakkour S, Aweeka F, Busch MP, Liegler T, Baker C, Milush J, Deeks SG, Stock PG. Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study. *Am J Transplant*. 2020 Aug 11. PMID: 32780519
- 2020 Telwatte S, Kim P, Chen TH, Milush JM, Somsouk M, Deeks SG, Hunt PW, Wong JK, Yukl SA. Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents. *AIDS*. 2020 11 15; 34(14):2013-2024. PMID: 32910065
- 2020 Cohn LB, Deeks SG. The immune response fails to control HIV early in initial virus spread. *J Clin Invest*. 2020 Apr 27. PMID: 32338639. PMCID: PMC7259984
- 2020 Bakkour S, Deng X, Bacchetti P, Grebe E, Montalvo L, Worlock A, Stone M, Deeks SG, Richman DD, Busch MP. Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral Therapy. *J Clin Microbiol*. 2020 Nov 18; 58(12). PMID: 32967900. PMCID: PMC7685884
- 2020 Appa A, Takahashi S, Rodriguez-Barraquer I, Chamie G, Sawyer A, Duarte E, Hakim J, Turcios K, Vinden J, Janson O, Manglik A, Peluso MJ, Deeks SG, Henrich TJ, Torres L, Rodgers M, Hackett J, Chiu CY, Havlir D, Greenhouse B. Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community. *medRxiv*. 2020 Aug 17. PMID: 32839781. PMCID: PMC7444294
- 2020 Peluso MJ, Bakkour S, Busch MP, Deeks SG, Henrich TJ. A High Percentage of People with HIV on Antiretroviral Therapy Experience Detectable Low-Level Plasma HIV-1 RNA Following COVID-19. *Clin Infect Dis*. 2020 Nov 19. PMID: 33211091. PMCID: PMC7717237
- 2020 Kwon KJ, Timmons AE, Sengupta S, Simonetti FR, Zhang H, Hoh R, Deeks SG, Siliciano JD, Siliciano RF. Different human resting memory CD4+ T cell subsets show similar low inducibility of latent HIV-1 proviruses. *Sci Transl Med*. 2020 Jan 29; 12(528). PMID: 31996465
- 2020 Baker JV, Wolfson J, Collins G, Morse C, Rhame F, Liappis AP, Rizza S, Temesgen Z, Mystakelis H, Deeks S, Neaton J, Schacker T, Sereti I, Tracy RP. Losartan to reduce inflammation and fibrosis endpoints in HIV disease (LIFE-HIV): results from a randomized placebo-controlled trial. *AIDS*. 2020 Nov 25. PMID: 33252490

- 2020 Peluso MJ, Dee L, Shao S, Taylor J, Campbell D, Collins S, Gandhi M, Johnston R, Deeks SG, Saucedo JA, Dubé K. Operationalizing HIV cure-related trials with analytic treatment interruptions during the SARS-CoV-2 pandemic: A collaborative approach. *Clin Infect Dis*. 2020 Aug 25. PMID: 32841311
- 2020 Dybul M, Attoye T, Baptiste S, Cherutich P, Dabis F, Deeks SG, Dieffenbach C, Doehle B, Goodenow MM, Jiang A, Kempf D, Lewin SR, Lumpkin MM, Mathae L, McCune JM, Ndung'u T, Nsubuga M, Peay HL, Pottage J, Warren M, Sikazwe I. The case for an HIV cure and how to get there. *Lancet HIV*. 2020 Nov 27. PMID: 33271124. PMCID: PMC7773626
- 2020 Scharf L, Tauriainen J, Buggert M, Hartogensis W, Nolan DJ, Deeks SG, Salemi M, Hecht FM, Karlsson AC. Delayed expression of PD1 and TIGIT on HIV-specific CD8 T-cells in untreated HLA-B*57:01 individuals followed from early infection. *J Virol*. 2020 Apr 29. PMID: 32350076
- 2020 Lewin SR, Attoye T, Bansbach C, Doehle B, Dubé K, Dybul M, SenGupta D, Jiang A, Johnston R, Lamplough R, McCune JM, Nabel GJ, Ndung'u T, Pottage J, Ripin D, Rooney JF, Sikazwe I, Nsubuga M, Warren M, Deeks SG. Multi-stakeholder consensus on a target product profile for an HIV cure. *Lancet HIV*. 2020 Nov 27. PMID: 33271125. PMCID: PMC7773628
- 2020 Shiao S, Bender AA, O'Halloran JA, Sundermann E, Aggarwal J, Althoff KN, Baker JV, Deeks SG, Fried LP, Karpiak S, Karris M, Marcotte T, Nachega JB, Margolick JB, Erlandson KM, Moore DJ. The Current State of HIV and Aging: Findings Presented at the 10th International Workshop on HIV and Aging. *AIDS Res Hum Retroviruses*. 2020 Aug 26. PMID: 32847368
- 2020 Fidler S, Lewin S, Deeks S, Sogaard OS, Vanderkerckhove L, Collins S, Kelly D, Singh J, Caskey M, Frater J. HIV cure research in the time of COVID-19 - antiretroviral therapy treatment interruption trials: a discussion paper. *J Virus Erad*. 2020 Dec 06; 100025. PMID: 33312681. PMCID: PMC7719279
- 2020 Peluso MJ, Dee L, Campbell D, Taylor J, Hoh R, Rutishauser RL, Saucedo J, Deeks SG, Dubé K. A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption. *J Virus Erad*. 2020 Feb 20; 6(1):34-37. PMID: 32175090. PMCID: PMC7043899
- 2020 Simonetti FR, Zhang H, Soroosh GP, Duan J, Rhodehouse K, Hill AL, Beg SA, McCormick K, Raymond HE, Nobles CL, Everett JK, Kwon KJ, White JA, Lai J, Margolick JB, Hoh R, Deeks SG, Bushman FD, Siliciano JD, Siliciano RF. Antigen-driven clonal selection shapes the persistence of HIV-1 infected CD4+ T cells in vivo. *J Clin Invest*. 2020 Dec 10. PMID: 33301425

- 2020 Jiang C, Lian X, Gao C, Sun X, Einkauf KB, Chevalier JM, Chen SMY, Hua S, Rhee B, Chang K, Blackmer JE, Osborn M, Peluso MJ, Hoh R, Somsouk M, Milush J, Bertagnolli LN, Sweet SE, Varriale JA, Burbelo PD, Chun TW, Laird GM, Serrao E, Engelman AN, Carrington M, Siliciano RF, Siliciano JM, Deeks SG, Walker BD, Lichterfeld M, Yu XG. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. *Nature*. 2020 Aug 26. PMID: 32848246
- 2020 Rutishauser RL, Deguit CDT, Hiatt J, Blaeschke F, Roth TL, Wang L, Raymond KA, Starke CE, Mudd JC, Chen W, Smullin CP, Matus-Nicodemos R, Hoh R, Krone MR, Hecht FM, Pilcher CD, Martin JN, Koup RA, Douek DC, Brenchley JM, Sékaly RP, Pillai SK, Marson A, Deeks SG, McCune JM, Hunt PW. TCF-1 regulates HIV-specific CD8+ T cell expansion capacity. *JCI Insight*. 2020 Dec 22. PMID: 33351785
- 2020 Hsiao F, Frouard J, Gramatica A, Xie G, Telwatte S, Lee GQ, Roychoudhury P, Schwarzer R, Luo X, Yukl SA, Lee S, Hoh R, Deeks SG, Jones RB, Cavrois M, Greene WC, Roan NR. Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection. *PLoS Pathog*. 2020 04; 16(4):e1008450. PMID: 32353080. PMCID: PMC7192375
- 2020 Yukl SA, Khan S, Chen TH, Trapecar M, Wu F, Xie G, Telwatte S, Fulop D, Pico AR, Laird GM, Ritter KD, Jones NG, Lu CM, Siliciano RF, Roan NR, Milush JM, Somsouk M, Deeks SG, Hunt PW, Sanjabi S. Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103+ and Gut CD4+ T Cells. *J Virol*. 2020 Dec 22; 95(2). PMID: 33115867
- 2020 Lee E, von Stockenstrom S, Morcilla V, Odevall L, Hiener B, Shao W, Hartogensis W, Bacchetti P, Milush J, Liegler T, Sinclair E, Hatano H, Hoh R, Somsouk M, Hunt P, Boritz E, Douek D, Fromentin R, Chomont N, Deeks SG, Hecht FM, Palmer S. Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites. *J Virol*. 2020 Jan 17; 94(3). PMID: 31723024
- 2020 Phan BAP, Ma Y, Scherzer R, Deeks SG, Hsue PY. Association between statin use, atherosclerosis, and mortality in HIV-infected adults. *PLoS One*. 2020; 15(4):e0232636. PMID: 32353062. PMCID: PMC7192415
- 2020 Stone M, Rosenbloom D, Bacchetti P, Deng X, Dimapasoc M, Keating S, Bakkour S, Richman D, Mellors J, Deeks S, Lai J, Beg S, Siliciano J, Pagliuzza A, Chomont N, Lackman-Smith C, Ptak RG, Busch MP. Assessing suitability of next-generation viral outgrowth assays as proxies for classic QVOA to measure HIV-1 latent reservoir size. *J Infect Dis*. 2020 Mar 09. PMID: 32147687

- 2020 Grossman Z, Singh NJ, Simonetti FR, Lederman MM, Douek DC, Deeks SG. 'Rinse and Replace': Boosting T Cell Turnover To Reduce HIV-1 Reservoirs. *Trends Immunol.* 2020 May 12. PMID: 32414695
- 2020 Peluso MJ, Bacchetti P, Ritter KD, Beg SA, Lai J, Martin JN, Hunt PW, Henrich TJ, Siliciano JD, Siliciano RF, Laird GM, Deeks SG. Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. *JCI Insight.* 2020 Feb 11. PMID: 32045386
- 2020 Liu R, Yeh YJ, Varabyou A, Collora JA, Sherrill-Mix S, Talbot CC, Mehta S, Albrecht K, Hao H, Zhang H, Pollack RA, Beg SA, Calvi RM, Hu J, Durand CM, Ambinder RF, Hoh R, Deeks SG, Chiarella J, Spudich S, Douek DC, Bushman FD, Pertea M, Ho YC. Single-cell transcriptional landscapes reveal HIV-1-driven aberrant host gene transcription as a potential therapeutic target. *Sci Transl Med.* 2020 May 13; 12(543). PMID: 32404504
- 2020 Antar AAR, Jenike KM, Jang S, Rigau DN, Reeves DB, Hoh R, Krone MR, Keruly JC, Moore RD, Schiffer JT, Nonyane BA, Hecht FM, Deeks SG, Siliciano JD, Ho YC, Siliciano RF. Longitudinal study reveals HIV-1-infected CD4+ T cell dynamics during long-term antiretroviral therapy. *J Clin Invest.* 2020 Mar 19. PMID: 32191639
- 2020 Jilg N, Garcia-Broncano P, Peluso M, Segal FP, Bosch RJ, Roberts-Toler C, Chen SMY, Van Dam CN, Keefer MC, Kuritzkes DR, Landay AL, Deeks S, Yu XG, Sax PE, Li JZ. Hiv Controllers Maintain Viral Suppression Despite Waning T-Cell Responses On Art. *J Infect Dis.* 2020 Jun 04. PMID: 32496516
- 2020 Wang Y, Lifshitz L, Gellatly K, Vinton CL, Busman-Sahay K, McCauley S, Vangala P, Kim K, Derr A, Jaiswal S, Kucukural A, McDonel P, Hunt PW, Greenough T, Houghton J, Somsouk M, Estes JD, Brenchley JM, Garber M, Deeks SG, Luban J. HIV-1-induced cytokines deplete homeostatic innate lymphoid cells and expand TCF7-dependent memory NK cells. *Nat Immunol.* 2020 Mar; 21(3):274-286. PMID: 32066947. PMCID: PMC7044076
- 2020 Vallejo-Gracia A, Chen IP, Perrone R, Besnard E, Boehm D, Battivelli E, Tezil T, Krey K, Raymond KA, Hull PA, Walter M, Habrylo I, Cruz A, Deeks S, Pillai S, Verdin E, Ott M. FOXO1 promotes HIV latency by suppressing ER stress in T cells. *Nat Microbiol.* 2020 Jun 15. PMID: 32541947
- 2020 Herrera S, Fernandez-Felix BM, Hunt PW, Deeks SG, Sainz T, Heath SL, Achenbach CJ, Rodríguez B, Mathews C, Christopoulos K, Mayer K, Napravnik S, Moreno S, Serrano-Villar S. Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort. *J Antimicrob Chemother.* 2020 Mar 24. PMID: 32211777

- 2020 Yeh YJ, Jenike KM, Calvi RM, Chiarella J, Hoh R, Deeks SG, Ho YC. Filgotinib suppresses HIV-1-driven gene transcription by inhibiting HIV-1 splicing and T cell activation. *J Clin Invest*. 2020 Jun 23. PMID: 32573496
- 2020 Abdelsamed HA, Zebley CC, Nguyen H, Rutishauser RL, Fan Y, Ghoneim HE, Crawford JC, Alfei F, Alli S, Ribeiro SP, Castellaw AH, McGargill MA, Jin H, Boi SK, Speake C, Serti E, Turka LA, Busch ME, Stone M, Deeks SG, Sekaly RP, Zehn D, James EA, Nepom GT, Youngblood B. Beta cell-specific CD8+ T cells maintain stem cell memory-associated epigenetic programs during type 1 diabetes. *Nat Immunol*. 2020 Mar 30. PMID: 32231298
- 2020 Cohn LB, Chomont N, Deeks SG. The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies. *Cell Host Microbe*. 2020 04 08; 27(4):519-530. PMID: 32272077
- 2020 Lee SA, Telwatte S, Hatano H, Kashuba ADM, Cottrell ML, Hoh R, Liegler TJ, Stephenson S, Somsouk M, Hunt PW, Deeks SG, Yukl S, Savic RM. Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay. *J Acquir Immune Defic Syndr*. 2020 Apr 15; 83(5):530-537. PMID: 32168200
- 2021 Pahwa S, Deeks S, Zou S, Tomitch N, Miller-Novak L, Caler E, Justice A, Sacktor N, Gabuzda D, Hunt PW, Brown T, Kurth A, Baral S, Mugavero M, Mayer KH, Mendenhall E, Detels R, Mutabazi V. NIH Workshop on HIV-Associated Comorbidities, Coinfections, and Complications: Summary and Recommendation for Future Research. *J Acquir Immune Defic Syndr*. 2021 Jan 01; 86(1):11-18. PMID: 33306561
- 2021 Lian X, Gao C, Sun X, Jiang C, Einkauf KB, Seiger KW, Chevalier JM, Yuki Y, Martin M, Hoh R, Peluso MJ, Carrington M, Ruiz-Mateos E, Deeks SG, Rosenberg ES, Walker BD, Lichterfeld M, Yu XG. Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers. *Sci Transl Med*. 2021 Dec 15; 13(624):eabl4097. PMID: 34910552
- 2021 Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, Lambotte O, Lamplough R, Ndung'u T, Sugarman J, Tiemessen CT, Vandekerckhove L, Lewin SR, International AIDS Society (IAS) Global Scientific Strategy working group. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. *Nat Med*. 2021 Dec; 27(12):2085-2098. PMID: 34848888

- 2021 Santiago-Rodriguez EI, Maiorana A, Peluso MJ, Hoh R, Tai V, Fehrman EA, Hernandez Y, Torres L, Spinelli MA, Gandhi M, Kelly JD, Martin JN, Henrich TJ, Deeks SG, Saucedo JA. Characterizing the COVID-19 Illness Experience to Inform the Study of Post-acute Sequelae and Recovery. *Int J Behav Med*. 2021 Dec 16. PMID: 34918211. PMCID: PMC8675303
- 2021 Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, Forman CA, Munter SE, Hoh R, Tai V, Chenna A, Yee BC, Winslow JW, Petropoulos CJ, Greenhouse B, Hunt PW, Hsue PY, Martin JN, Daniel Kelly J, Glidden DV, Deeks SG, Henrich TJ. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *J Infect Dis*. 2021 Sep 27. PMID: 34677601. PMCID: PMC8643408
- 2021 Spinelli MA, Peluso MJ, Lynch KL, Yun C, Glidden DV, Henrich TJ, Deeks SG, Gandhi M. Differences in Post-mRNA Vaccination SARS-CoV-2 IgG Concentrations and Surrogate Virus Neutralization Test Response by HIV Status and Type of Vaccine: a Matched Case-Control Observational Study. *Clin Infect Dis*. 2021 Dec 05. PMID: 34864962. PMCID: PMC8689738
- 2021 Takahashi S, Peluso MJ, Hakim J, Turcios K, Janson O, Routledge I, Busch MP, Hoh R, Tai V, Kelly JD, Martin JN, Deeks SG, Henrich TJ, Greenhouse B, Rodríguez-Barraquer I. SARS-CoV-2 serology across scales: a framework for unbiased seroprevalence estimation incorporating antibody kinetics and epidemic recency. *medRxiv*. 2021 Sep 14. PMID: 34545373. PMCID: PMC8452112
- 2021 Adair JE, Androski L, Bayigga L, Bazira D, Brandon E, Dee L, Deeks S, Draz M, Dubé K, Dybul M, Gurkan U, Harlow E, Kityo C, Louella M, Malik P, Mathews V, McKemey A, Mugerwa H, Muyanja D, Olayiwola O, Orentas RJ, Popovski A, Sheehy J, Ssali F, Nsubuga MS, Tisdale JF, Verhoeven E, Dropulic B. Correction: Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI). *Gene Ther*. 2021 Sep 29. PMID: 34584245
- 2021 Byrum JR, Waltari E, Janson O, Guo SM, Folkesson J, Chhun BB, Vinden J, Ivanov IE, Forst ML, Li H, Larson AG, Wu W, Tato CM, McCutcheon KM, Peluso MJ, Henrich TJ, Deeks SG, Prakash M, Greenhouse B, Pak JE, Mehta SB. multiSero: open multiplex-ELISA platform for analyzing antibody responses to SARS-CoV-2 infection. *medRxiv*. 2021 May 11. PMID: 34013298. PMCID: PMC8132273
- 2021 Peluso MJ, Thomas IJ, Munter SE, Deeks SG, Henrich TJ. Lack of Antinuclear Antibodies in Convalescent COVID-19 Patients with Persistent Symptoms. *Clin Infect Dis*. 2021 Oct 07. PMID: 34617982

- 2021 Morcilla V, Bacchus-Souffan C, Fisher K, Horsburgh BA, Hiener B, Wang XQ, Schlub TE, Fitch M, Hoh R, Hecht FM, Martin JN, Deeks SG, Hellerstein MK, McCune JM, Hunt PW, Palmer S. HIV-1 Genomes Are Enriched in Memory CD4+ T-Cells with Short Half-Lives. *mBio*. 2021 Sep 21; e0244721. PMID: 34544282
- 2021 Stern J, Solomon A, Dantanarayana A, Pascoe R, Reynaldi A, Davenport MP, Milush J, Deeks SG, Hartogensis W, Hecht FM, Cockerham L, Roche M, Lewin SR. Cell-associated HIV RNA has a Circadian Cycle in Males Living with HIV on Antiretroviral Therapy. *J Infect Dis*. 2021 Oct 16. PMID: 34655216
- 2021 Appa A, Takahashi S, Rodriguez-Barraquer I, Chamie G, Sawyer A, Duarte E, Hakim J, Turcios K, Vinden J, Janson O, Manglik A, Peluso MJ, Deeks SG, Henrich TJ, Torres L, Rodgers M, Hackett J, Chiu C, Havlir D, Greenhouse B. Universal Polymerase Chain Reaction and Antibody Testing Demonstrate Little to No Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in a Rural Community. *Open Forum Infect Dis*. 2021 Jan; 8(1):ofaa531. PMID: 34109255. PMCID: PMC7665736
- 2021 Dubé K, Kanazawa J, Dee L, Taylor J, Saucedo JA, Gianella S, Smith D, Deeks SG, Peluso MJ. Considerations for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the United States. *AIDS Res Ther*. 2021 10 18; 18(1):75. PMID: 34663375. PMCID: PMC8522863
- 2021 Peluso MJ, Munter SE, Lynch KL, Yun C, Torres L, Iyer NS, Donatelli J, Ryan L, Deitchman AN, Deeks SG, Rutishauser RL, Henrich TJ. Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease. *Open Forum Infect Dis*. 2021 Aug; 8(8):ofab393. PMID: 34395717. PMCID: PMC8344490
- 2021 Thakkar AB, Ma Y, Dela Cruz M, Wu Y, Arechiga V, Swaminathan S, Ganz P, Wu AHB, Scherzer R, Deeks S, Hsue PY. Effect of HIV-1 Infection on Angiopoietin 1 and 2 Levels and Measures of Microvascular and Macrovascular Endothelial Dysfunction. *J Am Heart Assoc*. 2021 Nov 16; 10(22):e021397. PMID: 34726064

- 2021 Bacchus-Souffan C, Fitch M, Symons J, Abdel-Mohsen M, Reeves DB, Hoh R, Stone M, Hiatt J, Kim P, Chopra A, Ahn H, York VA, Cameron DL, Hecht FM, Martin JN, Yukl SA, Mallal S, Cameron PU, Deeks SG, Schiffer JT, Lewin SR, Hellerstein MK, McCune JM, Hunt PW. Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART. *PLoS Pathog.* 2021 Jan 19; 17(1):e1009214. PMID: 33465157. PMCID: PMC7846027
- 2021 Abdulhaqq S, Ventura AB, Reed JS, Bashirova AA, Bateman KB, McDonald E, Wu HL, Greene JM, Schell JB, Morrow D, Wisskirchen K, Martin JN, Deeks SG, Carrington M, Protzer U, Früh K, Hansen SG, Picker LJ, Sacha JB, Bimber BN. Identification and Characterization of Antigen-Specific CD8+ T Cells Using Surface-Trapped TNF- α and Single-Cell Sequencing. *J Immunol.* 2021 Nov 22. PMID: 34810222
- 2021 Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, Donatelli J, Thanh C, Takahashi S, Hakim J, Turcios K, Janson O, Hoh R, Tai V, Hernandez Y, Fehrman EA, Spinelli MA, Gandhi M, Trinh L, Wrin T, Petropoulos CJ, Aweeka FT, Rodriguez-Barrquer I, Kelly JD, Martin JN, Deeks SG, Greenhouse B, Rutishauser RL, Henrich TJ. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. *Cell Rep.* 2021 08 10; 36(6):109518. PMID: 34358460. PMCID: PMC8342976
- 2021 Levy CN, Hughes SM, Roychoudhury P, Reeves DB, Amstutz C, Zhu H, Huang ML, Wei Y, Bull ME, Cassidy NAJ, McClure J, Frenkel LM, Stone M, Bakkour S, Wonderlich ER, Busch MP, Deeks SG, Schiffer JT, Coombs RW, Lehman DA, Jerome KR, Hladik F. A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir. *Cell Rep Med.* 2021 Apr 20; 2(4):100243. PMID: 33948574. PMCID: PMC8080125
- 2021 Kammers K, Chen A, Monaco DR, Hudelson SE, Grant-McAuley W, Moore RD, Alter G, Deeks SG, Morrison CS, Eller LA, Blankson JN, Laeyendecker O, Ruczinski I, Eshleman SH, Larman HB. HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression. *Front Immunol.* 2021; 12:740395. PMID: 34512672. PMCID: PMC8428532
- 2021 Corley MJ, Pang APS, Dody K, Mudd PA, Patterson BK, Seethamraju H, Bram Y, Peluso MJ, Torres L, Iyer NS, Premeaux TA, Yeung ST, Chandar V, Borczuk A, Schwartz RE, Henrich TJ, Deeks SG, Sacha JB, Ndhlovu LC. Genome-wide DNA methylation profiling of peripheral blood reveals an epigenetic signature associated with severe COVID-19. *J Leukoc Biol.* 2021 Jan 19. PMID: 33464637. PMCID: PMC8013321

- 2021 Collins DR, Urbach JM, Racenet ZJ, Arshad U, Power KA, Newman RM, Mylvaganam GH, Ly NL, Lian X, Rull A, Rassadkina Y, Yanez AG, Peluso MJ, Deeks SG, Vidal F, Lichterfeld M, Yu XG, Gaiha GD, Allen TM, Walker BD. Functional impairment of HIV-specific CD8+ Tcells precedes aborted spontaneous control of viremia. *Immunity*. 2021 Sep 02. PMID: 34496223
- 2021 Xie G, Luo X, Ma T, Frouard J, Neidleman J, Hoh R, Deeks SG, Greene WC, Roan NR. Characterization of HIV-induced remodeling reveals differences in infection susceptibility of memory CD4+ Tcell subsets *in vivo*. *Cell Rep*. 2021 Apr 27; 35(4):109038. PMID: 33910003. PMCID: PMC8202093
- 2021 Adair JE, Androski L, Bayigga L, Bazira D, Brandon E, Dee L, Deeks S, Draz M, Dubé K, Dybul M, Gurkan U, Harlow E, Kityo C, Louella M, Malik P, Mathews V, McKemey A, Mugerwa H, Muyanja D, Olayiwola O, Orentas RJ, Popovski A, Sheehy J, Ssali F, Nsubuga MS, Tisdale JF, Verhoeven E, Dropulic B. Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI). *Gene Ther*. 2021 Sep 08. PMID: 34493840
- 2021 Diepstra KL, Barr L, Palm D, Hogg E, Mollan K, Henley L, Stover A, Simoni J, Sugarman J, Brown B, Saucedo JA, Deeks SG, Fox L, Gandhi R, Smith DM, Li J, Dube K. Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause (IMAP): Results from the AIDS Clinical Trials Group (ACTG) A5345 Biomarker Study. *AIDS Res Hum Retroviruses*. 2021 Jan 20. PMID: 33472545
- 2021 Boltz VF, Ceriani C, Rausch JW, Shao W, Bale MJ, Keele BF, Hoh R, Milush JM, Deeks SG, Maldarelli F, Kearney MF, Coffin JM. CpG Methylation Profiles of HIV-1 Pro-Viral DNA in Individuals on ART. *Viruses*. 2021 04 29; 13(5). PMID: 33946976. PMCID: PMC8146454
- 2021 Zhang L, Abohashem S, Osborne MT, Naddaf N, Park R, Moore K, Patrich T, Deeks SG, Hsue PY, Tawakol AA. Lower Socioeconomic Status Associates with Greater Systemic and Arterial Inflammation in HIV. *J Acquir Immune Defic Syndr*. 2021 Jan 20. PMID: 33492022. PMCID: PMC8026700
- 2021 Horsburgh BA, Hiener B, Fisher K, Lee E, Morgan H, Eden JS, von Stockenstrom S, Odeval L, Milush JM, Hoh R, Fromentin R, Chomont N, Hecht FM, Schlub TE, Deeks SG, Palmer S. Cellular activation, differentiation and proliferation influence the dynamics of genetically-intact proviruses over time. *J Infect Dis*. 2021 May 26. PMID: 34037766

- 2021 Hellmuth J, Barnett TA, Asken BM, Kelly JD, Torres L, Stephens ML, Greenhouse B, Martin JN, Chow FC, Deeks SG, Greene M, Miller BL, Annan W, Henrich TJ, Peluso MJ. Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. *J Neurovirol.* 2021 Feb 02. PMID: 33528824. PMCID: PMC7852463
- 2021 Li JZ, Aga E, Bosch R, Pilkinton M, Kroon E, MacLaren L, Keefer M, Fox L, Barr L, Acosta E, Anaworanich J, Coombs R, Mellors J, Landay A, Macatangay B, Deeks S, Gandhi RT, Smith DM, AIDS Clinical Trials Group A5345 Study Team . Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies. *Clin Infect Dis.* 2021 Jun 12. PMID: 34117753
- 2021 Gramatica A, Schwarzer R, Brantley W, Varco-Merth B, Sperber HS, Hull PA, Montano M, Migueles SA, Rosenthal D, Hogan LE, Johnson JR, Packard TA, Grimmatt ZW, Herzig E, Besnard E, Nekorchuk M, Hsiao F, Deeks SG, Snape M, Kiernan B, Roan NR, Lifson JD, Estes JD, Picker LJ, Verdin E, Krogan NJ, Henrich TJ, Connors M, Ott M, Pillai SK, Okoye AA, Greene WC. Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity Ex Vivo and In Vivo. *J Virol.* 2021 Feb 03. PMID: 33536176
- 2021 Fajnzylber J, Sharaf R, Hutchinson JN, Aga E, Bosch RJ, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest DJ, Margolis D, Sneller MC, Little SJ, Gulick RM, Mellors JW, Gandhi RT, Schooley RT, Henry K, Tebas P, Deeks S, Chun TW, Collier AC, Hecht FM, Li JZ, CHAMP study team . Frequency of Post Treatment Control Varies by ART Restart and Viral Load Criteria. *AIDS.* 2021 Jun 14. PMID: 34127579
- 2021 Sun B, Tang N, Peluso MJ, Iyer NS, Torres L, Donatelli JL, Munter SE, Nixon CC, Rutishauser RL, Rodriguez-Barraquer I, Greenhouse B, Kelly JD, Martin JN, Deeks SG, Henrich TJ, Pulliam L. Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. *Cells.* 2021 02 13; 10(2). PMID: 33668514. PMCID: PMC7918597
- 2021 SenGupta D, Brinson C, DeJesus E, Mills A, Shalit P, Guo S, Cai Y, Wallin JJ, Zhang L, Humeniuk R, Begley R, Geleziunas R, Mellors J, Wrin T, Jones N, Milush J, Ferre AL, Shacklett BL, Laird GM, Moldt B, Vendrame E, Brainard DM, Ramgopal M, Deeks SG. The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. *Sci Transl Med.* 2021 06 23; 13(599). PMID: 34162752

- 2021 Zerbato JM, Khoury G, Zhao W, Gartner MJ, Pascoe RD, Rhodes A, Dantanarayana A, Gooley M, Anderson J, Bacchetti P, Deeks SG, McMahon J, Roche M, Rasmussen TA, Purcell DF, Lewin SR. Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. *EBioMedicine*. 2021 Feb 26; 65:103241. PMID: 33647768. PMCID: PMC7920823
- 2021 Truong HM, Fatch R, Deeks SG, Krone M, Martin JN, Hunt PW, Lum PJ. Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use. *Curr HIV Res*. 2021 Jun 24. PMID: 34176462
- 2021 Peluso MJ, Deitchman AN, Torres L, Iyer NS, Nixon CC, Munter SE, Donatelli J, Thanh C, Takahashi S, Hakim J, Turcios K, Janson O, Hoh R, Tai V, Hernandez Y, Fehrman E, Spinelli MA, Gandhi M, Trinh L, Wrin T, Petropoulos CJ, Aweeka FT, Rodriguez-Barraquer I, Kelly JD, Martin JN, Deeks SG, Greenhouse B, Rutishauser RL, Henrich TJ. Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19. *medRxiv*. 2021 Mar 01. PMID: 33688685. PMCID: PMC7941662
- 2021 Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, Turcios K, Janson O, Munter SE, Thanh C, Donatelli J, Nixon CC, Hoh R, Tai V, Fehrman EA, Hernandez Y, Spinelli MA, Gandhi M, Palafox MA, Vallari A, Rodgers MA, Prostko J, Hackett J, Trinh L, Wrin T, Petropoulos CJ, Chiu CY, Norris PJ, DiGermanio C, Stone M, Busch MP, Elledge SK, Zhou XX, Wells JA, Shu A, Kurtz TW, Pak JE, Wu W, Burbelo PD, Cohen JI, Rutishauser RL, Martin JN, Deeks SG, Henrich TJ, Rodriguez-Barraquer I, Greenhouse B. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. *Sci Adv*. 2021 Jul; 7(31). PMID: 34330709. PMCID: PMC8324059
- 2021 Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in people living with HIV with cancer on antiretroviral therapy: The AIDS Malignancy Consortium-095 study. *Clin Infect Dis*. 2021 Mar 02. PMID: 33677480
- 2021 Peluso MJ, Dee L, Taylor J, Campbell DM, Ehm A, Agosto-Rosario M, Shao S, Williams MC, Hoh R, Rutishauser RL, Deeks SG, Saucedo JA, Dubé K. SARS-CoV-2 Vaccination in the Context of Ongoing HIV Cure-Related Research Studies. *J Acquir Immune Defic Syndr*. 2021 08 01; 87(4):e232-e233. PMID: 33852502. PMCID: PMC8217209

- 2021 Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, Turcios K, Janson O, Munter SE, Thanh C, Nixon CC, Hoh R, Tai V, Fehrman EA, Hernandez Y, Spinelli MA, Gandhi M, Palafox MA, Vallari A, Rodgers MA, Prostko J, Hackett J, Trinh L, Wrin T, Petroplolous CJ, Chiu CY, Norris PJ, DiGermanio C, Stone M, Busch MP, Elledge SK, Zhou XX, Wells JA, Shu A, Kurtz TW, Pak JE, Wu W, Burbelo PD, Cohen JI, Rutishauser RL, Martin JN, Deeks SG, Henrich TJ, Rodriguez-Barraquer I, Greenhouse B. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. medRxiv. 2021 Mar 05. PMID: 33688675. PMCID: PMC7941652
- 2021 Marconi VC, Moser C, Gavegnano C, Deeks SG, Lederman MM, Overton ET, Tsibris A, Hunt PW, Kantor A, Sekaly RP, Tressler R, Flexner C, Hurwitz SJ, Moisi D, Clagett B, Hardin WR, Del Rio C, Schinazi RF, Lennox JJ. Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with HIV. Clin Infect Dis. 2021 Mar 06. PMID: 33693561
- 2021 Wu G, Zuck P, Goh SL, Milush JM, Vohra P, Wong JK, Somsouk M, Yukl SA, Shacklett BL, Chomont N, Haase AT, Hatano H, Schacker TW, Deeks SG, Hazuda DJ, Hunt PW, Howell BJ. Gag p24 is a Marker of HIV Expression in Tissues and Correlates with Immune Response. J Infect Dis. 2021 Mar 09. PMID: 33693750
- 2021 Peluso MJ, Kelly JD, Lu S, Goldberg SA, Davidson MC, Mathur S, Durstenfeld MS, Spinelli MA, Hoh R, Tai V, Fehrman EA, Torres L, Hernandez Y, Williams MC, Arreguin MI, Bautista JA, Ngo LH, Deswal M, Munter SE, Martinez EO, Anglin KA, Romero MD, Tavs J, Rugart PR, Chen JY, Sans HM, Murray VW, Ellis PK, Donohue KC, Massachi JA, Weiss JO, Mehdi I, Pineda-Ramirez J, Tang AF, Wenger M, Assenzio M, Yuan Y, Krone M, Rutishauser RL, Rodriguez-Barraquer I, Greenhouse B, Saucedo JA, Gandhi M, Hsue PY, Henrich TJ, Deeks SG, Martin JN. Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19. medRxiv. 2021 Mar 12. PMID: 33758895. PMCID: PMC7987054
- 2021 Santiago-Rodriguez EI, Maiorana A, Peluso MJ, Hoh R, Tai V, Fehrman EA, Hernandez Y, Torres L, Spinelli MA, Gandhi M, Kelly JD, Martin JN, Henrich TJ, Deeks SG, Saucedo JA. Characterizing the COVID-19 illness experience to inform the study of post-acute sequelae and recovery: a qualitative study. medRxiv. 2021 Mar 12. PMID: 33758881. PMCID: PMC7987040
- 2021 MacDonald DM, Collins G, Wendt CH, Wolfson J, Tracy RP, Rhame F, Deeks S, Rizza SA, Temesgen Z, Morse C, Liappis AP, Sereti I, Baker JV, Kunisaki KM. A pilot study of the effects of losartan vs. placebo on pneumoproteins in HIV: A secondary analysis of a randomized, double blind, study. AIDS Res Hum Retroviruses. 2021 Mar 22. PMID: 33749317

- 2022 Peluso MJ, Kelly JD, Lu S, Goldberg SA, Davidson MC, Mathur S, Durstenfeld MS, Spinelli MA, Hoh R, Tai V, Fehrman EA, Torres L, Hernandez Y, Williams MC, Arreguin MI, Ngo LH, Deswal M, Munter SE, Martinez EO, Anglin KA, Romero MD, Tavs J, Rugart PR, Chen JY, Sans HM, Murray VW, Ellis PK, Donohue KC, Massachi JA, Weiss JO, Mehdi I, Pineda-Ramirez J, Tang AF, Wenger MA, Assenzio MT, Yuan Y, Krone MR, Rutishauser RL, Rodriguez-Barraquer I, Greenhouse B, Saucedo JA, Gandhi M, Scheffler AW, Hsue PY, Henrich TJ, Deeks SG, Martin JN. Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. *Open Forum Infect Dis.* 2022 Feb; 9(2):ofab640. PMID: 35106317. PMCID: PMC8755302
- 2022 Packard TA, Schwarzer R, Herzig E, Rao D, Luo X, Egedal JH, Hsiao F, Widera M, Hultquist JF, Grimmett ZW, Messer RJ, Krogan NJ, Deeks SG, Roan NR, Dittmer U, Hasenkrug KJ, Greene WC. CCL2: a Chemokine Potentially Promoting Early Seeding of the Latent HIV Reservoir. *mBio.* 2022 10 26; 13(5):e0189122. PMID: 36073812. PMCID: PMC9600577
- 2022 Valentin A, Bergamaschi C, Rosati M, Angel M, Burns R, Agarwal M, Gergen J, Petsch B, Oostvogels L, Loeliger E, Chew KW, Deeks SG, Mullins JI, Pavlakis GN, Felber BK. Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques. *Front Immunol.* 2022; 13:945706. PMID: 35935984. PMCID: PMC9355630
- 2022 Peluso MJ, Anglin K, Durstenfeld MS, Martin JN, Kelly JD, Hsue PY, Henrich TJ, Deeks SG. Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies. *Pathog Immun.* 2022; 7(1):95-103. PMID: 35800257. PMCID: PMC9254867
- 2022 Freeman ML, Clagett BM, Moisi D, Yeh E, Morris CD, Ryu A, Rodriguez B, Stein JH, Deeks SG, Currier JS, Hsue PY, Anthony DD, Calabrese LH, Ribaldo HJ, Lederman MM. Methotrexate Inhibits T Cell Proliferation but Not Inflammatory Cytokine Expression to Modulate Immunity in People Living With HIV. *Front Immunol.* 2022; 13:924718. PMID: 35967371. PMCID: PMC9374564
- 2022 George AF, Luo X, Neidleman J, Hoh R, Vohra P, Thomas R, Shin MG, Lee MJ, Blish CA, Deeks SG, Greene WC, Lee SA, Roan NR. Deep Phenotypic Analysis of Blood and Lymphoid T and NK Cells From HIV+ Controllers and ART-Suppressed Individuals. *Front Immunol.* 2022; 13:803417. PMID: 35154118. PMCID: PMC8829545

- 2022 Garcia-Knight M, Anglin K, Tassetto M, Lu S, Zhang A, Goldberg SA, Catching A, Davidson MC, Shak JR, Romero M, Pineda-Ramirez J, Diaz-Sanchez R, Rugart P, Donohue K, Massachi J, Sans HM, Djomaleu M, Mathur S, Servellita V, McIlwain D, Gaudiliere B, Chen J, Martinez EO, Tavs JM, Bronstone G, Weiss J, Watson JT, Briggs-Hagen M, Abedi GR, Rutherford GW, Deeks SG, Chiu C, Saydah S, Peluso MJ, Midgley CM, Martin JN, Andino R, Kelly JD. Infectious viral shedding of SARS-CoV-2 Delta following vaccination: A longitudinal cohort study. *PLoS Pathog.* 2022 09; 18(9):e1010802. PMID: 36095030. PMCID: PMC9499220
- 2022 Daniel Kelly J, Lu S, Anglin K, Garcia-Knight M, Pineda-Ramirez J, Goldberg SA, Tassetto M, Zhang A, Donohue K, Davidson MC, Romero M, Sanchez RD, Djomaleu M, Mathur S, Chen JY, Forman CA, Servellita V, Montejano RD, Shak JR, Rutherford GW, Deeks SG, Abedi GR, Rolfes MA, Saydah S, Briggs-Hagen M, Peluso MJ, Chiu C, Midgley CM, Andino R, Martin JN. Magnitude and determinants of SARS-CoV-2 household transmission: a longitudinal cohort study. *Clin Infect Dis.* 2022 Jul 05. PMID: 35788827. PMCID: PMC9278251
- 2022 Giron LB, Peluso MJ, Ding J, Kenny G, Zilberstein NF, Koshy J, Hong KY, Rasmussen H, Miller GE, Bishehsari F, Balk RA, Moy JN, Hoh R, Lu S, Goldman AR, Tang HY, Yee BC, Chenna A, Winslow JW, Petropoulos CJ, Kelly JD, Wasse H, Martin JN, Liu Q, Keshavarzian A, Landay A, Deeks SG, Henrich TJ, Abdel-Mohsen M. Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF- κ B signaling. *JCI Insight.* 2022 09 22; 7(18). PMID: 36134654. PMCID: PMC9675436
- 2022 Apple AC, Oddi A, Peluso MJ, Asken BM, Henrich TJ, Kelly JD, Pleasure SJ, Deeks SG, Allen IE, Martin JN, Ndhlovu LC, Miller BL, Stephens ML, Hellmuth J. Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. *Ann Clin Transl Neurol.* 2022 Jan 19. PMID: 35043593. PMCID: PMC8862406
- 2022 Durstenfeld MS, Sun K, Tahir P, Peluso MJ, Deeks SG, Aras MA, Grandis DJ, Long CS, Beatty A, Hsue PY. Use of Cardiopulmonary Exercise Testing to Evaluate Long COVID-19 Symptoms in Adults: A Systematic Review and Meta-analysis. *JAMA Netw Open.* 2022 10 03; 5(10):e2236057. PMID: 36223120. PMCID: PMC9557896
- 2022 Altinbas A, Holmes JA, Salloum S, Lidofsky A, Alatrakchi N, Somsouk M, Hunt P, Deeks S, Chew KW, Lauer G, Kruger A, Lin W, Chung RT. LOXL-2 and TNC-C are markers of liver fibrogenesis in HCV/HIV-, HIV- and HCV-infected patients. *Biomark Med.* 2022 Jul 05. PMID: 35786977

- 2022 Rasmussen TA, Zerbato JM, Rhodes A, Tumpach C, Dantanarayana A, McMahon JH, Lau JSY, Chang JJ, Gubser C, Brown W, Hoh R, Krone M, Pascoe R, Chiu CY, Bramhall M, Lee HJ, Haque A, Fromentin R, Chomont N, Milush J, Van der Sluis RM, Palmer S, Deeks SG, Cameron PU, Evans V, Lewin SR. Memory CD4+ T_H cells that co-express PD1 and CTLA4 have reduced response to activating stimuli facilitating HIV latency. *Cell Rep Med*. 2022 10 18; 3(10):100766. PMID: 36198308. PMCID: PMC9589005
- 2022 Scully EP, Aga E, Tsibris A, Archin N, Starr K, Ma Q, Morse GD, Squires KE, Howell BJ, Wu G, Hosey L, Sieg S, Ehui L, Giguel F, Coxen K, Dobrowski C, Gandhi M, Deeks S, Chomont N, Connick E, Godfrey C, Karn J, Kuritzkes DR, Bosch RJ, Gandhi RT, A5366 study team. Impact of Tamoxifen on Vorinostat-Induced HIV Expression in Women on Antiretroviral Therapy (ACTG A5366:The MOXIE trial). *Clin Infect Dis*. 2022 Feb 17. PMID: 35176755
- 2022 Mathur S, Davidson MC, Anglin K, Lu S, Goldberg SA, Garcia-Knight M, Tassetto M, Zhang A, Romero M, Pineda-Ramirez J, Diaz-Sanchez R, Rugart P, Chen JY, Donohue K, Shak JR, Chenna A, Winslow JW, Petropoulos CJ, Yee BC, Lambert J, Glidden DV, Rutherford GW, Deeks SG, Peluso MJ, Andino R, Martin JN, Kelly JD. Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Antigen in the Blood as a Diagnostic Test for Infection and Infectious Viral Shedding. *Open Forum Infect Dis*. 2022 Nov; 9(11):ofac563. PMID: 36381627. PMCID: PMC9620332
- 2022 Peluso MJ, Spinelli MA, Deveau TM, Forman CA, Munter SE, Mathur S, Tang AF, Lu S, Goldberg SA, Arreguin MI, Hoh R, Tai V, Chen JY, Martinez EO, Yee BC, Chenna A, Winslow JW, Petropoulos CJ, Sette A, Weiskopf D, Kumar N, Lynch KL, Hunt PW, Durstenfeld MS, Hsue PY, Kelly JD, Martin JN, Glidden DV, Gandhi M, Deeks SG, Rutishauser RL, Henrich TJ. Post-acute sequelae and adaptive immune responses in people living with HIV recovering from SARS-COV-2 infection. *AIDS*. 2022 Jul 19. PMID: 35866847
- 2022 Anthony-Gonda K, Ray A, Su H, Wang Y, Xiong Y, Lee D, Block A, Chilunda V, Weiselberg J, Zemelko L, Wang YY, Kleinsorge-Block S, Reese JS, de Lima M, Ochsenbauer C, Kappes JC, Dimitrov DS, Orentas R, Deeks SG, Rutishauser RL, Berman JW, Goldstein H, Dropulic B. In vivo killing of primary HIV-infected cells by peripheral-injected early memory-enriched anti-HIV duoCAR T cells. *JCI Insight*. 2022 11 08; 7(21). PMID: 36345941. PMCID: PMC9675454

- 2022 Uldrick TS, Adams SV, Fromentin R, Roche M, Fling SP, Gonçalves PH, Lurain K, Ramaswami R, Wang CJ, Gorelick RJ, Welker JL, O'Donoghue L, Choudhary H, Lifson JD, Rasmussen TA, Rhodes A, Tumpach C, Yarchoan R, Maldarelli F, Cheever MA, Sékaly R, Chomont N, Deeks SG, Lewin SR. Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. *Sci Transl Med.* 2022 Jan 26; 14(629):eabl3836. PMID: 35080914
- 2022 Dub? K, Campbell CK, Eskaf S, Saucedo JA, Ndukwe S, Henley L, Persaud D, Deeks SG, Auerbach JD, Saberi P. Willingness of Racially Diverse Young Adults Living with HIV to Participate in HIV Cure Research: A Cross-Sectional Survey in the United States. *AIDS Res Hum Retroviruses.* 2022 Nov 10. PMID: 36226414
- 2022 Tomalka JA, Suthar MS, Deeks SG, Sekaly RP. Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses. *Nat Immunol.* 2022 03; 23(3):360-370. PMID: 35210622
- 2022 Henderson M, Fidler S, Mothe B, Grinsztejn B, Haire B, Collins S, Lau JSY, Luba M, Sanne I, Tatoud R, Deeks S, Lewin SR. Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19. *J Int AIDS Soc.* 2022 02; 25(2):e25882. PMID: 35138683. PMCID: PMC8826545
- 2022 Durstenfeld MS, Hsue PY, Peluso MJ, Deeks SG. Findings From Mayo Clinic's Post-COVID Clinic: PASC Phenotypes Vary by Sex and Degree of IL-6 Elevation. *Mayo Clin Proc.* 2022 03; 97(3):430-432. PMID: 35246280. PMCID: PMC8886352
- 2022 Swainson LA, Sharma AA, Ghneim K, Ribeiro SP, Wilkinson P, Dunham RM, Albright RG, Wong S, Estes JD, Piatak M, Deeks SG, Hunt PW, Sekaly RP, McCune JM. IFN α -blockade during ART-treated SIV infection lowers tissue vDNA, rescues immune function, and improves overall health. *JCI Insight.* 2022 Feb 01. PMID: 35104248
- 2022 Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. *Trends Immunol.* 2022 04; 43(4):268-270. PMID: 35272932. PMCID: PMC8901423
- 2022 Duette G, Hiener B, Morgan H, Mazur FG, Mathivanan V, Horsburgh BA, Fisher K, Tong O, Lee E, Ahn H, Shaik A, Fromentin R, Hoh R, Bacchus-Souffan C, Nasr N, Cunningham A, Hunt PW, Chomont N, Turville SG, Deeks SG, Kelleher AD, Schlub TE, Palmer S. The HIV-1 proviral landscape reveals Nef contributes to HIV-1 persistence in effector memory CD4+ T-cells. *J Clin Invest.* 2022 Feb 08. PMID: 35133986

- 2022 Beckford-Vera DR, Flavell RR, Seo Y, Martinez-Ortiz E, Aslam M, Thanh C, Fehrman E, Pardons M, Kumar S, Deitchman AN, Ravanfar V, Schulte B, Wu IK, Pan T, Reeves JD, Nixon CC, Iyer NS, Torres L, Munter SE, Hyunh T, Petropoulos CJ, Hoh R, Franc BL, Gama L, Koup RA, Mascola JR, Chomont N, Deeks SG, VanBrocklin HF, Henrich TJ. First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody. *Nat Commun.* 2022 03 09; 13(1):1219. PMID: 35264559. PMCID: PMC8907355
- 2022 Peluso MJ, Williams MC, Campbell DM, Dee L, Taylor J, Ngo LH, Hoh R, Dubé K, Saucedo JA, Deeks SG. SARS-CoV-2 Booster Vaccination for Participants in PMID: 35147584. PMCID: PMC8851852
- 2022 Fisher K, Wang XQ, Lee A, Morcilla V, de Vries A, Lee E, Eden JS, Deeks SG, Kelleher AD, Palmer S. Plasma-Derived HIV-1 Virions Contain Considerable Levels of Defective Genomes. *J Virol.* 2022 03 23; 96(6):e0201121. PMID: 35201897. PMCID: PMC8941922
- 2022 Peluso MJ, Deeks SG, Mustapic M, Kapogiannis D, Henrich TJ, Lu S, Goldberg SA, Hoh R, Chen JY, Martinez EO, Kelly JD, Martin JN, Goetzl EJ. SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. *Ann Neurol.* 2022 06; 91(6):772-781. PMID: 35285072. PMCID: PMC9082480
- 2022 Lee MJ, Collins S, Babalis D, Johnson N, Falaschetti E, Prevost AT, Ashraf A, Jacob M, Cole T, Hurley L, Pace M, Ogbe A, Khan M, Zacharopoulou P, Brown H, Sutherland E, Box H, Fox J, Deeks S, Horowitz J, Nussenzweig MC, Caskey M, Frater J, Fidler S. The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial. *Trials.* 2022 Apr 05; 23(1):263. PMID: 35382844. PMCID: PMC8981886
- 2022 Dubé K, Kanazawa J, Patel H, Louella M, Sylla L, Sheehy J, Dee L, Taylor J, Adair J, Anthony-Gonda K, Dropulic B, Saucedo JA, Peluso MJ, Deeks SG, Simoni J. Ethical and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States. *BMC Med Ethics.* 2022 Apr 09; 23(1):39. PMID: 35397551. PMCID: PMC8994300

- 2022 Dubé K, Eskaf S, Barr L, Palm D, Hogg E, Simoni JM, Sugarman J, Brown B, Saucedo JA, Henley L, Deeks S, Fox L, Gandhi RT, Smith D, Li JZ. Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study. *AIDS Res Hum Retroviruses*. 2022 Jun; 38(6):510-517. PMID: 35323030. PMCID: PMC9225827
- 2022 Luo Z, Health SL, Li M, Yang H, Wu Y, Collins M, Deeks SG, Martin JN, Scott A, Jiang W. Variation in blood microbial lipopolysaccharide (LPS) contributes to immune reconstitution in response to suppressive antiretroviral therapy in HIV. *EBioMedicine*. 2022 Apr 29; 80:104037. PMID: 35500539. PMCID: PMC9065923
- 2022 Ferrari B, Da Silva AC, Liu KH, Saidakova EV, Korolevskaya LB, Shmagel KV, Shive C, Pacheco Sanchez G, Retuerto M, Sharma AA, Ghneim K, Noel-Romas L, Rodriguez B, Ghannoum MA, Hunt PP, Deeks SG, Burgener AD, Jones DP, Dobre MA, Marconi VC, Sekaly RP, Younes SA. Gut-derived bacterial toxins impair memory CD4+ T cell mitochondrial function in HIV-1 infection. *J Clin Invest*. 2022 May 02; 132(9). PMID: 35316209. PMCID: PMC9057623
- 2022 Durstenfeld MS, Peluso MJ, Kelly JD, Win S, Swaminathan S, Li D, Arechiga VM, Zepeda V, Sun K, Shao S, Hill C, Arreguin MI, Lu S, Hoh R, Tai V, Chenna A, Yee BC, Winslow JW, Petropoulos CJ, Kornak J, Henrich TJ, Martin JN, Deeks SG, Hsue PY. Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. *JCI Insight*. 2022 May 23; 7(10). PMID: 35389890. PMCID: PMC9220849
- 2022 Serrano-Villar S, Wu K, Hunt PW, Lok JJ, Ron R, Sainz T, Moreno S, Deeks SG, Bosch RJ. Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events. *EBioMedicine*. 2022 May 26; 80:104072. PMID: 35644125. PMCID: PMC9156990
- 2022 Peluso MJ, Sans HM, Forman CA, Nylander AN, Ho HE, Lu S, Goldberg SA, Hoh R, Tai V, Munter SE, Chenna A, Yee BC, Winslow JW, Petropoulos CJ, Martin JN, Kelly JD, Durstenfeld MS, Hsue PY, Hunt PW, Greene M, Chow FC, Hellmuth J, Henrich TJ, Glidden DV, Deeks SG. Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection. *Neurol Neuroimmunol Neuroinflamm*. 2022 Sep; 9(5). PMID: 35701186. PMCID: PMC9210548

- 2022 Giron LB, Peluso MJ, Ding J, Kenny G, Zilberstein NF, Koshy J, Hong KY, Rasmussen H, Miller GE, Bishehsari F, Balk RA, Moy JN, Hoh R, Lu S, Goldman AR, Tang HY, Yee BC, Chenna A, Winslow JW, Petropoulos CJ, Kelly JD, Wasse H, Martin JN, Liu Q, Keshavarzian A, Landay A, Deeks SG, Henrich TJ, Abdel-Mohsen M. Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF- κ B signaling. *JCI Insight*. 2022 Jun 21. PMID: 35727635
- 2023 Gartner MJ, Tumpach C, Dantanarayana A, Stern J, Zerbato JM, Chang JJ, Angelovich TA, Anderson JL, Symons J, Deeks SG, Flynn JK, Lewin SR, Churchill MJ, Gorry PR, Roche M. Persistence of envelopes in different CD4+ T-cell subsets in antiretroviral therapy-suppressed people with HIV. *AIDS*. 2023 Feb 01; 37(2):247-257. PMID: 36541637. PMCID: PMC9794144
- 2023 Sperber HS, Raymond KA, Bouzidi MS, Ma T, Valdebenito S, Eugenin EA, Roan NR, Deeks SG, Winning S, Fandrey J, Schwarzer R, Pillai SK. The hypoxia-regulated ectonucleotidase CD73 is a host determinant of HIV latency. *Cell Rep*. 2023 Oct 31; 42(11):113285. PMID: 37910505
- 2023 Wong AC, Devason AS, Umana IC, Cox TO, Dohnalová L, Litichevskiy L, Perla J, Lundgren P, Etwebi Z, Izzo LT, Kim J, Tetlak M, Descamps HC, Park SL, Wisser S, McKnight AD, Pardy RD, Kim J, Blank N, Patel S, Thum K, Mason S, Beltra JC, Michieletto MF, Ngiow SF, Miller BM, Liou MJ, Madhu B, Dmitrieva-Posocco O, Huber AS, Hewins P, Petucci C, Chu CP, Baraniecki-Zwil G, Giron LB, Baxter AE, Greenplate AR, Kearns C, Montone K, Litzky LA, Feldman M, Henao-Mejia J, Striepen B, Ramage H, Jurado KA, Wellen KE, O'Doherty U, Abdel-Mohsen M, Landay AL, Keshavarzian A, Henrich TJ, Deeks SG, Peluso MJ, Meyer NJ, Wherry EJ, Abramoff BA, Cherry S, Thaiss CA, Levy M. Serotonin reduction in post-acute sequelae of viral infection. *Cell*. 2023 Oct 09. PMID: 37848036
- 2023 Durstenfeld MS, Peluso MJ, Spinelli MA, Li D, Hoh R, Chenna A, Yee B, Winslow J, Petropoulos C, Gandhi M, Henrich TJ, Aras MA, Long CS, Deeks SG, Hsue PY. Association of SARS-CoV-2 Infection and Cardiopulmonary Long COVID With Exercise Capacity and Chronotropic Incompetence Among People With HIV. *J Am Heart Assoc*. 2023 Oct 13; e030896. PMID: 37830367
- 2023 Reeves DB, Bacchus-Souffan C, Fitch M, Abdel-Mohsen M, Hoh R, Ahn H, Stone M, Hecht F, Martin J, Deeks SG, Hellerstein MK, McCune JM, Schiffer JT, Hunt PW. Estimating the contribution of CD4 T cell subset proliferation and differentiation to HIV persistence. *Nat Commun*. 2023 10 02; 14(1):6145. PMID: 37783718. PMCID: PMC10545742

- 2023 Proal AD, VanElzakker MB, Aleman S, Bach K, Boribong BP, Buggert M, Cherry S, Chertow DS, Davies HE, Dupont CL, Deeks SG, Eimer W, Ely EW, Fasano A, Freire M, Geng LN, Griffin DE, Henrich TJ, Iwasaki A, Izquierdo-Garcia D, Locci M, Mehandru S, Painter MM, Peluso MJ, Pretorius E, Price DA, Putrino D, Scheuermann RH, Tan GS, Tanzi RE, VanBrocklin HF, Yonker LM, Wherry EJ. Author Correction: SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). *Nat Immunol.* 2023 Sep 18. PMID: 37723351
- 2023 Byrum JR, Waltari E, Janson O, Guo SM, Folkesson J, Chhun BB, Vinden J, Ivanov IE, Forst ML, Li H, Larson AG, Blackmon L, Liu Z, Wu W, Ahyong V, Tato CM, McCutcheon KM, Hoh R, Kelly JD, Martin JN, Peluso MJ, Henrich TJ, Deeks SG, Prakash M, Greenhouse B, Mehta SB, Pak JE. MultiSero: An Open-Source Multiplex-ELISA Platform for Measuring Antibody Responses to Infection. *Pathogens.* 2023 May 02; 12(5). PMID: 37242341. PMCID: PMC10221076
- 2023 Durstenfeld MS, Peluso MJ, Kaveti P, Hill C, Li D, Sander E, Swaminathan S, Arechiga VM, Lu S, Goldberg SA, Hoh R, Chenna A, Yee BC, Winslow JW, Petropoulos CJ, Kelly JD, Glidden DV, Henrich TJ, Martin JN, Lee YJ, Aras MA, Long CS, Grandis DJ, Deeks SG, Hsue PY. Reduced exercise capacity, chronotropic incompetence, and early systemic inflammation in cardiopulmonary phenotype Long COVID. *J Infect Dis.* 2023 May 11. PMID: 37166076
- 2023 Bodansky A, Wang CY, Saxena A, Mitchell A, Kung AF, Takahashi S, Anglin K, Huang B, Hoh R, Lu S, Goldberg SA, Romero J, Tran B, Kirtikar R, Grebe H, So M, Greenhouse B, Durstenfeld MS, Hsue PY, Hellmuth J, Kelly JD, Martin JN, Anderson MS, Deeks SG, Henrich TJ, DeRisi JL, Peluso MJ. Autoantigen profiling reveals a shared post-COVID signature in fully recovered and long COVID patients. *JCI Insight.* 2023 06 08; 8(11). PMID: 37288661. PMCID: PMC10393220
- 2023 Siegel DA, Thanh C, Wan E, Hoh R, Hobbs K, Pan T, Gibson EA, Kroetz DL, Martin J, Hecht F, Pilcher C, Martin M, Carrington M, Pillai S, Busch MP, Stone M, Levy CN, Huang ML, Roychoudhury P, Hladik F, Jerome KR, Kiem HP, Henrich TJ, Deeks SG, Lee SA. Host variation in type I interferon signaling genes (MX1), C-C chemokine receptor type 5 gene, and major histocompatibility complex class I alleles in treated HIV+ noncontrollers predict viral reservoir size. *AIDS.* 2023 Mar 01; 37(3):477-488. PMID: 36695358. PMCID: PMC9894159

- 2023 Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, McCorkell L, Nadkarni GN, Parthasarathy S, Singh U, Walker TA, Selvaggi CA, Shinnick DJ, Schulte CCM, Atchley-Challenner R, Alba GA, Alicic R, Altman N, Anglin K, Argueta U, Ashktorab H, Baslet G, Bassett IV, Bateman L, Bedi B, Bhattacharyya S, Bind MA, Blomkalns AL, Bonilla H, Bush PA, Castro M, Chan J, Charney AW, Chen P, Chibnik LB, Chu HY, Clifton RG, Costantine MM, Cribbs SK, Davila Nieves SI, Deeks SG, Duven A, Emery IF, Erdmann N, Erlandson KM, Ernst KC, Farah-Abraham R, Farner CE, Feuerriegel EM, Fleurimont J, Fonseca V, Franko N, Gainer V, Gander JC, Gardner EM, Geng LN, Gibson KS, Go M, Goldman JD, Grebe H, Greenway FL, Habli M, Hafner J, Han JE, Hanson KA, Heath J, Hernandez C, Hess R, Hodder SL, Hoffman MK, Hoover SE, Huang B, Hughes BL, Jagannathan P, John J, Jordan MR, Katz SD, Kaufman ES, Kelly JD, Kelly SW, Kemp MM, Kirwan JP, Klein JD, Knox KS, Krishnan JA, Kumar A, Laiyemo AO, Lambert AA, Lanca M, Lee-Iannotti JK, Logarbo BP, Longo MT, Luciano CA, Lutrick K, Maley JH, Marathe JG, Marconi V, Marshall GD, Martin CF, Matusov Y, Mehari A, Mendez-Figueroa H, Mermelstein R, Metz TD, Morse R, Mosier J, Mouchati C, Mullington J, Murphy SN, Neuman RB, Nikolich JZ, Ofotokun I, Ojemakinde E, Palatnik A, Palomares K, Parimon T, Parry S, Patterson JE, Patterson TF, Patzer RE, Peluso MJ, Pemu P, Pettker CM, Plunkett BA, Pogreba-Brown K, Poppas A, Quigley JG, Reddy U, Reece R, Reeder H, Reeves WB, Reiman EM, Rischard F, Rosand J, Rouse DJ, Ruff A, Saade G, Sandoval GJ, Schlater SM, Shepherd F, Sherif ZA, Simhan H, Singer NG, Skupski DW, Sowles A, Sparks JA, Sukhera FI, Taylor BS, Teunis L, Thomas RJ, Thorp JM, Thuluvath P, Ticotsky A, Tita AT, Tuttle KR, Urdaneta AE, Valdivieso D, VanWagoner TM, Vasey A, Verduzco-Gutierrez M, Wallace ZS, Ward HD, Warren DE, Weiner SJ, Welch S, Whiteheart SW, Wiley Z, Wisnivesky JP, Yee LM, Zisis S, Horwitz LI, Foulkes AS, RECOVER Consortium. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. *JAMA*. 2023 06 13; 329(22):1934-1946. PMID: 37278994. PMCID: PMC10214179
- 2022 Martin HA, Kadiyala GN, Telwatte S, Wedrychowski A, Chen TH, Moron-Lopez S, Arneson D, Hoh R, Deeks S, Wong J, Yukl SA. New Assay Reveals Vast Excess of Defective over Intact HIV-1 Transcripts in Antiretroviral Therapy-Suppressed Individuals. *J Virol*. 2022 12 21; 96(24):e0160522. PMID: 36448806. PMCID: PMC9769383
- 2023 Wedrychowski A, Martin HA, Li Y, Telwatte S, Kadiyala GN, Melberg M, Etemad B, Connick E, Jacobson JM, Margolis DM, Skiest D, Volberding P, Hecht F, Deeks S, Wong JK, Li JZ, Yukl SA. Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control. *J Virol*. 2023 Jan 31; 97(1):e0125422. PMID: 36541802. PMCID: PMC9888280
- 2023 Landovitz RJ, Scott H, Deeks SG. Prevention, treatment and cure of HIV infection. *Nat Rev Microbiol*. 2023 Oct; 21(10):657-670. PMID: 37344551

- 2023 Lian X, Seiger KW, Parsons EM, Gao C, Sun W, Gladkov GT, Roseto IC, Einkauf KB, Osborn MR, Chevalier JM, Jiang C, Blackmer J, Carrington M, Rosenberg ES, Lederman MM, McMahon DK, Bosch RJ, Jacobson JM, Gandhi RT, Peluso MJ, Chun TW, Deeks SG, Yu XG, Lichterfeld M. Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy. *Cell Host Microbe*. 2023 01 11; 31(1):83-96.e5. PMID: 36596305. PMCID: PMC9839361
- 2023 Horwitz LI, Thaweethai T, Brosnahan SB, Cicek MS, Fitzgerald ML, Goldman JD, Hess R, Hodder SL, Jacoby VL, Jordan MR, Krishnan JA, Laiyemo AO, Metz TD, Nichols L, Patzer RE, Sekar A, Singer NG, Stiles LE, Taylor BS, Ahmed S, Algren HA, Anglin K, Aponte-Soto L, Ashktorab H, Bassett IV, Bedi B, Bhadelia N, Bime C, Bind MC, Black LJ, Blomkalns AL, Brim H, Castro M, Chan J, Charney AW, Chen BK, Chen LQ, Chen P, Chestek D, Chibnik LB, Chow DC, Chu HY, Clifton RG, Collins S, Costantine MM, Cribbs SK, Deeks SG, Dickinson JD, Donohue SE, Durstenfeld MS, Emery IF, Erlandson KM, Facelli JC, Farah-Abraham R, Finn AV, Fischer MS, Flaherman VJ, Fleurimont J, Fonseca V, Gallagher EJ, Gander JC, Gennaro ML, Gibson KS, Go M, Goodman SN, Granger JP, Greenway FL, Hafner JW, Han JE, Harkins MS, Hauser KSP, Heath JR, Hernandez CR, Ho O, Hoffman MK, Hoover SE, Horowitz CR, Hsu H, Hsue PY, Hughes BL, Jagannathan P, James JA, John J, Jolley S, Judd SE, Juskowich JJ, Kanjilal DG, Karlson EW, Katz SD, Kelly JD, Kelly SW, Kim AY, Kirwan JP, Knox KS, Kumar A, Lamendola-Essel MF, Lanca M, Lee-Lannotti JK, Lefebvre RC, Levy BD, Lin JY, Logarbo BP, Logue JK, Longo MT, Luciano CA, Lutrick K, Malakooti SK, Mallett G, Maranga G, Marathe JG, Marconi VC, Marshall GD, Martin CF, Martin JN, May HT, McComsey GA, McDonald D, Mendez-Figueroa H, Miele L, Mittleman MA, Mohandas S, Mouchati C, Mullington JM, Nadkarni GN, Nahin ER, Neuman RB, Newman LT, Nguyen A, Nikolich JZ, Ofotokun I, Ogbogu PU, Palatnik A, Palomares KTS, Parimon T, Parry S, Parthasarathy S, Patterson TF, Pearman A, Peluso MJ, Pemu P, Pettker CM, Plunkett BA, Pogreba-Brown K, Poppas A, Porterfield JZ, Quigley JG, Quinn DK, Raissy H, Rebello CJ, Reddy UM, Reece R, Reeder HT, Rischard FP, Rosas JM, Rosen CJ, Roupheal NG, Rouse DJ, Ruff AM, Saint Jean C, Sandoval GJ, Santana JL, Schlater SM, Scirba FC, Selvaggi C, Seshadri S, Sesso HD, Shah DP, Shemesh E, Sherif ZA, Shinnick DJ, Simhan HN, Singh U, Sowles A, Subbian V, Sun J, Suthar MS, Teunis LJ, Thorp JM, Ticotsky A, Tita ATN, Tragus R, Tuttle KR, Urdaneta AE, Utz PJ, VanWagoner TM, Vasey A, Vernon SD, Vidal C, Walker T, Ward HD, Warren DE, Weeks RM, Weiner SJ, Weyer JC, Wheeler JL, Whiteheart SW, Wiley Z, Williams NJ, Wisnivesky JP, Wood JC, Yee LM, Young NM, Zisis SN, Foulkes AS. Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design. *PLoS One*. 2023; 18(6):e0286297. PMID: 37352211. PMCID: PMC10289397

- 2023 Clark IC, Mudvari P, Thaploo S, Smith S, Abu-Laban M, Hamouda M, Theberge M, Shah S, Ko SH, P?rez L, Bunis DG, Lee JS, Kilam D, Zakaria S, Choi S, Darko S, Henry AR, Wheeler MA, Hoh R, Butrus S, Deeks SG, Quintana FJ, Douek DC, Abate AR, Boritz EA. HIV silencing and cell survival signatures in infected T cell reservoirs. *Nature*. 2023 Jan 04. PMID: 36599978. PMCID: PMC9908556
- 2023 Wang Y, Lifshitz L, Silverstein NJ, Mintzer E, Luk K, StLouis P, Brehm MA, Wolfe SA, Deeks SG, Luban J. Transcriptional and chromatin profiling of human blood innate lymphoid cell subsets sheds light on HIV-1 pathogenesis. *EMBO J*. 2023 08 15; 42(16):e114153. PMID: 37382276. PMCID: PMC10425848
- 2023 Peluso MJ, Mitchell A, Wang CY, Takahashi S, Hoh R, Tai V, Durstenfeld MS, Hsue PY, Kelly JD, Martin JN, Wilson MR, Greenhouse B, Deeks SG, DeRisi JL, Henrich TJ. Low Prevalence of Interferon a Autoantibodies in People Experiencing Symptoms of Post-Coronavirus Disease 2019 (COVID-19) Conditions, or Long COVID. *J Infect Dis*. 2023 01 11; 227(2):246-250. PMID: 36089700. PMCID: PMC9494362
- 2023 Reeves DB, Gaebler C, Oliveira TY, Peluso MJ, Schiffer JT, Cohn LB, Deeks SG, Nussenzweig MC. Impact of misclassified defective proviruses on HIV reservoir measurements. *Nat Commun*. 2023 Jul 13; 14(1):4186. PMID: 37443365. PMCID: PMC10345136
- 2023 Fisher K, Schlub TE, Boyer Z, Rasmussen TA, Rhodes A, Hoh R, Hecht FM, Deeks SG, Lewin SR, Palmer S. Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4. *Front Immunol*. 2023; 14:1064346. PMID: 36776833. PMCID: PMC9909745
- 2023 Augusto DG, Murdolo LD, Chatzileontiadou DSM, Sabatino JJ, Yusufali T, Peyser ND, Butcher X, Kizer K, Guthrie K, Murray VW, Pae V, Sarvadhavabhatla S, Beltran F, Gill GS, Lynch KL, Yun C, Maguire CT, Peluso MJ, Hoh R, Henrich TJ, Deeks SG, Davidson M, Lu S, Goldberg SA, Kelly JD, Martin JN, Vierra-Green CA, Spellman SR, Langton DJ, Dewar-Oldis MJ, Smith C, Barnard PJ, Lee S, Marcus GM, Olgin JE, Pletcher MJ, Maiers M, Gras S, Hollenbach JA. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. *Nature*. 2023 Aug; 620(7972):128-136. PMID: 37468623. PMCID: PMC10396966

- 2023 Deyoe JE, Kelly JD, Grijalva CG, Bonenfant G, Lu S, Anglin K, Garcia-Knight M, Pineda-Ramirez J, Briggs Hagen M, Saydah S, Abedi GR, Goldberg SA, Tassetto M, Zhang A, Donohue KC, Davidson MC, Diaz Sanchez R, Djomaleu M, Mathur S, Shak JR, Deeks SG, Peluso MJ, Chiu CY, Zhu Y, Halasa NB, Chappell JD, Mellis A, Reed C, Andino R, Martin JN, Zhou B, Talbot HK, Midgley CM, Rolfes MA. Association of culturable-virus detection and household transmission of SARS-CoV-2 - California and Tennessee, 2020-2022. *J Infect Dis.* 2023 Jan 27. PMID: 36705269
- 2023 Tumpach C, Rhodes A, Kim Y, Ong J, Liu H, Chibo D, Druce J, Williamson D, Hoh R, Deeks SG, Yukl SA, Roche M, Lewin SR, Telwatte S. Adaptation of Droplet Digital PCR-Based HIV Transcription Profiling to Digital PCR and Association of HIV Transcription and Total or Intact HIV DNA. *Viruses.* 2023 Jul 22; 15(7). PMID: 37515292. PMCID: PMC10384802
- 2023 Kincer LP, Joseph SB, Gilleece MM, Hauser BM, Sizemore S, Zhou S, Di Germanio C, Zetterberg H, Fuchs D, Deeks SG, Spudich S, Gisslen M, Price RW, Swanstrom R. Rebound HIV-1 in cerebrospinal fluid after antiviral therapy interruption is mainly clonally amplified R5 T cell-tropic virus. *Nat Microbiol.* 2023 Feb; 8(2):260-271. PMID: 36717718
- 2023 McMyn NF, Varriale J, Fray EJ, Zitzmann C, MacLeod H, Lai J, Singhal A, Moskovljevic M, Garcia MA, Lopez BM, Hariharan V, Rhodehouse K, Lynn K, Tebas P, Mounzer K, Montaner LJ, Benko E, Kovacs C, Hoh R, Simonetti FR, Laird GM, Deeks SG, Ribeiro RM, Perelson AS, Siliciano RF, Siliciano JM. The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy. *J Clin Invest.* 2023 09 01; 133(17). PMID: 37463049. PMCID: PMC10471168
- 2023 Peluso MJ, Deveau TM, Munter SE, Ryder D, Buck A, Beck-Engeser G, Chan F, Lu S, Goldberg SA, Hoh R, Tai V, Torres L, Iyer NS, Deswal M, Ngo LH, Buitrago M, Rodriguez A, Chen JY, Yee BC, Chenna A, Winslow JW, Petropoulos CJ, Deitchman AN, Hellmuth J, Spinelli MA, Durstenfeld MS, Hsue PY, Kelly JD, Martin JN, Deeks SG, Hunt PW, Henrich TJ. Chronic viral coinfections differentially affect the likelihood of developing long COVID. *J Clin Invest.* 2023 Feb 01; 133(3). PMID: 36454631. PMCID: PMC9888380
- 2023 Proal AD, VanElzakker MB, Aleman S, Bach K, Boribong BP, Buggert M, Cherry S, Chertow DS, Davies HE, Dupont CL, Deeks SG, Eimer W, Ely EW, Fasano A, Freire M, Geng LN, Griffin DE, Henrich TJ, Iwasaki A, Izquierdo-Garcia D, Locci M, Mehandru S, Painter MM, Peluso MJ, Pretorius E, Price DA, Putrino D, Scheuermann RH, Tan GS, Tanzi RE, VanBrocklin HF, Yonker LM, Wherry EJ. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). *Nat Immunol.* 2023 Sep 04. PMID: 37667052

- 2023 Hastie E, Moser C, Sun X, Lennox J, Hsue PY, Bosch RJ, Deeks S, Meneses MV, Lederman MM, Hunt P, Henrich TJ, Marconi VC, Gianella S. Effect of Immune-Modulatory Interventions on Asymptomatic Cytomegalovirus Shedding during Suppressive Antiretroviral Therapy. *J Infect Dis.* 2023 Mar 07. PMID: 36881933
- 2023 Li Z, Deeks SG, Ott M, Greene WC. Comprehensive synergy mapping links a BAF- and NSL-containing PMID: 37682714
- 2023 Chiu CY, Schou MD, McMahon JH, Deeks SG, Fromentin R, Chomont N, Wykes MN, Rasmussen TA, Lewin SR. Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy. *Front Immunol.* 2023; 14:1123342. PMID: 37056754. PMCID: PMC10086427
- 2023 Sengupta S, Zhang J, Reed MC, Yu J, Kim A, Boronina TN, Board NL, Wrabl JO, Shenderov K, Welsh RA, Yang W, Timmons AE, Hoh R, Cole RN, Deeks SG, Siliciano JD, Siliciano RF, Sadegh-Nasseri S. A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design. *J Exp Med.* 2023 Jul 03; 220(7). PMID: 37058141. PMCID: PMC10114365
- 2023 Takahashi S, Peluso MJ, Hakim J, Turcios K, Janson O, Routledge I, Busch MP, Hoh R, Tai V, Kelly JD, Martin JN, Deeks SG, Henrich TJ, Greenhouse B, Rodriguez-Barraquer I. SARS-CoV-2 Serology Across Scales: A Framework for Unbiased Estimation of Cumulative Incidence Incorporating Antibody Kinetics and Epidemic Recency. *Am J Epidemiol.* 2023 Apr 29. PMID: 37119030

OTHER PUBLICATIONS

- 1995 Deeks S, Volberding P. Clinical Trials and Experimental Treatments. In: Delaney, M Ed. *The Essential HIV/AIDS Treatment Handbook.* Simon and Schuster, 1995
- 1997 Deeks SG. New principles of HIV-related medical care. *Focus.* 1997 Apr; 12(5):5-7.
- 1997 Deeks S, Kahn J. The problem with protease inhibitor resistance. *HIV Newsline* 1997;3:52-56.
- 1997 Deeks S, Coleman R. Comparison of three clinical guidelines for the use of antiretroviral therapies. *Formulary* 1997; 32:1134-45.

- 1997 Deeks SG, Volberding PA. HIV-1 protease inhibitors. *AIDS Clin Rev.* 1997-1998; 145-85.
- 1997 Deeks S. Protease inhibitor resistance and salvage therapy. *HIV Newslines* 1997;6:132-135.
- 1998 Deeks SG. Antiretroviral agents: the next generation. *AIDS Clin Care.* 1998 May; 10(5):33-6, 39-40.
- 1998 Deeks SG, Sax PE. Should we argue with success? *AIDS Clin Care.* 1998 Sep; 10(9):68, 72.
- 1998 Holtzer CD, Deeks SG. Impact of HIV protease inhibitors on HIV/AIDS treatment costs. *AIDS Reader* 1998; 8:53-69.
- 1999 Deeks SG, Volberding PA. Antiretroviral therapy for HIV disease. In: Cohen PT, Sande MA, Volberding PA, editors. *The AIDS Knowledge Base, Third Edition.* Philadelphia: Lippicott Williams & Wilkins, Inc; 1999.
- 1999 Deeks SG. Failure of HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy. *Adv Exp Med Biol.* 1999; 458:175-82.
- 1999 Deeks SG, Kaufmann D, Telenti A. CD4 cell changes after virologic failure: the "viral load-CD4 disconnect". *HIV Advances in Research and Therapy* 1999;9:9-16.
- 1999 Deeks SG. Antiretroviral therapy for HIV disease. In: Volberding PA, Aberg JA, editors. *The San Francisco General Hospital Handbook of HIV Management.* New York: Parthenon Publishing Group; 1999.
- 1999 Deeks SG, Volberding PA. Antiretroviral therapy. In: Sande MA, Volberding PA, editors. *The Medical Management of AIDS, Sixth Edition.* Philadelphia: W.B Saunders Company; 1999.
- 1999 Deeks SG, Grant RM. Sustained CD4 responses after virological failure of protease inhibitor-containing therapy. *Antivir Ther.* 1999; 4 Suppl 3:7-11.
- 2004 Critchfield JM, Deeks SG. Treating the latent reservoir of HIV. *AIDS Read.* 2004 Sep; 14(9):485-6.
- 2004 Bangsberg DR, Moss A, Deeks SG. There are no paradoxes of adherence and drug resistance to HIV antiretroviral therapy - Reply. *Journal of Antimicrobial Chemotherapy* 2004; 54:694-95 (letter).

- 2007 Barbour JD, Deeks SG. Clinical Implications of HIV Fitness and Virulence. In: Global HIV/AIDS Medicine. Philadelphia: W.B Saunders Company; 2007.
- 2007 Hunt PW, Martin JN, Deeks SG. Reply to "More on the Treatment-Tropism Relationship: The Impact of Prior Antiretroviral Treatment on HIV Coreceptor Tropism among Subjects Entering AIDS Clinical Trials Group 175. J Infect Diseases 2007;196:329-30 (letter).
- 2007 Rodriguez B, Lederman MM, Sethi AK, Cheruv VK, Martin J, Deeks S. Presenting Plasma HIV RNA Level and Rate of CD4 T-Cell Decline-Reply. JAMA 2007; 297:806-807 (letter).

SIGNIFICANT PUBLICATIONS

Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, Ferre AL, Hayes TL, Somsouk M, Hsue PY, Van Natta ML, Meinert CL, Lederman MM, Hatano H, Jain V, Huang Y, Hecht FM, Martin JN, McCune JM, Moreno S, Deeks SG. HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality. PLoS Pathog. 2014 May; 10(5):e1004078. PMID: PMC4022662

We studied the T cell counts in inflammation in a diverse cohort of people living with HIV. We identified the CD4/CD8 ratio as a potential biomarker of disease outcomes during antiretroviral therapy. We also studied the association between this ratio and inflammation. I was the principle investigator of the cohort. I co-designed the study and help direct the data analysis.

We assembled a cohort of well-matched male and female people living with HIV. We found that the size and activity of the reservoir differed based on biologic sex. In a companion study published in PNAS, we found that estrogens prevent latency reversal, and that this affect may account for sex-related differences in viral load and latency. I was the principle investigator of the clinical cohort. I co-designed the study and help direct the data analysis.

2017

Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeier CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. *PLoS Med.* 2017 Nov; 14(11):e1002417. PMID: 29112956. PMCID: PMC5675377

Early initiation of antiretroviral therapy may be curative. This study describes the earliest treated HIV-infected adults reported to date and found that treatment in this setting reduced the amount of HIV by several orders of magnitude but was not curative. I designed the study and directed a massive collaboration involving a large team of public health experts, clinical scientists, virologists and immunologists.

Peluso MJ, Bacchetti P, Ritter KD, Beg SA, Lai J, Martin JN, Hunt PW, Henrich TJ, Siliciano JD, Siliciano RF, Laird GM, Deeks SG. Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. *JCI Insight.* 2020 Feb 11. PMID: 32045386

We describe the size of the HIV reservoir during long-term antiretroviral therapy. We found that putative intact (replication-competent) proviral genomes decayed more rapidly than defective genomes. I helped formulate the hypothesis, designed the study and co-directed the data analysis.

SenGupta D, Brinson C, DeJesus E, Mills A, Shalit P, Guo S, Cai Y, Wallin J, Zhang L, Humeniuk R, Begley R, Geleziunas R, Mellors J, Wrin T, Jones N, Milush J, Ferre A, Shacklett B, Laird G, Moldt B, Vendrame E, Brainard D, Ramgopal M, Deeks SG. The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. *Science Translational Medicine* 2021; 13(599): eabg3071.

This randomized clinical trial assessed the safety and efficacy of a novel TLR-7 agonist (vesatolimod) in people with HIV who controlled HIV prior to going on antiretroviral therapy. We found that vesatolimod enhanced innate immunity, reduced the size of the intact provirus level, and delayed time-to-rebound. I helped formulate the hypothesis, designed the study and co-directed the data analysis.

Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, Lambotte O, Lamplough R, Ndung'u T, Sugarman J, Tiemessen CT, Vandekerckhove L, Lewin SR, International AIDS Society (IAS) Global Scientific Strategy working group. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. *Nature Medicine* 2021 Dec; 27(12):2085-2098. PMID: 34848888

I chaired a program of several expert working groups that collectively developed a global strategy for developing an effective and scalable cure for HIV infection. The resulting publication provided a five-year roadmap for making progress towards a cure.

Prepared: November 19, 2023

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**

INFORMAZIONI PERSONALI

Nome Antonio Di Biagio
Indirizzo
Telefono
E-mail
Nazionalità
Codice Fiscale

Data di nascita

ESPERIENZA LAVORATIVA

- Date (da – a) Dal 14 agosto 2002 al 30 Novembre 2019
- Nome e indirizzo del datore di lavoro Ospedale Policlinico San Martino, IRCCS, Largo R. Benzi 10, 16132 Genova
- Tipo di azienda o settore Policlinico Università Ospedale
- Tipo di impiego Dirigente Medico
- Date (da – a) Responsabile dell'ambulatorio dal 2002 al 2004, Referente Day Hospital dal gennaio 2006 ad oggi
- Nome e indirizzo del datore di lavoro Dal 30 novembre 2019 Università degli Studi di Genova, Ricercatore di tipo B, convenzionato con Ospedale Policlinico San Martino di Genova IRCCS
- Tipo di azienda o settore Dal 30 novembre 2022 Università degli Studi di Genova, Professore Associato di Malattie Infettive convenzionato con Ospedale Policlinico San Martino di Genova IRCCS
- Tipo di impiego Responsabile dell'attività ambulatoriale e di Day Hospital
- Principali mansioni e responsabilità

ISTRUZIONE E FORMAZIONE

- Date (da – a) Settembre 1989 a Ottobre 1995
- Nome e tipo di istituto di istruzione o formazione Università degli Studi di Genova
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita Laurea in Medicina e Chirurgia
- Livello nella classificazione nazionale (se pertinente)

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
- Livello nella classificazione nazionale (se pertinente)
 - Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
- Livello nella classificazione nazionale (se pertinente)

CAPACITÀ E COMPETENZE

PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

PRIMA LINGUA

Novembre 1995 a Novembre 1999

Scuola di Specializzazione in Medicina Tropicale, Università degli Studi di Genova

Terapia Antibiotica, Terapia Antiretrovirale, Farmacocinetica e Farmacodinamica degli Antiretrovirali, Farmaco Economia
Specializzazione in Medicina Tropicale

ALTRE LINGUE

Italiano

Inglese

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

Buona

Buona

Buona

Francese

Buona

Sufficiente

Buona

CAPACITÀ E COMPETENZE

RELAZIONALI

Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.

Dal Febbraio 1999 al Dicembre 1999 Servizio Civile svolto presso la Casa Alloggio San Luca, per bambini e adolescenti, Cooperativa Agorà di Genova. Medico Specialista, in ambulatorio di Malattie Infettive e Medicina tropicale, Esperienza con bambini, adolescenti e adulti

CAPACITÀ E COMPETENZE

ORGANIZZATIVE

Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.

Sperimentatore principale, sub-investigatore di oltre 100 trials clinici multicentrici nazionali ed internazionali in tema di terapia antiretrovirale e terapia antibiotica. Responsabile dal 2001 al 2005 dell'ambulatorio e del Day Hospital dell'U.O. Clinica Malattie Infettive presso la A.O.U. San Martino; Responsabile dal 2005 ad oggi del Day Hospital dell'U.O. Clinica Malattie Infettive presso la A.O.U. San Martino; Responsabile dal 1999 al 2003 dei DRG della Clinica Malattie Infettive. Nel 1999 (6 mesi) membro del CIO dell'Ospedale Galliera di Genova.

CAPACITÀ E COMPETENZE
TECNICHE

*Con computer, attrezzature specifiche,
macchinari, ecc.*

CAPACITÀ E COMPETENZE
ARTISTICHE

Musica, scrittura, disegno ecc.

ALTRE CAPACITÀ E COMPETENZE

*Competenze non precedentemente
indicate.*

Ottima capacità nell'utilizzo di programmi Word, Excel, Power Point su PC e MC, utilizzo ampio del web.

Corso di aggiornamento Università C. Cattaneo nel management delle unità operative di Malattie Infettive (2014-2015)

Corso di Base di Metodologia e Statistica della Ricerca Clinica, Novembre-Dicembre 2008

PATENTE O PATENTI

Ulteriori informazioni

Autore di oltre 385 pubblicazioni censite su PubMed; autore di numerosi articoli su riviste nazionali ed internazionali, abstract a convegni nazionali ed internazionali; relatore in oltre 350 Conferenze e Corsi su argomenti riguardanti il tema delle malattie infettive. Professore a Contratto delle Scuole di Specializzazione in Medicina Tropicale e Malattie Infettive dell'Università degli Studi di Genova dall'anno accademico 2000-2001 al 2007-08.

H-INDEX SCOPUS 33, Total citations 6120.

Nel 2012 aveva conseguito abilitazione scientifica per il ruolo di Professore di II Fascia nel settore Disciplinare MED/17 Malattie Infettive

Nel 2018 ha conseguito abilitazione scientifica per il ruolo di Professore di I Fascia nel settore disciplinare MED/17, Malattie Infettive

Professore a Contratto del Corso di Laurea di Scienze delle Professioni Sanitarie dall'a.a. 2009-2010 all'2011-12

Dall'a.a. 2011-2012 Incarico di docenza nell'ambito del Corso di Laurea magistrale in Medicina e Chirurgia per l'insegnamento di Malattie infettive, Università degli Studi di Genova

Dal giugno 2012 membro dell'Advisory Board per redigere le linee guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con HIV-1 su mandato del Ministero della Salute e del Centro Nazionale AIDS.

Da Marzo 2019 Co-coordinatore gruppo nazionale CISAI

Membro del comitato scientifico di ICONA, ARCA, PRESTIGIO

Membro dello Steering Committe PENTA

Consigliere Eletto della Società italiana di Malattie Infettive e Tropicali 2013-17

Membro del gruppo europeo HIV/TB study group

Membro del Comitato di Programma di ICAR dal 2019

Membro eletto ICAR Government dal 2021

Coordinatore Abstract ICAR 2022, 2023

ALLEGATI

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

Autorizzo al trattamento dei dati personali ai sensi del GDPR e del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" ai fini di attività di Ricerca e Selezione del Personale e contatti lavorativi.

Genova, 25 Gennaio 2023

125

DOTT. SALVO PIERLUIGI FRANCESCO

23/07/2020 - Albo Provinciale dei Medici Chirurghi di ROMA (Ordine della Provincia di ROMA) n. 0000066691

abilitazioni

18/03/2020 - MEDICINA E CHIRURGIA (ROMA "UNIVERSITA CATTOLICA SACRO CUORE")

abilitazioni

2020 / 1 - Medicina e Chirurgia (ROMA "UNIVERSITA CATTOLICA SACRO CUORE")

abilitazioni

CURRICULUM VITAE



INFORMAZIONI PERSONALI

Nome

FABBIANI MASSIMILIANO

Nazionalità

Data di nascita

ISTRUZIONE E FORMAZIONE

• Data: **nel 1997**

Diploma di Maturità Scientifica presso il Liceo Scientifico Statale “Galileo Galilei” di Siena

• Data: **17 Luglio 2003**
(Anno Accademico
2002/2003):

Laurea in Medicina e Chirurgia presso l’Università degli Studi di Siena con votazione 110/110 e Lode, discutendo la tesi “Infezioni da *Staphylococcus aureus*: studio clinico e microbiologico”.

• Data: **2^a sessione anno 2003**

Abilitazione all’esercizio professionale presso l’Università degli Studi di Siena.

• Data: **dal 19 Febbraio 2004**

Iscrizione all’Albo professionale dei Medici Chirurghi di Siena al numero 4077.

• Data: **29 Novembre 2007**
(Anno Accademico
2006/2007):

Diploma di Specializzazione in Malattie Infettive presso l’Università degli Studi di Siena con votazione 70/70 e Lode, discutendo la tesi “Applicazione della strategia di Therapeutic Drug Monitoring nella gestione clinica dei pazienti HIV positivi in trattamento antiretrovirale”.

• Data: **27 Febbraio 2012**
(Anno Accademico
2010/2011):

Diploma di Dottorato di Ricerca in “Biologia e Clinica delle Malattie Infettive e Tropicali” presso l’Università Cattolica del Sacro Cuore di Roma, discutendo la tesi “Therapeutic Drug Monitoring dei farmaci antiretrovirali: evidenze a supporto di una crescente applicazione nella pratica clinica”.

Dall'a.a. 2001-2002 al 2007-2008 ha frequentato la Clinica e Laboratorio di Malattie Infettive dell'Università degli Studi di Siena, dapprima come studente interno, poi come medico specializzando e infine come medico interno. Durante tale periodo ha acquisito competenze sulla gestione clinica infettivologica ed internistica di pazienti adulti e pediatrici. Ha frequentato inoltre presso le U.O. di Malattie Infettive Ospedaliere di Siena, Arezzo e Grosseto approfondendo le conoscenze per il trattamento del paziente epatopatico ed HIV positivo.

Dal luglio 2007 al dicembre 2008 gli è stato conferito incarico a tempo determinato presso il Pronto Soccorso Pediatrico di Grosseto e dei Presidi ad esso correlati nel servizio per l'attivazione di Codici Bianchi e Azzurri. Durante tale periodo ha approfondito aspetti legati alla gestione delle malattie infettive in età pediatrica ed ha acquisito inoltre competenze sulla gestione di urgenze ed emergenze pediatriche mediche e chirurgiche.

Dall'aprile al giugno 2008 è stato titolare di incarico a tempo determinato per la Pediatria di libera scelta nei comuni di Sovicille, Chiusdino e Monticiano dell'USL 7 di Siena, acquisendo competenze per la valutazione clinico-anamnestica e impostazione diagnostico-terapeutica di soggetti pediatrici con patologie acute e croniche infettivologiche e non.

Da settembre 2008 al Marzo 2013 ha collaborato all'attività clinica presso le strutture dell'Istituto di Clinica delle Malattie Infettive dell'Università Cattolica del Sacro Cuore di Roma dapprima con contratto a progetto, poi come dottorando e infine con la qualifica di dirigente medico a tempo determinato. Durante tale periodo ha acquisito esperienza nella impostazione diagnostico-terapeutica ospedaliera e ambulatoriale di patologie infettivologiche acute e croniche (epatiti virali, tubercolosi, infezioni virali, batteriche, fungine e parassitarie nell'ospite immunocompetente e immunodepresso).

In particolare si è occupato della gestione ambulatoriale/day hospital e dell'assistenza domiciliare a pazienti HIV-positivi. E' stato responsabile dell'arruolamento e della gestione di pazienti HIV+ nell'ambito di trials clinici. Ha partecipato alla gestione della sorveglianza epidemiologica sull'infezione da HIV presso il Centro di Riferimento AIDS del Policlinico.

Ha prestato la propria opera presso l'Unità di Consulenza Infettivologica Integrata del Policlinico, struttura dedicata, oltre che alla tradizionale gestione delle consulenze infettivologiche presso i reparti di medicina, chirurgia e terapia intensiva, anche alla sorveglianza attiva e gestione delle infezioni da germi multiresistenti, alla sorveglianza e gestione delle profilassi post-esposizione occupazionale ad agenti a trasmissione parenterale (HIV, HBV, HCV) e respiratoria (tubercolosi e virus respiratori). Nell'ambito dell'attività di consulenza ha dedicato principalmente la propria attenzione alla gestione delle complicanze infettivologiche nel paziente sottoposto a trapianto d'organo, nel

paziente dializzato e nel paziente con problematiche neurologiche e gastroenterologiche, oltre che in pazienti con varie patologie internistiche o chirurgiche.

Ha inoltre partecipato a turni di guardia interdivisionale comprendente reparti di malattie infettive, geriatria e riabilitazione.

Durante tale periodo ha perfezionato le proprie competenze nell'autonoma gestione dei pazienti con problematiche infettivologiche, migliorando la propria manualità nell'esecuzione di manovre invasive di pertinenza infettivologica (es. rachicentesi). Ha inoltre acquisito competenze di base di tecnica ecografica, con particolare riguardo alla misurazione dello spessore medio-intimale carotideo e valutazione della funzionalità endoteliale mediante flow-mediated dilation (FMD).

Dal Maggio 2013 al Dicembre 2014 ha proseguito la propria attività clinica come Medico a tempo determinato presso il Complesso Integrato Columbus – Policlinico Universitario “Agostino Gemelli”, Roma. Ha prestato la propria attività come unico consulente infettivologo del Complesso, costituito da reparti internistici (medicina interna, cardiologia, riabilitazione cardiologica post interventi di cardiocirurgia, reumatologia, gastroenterologia, chemio-radioterapia, nefrologia e dialisi), chirurgici (chirurgia generale e specialistica: ortopedia, chirurgia della mano, chirurgia maxillo-faciale, urologia, ginecologia, oculistica) e un'unità di terapia intensiva. Durante tale periodo ha messo in atto strategie di antimicrobial stewardship al fine migliorare la gestione delle infezioni ospedaliere da germi multi resistenti. Ha collaborato inoltre con la Direzione Sanitaria del Complesso al fine di implementare protocolli di monitoraggio, prevenzione e gestione della diffusione intraospedaliera di germi multi resistenti.

Dal Marzo 2015 lavora come Dirigente Medico a tempo determinato presso l'Unità Operativa di Malattie Infettive dell'Ospedale San Gerardo di Monza. Svolge la propria attività clinica presso il reparto divisionale occupandosi della gestione di pazienti affetti da problematiche infettivologiche ospedaliere o acquisite in comunità. Partecipa inoltre alla gestione ambulatoriale e all'arruolamento in trial clinici di pazienti HIV-positivi.

<hr/> Data: da Ottobre 2003 ad Ottobre 2007 <hr/>	UOC Malattie Infettive Universitarie, AOUS Siena e presidi di rete formativa UU.OO. di Malattie Infettive Ospedaliere di Siena, Arezzo e Grosseto
<ul style="list-style-type: none"> • Nome e indirizzo del datore di lavoro 	
<ul style="list-style-type: none"> • Tipo di impiego 	Medico in formazione specialistica in Malattie Infettive
<ul style="list-style-type: none"> • Principali mansioni e responsabilità 	Partecipazione all'attività clinica di degenza ed ambulatorio infettivologico Partecipazione all'attività di consulenza e di guardia divisionale ed interdivisionale Partecipazione alle attività di Day Hospital specialistico Partecipazione all'esecuzione di rachicentesi Partecipazione all'attività di diagnostica infettivologica e microbiologica Partecipazione all'attività di laboratorio di microbiologia clinica per diagnostica batteriologica, parassitologica e sierologica. Graduale assunzione di autonomia nei compiti assistenziali e nell'esecuzione di interventi
<ul style="list-style-type: none"> • Principali materie/abilità professionali oggetto dello studio 	Malattie infettive acute e croniche in età infantile, nell'adulto e nell'anziano Patologia infettiva nell'adulto immunocompetente e immunodepresso Gestione profilattica e terapeutica di patologia infettiva durante la gravidanza Patologia infettiva del viaggiatore e del migrante Profilassi del viaggiatore
<hr/> Data: da Luglio 2007 a Dicembre 2008 <hr/>	USL 9 Grosseto, Pronto Soccorso Pediatrico di Grosseto e Presidi ad esso correlati
<ul style="list-style-type: none"> • Nome e indirizzo del datore di lavoro 	<ul style="list-style-type: none"> • Tipo di impiego Incarico a tempo determinato per l'attivazione di Codici Bianchi e Azzurri
<ul style="list-style-type: none"> • Principali mansioni e responsabilità 	In autonomia: Valutazione clinico-anamnestica, impostazione diagnostico-terapeutica di soggetti pediatrici ad accesso diretto in Pronto Soccorso codificati in triage con Codici Bianchi e Azzurri In collaborazione: Valutazione clinico-anamnestica, impostazione diagnostico-terapeutica di soggetti pediatrici ad accesso diretto in Pronto Soccorso codificati in triage con Codici Verdi, Gialli e Rossi
<ul style="list-style-type: none"> • Principali materie/abilità professionali oggetto dello studio 	Malattie infettive pediatriche Urgenze ed emergenze pediatriche mediche e chirurgiche Traumatismi

**Data: Da Aprile 2008
a Giugno 2008**

- Nome e indirizzo del datore di lavoro
USL 7 di Siena
- Tipo di impiego
Titolare di incarico a tempo determinato per la Pediatria di libera scelta nei comuni di Sovicille, Chiusdino e Monticiano
- Principali mansioni e responsabilità
Valutazione clinico-anamnestica, impostazione diagnostico-terapeutica di soggetti pediatrici con patologie acute e croniche
Valutazione del neonato e successivo follow up
Bilanci di salute
Vaccinazioni
Interventistica ambulatoriale
Visite domiciliari
- Principali materie/abilità professionali oggetto dello studio
Malattie infettive pediatriche
Valutazione dello sviluppo psicomotorio in età pediatrica
Impostazione di regimi dietetici nel neonato, nel lattante e nel bambino
Traumatismi

Data: Da Dicembre 2009 al Marzo 2010 e da Settembre 2010 al Marzo 2013

- Nome e indirizzo del datore di lavoro
Istituto di Clinica delle Malattie Infettive dell'Università Cattolica del Sacro Cuore di Roma
- Tipo di impiego
Dirigente medico a tempo determinato presso il Policlinico Universitario "A. Gemelli" dell'Università Cattolica del Sacro Cuore, Roma.
- Principali mansioni e responsabilità
Valutazione clinico-anamnestica, impostazione diagnostico-terapeutica nel paziente con problematiche infettivologiche ed internistiche.
Assistenza domiciliare a pazienti HIV positivi
Gestione ambulatoriale del paziente con patologia infettivologica acuta e cronica (HIV, epatiti virali, tubercolosi, infezioni batteriche, virali e parassitarie)
Partecipazione ai turni di guardia interdivisionale (comprendente reparti di malattie infettive, geriatria e riabilitazione) e di consulenza infettivologica
Esecuzione delle principali manovre infettivologiche (es. rachicentesi).
- Principali materie/abilità professionali oggetto dello studio
Malattie infettive acute e croniche nell'adulto e nell'anziano
Patologia infettiva nell'adulto immunocompetente e immunodepresso
Patologia infettiva del viaggiatore e del migrante.

Data: **da Maggio 2013
a Dicembre 2014**

• Nome e indirizzo del datore di lavoro

• Tipo di impiego

• Principali mansioni e responsabilità

Complesso Integrato Columbus, Policlinico Gemelli, Roma

Medico a tempo determinato

Attività di consulenza infettivologica

Attività di controllo e gestione delle infezioni ospedaliere

Antimicrobial stewardship

Gestione infettivologica del paziente immunodepresso (trapiantato renale; pazienti affetti da patologie reumatologiche e gastroenterologiche in terapia immunosoppressiva)

• Principali materie/abilità professionali oggetto dello studio

Valutazione clinico-anamnestica, impostazione diagnostico-terapeutica nel paziente con problematiche infettivologiche ed internistiche. Esecuzione delle principali manovre infettivologiche (es. rachicentesi). Gestione di protocolli per il controllo delle infezioni ospedaliere. Implementazione e gestione diretta di strategie di “antimicrobial stewardship”.

Data: **da Marzo 2015
ad oggi**

• Nome e indirizzo del datore di lavoro

• Tipo di impiego

• Principali mansioni e responsabilità

U.O. Malattie Infettive, Ospedale San Gerardo, Monza.

Dirigente Medico a tempo determinato

Attività clinica presso reparto divisionale

Gestione ambulatoriale del paziente con patologia infettivologica acuta e cronica (HIV, epatiti virali, tubercolosi, infezioni batteriche, virali e parassitarie)

• Principali materie/abilità professionali oggetto dello studio

Valutazione clinico-anamnestica, impostazione diagnostico-terapeutica nel paziente con problematiche infettivologiche ed internistiche. Esecuzione delle principali manovre infettivologiche (es. rachicentesi). Gestione di trial clinici nel paziente HIV-positivo.

**ATTIVITÀ DI RICERCA
E DOCENZA**

Dal 2001 al 2008 attività di ricerca sull'epidemiologia delle infezioni respiratorie da virus emergenti (Metapneumovirus, Bocavirus) in età pediatrica, da *Staphylococcus aureus* e *Mycobacterium tuberculosis complex* e sulla profilassi dell'infezione perinatale da HBV, presso la Clinica e Laboratorio di Malattie Infettive (Dipartimento di Biologia Molecolare, Università di Siena).

Dal 2008, presso l'Istituto di Clinica delle Malattie Infettive dell'Università Cattolica del Sacro Cuore di Roma, attività di ricerca incentrata principalmente sull'infezione da HIV e la terapia antiretrovirale. In particolare, partecipa alle seguenti tematiche di ricerca:

- Trial clinici su terapia antiretrovirale
- Aspetti di farmacologia clinica dei farmaci antiretrovirali, valutando l'utilità dell'applicazione della strategia di Therapeutic Drug Monitoring nella popolazione HIV positiva allo scopo di migliorare l'efficacia della HAART e ridurre l'incidenza di effetti collaterali.
- Disturbi neurocognitivi associati all'infezione da HIV.
- Epidemiologia e meccanismi di resistenza ai farmaci antiretrovirali.
- Metodologie di determinazione del tropismo virale e correlati clinici.
- Efficacia e tollerabilità della terapia antiretrovirale.
- Risposta immunologica alla vaccinazione anti influenzale in pazienti HIV-positivi.
- Aderenza alla terapia antiretrovirale.
- Epidemiologia e clinica dell'infezione da virus influenzali.
- Risposta sierologica alla vaccinazione antipneumococcica e relativo effetto sulla colonizzazione nasale da *Streptococcus pneumoniae* in adulti HIV positivi: studio prospettico sull'efficacia del vaccino coniugato 13-valente (studio multicentrico, farmacologico, interventistico, progetto PRIN 2009, cofinanziato dal MIUR).

La sua attività di ricerca è documentata da numerose pubblicazioni su riviste scientifiche nazionali ed internazionali, oltre che da comunicazioni ed abstract presentati a congressi. In particolare sono attualmente presenti in Scopus 44 pubblicazioni che hanno ricevuto 428 citazioni per un H Index pari a 11.

E' inoltre autore di capitoli di libri e trattati medici.

Ha prestato assistenza come reviewer per riviste scientifiche internazionali (British Medical Journal, Thorax, PLOS ONE, Clinical Microbiology and Infection, Journal of the International AIDS Society, BMC Infectious Diseases, AIDS Research and Human Retroviruses, HIV Clinical Trials, International Journal of Microbiology, North American Journal of Medical Sciences, International Journal of Clinical Practice, HIV/AIDS - Research and Palliative Care, Tropical Medicine and Surgery).

Ha tenuto relazioni a numerosi congressi scientifici ed effettuato docenze durante lo svolgimento dei corsi AIDS per personale medico e non medico.

**CAPACITÀ E COMPETENZE
PERSONALI**

MADRELINGUA

ITALIANO

ALTRA LINGUA

INGLESE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

OTTIMO

OTTIMO

BUONO

**CAPACITÀ E COMPETENZE
RELAZIONALI**

HA PARTECIPATO E PARTECIPA A GRUPPI DI RICERCA CHE PREVEDONO LA COLLABORAZIONE CON:

- Centri afferenti alle coorti ICONA, MASTER, ARCA.
- Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore di Roma.
- Istituto di Farmacologia, Università Cattolica del Sacro Cuore di Roma.
- Istituto di Microbiologia, Università Cattolica del Sacro Cuore di Roma.
- UO Malattie Infettive Universitarie, Dipartimento di Biotecnologie Mediche, Università di Siena.
- Sezione di Microbiologia, Dipartimento di Biotecnologie Mediche, Università di Siena.
- Clinica delle Malattie Infettive, Università di Brescia.
- Istituto di Malattie Infettive, Università La Sapienza, Roma.
- Clinica di Malattie Infettive, Università di Chieti.
- UO Malattie Infettive, Ospedale Universitario Careggi, Firenze.
- UO Malattie Infettive, Ospedale di Pescara.
- UO Malattie Infettive, Ospedale di Galatina, Lecce.
- U.O. Malattie Infettive ed Epatologia, U.O. Fisiopatologia e Riabilitazione Respiratoria dell'Azienda Ospedaliera Universitaria Senese.

**CAPACITÀ E COMPETENZE
ORGANIZZATIVE**

E' RESPONSABILE DELL'ARRUOLAMENTO ATTIVO DI PAZIENTI IN TRIALS CLINICI SPERIMENTALI SULL'INFEZIONE DA HIV.

**CAPACITÀ E COMPETENZE
TECNICHE**

Ottima conoscenza dei programmi informatici Microsoft Office Word, Excel e PowerPoint

Ottima conoscenza del calcolo statistico con padronanza del programma SPSS.

ULTERIORI INFORMAZIONI

A) Articoli *in extenso*

“*Staphylococcus aureus*: studio clinico e microbiologico”

Zanelli G, Sansoni A, Donati E, Pollini S, Fabbiani M, Cellesi C.
Giornale Italiano di Malattie Infettive; 2004, 10(2): 1-6.

“Studio retrospettivo sui ricoveri per tubercolosi nella provincia di Siena”

Santori D, Fabbiani M, Zanelli G, Sansoni A, Pippi F, Braitto A, Pippi L, Rossi M, Rottoli P.

Le infezioni in medicina 2005; 3: 175-181.

“Human bocavirus detection in an atopic child affected by pneumonia associated with wheezing”

Terrosi C, Fabbiani M, Cellesi C, Cusi MG.

J Clin Virol 2007; 40: 43-45.

“Epidemiological and clinical study of viral respiratory tract infections in children from Italy”

Fabbiani M, Terrosi C, Martorelli B, Valentini M, Bernini L, Cellesi C, Cusi MG.

J Med Virol 2009; 81: 750-756.

“Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years of experience in routine clinical practice”

Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cauda R, Navarra P, De Luca A.

J Antimicrob Chemother 2009; 64: 109-117.

“Impact of hepatitis B vaccination in children born to HBsAg-positive mothers: a 20-year retrospective study”

Bracciale L, Fabbiani M, Sansoni A, Luzzi L, Bernini L, Zanelli G.

Infection 2009; 37: 340-343.

“Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection”

Fabbiani M, Di Giambenedetto S, Ragazzoni E, Colafigli M, Prosperi M, Cauda R, Navarra P, De Luca A.

HIV Med 2010; 11: 326-333.

“Comparative determination of HIV-1 coreceptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping”

Prosperi MC, Bracciale L, Fabbiani M, Di Giambenedetto S, Razzolini F, Meini G, Colafigli M, Marzocchetti A, Cauda R, Zazzi M, De Luca A.

Retrovirology 2010; 7(1):56.

“Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over Time”

Frentz D, Boucher CA, Assel M, De Luca A, Fabbiani M, Incardona F, Libin P, Manca N, Müller V, Nualláin BO, Paredes R, Prosperi M, Quiros-Roldan E, Ruiz L, Sloot PM, Torti C, Vandamme AM, Van Laethem K, Zazzi M, van de Vijver DA.
PLoS One. 2010 Jul 9;5(7):e11505.

“Asymmetry of the Regimen is Correlated to Self-reported suboptimal Adherence: Results from AdUCSC, a Cohort Study on Adherence in Italy”

Murri R, Cingolani A, De Luca A, Di Giambenedetto S, Marasca G, De Matteis G, Mazzocato V, Fabbiani M, Pinnetti C, Tamburrini E
J Acquir Immune Defic Syndr 2010; 55:411-2.

“The Threshold Bootstrap Clustering: A New Approach to Find Families or Transmission Clusters within Molecular Quasispecies”

Prosperi MCF, De Luca A, Di Giambenedetto S, Bracciale L, Fabbiani M, Cauda R, Salemi M.
PLoS ONE 2010; 5(10): e13619.

“Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction”

Fabbiani M, Di Giambenedetto S, Ragazzoni E, D’Ettorre G, Parruti G, Prosperi M, Bracciale L, Cauda R, Navarra P, De Luca A.
Pharmacol Res 2011 Mar;63(3):249-53.

“Clinical Presentation, Microbiological Features and Correlates of Disease Severity of 2009 Pandemic Influenza A (H1N1) Infection”

Di Giambenedetto S, Zileri Dal Verme L, Sali M, Farina S, Di Cristo V, Manzara S, De Luca A, Pignataro G, Prosperi M, Di Franco A, Gentiloni Silveri N, Delogu G, Cauda R, Fabbiani M, Fadda G.
Eur J Clin Microbiol Infect Dis 2011; 30: 541-549.

“Lipid-lowering effect of tenofovir in HIV-infected patients”

Fabbiani M, Bracciale L, Doino M, Sidella L, Farina S, Di Cristo V, Cauda R, De Luca A, Di Giambenedetto S.
J Antimicrob Chemother 2011; 66(3): 682-683.

“Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients”

Fabbiani M, Bracciale L, Doino M, D’Avino A, Marzocchetti A, Navarra P, Cauda R, De Luca A, Di Giambenedetto S.
J Infect 2011; 62(4): 319-321.

“Immune response to influenza A (H1N1)v monovalent MF59- adjuvanted vaccine in HIV-infected patients”

Fabbiani M, Di Giambenedetto S, Sali M, Farina S, Sansonetti P, Tamburrini E, Zileri Dal Verme L, Delogu G, De Luca A, Kelvin D, Cauda R, Fadda G.
Vaccine 2011; 29: 2836-2839.

“Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients”

Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L, Tamburrini E, Cauda R, De Luca A, Silveri MC. Neurology 2011; 76: 1403-1409.

“Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009”

Di Giambenedetto S, Prosperi M, Fanti I, Bruzzone B, Paolucci S, Penco G, Meini G, Di Biagio A, Paolini E, Micheli V, Meraviglia P, Castelli P, Corsi P, Gonnelli A, Fabbiani M, Zazzi M, De Luca A; on behalf of the ARCA Collaborative Group. Clin Microbiol Infect 2011; 17: 1352-1355.

“Prospective evaluation of epidemiological, clinical and microbiological features of pandemic influenza A (H1N1) virus infection in Italy”

Fabbiani M, Sali M, Di Cristo V, Pignataro G, Prete V, Farina S, D’Avino A, Manzara S, Zileri dal Verme L, Gentiloni Silveri N, Cauda R, Delogu G, Fadda G, Di Giambenedetto S. J Med Virol 2011; 83: 2057-2065.

“Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure”

Fabbiani M, Bracciale L, Ragazzoni E, Santangelo R, Cattani P, Di Giambenedetto S, Fadda G, Navarra P, Cauda R, De Luca A. Infection 2011; 39: 563-569.

“The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected caucasians starting antiretroviral therapy”

Marzocchetti A, Schwarz J, Di Giambenedetto S, Colafigli M, Bracciale L, Fabbiani M, Fantoni M, Treçarichi E, Cauda R, De Luca A. AIDS Res Hum Retroviruses 2011; 27: 1299-1309.

“Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area”

D’Avino A, Di Giambenedetto S, Fabbiani M, Farina S. Diagn Microbiol Infect Dis 2012; 72: 185-187.

“Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy”

De Luca A, Nasi M, Di Giambenedetto S, Cozzi Lepri A, Pinti M, Marzocchetti A, Mussini C, Fabbiani M, Bracciale L, Cauda R, Cossarizza A. J Acquir Immune Defic Syndr 2012; 59: 113-120.

“Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy”

Torti C, Prosperi M, Motta D, Di Giambenedetto S, Maggiolo F, Paraninfo G, Ripamonti D, Cologni G, Fabbiani M, Lo Caputo S, Sighinolfi L, Ladisa N, El-Hamad I, Quiros-Roldan E, Frank I.
Clin Microbiol Infect 2012; 18: 449-458.

“Is there a drug-drug interaction between darunavir/ritonavir and raltegravir?”

Fabbiani M, Navarra P, Cauda R, De Luca A, Di Giambenedetto S.
J Acquir Immune Defic Syndr 2012; 60: e18-20.

“Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received”

Motta D, Brianese N, Focà E, Nasta P, Maggiolo F, Fabbiani M, Cologni G, Di Giambenedetto S, Di Pietro M, Ladisa N, Sighinolfi L, Costarelli S, Castelnuovo F, Torti C.
AIDS Res Ther 2012; 9:18.

“Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients”

Grima P, Fabbiani M, Ciccarelli N, Tana M, Farina S, Colafigli M, Mondì A, Cauda R, Di Giambenedetto S.
J Infect 2012; 65: 439-446.

“Effect of Aging and Human Immunodeficiency Virus Infection on Cognitive Abilities”

Ciccarelli N, Fabbiani M, Baldonero E, Fanti I, Cauda R, Di Giambenedetto S, Silveri MC.
J Am Geriatr Soc 2012; 60: 2048-2055.

“Predictors of First-Line Antiretroviral Therapy Discontinuation Due to Drug-Related Adverse Events in HIV-Infected Patients: a Retrospective Cohort Study”

Prosperi MCF, Fabbiani M, Fanti I, Zaccarelli M, Colafigli M, Mondì A, D'Avino A, Borghetti A, Cauda R, Di Giambenedetto S.
BMC Infect Dis 2012; 12: 296.

“Cardiovascular risk factors and carotid intima-media thickness are associated to lower cognitive performance in HIV-infected patients”

Fabbiani M, Ciccarelli N, Tana M, Farina S, Baldonero E, Di Cristo V, Colafigli M, Tamburrini E, Cauda R, Silveri MC, Grima P, Di Giambenedetto S.
HIV Med 2013; 14: 136-144.

“Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance”

Baldonero E, Ciccarelli N, Fabbiani M, Colafigli M, Improta E, D'Avino A, Mondì A, Cauda R, Di Giambenedetto S, Silveri MC.
BMC Psychology 2013; 1: 3.

“Validation of an UPLC-MS/MS method for quantitative analysis of raltegravir in human plasma samples”

Fortuna S, Ragazzoni E, Lisi L, Di Giambenedetto S, Fabbiani M, Navarra P.
Ther Drug Monit 2013; 35: 258-263.

“Revised central nervous system neuropenetration-effectiveness score is associated to cognitive disorders in HIV-infected patients with controlled plasma viremia”

Ciccarelli N, Fabbiani M, Colafigli M, Trearichi EM, Silveri MC, Cauda R, Murri R, De Luca A, Di Giambenedetto S.
Antivir Ther 2013; 18: 153-160.

“Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virologic suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study)”

Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, D'Avino A, Mondì A, Cingolani A, Tamburrini E, Murri R, Navarra P, Cauda R, De Luca A.
J Antimicrob Chemother 2013; 68: 1364-1372.

“HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects”

Fabbiani M, Sidella L, Corbi M, Martucci R, Sali M, Colafigli M, Cauda R, Delogu G, Sgambato A, Di Giambenedetto S.
Vaccine 2013; 31: 2914-2918.

“Variability of raltegravir plasma levels in the clinical setting”

Fortuna S, Fabbiani M, Di Giambenedetto S, Ragazzoni E, Lisi L, Cauda R, Navarra P.
Pharmacology 2013; 92: 43-48.

“Combining social and genetic networks to study HIV transmission in mixing risk groups”

Zarrabi N, Prosperi MCF, Belleman RG, Di Giambenedetto S, Fabbiani M, De Luca A, Sloot PMA.
Eur Phys J Special Topics 2013; 222: 1377–1387.

“Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients”

Ciccarelli N, Fabbiani M, Grima P, Falasca K, Tana M, Baldonero E, Colafigli M, Silveri MC, Vecchiet J, Cauda R, Di Giambenedetto S. *Infection* 2013; 41: 1103-1109.

“Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48 weeks results from a randomized pilot study (RALtegravir Switch for Toxicity or Adverse events, RASTA study)”

Fabbiani M, Mondì A, Colafigli M, D’Ettorre G, Paoletti F, D’Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S. *Scand J Infect Dis* 2014; 46: 34-45.

“Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients”

Fabbiani M, Zaccarelli M, Grima P, Prosperi M, Fanti I, Colafigli M, D’Avino A, Mondì A, Borghetti A, Fantoni M, Cauda R, Di Giambenedetto S. *BMC Infect Dis* 2014; 14: 26.

“Immune response to influenza A(H1N1)v in HIV-infected patients”

Sansonetti P, Sali M, Fabbiani M, Morandi M, Martucci R, Danesh A, Delogu G, Bermejo-Martin J, Sanguinetti M, Kelvin D, Cauda R, Fadda G, Rubino S. *J Infect Dev Ctries* 2014; 8: 101-109.

“Detection of HLA-B*57:01 in Real-Time PCR: Implementation into Routine Clinical Practice, and Additional Validation Data”

Dello Russo C, Lisi L, Fabbiani M, Gagliardi D, Fanti I, Di Giambenedetto S, Cauda R, Navarra P. *Pharmacogenomics* 2014; 15: 319-327.

“Ophthalmic artery resistance index is increased in HIV-infected patients and is influenced by protease inhibitors exposure”

Fabbiani M, Grima P, Borghetti A, Colafigli M, D’Avino A, Mondì A, Gagliardini R, De Luca A, Cauda R, Di Giambenedetto S. *J Infect* 2014; 68: 500-503.

“Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study”

Gotti D, Raffetti E, Albini L, Sighinolfi L, Maggiolo F, Di Filippo E, Ladisa N, Angarano G, Lapadula G, Pan A, Esposti AD, Fabbiani M, Focà E, Scalzini A, Donato F, Quiros-Roldan E, Master Cohort Group. *PLoS One* 2014; 9:e94768.

“Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis”

Gagliardini R, Fabbiani M, Fortuna S, Visconti E, Navarra P, Cauda R, Colafigli M, De Luca A, Treçarichi EM, Di Giambenedetto S. Infection 2014; 42: 775-778.

“Atazanavir-Induced Severe Episodes of Kidney Stones in an HIV-1-Infected Subject Characterized by a CYP3A Poor Metabolizer Phenotype”

Rusconi S, Gagliardini R, Falvella FS, Cattaneo D, Di Cristo V, De Luca A, Fabbiani M, Clementi E, Galli M, Di Giambenedetto S. Br J Pharm Res 2014; 4: 2594-2598.

“Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model?”

Fantoni M, Murri R, Scoppettuolo G, Fabbiani M, Ventura G, Losito R, Berloco F, Spanu T, Sanguinetti M, Cauda R. Future Microbiol 2015; 10: 15-20.

“Cancer incidence and mortality for all causes in HIV-Infected patients over a Quarter Century. A multicentre cohort study”

Raffetti E, Albini A, Gotti D, Segala D, Maggiolo F, Di Filippo E, Saracino A, Ladisa N, Lapadula G, Fornabaio C, Casari S, Castelnuovo F, Fabbiani M, Pierotti P, Donato F, Quiros-Roldan E. BMC Public Health 2015; 15: 235.

“Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virologic suppression: 144-week follow-up of the AtLaS pilot study”

Mondi A, Fabbiani M, Ciccarelli N, Colafigli M, D'Avino A, Borghetti A, Gagliardini R, Cauda R, De Luca A, Di Giambenedetto S. J Antimicrob Chemother 2015; 70: 1843-9.

“Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/ μ l Despite Effective HAART”

Lapadula G, Chatenoud L, Gori A, Castelli F, Di Giambenedetto S, Fabbiani M, Maggiolo F, Focà E, Ladisa N, Sighinolfi L, Di Pietro M, Pan A, Torti C; Italian MASTER Cohort. PLoS One 2015; 10: e0124741.

“Antiretroviral Neuropenetration Scores Better Correlate with Cognitive Performance of HIV-infected Patients after Accounting for Drug Susceptibility”

Fabbiani M, Grima P, Milanini B, Mondì A, Baldonero E, Ciccarelli N, Cauda R, Silveri MC, De Luca A, Di Giambenedetto S. Antivir Ther 2015, in press.

“Baseline CD4 Cell Count and Cardiovascular Risk Factors Predict the Evolution of Cognitive Performance during Two Years Follow Up in HIV-Infected Patients”

Ciccarelli N, Grima P, Fabbiani M, Baldonero E, Borghetti A, Milanini B, Limiti S, Colafigli M, Tamburrini E, Cauda R, De Luca A, Di Giambenedetto S.

Antivir Ther 2015, in press.

“Two distinct HCV genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors”

De Luca A, Di Giambenedetto S, Lo Presti A, Sierra S, Prosperi M, Cella E, Giovanetti M, Torti C, Caudai C, Vicenti I, Saladini F, Almi P, Grima P, Blanc P, Fabbiani M, Rossetti B, Gagliardini R, Kaiser R, Ciccozzi M, Zazzi M.

Open Forum Infect Dis 2015, in press.

“Switching to Co-Formulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data from a Multicenter Cohort”

Pinnetti C, Di Giambenedetto S, Maggiolo F, Fabbiani M, Sterrantino G, Latini A, Lorenzini P, Ammassari A, Loiacono L, Bellagamba R, D’Ettorre G, Cauda R, Antinori A, Zaccarelli M.

J Acquir Immune Defic Syndr 2015, in press.

“HIV-1 non-R5 co-receptor tropism is associated with a larger size of the viral reservoir but not with a higher risk of virological rebound in patients on effective antiretroviral therapy”

Lombardi F, Belmonti S, Fabbiani M, Cauda R, De Luca A, Di Giambenedetto S.

International Trends in Immunity 2015, in press.

PUBBLICAZIONI

B) COLLEGATE A

CONGRESSI

COMUNICAZIONI ORALI

“Indagine retrospettiva sull’andamento dell’infezione tubercolare in Toscana negli anni 2000-2004”

Nencioni C, Chigiotti S, Trezzi M, Leoncini F, Rogasi PG, Vicidomini S, Faraone A, Moneta S, Meini M, Santori D, Fabbiani M, Pippi L, Gabutti A, Toti M.

Comunicazione al III Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT); Firenze, 11-14 ottobre 2004.

Giornale Italiano di Malattie Infettive; 2004, 10 (S1): s124.

“Impatto della vaccinazione anti epatite B in soggetti ad alto rischio: 20 anni di studio retrospettivo”

Fabbiani M.

Comunicazione al convegno IDA (Infectious Diseases Academy), Genova 6-7 Luglio 2006.

“Therapeutic Drug Monitoring (TDM) di Atazanavir in rapporto a differenti orari di assunzione: correlazione con risposta virologica e iperbilirubinemia”

Fabbiani M, Di Giambenedetto S, Ragazzoni E, Colafigli M, Prosperi M, Cauda R, Navarra P, De Luca A.

Comunicazione di Poster al Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT); Bergamo, 19-22 Novembre 2008.

“Protease inhibitors plasma concentration can predict the emergence of newly-acquired HIV-1 protease resistance mutations at treatment failure”

Fabbiani M, Bracciale L, Ragazzoni E, De Simone A, Santangelo R, Cattani P, Di Giambenedetto S, Fadda G, Navarra P, Cauda R, De Luca A.

Oral Presentation at 7th European HIV Drug Resistance Workshop, Stockholm 25-27 March 2009.

“Baseline and follow-up gp120-V3 genotyping using plasma viral RNA and whole blood viral DNA in patients whose viral tropism had been determined by the enhanced sensitivity Trofile”

Bracciale L, Fabbiani M, Razzolini F, Balestrieri M, Colafigli M, Marzocchetti A, Di Giambenedetto S, Zazzi M and De Luca A.

Oral Presentation at 7th European HIV Drug Resistance Workshop, Stockholm 25-27 March 2009.

“Darunavir and Raltegravir in the plasma of HIV-infected patients: TDM and pharmacokinetics”

De Simone A, Ragazzoni E, Di Giambenedetto S, Fabbiani M, Bracciale L, Colafigli M, Cauda R, De Luca A, Navarra P.

Oral Presentation at 1° ICAR, Italian Conference on AIDS and Retroviruses, Milano 24-26 May 2009.

“People with intermediate level of adherence taking PI or NNRTI have different viro-immunological outcomes”

Murri R, Cingolani A, De Luca A, Di Giambenedetto S, Marasca G, De Matteis G, Fabbiani M, Pinnetti C, Tamburrini E.

Oral Presentation at 2° ICAR, Italian Conference on AIDS and Retroviruses, Brescia 20-22 June 2010 (Abstract CO21, Infection 2010; 38 Suppl. 1: 20).

“Causes of death in persons infected with the Human Immunodeficiency Virus”

Leone S, Torti C, Di Giambenedetto S, Lo Caputo S, Ladisa N, Sighinolfi L, Quiros-Roldan E, Airoidi M, Pan A, Fabbiani M, Castelnovo F, Suter F, Maggiolo F, for the MASTER group.

Oral Presentation at 2° ICAR, Italian Conference on AIDS and Retroviruses, Brescia 20-22 June 2010 (Abstract CO40, Infection 2010; 38 Suppl. 1: 30).

“Comparison of different antiretroviral neuropenetration scores for the prediction of minor neurocognitive disorders in HIV-positive patients with controlled plasma viremia”

Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Colafigli M, Bracciale L, Marzocchetti A, Murri R, Silveri MC, Cauda R, De Luca A.

Oral Presentation at 2° ICAR, Italian Conference on AIDS and Retroviruses, Brescia 20-22 June 2010 (Abstract LB5, Infection 2010; 38 Suppl. 1: 95).

“Safety and Efficacy of Treatment Simplification to Atazanavir/Ritonavir plus Lamivudine in Patients on Two NRTIs plus Atazanavir/Ritonavir With Optimal Virologic control: 24 weeks results from a pilot study (Atazanavir and Lamivudine Simplification Study, ATLAS)”

De Luca A, Bracciale L, Doino M, Fabbiani M, Sidella L, Marzocchetti A, Farina S, D’Avino A, Cauda R, Di Giambenedetto S.

Oral presentation at XVIII International AIDS Conference, Wien 18-23 July 2010 (Abstract THLBB207).

“Cardiovascular risk factors and carotid intima-media thickness are correlated to lower neurocognitive performance in HIV-infected patients”

Fabbiani M, Ciccarelli N, Silveri MC, Tana M, Farina S, Baldonero E, Di Cristo V, Cauda R, Grima P, Di Giambenedetto S.

Themed Discussion Session at 18th Conference on Retroviruses and Opportunistic Infections, Boston 27 February – 2 March 2011 (Abstract 403).

“Treatment simplification to atazanavir/ritonavir plus lamivudine qd in patients on two NRTIs plus atazanavir/ritonavir with optimal virologic control: 48 weeks safety and efficacy results from a pilot study (ATazanavir and LAmivudine Simplification study, ATLAS)”

De Luca A, Doino M, Fabbiani M, Bracciale L, Ciccarelli N, Farina S, Sidella L, D’Avino A, Mondì A, Murri R, Cauda R, Di Giambenedetto S.

Oral Presentation at 3° ICAR, Italian Conference on AIDS and Retroviruses, Firenze 27-29 March 2011 (Abstract CO44, Infection 2011; 39 (Suppl 1): S27).

“Efficacy, safety, discontinuation rates and pharmacokinetics of boosted or unboosted atazanavir when combined with a tenofovir or abacavir containing backbone”

Fabbiani M, Mondì A, Fanti I, Farina S, Fortuna S, Sidella L, Doino M¹, Navarra P, Cauda R, Di Giambenedetto S

Short communication at 3° ICAR, Italian Conference on AIDS and Retroviruses, Firenze 27-29 March 2011 (Abstract SC10, Infection 2011; 39 Suppl 1: S36).

“Predictors of worsening liver fibrosis evaluated through FIB-4 in HIV-HCV co-infected patients starting combined antiretroviral therapy (cART)”

Fabbiani M, Di Giambenedetto S, Colafigli M, Nasta P, Maggiolo F, Sighinolfi L, Costarelli S, Marino M, Ladisa N, Torti C.

Oral presentation at 13th European AIDS Conference (EACS 2011), October 12-15 2011, Belgrade, Serbia (Abstract PS7/2).

“Predictors of First-Line Antiretroviral Therapy Discontinuation due to Drug-related Adverse Events in HIV-infected Patients”

Fabbiani M, Prosperi MCF, Fanti I, Zaccarelli M, Colafigli M, Mondì A, D’Avino A, Borghetti A, Cauda R, Di Giambenedetto S.

Oral presentation at 4° ICAR, Italian Conference on AIDS and Retroviruses, Napoli 10-12 Giugno 2012 (Abstract OC41).

“Impact of transmitted resistance to antiretroviral drugs on predicted HIV-1 susceptibility to single-tablet-regimens (STR)”

Rossetti B, Bianco C, Fabbiani M, Colafigli M, Pecorari M, Borghi V, Zoncada A, Bruzzone B, Penco G, Bartolozzi D, Paolucci S, Gonnelli A, Rosi A, Zazzi M, De Luca A.

Oral Presentation at 11th European Meeting on HIV & Hepatitis Treatment Strategies and Antiviral Drug Resistance, 20-22 March, Rome, Italy (Abstract O05).

“Characterization of two distinct HCV genotype 1a clades: association with primary resistance mutations to HCV protease inhibitor”

Zazzi M, Di Giambenedetto S, Torti C, Lo Presti A, Caudai C, Vicenti I, Saladini F, Almi P, Grima P, Blanc P, Fabbiani M, Rossetti B, Gagliardini R, Ciccozzi M, De Luca A.

Oral Presentation at 11th European Meeting on HIV & Hepatitis Treatment Strategies and Antiviral Drug Resistance, 20-22 March, Rome, Italy (Abstract O12).

“Low impact of transmitted resistance to antiretroviral drugs on predicted HIV-1 susceptibility to current and future single-tablet-regimens (STR)”

Rossetti B, Bianco C, Fabbiani M, Colafigli M, Pecorari M, Borghi V, Zoncada A, Bruzzone B, Penco G, Bartolozzi D, Paolucci S, Gonnelli A, Rosi A, Zazzi M, De Luca A.

Oral presentation at 5° ICAR, Italian Conference on AIDS and Retroviruses, Torino 12-14 Maggio 2013 (Abstract CO26).

“Strumenti di screening neuropsicologico nei pazienti HIV: MOCA e MMSE a confronto”

Milanini B, Ciccarelli N, Baldonero E, Fabbiani M, Limiti S, Gagliardini R, Borghetti A, D’Avino A, Mondì A, Colafigli M, Cauda R, Di Giambenedetto S.

Comunicazione orale al XII convegno Nazionale Società Italiana di Malattie Infettive e Tropicali (SIMIT), Milano 27-30 Ottobre 2013 (Abstract 25).

“Predictors of 24-weeks treatment failure in a randomized trial comparing switch to a dual therapy with atazanavir/ritonavir + lamivudine to continuation of atazanavir/ritonavir + 2NRTIs in virologically suppressed patients”

Fabbiani M, Di Giambenedetto S, Antinori A, Quiros-Roldan E, Latini A, Tierno F, Farenga M, Grima P, Madeddu G, Grilli E, Brianese N, Colafigli M, De Luca A, Cauda R and ATLAS Group.

Oral presentation at 6° ICAR, Italian Conference on AIDS and Retroviruses, Roma 25-27 Maggio 2014 (Abstract OC2).

“Simplification therapy with lamivudine and boosted darunavir in a cohort of treatment experienced HIV-infected patients”

Borghetti A, Fabbiani M, Piccoli B, Mondì A, D’Avino A, Gagliardini R, Lamonica S, Ciccarelli N, Fanti I, Cauda R, De Luca A, Di Giambenedetto S.

Oral presentation at 6° ICAR, Italian Conference on AIDS and Retroviruses, Roma 25-27 Maggio 2014 (Abstract OC6).

“Switching to rilpivirine/tenofovir/emtricitabine (EPA) from current antiretroviral regimen (cARV) in clinical practice: virologic failure and treatment discontinuation in a multicenter Italian cohort”

Pinnetti C, Di Giambenedetto S, Lorenzini P, Fabbiani M, Tommasi C, Ammassarri A, Latini A, Loiacono L, Sterrantino G, Bellagamba R., Mezzaroma I, Liuzzi G, Cristaudo A, Boumis E, Di Sora F, Cauda R, Antinori A, Zaccarelli M.

Oral presentation at 6° ICAR, Italian Conference on AIDS and Retroviruses, Roma 25-27 Maggio 2014 (Abstract OC57).

“Efficacy, safety and laboratory changes in a cohort of HIV-infected patients starting abacavir/lamivudine and boosted darunavir: a retrospective, longitudinal study”

Borghetti A, Fabbiani M, Piccoli B, Mondì A, D’Avino A, Gagliardini R, Lamonica S, Ciccarelli N, Fanti I, Cauda R, De Luca A, Di Giambenedetto S.

Oral presentation at 6° ICAR, Italian Conference on AIDS and Retroviruses, Roma 25-27 Maggio 2014 (Abstract OC59).

“Changes in routine laboratory tests after switching to co-formulated rilpivirine-containing antiretroviral regimen: data from multicenter study group”

Fabbiani M, Zaccarelli M, Pinnetti C, Lorenzini P, Tommasi C, Sterrantino G, Loiacono L, Colafigli M, Ammassarri A, D’Ettore G, Nicastrì E, Latini A, Giuliani M, boumis E, Plazzi M, Cauda R, Di Giambenedetto S, Antinori A.

Poster discussion at 6° ICAR, Italian Conference on AIDS and Retroviruses, Roma 25-27 Maggio 2014 (Abstract PD2).

“Evolution of cognitive performance after simplification to dual therapies in HIV+ patients”

Ciccarelli N, Fabbiani M, Colafigli M, Limiti S, Borghetti A, Lamonica S, D’Avino A, Mondì A, Gagliardini R, Cauda R, De Luca A, Di Giambenedetto S.

Poster discussion at 6° ICAR, Italian Conference on AIDS and Retroviruses, Roma 25-27 Maggio 2014 (Abstract PD5).

“Virological outcomes of first line antiretroviral therapy in routine clinical practice”

Colafigli M, Latini A, Fabbiani M, Donà MG, Giuliani M, Grima P, Cristaudo A, Cauda R, De Luca A, Di Giambenedetto S.

Poster discussion at 6° ICAR, Italian Conference on AIDS and Retroviruses, Roma 25-27 Maggio 2014 (Abstract PD18).

“Studio retrospettivo della malattia tubercolare nei reparti di Malattie Infettive di Siena (1994-2003)”

Santori D, Fabbiani M, Zanelli G, Sansoni A, Pippi F, Bracciale L, Marri D, Pippi L.

Poster al III Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali; Firenze, 11-14 ottobre 2004.

Giornale Italiano di Malattie Infettive; 2004, 10 (S1): s191.

“S. aureus: casistica clinica e tipizzazione molecolare”

Zanelli G, Sansoni A, Pollini S, Cresti S, Fabbiani M, Donati E, Rossolini GM, Cellesi C.

Poster al III Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali; Firenze, 11-14 ottobre 2004.

Giornale Italiano di Malattie Infettive; 2004, 10 (S1): s263.

“Efficacia della vaccinazione anti epatite B in neonati da madre HbsAg positiva nell’area senese: 20 anni di studio retrospettivo”

Zanelli G, Sansoni A, Bracciale L, Mugnaini F, Fabbiani M, Cellesi C.

Poster al IV Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali; Fiuggi, 12-15 Dicembre 2005.

Giornale Italiano di Malattie Infettive; 2005, 11 (S1): s82.

“Utilità del Therapeutic Drug Monitoring nella gestione dei pazienti in HAART”

Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cellesi C, Cauda R, Navarra P, De Luca A.

VI convegno Nazionale SIMIT, Napoli 20-23 Novembre 2007.

“Ruolo dei virus respiratori emergenti in una popolazione pediatrica della Toscana”

Fabbiani M, Terrosi C, Cusi MG, Bernini L, Martorelli B, Cellesi C.

VI convegno Nazionale SIMIT, Napoli 20-23 Novembre 2007.

“Atazanavir plasma concentrations at different times after drug uptake: associations with virologic response and hyperbilirubinemia”

Fabbiani M, Di Giambenedetto S, Ragazzoni E, Colafigli M, Prosperi M, Cauda R, Navarra P, De Luca A.

HIV 9, Ninth International Congress on Drug Therapy in HIV Infection, 9-13 Novembre 2008, Glasgow, UK.

“Pharmacokinetic variability of darunavir and raltegravir in routine clinical practice”

Fabbiani M, Di Giambenedetto S, Ragazzoni E, De Simone A, Bracciale L, Colafigli M, Cauda R, De Luca A, Navarra P.

10th International Workshop on Clinical Pharmacology of HIV Therapy, 15-17 April 2009, Amsterdam, Netherland.

“Emergence of HIV-1 resistance mutations at treatment failure and correlation with plasma antiretroviral drug levels”

Fabbiani M, Bracciale L, Ragazzoni E, De Simone A, Santangelo R, Cattani P, Di Giambenedetto S, Fadda G, Navarra P, Caura R, De Luca A.

Poster at 1° ICAR, Italian Conference on AIDS and Retroviruses, Milano 24-26 May 2009.

“Correlation between viral tropism determined by Trofile phenotypic assay and gp120-V3 genotyping of HIV RNA and DNA in 37 patients at baseline and during follow-up”

Di Giambenedetto S, Bracciale L, Fabbiani M, Razzolini F, Balestrieri M, Colafigli M, Marzocchetti A, Zazzi M, De Luca A.

Poster at 1° ICAR, Italian Conference on AIDS and Retroviruses, Milano 24-26 May 2009.

“Use of gp120-V3 RNA and DNA genotype to predict tropism in HIV-infected patients”

Prosperi M, Bracciale L, Di Giambenedetto S, Fabbiani M, Razzolini F, Meini G, Colafigli M, Marzocchetti A, Zazzi M, De Luca A.

Poster at 12th European AIDS Conference (EACS), 11-14 November 2009, Cologne, Germany (Abstract PE 3.4/9).

“Unexpected drug interaction between darunavir and raltegravir”

Fabbiani M, Di Giambenedetto S, Ragazzoni E, D’Ettorre G, Parruti G, Colafigli M, Bracciale L, Sozio F, Vullo V, Cauda R, Navarra P, De Luca A.

Poster at 12th European AIDS Conference (EACS), 11-14 November 2009, Cologne, Germany (Abstract 4.3/4).

“Safety and efficacy of abacavir: an over 10 years observation in a single centre cohort”

Colafigli M, Fanti I, Di Giambenedetto S, Bracciale L, Fabbiani M, Prosperi M, De Luca A, Cauda R.

Poster at 12th European AIDS Conference (EACS), 11-14 November 2009, Cologne, Germany (Abstract PE 9.11/1).

“Comparison of self-reported adherence and therapeutic drug monitoring in the late HAART era”

Fabbiani M, Di Giambenedetto S, Ragazzoni E, Cingolani A, Fanti I, Bracciale L, Colafigli M, Tamburrini E, Navarra P, Cauda R, De Luca A, Murri R.

Poster at 12th European AIDS Conference (EACS), 11-14 November 2009, Cologne, Germany (Abstract 10.1/8).

“Once daily regimens were associated to an higher rate of self-chosen discontinuation”

Murri R, Cingolani A, De Luca A, Di Giambenedetto S, Marasca G, De Matteis G, Mazzocato V, Bracciale L, Fabbiani M, Tamburrini E.

Poster at 12th European AIDS Conference (EACS), 11-14 November 2009, Cologne, Germany (Abstract Pe 10.1/7).

“Prevalence and correlates of minor neurocognitive disorders in asymptomatic HIV-infected outpatients”

Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Colafigli M, Bracciale L, Tamburrini E, Cauda R, De Luca A, Silveri MC.
Poster at 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010), 16-19 February 2010, San Francisco, USA (Abstract 417).

“Bone density and renal function and their predictors in a cohort of HIV infected patients eligible for a simplification regimen”

Bracciale L, Doino M, Sidella L, Fanti I, Farina S, D’Avino A, Fabbiani M, De Luca A, Cauda R, Di Giambenedetto S.
Poster Presentation at 2° ICAR, Italian Conference on AIDS and Retroviruses, Brescia 20-22 June 2010 (Abstract PO05, Infection 2010; 38 Suppl. 1: 45).

“Adherence level and NNRTI regimens are independently correlated with immunological response”

Murri R, Cingolani A, De Luca A, Di Giambenedetto S, Marasca G, De Matteis G, Fabbiani M, Pinnetti C, Tamburrini E.
Poster Presentation at 2° ICAR, Italian Conference on AIDS and Retroviruses, Brescia 20-22 June 2010 (Abstract PO08, Infection 2010; 38 Suppl. 1: 47).

“Excellent immune recovery over the long term in patients with sustained undetectable HIV-RNA: concomitant evaluation of CD4+ and CD8+ is more predictive than CD4+ count alone”

Prosperi M, Maggiolo F, Di Giambenedetto S, Paraninfo G, Ripamonti D, Suter F, Fabbiani M, Lo Caputo S, Sighinolfi L, Ladisa N, El Hamad I, Motta D, Frank I, Torti C.
Poster Presentation at 2° ICAR, Italian Conference on AIDS and Retroviruses, Brescia 20-22 June 2010 (Abstract PO38, Infection 2010; 38 Suppl. 1: 60).

“Correlates of immunological response to H1N1 adjuvant vaccine in HIV-infected subjects”

Di Giambenedetto S, Fabbiani M, Sali M, Farina S, Sansonetti P, Pinnetti C, Kelvin DJ, Zileri Dal Verme L, Delogu G, Cauda R, De Luca A, Fadda G.
Poster presentation at XVIII International AIDS Conference, Wien 18-23 July 2010 (Abstract MOPE0206).

“People with intermediate level of adherence taking PI or NNRTI have different viroimmunological outcomes”

Murri R, Cingolani A, De Luca A, Di Giambenedetto S, Marasca G, De Matteis G, Fabbiani M, Pinnetti C, Tamburrini E.
Poster presentation at XVIII International AIDS Conference, Wien 18-23 July 2010 (Abstract TUPE0186).

“Relationships between antiretroviral neuroeffectiveness, adherence and minor cognitive disorders in HIV-infected patients”

Fabbiani M, Ciccarelli N, Di Giambenedetto S, Fanti I, Colafigli M, Bracciale L, De Matteis G, Pinnetti C, Cauda R, Silveri MC, De Luca A, Murri R.

Poster presentation at XVIII International AIDS Conference, Wien 18-23 July 2010 (Abstract WEPE0080).

“Do people virologically suppressed are really in optimal clinical conditions?”

Murri R, Cingolani A, De Luca A, Di Giambenedetto S, Marasca G, De Matteis G, Fabbiani M, Jacoboni E, Mastrosera I, Tamburrini E.

Poster presentation at 3° ICAR, Italian Conference on AIDS and Retroviruses, Firenze 27-29 March 2011 (Abstract PP04, Infection 2011; 39 Suppl 1: S45-46).

“Treatment simplification to atazanavir/ritonavir plus lamivudine is correlated to an increase of health-related quality of life (HRQOL) (atazanavir and lamivudine simplification study, ATLAS)”

Murri R, De Luca A, Fabbiani M, Bracciale L, Farina S, Ciccarelli N, Sidella L, Doino M, D’Avino A, Fanti I, Mondì A, Cauda R, Di Giambenedetto S.

Poster presentation at 3° ICAR, Italian Conference on AIDS and Retroviruses, Firenze 27-29 March 2011 (Abstract PP24, Infection 2011; 39 Suppl 1: S54).

“Evolution of bone mineral density and metabolism and of subcutaneous fat in patients enrolled in the atazanavir/r + lamivudine simplification study (ATLAS)”

De Luca A, Fabbiani M, Doino M, Farina S, Mondì A, Ciccarelli N, Sidella L, D’Avino A, Fanti I, Bracciale L, Cauda R, Di Giambenedetto S.

Poster presentation at 3° ICAR, Italian Conference on AIDS and Retroviruses, Firenze 27-29 March 2011 (Abstract PP25, Infection 2011; 39 Suppl 1: S54).

“Impact of aging and HIV infection on neurocognitive performance”

Ciccarelli N, Fabbiani M, Baldonero E, Fanti I, Farina S, D’Avino A, Mondì A, Sidella L, Doino M, Silveri MC, Di Giambenedetto S.

Poster presentation at 3° ICAR, Italian Conference on AIDS and Retroviruses, Firenze 27-29 March 2011 (Abstract PO18, Infection 2011; 39 Suppl 1: S61).

“Efficacy and safety of tenofovir disoproxil fumarate in a single center cohort”

Colafigli M, Prosperi M, Fabbiani M, Doino M, Farina S, Mondì A, D’Avino A, Fanti I, Cauda R, Di Giambenedetto S

Poster presentation at 3° ICAR, Italian Conference on AIDS and Retroviruses, Firenze 27-29 March 2011 (Abstract PO54, Infection 2011; 39 Suppl 1: S75).

“Effect of HCV therapy on immunological homeostasis in HIV/HCV co-infected patients”

Airoldi M, Nasta P, Maggiolo F, Di Giambenedetto S, Ladisa N, Gatti F, Suter F, Fabbiani M, Bandera A, Gori A.

Poster presentation at 3° ICAR, Italian Conference on AIDS and Retroviruses, Firenze 27-29 March 2011 (Abstract PO64, Infection 2011; 39 Suppl 1: S78).

“Less symptoms, better quality of life and adherence persist over time in HIV-infected people taking NNRTI compared to PI”

Murri R, Cingolani A, De Luca A, Di Giambenedetto S, Marasca G, De Matteis G, Fabbiani M, Jacoboni E, Mastrosera I, Tamburrini E.

Poster presentation at 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July 2011, Rome, Italy. (Abstract MOPE194).

“Viro-immunological effectiveness of HAART by HCV antibody status in the Italian MASTER cohort over short-term follow-up”

Torti C, Quiros-Roldan E, Maggiolo F, Cologni G, Di Giambenedetto S, Fabbiani M, Marino N, Ladisa N, Paraninfo G, Sighinolfi L, Costarelli S, Castelnuovo F, Carosi G, Italian MASTER Cohort.

Poster presentation at 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July 2011, Rome, Italy. (Abstract TUPE106).

“Concomitant evaluation of CD4+ and CD8+ counts improves prediction of long-term immune recovery in HIV-infected patients during suppressive HAART in the Italian Master Cohort”

Torti C, Prosperi M, Motta D, Di Giambenedetto S, Maggiolo F, Paraninfo G, Ripamonti D, Cologni G, Fabbiani M, Lo Caputo S, Sighinolfi L, Ladisa N, El Hamad I, Quiros Roldan E, Frank I.

Poster presentation at 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July 2011, Rome, Italy. (Abstract CDB007).

“Treatment simplification to atazanavir/ritonavir plus lamivudine qd in patients on two NRTIs plus atazanavir/ritonavir with optimal virologic control: 48 weeks safety and efficacy results from a pilot study (Atazanavir and Lamivudine Simplification Study, ATLAS)”

De Luca A, Doino M, Fabbiani M, Bracciale L, Ciccarelli N, Colafigli M, Farina S, Sidella L, D'Avino A, Mondì A, Murri R, Cauda R, Di Giambenedetto S.

Poster presentation at 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July 2011, Rome, Italy. (Abstract CDB357).

“Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients on PI, NNRTI or NRTI-based therapy with optimal virologic control: 24 weeks results from a randomized pilot study (RALtegravir Simplification for Toxicity or Adverse events, RASTA study)”

Di Giambenedetto S, Fabbiani M, Colafigli M, Bracciale L, D’Ettorre G, Paoletti F, Mondi A, Doino M, Farina S, Sidella L, D’Avino A, Vullo V, Cauda R, De Luca A.

Poster presentation at 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July 2011, Rome, Italy. (Abstract CDB365).

“Evolution of bone mineral density and metabolism and of subcutaneous fat in patients enrolled in the atazanavir/r + lamivudine simplification study (ATLAS)”

Fabbiani M, Di Giambenedetto S, Doino M, Farina S, Mondi A, Colafigli M, Sidella L, D’Avino A, Fanti I, Bracciale L, Cauda R, De Luca A.

Poster presentation at 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July 2011, Rome, Italy. (Abstract CDB468).

“Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients on PI, NNRTI or NRTI-based therapy with optimal virologic control: 48 weeks results from a randomized pilot study (RALtegravir Simplification for Toxicity or Adverse events, RASTA study)”

Colafigli M, Fabbiani M, Bracciale L, D’Ettorre G, Paoletti F, Mondi A, Doino M, Farina S, Sidella L, Trearichi EM, D’Avino A, Vullo V, Cauda R, De Luca A, Di Giambenedetto S.

Poster presentation at 13th European AIDS Conference (EACS 2011), October 12-15 2011, Belgrade, Serbia (Abstract PE7.5/9).

“Subcutaneous fat and bone outcomes after treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients on PI, NNRTI or NRTI-based therapy with optimal virologic control: 48 weeks results from a randomized pilot study (RALtegravir Simplification for Toxicity or Adverse events, RASTA study)”

Fabbiani M, Colafigli M, Bracciale L, Losito R, D’Ettorre G, Paoletti F, Mondi A, Doino M, Farina S, Sidella L, D’Avino A, Vullo V, Cauda R, De Luca A, Di Giambenedetto S.

Poster presentation at 13th European AIDS Conference (EACS 2011), October 12-15 2011, Belgrade, Serbia (Abstract PE7.5/10).

“Increased Ophthalmic Artery Resistance Index Is Associated with Cognitive Impairment in HIV⁺ Patients”

Grima P, Fabbiani M, Tana M, Ciccarelli M, Colafigli M, Mondi A, D’Avino A, Farina S, Cauda R, Di Giambenedetto S.

Poster at 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012), 4-8 March 2012, Seattle, USA (Abstract 515).

“Treatment simplification to atazanavir/ritonavir plus lamivudine QD in patients on two NRTIs plus atazanavir/ritonavir with optimal virologic control: 96 weeks follow-up of a pilot study (Atazanavir and Lamivudine Simplification Study, ATLAS)”

Fabbiani M, Colafigli M, Farina S, D'Avino A, Mondì A, Bianco C, Rossetti B, Cauda R, De Luca A, Di Giambenedetto S.

Poster at XIX International AIDS Conference (AIDS 2012), 22-27 July 2012, Washington, USA (Abstract TUPE097).

“Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral naïve or switching for simplification HIV-infected patients”

Fabbiani M, Grima P, Prosperi M, Fanti I, Colafigli M, Zaccarelli M, D'Avino A, Mondì A, Borghetti A, Fantoni M, Cauda R, Di Giambenedetto S.

Poster at Eleventh International Congress on Drug Therapy in HIV Infection (HIV11), 11-15 November 2012, Glasgow, UK (Abstract P011).

“Central Nervous System Penetration Effectiveness Score Better Correlates with Cognitive Performance of HIV+ Patients after Accounting for Drug Susceptibility of Plasma Virus”

Fabbiani M, Grima P, Milanini B, Mondì A, Colafigli M, Gagliardini R, Cauda R, Silveri MC, De Luca A, Di Giambenedetto S.

Poster at 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), 3-6 March 2013, Atlanta, USA (Abstract 405).

“Baseline CD4 Cell Count and Cardiovascular Risk Factors Predict Cognitive Performance after 2 Years”

De Luca A, Ciccarelli N, Grima P, Colafigli M, Fabbiani M, Baldonero E, Borghetti A, Tamburrini E, Cauda R, Di Giambenedetto S.

Poster at 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), 3-6 March 2013, Atlanta, USA (Abstract 448).

“High Grade Liver Steatosis and Cognitive Impairment in HIV+ Patients”

Grima P, Fabbiani M, Mondì A, D'Avino A, Limiti S, Colafigli M, Milanini B, Baldonero E, Cauda R, Di Giambenedetto S.

Poster at 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), 3-6 March 2013, Atlanta, USA (Abstract 452).

“Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients on PI, NNRTI or NRTI-based therapy with optimal virologic control: 144 weeks results from a randomized pilot study (RALtegravir Simplification for Toxicity or Adverse events, RASTA study)”

Mondì A, Colafigli M, Borghetti A, D'Avino A, Gagliardini R, Belmonti S, Lombardi F, D'Ettorre G, Paoletti F, Vullo V, Cauda R, De Luca A, Fabbiani M, Di Giambenedetto S.

Poster at 5^o ICAR, Italian Conference on AIDS and Retroviruses, Torino 12-14 Maggio 2013 (Abstract P49).

“Changes in cardiovascular risk after switching from a tenofovir sparing to a tenofovir containing regimen for HIV-1 infection”

Gagliardini R, Fabbiani M, Lamonica S, Colafigli M, Borghetti A, Mondì A, D'Avino A, Cauda R, De Luca A, Di Giambenedetto S.
Poster at 5° ICAR, Italian Conference on AIDS and Retroviruses, Torino 12-14 Maggio 2013 (Abstract P63).

“Central nervous system symptoms and evolution of cognitive performance during raltegravir treatment”

Ciccarelli N, Mondì A, Baldonero E, Milanini B, Borghetti A, Gagliardini R, D'Avino A, Colafigli M, Cauda R, Di Giambenedetto S, Fabbiani M
Poster at 5° ICAR, Italian Conference on AIDS and Retroviruses, Torino 12-14 Maggio 2013 (Abstract P84).

“Detection of HLA-B*57:01 in real-time PCR: implementation into routine clinical practice, additional validation data and comparison with commercially available methods”

Dello Russo C, Lisi L, Fabbiani M, Cauda R, Navarra P.
Poster at 5° ICAR, Italian Conference on AIDS and Retroviruses, Torino 12-14 Maggio 2013 (Abstract P122).

“Il privato sociale: un'opportunità per i pazienti e per le strutture sanitarie nell'attuale contesto economico”

Di Donato M, Fabbiani M, Moscato U, Giannetti G, Contegiacomo P.
XLVI Congresso Nazionale Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SITI), Giardini Naxos - Taormina (ME), 17-20 ottobre 2013 (Abstract 2413).

“Sorveglianza e prevenzione della trasmissione intraospedaliera di germi multiresistenti: esperienza di un ospedale romano”

Fabbiani M, Di Donato M, D'Andrea G, Contegiacomo P.
XLVI Congresso Nazionale Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SITI), Giardini Naxos - Taormina (ME), 17-20 ottobre 2013 (Abstract 2257).

“Outcomes of Abacavir/Lamivudine + Darunavir/Ritonavir in Clinical Practice: A Single Center, Observational Study”

Colafigli M, Gagliardini R, Ciccarelli N, Fabbiani M, Fanti I, Borghetti A, Lamonica S, D'Avino A, Mondì A, Cauda R, Di Giambenedetto S.
Poster presentation at 14th European AIDS Conference (EACS 2013), October 16-19 2013, Brussels, Belgium (Abstract PE 8/25).

“Efavirenz Discontinuation in Naïve Patients Starting First-line Antiretroviral Therapy with Single Tablet Regimens (STR) versus Non-STR”

Fabbiani M, Latini A, Sterrantino G, D'Ettorre G, Grima P, Mondì A, Rossetti B, Borchì B, Cavallari EN, Giuliani M, De Luca A, Zaccarelli M, Di Giambenedetto S.
Poster presentation at 14th European AIDS Conference (EACS 2013), October 16-19 2013, Brussels, Belgium (Abstract PE 8/48).

“Factors Associated with All-cause Mortality in HIV-infected Patients with/without Cancer: The Italian MASTER Cohort”

Albini L, Raffetti E, Gotti D, Segala D, Maggiolo F, Di Filippo E, Angarano G, Ladisa N, Lapadula N, Fornabaio C, Castelnuovo F, Casari S, Fabbiani M, Lo Caputo S, Donato F, Quiros-Roldan E, Italian MASTER Cohort.

Poster presentation at 14th European AIDS Conference (EACS 2013), October 16-19 2013, Brussels, Belgium (Abstract PE 12/23).

“Impact of cART on the Prognostic Value of Simplified Acute Physiology Score (SAPSII) in HIV-infected Patients Admitted to Intensive Care Unit (ICU)”

Cingolani A, Maviglia R, Fabbiani M, Murri R, Piervincenzi E, Gagliardini R, Silvestri D, Fanti I, Di Giambenedetto S, Cauda R.

Poster presentation at 14th European AIDS Conference (EACS 2013), October 16-19 2013, Brussels, Belgium (Abstract PE 12/24).

“Correlates of Ophthalmic Artery Resistance Index in HIV-infected Patients”

Fabbiani M, Grima P, Borghetti A, Colafigli M, D’Avino A, Mondì A, Gagliardini R, De Luca A, Cauda R, Di Giambenedetto S.

Poster presentation at 14th European AIDS Conference (EACS 2013), October 16-19 2013, Brussels, Belgium (Abstract PE 15/45).

“Survival and Risk factors in HIV-infected Patients after a Cancer Diagnosis: A MASTER Cohort Study”

Gotti D, Raffetti E, Albini L, Sighinolfi L, Maggiolo F, Di Filippo E, Angarano G, Ladisa N, Lapadula G, Pan A, Degli Esposti A, Fabbiani M, Focà E, Scalzini A, Donato F, Quiros-Roldan E, Master Cohort.

Poster presentation at 14th European AIDS Conference (EACS 2013), October 16-19 2013, Brussels, Belgium (Abstract PE 21/31).

“Impatto della cART sul Valore Prognostico del Simplified Acute Physiology Score (Sapsii) in Pazienti HIV+ Ricoverati in Unità di Terapia Intensiva”

Gagliardini R, Cingolani A, Maviglia R, Fabbiani M, Murri R, Piervincenzi E, Silvestri D, Fanti I, Di Giambenedetto S, Cauda R.

XII convegno Nazionale Società Italiana di Malattie Infettive e Tropicali (SIMIT), Milano 27-30 Ottobre 2013 (Abstract 187).

“Attività di un’Unità di Consulenza Infettivologica per la Gestione delle Infezioni Gravi nel Policlinico Universitario A. Gemelli”

Fantoni M, Murri R, Ventura G, Scoppettuolo G, Fabbiani M, Cauda R.

XII convegno Nazionale Società Italiana di Malattie Infettive e Tropicali (SIMIT), Milano 27-30 Ottobre 2013 (Abstract 204).

“Nelle donne con co-infezione HIV/HCV, mai esposte alla terapia anti HCV, l’età maggiore di 45 anni e le alterazioni del metabolismo glucidico espongono ad una più rapida progressione verso la cirrosi”

Nasta P, Odolini S, Fabbiani M, Lapadula G, Castelli F, Maggiolo F, Lo Caputo S, Marino N, Sighinolfi L, Ladisa N, Astuti N, Carosi G.

XII convegno Nazionale Società Italiana di Malattie Infettive e Tropicali (SIMIT), Milano 27-30 Ottobre 2013 (Abstract 215).

“Patogeni colonizzanti il nasofaringe di soggetti HIV positivi e HIV negativi”

Bianco C, Lombardi F, Buracci A, Belmonti S, Tordini G, Borghetti A, Fabbiani M, De Luca A, Montagnani F.

XII convegno Nazionale Società Italiana di Malattie Infettive e Tropicali (SIMIT), Milano 27-30 Ottobre 2013 (Abstract 235).

“Is Clostridium difficile infection (CDI) correlated to candidaemia?”

Murri R, Fantoni M, Scoppettuolo G, Ventura G, Fabbiani M, Cauda R.

24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain 10 – 13 May 2014 (Poster eP346).

“Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk”

D'Avino A, Lassandro A, Lamonica S, Piccoli B, Fabbiani M, Mondì A, Gagliardini R, Borghetti A, Fanti I, Pallavicini F, Cauda R, Di Giambenedetto S.

HIV Drug Therapy Glasgow Congress 2014, 2-6 November 2014, Glasgow, UK. Abstract P038. J Int AIDS Soc 2014; 17 (4 Suppl 3): 19570.

“Liver fibrosis is associated with cognitive impairment in HIV-positive patients”

Cicarelli N, Fabbiani M, Grima P, Limiti S, Fanti I, Mondì A, Gagliardini R, D'Avino A, Borghetti A, Cauda R, Di Giambenedetto S.

HIV Drug Therapy Glasgow Congress 2014, 2-6 November 2014, Glasgow, UK. Abstract P190. J Int AIDS Soc 2014; 17 (4 Suppl 3): 19722.

“Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis”

Zaccarelli M, Fabbiani M, Pinnetti C, Borghi V, Giannetti A, Sterrantino G, Lorenzini P, Latini A, Loiacono L, Colafigli M, Ammassari A, D'Ettore G, Plazzi M, Di Giambenedetto S, Antinori A.

HIV Drug Therapy Glasgow Congress 2014, 2-6 November 2014, Glasgow, UK. Abstract P270. J Int AIDS Soc 2014; 17 (4 Suppl 3): 19802.

“Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial”

Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, Del Pin B, Mondì A, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R.

HIV Drug Therapy Glasgow Congress 2014, 2-6 November 2014, Glasgow, UK. Abstract P276. J Int AIDS Soc 2014; 17 (4 Suppl 3): 19808.

“Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort”

Pinnetti C, Di Giambenedetto S, Maggiolo F, Lorenzini P, Fabbiani M, Tommasi C, Latini A, Ammassari A, Loiacono L, Sterrantino G, Bellagamba R, Boumis E, Antinori A, Zaccarelli M.

HIV Drug Therapy Glasgow Congress 2014, 2-6 November 2014, Glasgow, UK. Abstract P280. J Int AIDS Soc 2014; 17 (4 Suppl 3): 19812.

“Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre”

Borghetti A, Mondì A, Piccoli B, Gagliardini R, Lamonica S, Ciccarelli N, D'Avino A, Pallavicini F, Cauda R, De Luca A, Fabbiani M, Di Giambenedetto S.

HIV Drug Therapy Glasgow Congress 2014, 2-6 November 2014, Glasgow, UK. Abstract P285. J Int AIDS Soc. 2014; 17 (4 Suppl 3): 19817.

PUBBLICAZIONI

C) LIBRI E TRATTATI

“Emerging problems in Public Health”

Fabbiani M, Cauda R.

Book chapter for a publication from the Slovak Health Ministry, 2011.

“La Peste – Tra memoria e contemporaneità”

Cauda R, Fabbiani M.

In: Io sono il Signore, colui che ti guarisce - Malattia vs religione tra antico e moderno. Edizioni Dehoniane Bologna, 2012.

“Infezioni dell’apparato digerente”

Cauda R, Fabbiani M, Treccarichi EM.

In: Moroni M et al. Malattie Infettive, VIII Edizione, Elsevier Masson 2014, in press.

DOCENZE

“Valutazione dei disturbi neuro-cognitivi in pazienti HIV-positivi”

Corso di formazione e aggiornamento professionale AIDS (legge 135/90 ciclo 2008), Roma 4 Ottobre 2010.

“Infezione da HIV: nuove problematiche e problemi legati alla farmaco resistenza – Aspetti clinici ed epidemiologici”

Progetto formativo “Il microbiologo incontra il clinico”, Roma 21-28 Ottobre 2010.

“Aggiornamento sulla profilassi anti-HIV post esposizione”

Corso di formazione e aggiornamento professionale AIDS (legge 135/90 ciclo 2009), Roma 10 Novembre 2011.

Partecipazione a Corsi e Congressi in qualità di Relatore:

- “Questioni aperte in HIV”, Roma, 13 Maggio 2010.
- “Expert meeting I Nuovi ARV: un miglior profilo virologico, un minor impatto tossicologico”, Roma 24-25 Giugno 2010.
- “Gli NNRTI: due generazioni a confronto”, Roma 24-25 Ottobre 2011.
- “Expert meeting – La terapia antiretrovirale tra attualità e prospettive future”, 25-26 Ottobre 2012, Assisi (PG).
- “Raltegravir efficace ma non solo”, 19 Marzo 2013, Roma.
- “Le co-morbidità nel paziente con co-infezione HIV/virus epatite – Impatto sulla scelta della terapia antiretrovirale”, 24 Aprile 2014, Milano.
- Differenziazione tra i regimi terapeutici per l’HIV: elementi di confronto e condivisione delle esperienze, 5 Maggio 2015, Padova.

Partecipazione a Corsi e Congressi in qualità di Uditore:

- “Corso AIDS 2004”, Corso di aggiornamento per i medici delle UU.OO. Malattie Infettive delle aziende sanitarie toscane, Artimino (PO) 5-6 Febbraio, 19-20 Febbraio 2004.
- “La malattia cronica di fegato: la cirrosi epatica e l’epatocarcinoma virale da HBV e HCV”, Forum di Epatologia, Forte dei Marmi (Lu) 6 Novembre 2004.
- “1° Corso Nazionale di ecografia e Malattie Infettive”, Salice Terme 6-9 Aprile 2005.
- “La Tuberculosis”, Corso di formazione SIMIT, Riccione 11-13 Aprile 2005.
- “IDA 2005”, Riunione delle Scuole di Specializzazione in Malattie Infettive e Tropicali, Roma 29-30 Giugno 2005.
- “IV Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT)”, Fiuggi, 12-15 Dicembre 2005.
- “IDA 2006”, Riunione delle Scuole di Specializzazione in Malattie Infettive e Tropicali, Genova 6-7 luglio 2006.
- “La sfida della resistenza antimicrobica”, VII giornata infettivologica Toscana, Pisa 3 Ottobre 2006.
- “Corso AIDS 2006”, Corso di aggiornamento per i medici delle UU.OO. Malattie Infettive delle aziende sanitarie toscane, Pistoia 26-27 Marzo 2007.
- “III Workshop sulle reazioni avverse da farmaci antiretrovirali”, Firenze 10-11 Maggio 2007.
- “Medicina delle Migrazioni e Patologia Infettiva”, Corso di aggiornamento SIMIT, San Marino 18-20 Giugno 2007.
- “IDA 2007”, Riunione delle Scuole di Specializzazione in Malattie Infettive e Tropicali, Roma 27-28 Giugno 2007.
- “II Workshop Nazionale Innovazione e Ricerca per la pratica Clinica: Aderenza, Farmacocinetica, Resistenze nella terapia dell’infezione da HIV”, Castello di Vincigliata (FI) 24-26 Settembre 2007.
- “Il trattamento della neutropenia febbrile in ematologia”, Siena 2 Ottobre 2007.

- “Le problematiche renali nel paziente HIV”, Bari 16 Luglio 2008.
- “La gestione del paziente HIV pediatrico-adolescente”, Genova 10 Settembre 2008.
- “Terapia antiretrovirale: neuropenetrazione e malattia neurologica”, Roma 15 Settembre 2008.
- “News from 17th International AIDS Conference”, Milano 24 Settembre 2008.
- “How to optimally use CCR5 antagonists in clinical practice”, Roma 6 Ottobre 2008.
- “Il ruolo dell’infettivologo nel trapianto di organo solido”, Riccione (RN) 13-15 Ottobre 2008.
- “Ninth International Congress on Drug Therapy in HIV Infection”, Glasgow, Scotland, 9-13 Novembre 2008.
- “News from 9th International Congress on Drug Therapy in HIV Infection”, Milano 25 Novembre 2008.
- “Una nuova era nella terapia dell’HIV”, Roma 19-20 Febbraio 2009.
- “Holding back resistance: improving long-term outcomes in chronic hepatitis B”, Istanbul, Turchia, 6-7 Marzo 2009.
- “Top seminar in HBV: strategie terapeutiche tra linee guida e pratica clinica ”, Roma, 13 Marzo 2009.
- “7th European HIV Drug Resistance Workshop”, Stockholm, Sweden, 25-27 March 2009.
- “10th International Workshop on Clinical Pharmacology of HIV Therapy”, Amsterdam, The Netherlands, 15-17 April 2009.
- “La gestione del paziente HIV anziano”, Milano, 13 Maggio 2009.
- “V Convegno Nazionale – AIDS, quello che ancora non conosciamo”, Napoli, 10-11 Giugno 2009.
- “Complicanze metaboliche, semplificazione e sequenziamento terapeutico in corso di HAART: ruolo dei farmaci di nuova generazione”, Grottaferrata (RM), 22-23 Ottobre 2009.

- “17th Conference on Retroviruses and Opportunistic Infections (CROI 2010)”, 16-19 February 2010, San Francisco, USA.
- “20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2010)”, 10-13 April 2010, Vienna, Austria.
- “Expert meeting sugli inibitori dell’integrasi: le nuove linee guida”, San Martino in Campo (PG), 11-12 Giugno 2010.
- “Italian Conference on AIDS and Retroviruses (ICAR 2010)”, Brescia 20-22 Giugno 2010.
- “XVIII International AIDS Conference (IAS 2010)”, 18-23 July 2010, Wien, Austria.
- “Corsi di formazione e aggiornamento professionale (edizione 2008 – anno di svolgimento 2010) previsti dal piano di interventi contro l’AIDS” (Regione Lazio).
- “18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)”, 27 February - 2 March 2011, Boston, USA.
- “Italian Conference on AIDS and Retroviruses (ICAR 2011)”, Firenze 27-29 Marzo 2011.
- “6th IAS Conference on HIV Pathogenesis, Treatment and Prevention”, 17-20 July 2011, Rome, Italy.
- “Corsi di formazione e aggiornamento professionale (edizione 2009 – anno di svolgimento 2011) previsti dal piano di interventi contro l’AIDS” (Regione Lazio).
- “Expert meeting sugli inibitori dell’integrasi: costo/beneficio di una terapia innovativa”, 30 Settembre 2011, Roma.
- “13th European AIDS Conference (EACS 2011)”, October 12-15 2011, Belgrade, Serbia.
- “HIV experience Exchange”, 24-25 November 2011, Berlin, Germany.
- “19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)”, 4 - 8 March 2012, Seattle, USA.
- “Dopo la soppressione virologica: ottimizzazione della terapia antiretrovirale. Le strategie di switch e di semplificazione”, 2-3 Aprile 2012, Firenze.

- “Corsi di formazione e aggiornamento professionale (edizione 2010 – anno di svolgimento 2012) previsti dal piano di interventi contro l’AIDS” (Regione Lazio).
- “Expert meeting - Raltegravir: quali obiettivi di una scelta strategica meditata”, 22 Giugno 2012, Roma.
- “20th Conference on Retroviruses and Opportunistic Infections (CROI 2013)”, 3-6 March 2013, Atlanta, USA.
- “MISSION – Multidisciplinary experience on systemic fungal infections”, 4 Luglio 2013, Padova.
- “21st Conference on Retroviruses and Opportunistic Infections (CROI 2014)”, 3-6 March 2014, Boston, USA.
- “Switch degli antiretrovirali nel paziente con soppressione virologica: Terza edizione – Le strategie di switch, di semplificazione e di intensificazione nell’ottica dell’ottimizzazione della ART”, 9-10 Febbraio 2015, Firenze.
- “22nd Conference on Retroviruses and Opportunistic Infections (CROI 2015)”, 23-26 February 2015, Seattle, USA.
- ARCA MENTOR SCHOOL, SIENA 28-29 Maggio 2015.

Io sottoscritto Fabbiani Massimiliano dichiaro che quanto enunciato nel *curriculum vitae* corrisponde a verità ai sensi delle norme in materia di dichiarazioni sostitutive di cui agli artt.46 e seguenti del D.P.R. 145/2000.

Fornisco inoltre il consenso al trattamento dei dati personali ai sensi della L. 675/96.

Fiscon Marta, Medico Chirurgo Specialista in Malattie Infettive.

Psicoterapeuta ad indirizzo sistemico-relazionale.

Formazione:

- 2023: Specializzazione in Psicoterapia Sistemico Relazionale, Centro Padovano di Terapia della Famiglia
- 2017: Dottorato di ricerca in Biomedicina, Università degli Studi di Padova
- 2016: Post graduate certificate in Clinical Research, University of Liverpool
- 2011: Specializzazione in Malattie Infettive, Università degli Studi di Padova
- 2009: Diploma in Tropical Medicine & Hygiene, Liverpool School of Tropical Medicine
- 2006: Laurea in Medicina e Chirurgia, Università degli Studi di Padova

Attività Lavorativa:

- Da gennaio 2023 ad oggi: **Specialista ambulatoriale di Malattie Infettive, contratto SAI a tempo indeterminato** presso AULSS 9 Scaligera Verona
 - Attività in convenzione presso l'UOS Osservatorio Infettivologico, con partecipazione alle seguenti attività:
 - Ambulatorio testing e terapia per HIV
 - Ambulatorio profilassi pre-esposizione HIV (PrEP)
 - Ambulatorio testing e terapia infezioni sessualmente trasmesse
 - Ambulatorio epatologico
 - Ambulatorio infettivologico CUP e consulenze infettivologiche per infezioni ospedaliere
 - Ricerca clinica e Collaborazioni scientifiche nazionali e internazionali
 - Attività in convenzione presso l'UOC Salute in Carcere, come consulente infettivologo per la Casa Circondariale di Montorio (VR)
- Da gennaio 2023 ad oggi: **Psicoterapeuta libero professionista ad orientamento sistemico-relazionale**
 - - Attività privata di consulenza e terapia
 - Collaborazione a progetti di ricerca multidisciplinari
 - Attività di tirocinio formativo presso Associazione Eimì e Servizio "Giocatori Noti – Poliambulatorio Arcella"

Precedenti attività lavorative

- 2013- 2022: Dirigente Medico di Malattie Infettive a tempo pieno, con contratto di dipendente a tempo indeterminato presso AULSS 9 Scaligera — Verona (ex-ULSS 20 Verona)
- 2013: Medico di continuità assistenziale presso la Casa di Reclusione di Padova, ULSS 16 Padova
- 2011: Incarico provvisorio di Medico di continuità assistenziale presso il carcere femminile di Venezia, ULSS 12 Veneziana
- 2007-2011: Medico in formazione specialistica in Malattie Infettive presso Università degli studi di Padova

- 2007: Incarico di medico di medicina turistica presso ULSS 10 Veneto Orientale

Altre attività lavorative

- Relazioni a congressi nazionali e internazionali
- Docenza a corsi accreditati dalla regione Veneto per operatori sanitari sulle misure di prevenzione e controllo delle infezioni nei contesti assistenziali
- Partecipazione a numerosi progetti di ricerca locali, nazionali e internazionali
- Collaborazione a numerose pubblicazioni scientifiche su riviste internazionali

PERSONAL INFORMATION **Emanuele Focà, MD, PhD**

At present temporary Assistant professor (RTDB) – Chair of Infectious Diseases, University of Brescia and Attending Physician, Unit of Infectious Diseases, Brescia ASST Spedali Civili General Hospital.

ACADEMIC QUALIFICATIONS

- Ordinary Professor Qualification: National Scientific Qualification (art.16 of the law 30 December 2010, n.240) for Ordinary Professor obtained on February 8st 2022 (and valid until February 8st 2031).
- Associate Professor Qualification: National Scientific Qualification (art.16 of the law 30 December 2010, n.240) for Associate Professor obtained on August 3rd, 2017 (and valid until August 2nd, 2023).
- Member of the Faculty of Medicine and Surgery of the University of Brescia,
- Lecturer of Nurses and Dieticians Degree Courses.
- Teaching activities at post-graduated school in Infectious and tropical Diseases and Clinical Pharmacology.
- Board Member of the PhD programme in Civil and Environmental Engineering, Internationa Cooperation and Mathematica of the University of Brescia
- Teaching activities at the annual Post-graduated Course on Global Health of the University of Brescia

WORK EXPERIENCE

At present: Attending Physician, Unit of Infectious Diseases, Brescia ASST Spedali Civili General Hospital.

- HIV/AIDS outpatient care,
- Infectious Diseases consultancy activities.
- Infectious Diseases consultancy activities in Penitentiary Medicine Unit at the Brescia Provence Jails. Responsible for the ASST Spedali Civili General Hospital of occupational and accidental exposure to infectious biological agent and post-exposure prophylaxis to prevent HIV infections.
- Medical activity in highly isolated Infectious Diseases ward

Clinical Trial Activities: involvement with the role of sub-investigator in more than 30 studies (phase I, II, III, IV) clinical trials on HIV / AIDS andn SARS-CoV-2 infection, both spontaneous and funded including the 2 Italian trials on the testing of therapeutic HIV vaccines

2008-2009 HIV/AIDS outpatient care and clinical research in Burkina Faso: project ESTHER (*Ensemble pour une Solidarité Therapeutique en Réseau*): Outpatient activities in the prevention of mother to child transmission (PMTCT) program in Ouagadougou (Centre Médicale Saint Camille and Centre de Recherche Biomoleculaire Pietro Annigoni (CERBA)

EDUCATION AND TRAINING

- 01 November 2010 – 05 February 2014
PhD in Methodologies of Clinical Trials, University of Brescia, Italy (EQF level 8)

- 01 November 2005 - 08 March 2010
Post-graduated school - Specialisation in Infectious Diseases, University of Brescia, Italy (EQF level 8)
- 24 October 2005
Qualification Degree in Medicine and Surgery, University of Messina, Italy

RESEARCH ACTIVITIES AND PUBLICATION SCORES

The scientific production of Dr. Focà per has focused on HIV/AIDS and other chronic infection and COVID-19; innovative and highly original themes were identified, such as clinical characteristics of the aging population living with HIV, the long-term toxicity of antiretroviral drugs, screening and counselling strategies for HIV infection and other sexually transmitted diseases, HIV/AIDS infection in resources-limited countries. Moreover Dr. Focà focused his scientific interest on Vaccine and vaccination strategies among frail population. From the beginning of COVID-19 epidemic in Italy, he participated in building a local multidisciplinary group in Brescia to study treatment approach of COVID-19.

He coordinated the working group for the drafting of the guidelines for the treatment of COVID-19 of the Lombardy section of Italian society of infectious and tropical diseases,

- **Author of 106 Publications on peer review Scientific Journal:**
- **Total Impact Factor (ISI 2022): 293,134;**
- **H Index (Scopus 2022): 23;**
- **Total Citations (Scopus 2022): 2313**
- **Author of 23 other Publications (including 11 book chapters)**
- **Author of 7 invited lectures to National and International Conferences**
- **Participation as Faculty members at 51 national Conference in the last 5 years**
- **Author of 151 Abstract accepted on National (104) and International (47) Conferences**
- **ORC-ID: 0000-0003-4395-5379**

RESEARCH PROJECTS AND GRANTS

GEPPPO (Geriatric Patients living with HIV/AIDS: a Prospective multidimensional cOhort) Consortium: Included in the National Scientific Committee. Principal Investigator of the national coordinating Centre of the entire Cohort.

Gilead Fellowship program 2019: Notice of competition intended to support the conception and implementation of scientific and social projects aimed at improving the outcome and quality of life of patients affected by: HIV, Liver disorders, Onco-haematological disorders. Principal Investigator: Emanuele Focà - Contribution of Euro 25,000.

2020 CARIPO Foundation: Measure to support the development of collaborations for the identification of therapies and diagnostic systems, protection and analysis to counter the Coronavirus emergency and other viral emergencies of the future Funding of 175,600 Euros. Project title: "The effect of frailty on the clinical outcomes of patients infected by COVID-19 and on the risk of infection in the elderly: FraCOVID study ". Dr. Focà was sub-unit Principal Investigator

2021 FISR call for special supplementary fund for research (FISR2020IP_04373). Title "Tools of Artificial Intelligence to predict the prognosis of Covid-19 patients starting from laboratory and radiological data to support clinical decisions and hospital resource management in emergency situations". The overall loan granted by the Ministry is equal to € 56,518.40. As part of the inter-departmental project, as a participant for the clinical part, Dr. Focà has received a specific contribution of € 6,000

PRIZES AND HONORS

CROI Young Investigator Award 19th Conference on Retroviruses and Opportunistic Infections – March 5-8 2012. Seattle.

ICAR–CROI Awards 2012 for young Italian Research (2012)

“Hippocrates Prize for Scientific and Social Progress” 9th edition. Silver medal award of President of the Republic. Category: Young Doctors. Motivation: “Young Calabrian doctor. For having proposed himself in the field of research, projected towards wider and more authoritative boundaries ". (2016)

Individual annual funding of basic research activities. LAW 11 December 2016, n. 232, Article 1, paragraphs 295-302. Italian Ministry of Education, University and Research, 2017. Prize of Euro 3,000.

SCIENTIFIC SOCIETIES MEMBERSHIP

Member of the following scientific societies: Società Italiana di Malattie Infettive (SIMIT) Società Italiana di Medicina Tropicale (SIMET), International AIDS Society (IAS), European AIDS Clinical Society (EACS) and Medicus Mundi Italia (MMI), non-governative organization (NGO)
2018-2022: Board Member (secretary) of the Lombardy Section of Italian Society of Infectious and Tropical Diseases (SIMIT)

PERSONAL SKILLS

Mother tongue: Italian

Other language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C1	B2	B2	B2
French	B2	B2	B2	B2	B2
Spanish	B2	B2	B2	B2	B2

Brescia, Italy, 31 March 2022

FORMATO EUROPEO
PER IL CURRICULUM
VITAE



INFORMAZIONI PERSONALI

ROBERTA GAGLIARDINI

Indirizzo

Telefono

CF

E-mail

Nazionalità

Data di nascita

ESPERIENZE LAVORATIVE

Date
Occupazione

Dal 20.07.2018 - in corso

Dirigente medico presso la UOC Immunodeficienze virali, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS, Roma.

Dal 1.03.2018- 19.07.2018

Assegno di ricerca: tematica di ricerca "Costruzione di un database integrato di dati clinici e virologici, inclusi dati genotipici di resistenza, per l'ottimizzazione degli esiti dei trattamenti anti-HIV-1 con inibitori dell'integrasi virale – INTEGRATE"; S.C.06/D4, S.S.D.MED/17, Settore Scientifico Disciplinare MED/17 Malattie infettive; Settore concorsuale: 06/D4 Malattie cutanee, malattie infettive e malattie dell'apparato digerente; responsabile scientifico Prof. Andrea De Luca, Dipartimento di Biotecnologie mediche.

Dal 1.09.2017- 19.07.2018

Contratto di collaborazione libero professionale per attività specialistica in Malattie Infettive presso la UOC Malattie Infettive dell'Azienda Ospedaliera Universitaria Senese, Siena.

Dal 8.08.2017 al 31.08.2017

Borsa di studio SIMIT 2017 per ricerche nel campo delle infezioni da HCV, svolta presso l'Istituto di Malattie Infettive del Policlinico Gemelli, Roma.

Date Da settembre 2012 a luglio 2013

Occupazione Contratto di collaborazione coordinata e continuativa in progetti di ricerca presso l'Istituto di Malattie Infettive dell'Università Cattolica del Sacro Cuore; in particolare l'incarico è finalizzato alla realizzazione dello studio Atlas ("sicurezza ed efficacia dello switch di una terapia antiretrovirale combinata stabile con 2 NRTI+atazanavir/ritonavir ad atazanavir/ritonavir + lamivudina in pazienti con precedenti esperienze di trattamento e completa e stabile soppressione virologica").

Partecipazione a trial clinici Sub-investigator in diversi trial clinici (aree: HIV, HCV, Covid-19)

ISTRUZIONE E FORMAZIONE

Date 2001-2006

Nome e tipo di istituto di istruzione o formazione

Liceo scientifico indirizzo P.N.I. "Leonardo da Vinci" di Jesi (An).

Qualifica conseguita

Diploma con 100/100.

Date

3.05.2005

Nome e tipo di istituto di istruzione o formazione

Certificazione FCE (First Certificate English) rilasciata dall'università di Cambridge.

Date

2006-2012

Nome e tipo di istituto di istruzione o formazione

Corso di laurea in Medicina e Chirurgia presso l'Università degli Studi di Roma Tor Vergata.

Qualifica conseguita

Diploma di laurea conseguito con 110/110 e lode, discutendo la tesi sperimentale "Mutazioni di resistenza nel sottotipo 1 dell'epatite C per gli inibitori della proteasi NS3/4A in pazienti monoinfetti e coinfetti HIV/HCV", relatore prof. Massimo Andreoni dell'università di Roma Tor Vergata, correlatrice Dott.ssa Simona di Giambenedetto dell'Università Cattolica del Sacro Cuore. Lo studio è stato eseguito nell'ambito di un tirocinio volontario svolto presso l'Istituto di Malattie Infettive dell'Università Cattolica del Sacro Cuore (Policlinico Gemelli, Roma).

Nome e tipo di istituto di istruzione o formazione

Diploma di Abilitazione all'esercizio della Professione di Medico Chirurgo presso l'Università Cattolica del Sacro Cuore di Roma (superamento dell'Esame di Stato a febbraio 2013)

07 marzo 2013

Date

Iscrizione **all'Ordine Professionale dei Medici e Chirurghi di Roma** (numero di iscrizione albo 59971)

Nome e tipo di istituto di istruzione o formazione

<p>Date</p> <p>Nome e tipo di istituto di istruzione o formazione</p>	<p>Dal 8.08.2013 al 24.07.2017</p> <p>Diploma di Specializzazione in Malattie Infettive e Tropicali, conseguito presso l'Università Cattolica del Sacro Cuore di Roma, con votazione di 50/50 e lode con discussione di tesi dal titolo "Impatto della mutazione M184V sull'efficacia virologica delle dual therapies di mantenimento con lamivudina: uno studio di coorte"</p>
<p>Date</p> <p>Nome e tipo di istituto di istruzione o formazione</p>	<p>Partecipazione a congressi di Malattie Infettive nazionali ed internazionali: SIMIT 2014, CROI 2015, EACS 2015, ICAR 2015, CROI 2016, ICAR 2016, HIV Glasgow 2016, ICAR 2017, 15th EU Meeting on HIV & Hepatitis nel 2017, EACS 2017, CROI 2018, ICAR 2018, Congresso nazionale Simit 2018, CROI 2019, 17th EU Meeting on HIV & Hepatitis, ICAR 2019, CROI 2020, ICAR 2020, HIV Glasgow 2020, EU Meeting on HIV & Hepatitis nel 2020, CROI 2021, ICAR 2021.</p> <p>Partecipazione a corsi nazionali: corso Simit/advanced course HIV/HCV coinfection and comorbidities (Roma, 2.12.2015), Arca mentor school (Siena, 28-29.11.2015), V Icona Foundation meeting, Corso teorico-pratico di base sulla gestione dei pazienti con malattie infettive altamente contagiose.</p>
<p>Date</p> <p>Nome e tipo di istituto di istruzione o formazione</p>	<p>24-01-2017</p> <p>Ottenimento del Diploma nazionale SIUMB di competenza in Ecografia clinica</p>
<p>Date</p> <p>Nome e tipo di istituto di istruzione o formazione</p>	<p>13 e 14-10-2016</p> <p>Superamento del corso esecutore ALS- Advanced Life Support presso l'Università Cattolica del Sacro Cuore</p>
<p>Date</p> <p>Nome e tipo di istituto di istruzione o formazione</p>	<p>13.05.2017</p> <p>Diploma di corso di perfezionamento in Terapia antiretrovirale con votazione finale 110/110 (corso della durata di 9 mesi) presso l'Università degli Studi di Roma "Tor Vergata"</p>

ALTRO

Autrice di oltre 40 pubblicazioni su riviste peer-reviewed.

Attualmente membro della Società Italiana di Malattie Infettive (SIMIT) e membro della steering committee di Icona.

MADRELINGUA	ITALIANA
ALTRE LINGUE	
<ul style="list-style-type: none"> • <i>Capacità di lettura</i> • <i>Capacità di scrittura</i> • Capacità di espressione orale 	INGLESE OTTIMA BUONA BUONA
<ul style="list-style-type: none"> • <i>Capacità di lettura</i> • <i>Capacità di scrittura</i> • Capacità di espressione orale 	PORTOGHESE BUONA BUONA BUONA
CAPACITÀ E COMPETENZE RELAZIONALI	Buona capacità di integrazione e cooperazione.
CAPACITÀ E COMPETENZE TECNICHE	Elaborazioni di testi, presentazioni e fogli di calcolo, SPSS.

Autorizzo il trattamento dei miei dati personali ai sensi del Regolamento europeo n. 679/2016 (GDPR).

Il sottoscritto è consapevole che le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi, nei casi previsti dalla legge, sono puniti dal codice penale e dalle leggi speciali in materia (artt. 75 e 76 del Testo Unico sulla documentazione amministrativa DPR 445/2000".

Roma, 21.02.2022

Curriculum Vitae

PERSONAL INFORMATION

Name **Andrea Galli**

Address

Telephone

E-mail

Nationality

Date of birth

1994

EDUCATION AND TRAINING

Registration to "Ordine Nazionale dei Biologi" number 39663

1993

Biologist qualification

University of Pavia

1990

Master's Degree in Biological sciences

University of Milano

Experimental Thesis

Monitoring of lymphocyte subpopulations in patients undergoing orthotopic liver transplantation

1991

Achieving scientific maturity

Liceo Statale P.Frisi di Monza

WORK EXPERIENCE

2000-today

Consultant // Temporary employment / Project collaborator

San Raffaele Hospital

Department of Infectious Diseases

Via Stamira d'Ancona 20

20127 Milan

Head of the Clinical Immunology Laboratory at the Clinical Protocols Unit

Processing, storage and cataloging of biological samples

Data base management

Preparation and sending of biological samples according to the regulations in force (IATA certified)

1999

Consultant

Ristohelp Consultant S.r.l.
Milan

HACCP Self-Control Preparation Manager
Surface and food sampling management to verify the presence of pathogenic microorganisms

1999

Consultant
Italian Stomatological Institute
Milan
Analysis Laboratory Manager
Biochemical analysis
Urine analysis
Clinical biochemical analysis
Coagulation analysis and blood groups
Virological and bacterial analyzes

1997-1998

Tutor
Internal Medicine Department
Ospedale Maggiore Policlinico Milan
Advanced course in Flow Cytometry

1992-1999

Fellow
Department of Internal Medicine, Infectious Diseases and Immunopathology
Ospedale Maggiore Policlinico

AREAS OF INTEREST

Flow Cytometry
Expression of functional membrane markers on various cell types (leukocytes, endothelium, hematopoietic stem cells, cell lines)
Expression of chemokine receptors
Cellular apoptosis
Functional tests
ELISA and ELISPOT tests
Processing, storage and sending of biological samples
Planning and management of Clinical Trials

ORGANISATIONAL SKILLS AND COMPETENCES

MOTHER TONGUE

Italian

OTHER LANGUAGES

English
French

ORGANISATIONAL SKILLS AND COMPETENCES

Excellent organizational and technical skills in the application of experimental methodologies and in the design of experimental research projects and Clinical Trials

COMPUTER SKILLS AND COMPETENCES

Good knowledge of Office, Windows, Mac Os X package
Experience in compilation of Electronic Clinical Records and Computer Data Base

DRIVING LICENCE

B

TRAINING AND UPDATE COURSES

- Second World Week of Professional Updating in Surgery and in Surgical and Oncological Disciplines of the University of Milan. Milano, 15-21 luglio 1990
- Corso Postuniversitario Teorico-Pratico di Allergologia e Immunologia Clinica sul tema "Autoimmunità". Milano, 15-17 aprile 1993
- X Riunione Nazionale di Citometria. Palazzo del Popolo, Orvieto, 28 settembre-1 ottobre 1993
- XIII Congresso Nazionale della Società Italiana di Immunologia e di Immunopatologia. Centro Congressi Hotel Cavalieri Hilton, Roma, 12-15 dicembre 1993
- XII Riunione Nazionale di Citometria. Centro Congressi Cocumella, Sant'Agello di Sorrento, 18-20 ottobre 1995
- Convegno "Progenitori emopoietici circolanti: aspetti biologici ed applicazioni in oncologia". Università di Pavia, Pavia, 12 giugno 1996
- VI European Workshop on Cytokines . San Raffaele Biomedical Science Park, Milano. 29-31 marzo 2001
- VII Workshop Nazionale Studio I.CO.NA.. Bari, 12-14 giugno 2002
- Meeting "Trial Clinici (preventivo e terapeutico) di Fase I per la Sperimentazione del Vaccino anti HIV/AIDS basato sulla Proteina Tat Biologicamente Attiva". Hotel Turner, Roma, 14 ottobre 2002
- Corso CEFAR "L'evoluzione della virologia molecolare". Milano, 12 dicembre 2002. Crediti acquisiti 4
- I Forum SIVIM "Epatite virale dal laboratorio alla pratica clinica". Università Vita e Salute San Raffaele, Milano, 31 gennaio 2003. Crediti acquisiti 6

- Corso “Tecnologie per l’analisi degli acidi nucleici”. Università Vita e Salute San Raffaele, Milano, dal 18 marzo al 10 aprile 2003. Crediti acquisiti 10
- Simposio “Perfezionare le strategie di trattamento dell’infezione da HIV”. Modena, 14 aprile 2003
- Convegno “Immune Reconstitution and Control of HIV”. Stresa, 5-6 giugno 2003. Crediti acquisiti 9
- VIII Workshop Nazionale Studio I.CO.NA.. Firenze, 23-24 giugno 2003.
- Corso “La biologia molecolare nel monitoraggio delle infezioni da HIV e HCV”. Milano, 30 settembre 2003. Crediti acquisiti 5
- Corso “Aspetti fondamentali di Ematologia Clinica e Coagulazione”. Università Vita e Salute San Raffaele, Milano, dal 2 al 16 dicembre 2003. Crediti acquisiti 6
- II Forum SIVIM “Genotipo, Fenotipo e Fitness virale nella valutazione della terapia anti HIV-1”. Università Vita e Salute San Raffaele, Milano, 29-30 gennaio 2004. Crediti acquisiti 6
- Seminario “Tossicità mitocondriale: nuove prospettive”. Dipartimento di Malattie Infettive, Università Vita e Salute San Raffaele, Milano, 24 marzo 2004. Crediti acquisiti 3
- Corso Interregionale di Formazione “La Sindrome Acuta Respiratoria SARS. Raccomandazioni per la prevenzione ed il controllo”, Ospedale San Raffaele, Milano, 26 aprile 2004. Crediti acquisiti 6
- IX Workshop Nazionale Studio I.CO.NA.. Portonovo Ancona, 17-18 maggio 2004.
- Corso di Manipolazione in Sicurezza Azoto Liquido, Ospedale San Raffaele, Milano, 13 ottobre 2004. Crediti acquisiti 4
- Corso “Rischio Biologico nei laboratori con livelli di biosicurezza P2 e P3”, Ospedale San Raffaele, Milano, 8 novembre 2004. Crediti acquisiti 3
- II Congresso Nazionale SIVIM, Roma, 16-18 maggio 2005. Crediti acquisiti 11
- X Workshop Nazionale Studio ICONA. Torino 31 maggio-1giugno 2005
- Corso “La gestione del rischio da agenti chimici, cancerogeni e mutageni in laboratorio”, Ospedale San Raffaele, Milano, 25 novembre 2005. Crediti acquisiti 3
- IV Forum SIVIM “Infezione da HIV: diagnostica avanzata e terapie antiretrovirali innovative”. Università Vita e Salute San Raffaele, Milano, 26-27 gennaio 2006. Crediti acquisiti 9
- V Forum SIVIM “Infezioni nell’ospite immunocompromesso”. Università Vita e Salute San Raffaele, Milano, 1-3 febbraio 2007. Crediti acquisiti 12
- VI Forum SIVIM “HCV e IFN” Università Vita e Salute San Raffaele, Milano, 8-9 novembre 2007. Crediti acquisiti 9
- VII Forum SIVIM “I nuovi virus dell’uomo e le patologie virali emergenti” Università Vita e Salute San Raffaele, Milano, 2-4 aprile 2009. Crediti acquisiti 9
- ICAR- Italian Conference on AIDS and Retroviruses. Milano 24-26 maggio 2009. Crediti acquisiti 14
- La criopreservazione di materiale biologico. Milano, 9 marzo 2010.
- IV Congresso Nazionale SIVIM, Milano, 5-7 maggio 2010. Crediti acquisiti 12
- Congresso ICONA INCONTRA 2, Milano, 26-27 gennaio 2012, crediti acquisiti 6
- Progetto di formazione a distanza: CORSO SUL RISCHIO INCENDIO E GESTIONE DELLE EMERGENZE IN AMBITO SANITARIO. Dal 01/01/2016 al 31/12/2016 Ospedale San Raffaele Milano. Crediti acquisiti 3
- Evento residenziale: SICUREZZA AREA SCIENTIFICA. Dal 13/07/2016 al 13/07/2016. Ospedale San Raffaele Milano. Crediti acquisiti 4.2
- Progetto di formazione sul campo: AGGIORNAMENTO IN MALATTIE INFETTIVE: NUOVI SCENARI CLINICI III. Dal 12/01/2016 al 31/05/2016. Ospedale San Raffaele Milano. Crediti acquisiti 36
- Progetto di formazione sul campo: AGGIORNAMENTO IN MALATTIE INFETTIVE: NUOVI SCENARI CLINICI IV. Dal 27/09/2016 al 13/12/2016. Ospedale San Raffaele Milano. Crediti acquisiti 20
- Progetto di formazione sul campo: AGGIORNAMENTO IN MALATTIE INFETTIVE : NUOVI SCENARI CLINICI V. Dal 10/01/2017 al 07/02/2017. Ospedale San Raffaele Milano. Crediti acquisiti 10

- Progetto di formazione sul campo: AGGIORNAMENTO IN MALATTIE INFETTIVE : NUOVI SCENARI CLINICI VI. Dal 28/02/2017 al 19/12/2017. Ospedale San Raffaele Milano. Crediti acquisiti 50
- 4TH ICONA FOUNDATION MEETING: HIV AND COINFECTIONS. Roma 25-26 gennaio 2018
- Progetto di formazione sul campo: AGGIORNAMENTO IN MALATTIE INFETTIVE : NUOVI SCENARI CLINICI VII. Dal 23/01/2018 al 17/04/2018. Ospedale San Raffaele Milano. Crediti acquisiti 20
- Progetto di formazione sul campo: AGGIORNAMENTO IN MALATTIE INFETTIVE : NUOVI SCENARI CLINICI VII-PARTE II. Dal 08/05/2018 al 10/07/2018. Ospedale San Raffaele Milano. Crediti acquisiti 26
- Progetto di formazione sul campo: AGGIORNAMENTO IN MALATTIE INFETTIVE : NUOVI SCENARI CLINICI VII-PARTE III. Dal 02/10/2018 al 11/12/2018. Ospedale San Raffaele Milano. Crediti acquisiti 26

ADDITIONAL INFORMATIONS

Member of the Italian Society of Infectious and Tropical Diseases (SIMIT)
Member of the Italian Society of Medical Virology (SIVIM)

PUBLICATIONS:

1- Mocellin C., Bonara P., Gridelli B., **Galli A.**, Maggioni L.: LYMPHOCYTE SUBSETS IN BABOONS UNDERGOING ORTHOTOPIC LIVER TRANSPLANTATION FROM ALLO- AND XENOGENEIC DONORS. European Journal Histochemistry, 37/suppl.1993, pag. 31.

2- Maggioni L., Bonara P., Gatti S., Mocellin C., **Galli A.**: RELIABILITY OF FLOWCYTOMETRIC (FCM) FOLLOW-UP OF RATS TREATED WITH ANTI-LYMPHOCYTE SERUM. European Journal Histochemistry, 37/suppl., 1993, pag. 30.

3- **Galli A.**, Capsoni F., Bonara P., Minonzio F., Zanussi C.: CYTOKINES AND SURFACE EXPRESSION OF BETA-2-INTEGRINS ON PHAGOCYtic CELLS IN HUMAN WHOLE BLOOD. European Journal Histochemistry, 37/suppl., 1993, pag. 39.

4- Capsoni F., Minonzio F., Ongari A.M., Carbonelli V., **Galli A.**, Zanussi C.: IL-10 UP-REGULATES HUMAN MONOCYTE PHAGOCYTOSIS IN FINE BALANCE WITH IL-4 AND IFN γ . Journal Leucocyte Biology, Volume 58, September 1995, pag.351-358.

5- **Galli A.**, Bonara P., Mocellin M.C., Gridelli B.: CLASS CHARACTERIZATION AND LYMPHOCYTOTOXIC ACTIVITY EVALUATION OF PERFORMED ANTI-DONOR ANTIBODIES IN DISCORDANT XENOTRANSPLANTATION. European Journal Histochemistry, 39/suppl.3, 1995, pag 62.

6- Bonara P., Mocellin M.C., **Galli A.**, Gatti S.: A NEW CYTOFLUORIMETRIC CELL MEDIATED LYMPHOCYTOTOXICITY (CML) TEST IN XENOGENEIC TRANSPLANTATION. European Journal Histochemistry, 39/suppl.3, 1995, pag 59.

7- Tedeschi S., Bonara P., Gridelli B., Gatti S., **Galli A.**, Mocellin M.C., Galmarini D.: EFFECTS OF POLYCLONAL HUMAN INTRAVENOUS IMMUNOGLOBULINS (Ivlg) IN DISCORDANT XENOTANSPLANTATION: IN VITRO AND EX VIVO FLOWCYTOMETRIC EVALUATION. European Journal Histochemistry, 39/suppl.3, 1995, pag 67.

8- Mocellin M.C., Bonara P., Della Volpe A., **Galli A.**, Frugoni C., Tedeschi S., Lambertenghi Delilieri G.: EFFECT OF G-CSF THERAPY ON IMMUNOLOGICAL RECONSTITUTION AFTER AUTOLOGUS BONE MARROW TRANSPLANTATION. European Journal Histochemistry, 39/suppl.3, 1995, pag 48.

9- Bonara P., Gridelli B., **Galli A.**, Gatti S., Tedeschi S., Reggiani P., Mocellin C.M., Piazzini A., Galmarini D.: IN VITRO AND IN VIVO EFFECTS OF POLYCLONAL HUMAN INTRAVENOUS IMMUNOGLOBULINS (Ivlg) IN DISCORDANT XENOTRANSPLANTATION. Transplantation Proceedings, volume 28, NO 2, aprile 1996, pag. 778-783.

- 10- Bonara P., Solca M., Baisi A., Bauer D., **Galli A.**, Mocellin C., Maturri L. and Lung Transplant Group of Ospedale Maggiore di Milano: FLOW CYTOMETRIC ANALYSIS OF BRONCHOALVEOLAR LAVAGE AND VENOUS BLOOD LYMPHOCYTES PHENOTYPE FOR DIAGNOSIS OF ACUTE GRAFT REJECTION IN LUNG TRANSPLANTED PATIENTS. *Analytical and Quantitative Cytology and Histology*, anno 18, volume 4, pag.293-297, 1996.
- 11- Colosio C., Barcellini W., Maroni M., Alcini D., Bersani M., Cavallo D., **Galli A.**, Meroni PL., Pastorelli R., Rizzardi G.P., Soleo L., Foa V.: IMMUNOMODULATORY EFFECTS OF OCCUPATIONAL EXPOSURE TO MANCOZEB. *Archives of Environmental Health*. 1996 Nov-Dec, 51(6):445-51.
- 12- Capsoni F., Minonzio F., Ongari A.M., Carbonelli V., **Galli A.**, Zanussi C.: INTRLEUKIN-10 DOWN-REGULATES OXIDATIVE METABOLISM AND ADCC OF HUMAN NEUTROPHILS. *Scandinavian Journal of Immunology*, vol 45, pag.269-275, 1997.
- 13- Capsoni F., Minonzio F., Ongari A.M., Carbonelli V., **Galli A.**, Zanussi C.: INTRLEUKIN-10 DOWN-REGULATES OXIDATIVE METABOLISM AND ADCC OF HUMAN NEUTROPHILS. 2nd International Congress on Phagocytes. Pavia, Italy, september 4-7, 1996. *European Journal of Haematology*, suppl.NO. 59, volume 57, settembre 1996, pag. 29.
- 14- P.Biswas, **A.Galli**, B.Capiluppi, D.Ciuffreda, A.Lazzarin, G.Tambussi: SELECTIVE ENRICHMENT OF CD30-EXPRESSING CELLS WITHIN THE BLAST REGION OF LYMPHOCYTES FROM PATIENTS WITH PRIMARY HIV INFECTION (PHI). *Journal of Biological Regulators & Homeostatic Agents (JBRHA)*. Volume 16, Number 1, january-march 2002. pag 33-36.
- 15- C.Pastori, C.Barassi, F.Lillo, R.Llonghi, B.Capiluppi, S.Noza, **A.Galli**, C.Uberti-Foppa, A.Lazzarin, G.Tambussi, L.Lopalco: THE EFFECT OF HAART ON HUMORAL IMMUNE RESPONSE IN PRIMARY HIV-1 INFECTED PATIENTS. *Journal of Biological Regulators & Homeostatic Agents (JBRHA)*. Volume 16, Number 1, january-march 2002. pag 9-17.
- 16- Guffanti M, De Pascalis CR, Seminari E, Fusetti G, Gianotti N, Bassetti D, **Galli A**, Castagna A, Lazzarin A: PHARMACOKINETICS OF AMPRENAVIR GIVEN ONCE OR TWICE A DAY WHEN COMBINED WITH ATAZANAVIR IN HEAVILY PRE-TRATED HIV-POSITIVE PATIENTS. *AIDS*, Volume 17(18) dec 5 2003, pag. 2669-71.
- 17- N.Gianotti, E.Seminari, G.Fusetti, S.Salpietro, E.Boeri, **A.Galli**, A.Lazzarin, M.Clementi, A.Castagna : IMPACT OF A TREATMENT INCLUDING TENOFOVIR PLUS DIDANOSINE ON THE SELECTION OF THE 65R MUTATION IN HIGHLY DRUG-EXPERIENCED HIV-INFECTED PATIENTS. *AIDS*, Volume 18 n°16, Nov. 2004, pag 2205-2207.
- 18- Monforte AD, Cozzi-Lepri A, Phillips A, De Luca A, Murri R, Mussini C, Grossi P, **Galli A**, Zauli T, Montroni M, Tundo P, Moroni M; for Italian Cohort of Antiretroviral-Naïve Patients Study Group. INTERRUPTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN HIV CLINICAL PRACTICE: RESULTS FROM THE ITALIAN COHORT OF ANTIRETROVIRAL-NAÏVE PATIENTS. *J. Acquir. Immune Defic. Syndr.* 2005 April 1;38(4):407-416
- 19- E.Seminari, M.Guffanti, P.Villani, N.Gianotti, M.Cusato, G.Fusetti, **A.Galli**, A.Castagna, M.Regazzi, A.Lazzarin. STEADY STATE PHARMACOKINETICS OF ATAZANAVIR GIVEN ALONE OR IN COMBINATION WITH SAQUINAVIR-HARD GEL CAPSULES OR AMPRENAVIR IN HIV-1 INFECTED PATIENTS. *European Journal of Clinical Pharmacology*, Aug 2005 61(7):545-549
- 20- G.Morsica, S.Tasca, P.Biswas, **A.Galli**, M.Malnati, C.Paties, M.Marinelli, S.Bagaglio, A.Lazzarin, C.Fortis. NATURAL KILLER-CELL CYTOTOXICITY IN HIV-POSITIVE AND HIV-NEGATIVE PATIENTS WITH AND WITHOUT SEVERE COURSE OF HEPATITIS B VIRUS INFECTION. *Scandinavian Journal of immunology*, 2005 sep; 62(3), 318-324
- 21- Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, Boeri E, **Galli A**, Cernuschi M, Hasson H, Clementi M, Lazzarin A. LAMIVUDINE MONOTHERAPY IN HIV-1 INFECTED PATIENTS HARBOURING A LAMIVUDINE-RESISTANT VIRUS: A RANDOMIZED PILOT STUDY (E-184V STUDY). *AIDS*, 2006 apr. 4;20(6):795-803.

- 22- Biswas P, Cozzi-Lepri A, Delfanti F, **Galli A**, Colangeli V, Moioli MC, Scarchilli A, Abrescia N, Vigevani G, D'Arminio-Monforte A, Novati R, Lazzarin A: SIGNIFICANT LINK BETWEEN sCD30 CHANGES AND HIV VIREMIA IN PATIENTS TREATED WITH HAART. *J.Med. Virol.* 2006 Oct 24; (12):1513-1519.
- 23- Guffanti M, Caumo A, Galli L, Bigoloni A, **Galli A**, Dagba G, Danise A, Luzi L, Lazzarin A, Castagna A. SWITCHING TO UNBOOSTED ATAZANAVIR IMPROVES GLUCOSE TOLERANCE IN HIGHLY PRETREATED HIV-1 INFECTED SUBJECTS. *European Journal of Endocrinology*, 56(4):503-509 apr.2007.
- 24- Biswas P, **Galli A**, Galli L, Tassan Din C, Vecchi A, Maknati M, Lazzarin A, Tambussi G. DOES CYCLOSPORIN A AFFECT CCR5 AND CXCR4 EXPRESSION IN PRIMARY HIV-1 INFECTED PATIENTS. *Cytometry B Clin. Cytom.* may 1 2007
- 25- P.Cicconi, A.Cozzi-Lepri, G.Orlando, A.Matteelli, E.Girardi, A.Degli Esposti, C.Moioli, G.Rizzardini, A.Chiodera, G.Ballardini, C.Tincati, A.d'Arminio Monforte for the I.Co.N.A. Study Group. RECENT ACQUIRED STD AND THE USE OF HAART IN THE ITALIAN COHORT OF NAÏVE FOR ANTIRETROVIRALS (I.Co.N.A.): ANALYSIS OF THE INCIDENCE OF NEWLY ACQUIRED HEPATITIS B INFECTION AND SYPHILIS. *Infection.* 2008 Feb; 36(1):46-53.
- 26- Saracino A, Gianotti N, Marangi M, Cibelli DC, Galli A, Punzi G, Monno L, Lazzarin A, Angarano G, on behalf of the Mutations , Salvage (MuSa) Study Group Members. ANTIRETROVIRAL GENOTYPIC RESISTANCE IN PLASMA RNA AND WHOLE BLOOD DNA IN HIV-1 INFECTED PATIENTS FAILING HAART. *J Med Virol.*2008 Aug 19;80(10):1695-1706
- 27- Zanone Poma B, Riva A, Nasi M, Cicconi P, Broggin V, Lepri AC, Mologni D, Mazzotta F, Monforte AD, Mussini C, Cossarizza A, Galli M, Icona Foundation Study Group. GENETIC POLYMORPHISMS DIFFERENTLY INFLUENCING THE EMERGENCE OF ATROPHY AND FAT ACCUMULATION IN HIV-RELATED LIPODYSTROPHY. *AIDS* 2008 Sep 12;22(14):1769-78.
- 28- Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Low M, De Wit S, Friis-Moller N, Phillips AN, Sabin CA, Lundgren JD, Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-INDUCED IMMUNODEFICIENCY AND MORTALITY FROM AIDS-DEFINING AND NON-AIDS-DEFINING MALIGNANCIES. *AIDS* 2008 Oct 18;22(16):2143-53.
- 29- Antiretroviral Therapy Cohort Collaboration (ART-CC), Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Gunthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Mirò JM, Staszewski S, Sterne JA. DOES SHORT-TERM VIROLOGIC FAILURE TRANSLATE TO CLINICAL EVENTS IN ANTIRETROVIRAL-NAÏVE PATIENTS INITIATING ANTIRETROVIRAL THERAPY IN CLINICAL PRACTICE? *AIDS*, 2008 Nov 30;22(18):2481-92.
- 30- Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, **Galli A**, Castagna A, Lazzarin A, Clementi M, Gianotti N. DYNAMIC PATTERNS OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INTEGRASE GENE EVOLUTION IN PATIENTS FAILING RALTEGRAVIR-BASED SALVAGE THERAPIES. *AIDS* 2009 Feb 20;23(4):455-60.
- 31- Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Farkhenheuer G, Justivc A, Reiss P, D'Arminio Manforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. VARIABLE IMPACT ON MORTALITY OF AIDS-DEFINING EVENTS DIAGNOSED DURING COMBINATION ANTIRETROVIRAL THERAPY: NOT ALL AIDS-DEFINING CONDITIONS ARE CREATED EQUAL. *Clin.Infect.Dis.* 2009 apr 15;48(8):1138-51.
- 32- Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD; Hepa I.C.o.N.A the Icona Foundation Study Groups. VIRAL INTERFERENCE BETWEEN HEPATITIS B, C, AND D VIRUSES IN DUAL AND TRIPLE INFECTIONS IN HIV-POSITIVE PATIENTS. *J.Acquir. Immune. Defic. Syndr.* 2009 Aug 15;51(5):574-81.

- 33- Vecchi A, Hasson H, **Galli A**, Castagna A, Lazzarin A, Biswas P. IN VIVO TREATMENT WITH FUSION INHIBITOR ENFUVIRTIDE LEADS TO INCREASED IL-2 PRODUCTION BY AUTOLOGOUS IN VITRO ACTIVATED MONOCYTES FROM HIV-INFECTED INDIVIDUALS. *JAA*, Volume 1(1): 043-050 (2009)-043
- 34- Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi EM, Antinori A, Gatti F, Cassola G, Sighinolfi L, Castelli P, d'Arminio Manforte A; ICONA Foundation Study Group. INSIGHTS INTO REASONS FOR DISCONTINUATION ACCORDING TO YEAR OF STARTING FIRST REGIMEN OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN A COHORT OF ANTIRETROVIRAL-NAIVE PATIENTS. *HIV Med*. 2010 Feb;11(2):104-113
- 35- Trotta M.P., Cozzi-Lepri A, Ammassari A, Vecchiet J, Cassola G, Caramello P, Vullo P, Soscia F, Chiodera A, Ladina N, Abeli C, Cauda R, Buonomo A.R, Antinori A, d'Arminio Manforte A, ICONA Foudation Study. RATE OF CD4+ CELLS COUNT INCREASE OVER PERIOD OF VIRAL LOAD SUPPRESSION: RELATIONSHIP WITH THE NUMBER OF PREVIOUS VIROLOGICAL FAILURES. *Clin. Infect. Dis*. 2010 Aug 15;51(4):456-64.
- 36- Canducci F, Barda B, Ceresola E, Spagnolo V, Sampaolo M, Boeri E, Nozza S, Cossarin F, Galli A, Gianotti N, Castagna A, Lazzarin A, Clementi M. EVOLUTION PATTERNS OF RALTEGRAVIR RESISTANCE MUTATIONS AFTER INTEGRASE INHIBITOR INTERRUPTION. *Clin. Microbiol. Infect*. 2010 Sep 20.
- 37-Torti C, d'Arminio-Monforte A, Pozniak AL, Lapadula G, Cologni G, Antinori A, De Kuca A, Mussini C, Castagna A, Cicconi P, Minoli L, Costantini A, Carosi G, Liang H, Cesana BM.; MASTER, Chelsea & Westminster, ICONA, Modena and S.Raffaele HIV Cohorts. LONG TERM CD4+ T-CELL COUNT EVOLUTION AFTER SWITCHING FROM REGIMENS INCLUDING HIV NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI) PLUS PROTEASE INHIBITORS TO REGIMENS CONTAINING NRTI PLUS NON-NRTI OR ONLY NRTI. *BMC Infect.Dis*. 2011 Jan 25;11:23.
- 38- Nozza S, Galli L, Bigoloni A, Nicola G, Pogliaghi M, Cossarini F, Sampietro S, Galli A, Della Torre L, Tambussi G, Lazzarin A, Castagna A. DURABILITY AND SAFETY OF A NOVEL SALVAGE THERAPY IN R5-TROPIC HIV-INFECTED PATIENTS: MARAVIROC, RALTEGRAVIR, ETRAVIRINE. *J. Acquir. Defic. Syndr*. 2011 Apr;56(4):e113-5.
- 39- Nozza S, Canducci F, Galli L, Cozzi-Lepri A, Capobianchi M.R, Ceresola E.R, Narciso P, Liberatone R, Castelli P, Miodi M, D'Arminio-Monforte A, Castagna A, ICONA Foundation. VIRAL TROPISM BY GENO2PHENO AS A TOOL FOR PREDICTING CD4 DECREASE IN HIV-1 INFECTED NAIVE PATIENTS WITH HIGH CD4 COUNTS. *J.Antimicrob. Chemother*. 2012 May;67(5):1224-7.
- 40- De Luca A, De Gaetano Donati K, Cozzi-Lepri A, Colafigli M, De Curtis A, Capobianchi M.R, Antinori A, Giacometti A, Magnani G, Vullo V, Cauda R, Iacoviello L, D'Arminio-Monforte A, ICONA Foundation. EXPOSURE TO ABACAVIR AND BIOMARKERS OF CARDIOVASCULAR DISEASE IN HIV-1 INFECTED PATIENTS ON SUPPRESSIVE ANTIRETROVIRAL THERAPY: A LONGITUDINAL STUDY. *J. Acquir. Immune Defic. Syndr*. 2012 Jul 1;60(3) e98-101.
- 41- Cossarini F, **Galli A**, Galli L, Bigoloni A, Salpietro S, Vinci C, Della Torre L, Gianotti N, Spagnolo V, Lazzarin A, Castagna A, Nozza S. IMMUNE RECOVERY AND T CELL SUBSET ANALYSIS DURING EFFECTIVE TREATMENT WITH MARAVIROC. *J. Antimicrob. Chemother*. 2012 Oct;67(10):2474-8.
- 42- May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Lederberger B, Thiebaut R, Gill MJ, Kirk O, Van Sighem A, Saag MS, Navarro G, Sobrio-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA, Antiretroviral Therapy Cohort Collaboration (ART_CC)) HETEROGENEITY IN OUTCOMES OF TREATED HIV-POSITIVE PATIENTS IN EUROPE AND NORTH AMERICA: RELATION WITH PATIENT AND COHORT CHARACTERISTICS. *Int J Epidemiol* 2012 Dec;41(6):1807-20

- 43- Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Morante O, Smith C, Lundgren JD, D:A:D Study Group. ASSOCIATION BETWEEN ANTIRETROVIRAL EXPOSURE AND RENAL IMPAIRMENT AMONG HIV-POSITIVE PERSON WITH NORMAL BASELINE RENAL FUNCTION: THE D:A:D STUDY. *J Infect Dis.* 2013 May 1;207 (9):1359-69
- 44- Calcagno A, Nozza S, Gonzales de Requena D, **Galli A**, D'Avollo A, Simile M, Chiappetta S, De Perri G, Lazzarin A, Bonora S. PHARMACOKINETICS OF MARAVIROC ADMINISTERED AT 150 mg ONCE DAILY IN ASSOCIATION WITH LOPINAVIR/RITONAVIR IN HIV-POSITIVE TREATMENT- NAIVE PATIENTS. *J Antimicrob Chemother*, 2013 Marr 14.
- 45- Rotger M, Glass TR, Junior T, Talenti A, Tarr PE, MAGNIFICENT Consortium, INSIGHT, Swiss HIV Cohort Study. CONTRIBUTION OF GENETIC BACKGROUND, TRADITIONAL RISK FACTORS, AND HIV-RELATED FACTORS TO CORONARY ARTERY DISEASE EVENTS IN HIV-POSITIVE PERSONS. *Clin. Infect.Dis.* 2013 Jul;57(1):112-21
- 46- Spagnolo V, Cocorullo D, Galli L, Bigoloni A, **Galli A**, Rubinacci A, Mignogna G, Carbone A, Lazzarin A, Castagna A. PLASMA FIBROBLAST GROWTH FACTOR 23 AND OSTEOCALCIN SERUM LEVELS ARE ASSOCIATED WITH CARDIOVASCULAR RISK IN HIV-1 INFECTED PATIENTS RECEIVING ANTIRETROVIRAL TREATMENT. *J. Antimicrob. Chemother.* 2013 Dec;68(12):2960-3
- 47- Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Manforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J, D:A:D Study Group. ASSOCIATIONS BETWEEN IMMUNE DEPRESSION AND CARDIOVASCULAR EVENTS IN HIV INFECTION. *AIDS* 2013 Nov 13;27(17):2735-48.
- 48- Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fatkenheuer G, D'Arminio Manforte A, Abrams DL, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lungren JD, Sabin CA., D:A:D Study Group. NON-AIDS DEFINING CANCERS IN THE D:A:D STUDY-TIME TRENDS AND PREDICTORS OF SURVIVAL: A COHORT STUDY. *BMC Infect. Dis.* 2013 Oct 9;13:471
- 49- Nozza S, Pignataro AR, Galli L, Ripa M, Boeri E, Chiappetta S, **Galli A**, Canducci F, Sampaolo M, Clementi M, Lazzarin A, Tambussi G. IMMUNOLOGICAL RECOVERY AFTER 24 WEEKS OF ANTIRETROVIRAL THERAPY IN PATIENTS WITH X4 VIRUS DURING PRIMARY HIV INFECTION. *J. Acquir. Immune Defic. Syndr.* 2014 Jan 1;65(1):e27-9
- 50- Caravelli M, Mainetti L, Pignataro AR, Bigoloni A, Tolazzi M, **Galli A**, Nozza S, Castagna A, Sampaolo M, Boeri E, Scarlatti G. COMPLEXITY AND DYNAMICS OF HIV-1 CHEMOKINE RECEPTOR USAGE IN A MULTIDRUG-RESISTANT ADOLESCENT. *AIDS Res Hum Retroviruses* 2014 Dec;30(12):1243-50
- 51- S.Nozza, L.Galli, A.Antinori, S.Chiappetta, F.Mazzotta, M.Zaccarelli, S.Ottou, D.De Battista, M.Pogliaghi, M.Di Pietro, M.Malnati, M.Ripa, S.Bonora, A.Lazzarin, VEMAN Study Group. MARAVIROC 150mg DAILY PLUS LOPINAVIR/RITONAVIR, A NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR-SPARING REGIMEN FOR HIV-INFECTED NAIVE PATIENTS: 48-WEEK FINAL RESULTS OF VEMAN STUDY. *Clin.Microbiol.Infect.* 2015 May 12 21(5);510e1-9
- 52- Katlama C, Lambert-Niclot S, Assoumou L, Papagno L, Lecardonel F, Zoarab R, Tambussi G, Closet B, Youle M, Achenbach C, Murphy R, Calvez V, Costagliola D, Autran B, on behalf of the EraMune-01 study team. TREATMENT INTENSIFICATION FOLLOWED BY INTERLEUKIN-7 REACTIVATES HIV WITHOUT REDUCING TOTAL HIV DNA: A RANDOMIZED TRIAL. *AIDS* January 2016 volume 30 issue 2- p 221-230.
- 53- S.Bagaglio, C.Uberti-Foppa, E.Messina, M.Merli, H.Hasson, A.Andolina, **A.Galli**, A.Lazzarin, G.Morsica. DISTRIBUTION OF NATURAL RESISTANCE TO NS3 PROTEASE INHIBITORS IN HEPATITIS C GENOTYPE 1° SEPARATED INTO CLADES 1 AND 2 AND IN GENOTYPE 1B OF HIV-INFECTED PATIENTS. *Clin.Microbiol.Infect.* 2016 volume 22 number 4, april
- 54- S.Ciappetta, M.Ripa, L.Galli, C.Razzari, V.Longo, **A.Galli**, E.M.Faioni, S.Nozza, A.Lazzarin, G.Tambussi. SOLUBLE ENDOTHELIAL PROTEIN C RECEPTOR (Sepcr) AS AN INFLAMMATORY

BIOMARKER IN NAIVE HIV-INFECTED PATIENTS DURING ART. J.Antimicrob.Chemother. 2016 Feb 16

55- L.Galli, V.Spagnuolo, A.Bigoloni, A.D'Arminio-Monforte, F.Montella, A.Antinori, A.Di Biagio, S.Rusconi, G.Guaraldi, S.Di Giambenedetto, M.Borderi, D.Gibellini, G.Caramatti, A.Lazzarin, A.Castagna, MODAT Study Group. ATAZANAVIR/RITONAVIR MONO THERAPY: 96 WEEK EFFICACY, SAFETY AND BONE MINERAL DENSITY FROM THE MODAT RANDOMIZED TRIAL. J.Antimicrob.Chemother. 2016 Mar 5

56- G.Morsica, S.Bagaglio, V.Spagnuolo, A.Castagna, C.Di Serio, **A.Galli**, L.Della Torre, A.Andolina, A.Pramov, C.Uberti-Foppa. IMMUNE RESPONSE TO HEPATITIS B VACCINATION IN HIV-POSITIVE INDIVIDUALS WITH ISOLATED ANTIBODIES AGAINST HEPATITIS B CORE ANTIGEN: RESULTS OF A PROSPECTIVE ITALIAN STUDY. Plos One. 2017 sep 1;12(9)

57- Merlini E, Galli L, Tincati C, Cannizzo ES, **Galli A**, Gianotti N, Ancona G, Muccini C, Monforte AD, Marchetti G, Castagna A, MODAT Study Group. IMMUNE ACTIVATION, INFLAMMATION AND HIV DNA AFTER 96 WEEKS OF ATV/MONOTHERAPY: A MODAT STUDY. Antivir. Ther. 2018 Mar 28 doi: 10.3851/IMP3239

58- Bagaglio S, Messina E, Hasson H, Galli A, Uberti-Foppa C, Morsica G. GEOGRAPHIC DISTRIBUTION OF HCV-GT3 SUBTYPES AND NATURALLY OCCURRING RESISTANCE ASSOCIATED SUBSTITUTIONS. Viruses 2019 Feb 11;11(2). Pii E148. Doi10.3390/v11020148.

59- CastagnaA, Muccini C, Galli L, Bigoloni A, Poli A, Spagnuolo V, Nozza S, Racca S, Galli A, Cinque P, Carini E, Lazzarin A. ANALYTICAL TREATMENT INTERRUPTION IN CHRONIC HIV-1 INFECTION: TIME AND MAGNITUDE OF VIRAL REBOUND IN ADULTS WITH 10 YEARS OF UNDETECTABLE VIRAL LOAD AND LOW HIV-DNA (APACHE STUDY). Antimicrob. Chemother. 2019 Jul 1;74(7):2039-2046, doi:10.1093/jac/dkz138.

60- Sabrina Bagaglio, Hamid Hasson, Luca Peano, Riccardo Vercesi, Emanuela Messina, Andrea Galli, Caterina Uberti-Foppa and Giulia Morsica A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome. Viruses 2020, 12, 269; doi:10.3390/v12030269

61- Laura Galli, Maria Rita Parisi, Andrea Poli, Marianna Menozzi, Marta Fiscon, Elisa Garlassi, Daniela Francisci, Antonio Di Biagio, Gaetana Sterrantino,, Chiara Fornabaio, Anna Degli Antoni, Gioacchino Angarano, Francesco Maria Fusco, Antonella D'Arminio Monforte, Giulio Maria Corbelli, Maria Mercedes Santoro, Maurizio Zazzi, and Antonella Castagna; on behalf of the PRESTIGIO Study Group. Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry Open Forum Infect Dis. 2020 Sep 26;7(11):ofaa456. doi: 10.1093/ofid/ofaa456. eCollection 2020 Nov. PMID: 33241063

62- Saladini F, Giannini A, Giammarino F, Maggiolo F, Vichi F, Corbelli GM, **Galli A**, Bigoloni A, Poli A, Santoro MM, Zazzi M, Castagna A. In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients. J Antimicrob Chemother. 2020 Sep 1;75(9):2547-2553. doi: 10.1093/jac/dkaa178. PMID: 32464638

63- Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study) [Andrea Mastrangelo](#)¹, [Peter D Burbelo](#)², [Laura Galli](#)³, [Andrea Poli](#)³, [Claudia Alteri](#)⁴, [Rossana Scutari](#)⁵, [Camilla Muccini](#)¹, [Vincenzo Spagnuolo](#)^{1,3}, [Roberta Caccia](#)¹, [Filippo Turrini](#)¹, [Alba Bigoloni](#)³, **[Andrea Galli](#)**³, [Antonella Castagna](#)^{1,3}, [Paola Cinque](#)³J Antimicrob Chemother . 2021 May 12;76(6):1646-1648.

64- Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen [Nicola Gianotti](#)¹, [Laura Galli](#)¹, [Andrea Poli](#)¹, [Liviana Della Torre](#)¹, [Concetta Vinci](#)¹, [Elisabetta Carini](#)¹, **[Andrea Galli](#)**¹, [Silvia Nozza](#)¹, [Vincenzo Spagnuolo](#)^{1,2}, [Camilla Muccini](#)¹, [Adriano Lazzarin](#)¹, [Antonella Castagna](#)^{1,2} AIDS . 2021 Jul 15;35(9):1513-1516.

65- Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study [Rossana Scutari](#)¹, [Valentino Costabile](#)², [Laura Galli](#)³, [Maria Concetta Bellocchi](#)¹, [Luca Carioti](#)¹, [Silvia Barbaliscia](#)¹, [Andrea Poli](#)³, **[Andrea Galli](#)**³, [Carlo Federico Perno](#)⁴, [Maria Mercedes Santoro](#)¹, [Antonella Castagna](#)^{3 5}, [Francesca Ceccherini-Silberstein](#)¹, [Claudia Alteri](#)^{2 5}, [Vincenzo Spagnuolo](#)^{3 5} *Viruses* . 2021 Jul 19;13(7):1403

66- Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV [Daniele Armenia](#)¹, [Maria Mercedes Santoro](#)², [Maria Concetta Bellocchi](#)³, [Luca Carioti](#)³, [Laura Galli](#)⁴, **[Andrea Galli](#)**⁴, [Rossana Scutari](#)³, [Eleonora Salsi](#)⁵, [Cristina Mussini](#)⁶, [Gaetana Sterrantino](#)⁷, [Leonardo Calza](#)⁸, [Barbara Rossetti](#)⁹, [Maurizio Zazzi](#)¹⁰, [Antonella Castagna](#)¹¹, [PRESTIGIO Registry Study Group](#) 2021 Dec 3;106492.

I authorize the processing of my personal data pursuant to Legislative Decree 30 June 2003, n. 196 "Code regarding the protection of personal data"

Milano,23/02/2022

Andrea Galli

Giacomelli Andrea

INFORMAZIONI PERSONALI

POSIZIONE RICOPERTA
01/04/2020-ALLA DATA
ATTUALEMedico specialista in malattie infettive, Dirigente Medico presso
l'ASST-Fatebenefratelli-Sacco, Malattie Infettive III DivisioneESPERIENZA
PROFESSIONALE

01/08/2013–12/09/2018

Medico specializzando in malattie infettive

ASST-FBF Sacco Università degli studi di Milano, Milano (Italia)

-Attività ambulatoriale e di reparto nell'ambito dell'infezione da HIV

-Principal investigator in trial clinici di fase II, III e IV

- Attività di ricerca in ambito HIV, SARS-CoV-2 e malattie da importazione

03/2013–08/2013

Medico volontario

III Divisione di Malattie Infettive ASST-FBF Sacco, Milano (Italia)

30/11/2018–31/03/2020

Medico infettivologo libero professionista, Malattie Infettive III Divisione ASST-FBF-Sacco

01/03/2019-31/03/2020

Assegnista di ricerca (Tipo A), Università degli Studi di Milano

Disegno, implementazione e sviluppo di un programma di *Antimicrobial Stewardship* volto alla riduzione delle prescrizioni non indicate di antimicrobici e alla ottimizzazione delle terapie antimicrobiche all'interno dell'azienda ospedaliera ASST-FBF-SaccoISTRUZIONE E
FORMAZIONE

2001–2006

Diploma di maturità classica

2006–2012

Laurea magistrale in medicina e chirurgia

Università degli studi di Milano, Milano (Italia) conseguita 19/7/2012 (Milano)

Votazione conseguita 110 L

2013–2018

Scuola di specializzazione in malattie infettive

70/70 e Lode

Università degli Studi di Milano, conseguita in data 12/09/2018 (Milano)

COMPETENZE PERSONALI

Lingua madre

italiano

Lingue straniere

COMPRESIONE	PARLATO	PRODUZIONE SCRITTA
-------------	---------	--------------------

	Ascolto	Letture	Interazione	Produzione orale
inglese	B2	B2	B2	B2
Toefl IBT Settembre 2018 Score 88 punti				
Livelli: A1 e A2: Utente base - B1 e B2: Utente autonomo - C1 e C2: Utente avanzato				
<u>Quadro Comune Europeo di Riferimento delle Lingue</u>				

Competenze digitali

AUTOVALUTAZIONE				
Elaborazione delle informazioni	Comunicazione	Creazione di Contenuti	Sicurezza	Risoluzione di problemi
Utente avanzato	Utente avanzato	Utente autonomo	Utente base	Utente base

Competenze digitali - Scheda per l'autovalutazione

Patente di guida B

ULTERIORI INFORMAZIONI

Publicazioni

1. Andreoni M, Marcotullio S, Puro V, De Carli G, Tambussi G, Nozza S, Gori A, Rusconi S, Santoro MM, Clementi M, Perno CF, d'Arminio Monforte A, Maggiolo F, Castagna A, De Luca A, Galli M, Giacomelli A, Borderi M, Guaraldi G, Calcagno A, Di Perri G, Bonora S, Mussini C, Di Biagio A, Puoti M, Bruno R, Zuccaro V, Antinori A, Cinque P, Croce D, Restelli U, Rizzardini G, Lazzarin A. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. *New Microbiol.* 2015 Nov;38(4):443-90.
2. Giacomelli A, Oreni L, Franzetti M, Di Cristo V, Colella E, Ridolfo AL, Galli M, Rusconi S. Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients. *Antiviral Res.* 2016 May;129:52-57.
3. Sollima S, Antinori S, Torre A, Binda F, Giacomelli A, Milazzo L. Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient. *International Journal of STD & AIDS*, First online Published 13 Dec 2016. Doi: 10.1177/0956462416684462
4. Salvaggio SE, Giacomelli A, Falvella FS, Oreni ML, Meraviglia P, Atzori C, Clementi EGI, Galli M, Rusconi S. Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients. *BMC Infect Dis.* 2017 Jun 5;17(1):396. doi: 10.1186/s12879-017-2497-3.
5. Cattaneo D, Minisci D, Baldelli S, Mazzali C, Giacomelli A, Milazzo L, Meraviglia P, Resnati C, Rizzardini G, Clementi E, Galli M, Gervasoni C. Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. *J Acquir Immune Defic Syndr.* 2018 Jan 1;77(1):86-92.
6. Ranzani A, Oreni L, Agrò M, van den Bogaart L, Milazzo L, Giacomelli A, Cattaneo D, Gervasoni C, Ridolfo AL. Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older. *J Acquir Immune Defic Syndr.* 2018 Jun 1;78(2):193-201.
7. Giacomelli A, Rusconi S, Falvella FS, Oreni ML, Cattaneo D, Cozzi V, Renisi G, Monge E, Cheli S, Clementi E, Riva A, Galli M, Ridolfo AL. Clinical and genetic determinants of nevirapine plasma trough concentration. *SAGE Open Med.* 2018 Jun 5;6:2050312118780861.

8. Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; NEAT022 Study Group. Immediate vs. Deferred Switching from a Boosted Protease Inhibitor (PI/r) Based Regimen to a Dolutegravir (DTG) Based Regimen in Virologically Suppressed Patients with High Cardiovascular Risk or Age ≥ 50 years: Final 96 Weeks Results of NEAT 022 study. *Clin Infect Dis*. 2018 Jun 14.
9. Cattaneo D, Baldelli S, Resnati C, Giacomelli A, Meraviglia P, Minisci D, Astuti N, Ridolfo A, De Socio GV, Clementi E, Galli M, Gervasoni C. Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice. *World J Biol Psychiatry*. 2018 Jul 30:1-21.
10. Cattaneo D, Giacomelli A, Gervasoni C. Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution? *Obesity (Silver Spring)*. 2018 Aug;26(8):1251-1252.
11. Ciccullo A, Baldin G, Capetti A, Rusconi S, Sterrantino G, d'Ettorre G, Colafigli M, Modica S, Lagi F, Giacomelli A, Cossu MV, Restelli S, De Luca A, Di Giambenedetto S. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients. *Antivir Ther*. 2018 Oct 2. doi: 10.3851/IMP3270. [Epub ahead of print]
12. Giacomelli A, Riva A, Falvella FS, Oreni ML, Cattaneo D, Cheli S, Renisi G, Di Cristo V, Lupo A, Clementi E, Rusconi S, Galli M, Ridolfo AL. Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. *BMC Infectious Diseases* 2018 18:556 <https://doi.org/10.1186/s12879-018-3462-5>
13. A, Baldin G, Ciccullo A, Capetti A, Rusconi S, Serrantino G, Cossu MV, Giacomelli A, Lagi F, Latini A, Bagella P, De Luca A, Di Giambenedetto S, Madeddu G. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study. *HIV Medicine* 20 Nov 2018. <https://doi.org/10.1111/hiv.12688>
14. Giacomelli A, de Rose S, Rusconi S. Clinical pharmacology in HIV cure research - what impact have we seen? *Expert Rev Clin Pharmacol*. 2018 Dec 20. doi:10.1080/17512433.2019.1561272. [Epub ahead of print]
15. Galli M, Ridolfo A, van denBogaart L, Negri C, Giacomelli A. HCV and drug addiction in the historical scenario of infection entry in Italy. *Acta Biomed* 7Dec.2018;89(10-S):5-8.
16. Galli M, Ridolfo A, van denBogaart L, Negri C, Giacomelli A. HCV and immigration in Italy. *Acta Biomed*. 7Dec.2018;89(10-S):19-2.
17. Cattaneo D, Baldelli S, Giacomelli A, Minisci D, Meraviglia P, Astuti N, Fusi M, Cozzi V, Clementi E, Galli M, Gervasoni C. Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis. *Clin Pharmacokinet*. 2019 Apr 4. doi: 10.1007/s40262-019-00752-6. [Epub ahead of print]
18. Cattaneo D, Giacomelli A, Minisci D, Astuti N, Meraviglia P, Gervasoni C. Association of HIV Infection with Epilepsy and Other Comorbid Conditions. *AIDS Behav*. 2019 May 3. doi: 10.1007/s10461-019-02530-8. [Epub ahead of print]
19. Giacomelli A, Fabbiani M, De Benedetto I, Nozza S, Focà E, Celesia BM, Marchetti G, Mussini C, Antinori A, d'Ettorre G, Madeddu G, Bandera A, Muscatello A, Rusconi S; INACTION study group. Impact of genotypic susceptibility score on cART outcomes during primary HIV infection. *J Med Virol*. 2019 Jun 14. doi: 10.1002/jmv.25517. [Epub ahead of print]

20. Giacomelli A, van den Bogaart L, Corbellino M, Oreni L, Dolci A, Panteghini M, Rizzardini G, Galli M, Antinori S. Is there a role for procalcitonin determination in avoiding unnecessary exposure to antibiotics in a non-intensive care setting? *Infez Med*. 2019 Jun 1;27(2):128-133.
21. Giacomelli A, Ranzani A, Oreni L, Gervasi E, Lupo A, Ridolfo A.L., Galli M., Rusconi S. Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects. *DRUG DESIGN, DEVELOPMENT AND THERAPY*. - ISSN 1177-8881. - Volume 13(2019 Jul), pp. 2271-2282.
22. Rusconi S and Giacomelli A. A push for 90-90-90: Initial treatment with INSTI-based regimens against HIV-1 infection. *ECLINICALMEDICINE*. - ISSN 2589-5370. - (2019 Jul 20). [Epub ahead of print]
23. Antinori S, Ridolfo AL, Giacomelli A, Bonazzetti C, Corbellino M, Galli M. A review of Chagas disease in Italy and the study's contribution of Italian researchers. *Panminerva Med*. 2019 Jul 30. doi: 10.23736/S0031-0808.19.03723-6. [Epub ahead of print]
24. Giacomelli A, Lai A, Franzetti M, et al. No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference. *Antiviral Res*. 2019;172:104635.
25. van den Bogaart L, Ranzani A, Oreni L, Giacomelli A, Corbellino M, Rusconi S, Galli M, Antinori S, Ridolfo AL. Overlooked cases of HIV infection: An Italian tale of missed diagnostic opportunities [published online ahead of print, 2019 Oct 18]. *Eur J Intern Med*. 2019;S0953-6205(19)30319-X.
26. Ciccullo A, Baldin G, Capetti A, Borghi V, Sterrantino G, Latini A, Madeddu G, Celani L, Vignale F, Rossetti B, Dusina A, Cossu MV, Restelli S, Gennari W, Lagi F, Giacomelli A, Colafigli M, Brescini L, Borghetti A, Mussini C, Rusconi S, Di Giambenedetto S. et al. Cohort profile: The Observational cohort for the study of Dolutegravir in Antiretroviral Combination REgimens (ODOACRE). *BMJ Open*. 2019;9(12):e029960.
27. Monge E, Colombo V, Giacomelli A. Iatrogenic Cushing syndrome due to drug interaction between inhaled fluticasone and cobicistat. *Infez Med*. 2019;27(4):27–28.
28. Baldin G, Ciccullo A, Rusconi S, Madeddu G, Sterrantino G, Freedman A, Giacometti A, Celani L, Latini A, Rossetti B, Cossu MV, Giacomelli A, Lagi F, Capetti A, Di Giambenedetto S. Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study. *Infez Med*. 2019 Dec 1;27(4):410-414. PMID: 31846991.
29. Giacomelli A, Bassoli C, Corbellino M, et al. Legionellosis Complicated by Invasive Aspergillosis in a Patient With Rheumatoid Arthritis [published online ahead of print, 2020 Feb 11]. *J Clin Rheumatol*. 2020;10.
30. Antinori, S., Morena, V., Pagani, G., Venturi, G., Giacomelli, A., Milazzo, L., Ridolfo, A. L., & Zanchetta, N. (2020). Dengue fever complicated by liver dysfunction due to possible co-infection with hepatitis E in a returning traveller from Cuba. *Le infezioni in medicina*, 28(1), 98–103.
31. Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study [published online ahead of print, 2020 Mar 26]. *Clin Infect Dis*. 2020;ciaa330.
32. Giacomelli A, Micheli V, Cattaneo D, Mancon A, Gervasoni C. Multidrug-resistant HIV viral rebound during early syphilis: a case report. *BMC Infect Dis*. 2020;20(1):273. Published 2020 Apr 7.
33. Gervasoni C, Meraviglia P, Riva A, Giacomelli A, Oreni L, Minisci D, Atzori C, Ridolfo A, Cattaneo D. Clinical features and outcomes of HIV patients with

- coronavirus disease 2019. *Clin Infect Dis*. 2020 May 14:ciaa579.
34. Antinori S, Cossu MV, Ridolfo AL, Rech R, Bonazzetti C, Pagani G, Gubertini G, Coen M, Magni C, Castelli A, Borghi B, Colombo R, Giorgi R, Angeli E, Mileto D, Milazzo L, Vimercati S, Pellicciotta M, Corbellino M, Torre A, Rusconi S, Oreni L, Gismondo MR, Giacomelli A, Meroni L, Rizzardini G, Galli M. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. *Pharmacol Res*. 2020 May 11;158:104899.
 35. Giacomelli A, Ridolfo AL, Milazzo L, et al. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study [published online ahead of print, 2020 May 22]. *Pharmacol Res*. 2020;158:104931.
 36. Riccardi N, Giacomelli A, Canetti D, et al. Clofazimine: an old drug for never-ending diseases [published online ahead of print, 2020 Jun 1]. *Future Microbiol*. 2020;10.2217/fmb-2019-0231.
 37. Pagani G, Zanchetta N, Galimberti L, Oreni L, Passerini S, Giacomelli A, Cordier L, Gismondo MR, Rizzardini G, Galli M, Antinori S. Imported dengue fever: a 16-years retrospective analysis in Milan (Italy) and a brief review of the European literature. *Infez Med*. 2020 Jun 1;28(2):243-252.
 38. Giacomelli A, Conti F, Rusconi S. Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter? [published online ahead of print, 2020 Jun 4]. *EBioMedicine*. 2020;56:102820.
 39. Martini M, Riccardi N, Giacomelli A, Gazzaniga V, Besozzi G. Tuberculosis: an ancient disease that remains a medical, social, economical and ethical issue. *J Prev Med Hyg*. 2020;61(1 Suppl 1):E16-E18.
 40. Antinori S, Giacomelli A, Corbellino M, Ridolfo AL. Cryptococcal Disease Presenting With Cellulitis in Kidney Transplant Recipients. *Am J Med*. 2020;133(6):e326-e327.
 41. Giacomelli A, Pezzati L, Rusconi S. The crosstalk between antiretrovirals pharmacology and HIV drug resistance [published online ahead of print, 2020 Jun 14]. *Expert Rev Clin Pharmacol*. 2020;10.1080/17512433.2020.1782737.
 42. Adorni F, Prinelli F, Bianchi F, Giacomelli A, Pagani G, Bernacchia D, Rusconi S, Maggi S, Trevisan C, Noale M, Molinaro S, Bastiani L, Fortunato L, Jesuthasan N, Sojic A, Pettenati C, Tavio M, Andreoni M, Mastroianni C, Antonelli Incalzi R, Galli M, et al. Self-reported symptoms of SARS-CoV-2 infection in a non-hospitalized population: results from the large Italian web-based EPICOV19 cross-sectional survey [published online ahead of print, 2020 Jul 10]. *JMIR Public Health Surveill*. 2020;10.2196/21866.
 43. Mancuso P, Gidaro A, Gregato G, Raveane A, Cremonesi P, Quarna J, Caccia S, Gusso L, Rusconi S, Giacomelli A, Cogliati C, Bertolini F, et al. Circulating endothelial progenitors are increased in Covid-19 patients and correlate with SARS-CoV-2 RNA in severe cases [published online ahead of print, 2020 Aug 6]. *J Thromb Haemost*. 2020;10.1111/jth.15044.
 44. Giacomelli A, Pagani G, Ridolfo AL, et al. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study [published online ahead of print, 2020 Aug 10]. *J Med Virol*. 2020;10.1002/jmv.26407.
 45. Noale, M., Trevisan, C., Maggi, S., Antonelli Incalzi, R., Pedone, C., Di Bari, M., Adorni, F., Jesuthasan, N., Sojic, A., Galli, M., Giacomelli, A., Molinaro, S., Bianchi, F., Mastroianni, C., Prinelli, F., & Group, O. (2020). The Association between Influenza and Pneumococcal Vaccinations and SARS-Cov-2 Infection: Data from the EPICOV19 Web-Based Survey. *Vaccines*, 8(3), 471. <https://doi.org/10.3390/vaccines8030471>

46. Riccardi N, Villa S, Alagna R, Giacomelli A, Saderi L, Cirillo DM, Besozzi G, Sotgiu G, Codecasa L. Advantages and Challenges of Tailored Regimens for Drug-Resistant Tuberculosis: A StopTB Italia Look into the Future. *Infect Drug Resist*. 2020 Aug 11;13:2795-2800. doi: 10.2147/IDR.S257480.
47. Bonazzetti C, Pagani G, Giacomelli A, Morena V, Bassoli C, Corbellino M, Bestetti G, Galimberti L, Grande R, Antinori S. A case of crusted scabies with a delayed diagnosis and inadequate therapy. *Infez Med*. 2020 Sep 1;28(3):436-440.
48. Colombo V, Giacomelli A, Casazza G, Galimberti L, Bonazzetti C, Sabaini F, Ridolfo AL, Antinori S. Trypanosoma cruzi infection in Latin American pregnant women living outside endemic countries and frequency of congenital transmission: a systematic review and meta-analysis. *J Travel Med*. 2020 Sep 18:taaa170. doi: 10.1093/jtm/taaa170.
49. Cattaneo D, Giacomelli A, Pagani G, Filice C, Gervasoni C. Ritonavir/Cobicistat-Induced Cushing Syndrome in HIV Patients Treated With Non-Oral Corticosteroids: A Call for Action? *Am J Med Sci*. 2020 Aug 10:S0002-9629(20)30365-7.
50. Pagani G, Conti F, Giacomelli A, Bernacchia D, Rondanin R, Prina A, Scolari V, Gandolfi CE, Castaldi S, Marano G, Ottomano C, Boracchi P, Biganzoli E, Galli M. Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening. *J Infect*. 2020 Sep 19:S0163-4453(20)30629-0.
51. Invernizzi A, Torre A, Parrulli S, Zicarelli F, Schiuma M, Colombo V, Giacomelli A, Cigada M, Milazzo L, Ridolfo A, Faggion I, Cordier L, Oldani M, Marini S, Villa P, Rizzardini G, Galli M, Antinori S, Staurenghi G, Meroni L. Retinal findings in patients with COVID-19: Results from the SERPICO-19 study. *EClinicalMedicine*. 2020 Oct;27:100550. doi: 10.1016/j.eclinm.2020.100550.
52. Schiavone M, Gasperetti A, Mancone M, Kaplan AV, Gobbi C, Mascioli G, Busana M, Saguner AM, Mitacchione G, Giacomelli A, Sardella G, Viecca M, Duru F, Antinori S, Carugo S, Bartorelli AL, Tondo C, Galli M, Fedele F, Forleo GB. Redefining the Prognostic Value of High-Sensitivity Troponin in COVID-19 Patients: The Importance of Concomitant Coronary Artery Disease. *J Clin Med*. 2020 Oct 12;9(10):3263.
53. Bonazzetti C, Morena V, Giacomelli A, et al. Unexpectedly High Frequency of Enterococcal Bloodstream Infections in Coronavirus Disease 2019 Patients Admitted to an Italian ICU: An Observational Study [published online ahead of print, 2020 Oct 29]. *Crit Care Med*. 2020;10.1097/CCM.0000000000004748.
54. Cattaneo D, Pasina L, Maggioni AP, Giacomelli A, Oreni L, Covizzi A, Bradanini L, Schiuma M, Antinori S, Ridolfo A, Gervasoni C. Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. *Drugs Aging*. 2020 Nov 5:1–9. doi: 10.1007/s40266-020-00812-8.
55. Giacomelli A, Galli M, Maggi S, et al. Missed Opportunities of Flu Vaccination in Italian Target Categories: Insights from the Online EPICOVID 19 Survey. *Vaccines (Basel)*. 2020;8(4):E669.
56. Lombardi F, Giacomelli A, Armenia D, et al. Prevalence and factors associated with HIV-1 multidrug resistance over the past two decades in the Italian Arca database [published online ahead of print, 2020 Nov 28]. *Int J Antimicrob Agents*. 2020;106252.
57. Niccolò Riccardi, Simone Villa, Diana Canetti, Andrea Giacomelli, Lucia Taramasso, Mariano Martini, Antonio Di Biagio, Nicola Luigi Bragazzi, Francesco Brigo, Giovanni Sotgiu, Giorgio Besozzi, Luigi Codecasa. Missed opportunities in tb clinical practice: How to bend the curve? A medical, social, economic and ethical point of view. *Tuberculosis*. 126, 2021; 102041

58. Giacomelli A, Anna Lisa Ridolfo, Letizia Oreni, Stefania Vimercati, Maria Albrecht, Dario Cattaneo, Sara Giordana Rimoldi, Giuliano Rizzardini, Massimo Galli, Spinello Antinori. Consumption of antibiotics at an Italian university hospital during the early months of the COVID-19 pandemic: Were all antibiotic prescriptions appropriate? *Pharmacological Research*. 164, 2021; 105403.
59. Anna Lisa Ridolfo, Laura Milazzo, Andrea Giacomelli, Letizia Oreni, Catia Borriello, Spinello Antinori. Low influenza vaccination coverage among hospitalized COVID-19 patients in Milan: a gap to be urgently filled. *European Journal of Internal Medicine*. 2020, <https://doi.org/10.1016/j.ejim.2020.12.019>.
60. Giacomelli A, Pagani G, Conti F, Bassoli C, Galli M. Detecting HCV infection by means of mass population SARS-CoV-2 screening: A pilot experience in Northern Italy [published online ahead of print, 2021 Jan 13]. *J Hepatol*. 2021;S0168-8278(21)00009-X.
61. Deledda G, Riccardi N, Gori S, Poli S, Giansante M, Geccherle E, Mazzi C, Silva R, Desantis N, Giovannetti AM, Solari A, Confalonieri P, Grazzi L, Sarcletti E, Biffa G, Biagio AD, Sestito C, Keim R, Gangi Hermis AMRD, Mazzoldi M, Failo A, Scaglione A, Faldetta N, Dorangricchia P, Moschetto M, Soto Parra HJ, Faietti J, Profio AD, Rusconi S, Giacomelli A, Marchioretto F, Alongi F, Marchetta A, Molon G, Bisoffi Z, Angheben A. The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The "ImpACT-COVID-19 for Patients" Multi-Centre Observational Study. *Int J Environ Res Public Health*. 2021 Jan 5;18(1):340.
62. Borgonovo F, Passerini M, Piscaglia M, Morena V, Giacomelli A, Oreni L, Dedivitiis G, Lupo A, Falvella S, Cossu MV, Capetti AF. Is COVID-19 severity associated with anti-spike antibody duration? Data from the ARCOVID prospective observational study. *J Infect*. 2021 May;82(5):e28-e30.
63. Bonazzetti C, Milazzo L, Giacomelli A, et al. Comment on: Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. *J Antimicrob Chemother*. 2021;76(6):1650-1651.
64. Trevisan C, Noale M, Prinelli F, Maggi S, Sojic A, Di Bari M, Molinaro S, Bastiani L, Giacomelli A, Galli M, Adorni F, Antonelli Incalzi R, Pedone C; EPICOID19 Working Group. Age-Related Changes in Clinical Presentation of Covid-19: the EPICOID19 Web-Based Survey. *Eur J Intern Med*. 2021 Apr;86:41-47.
65. Cattaneo D, Giacomelli A, Gervasoni C. Liver Injury After Dietary Supplements in Patients Living With HIV: A Call to Action [published online ahead of print, 2021 Feb 20]. *Clin Gastroenterol Hepatol*. 2021;S1542-3565(21)00209-3.
66. Pagani G, Giacomelli A, Conti F, et al. Prevalence of SARS-CoV-2 in an area of unrestricted viral circulation: Mass seroepidemiological screening in Castiglione d'Adda, Italy. *PLoS One*. 2021;16(2):e0246513.
67. Giacomelli A, Pagani G, Covizzi A, Antinori S, Cattaneo D, Gervasoni C. The importance of anamnesis in differential diagnosis: a case of SARS-CoV-2 and dengue virus co-infection. *Infez Med*. 2021 Mar 1;29(1):114-116. U
68. Prinelli F, Bianchi F, Drago G, Ruggieri S, Sojic A, Jesuthasan N, Molinaro S, Bastiani L, Maggi S, Noale M, Galli M, Giacomelli A, Antonelli Incalzi R, Adorni F, Cibella F; EPICOID19 Working Group. Association Between Smoking and SARS-CoV-2 Infection: Cross-sectional Study of the EPICOID19 Internet-Based Survey. *JMIR Public Health Surveill*. 2021 Apr 28;7(4):e27091.
69. Capetti AF, Stangalini CA, Borgonovo F, Mileto D, Oreni L, Dedivitiis G, Lupo A, Cossu MV, Bilardo L, Giacomelli A, Galli M, Rizzardini G. Impressive boosting of anti-S1/S2 IgG production in COVID-19-experienced patients after the first shot of the BNT162b2 mRNA COVID-19 Vaccine. *Clin Infect Dis*. 2021 Mar 6:ciab214.
70. Antinori S, Bonazzetti C, Giacomelli A, et al. Non-Human Primate and Human

Malaria: Past, Present and Future [published online ahead of print, 2021 Mar 8]. *J Travel Med.* 2021;taab036.

71. Giacomelli A, De Falco T, Oreni L, et al. Impact of gender on patients hospitalized for SARS-COV-2 infection: A prospective observational study. *J Med Virol.* 2021;93(7):4597-4602.
72. Cori L, Curzio O, Adorni F, Prinelli F, Noale M, Trevisan C, Fortunato L, Giacomelli A, Bianchi F. Fear of COVID-19 for Individuals and Family Members: Indications from the National Cross-Sectional Study of the EPICOVID19 Web-Based Survey. *Int J Environ Res Public Health.* 2021 Mar 21;18(6):3248.
73. Riccardi N, Villa S, Giacomelli A, et al. Tuberculosis treatment outcomes in a rural area of Senegal: a decade of experience from 2010 to 2019 by StopTB Italia. *Future Microbiol.* 2021;16:399-407.
74. Riccardi N, Giacomelli A, Antonello RM, Gobbi F, Angheben A. Rabies in Europe: An epidemiological and clinical update. *Eur J Intern Med.* 2021;88:15-20.
75. Cattaneo D, Pasina L, Conti F, Giacomelli A, Oreni L, Pezzati L, Bonazzetti C, Piscaglia M, Carrozzo G, Antinori S, Gervasoni C. Risks of potential drug-drug interactions in COVID-19 patients treated with corticosteroids: a single-center experience. *J Endocrinol Invest.* 2021 May 30:1–3. doi: 10.1007/s40618-021-01604-6.
76. Pezzati L, Giacomelli A, Mileto D, et al. Rapid lateral-flow immunochromatographic tests to assess anti N/S IgG seropositivity after BNT162b2 vaccine: a cross-sectional study.: Rapid lateral-flow immunochromatographic tests after BNT162b2 vaccine [published online ahead of print, 2021 May 29]. *J Infect.* 2021;S0163-4453(21)00271-1.
77. Bonazzetti C, Giacomelli A, Pavia M, et al. Remdesivir in moderate to severe COVID-19: a matter of time? [published online ahead of print, 2021 Jun 2]. *Pharmacol Res.* 2021;170:105711.
78. Giacomelli A, Cozzi-Lepri A, Cingolani A, et al. Does syphilis increase the risk of HIV-RNA elevation >200 copies/mL in HIV positive patients under effective antiretroviral treatment? Data from the ICONA cohort [published online ahead of print, 2021 Jun 15]. *J Acquir Immune Defic Syndr.* 2021;10.1097/QAI.0000000000002749.
79. Giacomelli A, Conti F, Pezzati L, et al. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study. *BMC Infect Dis.* 2021;21(1):595.
80. Antinori S, Giacomelli A, Corbellino M, et al. Histoplasmosis Diagnosed in Europe and Israel: A Case Report and Systematic Review of the Literature from 2005 to 2020. *J Fungi (Basel).* 2021;7(6):481.
81. Gidaro A, Samartin F, Brambilla AM, Cogliati C, Ingrassia S, Banfi F, Cupiraggi V, Bonino C, Schiuma M, Giacomelli A, Rusconi S, Currà J, Brucato AL, Salvi E. Correlation between continuous Positive end-expiratory pressure (PEEP) values and occurrence of Pneumothorax and Pneumomediastinum in SARS-CoV2 patients during non-invasive ventilation with Helmet. *Sarcoidosis Vasc Diffuse Lung Dis.* 2021;38(2):e2021017.
82. Borghetti A, Giacomelli A, Borghi V, Ciccullo A, Dusina A, Fabbiani M, Rusconi S, Zazzi M, Mussini C, Di Giambenedetto S. Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice. *Open Forum Infect Dis.* 2021 Mar 6;8(7):ofab103.
83. Ciccullo A, Borghi V, Giacomelli A, et al. Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding. *J Acquir*

- Immune Defic Syndr.* 2021;88(3):234-237.
84. Invernizzi A, Schiuma M, Parrulli S, Torre A, Zicarelli F, Colombo V, Marini S, Villella E, Bertoni A, Antinori S, Rizzardini G, Galli M, Meroni L, Giacomelli A, Staurengi G. Retinal vessels modifications in acute and post-COVID-19. *Sci Rep.* 2021 Sep 29;11(1):19373.
 85. Trevisan C, Pedone C, Maggi S, Noale M, Di Bari M, Sojic A, Molinaro S, Giacomelli A, Bianchi F, Tavio M, Rusconi S, Pagani G, Galli M, Prinelli F, Adorni F, Antonelli Incalzi R; Epicovid Working Group. Accessibility to SARS-CoV-2 swab test during the Covid-19 pandemic: Did age make the difference? *Health Policy.* 2021 Dec;125(12):1580-1586.
 86. Giacomelli A, Bonazzetti C, Conti F, et al. Brief Report: Impact of the COVID-19 Pandemic on Virological Suppression in People Living With HIV Attending a Large Italian HIV Clinic. *J Acquir Immune Defic Syndr.* 2021;88(3):299-304.
 87. Pagani G, Conti F, Giacomelli A, et al. Differences in the Prevalence of SARS-CoV-2 Infection and Access to Care between Italians and Non-Italians in a Social-Housing Neighbourhood of Milan, Italy. *Int J Environ Res Public Health.* 2021;18(20):10621.
 88. Antinori S, Casalini G, Giacomelli A. Cryptococcal meningitis: a review for emergency clinicians-comment. *Intern Emerg Med.* 2022;17(2):599-600.
 89. Mazzitelli M, Ciccullo A, Baldin G, Cauda R, Rusconi S, Giacomelli A, Oreni L, Borghi V, Mussini C, Guaraldi G, Sterrantino G, Lagi F, Candelaresi B, Cirioni O, De Vito A, Rossetti B, Torti C, Di Giambenedetto S. Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience. *Medicine (Baltimore).* 2021 Oct 15;100(41):e27418.
 90. Casalini G, Giacomelli A, Ridolfo A, Gervasoni C, Antinori S. Invasive Fungal Infections Complicating COVID-19: A Narrative Review. *J Fungi (Basel).* 2021 Oct 29;7(11):921.
 91. Casalini G, Pozza G, Giacomelli A, Antinori S. Bacterial Coinfections in COVID-19 Patients without a Positive Microbiologic Result: a Word of Caution. *Antimicrob Agents Chemother.* 2022 Mar 15;66(3):e0229621.
 92. Giacomelli A, Monti ME, Grande R, et al. The value of lamp to rule out imported malaria diagnosis: a retrospective observational study in Milan, Italy. *Infect Dis (Lond).* 2022;54(6):410-417.
 93. Giacomelli A, Ridolfo AL, Bonazzetti C, et al. Mortality among Italians and immigrants with COVID-19 hospitalised in Milan, Italy: data from the Luigi Sacco Hospital registry. *BMC Infect Dis.* 2022;22(1):63.
 94. Ciccullo A, Baldin G, Borghi V, Lagi F, Latini A, d'Ettorre G, Oreni L, Fusco P, Capetti A, Fabbiani M, Giacomelli A, Grimaldi A, Madeddu G, Sterrantino G, Mussini C, Di Giambenedetto S. Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort. *Viruses.* 2022 Jan 17;14(1):163.
 95. Antinori S, Ridolfo AL, Grande R, Galimberti L, Casalini G, Giacomelli A, Milazzo L. Loop-mediated isothermal amplification (LAMP) assay for the diagnosis of imported malaria: a narrative review. *Infez Med.* 2021 Sep 10;29(3):355-365.
 96. Adorni F, Jesuthasan N, Perdixi E, Sojic A, Giacomelli A, Noale M, Trevisan C, Franchini M, Pieroni S, Cori L, Mastroianni CM, Bianchi F, Antonelli-Incalzi R, Maggi S, Galli M, Prinelli F, On Behalf Of The Epicovid Working Group. Epidemiology of SARS-CoV-2 Infection in Italy Using Real-World Data: Methodology and Cohort Description of the Second Phase of Web-Based EPICOVID19 Study. *Int J Environ Res Public Health.* 2022 Jan 24;19(3):1274.
 97. Giacomelli A, Galli M, Maggi S, et al. Influenza Vaccination Uptake in the General Italian Population during the 2020-2021 Flu Season: Data from the EPICOVID-19 Online Web-Based Survey. *Vaccines (Basel).* 2022;10(2):293.
 98. Prinelli F, Trevisan C, Noale M, Franchini M, Giacomelli A, Cori L, Jesuthasan N,

- Incalzi RA, Maggi S, Adorni F; EPICOV19 Working Group. Sex- and gender-related differences linked to SARS-CoV-2 infection among the participants in the web-based EPICOV19 survey: the hormonal hypothesis. *Maturitas*. 2022 Apr;158:61-69.
99. Antinori S, Ridolfo AL, Casalini G, Giacomelli A. Endemic mycoses: geographical distribution is still a work in progress. *Lancet Infect Dis*. 2022 Apr;22(4):451.
100. Giacomelli A, Ridolfo AL, Pezzati L, et al. Mortality rates among COVID-19 patients hospitalised during the first three waves of the epidemic in Milan, Italy: A prospective observational study. *PLoS One*. 2022;17(4):e0263548.
101. Saumoy M, Sánchez-Quesada JL, Assoumou L, Gatell JM, González-Cordón A, Guaraldi G, Domingo P, Giacomelli A, Connault J, Katlama C, Masiá M, Ordóñez-Llanos J, Pozniak A, Martínez E, Podzamczar D. Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study. *J Antimicrob Chemother*. 2022 Apr 12:dkac117.
102. Bozzi G, Fabeni L, Abbate I, Berno G, Muscatello A, Taramasso L, Fabbiani M, Nozza S, Tambussi G, Rusconi S, Giacomelli A, Focà E, Pinnetti C, d'Ettorre G, Mussini C, Borghi V, Celesia BM, Madeddu G, Di Biagio A, Ripamonti D, Squillace N, Antinori A, Gori A, Capobianchi MR, Bandera A; INACTION study group. Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy. *Sex Transm Infect*. 2022 Apr 20:sextrans-2021-055289
103. Bonazzetti C, Rinaldi M, Giacomelli A, Colombo R, Ottolina D, Rimoldi SG, Pagani C, Morena V, Ridolfo AL, Vatamanu O, Giacomini ME, Campoli C, Oreni L, Rizzardini G, Viale P, Antinori S, Giannella M. Risk factors associated with bacteremia in COVID-19 patients admitted to intensive care unit: a retrospective multicenter cohort study. *Infection*. 2022 Jun 10:1–8.
104. Giacomelli A, Cozzi-Lepri A, Casalini G, Oreni L, Ridolfo AL, Antinori S. Estimating the effectiveness of remdesivir on risk of COVID-19 mortality: The role of observational data. *Pharmacol Res*. 2022 May 20;181:106268.
105. Antinori S, Galimberti L, Grande R, Ricaboni D, Sala S, Giacomet V, Colombo V, Corbellino M, Angheben A, Giacomelli A, Ridolfo AL. Family cluster of Chagas disease among Bolivian immigrants in Italy: High rate of materno-fetal transmission. *Travel Med Infect Dis*. 2022 Jun 7:102370. doi: 10.1016/j.tmaid.2022.102370.
106. Mileto D, Riva A, Cutrera M, Moschese D, Mancon A, Meroni L, Giacomelli A, Bestetti G, Rizzardini G, Gismondo MR, Antinori S. New challenges in human monkeypox outside Africa: A review and case report from Italy. *Travel Med Infect Dis*. 2022 Jun 20;49:102386. doi: 10.1016/j.tmaid.2022.102386.

Libri di testo come coautore

107. HIV-AIDS: storia, cura, prevenzione. Una epidemia globale tra passato e futuro. Edited by M. Galli and S.Vella. Published by Franco Angeli; 1 edition (5 Dec 2016)
108. The Microbiome in Rheumatic Diseases and Infection. Edited by Gaafar Ragab, T. Prescott Atkinson and Matthew L. Stoll. Published by Springer International Publishing. DOI 10.1007/978-3-319-79026-8 Chapter: RNA viruses a short overview. Galli M, Bozzi G and Giacomelli A. June 2018 DOI:10.1007/978-3-319-79026-8_12
109. Manuale di Malattie Infettive III Edizione. Edited by Mauro Moroni, Spinello Antinori, Claudio Mastroianni. Published by Edra. Antinori S, Giacomelli A. Chapter: Infezioni in gravidanza. March 2019.

110. Handbook of Systemic Autoimmune Diseases: Risk factors and management. Edited by Fabiola Atzeni, James B. Galloway, Juan J. Gomez-Reino, Massimo Galli Chapter 2 - Invasive fungal diseases in patients with rheumatic diseases. S. Antinori, A. Giacomelli. <https://doi.org/10.1016/B978-0-444-64217-2.00002-6>

Attività di revisore per le seguenti riviste scientifiche: BMJ, Lancet Infectious Diseases, Lancet HIV, Lancet Regional Health, Clinical Infectious Diseases, Annals of Internal Medicine, HIV medicine, AIDS and behaviour, Annals of pharmacotherapy, Canadian respiratory journal, EBioMedicine, Expert review of clinical pharmacology, Journal of Infection, Journal of Clinical Medicine, Lipids in Health and Disease, BMC ID, BMC pulmonary medicine, Canadian medical association journal, European Journal of Neurology, International Journal of STD&AIDS, Journal of Clinical Rheumatology, Pharmacogenomics.

Membro del board editorial
BMC Infectious Diseases

Indicatori bibliometrici:

ORCID ID 0000-0003-3685-4289

Scopus ID 56973943800 (108 documenti 1,665 citazioni 16 H-index)

Web of Science Researcher ID AAA-4642-2019

Abilitazione scientifica nazionale: idoneità a professore di II fascia valida dal 07/06/2022 AL 07/06/2032

Membro del Consiglio Direttivo Nazionale SIMIT

Conferenze **Contributi scientifici**

Poster presentation a congressi nazionali (SIMIT 2016, 2017 and 2018, ICAR 2017, 2018) ed internazionali (HIV Glasgow 2017, EACS 2018).

Comunicazioni orali a congressi nazionali (SIMIT 2017, Giornate Infettivologiche 2016, 2017 and ICAR 2017,2018 and 2019).

Awards

- Luigi Sacco Award, Giornate Infettivologiche 2017. Migliore comunicazione orale
- Secondo premio Convegno Infection Lab Under 40 nella categoria studi clinici "Impact of genotypic susceptibility score and viral tropism on cART outcomes during primary HIV infection"

Il sottoscritto è a conoscenza che dichiarazioni mendaci, falsità negli atti e uso di atti falsi sono punibili ai sensi dell'art. 483 del Codice Penale. Inoltre autorizza al trattamento dei dati secondo quanto previsto dal Reg. UE 2016/679; la durata del trattamento è valida fino a che sia valida la finalità del trattamento, a meno di condizioni cogenti del Titolare del Trattamento.

Milano 09/08/22

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome **Giovanni Guaraldi**
Indirizzo
Codice fiscale
Telefono
Fax
E-mail

Nazionalità

Data e luogo di nascita

ESPERIENZA LAVORATIVA

- Dal/al** 1/12/16 a tutt'oggi

• Nome e indirizzo del datore di lavoro Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con interesse Trapiantologico, Oncologico e di Medicina Rigenerativa
Clinica delle Malattie Infettive e Tropicali
Università degli Studi di Modena e Reggio Emilia
via del Pozzo, 71 - 41100 Modena

• Tipo di azienda o settore Azienda Ospedaliero Universitaria Policlinico di Modena

 - Tipo di impiego Professore associato
 - Principali mansioni e responsabilità Coordinatore del centro polispecialistico “clinica Metabolica” per la diagnosi e il trattamento della lipodistrofia HIV correlata
Consulente infettivologo del Centro Trapianti di Fegato e Multiviscerale dell’Azienda Policlinico di Modena.

- Dal/al** 1999 al 30/11/16

• Nome e indirizzo del datore di lavoro Dipartimento di Medicine e Specialità Mediche
Clinica delle Malattie Infettive e Tropicali
Università degli Studi di Modena e Reggio Emilia
via del Pozzo, 71 - 41100 Modena

• Tipo di azienda o settore Azienda Ospedaliero Universitaria Policlinico di Modena

 - Tipo di impiego Ricercatore Universitario
 - Principali mansioni e responsabilità Coordinatore del centro polispecialistico “clinica Metabolica” per la diagnosi e il trattamento della lipodistrofia HIV correlata
Consulente infettivologo del Centro Trapianti di Fegato e Multiviscerale dell’Azienda Policlinico di Modena.

- Dal/al** 1996/1998

• Nome e indirizzo del datore di lavoro Azienda Ospedaliero Universitaria Policlinico di Modena
via del Pozzo, 71 - 41100 Modena

- Tipo di azienda o settore Azienda Ospedaliero Universitaria Policlinico di Modena
 - Tipo di impiego Dirigente di I livello
 - Principali mansioni e responsabilità Assistente/Aiuto ospedaliero di Malattie Infettive
- **Dal/al** 1995/1996
- Nome e indirizzo del datore di lavoro Azienda Ospedale Maggiore di Bologna
Largo B. Nigrisoli, 2 - 40133 BOLOGNA
- Tipo di azienda o settore Azienda Ospedale Maggiore di Bologna
 - Tipo di impiego Dirigente di I livello
 - Principali mansioni e responsabilità Assistente/Aiuto ospedaliero di Malattie Infettive

ISTRUZIONE E FORMAZIONE

- **Dal/al** 1990/1994
 - Nome e tipo di istituto di istruzione o formazione Università degli Studi di Modena
 - Principali materie / abilità professionali oggetto dello studio Malattie Infettive e Tropicali
 - Qualifica conseguita Specializzazione
 - Livello nella classificazione nazionale (se pertinente) 50/50 e lode
- **Dal/al** 1984/1990
 - Nome e tipo di istituto di istruzione o formazione Università degli studi di Modena
 - Principali materie / abilità professionali oggetto dello studio Medicina e Chirurgia
 - Qualifica conseguita Laurea
 - Livello nella classificazione nazionale (se pertinente) 110/110 e lode
- **Dal/al** 1979/1984
 - Nome e tipo di istituto di istruzione o formazione Liceo scientifico "A. Tassoni", Modena.
 - Principali materie / abilità professionali oggetto dello studio Liceo scientifico
 - Qualifica conseguita Maturità
 - Livello nella classificazione nazionale (se pertinente)

CAPACITÀ E COMPETENZE

PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

PRIMA LINGUA

Italiano

ALTRE LINGUE

Inglese

Eccellente

Eccellente

Eccellente

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

CAPACITÀ E COMPETENZE

RELAZIONALI

Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.

CAPACITÀ E COMPETENZE

ORGANIZZATIVE

Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.

CAPACITÀ E COMPETENZE

TECNICHE

Con computer, attrezzature specifiche, macchinari, ecc.

Analisi statistica per la ricerca scientifica:

Modulo SRS 1

Modulo SRS 2

Modulo SRS 3

SPSS

Database Microsoft Access

CAPACITÀ E COMPETENZE

ARTISTICHE

Musica, scrittura, disegno ecc.

ALTRE CAPACITÀ E

COMPETENZE

Competenze non precedentemente indicate.

ULTERIORI INFORMAZIONI

ALLEGATI

Dichiaro che le informazioni riportate nel presente Curriculum Vitae sono esatte e veritiere.

Autorizzo il trattamento dei dati personali, ivi compresi quelli sensibili, ai sensi e per gli effetti del decreto legge 196/2003 per le finalità di cui al presente avviso di candidatura.

23/7/21

FILIPPO LAGI

Date of birth:
Nationality:
Home Address:
(Correspondence)
Mobile:
E-mail:
ORCID ID:
Scopus Author ID:

EDUCATION

- OCTOBER 2016-DECEMBER-2020 | MSc Epidemiology by Distance Learning
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
- NOVEMBER 2018-JANUARY 2022 | Ph.D. in Clinical Science; XXXIV Ciclo
UNIVERSITY OF FLORENCE
- OCTOBER 2016-NOVEMBER 2018 | SITA scholarship winner | Antimicrobial Stewardship programs:
development, implementation impact assessment in the Careggi University Hospital, Florence
- JUNE 2011- JULY 2016: Specialization school in Infectious Diseases | 70/70 cum laude
THE UNIVERSITY OF FLORENCE, MEDICAL SCHOOL FLORENCE
- SEPTEMBER 2010-MARCH 2011: Research grant |
INFECTIOUS DISEASES DEPARTMENT, A.O.U. CAREGGI, FLORENCE
Clinical, laboratory research and subsequent processing of data about neglected tropical diseases
- MARCH 2010: Diploma conferring the right to practice medicine and surgery |
ORDINE DEI MEDICI FIRENZE; ID 12971
- 2003-2009: Graduate in medicine and surgery |
UNIVERSITY OF FLORENCE, MEDICAL SCHOOL FLORENCE; Summa con Laude;
Thesis in: Non-Hodgkin lymphomas in HIV patients studied at Ospedale di Careggi: a review of the series of cases in
the period from 2004 to 2008
- 1998-2003 High School diploma in classical studies |
MICHELANGIOLO HIGH SCHOOL FLORENCE

PROFESSIONAL EXPERIENCE

Physician (full-time) | APRIL 2020-TODAY
INFECTIOUS DISEASES DEPARTMENT, A.O.U. CAREGGI, FLORENCE | Prof. A. Bartoloni

Teacher | COURSE "INFECTIOUS DISEASES: HIV / AIDS ASPECTS OF PREVENTION AND TREATMENT"
Held in November / December 2018 at Careggi University Hospital

Reviewer | Internal and emergency medicine journal | Plos One |

Resident | JUNE 2011-JUNE 2016
INFECTIOUS DISEASES DEPARTMENT, A.O.U. CAREGGI, FLORENCE, | Prof. A. Bartoloni

Observership | MARCH 2016- APRIL 2016
DEPARTMENT OF MEDICINE, UNIVERSITY OF MICHIGAN, ANN ARBOR, MICHIGAN | Prof. S. Saint
DEPARTMENT OF INFECTIOUS DISEASES, VA HOSPITAL, ANN ARBOR, MICHIGAN | Prof. A. Kauffman

- Daily round in Medicine and Infectious diseases department
- Daily meetings on clinical case vignettes and simulation

- Daily lecture and updates on preventing infectious diseases in hospital

Sub-Investigator in clinical trials

Observership | JULY-AGOUST 2008

CARDIO-THORACIC SURGERY DEPARTMENT, ERASMUS MC, ROTTERDAM (NL) | Prof.dr. Ad Bogers

Observership | MAY-JUNE 2008

CARDIOLOGY DEPARTMENT, ERASMUS MC, ROTTERDAM (NL) | Dr. A.P.J. Klootwijk

Internship | MARCH-APRIL 2008

INFECTIOUS DISEASE DEPARTMENT, ERASMUS MC, ROTTERDAM (NL), | Dr. C.A.M. Schurink

PROFESSIONAL CERTIFICATION

- **MSc in Epidemiology | December 2020**
- **Good clinical practice | July 2021**
- **Advanced life support course (ALS) Certificate | JANUARY 2016**
- **SPSS Statistics Course | AGOUST 2015**
Cesenatico, (FC): Dr.ssa Elisabetta Crocetti (Utrecht University, NL)
- **SIUMB Diploma in general Ultrasonography | JANUARY 2015**
Dr. Magnolfi, Dr. Caremani
- **Good Clinical Practice Certificate | APRIL 2015**
Global Health Training Center: Certificate number 49443
- **Theorical Ultrasonography Course | 13-16 OCTOBER 2012**
Siumb, Montesilvano, (PE)
- **Interactive Ultrasonography Course of the Liver | 01-03 OCTOBER 2012**
Magnolfi, Dr. Caremani, Castello di Gargonza, Monte San Savino.
- **Meta-analysis Course | 28 MAY - 01 JUNE 2012**
Cesenatico, (FC): Dr.ssa Elisabetta Crocetti (Utrecht University, NL)

IT SKILLS

- MS Office excellent, Word, Outlook, Excel and Powerpoint
- Statistical analysis: good experience with STATA and Excel
- Operating Systems: *Windows (XP, Vista, 8), MAC OS*
- Video and audio editing: good experience (Logic Pro X, Final Cut)

LANGUAGES

- Italian: Native speaker
- English: Fluent in written and spoken English
as certified by Cambridge University IELTS certification 7 (2010)
- Spanish: intermediate

RESEARCH

2022

- Author | **SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes: implications for booster strategies.** | Mazzoni A, Vanni A, Spinicci M, Lamacchia G, Kiros ST, Rocca A, Capone M, Lauria N, Salvati L, Carnasciali A, Mantengoli E, Farahvachi P, Zammarchi L, **Lagi F**, Colao MG, Liotta F, Cosmi L, Maggi L, Bartoloni A, Rossolini GM, Annunziato F. | *J Clin Invest.* 2022
- Author | **Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort.** | Ciccullo A, Baldin G, Borghi V, Lagi F, Latini A, d'Ettorre G, Oreni L, Fusco P, Capetti A, Fabbiani M, Giacomelli A, Grimaldi A, Madeddu G, Sterrantino G, Mussini C, Di Giambenedetto S. | *Viruses.* 2022
- Author | **Comparison of the efficacy, safety, and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.** | **Lagi F**, Botta A, Kiros ST, Meli M, Borchi B, Cavallo A, Pozzi M, Bartoloni A, Sterrantino G. | *Int J Antimicrob Agents.* 2022

2021

- Author | **Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort.** Arturo Ciccullo, Gianmaria Baldin, Vanni Borghi, Gaetana Sterrantino, Giordano Madeddu, Alessandra Latini, Gabriella d'Ettorre, Alessandro Lanari, Maria Mazzitelli, Manuela Colafigli, Amedeo Ferdinando Capetti, Letizia Oreni, **Filippo Lagi**, Stefano Rusconi, Simona Di Giambenedetto | *AIDS Res Hum Retroviruses*
- Author | **Transgender people living with HIV: characteristics and comparison to homosexual and heterosexual cisgender patients in two Italian teaching hospitals.** Chiara Papalini, **Filippo Lagi**, Elisabetta Schiaroli, Gaetana Sterrantino, Daniela Francisci | *Int J STD AIDS*
- Author | **High-dose steroids for the treatment of severe COVID-19.** Piccica M, **Lagi F**, Trotta M, Spinicci M, Zammarchi L, Bartoloni A; COCORA Working Group. | *Intern Emerg Med.*
- Author | **Early discontinuation of DTG/ABC/3TC and BIC/TAF/FTC single-tablet regimens: a real-life multicenter cohort study.** **Lagi F**, Botta A, Ciccullo A, Picarelli C, Fabbiani M, di Giambenedetto S, Borghi V, Mussini C, Bartoloni A, Sterrantino G. *HIV Res Clin Pract.* 2021
- Author | **Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review.** Piccica M, **Lagi F**, Bartoloni A, Zammarchi L. *Travel Med.* 2021
- Author | **Use of the FebriDx point-of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection during the second (COVID-19) wave in Italy.** **Lagi F**, Trevisan S, Piccica M, Graziani L, Basile G, Mencarini J, Borchi B, Menicacci L, Vaudo M, Scotti V, Fabbri A, Bandini G, Tozzetti C, Berni A, Aiezza N, Pestelli G, Turchi V, Pignone AM, Poggesi L, Nozzoli C, Morettini A, Rossolini GM, Bartoloni A. *Int J Infect Dis.* 2021
- Author | **Diagnostic accuracy of physician's gestalt in suspected COVID-19: Prospective bicentric study.** Nazerian P, Morello F, Prota A, Betti L, Lupia E, Apruzzese L, Oddi M, Grosso F, Grifoni S, Pivetta E; Acad Emerg Med. 2021
- Author | **Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort.** | Fabbiani M, Rossetti B, Ciccullo A, Oreni L, **Lagi F**, Celani L, Colafigli M, De Vito A, Mazzitelli M, Dusina A, Durante M, Montagnani F, Rusconi S, Capetti A, Sterrantino G, D'Ettorre G, Di Giambenedetto S; *HIV Med.* 2021
- Author | **First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19.** | Mazzoni A, Di Lauria N, Maggi L, Salvati L, Vanni A, Capone M, Lamacchia G, Mantengoli E, Spinicci M, Zammarchi L, Kiros ST, Rocca A, **Lagi F**, Colao MG, Parronchi P, Scaletti C, Turco L, Liotta F, Rossolini GM, Cosmi L, Bartoloni A, Annunziato F. | *J Clin Invest.* 2021

- Author | **Semen impairment and occurrence of SARS-CoV-2 virus in semen after recovery from COVID-19.** | M Gacci, M Coppi, E Baldi, A Sebastianelli, C Zaccaro, S Morselli, A Pecoraro, A Manera, R Nicoletti, A Liaci, C Bisegna 1, L Gemma, S Giancane, S Pollini, A Antonelli, **F Lagi**, S Marchiani, S Dabizzi, S Degl'Innocenti, F Annunziato, M Maggi 6, L Vignozzi, A Bartoloni, G M Rossolini, S Serni | *Hum Reprod*
- Author | **Can SSRI/SNRI antidepressants decrease the 'cytokine storm' in the course of COVID-19 pneumonia?** Fei L, Santarelli G, D'Anna G, Moretti S, Mirossi G, Patti A, Sanfilippo G, Almerigogna F, Berni A, Caldini E, Lagi F, Para O, Vaudo M, Vultaggio A. *Panminerva Med.* 2021
- Author | **Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience.** Mazzitelli M, Ciccullo A, Baldin G, Cauda R, Rusconi S, Giacomelli A, Oreni, L, Borghi V, Mussini C, Guaraldi G, Sterrantino G, Lagi F, Candelaresi B, Cirioni O, De Vito A, Rossetti B, Torti C, Di Giambenedetto S. *Medicine (Baltimore).* 2021
- Author | **The prognostic role of IL-10 in non-severe COVID-19 with chemosensory dysfunction.** Locatello LG, Bruno C, Maggiore G, Cilona M, Orlando P, Fancello G, Piccica M, Vellere I, **Lagi F**, Trotta M, Gallo O. *Cytokine.* 2021
- Author | **Male reproductive system inflammation after healing from coronavirus disease.** Morselli S, Sebastianelli A, Liaci A, Zaccaro C, Pecoraro A, Nicoletti R, Manera A, Bisegna C, Campi R, Pollini S, Antonelli A, Lagi F, Coppi M, Baldi E, Marchiani S, Nicolò S, Torcia M, Annunziato F, Maggi M, Vignozzi L, Bartoloni A, Rossolini GM, Serni S, Gacci M. | 2019. *Andrology.* 2021 Dec
- Author | **Prospective Study on Incidence, Risk Factors and Outcome of Recurrent Clostridioides difficile Infections** | Granata G, Petrosillo N, Adamoli L, Bartoletti M, Bartoloni A, Basile G, Bassetti M, Bonfanti P, Borromeo R, Ceccarelli G, De Luca AM, Di Bella S, Fossati S, Franceschini E, Gentile I, Giacobbe DR, Giacometti E, Ingrassia F, **Lagi F**, Lobreglio G, Lombardi A, Lupo LI, Luzzati R, Maraolo AE, Mikulska M, Mondelli MU, Mularoni A, Mussini C, Oliva A, Pandolfo A, Rogati C, Trapani FF, Venditti M, Viale P, Caraffa E, Cataldo MA, On Behalf Of The ReCloDi Recurrence Of Clostridioides Difficile Infection Study Group. | *J Clin Med.* 2021

2020

- Author | **Long-term maintenance of virologic suppression in native and migrant HIV-1 naïve patients: an Italian cohort study.** Lagi F, Kiros ST, Di Giambenedetto S, Lombardi F, Pecorari M, Borghi V, Lepore L, Monno L, Setti M, Micheli V, Bagnarelli P, Paolini E, Bai F, Bartoloni A, Sterrantino G. | *AIDS Care* |
- Author | **Arbo-Score: A Rapid Score for Early Identification of Patients with Imported Arbovirolosis Caused by Dengue, Chikungunya and Zika Virus.** Vellere I, **Lagi F**, Spinicci M, Mantella A, Mantengoli E, Corti G, Colao MG, Gobbi F, Rossolini GM, Bartoloni A, Zammarchi L. | *Microorganisms.* |
- Author | **Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort.** Ciccullo A, Baldin G, Borghi V, Sterrantino G, Madeddu G, Latini A, d'Ettore G, Lanari A, Mazzitelli M, Colafigli M, Capetti AF, Oreni L, Lagi F, Rusconi S, Di Giambenedetto S. | *AIDS Res Hum Retroviruses*
- Author | **Cancer population may be paradoxically protected from severe manifestations of COVID-19.** Gallo O, Locatello LG, Orlando P, Martelli F, Piccica M, **Lagi F**, Trotta M. | *J Infect.* 2020
- Author | **Results of comprehensive cardiovascular diagnostic work-up in HIV positive patients.** Pontecorboli G, **Lagi F**, Bagli M, De Vito E, Millotti G, Botta A, Cappelli F, Mattesini A, Acquafresca M, Barletta G, Del Bene R, Colagrande S, Marcucci R, Bartoloni A, Di Mario C, Martinelli CV. | *Infez Med.* 2020
- Author | **Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study.** Vultaggio A, Vivarelli E, Virgili G, Lucenteforte E, Bartoloni A, Nozzoli C, Morettini A, Berni A, Malandrino D, Rossi O, Nencini F, Pieralli F, Peris A, Lagi F, Scocchera G, Spinicci M, Trotta M, Mazzetti M, Parronchi P, Cosmi L, Liotta F, Fontanari P, Mazzoni A, Salvati L, Maggi E, Annunziato F, Almerigogna F, Matucci A. | *J Allergy Clin Immunol Pract.* 2020 |
- Author | **Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020.** | *Euro Surveill.* 2020 | Lagi F, Piccica M, Graziani L, Vellere I, Botta A, Tilli M, Ottino L, Borchì B, Pozzi M, Bartalesi F, Mencarini J, Spinicci M, Zammarchi L, Pieralli F, Zagli G, Nozzoli C, Romagnoli S, Bartoloni A, The Cocora Working Group.
- Author | **Clinical role of viral identification by a polymerase chain reaction-based diagnostic panel in adults**

hospitalized with community-acquired pneumonia. | *Intern Emerg Med.* 2020
Lagi F, Pollini S, Zammarchi L.

- Author | **Seasonal Allergic Rhinitis Symptoms in Relation to COVID-19** | Bruno C, Locatello LG, Cilona M, Fancello G, Vultaggio A, Maltagliati L, Rossi O, Vivarelli E, Almerigogna F, Piccica M, **Lagi F**, Maggiore G, Matucci A, Trotta M, Gallo O | *Allergy Rhinol* (Providence). 2020 Nov
- Author | **The Burden of Clostridioides Difficile Infection during the COVID-19 Pandemic: A Retrospective Case-Control Study in Italian Hospitals (CloVid)** | Granata G, Bartoloni A, Codeluppi M, Contadini I, Cristini F, Fantoni M, Ferraresi A, Fornabaio C, Grasselli S, Lagi F, Masucci L, Puoti M, Raimondi A, Taddei E, Trapani FF, Viale P, Johnson S, Petrosillo N, On Behalf Of The CloVid Study Group | *J Clin Med.* 2020 Nov

2019

- Author | **Single Tablet Regimen With Abacavir/Lamivudine/Dolutegravir Compared With Two-Drug Regimen With Lamivudine and Dolutegravir as Different Strategies of Simplification From a Multicenter HIV Cohort Study** | *Infect Med* 2019 | Gianmaria Baldin, Arturo Ciccullo, Stefano Rusconi, Giordano Madeddu, Gaetana Sterrantino, Andrew Freedman, Andrea Giacometti, Luigi Celani, Alessandra Latini, Barbara Rossetti, Maria Vittoria Cossu, Andrea Giacomelli, **Filippo Lagi**, Amedeo Capetti, Simona Di Giambenedetto
- Author | **Cohort Profile: The Observational Cohort for the Study of Dolutegravir in Antiretroviral Combination Regimens (ODOACRE)** | *BMJ Open* 2019 | Arturo Ciccullo, Gianmaria Baldin, Amedeo Capetti, Vanni Borghi, Gaetana Sterrantino, Alessandra Latini, Giordano Madeddu, Luigi Celani, Francesca Vignale, Barbara Rossetti, Alex Dusina, Maria Vittoria Cossu, Sibilla Restelli, William Gennari, **Filippo Lagi**, Andrea Giacomelli, Manuela Colafigli, Lucia Brescini, Alberto Borghetti, Cristina Mussini, Stefano Rusconi, Simona Di Giambenedetto
- Author | **Efficacy and Safety of Dolutegravir-Based Regimens in Advanced HIV-infected Naïve Patients: Results From a Multicenter Cohort Study** | *Antiviral Res* 2019 | Barbara Rossetti, Gianmaria Baldin, Gaetana Sterrantino, Stefano Rusconi, Andrea De Vito, Andrea Giacometti, Roberta Gagliardini, Manuela Colafigli, Amedeo Capetti, Gabriella d'Ettore, Luigi Celani, **Filippo Lagi**, Arturo Ciccullo, Andrea De Luca, Simona Di Giambenedetto, Giordano Madeddu
- Author | **Early discharge criteria in patients with acute bacterial skin and skin structure infections in a large tertiary-care teaching hospital in Florence, Italy. [In Press]** | *Eur J Clin Microbiol Infect Dis.* | **Filippo Lagi**, Letizia Ottino, Elisabetta Mantengoli, Alberto Distefano, Giampaolo Corti, Alberto Farese, Bassam Dannaoui, Alessandra Ipponi, Tiziana Falai, Gian Maria Rossolini, Alessandro Bartoloni, Filippo Bartalesi
- Author | **Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: a multicenter retrospective cohort study.** | *Int J Antimicrob Agents.* | **Lagi F**, Baldin G, Colafigli M, Capetti A, Madeddu G, Kiros ST, Di Giambenedetto S, Sterrantino G.
- Author | **Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriales infection: are they the same in neutropenic and non-neutropenic patients?** | *Intern Emerg Med* | **Lagi F**, Corti G.
- Author | **Use of colistin in adult patients: a cross-sectional study.** | *I J Glob Antimicrob Resist.* Giacobbe DR, Saffioti C, Losito AR, Rinaldi M, Aurilio C, Bolla C, Boni S, Borgia G, Carannante N, Cassola G, Ceccarelli G, Corcione S, Gasperina DD, De Rosa FG, Dentone C, Di Bella S, Di Lauria N, Feasi M, Fiore M, Fossati S, Franceschini E, Gori A, Granata G, Grignolo S, Grossi PA, Guadagnino G, **Lagi F**, Maraolo AE, Marinò V, Mazzitelli M, Mularoni A, Oliva A, Pace MC, Parisini A, Patti F, Petrosillo N, Pota V, Raffaelli F, Rossi M, Santoro A, Tascini C, Torti C, Treccarichi EM, Venditti M, Viale P, Signori A, Bassetti M, Del Bono V, Giannella M, Mikulska M, Tumbarello M, Viscoli C; SITA GIOVANI

2018

- Author | **Continuum of care among HIV-1 positive patients in a single center in Italy (2007–2017)** | *Patient Preference and Adherence* | **Filippo Lagi**, Seble Tekle Kiros, Irene Campolmi, Susanna Giachè, Pier Giorgio Rogasi, Marcello Mazzetti, Filippo Bartalesi, Michele Trotta, Patrizia Nizzoli, Alessandro Bartoloni, Gaetana Sterrantino.
- Author | **Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort** | *HIV Medicine.* | Modica S, Rossetti B, Lombardi F, Lagi F, Maffeo M, D'Autilia R, Pecorari M, Vicenti I, Bruzzone B, Magnani G, Paolucci S, Francisci D, Penco G, Sacchini D, Zazzi M, De Luca A, Di Biagio A.
- Author | **Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in**

clinical practice: results from a multicentre, observational study. | *HIV Medicine*. Baldin G, Ciccullo A, Capetti A, Rusconi S, Sterrantino G, Cossu MV, Giacomelli A, Lagi F, Latini A, Bagella P, De Luca A, Di Giambenedetto S, Madeddu G.

- Author | **A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1 infected patients** | *Antivir Ther*. Ciccullo A, Baldin G, Capetti A, Rusconi S, Sterrantino G, d'Ettorre G, Colafigli M, Modica S, Lagi F, Giacomelli A, Cossu MV, Restelli S, De Luca A, Di Giambenedetto S.
- Author | **Tubercular prosthetic joint infection: two case reports and literature review** | *Infection*. Veloci S, Mencarini J, Lagi F, Beltrami G, Campanacci DA, Bartoloni A, Bartalesi F.

2017

- Author | **Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice** | *Antivir Ther*. Santoro MM, Di Carlo D, Armenia D, Zaccarelli M, Pinnetti C, Colafigli M, Prati F, Boschi A, Antoni AMD, **Lagi F**, Sighinolfi L, Gervasoni C, Andreoni M, Antinori A, Mussini C, Perno CF, Borghi V, Sterrantino G.
- Author | **Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.** *AIDS* | Borghetti A, Baldin G, Capetti A, Sterrantino G, Rusconi S, Latini A, Giacomelli A, Madeddu G, Picarelli C, De Marco R, Cossu MV, **Lagi F**, Cauda R, De Luca A, Di Giambenedetto S; Odoacre Study Group.

2016

- Author | **Proposal for a New Score-Based Approach To Improve Efficiency of Diagnostic Laboratory Workflow for Acute Bacterial Meningitis in Adults** | *Journal of Clinical Microbiology*
Filippo Lagi, Filippo Bartalesi, Patrizia Pecile, Tiziana Biagioli, Anna Lucia Caldini, Alessandra Fanelli, Giuseppe Giannazzo, Stefano Grifoni, Luca Massacesi, Alessandro Bartoloni, Gian Maria Rossolini.
- Author | **Efficacy and tolerability of EVG/COBI/FTC/TDF in HIV-positive experienced-patients with detectable and undetectable baseline viremia** | poster, ICAR 2016, Milan, Italy

2014

- Author | **Imported Dengue Fever in Tuscany, Italy, in the Period 2006-2012** | *Journal of Travel Medicine*
Filippo Lagi, MD, Lorenzo Zammarchi, MD, Marianne Strohmeyer, MD, Filippo Bartalesi, MD, Antonia Mantella, BSc, Massimo Meli, MD, Pierluigi Blanc, MD, Danilo Tacconi, MD, Alberto Farese, MD, Giacomo Zanelli, MD, Francesco Pippi, MD, Donatella Aquilini, MD, Aniello Tonziello, MD, Cesira Nencioni, MD, Maria Benvenuti, MD, Sara Moneta, MD, Franca Furnari, MD, Maria G. Ciufolini, BSc, Loredana Nicoletti, BSc, and Alessandro Bartoloni, MD, DTM
- Author | **Incidence of hypoglycaemia associated with transient loss of consciousness. A retrospective cohort study** | *International Journal of Clinical Practice*
Lagi A, Cencetti S, Lagi F.

2013

- Author | **Clostridium difficile infections: preliminary data from an observational study in a large tertiary care Italian hospital** | Poster ICAAC 2013, Denver (USA).
E. Mantengoli, F. Lagi, E. Salomoni, S. Veloci, N. Della Malva, P. Pecile, L. Magistri, M.B. Pulci, F. Niccolini, G.M. Rossolini, A. Bartoloni

2012

- Author | **Leptospirosis Acquired by Tourists in Venice, Italy** | *Journal of Travel Medicine*
F. Lagi, G. Corti, M. Meli, A. Pinto, A. Bartoloni.

2009

- **Degree medical School**

Non Hodgkin lymphomas in HIV patients studied at Ospedale di Careggi: a review of the series of cases in the period from 2004 to 2008

Supervisor: Prof. Alessandro Bartoloni, Careggi Hospital

Study design: Observe the correlation between Non Hodgkin Lymphomas (LNH) and HIV patients, with particular attention towards treatment and prognosis. 17 patients with a diagnosis of LNH and HIV were studied in a period of time lasting from 2004 to 2008. Mean age of the patients was 46 years (range 32-76), 16 males and 1 female. They were observed for a mean time of 25 months, at the end of the observation period 12 patients were still alive, 4 died and 1 dropped out from the study. All the death cases were not related to the treatment received but were determined by disease progression. Our study demonstrated that it is possible to provide the same “dose dense” to HIV and non HIV-patients without experiencing significant differences in terms of toxicity and adverse effects.

I've been a speaker in the national and international congress on HIV. I've been a sub-investigator in four RCT (LCD-CDAD-10-07 [antibiotics], Rempex 505 [antibiotics], studio A0001B [mAbs], EDOLAS [antivirals]). I have been a teacher of several courses for nurses that have been held in my institution. I am fluent in English (as certified by Cambridge University IELTS certification 7 in 2010) and familiar with Spanish. Together with other colleagues, I edited the translation of the book "Prevenzione delle infezioni correlate all'assistenza" by Sanjay Saint et al. Excellent user of MS Office (Word, PowerPoint, Excel). I have good experience in Statistical analysis with Stata (v 14.0).

t

Firenze 15/02/2022

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome
Indirizzo
Telefono
Fax
E-mail

Nazionalità

Data di nascita

LOLATTO RICCARDO

ESPERIENZA LAVORATIVA

- Date (da – a)
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
- Principali mansioni e responsabilità

- Date (da – a)
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
- Principali mansioni e responsabilità

01/12/2021 – data attuale
Ospedale San Raffaele S.r.l., Via Olgettina n. 60, 20132 Milano

Ospedale universitario e di ricerca
Clinical Data Manager
Ricerca

15/11/2017 – 30/11/2021
Politecnico di Milano

Università
Assegnista di Ricerca
Ricerca

ISTRUZIONE E FORMAZIONE

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
 - Livello nella classificazione nazionale (se pertinente)

2015 - 2017
Politecnico di Milano

Ingegneria Biomedica

Laurea magistrale in Ingegneria Biomedica

CAPACITÀ E COMPETENZE

PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

MADRELINGUA

ITALIANO

ALTRE LINGUA

INGLESE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

ECCELLENTE

BUONO

BUONO

PATENTE O PATENTI

B

Curriculum Vitae Europass

Informazioni personali

Nome(i) / Cognome(i) Giulia Marchetti

Indirizzo(i)

Telefono(i)

Fax

E-mail

CF

Cittadinanza

Data di nascita

Sesso

Occupazione desiderata/Settore professionale

Esperienza professionale

Date Da Febbraio 2022 a tutt'oggi:

Lavoro o posizione ricoperti Professore ordinario presso l'Università degli Studi di Milano, settore concorsuale 06/D4, settore scientifico-disciplinare MED/17 – Malattie Infettive, presso il Dipartimento di Scienze della Salute (Direttore: Prof Stefano Centanni)- Clinica di Malattie Infettive e Tropicali Università degli Studi di Milano. (Direttore: Prof.ssa Antonella d'Arminio Monforte).

Principali attività e responsabilità Professore ordinario, Dirigente medico di I livello

Nome e indirizzo del datore di lavoro Università degli Studi di Milano
ASST Santi Paolo e Carlo

Tipo di attività o settore Malattie infettive

Esperienza professionale	
Date	Dal 24 febbraio 2015 a febbraio 2022:
Lavoro o posizione ricoperti	Professore Associato presso l'Università degli Studi di Milano, settore concorsuale 06/D4, settore scientifico-disciplinare MED/17 – Malattie Infettive, presso il Dipartimento di Scienze della Salute (Direttore: Prof Stefano Centanni)- Clinica di Malattie Infettive e Tropicali Università degli Studi di Milano. (Direttore: Prof.ssa Antonella d'Arminio Monforte). Dirigente medico I livello presso la Clinica delle Mal Infettive e Tropicali Università degli Studi di Milano. (Direttore: Prof.ssa Antonella d'Arminio Monforte). Professore Associato Dirigente medico I livello - Università degli Studi di Milano
Date	Dal 3 gennaio 2008 al 23 febbraio 2015:
Lavoro o posizione ricoperti	Conferma nel ruolo di ricercatore universitario presso l'Università degli Studi di Milano, settore scientifico-disciplinare MED/17 – Malattie Infettive, presso il Dipartimento di Medicina, Chirurgia, Odontoiatria (Direttore: Prof.ssa Anna Maria Di Giulio) - Clinica di Malattie Infettive e Tropicali Università degli Studi di Milano. (Direttore: Prof.ssa Antonella d'Arminio Monforte). Dirigente medico I livello presso la Clinica delle Mal Infettive e Tropicali Università degli Studi di Milano. (Direttore: Prof.ssa Antonella d'Arminio Monforte).
Principali attività e responsabilità	Ricercatore universitario Dirigente medico I livello
Nome e indirizzo del datore di lavoro	Università degli Studi di Milano ASST Santi Paolo e Carlo
Tipo di attività o settore	
Esperienza professionale	
Date	Dal 3 gennaio 2005 a maggio 2007:
Lavoro o posizione ricoperti	Ricercatore universitario presso l'Università degli Studi di Milano, settore scientifico-disciplinare MED/17 – Malattie Infettive, presso l'Istituto di Malattie Infettive e Tropicali Università degli Studi di Milano. (Direttore: Prof. Mauro Moroni)
Principali attività e responsabilità	Ricercatore universitario
Nome e indirizzo del datore di lavoro	Università degli Studi di Milano
Tipo di attività o settore	
Date	Dal 25 giugno 2001 al 15 settembre 2001:

Lavoro o posizione ricoperti	Dirigente Medico di I livello supplente presso l'Istituto di Malattie Infettive e Tropicali, Ospedale "L. Sacco", Università degli Studi di Milano. Direttore: Prof. Mauro Moroni
Principali attività e responsabilità	Dirigente Medico di I livello supplente
Nome e indirizzo del datore di lavoro	Ospedale "L. Sacco", Milano
Tipo di attività o settore	

Capacità e competenze personali

Madrelingua(e) **Precisare madrelingua(e)**

Altra(e) lingua(e)

Autovalutazione

Livello europeo ()*

INGLESE

FRANCESE

Comprensione		Parlato		Scritto
Ascolto	Lettura	Interazione orale	Produzione orale	
OTTIMO	OTTIMO	OTTIMO	OTTIMO	OTTIMO
BUONO	BUONO	SCOLASTICO	SCOLASTICO	SCOLASTICO

ISTRUZIONE E FORMAZIONE

- Date (da – a)
 - Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
 - Livello nella classificazione nazionale (se pertinente)
 - Date (da – a)

 - Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
 - Livello nella classificazione nazionale (se pertinente)
 - Date (da – a)

 - Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
 - Livello nella classificazione nazionale (se pertinente)
 - Date (da – a)

 - Nome e tipo di istituto di istruzione o formazione
- 1989-1995:**
Laurea in Medicina e Chirurgia, Università degli Studi di Milano
- Laurea in Medicina e Chirurgia, cum laude
Laurea in Medicina e Chirurgia, cum laude
- 1997-2000:** specializzazione in Malattie Infettive, *cum laude*, Università degli Studi di Milano (Direttore: Prof. M. Moroni)
- specializzazione in Malattie Infettive, cum laude
- specializzazione in Malattie Infettive, cum laude
specializzazione in Malattie Infettive, cum laude
- 2001-2003:** dottorato in “Fisiopatologia, clinica e diagnostica delle infezioni dell’ospite immunocompromesso e dell’infezione da immunodeficienza acquisita” (Ciclo XVI), Università degli Studi di Milano. (Direttore: Prof. Mauro Moroni)
- dottorato in “Fisiopatologia, clinica e diagnostica delle infezioni dell’ospite immunocompromesso e dell’infezione da immunodeficienza acquisita”
- Dottorato in “Fisiopatologia, clinica e diagnostica delle infezioni dell’ospite immunocompromesso e dell’infezione da immunodeficienza acquisita”
- 2004-2005:** assegnista di ricerca presso l’Istituto di Malattie Infettive e Tropicali, Università degli Studi di Milano. Responsabile scientifico: Prof. Mauro Moroni.
- Giugno 1996:** visiting fellow
Department of Mycobacteriology and Molecular Microbiology, National Institute of Public Health and Environmental Protection, Bilthoven, the Netherlands. Direttore: Jan D.A. van Embden.
- Ottobre 1998-Dicembre 1999:** visiting fellow
Department of Immunology and Microbiology, Rush-Presbyterian St. Luke's Medical Center, Rush University, Chicago, IL (USA). Direttore: Henry Gewurz.
- Giugno 2002:** visiting fellow
Human Immunology Section, NIH Vaccine Research Center, Bethesda, MD (USA). Direttore: Daniel C. Douek.

(*) [Quadro comune europeo di riferimento per le lingue](#)

Capacità e competenze organizzative

Da Luglio 2012 a tutt'oggi partecipazione alla stesura delle "Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1" in qualità di membro dell'HIV/AIDS ITALIAN EXPERT PANEL.

Dal 2014 a tutt'oggi membro del Consiglio Direttivo Regionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT), Sezione Regione Lombardia.

Dal 2 febbraio 2015 a tutt'oggi membro del Comitato Scientifico dell'Associazione Nazionale per la Lotta contro l'AIDS (ANLAIDS).

Dal 2016 fa parte dell'Editorial Board della rivista peer-review *Pathogens and Immunity; Open AIDS Journal*.

Dal luglio 2010 socia della Società Italiana di Malattie Infettive e Tropicali (SIMIT).

Da ottobre 2013 membra della European AIDS Clinical Society (EACS).

2016 membro dell'Abstract Mentor Program (AMP) in qualità di mentore, promosso dalla International AIDS Society (AIDS 2016)

Partecipazione scientifica a progetti di ricerca.

1. Responsabile scientifico del working package #3 nell'ambito del progetto di rete: "Implication for strategies of long term control of viral replication in patients with primary HIV infection (PHI) treated with multitarget antiviral therapy (MT-ART): kinetics of viral reservoirs, immunological response and drug penetration in lymphoid tissues" (NET-2013-02355333), finanziato dal Ministero della Salute- "Programmi di Rete 2013". Finanziamento pari a Euro 393.343.
2. Responsabile scientifico del progetto: "Infiammazione, immunoattivazione e funzione T linfocitaria nel sangue periferico e nel compartimento del Sistema Nervoso Centrale (SNC) e disturbi neuro-cognitivi nei pazienti HIV-positivi: studio in pazienti naive e dopo 12 mesi di HAART" (F61bd8c044) finanziato da Gilead s.r.l. nell'ambito del progetto "Fellowship Program 2012". Finanziamento pari a Euro: 40.000. Durata del progetto: 18 mesi
3. Responsabile scientifico del progetto: "Study of the Causal Relationship between Intestinal Permeability, Microbial Translocation and T-Lymphocyte Hyperactivation in HIV-Infected Patients with Poor Immunological Response in Course of Suppressive HAART" (GR-2009-1592029) finanziato dalla Ministero della Salute nell'ambito del bando "Ricerca finalizzata-Giovani Ricercatori 2009". Finanziamento pari a Euro 132.8188,00). Durata del progetto: 36 mesi
4. Partecipante al gruppo di ricerca del progetto: "INFEZIONE DA HPV IN PAZIENTI HIV POSITIVI DI SESSO MASCHILE: SIGNIFICATO DELLA LOCALIZZAZIONE IN SEDI DIVERSE (2009-ATE-0484)". Finanziato da Università degli Studi di Milano (PUR 2009). Durata. 12 mesi
5. Responsabile scientifico del Progetto dal titolo "Ruolo dell'asse interleuchina-7 (IL-7)/IL-7R su sangue periferico e midollo osseo in pazienti HIV+ con severa linfopenia CD4. (2008-ATE-0863)". Finanziato da Università degli Studi di Milano (PUR 2008). Durata: 12 mesi
6. Responsabile scientifico del progetto "Studio delle dinamiche e della regolazione dell'omeostasi T-linfocitaria in pazienti HIV-positivi immunological-non-responders (INR) sottoposti a diverse strategie terapeutiche antiretrovirali ed immunoadiuvanti (2007-ATE-0593). Finanziato da Università degli Studi di Milano (PUR 2007). Durata: 12 mesi

6. Responsabile scientifico del progetto: "Ruolo clinico ed immunologico di un approccio di intensificazione terapeutica e di immunoterapia adiuvante in pazienti con buona risposta virologica ma mancato recupero immunologico alla terapia antiretrovirale ad alta efficacia (HAART) (2006-ATE 0322)". Finanziato da Università degli Studi di Milano (PUR 2006). Durata: 12 mesi

Publicazioni scientifiche

1. M. Moroni, C. Rossi, **G. Marchetti**, G. Nardi, S. Vezzoli, F. Franzetti, A. Gori. Problematiche attuali della tubercolosi nei pazienti HIV-1 positivi. Estratto da: "Lotta contro la tubercolosi e le malattie polmonari sociali". Anno LXV, N. 4 – 1995
2. Gori, F. Franzetti, **G. Marchetti**, L. Catozzi, M. Corbellino. Specific Detection of *Mycobacterium tuberculosis* by *mtp40* Nested PCR. J Clin Microbiol Nov 1996; 34(11): 2866. **Numero citazioni: 10- I.F. 4.23**
3. Gori, F. Franzetti, G. Bestetti, L. Catozzi, G. Nardi, **G. Marchetti**, S. Rusconi, M. Corbellino. Use of Multiplex PCR assay and DNA Fingerprinting Analysis for Typing of Multidrug-resistant *Mycobacterium tuberculosis* Strains. Journal of Infection Nov 1997; 35(3): 322-323. DOI:10.1016/S0163-4453(97)93802-0. **Numero citazioni: 0- I.F. 4.017**
4. S. Rusconi, A. Gori, L. Vago, **G. Marchetti**, F. Franzetti. Cutaneous Infection Caused by *Mycobacterium gordonae* in a Human Immunodeficiency Virus-Infected Patient receiving Antimycobacterial Treatment. Clin Infect Dis Dec 1997; 25(6): 1490-91. DOI: 10.1086/517006. **Numero citazioni: 9- I.F. 9.416**
5. Gori, F. Franzetti, **G. Marchetti**, L. Catozzi, M.C. Rossi, G.P. Nardi, M. Degl'Innocenti, A. Grassini, M. R. Gismondo, M. Moroni. Valutazione dell'utilizzo clinico della polymerase chain reaction nella diagnosi di malattia tubercolare. Clinical evaluation of polymerase chain reaction in tuberculosis diagnosis. Giorn It Mal Inf 1997;3:150-155.
6. L. Vago, M. Barberis, A. Gori, P. Scarpellini, E. Sala, M. Nebuloni, S. Bonetto, M. Cannone, **G. Marchetti**, F. Franzetti, G. Costanzi. Nested Polymerase Chain Reaction for *Mycobacterium tuberculosis* IS6110 Sequence on Formalin-Fixed, Paraffin-Embedded Tissues with Granulomatous Diseases for Rapid Diagnosis of Tuberculosis. Am J Clin Pathol Apr 1998; 109(4): 411-415. **Numero citazioni: 37- I.F. 3.005**
7. M. Moroni, A. Gori, **G. Marchetti**. La tubercolosi nell'era dell'HIV. Estratto da: "Lotta contro la tubercolosi e le malattie polmonari sociali". Anno LVIII, N. 1-2 – 1998.
8. Gori, F. Franzetti, **G. Marchetti**, C. Rossi, M.L. Fusi, S. Ruzzante, and M. Clerici. Clinical and Immunological Improvement in a Patient who Received Thalidomide Treatment for refractory *Mycobacterium avium* Complex Infection. Clin Infect Dis Jan 1998; 26(1): 184-185. DOI: 10.1086/517054. **Numero citazioni: 7- I.F. 9.416**
9. M.L. Moro, A. Gori, I. Errante, A. Infuso, F. Franzetti, L. Sodano, E. Iemoli, & the Italian Multidrug-Resistant Tuberculosis Outbreak Study Group (Liliana Caggese, Antonietta Cargnel, Lidia Catozzi, Concettina D'Amico, Fabio Giannelli, Maria Rita Gismondo, Paolo Valerio Mantellini, **Giulia Marchetti**, Francesco Milazzo, Mauro Moroni, Gianpiero Nardi, Carlo Andrea Orcese, Carmela Perna, Tiziana Quirino, Giuseppe Salamina). An Outbreak of Multidrug-Resistant Tuberculosis Involving HIV-Infected Patients of Two Hospitals in Milan, Italy. AIDS Jun 1998; 12(9): 1095-1102. **Numero citazioni: 57- I.F. 6.557**
10. Gori, **G. Marchetti**, L. Catozzi, C. Nigro, G. Ferrario, M.C. Rossi, A. Degli Esposti, A. Orani, and F. Franzetti. Molecular Epidemiology Characterization of a Multidrug-Resistant *Mycobacterium bovis* Outbreak amongst HIV-positive Patients. AIDS Feb 1998; 12(4):445-6. **Numero citazioni: 8- I.F. 6.557**
11. **G. Marchetti**, A. Gori, L. Catozzi, L. Vago, M. Nebuloni, M.C. Rossi, A. Degli Esposti, A. Orani, and F. Franzetti. Evaluation of PCR in Detection of *Mycobacterium tuberculosis* from Formalin-Fixed, Paraffin-Embedded Tissues: Comparison of Four Amplification Assays. J Clin Microbiol Jun 1998; 36(6): 1512-1517. **Numero citazioni: 81- I.F. 4.232**
12. Gori, S. Rusconi, C. Negri, **G. Marchetti**, G. Ferrario, R. Sampietro, F.

12. C.M. Steffens, **G. Marchetti**, A. Landay and L. Al-Harhi. The Human Thymus: A New Perspective on Thymic Function, Aging, and HIV infection. *Clinical Immunology Newsletter* June/July 1999; 19 No 6/7: 72-79.
13. Gori, M.C. Rossi, **G. Marchetti**, D. Trabattoni, C. Molteni, M. Cogliati, A. Bandera, M. Clerici and F. Franzetti. Clinical and Immunological Benefit of Adjuvant Therapy with Thalidomide in the Treatment of Tuberculosis Disease. *AIDS* Aug 18 2000; 14(12): 1859-61. DOI: 10.1097/00002030-200008180-00026. **Numero citazioni: 11- I.F. 6.557**
14. L. Al-Harhi, **G. Marchetti**, C. M. Steffens, J-F. Poulin, R-P. Sekaly, A. Landay. Detection of T Cell Receptor Circles (TRECs) as Biomarkers for *de novo* T Cell Synthesis Using a Quantitative Polymerase Chain Reaction-Enzyme Linked Immunosorbent Assay (PCR-ELISA). *Journal of Immunological Methods* Apr 3 2000; 237(1-2): 187-197. DOI: 10.1016/S0022-1759(00)00136-8. **Numero di citazioni: 57- I.F. 2.005**
15. M.C. Rossi, A. Gori, G. Zehender, **G. Marchetti**, G. Ferrario, C. De Maddalena, L. Catozzi, A. Bandera, A. Degli Esposti and F. Franzetti. A PCR-Colorimetric Microwell Plate Hybridization Assay for Detection of *Mycobacterium tuberculosis* and *M. avium* from Culture Samples and Ziehl-Neelsen-positive Smears. *J Clin Microbiol* May 2000; 38(5): 1772-1776. **Numero di citazioni: 13- I.F. 4.232**
16. Gori, M.C. Rossi, D. Trabattoni, **G. Marchetti**, M.L. Fusi, C. Molteni, M. Clerici, and F. Franzetti. Tumor necrosis factor- α Increased Production during Thalidomide Treatment in Patients with Tuberculosis and HIV coinfection. *J Infect Dis* Aug 2000;182(2): 639. **Numero di citazioni: 10- I.F. 5.778**
17. Bandera, A. Gori, M.C. Rossi, A. degli Esposti, G. Ferrario, **G. Marchetti**, L. Tocalli, and F. Franzetti. A case of Costochondral Abscess due to *Corynebacterium minutissimum* in an HIV-infected Patient. *Journal of Infection* Jul 2000; 41(1): 103-105. DOI: 10.1053/jinf.2000.0679. **Numero di citazioni: 6- I.F. 4.017**
18. G. Ferrario, A. Gori, A. Rossi, L. Catozzi, C. Molteni, **G. Marchetti**, A. Bandera, M.C. Rossi, A. Degli Esposti, and F. Franzetti. PCR-Hybridization Assay for *Mycobacterium avium* complex: Optimization of Detection in Peripheral Blood from Humans. *J Clin Microbiol* Apr 2001;39(4):1638-1643. DOI: 10.1128/JCM.39.4.1638-1643.2001. **Numero di citazioni: 5- I.F. 4.232**
19. Bandera, A. Gori, L. Catozzi, A. Degli Esposti, **G. Marchetti**, C. Molteni, G. Ferrario, L. Codecasa, V. Penati, A. Matteelli, and F. Franzetti. Molecular Epidemiology Study of Exogenous Reinfection in an Area with a Low Incidence of Tuberculosis. *J Clin Microbiol* Jun 2001; 39 (6): 2213-18. DOI: 10.1128/JCM.39.6.2213-2218.2001. **Numero di citazioni: 84- I.F. 4.232**
20. **G. Marchetti**, L. Meroni, S. Varchetta, V. Terzieva, A. Bandera, D. Manganaro, C. Molteni, D. Trabattoni, S. Fossati, M. Clerici, M. Galli, M. Moroni, F. Franzetti, and A. Gori. Low-Dose Prolonged Intermittent Interleukin-2 Adjuvant Therapy: Results of a Randomized trial among Human Immunodeficiency Virus-Positive Patients with Advanced Immune Impairment. *J Infect Dis* Sep 1 2002; 186(5): 606-16. DOI: 10.1086/342479. **Numero di citazioni: 45- I.F. 5.778**
21. **G. Marchetti**, Luca Meroni, Fabio Franzetti, and Andrea Gori. Clinical Value of Adjunctive Interleukin-2: Clarifications and Corrections. Reply. *J Infect Dis* Jan 15 2003; 187(2): 340-341. DOI: 10.1086/346008. **Numero di citazioni: 0- I.F. 5.778**
22. L. Meroni, **G. Marchetti**, N. Gatti, A. d'Arminio Monforte, M. Galli. Delayed-Type Hypersensitivity Skin Testing Can Predict CD4 Count Increase in HIV Patient with Poor Immunological Response to HAART. *JAIDS- Journal of Acquired Immune Deficiency Syndromes* Jun 1 2003; 33(2): 277-278. DOI: 10.1097/00126334-200306010-00027. **Numero di citazioni: 2- I.F. 4.394**
23. **G. Marchetti**, L. Meroni, C. Molteni, A. Bandera, F. Franzetti, M. Galli, M. Moroni, M. Clerici, and A. Gori. Interleukin-2 Immunotherapy Exerts a Differential Effect on CD4 and CD8 T-Cell Dynamics. *AIDS* Jan 23 2004; 18(2):211-216. DOI: 10.1097/01.aids.0000104359.55632.94. **Numero di citazioni:19- I.F. 5. 632**

24. **G. Marchetti**, L. Meroni, C. Molteni, G. Taskaris, L. Gazzola, M. Galli, M. Clerici, M. Moroni, F. Franzetti, and A. Gori. IL-7/IL-7 Receptor System Regulation Following IL-2 Immunotherapy in HIV-Infected Patients. *Antiviral Therapy* Jun 2004; 9(3):447-52. **Numero di citazioni: 16- I.F. 3.143**
25. Gori, D. Trabattoni, A. Bandera, M. Saresella, **G. Marchetti**, L. Gazzola, M. Biasin, J. Rhodes, H. McDade, R. Panebianco, M. Galli, M. Moroni, P. Ferrante, N. Thomas, F. Franzetti, D. Bray, and M. Clerici. Immunomodulation Induced by Tucaresol in HIV-Infection: Results of a 16 Weeks Pilot Phase I/II Trial. *Antiviral Therapy* Aug 2004; 9(4):603-14. **Numero di citazioni: 6- I.F. 3.143**
26. **G. Marchetti**, F. Franzetti, A. Gori. Partial Immune Reconstitution Following Highly Active Antiretroviral Therapy: Can Adjuvant Interleukin-2 Fill the Gap? *Journal of Antimicrobial Chemotherapy* Apr 2005; 55(4):401-09. DOI: 10.1093/jac/dkh557. **Numero di citazioni: 27- I.F. 5.439**
27. Gori, A. Bandera, **G. Marchetti**, A. Degli Esposti, L. Catozzi, G.P. Nardi, L. Gazzola, G. Ferrario, J.D.A. van Embden, D. van Soolingen, M. Moroni, and F. Franzetti. Spoligotyping and Mycobacterium tuberculosis. *Emerging Infectious Diseases* Aug 2005; 11(8): 1242-48. **Numero di citazioni: 34- I.F. 7.327**
28. A. Bandera, **G. Marchetti**, A. Gori. Immunomodulants in HIV Infection. *Expert Opin. Ther. Patents* Sep 2005; 15(9):1115-1131. DOI: 10.1517/13543776.15.9.1115. **Numero di citazioni: 0- I.F. 3.441**
29. Gori, A. Degli Esposti, A. Bandera, M. Mezzetti, C. Sola, **G. Marchetti**, G. Ferrario, F. Salerno, M. Goyal, R. Diaz, L. Gazzola, L. Codecasa, V. Penati, N. Rastogi, M. Moroni, and F. Franzetti. Comparison between Spoligotyping and IS6110 Restriction Fragment Polymorphism in Molecular Genotyping Analysis of *Mycobacterium tuberculosis* strains. *Molecular and Cellular Probes* Aug 2005; 19(4):236-244. DOI: 10.1016/j.mcp.2005.01.001. **Numero di citazioni: 13- I.F. 1.859**
30. F. Franzetti, A. Grassini, M. Piazza, M. Degl'Innocenti, A. Bandera, L. Gazzola, **G. Marchetti**, A. Gori. Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy. *Infection*. Feb 2006;34(1):9-16. DOI: 10.1007/s15010-006-5007-x. **Numero di citazioni: 20- I.F. 2.864**
31. **G. Marchetti**, A. Gori, A. Casabianca, M. Magnani, F. Franzetti, M. Clerici, C-F. Perno, A. d'Arminio Monforte, M. Galli, L. Meroni, and the Study Group for Immunologic-non-Responders. Comparative Analysis of T-Cell Turnover and Homeostatic Parameters in HIV-Infected Patients with Discordant Immune-Virological Responses to HAART. *AIDS* Aug 22 2006; 20(13):1727-1736. DOI: 10.1097/01.aids.0000242819.72839.db. **Numero di citazioni: 70- I.F. 6.557**
32. Gori A, Tincati C, Rizzardini G, Torti C, Quirino T, Haarman M, Amor KB, van Schaik J, Vriesema A, Knol J, **Marchetti G**, Welling G, Clerici M. Early Impairment of Gut Function and Gut Flora Supporting a Role for Alteration of Gastrointestinal Mucosa in human immunodeficiency virus Pathogenesis. *Journal of Clinical Microbiology* Feb 2008;46(2):757-8. Epub 2007 Dec 19. DOI: 10.1128/JCM.01729-07. **Numero di citazioni: 56- I.F. 4.232**
33. L. Ferraris, G.M. Bellistri, V. Pegorer, C. Tincati, L. Meroni, M. Galli, A. d'Arminio Monforte, A. Gori, and **G. Marchetti**. Untangling the Immunological Implications of Nadir on CD4 recovery during Suppressive highly active antiretroviral therapy. *Clinical Infectious Diseases* Jan 1 2008;46(1): 149-150. DOI: 10.1086/524087. **Numero di citazioni: 4- I.F. 9.416**
34. S. Guzzetti, C. Fundaro, M. Pecis, G. Costantino, **G. Marchetti**, L. Meroni. Effective nocturnal oxygen therapy increases circulating level of tumor necrosis factor-[alpha] in heart failure. *J of Cardiovasc Med* Jan 1 2008;9(1): 64-67 **Numero di citazioni: 0- I.F. 1.407**

35. **G. Marchetti**, C. Tincati, A. d'Arminio Monforte and A. Gori. The Challenge of IL-2 Immunotherapy in HIV Disease: "No through Road" or Turning Point? *Current HIV Research* May 2008; 6 (3):189-199. DOI: 10.2174/157016208784325029. **Numero di citazioni: 8- I.F. 2.135**
36. M. Bongiovanni, R. Ranieri, C. Tincati, M. Casana, **G. Marchetti**, A. d'Arminio Monforte. Serum alpha-Fetoprotein Levels Predict early Virologic Response in HIV-Positive Subjects Treated for Chronic Hepatitis C. *JAIDS Journal of Acquired Immune Deficiency Syndromes* Jul 1 2008; 48(3):361-363. **Numero di citazioni: 0- I.F. 4.394**
37. Viganò, L. Meroni, **G. Marchetti**, A. Vanzulli, V. Giacomet, S. Fasan, A. Pradella, C. Cerini, G.V. Zuccotti. Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1. *Antiviral Therapy* 2008 13(6):839-43. **Numero di citazioni: 11- I.F. 3.143**
38. **G. Marchetti**, G.M. Bellistrì, E. Borghi, C. Tincati, S. Ferramosca, M. La Francesca, G. Morace, A. Gori, and A. d'Arminio Monforte. Microbial Translocation is Associated with Sustained Failure in CD4+ T-Cell Reconstitution in HIV-Infected Patients on Long-Term highly active antiretroviral therapy. *AIDS* Oct 1 2008;22(15):2035-8. DOI: 10.1097/QAD.0b013e3283112d29. **Numero di citazioni: 117- I.F. 6.557**
39. **G. Marchetti**, M. Casana, C. Tincati, G. M. Bellistrì, A. d'Arminio Monforte. Abacavir and Cardiovascular Risk in HIV-Infected Patients: Does T Lymphocyte Hyperactivation Exert a Pathogenic Role? *Clinical Infectious Diseases* Dec 1 2008;47(11):1495-6. DOI: 10.1086/593110. **Numero di citazioni: 2- I.F. 9.416**
40. Borghi E, La Francesca M, Gazzola L, **Marchetti G**, Zonato S, Foa P, d'Arminio Monforte A, Morace G. *Rhodococcus equi* infection in a patient with spinocellular carcinoma of unknown origin. *J Med Microbiol.* Nov 2008;57(11):1431-3. DOI: 10.1099/jmm.0.2008/002048-0. **Numero di citazioni: 3- I.F. 2.266**
41. Bandera A, Trabattoni D, Pacci M, Fasano F, Suardi E, Cesari M, **Marchetti G**, Pogliani EM, Franzetti F, Clerici M, Gori A. Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper response. *PLoS ONE.* Oct 31 2008;3(10):e3616. DOI: 10.1371/journal.pone.0003616. **Numero di citazioni: 3- I.F. 3.534**
42. Tincati C, Bauer D, Bellistrì GM, Casana M, Ranieri R, Bini T, **Marchetti G**, d'Arminio Monforte A. Sudden cardiac death in a young HIV-positive man on effective antiretroviral therapy. *Curr HIV Res.* Nov 2008;6(6):560-2. DOI: 10.2174/157016208786501517. **Numero di citazioni: 1- I.F. 2.135**
43. Gazzola L, Tincati C, Bellistrì GM, Monforte A, **Marchetti G**. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. *Clinical Infectious Diseases.* Feb 1 2009;48(3):328-37. DOI: 10.1086/595851. **Numero di citazioni: 76- I.F. 9.416**
44. Milazzo L, Meroni L, Galazzi M, Cesari M, Caramma I, **Marchetti G**, Galli M and Antinori S Does Fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfecting patients. *Journal of Viral Hepatitis.* Jul 2009;16(7):479-84. Epub 2009 Feb 8. DOI: 10.1111/j.1365-2893.2009.01104.x. **Numero di citazioni: 29- I.F. 3.307**

45. **Marchetti G**, Riva A, Cesari M, Bellistrì GM, Gianelli E, Casabianca A, Orlandi C, Magnani M, Meroni L, d'Arminio Monforte A, Mussini C, Cossarizza A, Galli M, and Gori A; for the Elvis Study Group. HIV-Infected Long-Term Non-Progressors Display a Unique Correlative Pattern between the Interleukin-7/Interleukin-7 Receptor Circuit and T-Cell Homeostasis. *HIV Medicine* Aug 2009;10(7):422-31. Epub 2009 May 5. DOI: 10.1111/j.1468-1293.2009.00710.x. **Numero di citazioni: 6- I.F. 3.454**
46. Tincati C, Biasin M, Bandera A, Violin M, **Marchetti G**, Piacentini L, Vago GL, Balotta C, Moroni M, Franzetti F, Clerici M, Gori A. Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection. *Antiviral Therapy* 2009;14(3):321-30. **Numero di citazioni: 19- I.F. 3.143**
47. Tincati C, Bellistrì GM, Casana M, Merlini E, Comi L, Bai F, Sinigaglia E, Cristina M, Carpani G, Bini T, d'Arminio Monforte A and **Marchetti G**. CD8+ Hyperactivation and Senescence Correlate with Early Carotid Intima-Media Thickness in HIV+ Patients with No Cardiovascular Disease. *JAIDS-J Acquir Immune Defic Syndr*. Aug 15 2009;51(5):642-4. **Numero di citazioni: 7- I.F. 4.394**
48. Tincati C, d'Arminio Monforte A, **Marchetti G**. Immunological mechanisms of interleukin-2 (IL-2) treatment in HIV/AIDS disease. *Curr Mol Pharmacol*. Jan 2009;2(1):40-5. **Numero di citazioni: 2**
49. **Marchetti G**, Gazzola L, Trabattoni D, Bai F, Ancona G, Ferraris L, Meroni L, Galli M, Clerici M, Gori A, and d'Arminio Monforte A. Skewed T-Cell Maturation and Function in HIV-Infected Patients Failing CD4+ Recovery upon Long-Term Virologically-Suppressive HAART. *AIDS* June 19 2010, 24(10):1455-1460. **Numero di citazioni: 13- I.F. 5.778**
50. Gazzola L, Comi L, Savoldi A, Tagliabue L, Del Sole A, Pietrogrande L, Bini T, d'Arminio Monforte A, and **Marchetti G**. Use of the FRAX Equation as First-Line Screening of Bone Metabolism Alteration in the HIV-Infected Population. *Journal of Infectious Diseases* Jul 15 2010;202(2):330-331. DOI: 10.1086/653584. **Numero di citazioni: 8- I.F. 5.778**
51. Alessandra Bandera, Giulio Ferrario, Marina Saresella, Ivana Marventano, Alessandro Soria, Fabio Zanini, Francesca Sabbatini, Monica Airoidi, **Giulia Marchetti**, Fabio Franzetti, Daria Trabattoni, Mario Clerici, Andrea Gori. CD4+ T Cell Depletion, Immune Activation and Increased Production of Regulatory T cells in the Thymus of HIV-infected Individuals. *PLOS One* May 24 2010;5(5):e10788. DOI: 10.1371/journal.pone.0010788. **Numero di citazioni: 16- I.F. 3.534**
52. Miriam Cesari, Monica Schiavini, **Giulia Marchetti**, Iliara Caramma, Massimiliano Ortu, Fabio Franzetti, Massimo Galli, Spinello Antinori, and Laura Milazzo. Noncirrhotic Portal Hypertension in HIV-Infected Patients: A Case Control Evaluation and Review of the Literature. *AIDS Patient Care and STDS*. Nov 2010;24(11): 697-703. DOI: 10.1089/apc.2010.0160. **Numero di citazioni: 9- I.F. 3.576**
53. Francesca Bai, Giusi Maria Bellistrì, Camilla Tincati, Alessia Savoldi, Alessandro Pandolfo, Teresa Bini, Giovanni Carpani, Elisabetta Sinigaglia, **Giulia Marchetti**, and Antonella d'Arminio Monforte. Reduced CD127 expression on peripheral CD4+ T cells impairs immunological recovery in course of suppressive highly active antiretroviral therapy. *AIDS* Oct 23 2010, 24:2590-2593. DOI: 10.1097/QAD.0b013e32833f9d64. **Numero di citazioni: 9- I.F. 6.557**

54. Francesca Sabbatini, Alessandra Bandera, Giulio Ferrario, Daria Trabattoni, **Giulia Marchetti**, Fabio Franzetti, Mario Clerici and Andrea Gori. Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients. PLOS One Nov 29 2010 ;5(11):e14119. DOI: 10.1371/journal.pone.0014119 **Numero di citazioni: 8- I.F. 3.534**
55. Giusi Maria Bellistri, Anna Casabianca, Esther Merlini, Chiara Orlandi, Giulio Ferrario, Luca Meroni, Massimo Galli, Mauro Magnani, Antonella d'Arminio Monforte, **and Giulia Marchetti**. Increased Bone Marrow Interleukin-7 (IL-7)/IL-7R Levels but Reduced IL-7 Responsiveness in HIV-Positive Patients Lacking CD4+ Gain on Antiviral Therapy. PLoS One. Dec 31 2010;5(12):e15663. DOI: 10.1371/journal.pone.0015663. **Numero di citazioni: 7- I.F. 3.534**
56. Paola Cicconi, Teresa Bini, Alessandra Barassi, Maddalena Casana, Olivia Turri, Francesca Pateri, **Giulia C. Marchetti**, Maria Luisa Biondi, Gianlodovico Melzi d'Eril, Antonella d'Arminio Monforte. Detrimental effect of Atazanavir plasma concentrations on total serum bilirubin levels in the presence of UGT1A1 polymorphisms. JAIDS-J Acquir Immune Defic Syndr. Mar 1 2011;56(3):e96-7. DOI: 10.1097/QAI.0b013e318203e7e7. **Numero di citazioni: 1- I.F. 4.394**
57. Esther Merlini, Francesca Bai, Giusi Maria Bellistri, Camilla Tincati, Antonella d'Arminio Monforte, and **Giulia Marchetti**. Evidence for Polymicrobial Flora Translocating in Peripheral Blood of HIV-infected Patients with Poor Immune Response to Antiretroviral Therapy. PLoS One. Apr 11 2011;6(4):e18580. DOI: 10.1371/journal.pone.0018580. **Numero di citazioni: 28- I.F. 3.534**
58. Esther Merlini, Giusi Maria Bellistri, Camilla Tincati, Antonella d'Arminio Monforte, **Giulia Marchetti**. Sequencing of bacterial microflora in peripheral blood: our experience with HIV-infected patients. J Vis Exp: JOVE. Jun 11 2011;(52). pii: 2830. doi: 10.3791/2830. **Numero di citazioni: 0**
59. **Giulia Marchetti**, Alessandro Cozzi-Lepri, Esther Merlini, Giusi Maria Bellistri, Antonella Castagna, Massimo Galli, Gabriella Verucchi, Andrea Antinori, Andrea Costantini, Andrea Giacometti, Antonino Di Caro, and Antonella d'Arminio Monforte for the Icona Foundation Study Group. Microbial Translocation Predicts Disease Progression of HIV-Infected Antiretroviral-Naive Patients with High CD4(+) Cell Count. AIDS. Jul 17 2011;25(11):1385-94. DOI: 10.1097/QAD.0b013e3283471d10. **Numero di citazioni: 56- I.F. 6.557**
60. Francesca Bai, Camilla Tincati, Esther Merlini, Carlotta Pacioni, Elisabetta Sinigaglia, Giovanni Carpani, Antonella D'Arminio Monforte and **Giulia Marchetti**. Reduced Central Memory CD4+ T Cells and Increased T cell Activation Characterise Treatment-Naive Patients Newly Diagnosed at Late Stage of HIV Infection. AIDS Research and Treatment. 2012 vol. 2012, Article ID 314849, 10 pages, 2012. doi:10.1155/2012/314849. **Numero di citazioni: 0**
61. Antonella D'Arminio Monforte, Andrea Antinori, Enrico Girardi, Francesca Ceccherini-Silberstein, **Giulia Marchetti**, Caroline Anne Sabin, and Julio S. Montaner. HIV-Infected Late Presenter Patients. AIDS Research and Treatment. Volume 2012 (2012), Article ID 902679, 2 pages- doi:10.1155/2012/902679. **Numero di citazioni: 0**
62. Camilla Tincati, Giusi Maria Bellistri, Giuseppe Ancona, Esther Merlini, Antonella D'Arminio Monforte and **Giulia Marchetti**. Role of in vitro Stimulation with Lipopolysaccharide on T-Cell Activation in HIV-Infected Antiretroviral-Treated

Patients. Clin Dev Immunol. 2012; 935425. Epub 2012 Feb 15. doi:10.1155/2012/935425 **Numero di citazioni: 0- I.F. 2.934**

63. **Giulia Marchetti**, Paola Nasta, Francesca Bai, Francesca Gatti, Giusi Maria Bellistrì, Camilla Tincati, Federica Borghi, Giampiero Carosi, Massimo Puoti and Antonella d'Arminio Monforte. Circulating sCD14 is Associated with Virological Response to Pegylated-Interferon-Alpha/Ribavirin Treatment in HIV/HCV Co-infected Patients. PLoS One. Feb 21 2012;7(2):e32028. Epub 2012. DOI: 10.1371/journal.pone.0032028. **Numero di citazioni: 13- I.F. 3.534**
64. **Giulia Marchetti**, Esther Merlini, Elisabetta Sinigaglia, Nathalie Iannotti, Francesca Bai, Alessia Savoldi, Camilla Tincati, Giovanni Carpani, Teresa Bini and Antonella d'Arminio Monforte. Immune Reconstitution in HIV+ Subjects on Lopinavir/ritonavir-based HAART According to The Severity of Pre-Therapy CD4+. Curr HIV Res. Oct 2012;10(7): 597-605. **Numero di citazioni: 1- I.F. 2.135**
65. Esther Merlini, Kety Luzi, Elisa Suardi, Alessandra Barassi, Maddalena Cerrone, Javier Sanchez Martinez, Francesca Bai, Gian Vico Melzi D'Eril, Antonella d'Arminio Monforte, and **Giulia Marchetti**. T-Cell Phenotypes, Apoptosis and Inflammation in HIV+ Patients on Virologically Effective cART with Early Atherosclerosis. PLoS One. Sep 27 2012;7(9):e46073. doi: 10.1371/journal.pone.0046073. **Numero di citazioni: 11- I.F. 4.411**
66. **Giulia Marchetti**, Camilla Tincati, Guido Silvestri. Microbial Translocation in the Pathogenesis of HIV Infection and AIDS. Clin Microbiol Rev. Jan 2013;26(1):2-18. doi: 10.1128/CMR.00050-12. **Numero di citazioni: 22- I.F. 16**
67. Lidia Gazzola, Giusi Maria Bellistrì, Camilla Tincati, Valentina Ierardi, Alessia Savoldi, Angelo Del Sole, Luca Tagliabue, Antonella d'Arminio Monforte, and **Giulia Marchetti**. Association between Peripheral T-Lymphocyte Activation and Impaired Bone Mineral Density in HIV-Infected Patients. Journal of Translational Medicine. Feb 28 2013, 11:51. DOI: 10.1186/1479-5876-11-51. **Numero di citazioni: 8- I.F. 3.991**
68. **Giulia Marchetti**, Laura Comi, Teresa Bini, Marco Rovati, Francesca Bai, Barbara Cassani, Marina Ravizza, Marco Tarozzi, Alessandro Pandolfo, Serena Dalzero, Enrico Opocher, S. Romagnoli, Antonio Carrassi, Silvano Bosari and Antonella d'Arminio Monforte. HPV infection in a cohort of HIV-positive men and women: prevalence of oncogenic genotypes and predictors of mucosal damage at genital and oral sites. Journal of Sexually Transmitted Diseases 2013, vol. 2013, Article ID 915169, 8 pages, 2013. doi:10.1155/2013/915169.
69. Lapadula G, Cozzi-Lepri A, **Marchetti G**, Antinori A, Chiodera A, Nicastri E, Parruti G, Galli M, Gori A, Monforte Ad; ICONA Foundation Study. Risk of clinical progression among patients with blunted immune-response despite virological suppression after combination antiretroviral treatment. AIDS. Mar 13 2013;27(5):769-79. doi: 10.1097/QAD.0b013e32835cb747. **Numero di citazioni: 4- I.F. 6.557**
70. Guaraldi G, Luzi K, Bellistrì GM, Zona S, Domingues da Silva AR, Bai F, Garlassi E, **Marchetti G**, Capeau J, Monforte Ad. CD8 T-Cell Activation is Associated With Lypodystrophy and Visceral Fat Accumulation in Antiretroviral Therapy-Treated Virologically Suppressed HIV-Infected Patients. JAIDS- J Acquir Immune Defic Syndr. Dec 1 2013;64(4):360-6. **Numero di citazioni: 4- I.F. 4.394**
71. Stefano Rusconi, Paola Vitiello, Fulvio Adorni, Elisa Colella, Emanuele Focà, Amedeo Capetti, Paola Meraviglia, Clara Abeli, Stefano Bonora, Marco

- D'Annunzio, Antonio Di Biagio, Massimo Di Pietro, Luca Butini, Giancarlo Orofino, Manuela Colafigli, Gabriella d'Ettore, Daniela Francisci, Giustino Parruti, Alessandro Soria, Anna Rita Buonomini, Chiara Tommasi, Silvia Mosti, Francesca Bai, Silvia Di Nardo Stuppino, Manuela Morosi, Marco Montano, Pamela Tau, Esther Merlini, **Giulia Marchetti**. Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial. PLOSOne November 14 2013; Volume 8 Issue 11: e80157. DOI: 10.1371/journal.pone.0080157. **Numero di citazioni: 2- I.F. 3.534**
72. Antonella d'Arminio Monforte, Valentina Svicher, Silvia Nozza, Adriano Lazzarin, **Giulia Marchetti**, Carlo-Federico Perno. Highlights on HIV Eradication in 2013. AIDS Jan 2 2014;28(1):1-7. doi: 10.1097/01.aids.0000433241.78739.79. **Numero di citazioni: 0- I.F. 6.557**
73. **Giulia Marchetti**, Alessandro Cozzi-Lepri, Camilla Tincati, Andrea Calcagno, Francesca Ceccherini Silberstein, Andrea De Luca, Andrea Antinori, Antonella Castagna, Massimo Puoti, and Antonella d'Arminio Monforte for the Icona Foundation Study Group. Immune Activation and Microbial Translocation in Liver Disease Progression in HIV/Hepatitis Co-infected Patients: Results from the Icona Foundation Study. BMC Infect Dis. Feb 12 2014;14:79. doi: 10.1186/1471-2334-14-79. **Numero di citazioni: 0- I.F. 2.561**
74. Gazzola L, Cicconi P, Ripamonti D, Di Filippo E, Gustinetti G, Di Biagio A, **Marchetti G**, Bini T, d'Arminio Monforte A. Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience. HIV Clin Trials. 2014 Jul-Aug;15(4):140-50. doi: 10.1310/hct1504-140. **Numero di citazioni: 0- IF 2.141**
75. Lichtner M, Cicconi P, Vita S, Cozzi-Lepri A, Galli M, Lo Caputo S, Saracino A, De Luca A, Moioli M, Maggiolo F, **Marchetti G**, Vullo V, d'Arminio Monforte A; for the ICONA Foundation Study. Cytomegalovirus Coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. J Infect Dis. Jul 31 2014. pii: jiu417. [Epub ahead of print]. **Numero di citazioni: 0- I.F. 5.778**
76. Camilla Tincati, Matteo Basilissi, Elisabetta Sinigaglia, Esther Merlini, Giovanni Carpani, Antonella d'Arminio Monforte, **and Giulia Marchetti**. Invariant Natural Killer T (iNKT) Cells in HAART-Treated, HIV-Positive Patients with Bone and Cardiovascular Impairment. PLoS One. 2014 Oct 17;9(10):e110287. doi: 10.1371/journal.pone.0110287
77. E. Stefania Cannizzo, Giusi M. Bellistrì, Anna Casabianca, Camilla Tincati, Nathalie Iannotti, Ambra Barco, Chiara Orlandi, Antonella d'Arminio Monforte **and Giulia Marchetti**. Immunophenotype and function of CD38-expressing CD4⁺ and CD8⁺ T-cells in HIV-infected patients undergoing suppressive cART. J Infect Dis. 2015 May1;211(9): 1511-3. doi: 10.1093/infdis/jiu634.
78. Cristina Mussini, Patrizia Lorenzini, Alessandro Cozzi-Lepri, Giuseppe Lapadula, **Giulia Marchetti**, Emanuele Nicastrì, Antonella Cingolani, Miriam Lichtner, Andrea Antinori, Andrea Gori, Antonella d'Arminio Monforte for the Icona Foundation Study Group. Incidence of CD4/CD8 ratio normalization and its role in the onset of non-AIDS related events in HIV-infected individuals achieving viral load suppression on cART: an observational cohort study. The Lancet HIV 2015 Vol. 2, No. 3, e98–e106.
79. Lidia Gazzola, Alessia Savoldi, Francesca Bai, Alberto Magenta, Michal Dziubak, Luca Pietrogrande, Luca Tagliabue, Angelo Del Sole, Teresa Bini, **Giulia**

Marchetti, Antonella d'Arminio Monforte. Assessment of Radiological Vertebral Fractures in HIV-Infected Patients: Clinical Implications and Predictive Factors. HIV Medicine 2015 May 6 doi: 10.1111/hiv.12267. [Epub ahead of print]

80. Camilla Tincati, Alessia Savoldi, E. Stefania Cannizzo, Giusi M. Bellistri, Roberta Termini, Marzia Garau, Daniela Mancusi, Antonella d'Arminio Monforte **and Giulia Marchetti**. T-cell Phenotype and Function Following a First cART Regimen Containing either a Protease Inhibitor or a Non-Nucleoside Retrotranscriptase Inhibitor in HIV-Infected Late Presenters: Results from a Retrospective, *Ex Vivo* Study. Antivir Ther 2015 Sep 10. doi: 10.3851/IMP2990. [Epub ahead of print]
81. Camilla Tincati, Esther Merlini, Paola Braidotti, Giuseppe Ancona, Federica Savi, Delfina Tosi, Elisa Borghi, Maria Luisa Callegari, Benedetto Mangiavillano, Alessandra Barassi, Gaetano Bulfamante, Antonella d'Arminio Monforte, Solange Romagnoli, Nicolas Chomont **and Giulia Marchetti**. Impaired Gut Junctional Complexes Feature Late-Treated Individuals with Suboptimal CD4+ T-Cell Recovery upon Virologically-Suppressive cART. AIDS. 2016 Apr 24;30(7):991-1003. doi: 10.1097/QAD.0000000000001015
82. Camilla Tincati, Daniel Cesar Douek, **Giulia Marchetti**. Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection. AIDS Res Ther. 2016 Apr 11;13:19. doi: 10.1186/s12981-016-0103-1
83. Camilla Tincati, Veronica Rainone, Laura Comi, Alessandro Pandolfo, Ambra Barco, Giusi M. Bellistri, Marco Rovati, Antonella d'Arminio Monforte, Daria Trabattoni **and Giulia Marchetti**. Cell-Mediated Immunity in HIV-Infected Males with HPV-Related Anal Dysplastic Lesions. Clin Infect Dis. 2016 Nov 15;63(10):1396-1398. Epub 2016 Aug 30.
84. S. Vita, M. Lichtner, **G. Marchetti**, C. Mascia, E. Merlini, P. Cicconi, V. Vullo, P. Viale, A. Costantini, A. D'Arminio Monforte, ICONA Foundation Study Group. Soluble CD163 in CMV Infected and Uninfected subjects on Virologically-Suppressive Antiretroviral therapy in the ICONA cohort. J. Acquir Immune Defic Syndr. 2016 Nov 4. [Epub ahead of print].
85. F. Bai, F. Iannuzzi, E. Merlini, L. Borghi, C. Tincati, M. Trunfio, T. Bini, A. d'Arminio Monforte and **G. Marchetti**. Clinical and viro-immunological correlates of HIV Associated Neurocognitive Disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients. AIDS. 2017 Jan 14;31(2):311-314. doi: 10.1097/QAD.0000000000001346.
86. Merlini E, Tincati C, Biasin M, Saulle I, Cazzaniga FA, d'Arminio Monforte A, Cappione AJ 3rd, Snyder-Cappione J, Clerici M, **Marchetti GC**. Stimulation of PBMC and Monocyte-Derived Macrophages *via* Toll-Like Receptor Activates Innate Immune Pathways in HIV-Infected Patients on Virologically Suppressive Combination Antiretroviral Therapy. Front Immunol. 2016 Dec 19;7:614. doi: 10.3389/fimmu.2016.00614.
87. F. Iannuzzi, F. Bai, L. Borghi, M. Trunfio, E. Vegni, A. d'Arminio Monforte, **G. Marchetti**. Cognitive Neuro-Rehabilitation of HIV-Associated Neurocognitive Disorders: Case Reports of A New Computer-Based Restorative Approach In 3 HIV-Positive Cart-Treated Patients. JOURNAL OF NEUROPHYSIOLOGY AND NEUROLOGICAL DISORDERS. - ISSN 2375-2491. - 3(2016 Nov 22), pp. 1-5.
88. Volpe M, Uglietti A, Castagna A, Mussini C, **Marchetti G**, Bellagamba R, Bini T, Mancusi D, Termini R. [Cardiovascular disease in women with HIV-1 infection](#). Int J

89. Valentina Svicher, **Giulia Marchetti**, Adrianna Ammassari, Francesca Ceccherini-Silberstein and Loredana Sarmati for the Impact Study Group. Novelty in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success? *AIDS Reviews AIDS Rev.* 2017 Oct-Dec;19(3):119-133.
90. Gianotti N, **Marchetti G**, Antinori A, Saracino A, Gori A, Rizzardini G, Lichtner M, Bandera A, Mussini C, Girardi E, Monforte AD, Cozzi-Lepri A; ICONA Foundation Study Group. [Drop in CD4+ counts below 200 cells/μL after reaching \(or starting from\) values higher than 350 cells/μL in HIV-infected patients with virological suppression.](#) *J Acquir Immune Defic Syndr.* 2017 Dec 1;76(4):417-422. doi: 10.1097/QAI.0000000000001522.
91. Di Biagio A, Lorenzini P, Gustinetti G, Rusconi S, De Luca A, Lapadula G, Lo Caputo S, Cicalini S, Castelli F, **Marchetti G**, Antinori A, Monforte AD. Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation. *AIDS Patient Care STDS.* 2017 Dec;31(12):487-494. doi: 10.1089/apc.2017.0140.
92. Nozza S, Cozzi-Lepri A, Bai F, Rusconi S, Gori A, Cinque P, Ammassari A, Caramello P, Tambussi G, D'Arminio Monforte A, **Marchetti G**; Icona Foundation Study Group. Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort. *PLoS One.* 2017 Dec 5;12(12):e0189045. doi: 10.1371/journal.pone.0189045. eCollection 2017.
93. Cannizzo ES, Tincati C, Binda F, Ronzi P, Cazzaniga FA, Antinori S, d'Arminio Monforte A, **Marchetti G**, Milazzo L. Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy: a randomized study. *J Viral Hepat.* 2017 Nov 1. doi: 10.1111/jvh.12820. [Epub ahead of print]
94. Stéphane Hua, Selena Vigano, Samantha Tse, Ouyang Zhengyu, Sean Harrington, Jordi Negron, Pilar Garcia-Broncano, **Giulia Marchetti**, Manuel Leal, Salvador Resino, Ezequiel Ruiz-Mateos, Mathias Lichterfeld, Xu G. Yu. Pegylated IFN- α -induced NK cell activation is associated with HIV-1 DNA decline in ART-treated HIV-1/HCV co-infected patients. *Clin Infect Dis.* 2017 Dec 20. doi: 10.1093/cid/cix1111. [Epub ahead of print].
95. Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation. A. Di Biagio, P. Lorenzini, G. Gustinetti, S. Rusconi, A. De Luca, G. Lapadula, S. Lo Caputo, S. Cicalini, F. Castelli, **G. Marchetti**, A. Antinori, M. Antonella D'Arminio. - AIDS PATIENT CARE AND STDS. - ISSN 1087-2914. - 31:12(2017 Dec), pp. 487-494.
96. Tincati C, Merlini E, d'Arminio Monforte A, **Marchetti G**. Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature. *BMC Infect Dis.* 2018 Jan 5;18(1):8. doi: 10.1186/s12879-017-2942-3. PubMed PMID: 29304776; PubMed Central PMCID: PMC5755455.
97. Esther Merlini, Laura Galli, Camilla Tincati, Elvira S Cannizzo, Andrea Galli, Nicola Gianotti, Giuseppe Ancona, Camilla Muccini, Antonella d'Arminio

Monforte, **Giulia Marchetti***, and Antonella Castagna, for the MODAt study group. Immune Activation, Inflammation and HIV-DNA after 96-week of ATV/r monotherapy: a MODAt substudy. *Antivir Ther.* 2018;23(7):633-637. doi: 10.3851/IMP3234.

98. Mussini C, Lorenzini P, Cozzi-Lepri A, **Marchetti G**, Rusconi S, Gori A, Nozza S, Lichtner M, Antinori A, Cossarizza A, d'Arminio Monforte A; Icona Foundation Study Group. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. *BMC Med.* 2018 May 29;16(1):79. doi: 10.1186/s12916-018-1046-2.
99. Merlini E, Iannuzzi F, Calcagno A, Bai F, Trunfio M, d'Arminio Monforte A, Bonora S and **Marchetti G** Peripheral and Cerebrospinal Fluid Immune Activation and Inflammation in Chronically HIV-Infected Patients Before and After Virologically-Suppressive Combination Antiretroviral Therapy (cART). *Journal of NeuroVirology* 2018 . Jul 9. doi: 10.1007/s13365-018-0661-1. [Epub ahead of print]
100. Tincati C, Ancona G, **Marchetti G**. The fecal microbiome directly drives immune activation in HIV infection. *Ann Transl Med.* 2018 Nov;6 (Suppl 1):S45. doi: 10.21037/atm.2018.09.66.
101. Dentone C, Di Biagio A, Cozzi Lepri A, Fenoglio D, Filaci G, Lichtner M, Carrara S, Giacometti A, Sighinolfi L, **Marchetti G**, Antinori A, D'Arminio Monforte A; ICONA Foundation Study Group. Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naive, HIV-1 infected patients. *HIV Clin Trials.* 2018 Aug;19(4):158-162. doi: 10.1080/15284336.2018.1488453. Epub 2018 Nov 13. PMID:30422095
102. Ceccherini-Silberstein F, Cozzi Lepri A, Alteri C, Merlini E, Surdo M, **Marchetti G**, Capobianchi MR, De Luca A, Gianotti N, Viale P, Andreoni M, Antinori A, Perno CF, d'Arminio Monforte A; ICONA Foundation Study Group. Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. *J Antimicrob Chemother.* 2018 Dec 1;73(12):3460-3470. doi: 10.1093/jac/dky350. PMID: 30247724
103. Basilissi M, Tincati C, Merlini E, Ancona G, Borghi E, Borgo F, Barassi A, d'Arminio Monforte A, and **Marchetti G**. Mucosal Cell Populations May Contribute to Peripheral Immune Abnormalities in HIV-Infected Subjects Introducing cART with Moderate Immune-Suppression. *PLoS One.* 2019 Feb 14;14(2):e0212075. doi: 10.1371/journal.pone.0212075. eCollection 2019. PMID: 30763359
104. Cannizzo ES, Cerrone M, Merlini E, van Wilgenburg B, Swandling L, Ancona G, De Bona A, d'Arminio Monforte A, Klenerman, P, and **Marchetti G**. Successful direct-acting antiviral therapy (DAA) in HIV/HCV co-infected patients fails to restore circulating mucosal-associated invariant T-cells. *European Journal of immunology* 2019. **IF 5,179**
105. T-Cell Subsets (T_{CM}, T_{EM}, T_{EMRA}) and Poly-Functional Immune Response in patients with different T-CD4 cell response” has been accepted for publication in the *Annals of Clinical & Laboratory Science*. The paper will be published in volume 49, # 4, 2019 (July-August Issue). *Annals of Clinical & Laboratory Science* 2019
106. Antinori A, Santoro MM, Gagliardini R, **Marchetti G**, Mondì A, Cento V, Perno CF, Andreoni M; Two-Drug Antiretroviral Regimens expert panel. Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naive and virologically suppressed HIV-1 infected patients. *New Microbiol.* 2019 Feb 20;42(1). [Epub ahead of print] PMID:30785209

107. d'Arminio Monforte A, Cozzi-Lepri A, Di Biagio A, **Marchetti G**, Lo Caputo S, Rusconi S, Gianotti N, Mazzotta V, Mazzarello G, Costantini A, Castagna A, Antinori A; ICONA Foundation Study Group. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. J Antimicrob Chemother. 2019 Jan 29. doi: 10.1093/jac/dky566. [Epub ahead of print] PMID: 30698801
108. Mondì A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, **Marchetti G**, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. J Int AIDS Soc. 2019 Jan;22(1):e25227. doi: 10.1002/jia2.25227. PMID: 30663278
109. Esther Merlini, Federico A Cazzaniga, Anna Casabianca, Chiara Orlandi, Mauro Magnani, Giuseppe Ancona, Camilla Tincati, Antonella d'Arminio Monforte, **Giulia Marchetti**. Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to Integrase Strand Transfer Inhibitor (INSTI)-containing Regimen: Results from an Observational Cohort Study. Clinical Drug Investigation 2019 (in press)

Milano, 05/12/2022 Firma

Quanto dichiarato è conforme alle disposizioni degli artt. 46 e 47 del DPR 445/00; la sottoscritta è a conoscenza che, ai sensi dell'art. 76 del DPR 445/00, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi, sono puniti ai sensi del codice penale e delle leggi speciali.

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art 13 del D Lgs 196/2003 e dell'art 13 GDPR 679/16 ai sensi del D Lgs 101/2018

Milano, 05/12/2022 Firma

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**

INFORMAZIONI PERSONALI

Nome **MAZZITELLI MARIA**

INFORMAZIONI PROFESSIONALI

MEDICO CHIRURGO (n° Iscrizione Ordine dei Medici: VV/1441)

GMC Registration (Full Licence to Practice, United Kingdom) n°7691505

SPECIALISTA IN MALATTIE INFETTIVE E TROPICALI

DIPLOMA NAZIONALE SIUMB DI COMPETENZA IN ECOGRAFIA CLINICA

DOTTORANDA DI RICERCA IN SCIENZE DELLA VITA

CULTORE DELLA MATERIA a.a. 2019/2020 – 2020/2021 (MED17), Università “*Magna Graecia*” di
Catanzaro

ORCID LINK: <https://orcid.org/0000-0003-0263-0703>

INDICI BIBLIOMETRICI al 10.10.2021

- **Google Scholar**
 - Documents: 92
 - H Index: 12
 - Citations: 591
- **Scopus**
 - Documents: 58
 - H Index: 10
 - Citations: 402

ESPERIENZA PROFESSIONALE

- Date (dal 19.04.2021 ad oggi) Dirigente Medico presso U.O. Malattie Infettive e Tropicali Azienda Ospedale Università di Padova
(contratto a tempo indeterminato)
- Date (dal 01.02.2021 ad 12.04.2021) Dirigente Medico presso U.O. Malattie Infettive e Tropicali A.O.U. "Mater Domini" di Catanzaro
(contratto a tempo determinato per mesi 6)
- Date (dal 26.03.2020 al 31.01.2021) Dirigente Medico presso U.O. Malattie Infettive e Tropicali A.O.U. "Mater Domini" di Catanzaro
(contratto Co.Co.Co.)
- Date (dall'11.01.2019 al 21.12.2019) Honorary Contract as Research Physician for clinical and research attachment on the management of HIV/AIDS and sexually transmitted diseases
St Stephen Center
Chelsea and Westminster Hospital NHS Foundation Trust, London (UK)
- Date (da 16.10.2015 – 02.11.2015) Co.Co.Co. Università degli Studi di Catanzaro per lo sviluppo del progetto: "Fellowship program GILEAD 2015 – Supporting Research to advance patient care : Screening, monitoraggio e trattamento delle infezioni croniche virali (HIV, HBV, HCV), nella popolazione migrante afferente ai centri calabresi. Creazione della 'Carta d'Identità sanitaria elettronica' del migrante"
Università degli Studi Magna Graecia di Catanzaro
- Date (da 12.03.15 AL 30.11.2018)
 - Nome e indirizzo del datore di lavoro ASP Vibo Valentia – Distretto di Tropea
 - Tipo di azienda o settore Azienda Sanitaria Provinciale
 - Tipo di impiego Servizio continuità assistenziale, incarichi trime (Postazioni di Mileto, San Calogero, San Costantino di Mileto, Tropea, Vibo Marina, Zungri)
- Date (da 01.10.2014 al 02.11.2015)
- Nome e indirizzo del datore di lavoro Azienda Ospedaliera Universitaria Mater Domini di Catanzaro U.O. Malattie Infettive e Tropicali
 - Tipo di impiego Frequenza volontaria a titolo gratuito
- Date (da 2013 al 2014)** Contratto di collaborazione part-time studenti (150 ore)
Università degli Studi "Magna Graecia" di Catanzaro
Assistenza ai servizi di segreteria didattica
- Date (da 2012 al 2013)** Contratto di collaborazione part-time studenti (150 ore)

	Università degli Studi "Magna Graecia" di Catanzaro Assistenza ai servizi di segreteria didattica
Date (da 2013 al 2015)	Articolista Rivista Universitaria "UMG News" Fondazione UMG di Catanzaro
Date (da 01.10.2010 al 20.07.2014)	Azienda Ospedaliera Universitaria Mater Domini di Catanzaro U.O. di Neurologia
Nome e indirizzo del datore di lavoro	Frequenza volontaria a titolo gratuito
Tipo di impiego	

PROGETTI DI RICERCA

E

STUDI CLINICI

Dicembre 2014 ad oggi: partecipazione a tutte le attività di ricerca in essere presso l'Unità Operativa di Malattie Infettive e Tropicali dell'A.O.U. dell'Azienda Ospedaliero-Universitaria "Mater Domini" di Catanzaro.

Dal 13 Marzo 2015 a Dicembre 2017: autore e co-investigatore studio CARDIAC – Cardiovascular Diseases in Antiviral Treatment for HCV - (PI Prof. Carlo Torti), risultati pubblicati su BMC Infectious diseases, 2018

Dal 21.07.2016 ad oggi: co-investigatore studio CRESO - Studio Osservazionale sul trattamento delle crioglobuline HCV correlate con DAA – Studio multicentrico, PI Centro Catanzaro Prof. Carlo Torti

Dal 21.07.2016 ad oggi: co-investigatore Studio multicentrico "Mantenimento in cura delle persone con infezione da HIV", PI centro Catanzaro Prof. Carlo Torti

Dal 20.07.2017 ad oggi: co-investigatore Studio Multicentrico "Strategie di controllo a lungo termine in pazienti con infezione da HIV primaria (PHI) trattati con terapia multi target (MT-ART) detto INACTION P25" PI centro Catanzaro Prof. Carlo Torti

Da Ottobre 2017 ad oggi: collaboratore (Co-investigatore) progetto PITER (Istituto Superiore di Sanità) per l'U.O. di Malattie Infettive e Tropicali, AOU Mater Domini di Catanzaro (PI Dr. Lorete Kondili).

Da Ottobre 2017 ad oggi: Study coordinator il per protocollo INACTION (Implication for strategies on long term control od viral replication in patient with primary HIV infection treated with multitarget antiviral therapy – Multicenter, parallel group, randomised, open label study) per l'U.O. di Malattie Infettive e Tropicali, AOU Mater Domini di Catanzaro (PI Prof. A. Gori)

Dal 17.05.2018 al 30.09.2019: co-investigatore Studio Multicentrico "Utilizzo di colistina negli Ospedali Italiani: Uno studio Cross-Sectional. Prot. COLI-CROSS", Centro Coordinatore Policlinico Gemelli Roma, PI Centro Catanzaro Prof. Carlo Torti, Submitted (MMazzitelli main authorship).

Dal 19.07.2018 ad oggi: autore del protocollo e co-investigatore Studio Multicentrico "Studio della qualità di vita in una coorte di pazienti HIV positivi in Calabria", PI Prof. Carlo Torti, paper in stesura, first author MMazzitelli

Dal 20.12.2018 ad oggi: autore del protocollo e co-investigatore Studio "Cardiac Diseases in Antiretroviral therapy for HIVinfected patients. Studio CARDIAC-HIV" PI Prof. Carlo Torti

Dal 17.01.2019 ad oggi: co-investigatore Studio "Registro Nazionale Dalbavancina" PI Prof. S.

Esposito, PI centro Catanzaro Prof. Carlo Torti

Da Febbraio 2019 a Dicembre 2019: Sub-investigator studio MASH trial - Maraviroc Add-On Therapy for Steatohepatitis in HIV- The MASH study - (Chelsea and Westminster Hospital, London, UK), PI Prof. Mark Nelson

Da Marzo 2019 a Dicembre 2019: Sub-investigator HEPMARC Study - A phase IV, open-label pilot study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus Maraviroc or OBT - (Chelsea and Westminster Hospital, London, UK), PI Prof. Marc Nelson

Da Aprile 2019 a Dicembre 2019: Co-investigator LAPTOP Study- Late Presenter Treatment Optimisation Study (Chelsea and Westminster Hospital, London, UK), PI Dr. Alessia Dalla Pria

Da Maggio 2019 a Dicembre 2019: Co-investigator TAF Switch Study in HBV/HIV coinfecting patients_- (Chelsea and Westminster Hospital, London, UK), PI Prof. Marc Nelson

Da Maggio 2019 a Dicembre 2019: Sub-PI POPPY Liver Sub Study (PI Dr. Ana Milinkovic)

Dal 3 Ottobre 2019 a Dicembre 2019: Sub-investigator Study DOLOMITE (multisite observational study to define safety and effectiveness of dolutegravir use in HIV positive pregnant women- Phase IV), PI Chelsea and Westminster site: Dr. Ana Milinkovic

Dal 3 Ottobre 2019 a Dicembre 2019: Sub-investigator Study COMBITE-2 (Real world evidence for effectiveness of two drug regimen antiretroviral therapy with integrase inhibitors plus a reverse transcriptase inhibitors – Phase IV) PI Chelsea and Westminster site: Dr. Ana Milinkovic

ALTRE ESPERIENZE

Anno 2020: Reviewer Journal of Medical Virology/PloS One/ BMC infectious Diseases

Associate Editor Rivista Internazionale Indicizzata Journal of Infection in Developing Countries (IF: 1,37)

2020-2021: EACS Mentorship Programme

From 2019: Active in YING, EACS (EACS Young Investigators Group), <https://www.eacsociety.org/education/ying-young-investigators/>

28-30 Novembre 2019: The VOICE program – Munich, Germany

12-13 Settembre 2019: The VOICE program – Munich, Germany

29 Ago- 3 Sett 2019: EACS (European AIDS Clinical Society) Summer School 2019, Research Module - Montpellier, France

13-15 Giugno 2019 - The VOICE program – Lisbon, Portugal (The Voice is a CPD-certified clinical research training programme to help develop future HIV research leaders. The course was run by Prof. Caroline Sabin, UCL, London and Prof. Patrick Mallon, Ireland)

01 Marzo 2019 – Good Clinical Practice Certificate – London, UK

03 Maggio 2018 – EuResist (European Mentor School), Colonia (Germania)

20-24 Ottobre 2017 – American Association for the Study of Liver Diseases (AASLD) –The Liver Meeting, Washington DC (USA)

5-9 Giugno 2017 – Corso Teorico Pratico "Diagnosi di laboratorio delle parassitosi intestinali ed organo sistemiche", Corso AMCLI Ospedale Sacco, Milano

6-10 Marzo 2017 – Corso di Statistica Medica e utilizzo del programma Epi Info (Prof. F. Donato), Università degli Studi di Brescia

2-6 Maggio 2016- Harvard Medical School “Infectious Diseases in Adults”, Boston (USA)

21 Novembre 2015- Antimicrobial Stewardship: improving clinical outcome by optimization of antibiotic practices – Stanford University (ACCME)

1- 30 Settembre 2014 : Professional Exchange presso il General Hospital di Alessandropoli (Grecia), U.O. di Malattie Infettive

3- 27 Agosto 2014 Periodo di tirocinio formativo /volontariato presso il Mulago Hospital (Makerere University) Kampala, Uganda

Aprile 2013 – Periodo Formativo di Tirocinio presso Università degli Studi di Ferrara (Ospedale di Cona), Dipartimento di Scienze Neurologiche

- Partecipazione negli anni ad oltre 70 eventi congressuali del campo medico-scientifico
- Agosto 2014- Marzo 2021: Attività di volontariato presso centro di accoglienza per migranti “Jungi Mundi”, Camini, Reggio Calabria
- 2017-2021: Attività di partecipazione e organizzazione eventi scientifici dell’associazione AIDM (Associazione Italiana Donne Medico) sede di Vibo Valentia (VV)

ISTRUZIONE E FORMAZIONE

Data (dal 11.01.2019 ad 31.12.2019)	Honorary Contract as Honorary Research Physician for clinical and research attachment on the management of HIV/AIDS and sexually transmitted diseases Chelsea and Westminster Hospital NHS Foundation Trust, London (UK)
Data (dal 10.12.2018 ad oggi)	Dottoranda in Scienze della vita, Dipartimento di Scienze della Salute, XXXIV Ciclo, Università degli Studi Magna Graecia di Catanzaro
14.03.2018	Diploma Nazionale SIUMB di Competenza in Ecografia Clinica
Data (dal 20.02.17 al 30.06.2017)	Stage clinico presso 2 ^a Divisione, Unità operativa Malattie Infettive e Tropicali, Azienda Ospedaliera Universitaria, Spedali Civili di Brescia – (Direttore Prof. F. Castelli)
Data (dal 20.02.17 al 30.06.2017)	Corso pratico ecografia clinica e interventistica 2 ^a Divisione, Unità operativa Malattie Infettive e Tropicali, Azienda Ospedaliera Universitaria, Spedali Civili di Brescia – (Medico Certificatore Dott. Luciano Biasi, Direttore Prof. F. Castelli)
Data (dal 21.10.16 al 17.02.2017)	Tirocinio formativo in “Diagnostica Ecografica” presso U.O. Epatologia Azienda Ospedaliera Universitaria “Mater Domini” di Catanzaro – (Direttore Dott. M. De Siena)
Data (dal 02.11.15 al 11.01.2019)	Tirocinio formativo ambulatorio multidisciplinare “Malattie Infettive in Gravidanza” presso U.O.

Data (dal 02.11.15 al 04.11.2019)

Nome istituto di istruzione

Università degli Studi di Messina

Qualifica

Scuola di Specializzazione in Malattie Infettive e Tropicali

Specialista in Malattie Infettive e Tropicali, titolo conseguito con votazione di 50/50 e lode con tesi sperimentale elaborata presso il Chelsea and Westminster Hospital (Londra, UK) dal titolo:

Agreement analysis between traditional cardiovascular risk predictors and coronary artery calcium computer tomography score in a cohort of people living with HIV over 50 years of age as implementation basis for new pathway of care at Chelsea and Westminster Hospital Foundation Trust (London, UK)

• 23.07.2014

Università degli Studi Magna Graecia di Catanzaro

• Qualifica conseguita

Laurea in Medicina e Chirurgia con tesi dal titolo "Studio epidemiologico, prospettico e di neuroimmagini in pazienti sani ed epilettici con déjà vu"

• Livello /Votazione

110/110 e lode

Dal 29.08.2019 ad oggi

Iscrizione General Medical Council (**GMC**) con full registration all'esercizio della professione medica nel Regno Unito – n°7691505

Dal 25.02.2015 ad oggi

Iscrizione ordine dei Medici Chirurghi all'Ordine dei Medici Chirurghi di Vibo Valentia (n° 1441/vv)

Data 17.02.2015

Abilitazione all'esercizio della professione di Medico Chirurgo

Data 19-20 Dicembre 2014

Borsa di Studio GIMBE4YOUNG "Evidence-Based Practice"

15-16 Gennaio 2015

Conseguimento EBP core curriculum (certificato da GIMBE e da European EBM Unity Project)

Data 18 Luglio 2014

Corso di Formazione Medicina dei Disastri (Basic Disaster)

CRIMEDIM (Centro di Ricerca Interdipartimentale in Medicina di Emergenza e dei Disastri e di Informatica applicata alla didattica e alla pratica Medica) di Novara

Data 24 Marzo 2014

Corso di Formazione BLS – Rianimazione Cardiopolmonare con uso del Defibrillatore Semiautomatico Esterno

Fondazione

UMG di Catanzaro - Centro Simulazione Università Magna Graecia di Catanzaro

Date (da 01.10. 2012 a 01.07.2014)

Internato presso l'U.O. di Neurologia dell'A.O.U. Mater Domini di Catanzaro

Pubblicazioni: articoli (Main authorship)

1. Estiri H, Strasser ZH, Brat GA, Semenov YR; Consortium for Characterization of COVID-19 by EHR (4CE): **Evolving phenotypes of non-hospitalized patients that indicate long COVID**. BMC Medicine, 2021. doi: 10.1186/s12916-021-02115-0.
2. Mazzitelli M, Pereira IB, Muramatsu T, Chriwa M, Mandalia S, Moyle G, Boffito M, Milinkovic M: **FRAX assessments in people ageing with HIV**. HIV Medicine, 2021. doi: 10.1111/hiv.13170.
3. Mazzitelli M, Pereira IB, Moyle G, Asboe D, Pozniak A, Boffito A, Milinkovic A. **Factors associated with overweight/obesity in a cohort of people living with HIV over 50 years of age**. AIDS Care, 2021 (in press)
4. Fabbiani M, Rossetti B, Ciccullo A, Oreni L, Lagi F, Celani L, Colafigli M, De Vito A, Mazzitelli M, Dusina A, Durante M, Montagnani F, Rusconi S, Capetti A, Sterrantino G, D'Ettorre G, Di Giambenedetto A, ODOACRE Group. **Efficacy and durability of two vs. three drug integrase inhibitor-based regimens in virologically suppressed HIV-Infected patients: data from real-life ODOACRE Cohort**. HIV Medicine, 2021, doi: 10.1111/hiv.13146.
5. Pereira B, Mazzitelli M, Milinkovic A, Casley C, Rubio H, Channa R, Girometti N, Asboe D, Pozniak A, Boffito M. **Evaluation of a clinic dedicated to people aging with HIV at Chelsea and Westminster Hospital: results from a 10-year experience**. AIDS Research and Human Retroviruses. "021. Doi: 10.1089/AID.2021.0083.
6. Mazzitelli M, Sasset Lolita, Marinello Serena, Trevenzoli M, Cattelan AM. **What is behind a strange encephalitis?** Gastroenterology open access open journal, 2021. Doi:10.33169/gastro.GOAOJ-2-110.
7. Mazzitelli M, Dastoli S, Mignogna C, Bennardo L, Lio E, Pelle MC, Trecarichi EM, Pereira BI, Nistico SP, Torti C. **Histopathology and immunophenotyping of late onset cutaneous manifestations of COVID-19 in elderly patients: three case reports**. World journal of clinical cases, July 2021 doi: 10.12998/wjcc.v9.i20.5744.
8. Polverino F, Stern DA, Ruocco G, Balestro E, Bassetti M, Candelli M, Cirillo B, Contoli M, Corsico A, D'amico F, D'elia E, Falco G, Gaparini S, Guerra S, Harari S, Kraft M, Mennella L, Papi A, Parrella A, Pelosi P, Poletti V, Polverino M, Tana C, Terribile, Woods JC, Di Marco F, Martinez M, **Comorbidities, cardiovascular Therapies, and COVID-19 Mortality: a nationwide, italian observational Study (ITALICO)**. Frontiers in Cardiovascular Medicine (2020, in press)
9. Ricchio M, Tassone B, Pelle MC, Mazzitelli M, Serapide F, Fusco P, Lionello R, Cancelliere A, Procopio G, Lio E, Trecarichi EM, Torti C, Irace C. **Characteristics, management and outcome of elderly patients with diabetes in a COVID-19 unit: lessons learned from a pilot study**. Medicina (in press)
10. The COVID-19 RISK and Treatment Collaboration: **Lopinavir/ritonavir and darunavir/cobicistat in hospitalised COVID-19 patients: findings from the multicentre Italian CORIST study**. Frontiers in Medicine (In press)
11. Marascio N, Costantino A, Taffon S, Lo Presti A, Equestre M, Bruni R, Pisani G, Barreca GS, Quirino A, Trecarichi EM, Costa C, Mazzitelli M, Serapide S, Matera G, Torti C, Liberto MC, Ciccaglione MR: **Phylogenetic and molecular analyses of more prevalent HCV1b subtype in the Calabria Region, Southern Italy**. JCM (In press)
12. Quaranta MG, Ferrigno L, Tata X, D'Angelo F, Coppola C, Ciancio A, Bruno SR, Loi M, Giorgini A, Margotti M, Cossiga V, Brancaccio G, Dallio M, De Siena M, Cannizzaro M, Cavalletto L, Massari M, Mazzitelli M, De Leo P, Laccabue D, Baiocchi L, Kondili LA. **Liver function following Hepatitis C Virus eradication by Direct Acting Antivirals in patients with liver cirrhosis: data from the PITER cohort**. BMC Infectious Diseases doi: 10.1186/s12879-021-06053-3.
13. Mazzitelli M, Greco G, Serapide S, Scaglione V, Morrone H, Marascio N, Giancotti A, Liberto MC, Matera G, Trecarichi EM, Torti C: **Outcome of HBV screening and vaccination in a cohort of migrant population in Southern Italy**. Le infezioni in Medicina (In press).
14. Torti C, Scaglione V, Cesana BM, Costa C, Marascio N, Schiaroli E, Busti C, Bastianelli S, Mazzitelli M, Trecarichi EM, Francisci D: **Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level**. Health Science Reports, in press
15. The COVID-19 RISK and Treatment Collaboration: **Heparin treatment in COVID-19 patients is associated with**

- reduced in-hospital mortality: findings from the multicentre Italian CORIST Study.** Blood (in press).
16. Tradigo G, Patrizia V, Gabriele G, Mazzitelli M, Torti C, Prosperi M, Guzzi PH, Veltri P: **On the use of clinical based infection data for pandemic case studies.** International Congress on Bioinformatics and Biomedicine, 2020.
 17. Aquila I, Ricci P, Bonetta CF, Sacco MA, Longhini F, Torti C, Mazzitelli M, Garogalo G, Bruni A, Trecarichi EM, Serapide F, Gratteri S, Quirino A, Barreca GS, Abenavoli L, Arena V, Oliva A, Giancotti A, Iavicoli I, Liberto MC, Matera G: **Analysis of the persistence time of the SARS-CoV-2 virus in the cadaver and the risk of passing infection to autopsy staff.** The Medico-Legal Journal, 2021. DOI:[10.1177/0025817220980601](https://doi.org/10.1177/0025817220980601)
 18. Cancelliere A, Procopio G, Mazzitelli M, Lio E, Petullà M, Serapide F, Pelle MC, Davoli C, Trecarichi EM, Torti C: **A case report of pneumomediastinum in a COVID-19 patient treated with high-flow nasal cannula and review of the literature: is this a “spontaneous” complication?** Clinical Case Reports. (In press)
 19. Biamonte F, Botta C, Mazzitelli M, Rotundo S, Trecarichi EM, Foti D, Torti C, Viglietto G, Torella D, Costanzo FS: **Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility.** Journal of Translational Medicine (in press).
 20. Spaccarotella C, Mazzitelli M, Migliarino S, Curcio A, De Rosa S, Torti C, Indolfi C: **The therapy with RAS inhibitors during the COVID-19 pandemic.** J of Cardiovascular Medicine (in press).
 21. Trecarichi EM, Mazzitelli M, Serapide F, Pelle M, Tassone B, Arrighi E, Perri G, Fusco P, Scaglione V, Davoli C, Lionello, La Gamba V, Marrazzo G, Busceti MT, Giudice A, Ricchio M, Cancelliere A, Lio E, Procopio G, Costanzo FS, Foti DP, Matera G, Torti C. **Clinical characteristics and predictors of mortality associated with COVID-19 in elderly patients from a long-term care facility.** 30 Nov 2020. Scientific report. <https://doi.org/10.1038/s41598-020-77641-7>
 22. Pelle MC, Tassone B, Ricchio M, Mazzitelli M, Davoli C, Procopio G, Cancelliere A, La Gamba V, Lio E, Trecarichi EM, Torti C: **Late onset autoimmune haemolytic anaemia and myocardial infarction in a COVID-19 patient without respiratory symptoms, concomitant to a paradoxical increase of inflammatory markers. A case report.** Journal of Clinical Case Report (DOI: 10.1186/s13256-020-02595-3).
 23. Pagano L, Cattaneo C, Quattrone M, Oberti M, Mazzitelli M, Trecarichi EM. **Isavuconazole: animal data and clinical data.** Journal of Fungi (doi.org/10.3390/jof6040209)
 24. COVID-19 Risk and Treatment (CORIST) Collaboration. **Use of Hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: findings from the observational multicentre Italian CORIST study.** European Journal of Internal Medicine. Doi: 10.1016/j.ejim.2020.08.019.
 25. COVID-19 Risk and Treatment (CORIST) Collaboration. **RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.** Vascular Pharmacology (in press).
 26. Manciuoli T, Serraino R, D'Alessandro G, Cattaneo L, Mariconti M, Vola A, Taccari F, Narra R, De Vito G, Trecarichi EM, Mazzitelli M, Matera G, Casulli A, Marascio N, Brunetti E, Tamarozzi F, Torti C. **Evidence of Low Prevalence of Cystic Echinococcosis in the Catanzaro Province, Calabria Region, Italy.** The American Journal of Tropical Medicine, September 2020 doi:[10.4269/ajtmh.20-0119](https://doi.org/10.4269/ajtmh.20-0119)
 27. Procopio G, Cancelliere A, Trecarichi EM, Mazzitelli M, Arrighi E, Perri G, Serapide F, Pelaia C, Lio E, Busceti MT, Pelle MC, Ricchio M, Scaglione V, Davoli C, Fusco P, La Gamba V, Torti C, Pelaia G. **Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by SARS-CoV-2 infection: a real life observational study.** Therapeutic advance in Respiratory Disease (In press)
 28. Ciccullo A, Baldin G, Borghi V, Sterrantino G, Madeddu G, Latini A, D'Ettore G, Lanari A, Mazzitelli M, Colafigli M, Capetti Amedeo F, Oreni L, Lagi F, Rusconi S, Di Giambenedetto S. **Overall tolerability of integrase inhibitors in clinical practice: results from a multicenter Italian cohort.** AIDS Research and Human Retroviruses (In press)
 29. Mazzitelli M, Serapide F, Tassone B, Laganà D, Trecarichi EM, Torti C: **Spontaneous and Severe Haematomas in Patients with COVID-19 on Low- Molecular-Weight Heparin for Paroxysmal Atrial Fibrillation.** Mediterranean J

30. Mazzitelli M, Davoli C, Scaglione V, Fusco P, La Gamba V, Matera G, Trearichi EM, Torti C: **Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19.** Travel Med Infect Dis. 31 July 2020. doi: 10.1016/j.tmaid.2020.101826
31. Torti C, Mazzitelli M, Trearichi EM, Owachi D: **Potential implications of SARS-CoV-2 epidemic in Africa: where are we going from now?** BMC Infectious diseases. 2020 DOI:10.1186/s12879-020-05147-8
32. Chirwa M, Mazzitelli M, Pereira B, Milinkovic A, Mamatsu T, Patel Akhil, Renstrom S, kanani TH, Mandalia S, Boffito M: **Incidental findings in elderly people living with HIV undergoing computed tomography coronary artery calcium scoring.** AIDS. 2020, 33 (in press)
33. Mazzitelli M, Arrighi E, Serapide F, Pelle MC, Tassone B, Lionello R, Marrazzo G, Laganà D, Costanzo FS, Matera G, Trearichi EM, Torti C: **Use of subcutaneous Tocilizumab in patients with COVID-19 pneumonia.** J Med Virol. 2020 May 15. doi: 10.1002/jmv.26016. Online ahead of print.
34. Marascio N, Mazzitelli M, Scarlata GGM, Giancotti A, Barreca GS, Lamberti AG, Divenuto F, Costa C, Trearichi EM, Matera G, Liberto MC, Torti C: **HCV antibody prevalence and genotype evolution in a teaching hospital, calabria region, souther Italy over a decade (2008-2018).** The Open Microbiology Journal, 5 April 2020. DOI: 10.2174/18742858021401
35. Pereira B, Mazzitelli M, Milinkovic A, Moyle G, Ranasinghe A, Mandalia S, Pozniak A, Asboe D, Nelson M, Al hussaini A, Boffito M: **Use of Coronary Artery Calcium Scoring to improve cardiovascular risk stratification and guide decisions to start statin therapy in People living with HIV.** Journal of AIDS (in press)
36. Serraino R, Mazzitelli M, Greco G, Serapide F, Scaglione V, Marascio N, Trearichi EM, Torti C: **Risk factors for hepatitis B and C among healthy population: a community-based survey from four districts of Southern Italy.** Infezioni in Medicina (in press)
37. Scaglione V, Mazzitelli M, Costa C, Pisani V, Greco G, Serapide F, Lionello R, La Gamba V, Marascio M, Trearichi EM, Torti C: **Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy).** Medicina, 28 February 2020. DOI: 10.3390/medicina56030101
38. Marano V, Marascio N, Pavia G, Lamberti AG, Quirino A, Musarella R, Casalnuovo F, Mazzitelli M, Trearichi EM, Torti C, Matera G, Liberto MC: **Identification od pmrB mutations as putativa mechanism for colistin resistance in A.baumannii strain isolated after in vivo colistin exposure,** Microbial Pathogenesis, February 2020. DOI: 10.1016/j.micpath.2020.104058.
39. Mazzitelli M, Barone S, Greco G, Serapide F, Valentino P, Giancotti A, Costa C, Pisani V, Quirino A, Liberto MC, Matera G, Gambardella A, Trearichi EM, Torti C: **Listeria infection after treatment with Alemtuzumab: a case report and literature review. Would an antibiotic prophylaxis be considerable?** Infezioni in Medicina (in press)
40. Maraolo AE, Mazzitelli M, Trearichi EM, Buonomo AR, Torti C, Gentile I: **Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: a systematic review of its efficacy and safety for off-label indications.** International Journal of Antimicrobial Agents. 8 January 2020. Doi:10.1016/j.ijantimicag.2020.105891.
41. Mazzitelli M, Milinkovic A, Pereira B, Palmer J, Tong T, Asboe D, Boffito M: **Polypharmacy and evaluation of anticholinergic risk in a cohort of elderly people living with HIV.** AIDS, 1 December 2019. Doi: 10.1097/QAD.0000000000002403
42. Mazzitelli M, Garofalo E, Bruni A, Barreca GS, Quirino A, Giancotti A, Serapide F, Indolfi C, Matera G, Navalesi P, Trearichi EM, Torti C, Longhini F: **Severe myocarditis due to influenza A(H1N1)pdm09 viral infection in a young woman successfully treated with intravenous zanamivir: a case report.** Clinical Case Report, 7 December 2019. Doi:

43. Torti C, Mazzitelli M, Longhini F, Garofalo E, Bruni A, Giancotti A, Barreca GS, Quirino A, Liberto MC, Serapide S, Matera G, Treacarichi EM, Navalesi P: **Clinical outcome of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: a case report series.** BMC infectious diseases October 2019. Doi: 10.1186/s12879-019-4530-1.
44. Treacarichi EM, Quirino A, Scaglione V, Longhini F, Garofalo E, Bruni A, Biamone E, Lionello R, Serapide F, Mazzitelli M, Marascio N, Matera G, Liberto MC, Navalesi P, Torti C: **Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: first case report.** Journal of antimicrobial chemotherapy. 2019, 1 August. doi: 10.1093/jac/dkz318.
45. Giacobbe D, Saffioti C, Losito AR, Rinaldi M, Aurilio C, Bolla C, Boni S, Borgia G, Carannante N, Cassola G, Ceccarelli G, Corcione S, Dalla Gasperina D, De Rosa FG, Di Bella S, Di Lauria N, Feasi M, Fiore M, Fossati S, Franceschini E, Gori A, Granata G, Grignolo S, Guadagnino G, Lagi F, Maraolo AE, Marinò V, Mazzitelli M, Mularoni A, Oliva A, Pace MC, Parisini A, Patti F, Petrosillo N, Pota V, Raffaelli F, Rossi M, Santoro A, Tascini C, Torti C, Treacarichi EM, Venditti M, Viale P, Signori A, Bassetti M, del Bono V, Giannella M, Mikulska M, Tumbarello M, Viscoli C: **Use of colistin in adult patients: a cross-sectional study.** Journal of Global antimicrobial resistance. 2019, 14 June. doi: 10.1016/j.jgar.2019.06.009.
46. Marascio N, Mazzitelli M, Pavia G, Giancotti A, Barreca GS, Costa C, Pisani V, Greco G, Serapide F, Treacarichi EM, Csalinuoovo F, Liberto MC, Matera G, Torti C: **Clinical, virological characteristics and outcome treatment with sofosbuvir/ledipasvir in two paediatric patients infected by genotype 4.** Cells 2019 May 5, 8, 416; doi:10.3390/cells8050416
47. Marascio N, Quirino A, Barreca GS, Galati L, Costa C, Pisani V, Mazzitelli M, Matera G, Liberto MC, Focà A, Torti C: **Discussion on critical points for a tailored therapy to cure hepatitis C virus infection.** Clinical Molecular Hepatology, 2019 January 23. doi: 10.3350/cmh.2018.0061.
48. Mazzitelli M, Torti C, Greco G, Strazzulla A, Costa C, Pisani V, Sorace C, Giancotti A, Lamberti A, Barreca GS, Quirino A, Liberto MC, Focà A, Matera M: **Prevalence of parasitic infections in migrants: do official symptom-driven guidelines apply to the current situation? Le infezioni in Medicina, December 2018. N.4, 347-355**
49. Mazzitelli M, Torti C, Sabatino J, D'Ascoli GL, Costa C, Pisani V, Raffetti E, De Rosa S, Strazzulla A, Focà A, Liberto MC, Indolfi C: **Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir based regimens in HCV infected patient.** BMC Infectious Diseases, 2018 Novembre 16,doi.org/10.1186/s12879-018-3426-9
50. Matera G, Torti C, Mazzitelli M, Greco G, Rania A, Peronace C, Settembre P, Galati L, Giancotti A, Lamberti AG, Barreca GS, Rossi M, Quirino A, Liberto MC, Focà A: **Depression of lymphocyte activity during cutaneous Leishmaniasis: a case report.** Diagnostic Microbiology & Infectious Disease, 2018 June 2, doi: 10.1016/j.diagmicrobio.2018.05.025.
51. Mazzitelli M, Lamberti Ag, Quirino A, Marascio N, Barreca GS, Costa C, Pisani V, Strazzulla A, Greco G, Liberto MC, Focà A, Torti C: **Utility of molecular identification and quantitation of Bartonella Species with species-specific real-time PCR for monitoring treatment response: a case series.** The Open Microbiology Journal, 2018 May 5, doi: 10.2171/1874285801812010148.
52. Strazzulla A, Strazzulla A, Coppolino G, Barreca GS, Gentile I, Rivoli L, Postorino MC, Mazzitelli M, Greco G, Costa C, Pisani V, Marascio N, Simeoni M, Focà A, Fuiano G, Foti D, Gulletta E, Torti C: **Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals.** Clinical and Molecular Hepatology, 2018 Apr 24. doi: 10.3350/cmh.2017.0059.

53. Matera G, Loria MT, Peronace C, Catanzariti T, Settembre P, Giancotti A, Lamberti AG, Barreca GS, Galati G, Dodaro G, Mazzitelli M, Strazzulla A, Torti C, Quirino A, Liberto MC, Focà A: **Increase of Vascular Endothelial Growth Factor, decrease of MCP-1 and some updated epidemiology aspects of cystic echinococcosis human cases in Calabria region.** *Mediators of Inflammation*, vol. 2018, Article ID 4283672, 11 pages, 2018. doi:10.1155/2018/4283672.
54. Mazzitelli M, Micieli M, Votino C, Visconti F, Strazzulla A, Torti C, Zullo F: **Knowledge of Human Cytomegalovirus (HCMV) infection and prevention in pregnant women: a baseline, operational survey.** *Infectious Disease in Obstetrics and Gynecology Journal*. July 31 2017 vol. 2017, Article ID 5495927, 5 pages, 2017. doi:10.1155/2017/5495927
55. Reale M, Strazzulla A, Quirino A, Rizzo C, Marano V, Postorino MC, Mazzitelli M, Greco G, Pisani V, Costa C, Cesana BM, Liberto MC, Torti C, Focà A: **Pattern of multi-drug resistant bacteria at first culture from patients admitted to a third level University hospital in Calabria from 2011 to 2014: implications for empirical therapy and infection control.** *Le Infezioni in Medicina Journal*, 2017 Jun 1;25(2):98-107
56. Strazzulla A, Iemmolo MRM, Carbone E, Postorino MC, Mazzitelli M, DeSantis M, Di Benedetto F, Cristiani MC, Costa C, Pisani V, Torti C: **The risk of hepatocellular carcinoma after directly acting antivirals for hepatitis C virus treatment in liver transplanted patients: is it real?** *Hepatitis Monthly* 2016 Oct 30; 16 (11):e41933.doi:10.5812/hepatmon.41933.eCollection 2016.
57. Mazzitelli M, Matera G, Votino C, Visconti F, Strazzulla A, Loria MT, Peronace C, Settembre P, Giancotti A, Liberto MC, Focà A, Zullo F, Torti C: **A case report of Schistosoma haematobium infection in a pregnant migrant raises concerns about lack of screening policies.** *Journal of Travel Medicine* 2016 24 (1): taw076 doi: 10.1093/jtm/taw076
58. Mazzitelli M, Caridà G, Scigliano C, Vallone MC, Pirrò F, Lombardo MR, Clemente G, Bernaudo F, Postorino MC, Strazzulla A, Maselli R, Torti C: **Knowledge of HIV infection and ways of its transmission: a knowledge, attitudes, beliefs and practices (KABP) survey among a sample of students at the “Magna Graecia”, University of Catanzaro.** *Annali Istituto Superiore di Sanità*, vol. 52, fascicolo 4, Dic. 2016
59. Strazzulla A, Coppolino G, Di Fatta C, Giancotti F, D'Onofrio G, Postorino MC, Mazzitelli M, Mammone SV, Gentile I, Rivoli L, Palella E, Gravina T, Costa C, Pisani V, De Maria V, Barreca GS, Marascio N, Focà A, Fuiano G, Gulletta E, Torti C: **Is neutrophil gelatinase associated lipocain useful in hepatitis C virus Infection?** *World Journal of Hepatology*. 2016 June 16
60. Postorino MC, Torti C, Carè I, Pisani V, Strazzulla A, Vaccaro V, Costa C, Provenzano F, Mazzitelli M, Pujia A, Montalcini T: **Is hand-grip another culprit for the risk of fractures in HIV-positive patients?** *New Microbiol.* 2016 Jan;39(1):61-4.
61. Cannistrà M, Ruggiero M, Zullo A, Gallelli G, Serafini S, Mazzitelli M, Naso A, Grande R, Serra R, Nardo B: **Hepatic ischemia reperfusion injury: A systematic review of literature and the role of current drugs and biomarkers.** *Int Journal of Surgery*, May 30 (2016) 1-14
62. Postorino MC, Luciani F, Pellicanò G, Mangano C, Carpentieri MS, Scerbo P, Priamo A, Berardelli G, Marino R, Vallone A, Carioti J, Serrao N, Pisani V, Costa C, Cesario F, Terremoto A, Foti G, Cosco L, Corigliano A, Mazzitelli M, Strazzulla A, Nunnari G, Torti C: **Number and Characteristics of new HIV diagnoses in the Calabria Region and in one nearby centre in Messina: a resurgent or still hidden epidemic in Southern Italy?** *Infect Dis Trop Med*, 2016; 2(2): e297
63. Strazzulla A, Barreca GS, Giancotti A, Pisani V, Costa C, Mazzitelli M, Zicca E, La Boria A, Roveda L, Liberto MC, Tucci L, Donato G, Focà A, Torti C. **A case report of nasopharyngeal carcinoma in a Caucasia italian man.** *Infect Dis Trop Med*, 2015; 1(3): e132

Publicazione in collaborative groups

1. Bourgeois FT, Gutiérrez-Sacristán A, Keller MS, Liu M, Hong C, Bonzel CL, Tan ALM, Aronow BJ, Boeker M, Booth J,

- Cruz Rojo J, Devkota B, García Barrio N, Gehlenborg N, Geva A, Hanauer DA, Hutch MR, Issitt RW, Klann JG, Luo Y, Mandl KD, Mao C, Moal B, Moshal KL, Murphy SN, Neuraz A, Ngiam KY, Omenn GS, Patel LP, Jiménez MP, Sebire NJ, Balazote PS, Serret-Larmande A, South AM, Spiridou A, Taylor DM, Tippmann P, Visweswaran S, Weber GM, Kohane IS, Cai T, Avillach P; Consortium for Clinical Characterization of COVID-19 by EHR (4CE). **International Analysis of electronic Health records of Children and Young Hospitalized with COVID-19 infection in 6 Countries.** *JAMA Netw Open*, 2021. doi: 10.1001/jamanetworkopen.2021.12596
- Comorbidities, Cardiovascular Therapies and COVID-19 Mortality: a nationwide, italian, observational Study (ItaliCO), *Frontiers in Cardiovascular Medicine*, Oct, 2020. <https://doi.org/10.3389/fcvm.2020.585866>
 - Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: a real-life evaluation of the PITER cohort. **Digestive and Liver Disease** (in press).
 - Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. **PharmacoEconomics**, 2018. <https://doi.org/10.1007/s40273-018-0733-3>

Partecipazioni a congressi nazionali: abstracts

- Serraino R, De Vito G, Costa C, Pisani V, Mazzitelli M, Greco G, Serapide F, Scaglione V, Lionello R, La Gamba V, Marascio N, Trecarichi EM, Torti C: **Alta proporzione di popolazione a rischio ma scarso ricorso al *test* per le infezioni da HBV e HCV nella provincia di Catanzaro.** *Poster session n 201, 18° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT) – Evento ECM - Palermo, (Italia), Ottobre 24-27, 2019*
- Mazzitelli M, Greco G, Serapide F, Costa C, Pisani V, Berardelli G, D'Argenio L, Cosco L, Bulla F, Foti G, Mastroianni A, Caroti J, Trecarichi EM, Torti C: **Comorbidities, polypharmacy and anticholinergic burden in a cohort of elderly people living with HIV in Calabria Region.** *Poster session 18° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT) – Evento ECM - Palermo, (Italia), Ottobre 24-27, 2019 (poster session n°306)*
- Scaglione V, Quirino A, Tavano A, Pisani V, Costa C, Mazzitelli M, Greco G, Serapide F, Lionello R, La Gamba V, Torti C, Longhini F, Liberto MC, Trecarichi EM: **Caratteristiche cliniche e outcome delle infezioni severe causate da *Klebsiella pneumoniae* resistente ai carbapenemi.** *Poster session n°99, 18° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT) – Evento ECM - Palermo, (Italia), Ottobre 24-27, 2019*
- Marascio N, Scarlata GM, Reale M, Divenuto F, Lamberti AG, Barreca GS, Sinopoli R, Costa C, Pisani V, Trecarichi EM, Mazzitelli M, Greco G, Serapide F, Torti C, Matera G, Liberto MC: **Seroprevalence and genotype evolution of HCV in a Teaching Hospital, Southern Italy.** *Poster session n° 239, 18° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT) – Evento ECM - Palermo, (Italia), Ottobre 24-27, 2019*
- Scaglione V, Similia SD, Costa C, Pisani V, Mazzitelli M, Greco G, Serapide F, Lionello R, La Gamba V, Torti C: **Subgroup analysis of HCV infected patients treated with directly acting antivirals in real clinical practice: do age and cirrhosis have an impact?** *11° Italian Conference of AIDS and Antiviral Research (ICAR). Milano (Italia), Giugno 5-7, 2019 (Poster session, n° 125)*
- Mazzitelli, D'Elia D, Sorace C, Greco G, Serapide S, Vallone A, Berardelli G, Foti F, Mangano C, Cosco L, Scerbo P, Priamo A, Bulla F, Serrano N, Guadagnino G, Mastroianni A, Trecarichi EM, Torti C: **First exploratory analysis of quality of life among people living with HIV in Calabria region.** *11° Italian Conference of AIDS and Antiviral Research (ICAR). Milano (Italia), Giugno 5-7, 2019 (Poster session, n° 124)*
- Morelli P, Lamberti A, Quirino A, Marascio N, Marano V, Giancotti A, Barreca G, Matera G, Costa C, Pisani V, Trecarichi E, Mazzitelli M, Serapide F, Greco G, Torti C, Liberto MC, Focà A: **Bartonella infection in Calabria: need for both serological and molecular assay.** *17° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Torino, To, (Italia), Dicembre 2-5, 2018 (Poster session, Abstract n° 218)*
- Mazzitelli M, Giancotti A, Visconti F, Quaresima P, Marascio N, Serapide F, Greco G, Maltese S, Focà A, Di Carlo C, Noia R, Amendola G, Torti C: **Outcome virologico e clinico in pazienti con infezione presunta o accertata da CMV in gravidanza.** *17° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Torino, To, (Italia), Dicembre 2-5, 2018 (Poster session, Abstract n° 155)*

9. Mazzitelli M, Greco G, Serapide F, Garofalo G, Bruni A, Pisani V, Costa C, Alvaro G, Biamonte E, Giancotti A, Barreca GS, Liberto MC, Focà A, Navalesi P, Torti C: **100% di successo in termini di sopravvivenza in pazienti con influenza grave sottoposti a ECMO e trattati con zanamivir e.v.: case report di 5 pazienti.** 17° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Torino, To, (Italia), Dicembre 2-5, 2018 (Poster session, Abstract n° 156)
10. Mazzitelli M, Mastroianni A, Apuzzo G, Pellegrino R, Foti G, Mangano C, Carpentieri MS, Serrano N, Carioti J, Berardelli G, Marino R, Vallone A, Cosco C, Scerbo P, Greco G, Serapide F, Costa C, Pisani V, Torti C: **Coverage ed efficacia del trattamento per HCV con DAA nei pazienti HIV positivi in Calabria: a che punto siamo ?** 17° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Torino, To, (Italia), Dicembre 2-5, 2018 (Poster session, Abstract n° 131)
11. Marascio N, Reale MC, Pavia G, Barreca GS, Lamberti A, Costa C, Pisani V, Trecarichi EM, Mazzitelli M, Serapide F, Greco G, Matera G, Liberto MC, Torti C, Focà A: **Prevalenza di HCV3 e HCV4 nella nuova era dei DAA.** 17° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Torino, To, (Italia), Dicembre 2-5, 2018 (Poster session, Abstract n° 109)
12. Greco G, Mazzitelli M, Serapide F, Picicco F, De Vuono G, Costa C, Pisani V, Trecarichi EM, De Siena M, Quirino A, Focà A, Serraino GF, Mastroberto P, Torti C: **Caratteristiche cliniche, modalità di impiego e sopravvivenza in pazienti critici con infezione da K. pneumoniae KPC trattati con ceftazidime/avibactam in monoterapia funzionale.** 17° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Torino, To, (Italia), Dicembre 2-5, 2018 (Poster session, Abstract n° 024)
13. Mazzitelli M, Greco G, Serapide F, Pisani V, Costa C, Trecarichi EM, Liberto MC, Focà A, Torti C: **Screening e vaccinazione per HBV in una popolazione di migranti: analisi retrospettiva e outcome.** 17° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Torino, To, (Italia), Dicembre 2-5, 2018 (Poster session)
14. Quirino A, Galati L, Marano V, Pavia G, Mazzitelli M, Greco G, Serapide F, Gallo L, Matera G, Serraino GF, Mastroberto P, Trecarichi EM, Liberto MC, Torti C, Focà A: **Isolamento e caratterizzazione molecolare di K. pneumoniae KPC e resistenza a ceftazidime/avibactam in paziente non esposto al farmaco.** 17° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Torino, To, (Italia), Dicembre 2-5, 2018 (Poster session, Abstract n° 025)
15. Marascio N, Mazzitelli M, Pavia G, Costa C, Greco G, Postorino MC, Barreca GS, Pisani V, Casalnuovo F, Liberto MC, Torti C, Focà A: **Analysis of dominant viral populations isolated from two paediatric patients infected by HCV genotype 4.** 16th European Meeting on HIV and Hepatitis 2018 (Poster session, n° 77)
16. Mazzitelli M, Marascio N, Pavia G, Greco G, Postorino MC, Barreca GS, Liberto MC, Focà A, Torti C: **Clinical and virological characteristics of two paediatric patients on treatment with DAA.** 10° Italian Conference of AIDS and Antiviral Research (ICAR). Roma (Italia), Maggio 22-24, 2018 (Poster session, n° 138)
17. Torti C, Mazzitelli M, Raffetti E, Cosco L, Marino M, Mastroianni A, Serrao N, Apuzzo G, Berardelli G, Carioti J, Teti D, Nisticò S, Surace L, Foti G: **Impact of tuberculosis and HIV infection on health care activities of infectious diseases unit in Calabria region.** 10° Italian Conference of AIDS and Antiviral Research (ICAR). Roma (Italia), Maggio 22-24, 2018 (Poster session, n° 283)
18. Quirino A, Morelli P, Settembre P, Gallo L, Mazzitelli M, Greco G, Torti C, Liberto MC, Focà A: **Microbiological characterisation of *Candida spp.* from blood cultures over six years: should we skip fluconazole for all?** 16° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Salerno, SA, (Italia), Ottobre 15-18, 2017 (Poster session, Abstract 280)
19. Torti C, Mazzitelli M, Raffetti E, Cosco L, Marino R, Mastroianni A, Serrao N, Apuzzo G, Berardelli G, Carioti J, Teti D, Nisticò S, Surace L, Procopio G, Foti G: **Impatto clinico-assistenziale del fenomeno migratorio dal 2013 al 2016 e necessità di risorse per le Unità Operative di Malattie e Infettive e Tropicali in Regione Calabria.** 16° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Salerno, SA, (Italia), Ottobre 15-18, 2017 (Poster

session, Abstract 277)

20. Mazzitelli M, Matera G, Costa C, Pisani V, Strazzulla A, Rania A, Peronace C, Settembre P, Giancotti A, Lamberti A, Barreca GS, Torti C: **Diagnosi etiologica e caratterizzazione immunologica in un caso di leishmaniosi cutanea estesa con diagnosi tardiva dopo 7 anni dall'esordio.** 16° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Salerno, SA, (Italia), Ottobre 15-18, 2017 (Poster session, Abstract 274)
21. Mazzitelli M, Greco G, Costa C, Pisani V, Berardelli G, Strazzulla A, Di Virgilio A, Malta E, Musolino G, Lachina C, Mastroberto P, Torti C: **Un caso complicato di multiple infezioni opportunistiche in paziente non AIDS.** 16° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Salerno, SA, (Italia), Ottobre 15-18, 2017 (Poster session, Abstract 270)
22. Strazzulla A, Coppolino G, Barreca GS, Gentile I, Rivoli L, Postorino MC, Mazzitelli M, Greco G, Costa C, Pisani V, Simeoni MA, Foti D, Marascio N, Focà A, Fuiano G, Gulletta E, Torti C: **Evaluation of estimated glomerular filtration rate in hepatitis C virus positive patients treated with interferon free regimens with directly acting antivirals.** 9° Italian Conference of AIDS and Antiviral Research (ICAR). Siena (Italia), Giugno 12-14, 2017 (Poster session, Abstract #245).
23. Strazzulla A, Coppolino G, Barreca GS, Gentile I, Rivoli L, Postorino MC, Mazzitelli M, Greco G, Costa C, Pisani V, Simeoni MA, Foti D, Marascio N, Focà A, Fuiano G, Gulletta E, Torti C: **Evolution of estimated glomerular filtration rate and plasmatic neutrophil gelatinase-associated lipocalin in hepatitis C virus positive patients treated with directly acting antivirals.** 9° Italian Conference of AIDS and Antiviral Research (ICAR). Siena (Italia), Giugno 12-14, 2017 (Poster session, Abstract #246).
24. Ferrigno G, Mazza MR, Morelli M, Mazzitelli M, Torti C, Quattrone A, Bono F: **Chronic migraine as unusual presentation of syphilis.** Congresso Nazionale della Società Italiana di Neurologia (SIN), Venezia (Italia), Ottobre 22-25 Ottobre 2016
25. Pavia G, Marascio N, Romeo I, Talarico C, Costa G, Zicca E, Barreca GS, Postorino MC, Mazzitelli M, Torti C, Artese A, Alcaro S, Liberto MC, Focà A: **Structural analysis against HCV polymerase in presence of natural resistance-associated substitutions in HCV isolates from DAA-naive patients.** 3rd Innovative approaches for novel Antiviral Agents Summer School, September 28th – October 3rd 2016, Pula (Cagliari, Italy)
26. Mazzitelli M, Sacco A, Strazzulla A, Ietto C, Postorino MC, Pisani V, Costa C, Carè I, Montalcini T, Pujia A, Gulletta E, Focà A, Torti C: **Studio del valore del Fibrosis – 4 Index (FIB-4) e dell'AST to Platelet Ratio Index (APRI) con l'elastometria epatica nello stimare lo stadio di fibrosi del fegato, in pazienti risultati eleggibili alla terapia con directly active antivirals (DAAs).** 15° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Baveno, VB, (Italia), Ottobre 16-19, 2016 (Poster session- Abstract 143).
27. Mazzitelli M, Visconti F, Strazzulla A, Postorino MC, Matera G, Giancotti A, Votino C, Focà A, Zullo F, Torti C: **Uso del Praziquantel nel trattamento di Schistosomiasi da S. haematobium in gravidanza.** 15° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Baveno, VB, (Italia), Ottobre 16-19, 2016 (Poster session – Abstract 144).
28. Strazzulla S, Iemmalo RMR, Postorino MC, Mazzitelli M, De Santis M, Di Benedetto F, Costa C, Pisani V, Torti C: **Recidiva di epatocarcinoma in paziente trapiantato di fegato dopo eradicazione di HCV a seguito di terapia con farmaci antivirali ad azione diretta.** 15° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Baveno, VB, (Italia), Ottobre 16-19, 2016 (Poster session – Abstract 147).
29. Berardelli G, Nisticò S, Strazzulla A, Sacco A, Mazzitelli M, Postorino MC, Torti C: **Diagnosi e stadiazione di portatori cronici di HBsAg: Concordanza tra HBsAg quantitativo e HBV DNA.** 15° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Baveno, VB, (Italia), Ottobre 16-19, 2016 (Poster session – Abstract 174).
30. Pisani V, Mazzitelli M, Strazzulla A, Marascio N, Barreca GS, Aragri M, Perno CF, Bertoli A, Torti C: **Terapia di salvataggio per HCV in paziente immunocompromessa e multifallita: un nuovo riscontro terapeutico?** 15° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Baveno, VB, (Italia), Ottobre 16-19,

2016 (Poster session – ID DOC 57997).

31. Costa C, Pisani V, Postorino MC, Strazzulla A, Mazzitelli M, Marascio N, Barreca GS, Liberto MC, Focà A, Torti C: **Outcome virologico e clinico dei pazienti con infezione da HCV trattati con terapie interferon free in un centro prescrittore in Regione Calabria.** 15° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Baveno, VB, (Italia), Ottobre 16-19, 2016 (Poster session – Abstract 145).
32. Postorino MC, Costa C, Pisani V, Strazzulla A, Mazzitelli M, Marascio N, Barreca GS, Gulletta E, Liberto MC, Focà A, Torti C: **Studio della funzione renale in pazienti HCV positivi trattati con terapie interferon free in un centro prescrittore in Regione Calabria.** 15° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Baveno, VB, (Italia), Ottobre 16-19, 2016 (Oral session – Abstract 160).
33. Matera G, Mazzitelli M, Loria MT, Strazzulla A, Settembre P, Giancotti A, Lamberti AG, Barreca GS, Galati L, Quirino A, Liberto MC, Torti C, Focà A: **Ruolo dei metaboliti di ossido nitrico (NO3 e NO2) e di IgG4 come biomarcatori di patogenesi nell'echinococcosi cistica.** 15° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Baveno, VB, (Italia), Ottobre 16-19, 2016 (Poster session – Abstract 157).
34. Quirino A, Torti C, Mastroroberto P, Cortese G, Morelli P, Reale M, Costa C, Pisani V, Strazzulla A, Mazzitelli M, Matera G, Liberto MC, Focà A: **Utilità dello screening con tamponi microbiologici muco-cutanei nella scelta delle strategie di profilassi cardiocirurgica.** 15° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Baveno, VB, (Italia), Ottobre 16-19, 2016 (Poster session – Abstract 156).
35. Postorino MC, Luciani F, Pellicanò G, Mangano C, Carpentieri MS, Scerbo P, Priamo A, Berardelli G, Marino R, Vallone A, Serrao N, Pisani V, Costa C, Terremoto A, Foti G, Cosco L, Corigliano D, Mazzitelli M, Strazzulla A, Nunnari G, Torti C: **Prevalence and characteristics of new HIV diagnoses in the Calabria Region (CALABRHIV Cohort) and in one nearby Centre in Messina: lessons learned and call for collaboration.** 8° Italian Conference of AIDS and Antiviral Research (ICAR). Milano (Italia), Giugno 6-8, 2016 (Poster session, Abstract 310).
36. D'Ascoli GL, Sabatino J, Mazzitelli M, Ietto C, Capasso D, Strazzulla A, Costa C, Postorino MC, Pisani V, De Rosa S, Torti C, Indolfi C. **Valutazione della funzione ventricolare sinistra globale e regionale in pazienti con infezione da HCV in trattamento con sofosbuvir: risultati preliminari.** 76th SIC (Società Italiana Cardiologia) National Congress, Rome 11-14th December 2015 (Poster session, Abstract #154)
37. Torti C, Mazzitelli M, Sabatino J, Pisani V, Costa C, Strazzulla A, D'Ascoli GL, Capasso D, De Rosa S, Indolfi C: **Valutazione della funzione ventricolare sinistra in pazienti con infezione da HCV in trattamento con Sofosbuvir: risultati ad interim dello studio CARDIAC (cardiac diseases in antiviral therapy for HCV).** 14° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Catania (Italia), Novembre 8-11, 2015 (Poster session, Abstract #266).
38. Matera G, Nardo B, Cannistrà M, Giancotti A, Console D, Strazzulla A, Loria MT, Mazzitelli M, Pisani V, Zullo A, Sacco R, Lamberti AG, Liberto MC, Focà A, Torti C: **Aspetti epidemiologici, clinici, radiografici e microbiologici in una casistica di echinococcosi cistica in regione Calabria.** 14° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT). Catania (Italia), Novembre 8-11, 2015 (Poster session, Abstract #72).

Abstract su riviste

1. Coppolino G, Strazzulla A, Barreca G, Gentile I, Rivoli L, Postorino MC, Mazzitelli M, Greco G, Costa C, Pisani V, Marascio N, Simeoni MA, Focà A, Foti D, Gulletta E, Fuiano G, Torti C: **SP121 glomerula filtration rates and neutrophil gelatinase-associated lipocalin during treatment with Direct Acting Antivirals (DAA) for Chronic Hepatitis C Virus (HCV) Infection.** Nephrology Dialysis Transplantation, Volume 34, 2019, 13 June. <https://doi.org/10.1093/ndt/gfz103.SP121>

Partecipazioni a congressi internazionali: abstracts

1. **“Efficacy and durability of 2 drug vs 3 drug INSTI based regimens: data from real life”**: (Poster session – Abstract n°3305) CROI, Boston March 2020, coauthor
2. **“NRTI backbone modification impact on weight, lipid and cardiovascular risk in PLWH”** : (Poster Session – PE32/9) EACS (European AIDS Clinical Society), Basel, Switzerland, Novembre 6-9, 2019, coauthor
3. **“Results of 10 year experience of a specialist clinic for people living with HIV over 50 at Chelsea and Westminster Hospital”**: (Poster Session – PE9/28) EACS (European AIDS Clinical Society), Basel, Switzerland, Novembre 6-9, 2019, coauthor
4. **Incidental findings in PLWH over 50 undergoing Coronary Artery Calcium Scoring (CACS) for cardiovascular risk assessment**: (Poster Session – PE9/43) EACS (European AIDS Clinical Society), Basel, Switzerland, Novembre 6-9, 2019 – coauthor and presenter
5. **“Cardiovascular risk assessment in PLWH over 50: agreement between cardiovascular risk predictors and Coronary Artery Calcium CT Scoring (CACS)”** (Poster Session) EACS (European AIDS Clinical Society), Basel, Switzerland, Novembre 6-9, 2019 – coauthor and presenter
6. **“Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients”** : (Poster Session, Title Hepatitis C Therapeutic – Approved Agents I) AASLD (American Association for the Study of Liver Diseases), The Liver Meeting® 2017, Washington DC, October 20-24, 2017. First author and presenter

Comunicazioni orali a congressi regionali, nazionali e internazionali

1. **COVID-19 from clinical aspects to treatment. The 1st international electronic conference on Medicine, Session 1, Hune 22nd, 2021 (Invited speaker)**
2. **Terapie long-acting nel soggetto anziano e in poli-terapia (Invited speaker) 19.06.2021 Scuola di Specializzazione Malattie Infettive e Tropicali Milano (Progetto Formazione Pandora).**
3. **The impact of COVID-19 on People Living with HIV (invited speaker). EACS young investigator journal club June 12th, 2021**
4. **Statin eligibility in people living with HIV: are we using the right tools to identify patients of developing major cardiovascular disease? - 12^oItalian Conference of AIDS and Antiviral Research, ICAR 12-16 October, 2020 (Oral Communication 26, ID 1).**
5. **Pharmacokinetics of once-daily doravirine over 72 hours following drug cessation- 12^oItalian Conference of AIDS and Antiviral Research, ICAR 12-16 October, 2020 (Oral Communication 67, ID 2).**
6. **Overweight/obesity and comorbidities in a cohort of people living with HIV over 50 years of age. Oral communication 18^o Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT) – Evento ECM - Palermo, (Italia), Ottobre 24-27, 2019 (n° 19-027- Autorship: Mazzitelli M, Pereira B, Moyle G, Posniak A, Boffito M, Milinkovic A)**
7. **DXA Scan vs. FRAX score for the evaluation of fracture risk in a cohort of elderly people living with HIV – (Best Oral Communication session Ageing: long term comorbidities, n BPD2/1) (European AIDS Clinical Society), Basel, Switzerland, Novembre 6-9, 2019. Authors: Mazzitelli M, Pereira B, Muramatsu T, Chirwa M, S Mandalia, Boffito M, Milinkovic A.**
8. **DXA Scan vs. FRAX score for the evaluation of fracture risk in a cohort of elderly people living with HIV – Oral Communication n° ADRLH-71 at 21st International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV 5-6**

- November, Basel, Switzerland), Authors: Mazzitelli M, Pereira B, Muramatsu T, Chirwa M, S Mandalia, Boffito M, Milinkovic A.
9. **“Overall tolerability of Integrase Inhibitors in clinical practice: results from a multicenter Italian cohort”** - 11° *Italian Conference of AIDS and Antiviral Research (ICAR)*. Milano (Italia), Giugno 5-7, 2019 (Oral Communication 48, ID 180). Authorship: A Ciccullo, Baldini G, Borghi V, Sterrantino G, Latini A, d'Ettore G, Lanari A, Mazzitelli M, De Vito A, Colafigli M, Capetti A, Oreni L, Lagi F, Rusconi S, Di Giambenedetto S.
 10. **“Prevalenza di parassitosi intestinali in una popolazione di migranti di nuovo arrivo in Calabria”** Oral communication, 16° *Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT)* – Evento ECM - Salerno, SA, (Italia), Ottobre 15-18, 2017 (Oral communication, Abstract 268) (Autorship: Mazzitelli M, Greco G, Strazzulla A, Costa C, Pisani V, Matera G, Loria MT, Rania A, Peronace C, Settembre P, Adorasio C, Sgaramella M, Lamberti A, Torti C)
 11. **“Data presentation and discussion on cardiovascular complications of HCV chronic infection”** – UMG meets the experts: international workshop on HIV/HCV research and cure – Evento ECM – 2-3 Febbraio 2017, Università degli Studi Magna Graecia (Catanzaro)
 12. **“Studio della funzione renale nei pazienti HCV positivi trattati con terapie interferon free in un centro prescrittore in regione Calabria”** Oral presentation (Abstract 160), 15° *Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali (SIMIT)*. Baveno, VB, (Italia), Ottobre 16-19, 2016 (Authorship: Postorino MC, Costa C, Pisani V, Strazzulla A, Mazzitelli M, Marascio N, Barreca GS, Gulletta E, Liberto MC, Focà A, Torti C)
 13. **“Casi clinici esemplificativi sulla gestione delle infezioni da germi multiresistenti in ambito ospedaliero”** – L'ospedale pulito, ospedale sicuro: come fronteggiare l'emergenza delle infezioni e resistenze batteriche? – Evento ECM – 30 Settembre 2016, Università degli Studi Magna Graecia (Catanzaro)
 14. **“Schistosomiasi in gravidanza”** – Comunicazioni selezionate dalle Scuole di Specializzazione di Palermo, Catania, Messina, Catanzaro e U.O.C. Sicilia e Calabria – Congresso SIMIT Sicilia “Le malattie Infettive fra ospedale e territorio” – Evento ECM - 27-28 Maggio 2016 – Castellammare del Golfo (Trapani)
 15. **“Management diagnostico e terapeutico delle malattie infettive in gravidanza: casi clinici emblematici, esperienza dell'ambulatorio malattie infettive in gravidanza, UO Malattie Infettive AOU Mater Domini ”** - Associazione Italiana Donne Medico, Ordine dei Medici Chirurghi e Odontoiatri Vibo Valentia – 5 Marzo 2016 – Vibo Valentia
 16. **“Coinfezione HIV/HCV”** – Problemi attuali nel trattamento delle epatiti e ricerca clinica – Focus sulla Regione Calabria nella prospettiva del network dei centri di malattie infettive- 18 Dicembre 2015 – Lamezia Terme (Catanzaro)

Trattati, manuali, testi per la didattica

1. Handbook on Selected Topics in Tropical Diseases (edited by Roberto Cauda) **Capitolo 10. Bone Infections** a cura di Greco Giuseppe, Valentina La Gamba, Lionello Rosaria, **Mazzitelli Maria**, Treçarichi Enrico Maria. ISBN 978-88-343-4261-9 (Quaderni del CESI)
2. **COVID-19: manuale pratico per medici ed operatori sanitari** (a cura di Carlo Torti), ruolo: coautrice, 2020. ISBN: 9788849865905

CAPACITÀ E COMPETENZE

PERSONALI

MADRELINGUA [Italiana]

ALTRE LINGUA

[Inglese]

- Capacità di lettura C1
- Capacità di scrittura B2
- Capacità di espressione orale B2

Certificazione Level B1 “**British Institute**”- **Esol Certificate** (English Speakers of Other Languages) Level B1

IELTS Certificate (01.12.2018), number 5224: Competent User – Level B2

Occupational English Test (OET) Certificate, n 200042944 21.07.2019: B Score Band

[Francese]

- Capacità di lettura C1
- Capacità di scrittura A2
- Capacità di espressione orale A2

[Spagnolo]

- Capacità di lettura B2
- Capacità di scrittura A1
- Capacità di espressione orale A2

CAPACITÀ E COMPETENZE

RELAZIONALI

[Buona attitudine al lavoro di gruppo e alla comunicazione, spirito di adattamento ad ambienti multiculturali]

CAPACITÀ E COMPETENZE

ORGANIZZATIVE

[Buone capacità di coordinamento e di organizzazione]

CAPACITÀ E COMPETENZE

TECNICHE

[Ottima conoscenza del pacchetto Office]

C.I. Informatica e Sistemi di Elaborazione delle Informazioni (I e II) CdL Medicina e Chirurgia
Università degli Studi Magna Graecia di Catanzaro

ALTROIscrizioni a società scientifiche

- Società Italiana Malattie infettive e Tropicali (SIMIT) dal 2016
- Società Italiana Terapia Antinfettiva (SITA) dal 2018
- European AIDS Clinical Society (EACS) dal 2019
- International AIDS Society (IAS) dal 2020

Membro e Segretario del Direttivo SIMIT Calabria da Dicembre 2018

PATENTE

Tipo B

LA SOTTOSCRITTA MARIA MAZZITELLI, CONSAPEVOLE DELLE SANZIONI PENALI RICHIAMATE ALL'ART. 76 DEL DPR 28/12/2000 N. 455, IN CASO DI DICHIARAZIONI MENDACI E DI USO DI ATTI FALSI, E CONSAPEVOLE DELLA DECANDENZA DEI BENEFICI EVENTUALMENTE CONSEGUITI A SEGUITO DI DICHIARAZIONI NON VERITIERE, COSI' COME PREVISTO DALL'ART. 75 DEL DPR 445 DEL 28 DICEMBRE 2000, DICHIARA SOTTO LA SUA PERSONALE RESPONSABILITA' AI SENSI DELL'ART. 46 E 27 DEL DPR 445/2000 DI ESSERE IN POSSESSO DEL SEGUENTE CURRICULUM.

Maria Mazzitelli

Zaccanopoli, 08.10.2021

Rebecka Papaioannu Borjesson

ESPERIENZA LAVORATIVA

GEN 2021 – ATTUALE Milano, Italia

MEDICO SPECIALIZZANDO IN MALATTIE INFETTIVE E TROPICALI OSPEDALE SAN RAFFAELE E UNIVERSITÀ VITA-SALUTE SAN RAFFAELE

NOV 2023 – FEB 2024 Milano, Italia

MEDICO DI PRONTO SOCCORSO OSPEDALE SAN RAFFAELE

APR 2021 – LUG 2021 Genova, Italia

MEDICO DI CONTINUITÀ ASSISTENZIALE

Campagna vaccinale per SARS-CoV-2

MAG 2020 – GEN 2021 Genova, Italia

MEDICO DI CONTINUITÀ ASSISTENZIALE

Gestione domiciliare di infezione da SARS-CoV-2

NOV 2019 – GEN 2020 Genova, Italia

TIROCINIO ABILITANTE POST-LAUREA OSPEDALE PEDIATRICO GIANNINA GASLINI E OSPEDALE SAN MARTINO

UO di Reumatologia Pediatrica

UO di Anestesia e Rianimazione

OTT 2017 – OTT 2017 Calcutta, India

VOLONTARIATO MEDICO INSTITUTE FOR INDIAN MOTHER AND CHILD

ISTRUZIONE E FORMAZIONE

SET 2013 – LUG 2019 Genova, Italia

LAUREA IN MEDICINA E CHIRURGIA Università degli Studi di Genova

Voto finale 110 e lode | **Tesi** Comorbidities in perinatally HIV-infected young adults and adolescents

2008 – 2013 Genova, Italia

DIPLOMA LICEO SCIENTIFICO Liceo Scientifico Leonardo da Vinci

COMPETENZE LINGUISTICHE

Lingua madre: **ITALIANO**

Altre lingue:

	COMPRENSIONE		ESPRESSIONE ORALE		SCRITTURA
	Ascolto	Lettura	Produzione orale	Interazione orale	
INGLESE	B2	B2	B2	B2	B2

	COMPRESIONE		ESPRESSIONE ORALE		SCRITTURA
	Ascolto	Lettura	Produzione orale	Interazione orale	
SVEDESE	B1	B1	B1	B1	B1

Livelli: A1 e A2: Livello elementare B1 e B2: Livello intermedio C1 e C2: Livello avanzato

● ULTERIORI INFORMAZIONI

CONFERENZE E SEMINARI

8 FEB 2024 – 9 FEB 2024 – Milano

IDEA (Infectious Disease Expert Advocacy) in HIV

21 DIC 2023 – 21 DIC 2023 – Milano

Fostemsavir: 1 year of experience in HTE MDR PLHIV

18 OTT 2023 – 21 OTT 2023 – Varsavia

European AIDS Conference 2023

4 OTT 2023 – 4 OTT 2023 – Genova

Evolving Mindset in HIV Management

14 GIU 2023 – 16 GIU 2023 – Bari

ICAR (Italian Conference on AIDS and Antiviral Research)

16 MAR 2023 – 17 MAR 2023 – Milano

9th AMIT International Congress, Topics in Infectious and Tropical Diseases

21 DIC 2022 – 21 DIC 2022 – Milano

Fostemsavir: a BRIGHT future ahead

13 DIC 2022 – 13 DIC 2023 – Verona

Evolving Mindset in HIV Management

6 SET 2022 – 9 SET 2022 – Bordeaux

EACS HIV Summer School

28 GIU 2022 – 29 GIU 2022 – Genova

Game Changing in HIV

14 GIU 2022 – 16 GIU 2022 – Bergamo

ICAR (Italian Conference on AIDS and Antiviral Research)

2 MAG 2022 – 3 MAG 2022 – Milano

PRESTIGIO Ring

SET 2021 – DIC 2021 – Online

IDEA (Infectious Disease Expert Advocacy) in HIV

12 NOV 2021 – 12 NOV 2021 – Milano

Management of Multi Drug Resistant Gram negative bacteria: challenges and options

13 SET 2021 – 14 SET 2021 – Firenze

ARCA (Antiviral Response Cohort Analysis) Mentor School

5 FEB 2020 – 5 FEB 2020

BLSD course (basic and pediatric life support defibrillation), with authorization for use of AED

PUBBLICAZIONI

Switching to Integrase Inhibitors Unlinked to Weight Increase in Perinatally HIV-Infected Young Adults and Adolescents: A 10-Year Observational Study

L. Taramasso, A. Di Biagio, F. Bovis, F. Forlanini, E. Albani, R. Papaioannu, V. Giacomet
Microorganism, June 2020

High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19

M. Ripa et al., COVID-BioB Study Group

Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting

T. Clemente, L. Galli, A. Poli, R. Papaioannu Borjesson, L. Bresciani, C. Muccini, D. Canetti, C. Candela, S. Bossolasco, H. Hasson, A. Castagna, V. Spagnuolo
International Journal of Antimicrobial Agents, June 2023

Trend over time of HIV-1 drug resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and their drivers: A cohort study from Antiviral Response Cohort Analysis (ARCA)

I. Rancan, C. Cassol, L. Graziani, M. Tilli, C. Malcontenti, C. Russo, M. Bottanelli, F. Bracchitta, R. Papaioannu, L. Labate, S. Mora, A. Bezenchek, A. Shallvari, A. Di Biagio, B. Rossetti,
HIV Medicine, July 2023

Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic

R. Papaioannu Borjesson, L. Galli, C. Muccini, A. Poli, T. Clemente, M. Bottanelli, N. Gianotti, S. Nozza, A. Castagna, V. Spagnuolo
Frontiers in Medicine, September 2023

Sexually transmitted infections in people with multidrug-resistant HIV

T. Clemente, R. Lolatto, R. Papaioannu Borjesson, M. Fabbiani, E. Manzillo, E. Fronti, S. Di Giambenedetto, R. Gagliardini, S. Rusconi, M. M. Santoro, A. Castagna, V. Spagnuolo; PRESTIGIO Study Group
AIDS, December 2023

Lower AIDS-related hospitalizations in women living with HIV multidrug resistance

R. Papaioannu Borjesson, L. Galli, R. Lolatto, B. Menzaghi, M. Feasi, R. Gulminetti, C. Fornabaio, A. M. Cattelan, S. Bonora, F. Lagi, M. Zazzi, A. Castagna, V. Spagnuolo; PRESTIGIO Study Group
AIDS, March 2024

PRESENTAZIONI A CONGRESSI

Journal of HIV and Ageing, 2019

G. Sarteschi, M. Mirabella, A. Della Vecchia, L. Magnasco, R. Papaioannu, S. Mora, M. Giacomini, A. Di Biagio
Variazioni del filtrato glomerulare (eGFR) in una coorte di pazienti nati con HIV, risultati di uno studio osservazionale dal 2009 al 2018 (Variations of GFR in a cohort of perinatally HIV-infected patients, results from an observational study from 2009 to 2018)
pp 37

Poster presentato a SIMIT 2021

M. Bottanelli, T. Clemente, R. Monardo, R. Papaioannu, M. Guffanti, R. Finazzi, C. Uberti Foppa, A. Castagna, A. Danise, E. Messina
Sinusite invasiva da Aspergillus post COVID-19 in infezione da HIV: case report (Post-COVID19 invasive Aspergillus sinusitis in a person living with HIV: case report)

Poster presentato a ICAR 2021

N. Gianotti, A. Poli, L. Galli, S. Bossolasco, G. Morsica, G. Gaiera, T. Clemente, R. Papaioannu, M. Bottanelli, A. Lazzarin, A. Castagna
Did lockdown due to SARS-Cov-2 pandemic jeopardize the efficacy of antiretroviral therapy?

Presentazione orale ICAR 2022

R. Papaioannu, L. Galli, C. Muccini, A. Poli, T. Clemente, M. Bottanelli, N. Gianotti, S. Nozza, A. Castagna, V. Spagnuolo
Impact of COVID-19 Pandemic on Incidence and Prevalence of Metabolic Syndrome in PLWH

Presentazione orale ICAR 2023

R. Papaioannu Borjesson, L. Galli, R. Lolatto, B. Menzaghi, M. Feasi, R. Gulminetti, C. Fornabaio, A.M. Cattelan, S. Bonora, F. Lagi, M. Zazzi, A. Castagna, on behalf of PRESTIGIO Study Group
Lower AIDS-related hospitalizations in women living with HIV multidrug resistance: results from the PRESTIGIO Registry

Poster presentato a ICAR 2023

R. Papaioannu Borjesson, L. Galli, R. Gagliardini, M. Feasi, M. Ferrara, S. di Giambenedetto, F. Lagi, G. Marchetti, M. Malena, A. Cervo, A.M. Cattelan, F. Maggiolo, M. Fabbiani, V. Spagnuolo, A. Castagna, on behalf of PRESTIGIO Registry
CD4 and CD4/CD8 ratio gain in PLWH treated with Fostemsavir: results from the PRESTIGIO Registry

Presentazione orale ICAR 2023

T. Clemente, R. Lolatto, R. Papaioannu Borjesson, M. Fabbiani, E. Manzillo, E. Fronti, S. Di Giambenedetto, R. Gagliardini, S. Rusconi, M. M. Santoro, A. Castagna, V. Spagnuolo; PRESTIGIO Study Group
Sexually transmitted infections in people with multidrug-resistant HIV

Presentazione orale EACS 2023

R. Papaioannu Borjesson, T. Clemente, S. Diotallevi, R. Lolatto, A. Forniti, M. Bottanelli, L. Galli, F. Alberton, C. Muccini, H. Hasson, A. Castagna, V. Spagnuolo
Outcomes after virological failure to first-line second-generation INSTI-based therapy in a real-life setting

Poster presentato a EACS 2023

T. Clemente, D. Canetti, E. Messina, E. Carini, L. Della Torre, R. Papaioannu Borjesson, A. Castagna, V. Spagnuolo
How to choose the optimized background therapy with fostemsavir in viremic people with multidrug-resistant HIV? A clinical case

Autorizzo il trattamento dei miei dati personali presenti nel CV ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n. 196 - "Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 - "Regolamento europeo sulla protezione dei dati personali".



INFORMAZIONI PERSONALI

Nome STEFANO RUSCONI
Indirizzo Via Papa Giovanni Paolo II, 20025 Legnano (MI) (lavoro)
Telefono
Fax
E-mail

CF

ESPERIENZA LAVORATIVA

1988-89

Tipo di azienda o settore Laboratorio Analisi, Ospedale Militare di Milano

Tipo di impiego Servizio Militare

1992-1994

Nome e indirizzo del datore di lavoro Prof. M.S. Hirsch, Boston, MA, USA
Tipo di azienda o settore Infectious Disease Unit, Massachusetts General Hospital and Harvard Medical School
Tipo di impiego Borse di studio Ente Erogatore 1991-1992 Università degli Studi di Milano – 1991-1993 Istituto Superiore di Sanità
Principali mansioni e responsabilità Research Fellow

1998

Nome e indirizzo del datore di lavoro Prof. M.S. Hirsch, Boston, MA, USA
Tipo di azienda o settore Infectious Disease Unit, Massachusetts General Hospital and Harvard Medical School
Tipo di impiego Borsa di studio Ente Erogatore 1998 N.A.T.O. C.N.R., Roma
Principali mansioni e responsabilità Senior Research Fellow

1/12/1989 al 30/6/1990

Nome e indirizzo del datore di lavoro Ufficio di Igiene e Sanità
Tipo di azienda o settore Comune di Milano USSL 75/I
Tipo di impiego Contratto a tempo determinato
Principali mansioni e responsabilità Medico supplente addetto alla Medicina dei Servizi DPR 504/87 per la Campagna informativa sull'AIDS

1/7/1990 al 31/12/1990

Nome e indirizzo del datore di lavoro Ufficio di Igiene e Sanità
Tipo di azienda o settore Comune di Milano USSL 75/I
Tipo di impiego Contratto a tempo determinato
Principali mansioni e responsabilità Medico addetto alla Medicina dei Servizi DPR 504/87 per la Campagna informativa sull'AIDS

1/02/1994 al 5/12/1996

Nome e indirizzo del datore di lavoro Divisione clinicizzata di Malattie Infettive, Via G. B. Grassi, 74 20157 Milano
Tipo di azienda o settore Ospedale Luigi Sacco
Tipo di impiego Contratto a tempo indeterminato
Principali mansioni e responsabilità Assistente medico di Malattie Infettive di ruolo a tempo pieno

6/12/1996 al 30/11/2008

Nome e indirizzo del datore di lavoro Divisione clinicizzata di Malattie Infettive, Via G. B. Grassi, 74 20157 Milano
Tipo di azienda o settore Ospedale Luigi Sacco

Tipo di impiego	Contratto a tempo indeterminato
Principali mansioni e responsabilità	Dirigente medico di 1° livello di Malattie Infettive di ruolo a tempo pieno
1/1/2001 al 31/7/2008	
Nome e indirizzo del datore di lavoro	Divisione clinicizzata di Malattie Infettive, Via G. B. Grassi, 74 20157 Milano
Tipo di azienda o settore	Ospedale Luigi Sacco
Tipo di impiego	Contratto a tempo indeterminato
Principali mansioni e responsabilità	Incarico di natura professionale di base > di 5 anni (d1), ai sensi dell'art. 27-comma 1 lett. D) CCNL Dirigenza Medica
1/8/2008 a 31/01/2021	
Nome e indirizzo del datore di lavoro	Divisione clinicizzata di Malattie Infettive, Via G. B. Grassi, 74 20157 Milano
Tipo di azienda o settore	Ospedale Luigi Sacco
Tipo di impiego	Contratto a tempo indeterminato
Principali mansioni e responsabilità	Incarico di natura professionale di alta specializzazione c.1 "Gestione farmaci innovativi e sperimentali"
1999 al 02/2017	
Nome e indirizzo del datore di lavoro	Comitato Etico, Via G. B. Grassi, 74 20157 Milano
Tipo di azienda o settore	Ospedale Luigi Sacco
Principali mansioni e responsabilità	Segretario Scientifico Comitato Etico Interaziendale Milano area A
1/12/2008 al 29/01/2012	
Nome e indirizzo del datore di lavoro	Università degli Studi di Milano, Via Festa del Perdono, 7 20122 Milano
Tipo di azienda o settore	
Principali mansioni e responsabilità	Ricercatore (MED17), convenzione stipulata tra Università degli Studi di Milano e Azienda Ospedaliera Luigi Sacco di Milano, quale ricercatore universitario, per lo svolgimento delle funzioni assistenziali con l'incarico di dirigente medico presso l'U.O. convenzionata di Malattie Infettive 3
30/01/2012 al 31/01/2015	
Nome e indirizzo del datore di lavoro	Università degli Studi di Milano, Via Festa del Perdono, 7 20122 Milano
Tipo di azienda o settore	
Principali mansioni e responsabilità	Ricercatore (MED17) confermato, settore concorsuale 06/D4.
1/02/2015 a tutt'oggi	
Nome e indirizzo del datore di lavoro	Università degli Studi di Milano, Via Festa del Perdono, 7 20122 Milano
Tipo di azienda o settore	
Principali mansioni e responsabilità	Professore Associato (MED17), settore concorsuale 06/D4.
1/02/2021 a tutt'oggi	
Nome e indirizzo del datore di lavoro	ASST Ovest Milanese
Tipo di azienda o settore	
Principali mansioni e responsabilità	Direttore della Struttura Complessa di Malattie Infettive, Ospedale di Legnano (MI), convenzionata con l'Università degli Studi di Milano dallo 01-01-2023.

FINANZIAMENTI SCIENTIFICI E RICONOSCIMENTI

1999-2005	Titolarità del Progetto di Ricerca "Studio dei meccanismi di azione e dell'efficacia terapeutica in vitro delle combinazioni di inibitori dei co-recettori di HIV-1", finanziato dall' Istituto Superiore di Sanità (ISS), Roma – III, IV e V Programma nazionale di ricerca sull'AIDS (numeri 40C.80, 40D.74 e 30F.46)
2001	Premio Scientifico "Giovane Battista Rossi", ANLAIDS, Roma, quale migliore ricercatore italiano sull'AIDS di età inferiore a 40 anni

2001 a tutt'oggi	Membro dell'Editorial Board di: <i>Recent Patents on Anti-Infective Drug Discovery</i> , <i>HIV Therapy</i> , <i>HAART and correlated pathologies</i> , <i>Future Virology</i> , BMC Infectious Diseases (Associate Editor) , BMJ-STI (Associate Editor) e Journal of HIV and Ageing (Associate Editor) . E' reviewer per le seguenti riviste scientifiche: <i>AIDS</i> , <i>Journal of AIDS</i> , <i>Journal of Infectious Diseases</i> , <i>Antiviral Therapy</i> , <i>Journal of Antimicrobial Chemotherapy</i> , <i>Recent Patents on Anti-Infective Drug Discovery</i> , <i>HIV Therapy</i> , <i>PLoS ONE</i> , <i>EClinicalMedicine</i> , <i>Journal of Public Health and Epidemiology</i> , <i>HIV Medicine</i> , <i>AIDS Research and Human Retroviruses</i> , <i>HIV Clinical Trials</i> , <i>Antiviral Research</i> , <i>Infezioni in Medicina</i> .
2008	Finanziamento per il progetto Investigator Initiated Research "Use of maraviroc (MVC) in immunological non-responder HIV-1 infected patients" da parte di Pfizer Italia S.r.l.
2009-2010	Finanziamento per il progetto NEAT Integration Grant 2009-2010 "Efficacy and safety of a switch to unboosted atazanavir among HIV-infected patients well suppressed under HAART" da parte di NEAT ID Foundation, London, UK.
2010	E' stato eletto consigliere della Società Italiana di Malattie Infettive e Tropicali (SIMIT) sezione Lombardia il 24 maggio 2010, con mandato triennale.
2012	E' stato eletto regional representative dell'EACS (European Clinical AIDS Society) il 24 settembre 2012, con mandato quadriennale.
2013	Finanziamento per il progetto Ricerca Finalizzata 2013 "Implication for strategies of long term control of viral replication in patient with primary HIV infection (PHI) treated with multitarget antiviral therapy (MT-ART): kinetics of viral reservoir, immunological response and drug penetration in lymphoid tissues", codice progetto NET-2013-02355333, da parte del Ministero della Salute (principal investigator: Giuseppe Tambussi/Silvia Nozza).
2013-2014	Finanziamento per il progetto Investigator Initiated Research "STUDIO STRATEGICO DI TERAPIA DUPLICE CON DARUNAVIR/rtv E RILPIVIRINA QD VS TERAPIA TRIPLICE IN PAZIENTI CON VIREMIA SOPPRESSA: EFFICACIA VIROLOGICA E VALUTAZIONE DELLA MORBIDITA' NON-HIV CORRELATA. HLS03/2012" da parte di Janssen-Cilag SpA.
2015	Finanziamento per il progetto Fellowship Program "Strategie di miglioramento della qualità di vita di soggetti con recente diagnosi di sieropositività per HIV-1 attraverso interventi di web counseling. Identificazione di predittori psicosociali e neuroormonali correlati alla aderenza alla HAART" da parte di Gilead Sciences Italia S.r.l.
2015	Da marzo 2015 è responsabile del AAMC-VSLO program dell'Association of American Medical Colleges presso l'Università degli Studi di Milano per la frequenza di corsi all'estero da parte degli studenti di medicina.
2018	Dal 1 gennaio 2018 è stato nominato Associate Editor della rivista scientifica <i>BMC Infectious Diseases</i> .
2018	Finanziamento per il progetto PSR Linea 2 "From MSCs dysfunction to osteoporosis and lipodystrophy: a molecular study of HIV Protease and Integrase Inhibitors side effects" da parte di DIBIC Luigi Sacco, Università degli Studi di Milano [Investigators: Stefano Rusconi (Malattie Infettive), Jeanette Maier (Patologia Generale), Giovanni Casazza (Statistica Medica)].
2018-2020	E' stato eletto componente del Consiglio Direttivo dell'Ordine dei Medici Chirurghi e degli Odontoiatri di Milano per il triennio 2018-2020, dove è Referente della Commissione Bioetica.
2019	Dal 24 gennaio 2019 è stato nominato referente Assicurazione Qualità del Dipartimento DIBIC Luigi Sacco, Università degli Studi di Milano.
2019	Finanziamento per il progetto Grant for publication "Impatto dello switch a regimi STR contenenti tenofovir alafenamide con e senza cobicistat sul rischio cardiovascolare e profilo metabolico in pazienti HIV positivi in soppressione virologica stabile" da parte di Gilead Sciences Italia S.r.l.
2020	Membro dell'STI perspective panel, <i>BMJ</i> , London, UK.
2020	Finanziamento per il progetto "SARS Transmission Obstruction Platform - COVID-19 (STOP-Cov)" da parte di Regione Lombardia - POR FESR 2014-2020 – COVID 19 (capofila di progetto: AXXAM SpA, partners: Università Vita e Salute San Raffaele e Università degli Studi di Milano).
2020	Finanziamento per il progetto PSR Linea 2 "Aerosol molecolare per downregolare l'espressione di ACE2 e prevenire l'ingresso di SARS-CoV-2 nelle cellule target" da parte di DIBIC Luigi Sacco, Università degli Studi di Milano [Investigators: Cristian Loretelli (CRC Invernizzi - Pediatria), Stefano Rusconi (Malattie Infettive)].
2021	Finanziamento per il progetto presentato nell'ambito del "Bando COVID-19", promosso dalla DG Welfare di Regione Lombardia nel corso dell'anno 2020 "Identificazione e valutazione di marcatori diagnostici e opzioni terapeutiche per l'infezione da SARS-CoV-2" da parte della Fondazione Romeo ed Enrica Invernizzi [Investigator: Stefano Rusconi (Malattie Infettive)].

- 2022** Referente aziendale ASST Ovest Milanese del progetto finanziato dalla Fondazione Cariplo "The Post-Covid-19 Syndrome: network building and innovative management to address a new public health emergency (PASCNET) [Investigator: Stefano Rusconi (Malattie Infettive)].
- 2022** Referente aziendale ASST Ovest Milanese per il progetto "Programma per l'attuazione del piano per l'eliminazione dell'HCV in regione Lombardia", promosso dalla D.G. Welfare di Regione Lombardia nel corso dell'anno 2022.

INCARICHI DI INSEGNAMENTO

- 1990-1991** Incarico di insegnamento di Immunologia all'interno della Scuola per Infermieri Professionali, Ospedale Luigi Sacco, Milano
- 2000-2001** Professore a Contratto di Virologia Clinica presso la Scuola di Specializzazione in Malattie dell'Apparato Respiratorio, Dipartimento di Medicina Interna (DIMI), Università degli Studi di Genova
- 1994 a tutt'oggi** Collaboratore didattico per le attività pratiche, Laurea in Medicina e Chirurgia, Scuola di Specializzazione in Malattie Infettive e Scuola di Specializzazione in Malattie Tropicali, Università degli Studi di Milano
- 2002 a tutt'oggi** Professore a Contratto di Malattie Infettive per il Corso di Laurea in Medicina e Chirurgia, Università degli Studi di Milano
- 2004 a tutt'oggi** Tutore/valutatore per l'esame di Stato di abilitazione alla professione di Medico Chirurgo, Laurea in Medicina e Chirurgia, Università degli Studi di Milano
- 2009-2010-2011** Incarico di insegnamento di Malattie Infettive (MED17) all'interno del Corso integrato di Patologia Generale e Clinica, Laurea in Infermieristica Pediatrica, Università degli Studi di Milano: 15 ore annue di insegnamento (1 CFU)
- 2010-2011, a tutt'oggi** Aggregato all'insegnamento di Malattie Infettive (MED17) all'interno del Corso di Malattie Infettive del Prof. Massimo Galli, Professore Ordinario presso l'Università degli Studi di Milano, Laurea in Medicina e Chirurgia, Università degli Studi di Milano, polo Vialba: 6 ore annue di insegnamento
- 2012-2013, a tutt'oggi** Incarico di insegnamento di Malattie Infettive (MED 17), Laurea Magistrale in Scienze delle Professioni Sanitarie della Prevenzione, 16 ore annue di insegnamento. (2 CFU)
- 2015-2018** Incarico di insegnamento di Malattie Infettive (MED 17), Laurea Triennale in Igiene Dentale, 10 ore annue di insegnamento. (1 CFU)
- 2015-2016 a tutt'oggi** Incarico di insegnamento di Malattie Infettive (MED 17), Laurea Triennale in Podologia, 10 ore annue di insegnamento. (1 CFU)
- 2016-2017 a tutt'oggi** Incarico di insegnamento di Bioetica e Malattie Infettive (MED 17), Corso di Perfezionamento in Scienza dell'alimentazione e nutrizione applicata (4 ore)
- 2009 a tutt'oggi** Membro del Collegio dei Docenti del Dottorato in Malattie Infettive, Università degli Studi di Milano, ora Scuola di Dottorato in Ricerca Clinica.
- 2008-2009, 2009-2010, 2010-2011** Membro del CCD, Laurea in Infermieristica Pediatrica, Università degli Studi di Milano
- 2010-2011, a tutt'oggi** Membro del CCD, Laurea in Medicina e Chirurgia, Università degli Studi di Milano, polo Vialba

ISTRUZIONE E FORMAZIONE

- | | |
|--|---|
| 1981 | Maturità Scientifica 58/60 |
| 1988 | Laura in Medicina e Chirurgia (105/110) |
| Qualifica conseguita | Medico Chirurgo |
| Nome e tipo di istituto di istruzione o formazione | Università degli Studi di Milano |
| 1991 | Specialità in Allergologia e Immunologia Clinica (Direttore Prof. C. Zanussi) |
| Qualifica conseguita | Medico Specialista in Allergologia e Immunologia Clinica |
| Nome e tipo di istituto di istruzione o formazione | Università degli Studi di Milano |
| 1997 | Specialità in Malattie Infettive (Direttore Prof. Mauro Moroni) |
| Qualifica conseguita | Medico Specialista in Malattie Infettive |

Nome e tipo di istituto di istruzione o formazione	Università degli Studi di Milano
1985-1986	Internato
Nome e tipo di istituto di istruzione o formazione	Clinica Medica (Direttore Prof. Arnaldo Libretti) Università degli Studi di Milano
1986-1987	Internato
Nome e tipo di istituto di istruzione o formazione	Istituto di Malattie Infettive (Direttore Prof. Mauro Moroni) Università degli Studi di Milano

CAPACITÀ E COMPETENZE PERSONALI

CORSI DI SPECIALIZZAZIONE

1998	“Design and Conduct of Clinical Trials”, Clinical Research Program, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA
2003	Corso di perfezionamento in Bioetica, Facoltà di Scienze della Formazione, Centro di Bioetica, Università Cattolica del Sacro Cuore, Milano
2009	Corso di perfezionamento in Bioetica Progredito I, Facoltà di Scienze della Formazione, Centro di Bioetica, Università Cattolica del Sacro Cuore, Milano

CORSI DI FORMAZIONE MANAGERIALE

17/11/2021 al 12/5/2022	“Corso di formazione manageriale per dirigente di struttura complessa - DSC”, codice edizione UNILIUC DSC 2101/BE, accreditato da Accademia di formazione per il servizio sociosanitario Lombardo (PoliS Lombardia) ed erogato dall’Università Carlo Cattaneo – LIUC, svolto presso l’Università LIUC di Castellanza (VA)
--------------------------------	---

PRIMA LINGUA **italiano**

ALTRE LINGUE

inglese

Capacità di lettura	ottima
Capacità di scrittura	ottima
Capacità di espressione orale	ottima

CAPACITÀ E COMPETENZE RELAZIONALI

E’ attivamente impegnato nell’aiuto ai Paesi a basse risorse nell’ambito dell’infezione da HIV/AIDS con il **CUAMM – Medici con l’Africa**, per cui ha partecipato a missioni brevi in Uganda (Gulu 1990 e Matany 1999) e Tanzania (Tosamaganga 1997) e di cui fa parte del gruppo formatori. Ha fondato nel febbraio 2001 l’Associazione Cielo e Terre. L’Associazione è stata costituita come Onlus ed è iscritta al Registro Regionale Lombardo delle Organizzazioni di Volontariato dal 2003. Fa parte del Consiglio direttivo dell’Associazione e dal 1° gennaio 2002 è impegnato nella conduzione del “Progetto per la salute e la lotta contro l’AIDS in Guinea Bissau”, Bissau, Guinea Bissau. Nel 2007 (luglio-agosto) ha svolto l’attività di “Preceptor” per il programma PEPFAR del governo statunitense a Dar Es Salaam, Tanzania, impegnandosi nell’attività clinica e didattica nei centri ambulatoriali e ospedalieri per la cura dell’HIV/AIDS. **Fa parte dei gruppi di appoggio di CUAMM – Medici con l’Africa di Milano e di Rho. Dal 2000 fa parte del pool di medici volontari di Oltre il Diritto – Cooperatica Intrecci, Caritas rhodense.** **Negli anni 2010-2020 ha avuto un mandato triennale nel Consiglio Direttivo del Centro di Consulenza per la Famiglia – Decanato di Rho.** **Negli anni 2000-2023 ha fatto, e fa parte, del Consiglio Pastorale della Parrocchia di San Vittore Martire, Rho.** **Negli anni 2000-2023 ha fatto, e fa parte, del Consiglio Direttivo, con funzioni di segretario, della sezione milanese, dedicata a Santa Gianna Beretta Molla, dell’AMCI (Associazione Medici Cattolici Italiani).** **Ha voluto fortemente e contribuito all’adesione della città di Legnano alla iniziativa Fast Track Tities per azzerare le nuove infezioni da HIV e HCV nel mondo entro il 2030, firmando la dichiarazione di Parigi il 2 novembre 2022.**

CAPACITÀ E COMPETENZE ORGANIZZATIVE	E' responsabile di un gruppo di ricerca clinica e di base nelle seguenti aree: (i) Costruzione di modelli sperimentali di terapia antiretrovirale e di virus mutanti <i>in vitro</i> (ii) Analisi della resistenza genotipica e fenotipica ai farmaci antiretrovirali (iii) Disegno e conduzione di protocolli sperimentali di terapia antiretrovirale
CAPACITÀ E COMPETENZE TECNICHE Con computer, attrezzature specifiche, macchinari, ecc.	METODICHE LABORATORISTICHE DI BIOLOGIA CELLULARE E MOLECOLARE, ANALISI STATISTICHE DI BASE, USO DI PC E PROGRAMMI CORRELATI
PATENTE	"B"
ULTERIORI INFORMAZIONI	Pubblicazioni: 310 lavori su riviste scientifiche internazionali (Scopus) 9 capitoli di libro H-index (Web of Science): 38.

Membro del comitato scientifico della Fondazione ICONA;
 membro dello steering committee della coorte ARCA (ARCA Mentor School, ARCA Factory);
 membro dello steering committee del registro Prestigio;
 membro del gruppo Odoacre;
 membro della coorte CISAI;
 membro del writing committee delle Linee Guida italiane su HIV;
 membro dell'ICAR SPC (Scientific Program Committee);
 membro del Coordinamento Comitato di Redazione della rivista ReAd Files;
 ha ottenuto l'abilitazione scientifica nazionale a Professore di I fascia in Malattie Infettive (MED/17), settore concorsuale 06/D4 (malattie cutanee, malattie infettive e malattie dell'apparato digerente) il 10 aprile 2017 (validità al 10 aprile 2026).

Il sottoscritto è a conoscenza che, ai sensi dell'art. art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali ai sensi dell'art. 13 D. Lgs. 30 giugno 2003 n°196 – "Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 – "Regolamento europeo sulla protezione dei dati personali".

Rho, 23-4-2023

STEFANO RUSCONI

POSIZIONE ATTUALE

Borsista di ricerca presso il Dipartimento di Biotecnologie Mediche dell'Università di Siena (Italia), in possesso di abilitazione per il ruolo di professore di seconda fascia per le classi di insegnamento 06/A3 (Microbiologia e Microbiologia Clinica) e 05/12 (Microbiologia)

ESPERIENZA PROFESSIONALE

15/02/2019-14/02/2022

Ricercatore a tempo determinato tipo A (RTD-A)

Dipartimento di Biotecnologie mediche, Università di Siena

Attività: "Supporto virologico avanzato per lo studio ed il trattamento dell'infezione da HIV"

15/05/2012-14/05/2018

Assegnista di ricerca

Dipartimento di Biotecnologie mediche, Università di Siena

- Attività: sviluppo di sistemi diagnostici per il monitoraggio di infezioni virali umane causate da HIV, HBV, HCV, ZIKV, DENV, WNV

ISTRUZIONE E FORMAZIONE

02/11/2017 – 18/10/2021	Scuola di specializzazione in Microbiologia e Virologia	
	Università di Siena (Italia)	
	<ul style="list-style-type: none"> ▪ Titolo della tesi: "Evaluation of the Intact Proviral DNA Assay for monitoring HIV-1 reservoir in individuals under successful antiretroviral therapy" ▪ Votazione: 70/70 e lode 	
01/10/2007 – 30/09/2011	Dottorato di Ricerca in Biotecnologie Mediche	
	Sezione "Biotecnologie microbiche, vaccini e malattie infettive"	
	Università di Siena (Italia) <ul style="list-style-type: none"> ▪ Titolo della tesi di dottorato: "Advanced monitoring of HIV drug resistance" 	
01/10/2005 – 28/09/2007	Laurea magistrale in Biotecnologie per la salute umana (classe 9/S)	
	Università di Siena (Italia)	
	<ul style="list-style-type: none"> ▪ Titolo della tesi: "Development of a system for the identification of drug resistant minority species of HIV-1" ▪ Votazione: 110/110 e lode 	
01/10/2003 – 30/09/2005	Laurea triennale in Biotecnologie (classe L-2)	
	Università di Siena (Italia)	
	<ul style="list-style-type: none"> ▪ Titolo della tesi: "Utilizzo dei test genotipici di resistenza per la caratterizzazione dei sottotipi non-B di HIV-1" ▪ Votazione: 110/110 e lode 	

COMPETENZE PERSONALI

Lingua madre Italiano

Altre lingue

	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
Inglese	B1	B1	B1	B1	B1
2004 – Preliminary English Test, livello B2					

ULTERIORI INFORMAZIONI

Pubblicazioni	Autore di 60 pubblicazioni su riviste peer-reviewed, le pubblicazioni indicizzate su Pubmed sono consultabili al link https://www.ncbi.nlm.nih.gov/myncbi/francesco.saladini.1/bibliography/public/ Scopus ID 1630213870 ORCID ID 0000-0002-9934-377X H-index 16 (Scopus)
Progetti	Partecipazione in progetti finanziati a livello regionale ("UNAVIR", 2014; "PANVIR.NET", 2017; "TUSCAVIR.NET", 2018; finanziati da Regione Toscana), nazionale (PRIN 2008/2018/2021, Programma AIDS 2009, Gilead Fellowship 2012 e 2017) e internazionale ("EURESIST", 2006; "CHAIN", 2009; "THINPAD", 2013; "CARE", 2018; "EuCARE", 2021) finanziati dalla Comunità Europea)
Brevetti	Co-inventore del brevetto Europeo intitolato "HIV-1 Nucleocapsid Inhibitors" (numero applicazione EP16186511.8, data di sottomissione 11 Ottobre 2016)
Riconoscimenti e premi	<ul style="list-style-type: none"> ▪ Miglior abstract accettato come comunicazione orale in Virologia/Immunopatologia al 10° Congresso ICAR, 22-24 Maggio, Roma ▪ Miglior poster al 16° European Meeting on HIV and Hepatitis, 30 Maggio – 1 Giugno 2018, Roma. ▪ CROI-ICAR award, Seattle (USA), 4-7 Marzo 2019 ▪ CROI-ICAR award, Boston (Usa), 8-11 Marzo 2020
Attività didattica	Anno accademico 2021/22: <ul style="list-style-type: none"> • Docente del modulo di Microbiologia, Corso Integrato in Basi Morfologiche, Corso di Laurea in Dietistica, Università di Siena Anno accademico 2020/21: <ul style="list-style-type: none"> • Docente del modulo di Microbiologia, Corso Integrato in Basi Morfologiche, Corso di Laurea in Dietistica, Università di Siena • Docente del modulo di Virologia, Corso Integrato in Microbiologia, Corso di Laurea in Tecniche di Laboratorio Biomedico, Università di Siena Anno accademico 2019/2020: <ul style="list-style-type: none"> • Docente del modulo di Microbiologia, Corso integrato in Microbiologia, Corso di Laurea in Tecniche di Laboratorio Biomedico, Università di Siena
Incarichi istituzionali	Membro del Collegio dei Docenti della Scuola di Dottorato in Biotecnologie Mediche, Università di Siena, per gli anni accademici 2019/2020, 2020/2021 e 2021/2022.

Dati personali

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

Siena, li 21/02/2021
In fede,
Francesco Saladini

INFORMAZIONI PERSONALI

SANTORO MARIA

POSIZIONE RICOPERTA

Ricercatore a tempo determinato di tipo B presso la Cattedra di Virologia, Dipartimento di Medicina Sperimentale, Università di Roma "Tor Vergata", Via Montpellier 1, 00133 Roma

ESPERIENZA
PROFESSIONALE

(13/07/2017 - 13/07/2023)

Abilitata come professore di II Fascia II per il Settore Concorsuale 06/A3

(19/11/2018 - 19/11/2024)

Abilitata come professore di II Fascia II per il Settore Concorsuale 06/A3

(29/11/2019 – in corso)

Ricercatore a tempo determinato di tipo B

Università degli Studi di ROMA "Tor Vergata" - Via Cracovia 30-ROMA

L'attività attualmente consiste nel management e analisi di dati relativi al test di resistenza genotipica effettuato su pazienti con infezione croniche determinate da HIV e virus epatitici sia per routine clinica che per attività di ricerca. Inoltre svolgo attività di guida e supervisione delle attività di ricerca di laureandi in Biotecnologie Mediche e in Scienze Biologiche, di dottorandi di Microbiologia Medica e Immunologia, e specializzandi in Malattie Infettive e in Microbiologia e Virologia. Infine, svolgo attività didattica presso le Facoltà di Farmacia e di Medicina e Chirurgia dell'Univeristà degli Studi di ROMA "Tor Vergata".

Attività o settore Virologia

(01/12/2015 - 28/11/2019)

Funzionario tecnico (categoria D1)

Università degli Studi di ROMA "Tor Vergata" – Via Cracovia 50, Roma 00133

Attività o settore Virologia

(01/10/2013 - 30/11/2015)

Ricercatore a tempo determinato di tipo A

Università degli Studi di ROMA "Tor Vergata" - Via O. Raimondo, 18 Loc. La Romanina -ROMA

Attività o settore Virologia

(20/06/2010 – 20/08/2010)

Partecipazione ad un Visiting Research Scholar Program

▪ Department of Pathology, College of Medicine, University of Florida, Florida.

Studi di epidemiologia molecolare di HIV-1 nel bacino del Mediterraneo.

Attività o settore Virologia

(01/02/2008 - 30/09/13)

Assegnista di ricerca

Università degli Studi di ROMA "Tor Vergata" - Via O. Raimondo, 18 Loc. La Romanina - ROMA

▪ Analisi sperimentale, controllo e gestione di dati genotipici di HIV e virus epatitici.

[Attività o settore](#) Virologia

(2007) **Contratto (per tre mesi) di collaborazione occasionale**

Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani, Unità di Monitoraggio Terapie Antivirali e Antineoplastiche. ROMA

- Attività di ricerca sulle "Le resistenze ai farmaci anti-HIV: metodologie diagnostiche innovative e impatto clinico - azione concertata".

[Attività o settore](#) Virologia

(2006-2007) **Contratto di collaborazione**

Università degli Studi di ROMA "Tor Vergata" – Cattedra Virologia, Dipartimento di Medicina Sperimentale e Scienze Biochimiche - Via Montpellier,1 - ROMA

- Analisi e produzione dati al fine di definire il profilo di mutazioni genotipiche associate ai farmaci antiretrovirali come tenofovir per conto della Gilead Sciences Srl.

[Attività o settore](#) Virologia

(2005) **Contratto di collaborazione occasionale**

Università degli Studi di ROMA "Tor Vergata" - Via O. Raimondo,18 Loc. La Romanina - ROMA

- Analisi e produzione dati al fine di definire il profilo di mutazioni genotipiche associate ai farmaci antiretrovirali come tenofovir per conto della Gilead Sciences Srl.

[Attività o settore](#) Virologia

(2004) **Contratto di collaborazione occasionale**

Università degli Studi di ROMA "Tor Vergata" - Via O. Raimondo,18 Loc. La Romanina - ROMA

- Analisi e produzione dati genotipici di HIV.

[Attività o settore](#) Virologia

(01/10/2002-30/09/2004) **Borsista**

Università degli Studi di ROMA "Tor Vergata" - Via O. Raimondo,18 Loc. La Romanina - ROMA

- Analisi biomolecolare dei meccanismi associati alla Fitness virale.

[Attività o settore](#) Virologia

(01/06/2002-30/09/2002) **Contratto di collaborazione**

Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani, Unità di Monitoraggio Terapie Antivirali e Antineoplastiche. ROMA

- Compilazione e studio di un database di pazienti affetti da HIV.

[Attività o settore](#) Virologia

ISTRUZIONE E FORMAZIONE

(05/07/2006) **Conseguimento del titolo di dottore di ricerca in "Immunomicrobiologia Medica" presso la II Università di Roma "Tor Vergata", Dipartimento di Medicina Sperimentale e Scienze Biochimiche.**

(28/01/2004) **Abilitazione professionale di Biologo presso l'Università di Viterbo**

(05/07/2001) Laurea con votazione 108/110 in Scienze Biologiche, presso la II Università di Roma "Tor Vergata".

COMPETENZE PERSONALI

Lingua madre Italiano

Altre lingue	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
Inglese	B	B	B	B	B
Francese	B	B	A	A	A

Livelli: A1/2 Livello base - B1/2 Livello intermedio - C1/2 Livello avanzato

Competenze comunicative Discussione e presentazione di dati scientifici in congressi e workshop nazionali e internazionali. Frequente collaborazione con istituzioni quali ospedali e centri di ricerca nello scambio, discussione e analisi di dati scientifici.

Competenze organizzative e gestionali Esperienza nella gestione di studi clinici multicentrici e nel coordinamento del flusso di dati dai diversi centri. Collabora con diversi gruppi/enti di ricerca nazionali e internazionali grazie a fondi di ricerca dell'Istituto Superiore di Sanità, del Ministero della Salute, dell'Università e della Ricerca Scientifica, della Comunità Europea e del CNR.

Competenze professionali Oltre alle basilari procedure di laboratorio, la sottoscritta ha acquisito negli anni una padronanza di varie metodiche in diversi settori utili per la microbiologia.

ULTERIORI INFORMAZIONI

Attività didattica

- (01/07/2010 - 17/01/2011) Tutor, Docente e Collaboratrice nella segreteria scientifica per il Corso di Perfezionamento in Gestione Clinica delle Resistenze ai Farmaci Antivirali (Direttore del Corso Prof. Carlo Federico Perno), tenutosi presso la Facoltà di Medicina dell'Università degli Studi di Roma Tor Vergata (A.A. 2009-2010) (CFU: 20).
- (01/11/2014 - oggi) Docente di Virologia (CFU: 1) per il Corso di Medicina pratica 3 afferente al Corso di Laurea Magistrale in Medicina e Chirurgia (Macroarea di Medicina e Chirurgia) dell'Università degli Studi di Roma "Tor Vergata", Roma.
- (01/11/2014 - oggi) Docente (CFU: 1) di Virologia speciale e componente delle commissioni d'esame di profitto per il Corso Integrato di Microbiologia e Microbiologia Clinica I 2anno, nell'ambito del Corso di Laurea in Tecniche di Laboratorio Biomedico (Dipartimento di Medicina E Chirurgia) dell'Università degli Studi di Roma "Tor Vergata", Roma.
- (01/11/2015 - oggi) Docente di lezioni integrative e componente delle commissioni d'esame di profitto per il Corso Integrato di Microbiologia, nell'ambito del Corso di Laurea Magistrale a ciclo unico in Medicina e Chirurgia (Dipartimento di Medicina E Chirurgia) dell'Università degli Studi di Roma "Tor Vergata", Roma.
- (01/11/2015 - oggi) Cultore della materia e componente delle commissioni d'esame di profitto per il Corso Microbiology and Immunology (in inglese) nell'ambito del Corso di Laurea Magistrale in Farmacia (Area di Scienze MM.FF.NN. e Medicina e Chirurgia) dell'Università degli Studi di Roma "Tor Vergata", Roma.
- (22/03/2017 – 13/05/2017) Docente per il Corso di Perfezionamento in Terapia Antiretrovirale - Antiretroviral therapy (Direttore del Corso Prof. Paolo Rossi), presso la Facoltà di Medicina dell'Università degli Studi di Roma "Tor Vergata" nell'ambito della Scuola di Alta Formazione in Pediatria in convenzione con l'IRCCS Bambino Gesù (A.A. 2015-2016) (CFU: 9).

Incarichi speciali

- (28/05/2015 - oggi) Membro dello Steering Committee dell'Italian Cohort of antiretroviral-naive patients (ICONA) Study group.
- (21/05/2012 - oggi) Membro del panel delle "Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1"
- (05/12/2016 - oggi) Membro del Board Scientifico del Database ARCA (Antiviral Response Cohort Analysis). ARCA è una banca dati multicentrica a cui afferiscono circa 100 laboratori di virologia e cliniche di malattie infettive, operativa sul territorio nazionale dal 2002.
- (14/12/2017 - oggi) Membro dello Steering Committee del Registro Italiano dei Pazienti con Infezione da HIV-1 con RESistenza agli Inibitori della Trascrittasi inversa, dell'InteGrasI e della PrOteasi virale (PRESTIGIO). .

Attività editoriale

Dal 2008 ad oggi revisore di articoli scientifici dalle seguenti riviste "peer reviewed": AIDS patient CARE and STDs; Journal of Antivirals & Antiretrovirals; Journal of Public Health and Epidemiology; Future Virology; Clinical Microbiology and Infection; Journal of Global Antimicrobial Resistance; Journal of Antimicrobial Chemoterapy; Clinical Epidemiology; PlosOne; BMC Infectious Disease; HIV/AIDS - Research and Palliative Care; Journal of Medical Virology; Current HIV Research; Journal of the International AIDS Society; International Journal of Virology and AIDS; Journal of Medical Virology.

Premi e Riconoscimenti

Ha ricevuto 14 premi a riconoscimento della propria attività scientifica.

Attività scientifica personale

Autrice di >400 articoli scientifici e presentazioni a congressi, di cui 130 in extenso su riviste internazionali citate su PubMed con IF. Totale Citazioni (fonte: Google Scholar, 12/02/2022): 2543
Indice H (fonte: Google Scholar, 04/01/2022): 25
Impact Factor medio articoli pubblicati: 3,995
Le pubblicazioni della sottoscritta sono relative ai seguenti filoni di ricerca: infezione da HIV e la sua epidemiologia; farmaci antivirali; farmacoresistenza di HIV/HBV/HCV; patogenesi virale; tropismo virale; evoluzione e dinamica virale; diagnostica molecolare; analisi strutturale e funzionale delle proteine virali.

Partecipazione a congressi

Ha partecipato a numerosi congressi scientifici nazionali e internazionali presentandovi comunicazioni orali e poster. Ha tenuto letture a invito a Congressi Nazionali e/o Internazionali.

Altre competenze

- Dal 1992 al 2013 ho svolto anche altri tipi di attività lavorative quali: cameriera presso pub (2001 - ad al 2013), animatrice per feste, promoter; segretaria presso studio dentistico; commessa.
- Nuoto, yoga, bicicletta.

Patente di guida

B

Dati personali

Autorizzo il trattamento dei miei dati personali ai sensi del GDPR e del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" ai fini di attività di Ricerca e Selezione del Personale e contatti lavorativi.

La sottoscritta è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Ai sensi del D.P.R. 445/2000 attesto la veridicità di quanto riportato nel presente curriculum vitae.

Roma 22/02/2022

CURRICULUM VITAE

Vincenzo Spagnuolo

- **ATTIVITÀ LAVORATIVA**

OTTOBRE 2021-oggi

IRCCS Ospedale San Raffaele, Dipartimento Malattie Infettive, via Stamira d'Ancona 20, Milano
Infettivologo; Aiuto ospedaliero

OTTOBRE 2016-SETTEMBRE 2021

Università Vita-Salute San Raffaele, via Olgettina 58, Milano
Ricercatore a tempo determinato di tipo A, con funzioni assistenziali

AGOSTO 2011-SETTEMBRE 2016

IRCCS Ospedale San Raffaele, Dipartimento Malattie Infettive, via Stamira d'Ancona 20, Milano
Infettivologo; Medico Consulente

LUGLIO 2007-LUGLIO 2011

Università Vita-Salute San Raffaele, Via Olgettina 58, Milano
Dipartimento Malattie Infettive Ospedale san Raffaele, Via Stamira d'Ancona 20
Medico Specializzando, Scuola Specializzazione Malattie Infettive

SETTEMBRE 2006- LUGLIO 2007

Dipartimento Malattie Infettive, Ospedale San Raffaele, via Stamira d'Ancona 20
Medico Volontario

Attività di ricerca

Attività di ricerca clinica primariamente dedicata al trattamento dell'infezione da HIV, delle complicanze metaboliche e delle comorbidità associate, in primo luogo MST e patologie neoplastiche, e al fenomeno della multiresistenza in HIV.

Co-investigatore in numerosi trial clinici multicentrici internazionali e nazionali di terapia antiretrovirale (es. LAPTOP, MK-020, VIKING, VIKING III, SINGLE, GS-US-0102, GS-US-01089, GS-US-1090, GS-US-1717 ARIA, SAILING, MODAt, DOLATAV, MOLO, MONO, ATLAS, NEAT, GS-US-0110, GS-US-0115, ECHO, SENSE, DUET, STARTMRK, BENCHMRK, FLAMINGO. Co-autore del protocollo per gli studi MODAt (NCT01511809), DOLATAV (NCT02542852) e APACHE (NCT03198325).

Referente operativo per il Registro Italiano PRESTIGIO (NCT04098315) che include PWH con resistenza accertata ad almeno 4 classi di farmaci antiretrovirali.

Negli ultimi due anni partecipazione a diversi progetti di ricerca sull'infezione da SARS-CoV-2 e sub-investigatore in diversi trial clinici di terapia per il COVID-19 (favipiravir HS216C17; CT-P59 3.2; MK-4482/002 molnupiravir).

Reviewer per le seguenti riviste scientifiche: Lancet Global Health, Clinical Infectious Diseases, Journal of Antimicrobial Chemotherapy, International Journal of Cancer, Scientific Reports, Viruses, Expert Opinion on Drug Metabolism & Toxicology, Expert Review of Clinical Immunology, Sexually Transmitted Diseases, AIDS Research and Human Retroviruses, BMJ Open, BMC Infectious Diseases, Plos One.

Attività di docenza

Docente per i Corsi di Laurea in:

- Medicina e Chirurgia (Corso Integrato Malattie Infettive)
- Scienze Infermieristiche (Infermieristica Clinica in area medica)
- Igiene dentale (Principi di medicina generale)
- Odontoiatria e Protesi Dentali (Malattie infettive, Scienze Mediche II)
- International MD Program (Internal Medicine)
- International MD Program (Infectious Diseases)

Docenza Scuola di Specializzazione (OSR):

- Malattie Infettive e Tropicali
- Anestesia e Rianimazione
- Igiene e sanità Pubblica
- Seminari Scuole di Specializzazione Mediche (tronco comune)

Ideatore e Responsabile corso elettivo: "Innovations that changed Medicine"; 2°anno IMDP

Attività assistenziale

Gestione del paziente con problematiche infettivologiche in regime di degenza, Day Hospital e ambulatoriale.

Attività di guardia attiva infettivologica con mansioni di gestione clinica dei pazienti degenti presso il Dipartimento di Malattie Infettive e di consulenza infettivologica per i diversi Dipartimenti dell'Ospedale San Raffaele.

Valutazione ambulatoriale dei pazienti con problematiche infettivologiche urgenti, infezione da HIV /epatiti virali e gestione delle MST.

Responsabile medico Centro Antifumo SRT.

Da febbraio 2020 attività clinica nei reparti COVID sia di SRT che di OSR. Prescrizione antivirali e anticorpi monoclonali per l'ambulatorio paucisintomatici COVID-19. Attività di assistenza nel Pronto Soccorso COVID-19 (area respiratoria) OSR (Febbraio 2022)

Co-autore della "Tabella sinottica terapia farmacologica per la gestione del COVID-19" in uso presso OSR.

Certificazione BLS-D e ALS.

• **ISTRUZIONE E FORMAZIONE**

APRILE 2015-MARZO 2016

Società Italiana Malattie Infettive e Tropicali

Borsa di Studio 2014 per il progetto dal titolo: " Prevalenza di neurologie in pazienti con infezione da HIV-1 e mancata risposta sierologica al trattamento per sifilide precoce"

MARZO 2013-MARZO 2015

Università Vita-Salute San Raffaele

Assegnista di ricerca per il progetto: "Simplification strategy in virologically suppressed HIV-infected subjects: the role of peripheral reservoirs, residual viremia and chronic inflammation"

LUGLIO 2007-LUGLIO 2011

Università Vita-Salute San Raffaele

Scuola di Specializzazione in Malattie Infettive

Specialista in Malattie Infettive con pieni voti assoluti e lode con una tesi dal titolo "Long-term immune recovery and suppression of viral replication in HIV-related lymphoma survivors: a case-control study".

OTTOBRE 2000- LUGLIO 2006

Università Vita-Salute San Raffaele, Via Olgettina 58
Corso di Laurea Magistrale in Medicina e Chirurgia
Laurea Magistrale in Medicina e Chirurgia con pieni voti assoluti.

PREMI

ICAR CROI AWARDS 2019 for the abstract "Time To Undetectable Viral Load Achievement After Art Start And Risk Of Mortality".

New Investigator Award, 26th Conference on Retroviruses and Opportunistic Infections March 4-7, 2019 Seattle, Washington

BEST POSTER AWARD 16th European AIDS Conference, 25-27th October 2017, Milan; poster BPD 2/6: "Screening for inducible myocardial ischemia in asymptomatic HIV subjects"

ICAR CROI AWARDS 2015 for the abstract "RANKL predicts 96-week BMD changes in ATV/r monotherapy: a MODAt trial sub-study".

Young Investigator Award 2015 22th Conference on Retroviruses and Opportunistic Infections February 23-26, 2015 Seattle, Washington

ICAR CROI AWARDS 2013 for the abstract: "Association between statin use and type-2 diabetes mellitus occurrence among HIV-1 infected patients receiving antiretroviral therapy"

Young Investigator Award 2013, 20th Conference on Retroviruses and Opportunistic Infections March 3-6, 2013 at the Georgia World Congress Center in Atlanta.

2009 Read Files Research Award for the study "Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1 infected multidrug-resistance patients", published on J Acquir Immune Defic Syndr 2009 Feb 1; 50 (2): 192-5

SOCIETA' SCIENTIFICHE

Membro della Società Italiana Malattie Infettive e Tropicali (SIMIT)

Membro dell'European AIDS Clinical Society

Consigliere SIMIT Lombardia dal Giugno 2018 al Giugno 2022

FINANZIAMENTI

-Bando GILEAD Fellowship Program 2016: "Prevalenza di ridotta riserva coronarica diagnosticata tramite test ergometrico in soggetti HIV-positivi asintomatici (studio CORDIS)". Collaboratore; Principal Investigator: Prof. Antonella Castagna; Finanziamento 20.000 euro.

-Bando GILEAD Fellowship Program; AREA HIV 2018: "Implementazione ed efficacia di una strategia strutturata per la cessazione dell'abitudine al fumo in una coorte di persone con infezione da HIV: lo studio CENERE". Principal Investigator. Finanziamento 30.000 euro

- Bando GILEAD Fellowship Program; Area HIV 2021: "Impatto della pandemia da COVID-19 sull'incidenza e prevalenza di sindrome metabolica e sulla variazione del rischio cardiovascolare in persone con infezione da HIV". Principal Investigator. Finanziamento 30.000 euro

- PRIN2017 "IMmuno-VIrological DYnamics triggered by anti-HIV therapy Suspension (IMVIDYS)"; Partecipante. Coordinatore: Prof. Guido Poli. Finanziamento 799.800 euro.

Abilitazione Scientifica Nazionale.

Ottenimento Abilitazione a Professore di Seconda Fascia, sessione 2016, Quinto Quadrimestre, SSD 06/D4. Valida dal 31.10.2018

PUBBLICAZIONI 2021-2023

Clemente T, Caccia R, Galli L, Galli A, Poli A, Marchetti GC, Bandera A, Zazzi M, Santoro MM, Cinque P, Castagna A, **Spagnuolo V**; PRESTIGIO Study Group. Inflammation burden score in multidrug-resistant HIV-1 infection. *J Infect.* 2023 Mar 11;S0163-4453(23)00139-1. doi: 10.1016/j.jinf.2023.03.011

Muccini C, Ceccarelli D, Lolatto R, **Spagnuolo V**, Oltolini C, Danise A, Mainardi I, Monardo R, Castagna A. Should we expect weight changes in people with HIV and a reported weight gain only by switching antiretroviral therapy? *New Microbiol.* 2023 Feb;46(1):65-67.

Raccagni AR, Galli L, **Spagnuolo V**, Bruzzesi E, Muccini C, Bossolasco S, Ranzenigo M, Gianotti N, Lolatto R, Castagna A, Nozza S. Meningococcus B Vaccination Effectiveness against *Neisseria gonorrhoeae* Infection in People Living with HIV: a Case-control Study. *Sex Transm Dis.* 2023 Jan 13. doi: 10.1097/OLQ.0000000000001771.

Saladini F, Giammarino F, Maggiolo F, Ferrara M, Cenderello G, Celesia BM, Martellotta F, **Spagnuolo V**, Corbelli GM, Gianotti N, Santoro MM, Rusconi S, Zazzi M, Castagna A; PRESTIGIO Study Group. Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry. *Int J Antimicrob Agents.* 2023 Mar;61(3):106737. doi: 10.1016/j.ijantimicag.2023.

Raccagni AR, Bruzzesi E, **Spagnuolo V**, Canetti D, Castagna A, Nozza S. 'Multidrug-resistant *Mycoplasma genitalium* urethritis: successful eradication with sequential therapy. *Sex Transm Infect.* 2023 Feb;99(1):77. doi: 10.1136/sextrans-2022-055678.

Clemente T, **Spagnuolo V**, Bottanelli M, Ripa M, Del Forno B, Busnardo E, Di Lucca G, Castagna A, Danise A. Disseminated *Mycobacterium chimaera* infection favoring the development of Kaposi's sarcoma: a case report. *Ann Clin Microbiol Antimicrob.* 2022 Dec 9;21(1):57. doi: 10.1186/s12941-022-00547-x.

Alberton F, Nozza S, Raccagni AR, Galli L, **Spagnuolo V**, Bossolasco S, Cernuschi M, Canetti D, Hasson H, Castagna A, Gianotti N. The Propensity for Long-Acting Cabotegravir and Rilpivirine Every Two Months Among HIV-Infected People Eligible for Treatment. *J Med Virol.* 2022 Nov 22. doi: 10.1002/jmv.28330. Epub ahead of print. PMID: 36415058.

Ponta G, Ranzenigo M, Marzi A, Oltolini C, Tassan Din C, **Spagnuolo V**, Mazzone P, Carletti S, Mancini N, Uberti-Foppa C, Della Bella P, Scarpellini P, Castagna A, Ripa M. Cardiac implantable electronic device infections: impact of initiation of antimicrobial treatment before or after device removal on microbiological yield. *Clin Microbiol Infect.* 2022 Nov 3;S1198-743X(22)00545-6. doi: 10.1016/j.cmi.2022.10.031. Epub ahead of print. PMID: 36336235.

Spagnuolo V, Voarino M, Tonelli M, Galli L, Poli A, Bruzzesi E, Racca S, Clementi N, Oltolini C, Tresoldi M, Rovere Querini P, Dagna L, Zangrillo A, Ciceri F, Clementi M, Castagna A; COVID-BioB Study Group. Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study. *Drug Des Devel Ther.* 2022 Oct 19;16:3645-3654. doi: 10.2147/DDDT.S369473. PMID: 36268521; PMCID: PMC9578770.

Clemente T, Canetti D, Dagna L, Uberti Foppa C, Castagna A, **Spagnuolo V**, Nozza S, Campochiaro C. Monkeypox in a patient with undifferentiated connective tissue disease. *Rheumatology (Oxford).* 2022 Oct 4:keac568. doi: 10.1093/rheumatology/keac568. Epub ahead of print. PMID: 36193997.

Bruzzesi E, Galli L, Poli A, Bossolasco S, Cernuschi M, **Spagnuolo V**, Tamburini AM, Canetti D, Messina E, Gianotti N, Raccagni AR, Castagna A, Nozza S. Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization. *J Acquir Immune Defic Syndr.* 2022 Oct 1;91(2):226-231. doi: 10.1097/QAI.0000000000003057. PMID: 35973060.

Ranzenigo M, Gianotti N, Galli L, Poli A, Mastrangelo A, Bruzzesi E, Chiurlo M, Nozza S, Bossolasco S, **Spagnuolo V**, Mancusi D, Termini R, Carini E, Lazzarin A, Castagna A. Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice. *Drug Des Devel Ther.* 2022 Jun 27;16:1975-1982. doi: 10.2147/DDDT.S358976. PMID: 35783200; PMCID: PMC9249346.

Raccagni AR, Poli A, Galli L, **Spagnuolo V**, Bruzzesi E, Muccini C, Gianotti N, Canetti D, Mainardi I, Castagna A, Nozza S. Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV. *Sex Transm Infect.* 2022 May 6:sextrans-2021-055365.

Canetti D, Muccini C, **Spagnuolo V**, Galli L, Poli A, Gianotti N, Feasi M, Castagna A. Achieving virological control in pan-resistant HIV-1 infection: A case series. *EBioMedicine.* 2022 Mar;77:103906.

Byonanebye DM, Polizzotto MN, Neesgaard B, Sarcletti M, Matulionyte R, Braun DL, Castagna A, de Wit S, Wit F, Fontas E, Vehreschild JJ, Vesterbacka J, Greenberg L, Hatleberg C, Garges H, Gallant J, Volny Anne A, Öllinger A, Mozer-Lisewska I, Surial B, **Spagnuolo V**, Necsoi C, van der Valk M, Mocroft A, Law M, Ryom L, Petoumenos K; RESPOND study group. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. *HIV Med.* 2022 Mar 1. doi: 10.1111/hiv.13273.

Muccini C, Canetti D, Castagna A, **Spagnuolo V**. Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy. *Drug Des Devel Ther.* 2022 Jan 25;16:297-304. doi: 10.2147/DDDT.S273660.

Bruzzesi E, Ranzenigo M, Castagna A, **Spagnuolo V**. Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection. *New Microbiol.* 2021 Jul;44(3):135-144. PMID: 34783348.

Scutari R, Costabile V, Galli L, Bellocchi MC, Carioti L, Barbaliscia S, Poli A, Galli A, Perno CF, Santoro MM, Castagna A, Ceccherini-Silberstein F, Alteri C, **Spagnuolo V**. Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study. *Viruses.* 2021 Jul 19;13(7):1403. doi: 10.3390/v13071403.

Pastori C, Galli L, Siracusano G, **Spagnuolo V**, Muccini C, Mastrangelo A, Bruzzesi E, Ranzenigo M, Chiurlo M, Castagna A, Lopalco L. Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1-infected patients. *AIDS.* 2021 Aug 1;35(10):1549-1559.

Gianotti N, Galli L, Poli A, Torre LD, Vinci C, Carini E, Galli A, Nozza S, **Spagnuolo V**, Muccini C, Lazzarin A, Castagna A. Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen. AIDS. 2021 Jul 15;35(9):1513-1516.

Mastrangelo A, Burbelo PD, Galli L, Poli A, Alteri C, Scutari R, Muccini C, **Spagnuolo V**, Caccia R, Turrini F, Bigoloni A, Galli A, Castagna A, Cinque P. Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study). J Antimicrob Chemother. 2021 May 12;76(6):1646-1648.

Exercise ECG for coronary artery disease screening in people living with HIV.

Muccini C, Galli L, Poli A, Godino C, Gianotti N, Nozza S, Giusti MC, Lazzarin A, Margonato A, Castagna A, **Spagnuolo V**. AIDS. 2021 May 1;35(6):933-938. doi: 10.1097/QAD.0000000000002828. PMID: 33534202

Residual viremia in HIV-infected patients who continue a 2-drug or switch to a 3-drug integrase strand transfer inhibitor-based regimen.

Gianotti N, Galli L, Poli A, Torre LD, Vinci C, Carini E, Galli A, Nozza S, **Spagnuolo V**, Muccini C, Lazzarin A, Castagna A. AIDS. 2021 Apr 6. doi: 10.1097/QAD.0000000000002908. PMID: 33831909

Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study).

Mastrangelo A, Burbelo PD, Galli L, Poli A, Alteri C, Scutari R, Muccini C, **Spagnuolo V**, Caccia R, Turrini F, Bigoloni A, Galli A, Castagna A, Cinque P.

J Antimicrob Chemother. 2021 Mar 7:dkab060. doi: 10.1093/jac/dkab060. PMID: 33693943

Il sottoscritto è a conoscenza che, ai sensi dell'art. art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali ai sensi dell'art. 13 D. Lgs. 30 giugno 2003 n°196 – “Codice in materia di protezione dei dati personali” e dell'art. 13 GDPR 679/16 – “Regolamento europeo sulla protezione dei dati personali”.

Milano, 05 Aprile 2023

Vincenzo Spagnuolo

CURRICULUM VITAE

Personal Details

Surname:	Wensing	Sex:	Female
Christian names:	Adriana Maria Josephina	Nationality:	Dutch
Given name:	Annemarie	Date of Birth:	March 2, 1971

Positions & Qualifications

2012 - ongoing	Head of the Medical Microbiology Residency Program, UMC Utrecht
2012 - 2014	Head of Clinical Virology, Dept of Medical Microbiology, University Medical Center Utrecht (UMC Utrecht)
2002 – 2007	Junior Consultant Medical Microbiology, Dept of Medical Microbiology, UMC Utrecht
1999 – 2003	Junior Consultant at the HIV/AIDS out-patient clinic at the Dept. of Acute Medicine and Infectious Diseases
1999 – 2002	Research Physician, Dept. of Virology and Dept of Infectious Diseases, UMC Utrecht
1996 – 1998	Postgraduate rotations
1990 – 1996	Graduation from Medical School at Utrecht University

Management Experience

Committee memberships

2013	Member of the WHO Steering Group on Antiviral Resistance (RESNET)
2012 – ongoing	Regional Representative for region Europe West European Aids Clinical Society
2010 - ongoing	CEO European Society of translational Antiviral Research
2010 – 2012	Co-founder and member of the Board of the European HEPVIR Network
2007 –	(Ad hoc) Member of the Plenary Visitation Committee Medical Microbiology
2004 – 2007	Member of the board of the NVAMM, Dutch society of residents in Medical Microbiology and resident member of the board of the NVMM, Royal Dutch society of Medical Microbiology

Advisory Board memberships

2009 – ongoing	Member of the influenza and exposure to blood-borne pathogens committees UMC Utrecht
2006	Member of the committee on planning the demand for medical microbiologists in the Netherlands
Ongoing	Advisory Board Member of BMS, Gilead, Janssen

Guideline activities

2014	Chair of the European guidelines committee on HIV-1 low level viremia
2014	Member of the European HIV drug resistance panel
2014	Supervising author of the national Dutch HIV guideline of the National Institute of Public Health and Environment
2012	Member of the WHO Guideline Development Group on “Programmatic guidance” of programmes on the use of anti-retroviral drugs for the treatment and prevention of HIV infection.
2011 – ongoing	Member and since 2013 Chair of the IAS-USA HIV-1 Drug Resistance Mutations Panel.
2011 – 2013	Member of the WHO HIV Drug Resistance ResNet Expert Advisory Panel
2008 – ongoing	Member of the European guidelines committee on clinical management of HIV-tropism testing
2000 – 2003	Temporary advisor of the World Health Organisation on the international consultation on global monitoring of antiretroviral resistance, Rome 2000, Barcelona 2002, Oslo 2003

Editorial activities

2012	Guest editor September 2012 issue Current Opinion in HIV and AIDS (IF 4.474)
2006 – ongoing	Member of the editorial board of Reviews in antiviral therapy & infectious diseases
Ongoing	Ad-hoc reviewer for several international peer reviewed journals such as Antiviral Therapy, Clinical Infectious diseases, Journal of Antimicrobial Chemotherapy, Journal of AIDS, Journal of Clinical Virology, Journal of Infectious Diseases, Plos One, Retrovirology etc.

Conference Management

- 2014 - 2015 Programme Committee 13th European HIV & Hepatitis Workshop
- 2014 – 2015 Programme Committee 15th European AIDS Conference
- 2014 Co-chair Acute Hepatitis C Conference, Utrecht, April 24-25th
- 2012 – 2013 Member of the Scientific Committee of the 14th European AIDS conference
- 2012 Programme Committee Breakout Sessions 10th European HIV & Hepatitis Workshop
- 2011 – ongoing Member of the Scientific Committee of the European HIV & Hepatitis Workshop - Treatment Strategies & Antiviral Drug Resistance
- 2011 Initiator and scientific co-chair symposium: Klinische toepassing van en nieuwe ontwikkelingen rondom integrase remmers, October 27th and November 1st
- 2010 – 2012 Initiator and scientific co-chair Utrecht International HIV workshop
- 2010 Initiator and scientific co-chair symposium: University Medical Center Utrecht and Ndlovu care Group: Connecting North and South in Clinical Care and Science.
- 2009 Initiator and scientific co-chair symposium: Klinische toepassing van HIV Tropisme testen en CCR5 receptor antagonisten, November 5th and November 16th
- 2008 – ongoing Member of the scientific Poster Commission of the Royal Dutch society of Medical Microbiology
- 2006 – ongoing Member of the Organising Committee of the international HIV Transmission Workshop

Educational Experience

Teaching Experience (University Graduate/Post Graduate Lectures)

- 2007 – ongoing Utrecht University Pharmacy School. Lecture series for bachelor students: HIV pathogenesis and drug resistance
- 2009 Utrecht University, Veterinary School. Lecture for master students: Molecular Epidemiology of drug resistant HIV across Europe
- 2008 – ongoing Utrecht University Medical School. Lecture Series for bachelor students: Introduction into Virology and Antiviral Therapy_
- 2008 – ongoing Utrecht University Medical School. Lecture for master students: RNA Viruses: Evolution in a nutshell
- 2007 – ongoing Utrecht University Medical School. Lecture Series, workgroups and guided clinical meetings for bachelor students: Antiretroviral Resistance and Transmission of Therapy resistant HIV
- 2005 – 2007 Utrecht University Pharmacy School. Lecture Series for bachelor students: "HIV: pathogenesis and clinical implications
- 2003 – 2005 Utrecht University Pharmacy School. Lecture for bachelor students: Clinical implications of HIV

Teaching Experience (Courses, development of curricula)

- 2010 Activate clinical skills series at the National Institute for Infectious Diseases "Prof. Dr. Matei Bals" Bucharest. Lecture I: Transmission of HIV Drug Resistance in Europe; lessons from the SPREAD programme. Lecture II: Clinical management of HIV Drug Resistance. March 26th
- 2010 CME accredited Activate clinical skills series European HIV Drug Resistance Workshop, Sorrento Italy. Lecture: Resistance to New Antiviral drugs. March 18th
- 2010 Masterclass residents in Infectious Diseases: Interpretation of HIV-drug Resistance in 10 steps. AIOS Internal Medicine. Amsterdam. April 27th
- 2009 Clinical management of HIV tropism tests and CCR5-receptor antagonists. Accredited course for infectious disease specialists and microbiologists. Organizers: Wensing AM and Hoepelman IM. Lecture: Klinisch virologische aspecten van diagnostiek naar HIV Tropisme. Amersfoort, Eindhoven. November 5th and 16th
- 2009 CME accredited Activate clinical skills series at the European HIV Drug Resistance Workshop, Stockholm, Sweden. Lecture: Clinical management of Tropism testing. March 26th
- 2008 – 2010 Development of Curricula for Activate (DG Sanco EC project: 2006301) clinical skill series
- 2008 & 2011 HIV Master class for specialised nurses. Lecture. V&VN verpleegkundig consulenten HIV AIDS.
- 2005 Co-development of internet course for primary care physicians: HIV in the first line. Accredited by the Royal Dutch Society of Medicine. Organiser: Postgrade

TRACK RECORD

Name **ZAZZI, MAURIZIO**

WORK EXPERIENCE

<ul style="list-style-type: none">• Dates (from – to)• Name and address of employer<ul style="list-style-type: none">• Type of business or sector• Occupation or position held<ul style="list-style-type: none">• Main activities and responsibilities	01/11/2021 – present University of Siena , Via Banchi di Sotto 55, 53100 Siena, Italy University Full Professor of Microbiology Teaching: Microbiology and Virology, Laboratory Medicine for MD, Pharmacists, Lab Technicians, Biotechnologists. Hospital duties: Conventional and molecular diagnostics in virology, set up and running an HIV & Hepatitis dedicated service. Research: Development of molecular diagnostics applied to human viral infections, particularly HIV and hepatitis viruses, antiviral drug resistance, antiviral drug development.
<ul style="list-style-type: none">• Dates (from – to)• Name and address of employer<ul style="list-style-type: none">• Type of business or sector• Occupation or position held<ul style="list-style-type: none">• Main activities and responsibilities	01/11/2002 - present University of Siena , Via Banchi di Sotto 55, 53100 Siena, Italy University Associate Professor of Microbiology Teaching: Microbiology and Virology, Laboratory Medicine for MD, Pharmacists, Lab Technicians, Biotechnologists. Hospital duties: Conventional and molecular diagnostics in virology, set up and running an HIV & Hepatitis dedicated service. Research: Development of molecular diagnostics applied to human viral infections, particularly HIV and hepatitis viruses, antiviral drug resistance, antiviral drug development.
<ul style="list-style-type: none">• Dates (from – to)• Name and address of employer<ul style="list-style-type: none">• Type of business or sector• Occupation or position held<ul style="list-style-type: none">• Main activities and responsibilities	15/05/1990 – 30/10/2002 Azienda Ospedaliera Senese (formerly USL 30), Policlinico S. Maria alle Scotte, Viale Bracci 1, 53100 Siena, Italy University Hospital Biologist at the Service of Microbiology and Virology Development and use of molecular diagnostics applied to human viral infections
<ul style="list-style-type: none">• Dates (from – to)• Name and address of employer<ul style="list-style-type: none">• Type of business or sector• Occupation or position held<ul style="list-style-type: none">• Main activities and responsibilities	01/04/1988 – 31/03/1990 ENI , Rome, Italy Energy Fellowship Program “Lymphokines and synthetic vaccines”, topic “Adenovirus as a vector for influenza vaccine”
<ul style="list-style-type: none">• Dates (from – to)• Name and address of employer<ul style="list-style-type: none">• Type of business or sector• Occupation or position held<ul style="list-style-type: none">• Main activities and responsibilities	01/01/1988 – 31/03/1988 Ciba-Geigy S.P.A. , Origgio (VA), Italy Drug manufacturer Fellowship Isolation and characterization of influenza virus from clinical specimens in a trial evaluating the use of ribavirin as an anti-influenza agent

EDUCATION AND TRAINING

• Dates (from – to)	01/11/1995 – 31/10/1999
• Name and type of organisation providing education and training	University of Siena
• Principal subjects/occupational skills covered	Advanced Microbiology and Virology, particularly clinically oriented topics.
• Title of qualification awarded	Specialty School in Microbiology and Virology.
• Level in national classification (if appropriate)	Full marks cum laude

• Dates (from – to)	01/11/1981 – 31/10/1985
• Name and type of organisation providing education and training	University of Siena
• Principal subjects/occupational skills covered	General Biology, particularly Microbiology. Two-year practice at the Laboratory of Virology working with viral diagnostics.
• Title of qualification awarded	Degree in Biological Sciences.
• Level in national classification (if appropriate)	Full marks cum laude.

**PERSONAL SKILLS
AND COMPETENCES**

Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas.

MOTHER TONGUE	ITALIAN
OTHER LANGUAGES	ENGLISH
• Reading skills	Excellent (C1)
• Writing skills	Excellent (C1)
• Verbal skills	Excellent (C1)

<p>SOCIAL SKILLS AND COMPETENCES</p> <p><i>Living and working with other people, in multicultural environments, in positions where communication is important and situations where teamwork is essential etc.</i></p>	<ul style="list-style-type: none"> - Set-up, maintenance and updating of an HIV dedicated laboratory and research group at the Department of Molecular Biology of the University of Siena since 1990. - Supervisor of more than 30 thesis for the degree in Biological Sciences, in Biotechnology and for the Master in Microbiology and Virology. - Supervisor of more than 20 PhD students, teaching at the University of Siena since 1992 through lessons, laboratory practice and involvement in research projects. - Continuous cooperation with infectious diseases clinics in Italy since 1990. - Continuous cooperation with many HIV international experts from academy and industry through conferences, workshops and research projects since 1995. - Invited speakers at 125 CME events, 38 national and international conferences and 11 roundtables and consensus meetings. - Scientific peer-reviewed publications indexed in PubMed: 265. Impact factor: 1077.546. H index: 32 (Scopus).
---	---

<p>ORGANISATIONAL SKILLS AND COMPETENCES</p> <p><i>Coordination and administration of people, projects and budgets at work</i></p>	<ul style="list-style-type: none"> - Principal investigator in many HIV related research projects together with other academic scientists from Italy and abroad and with pharmaceutical companies. - Familiarity with allocation of resources and budgeting, selection of project dedicated staff with attention at team working capabilities. <p>Membership of national and international research consortia</p> <ul style="list-style-type: none"> - 2002-ongoing. President of the Scientific Board of the Antiretroviral Resistance Cohort Analysis (www.dbarca.net), a curated collection of HIV treatments and HIV drug resistance data throughout Italy. - 2003-2007. Founding member and then consultant of the Resistance Response Database Initiative (www.hivrdb.org), an international consortium dedicated to the development of artificial intelligence systems for optimizing anti-HIV therapy. - 2009-2011. Member of the OSCAR and DIVA national network involving laboratories developing molecular systems for the analysis of HIV coreceptor tropism. - 2009-ongoing. Founding member and then permanent member of the Steering Committee of the EuResist Network (www.euresist.org), a European consortium (plus non-European partners) for research studies based on large datasets related to anti-HIV therapy. - 2010. Expert member in the European Centre for Disease Prevention and Control (ECDC) tender "Public Health Value of HIV ARV Resistance monitoring within the EU/EEA" (Publication Reference: OJ/2010/02/22-PROC/2010/008). - 2011-ongoing. Member of the Steering Committee of the European HIV coreceptor study group (https://www.euresist.org/eucohiv), a research consortium aimed at studying HIV coreceptor tropism and the use of coreceptor antagonists. - 2012-2016. Coordinator of the Italian HLA Virological-Clinical Network, a national network of laboratories involved in the development of HLA-related
--	--

assays for optimization of antiviral therapy.

- 2013-2019. Member of the collaborative group for the management of the INIMAGE (Integrase Inhibitors Management by Genotype) national study.
- 2015-2020. Italian delegate for the European Society for Translational Antiviral Research (ESAR, www.esar-society.eu), a scientific society for the study of virus evolution and its pathogenetic implications.
- 2016-ongoing. Member of the Scientific Board and Coordinator of the Virology Group in the VIRONET-C collaboration (<https://www.vironetc.org/>), a national network of laboratories and clinics studying anti-HCV treatment.
- 2017-ongoing. Member of the Steering Committee of the INTEGRATE project, an activity coordinated by the EuResist consortium to optimize the use of HIV integrase inhibitors across Europe.
- 2018-ongoing. Member and Coordinator of the HIV DNA Network, a national initiative for setup and harmonization of quantitative HIV DNA assays.

Congress and Conference chairmanship

1. Aggiornamenti in tema di resistenze agli antiretrovirali: dal genotipo alla risposta virologica al trattamento. Firenze, Villa Le Rondini, 10 Aprile 2003.
2. Attualità in tema di interpretazione dei test di resistenza agli antiretrovirali. Roma, Università Cattolica del Sacro Cuore, 31 marzo - 1 aprile 2004.
3. HAART 10 anni dopo. Siena, Certosa di Pontignano, 6 Giugno 2006.
4. Biomedical informatics for optimised treatment of infectious diseases. Helsinki, November 22, 2006.
5. First Workshop on Italian HIV Cohorts. Siena, Certosa di Pontignano, October 9th, 2007.
6. EuResist Moscow Meeting. Moscow, Borodino Hotel, December 15-16, 2008.
7. EuResist Tallinn Meeting. Tallinn, Estonia, April 3, 2008.
8. HIV drug resistance genotyping. A practical course. Kenya Medical Research Institute, Nairobi, February 21-25, 2011.
9. HIV drug resistance genotyping. A practical course. Kenya Medical Research Institute, Nairobi, February 20-22, 2012.
10. ARCA Mentor School. Siena, 27-28 Maggio 2015.
11. Presente e futuro degli INSTI nella pratica clinica. Siena, 4 Ottobre 2016.
12. ARCA Mentor School. Siena, 6-7 Ottobre 2016.
13. 9th Italian Conference on AIDS and Antiviral Research (ICAR 2017). Siena, 12-14 Giugno 2017.
14. ARCA Mentor School. Siena, 20-21 settembre 2017.
15. Le terapie antiretrovirali a due farmaci. Un cambio di paradigma? Firenze, 5 Aprile 2018.
16. Scuola di Alta Formazione in Virologia Clinica – VIKT 2018. Siena 24-25 settembre 2018.
17. ARCA Mentor School. Siena, 18-19 Settembre 2019.
18. ARCA Factory. Web, 28-29 Settembre 2020.

Membership in the organizing/scientific committee of national and international congresses

1. Congress of the Italian Society for Virology. 2010-2015. Secretary of the Society from 10/2012 to 11/2015.
2. National Congress of the Società Italiana di Virologia - Italian Society for Virology. Consultant Member and Member of the Scientific Committee since 2016.
3. ICAR, Italian Conference on AIDS and Antiviral Research. Member of the Scientific and/or Program Committee since 2015.
4. European Meeting on HIV and Hepatitis. Member of the Scientific Committee since 2012.

Grants

1. 1990-1995. VII, VIII and IX AIDS Project, Istituto Superiore di Sanità, Ministry of

Health, Rome.

2. 1994-1996. I, II and III Project on Antiretroviral Therapy, Istituto Superiore di Sanità, Ministry of Health, Rome.
3. 1997-2006. I, II, III and IV National AIDS Programme, Istituto Superiore di Sanità, Ministry of Health, Rome.
4. 2004. INFOBIOMED (Network of Excellence of the European Community, IST-507585): "Biomedical Informatics to Support Individualised Healthcare".
5. 2005. PRIN 2005 (Ministry of University and Research, Italy): "Development and use of a dedicated database for the study of genotypic antiretroviral resistance in vivo: integrated management of the factors involved in antiretroviral resistance".
6. 2005. Targeted Research 2005 (Ministry of Health, Italy): "Management of HIV drug resistance in modeling novel antiretroviral therapy strategies"
7. 2005. University Research Plan 2005 (University of Siena): "Development of a surveillance system for the circulation of different human immunodeficiency virus type 1 (HIV-1) subtypes and recombinant forms"
8. 2006. EuResist (STREP of the European Community, IST-2004-027173), "Integration of viral genomics with clinical data to predict response to anti-HIV treatment"
9. 2008. PRIN 2008 (Ministry of University and Research, Italy): "Development of laboratory assays for advanced monitoring of HIV drug resistance"
10. 2009. CHAIN ("Collaborative HIV and Anti-HIV Drug Resistance Network", Large scale project of the European Community, Grant Agreement number 223131).
11. 2009. EDCTP Joint Program Activities, "Integrated training activities and IT infrastructures to improve capacities in Eastern African area"
12. 2009. AIDS Program 2009, Italy. "Implementation of an HIV drug resistance database as a platform for resistance related research proposals and for advanced HIV genotype interpretation" (grant 40h81).
13. 2012. Fellowship Program Gilead. The role of the viral reservoir and residual viremia in patients switched to raltegravir plus 2 NRTIs after virological suppression.
14. 2013. THINPAD (FP7-HEALTH-2013-INNOVATION-2): "Targeting the HIV-1 Nucleocapsid Protein to fight Antiretroviral Drug Resistance".
15. 2015. Fellowship Program Gilead. HBV DNA distribution in PBMC and plasma from HBV inactive carriers and patients with occult HBV infection (OBI).
16. 2016. Tuscany Region FAS-Salute: "UNAVIR: a novel strategy to combat multiple viral infections with one antiviral".
17. 2017. Fellowship Program Gilead. Changes in total and integrated HIV-1 DNA following treatment deintensification.
18. 2018. Tuscany Region POR-FESR 2014-2020 "PANVIR.NET: preclinical development of innovative PANVIRal antivirals in a specialized regional NETWORK".
19. 2019. CARE (H2020 Research and Innovation action: H2020-SC1-2018-Single-Stage-RTD - SC1-BHC-21-2018): "Common Action against HIV/TB/HCV across the Regions of Europe". Grant agreement ID: 825673.
20. 2019. PRIN 2017: "ORIGINALE CHEMIAE in Antiviral Strategy - Origin and Modernization of Multi-Component Chemistry as a Source of Innovative Broad Spectrum Antiviral Strategy". Prot. 2017BMK8JR.
21. 2019. AIFA 2017 Call for Independent Drug Research: "OPTIMA - Strategies to Contain HIV Drug-Resistance Emergence in Virologically Suppressed Patients Requiring Antiretroviral Therapy Optimization: Unraveling the Role of Mutational Burden in PBMCs". AIFA Code TRS-2018-00001336.
22. 2020. Tuscany Region Health Call 2018: TUSCAVIR (Tuscany Antiviral Research Network).
23. 2020. Tuscany COVID19 Call 2020: APICE (Antibodies and Peptides Inhibiting Coronavirus Entry).
24. 2020. Intesa San Paolo Bank COVID-19 Call: Blocking Coronavirus infection: developing inhibitors of SARS-CoV-2 protease and multifunctional compounds

interfering with virus entry and replication.

25. 2021. EuCARE (HORIZON-HLTH-2021-CORONA-01 — COVID19 - HERA Incubator): “European Cohorts of Patients and Schools to Advance Response to Epidemics”.
26. 2021. PRIN 2020: Multidisciplinary Assessment of the blood and gut-associated HIV Reservoir and Immunity following Switch from 3-drug to 2-drug Antiretroviral regimens in virologically suppressed patients (MARISA).

TECHNICAL SKILLS
AND COMPETENCES

*With computers, specific kinds of
equipment, machinery, etc.*

- Computers. Advanced use of the Windows operating system. Excellent knowledge of the main office suites. Advanced knowledge of DNA/protein analysis software packages (DNASTar, Vector NTI, Mega, BioEdit). Good knowledge of statistical packages (SSPS, Statistica, Sigmapstat). Continuous use of web resources such as medical education, scientific databases (e. g. PubMed, GenBank, NCBI, LANL). Basic knowledge of HTML and web design. Good knowledge of relational databases (Oracle, MySQL). Advanced programming skills in Visual Foxpro.
- Familiarity with many basic biomedical laboratory equipment and specialized microbiology and virology laboratory equipment.

ADDITIONAL INFORMATION

Associate Editor for the following journals
BMC Infect Dis

Reviewer for the following scientific journals

AIDS, AIDS Reviews, Antimicrobial Agents and Chemotherapy, Antiviral Therapy, BMC Infectious Diseases, Clinical Chemistry, Clinical Chemistry and Laboratory Medicine, Clinical Infectious Diseases, Clinical Microbiology and Infection, CNS Drugs, Current HIV Research, EClinicalMedicine, Epidemiology and Infection, HIV Clinical Trials, HIV Medicine, Indian Journal of Medical Research, International Journal of Antimicrobial Agents, Journal of Antimicrobial Chemotherapy, Journal of Clinical Microbiology, Journal of Infectious Diseases, Journal of the International AIDS Society, Journal of Medical Virology, Journal of Translational Medicine, Journal of Virological Methods, Lancet Infectious Diseases, Lancet Microbes, PLoS Computational Biology, PLoS ONE, Retrovirology, Scientific Reports, Virology, Virus Research.

Awards

1. 2008. Scientific coordinator of the EuResist project (FP6-2004-IST-4: Integration of viral genomics with clinical data to predict response to anti-HIV treatment), awarded the Project of the Month honor in November 2008.
2. 2009. Winner of the Computerworld Honors Program (Honoring those who use information technology to benefit society) with a case study based on the EuResist anti-HIV treatment response prediction engine.

Patents

1. Antiretroscan, 30/10/2002. Method for prediction of susceptibility to antiretroviral drugs. Deposit number RM2002A000544.
2. HIV-1 nucleocapsid inhibitors, 24/10/2016. Patent n. 16186511.8-1452.

Date: 14/02/2022

Signature:

I hereby authorize the handling of my personal data pursuant to the Personal Data Protection Code – Legislative Decree n. 196/2003.

Date: 14/02/2022

Signature: